

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 64.1754 Seconds  
(without alignments)  
761.757 Million cell updates/sec

Title: US-10-735-916A-83  
Perfect score: 625  
Sequence: 1 QVQLQESGPGLVKPSSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA Main: \*  
1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep: \*  
2: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep: \*  
3: /cgn2\_6/ptodata/1/pubpaa/US09\_PUBCOMB.pep: \*  
4: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep: \*  
5: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep: \*  
6: /cgn2\_6/ptodata/1/pubpaa/US11\_PUBCOMB.pep: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	625	100.0	117	5	US-10-735-916A-83 Sequence 83, Appl
2	625	100.0	135	5	US-10-735-916A-85 Sequence 85, Appl
3	615	98.4	117	5	US-10-735-916A-79 Sequence 79, Appl
4	615	98.4	135	5	US-10-735-916A-81 Sequence 81, Appl
5	611	97.8	117	5	US-10-735-916A-75 Sequence 75, Appl
6	611	97.8	135	5	US-10-735-916A-77 Sequence 77, Appl
7	529	84.6	117	5	US-10-735-916A-69 Sequence 69, Appl
8	529	84.6	127	5	US-10-735-916A-52 Sequence 52, Appl
9	517	82.7	119	4	US-10-309-762-143 Sequence 143, Appl
10	514.5	82.3	118	4	US-10-292-088-109 Sequence 109, Appl
11	514.5	82.3	120	4	US-10-383-447-26 Sequence 26, Appl
12	513.5	82.2	121	5	US-10-805-177-56 Sequence 56, Appl
13	513.5	82.2	122	4	US-10-309-762-25 Sequence 25, Appl
14	513.5	82.2	122	4	US-10-309-762-29 Sequence 29, Appl
15	512.5	82.0	120	4	US-10-309-762-128 Sequence 128, Appl
16	510.5	81.7	116	4	US-10-309-762-127 Sequence 127, Appl
17	510.5	81.7	121	4	US-10-010-729-11 Sequence 11, Appl
18	510.5	81.7	122	4	US-10-309-762-24 Sequence 24, Appl
19	510.5	81.7	122	4	US-10-309-762-27 Sequence 27, Appl
20	510	81.6	119	4	US-10-125-687-5 Sequence 5, Appl
21	510	81.6	119	5	US-10-996-191-5 Sequence 23, Appl
22	508	81.3	119	5	US-10-937-596-23 Sequence 2, Appl
23	507	81.1	117	5	US-10-890-945-2 Sequence 82, Appl
24	507	81.1	121	4	US-10-292-088-82 Sequence 86, Appl
25	507	81.1	466	4	US-10-292-088-86 Sequence 35, Appl
26	507	81.1	580	4	US-10-310-719-35 Sequence 37, Appl
27	507	81.1	580	4	US-10-310-719-37

ALIGNMENTS

RESULT 1  
US-10-735-916A-83  
; Sequence 83, Application US/10735916A  
; Publication No. US20050084906A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, Liliane  
; APPLICANT: CORVAIA, Nathalie  
; APPLICANT: LEGER, Olivier  
; APPLICANT: DUFLOS, Alain  
; APPLICANT: BECK, Alain  
; APPLICANT: HAUM, Jean-Francois  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-183  
; CURRENT APPLICATION NUMBER: US/10/735,916A  
; CURRENT FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 03/08 538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 02/00 653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/00 654  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/05 753  
; PRIOR FILING DATE: 2002-05-07  
; NUMBER OF SEQ ID NOS: 156  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 83  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-735-916A-83

Query Match 100.0%; Score 625; DB 5; Length 117;  
Best Local Similarity 100.0%; Pred. No. 5e-48;  
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 60  
  
QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAAYVCARYGRVFFDYWGQGLTVTVSS 117  
Db 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAAYVCARYGRVFFDYWGQGLTVTVSS 117

RESULT 2  
US-10-735-916A-85  
; Sequence 85, Application US/10735916A  
; Publication No. US20050084906A1

GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 85  
LENGTH: 135  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-735-916A-85

Query Match 100.0%; Score 625; DB 5; Length 135;  
Best Local Similarity 100.0%; Pred. No. 5.8e-48;  
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 78  
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYCYGRVFFDYWGQGLTVTVSS 117  
DB 79 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYCYGRVFFDYWGQGLTVTVSS 135

RESULT 3  
US-10-735-916A-79  
Sequence 79, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 79  
LENGTH: 117  
TYPE: PRT  
ORGANISM: Homo sapiens

US-10-735-916A-79  
Query Match 98.4%; Score 615; DB 5; Length 117;  
Best Local Similarity 98.3%; Pred. No. 3.9e-47;  
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYCYGRVFFDYWGQGLTVTVSS 117  
DB 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYCYGRVFFDYWGQGLTVTVSS 117  
RESULT 4  
US-10-735-916A-81  
Sequence 81, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 81  
LENGTH: 135  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-735-916A-81

Query Match 98.4%; Score 615; DB 5; Length 135;  
Best Local Similarity 98.3%; Pred. No. 4.5e-47;  
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78  
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYCYGRVFFDYWGQGLTVTVSS 117  
DB 79 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYCYGRVFFDYWGQGLTVTVSS 135  
RESULT 5  
US-10-735-916A-75  
Sequence 75, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF



```
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-52

Query Match      84.6%; Score 529; DB 5; Length 127;
Best Local Similarity 82.8%; Pred. No. 1.9e-39;
Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 2 VOLQESGPGLVKPSSTLSLTCTVSGYSISGGYLMNWIROPKGLWIGYISYDGTNNYK 61
Db 12 VOLQESGPGLVKPSQSLSLTCSVTGYSITGGYLMNWIROPKGLWIGYISYDGTNNYK 71

Qy 62 PSLKDRVTISVDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db 72 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGLTVTVSS 127

RESULT 9
US-10-309-762-143
; Sequence 143, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Peltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: AGENIX 027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: PaetSEQ for Windows Version 4.0
; SEQ ID NO 143
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-143

Query Match      82.7%; Score 517; DB 4; Length 119;
Best Local Similarity 85.0%; Pred. No. 2.1e-38;
Matches 102; Conservative 4; Mismatches 10; Indels 4; Gaps 2;

Qy 1 VOLQESGPGLVKPSSTLSLTCTVSGYSISGGYLMNWIROPKGLWIGYISYDGTNNYK 60
Db 1 VOLQESGPGLVKPSSTLSLTCTVSGGSIS-SYYWSWIRQPPKGLWIGYISYDGTNNYK 59

Qy 61 KPSLKDRTVISVDTSKNQFSLKSSVTAADTAVYYCARYGRV---FFDYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVYYCARYDILTGYFFDYWGQGLTVTVSS 119

RESULT 10
US-10-292-088-109
; Sequence 109, Application US/10292088
; Publication No. US20030211100A1
; GENERAL INFORMATION:
; APPLICANT: BEDIAN, VAHE
; APPLICANT: GLADUE, RONALD P.
; APPLICANT: CORVALAN, JOSE
; APPLICANT: JIA, XIAO-CHI
; APPLICANT: FENG, XIAO

; TITLE OF INVENTION: ANTIBODIES TO CD40
; FILE REFERENCE: ABX-PF/3 US
; CURRENT APPLICATION NUMBER: US/10/292,088
; CURRENT FILING DATE: 2003-03-14
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 109
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-292-088-109

Query Match      82.3%; Score 514.5; DB 4; Length 118;
Best Local Similarity 85.7%; Pred. No. 3.5e-38;
Matches 102; Conservative 3; Mismatches 11; Indels 3; Gaps 2;

Qy 1 VOLQESGPGLVKPSSTLSLTCTVSGYSISGGYLMNWIROPKGLWIGYISYDGTNNYK 60
Db 1 VOLQESGPGLVKPSSTLSLTCTVSGGSIS-SYYWSWIRQPPKGLWIGYISYDGTNNYK 59

Qy 61 KPSLKDRTVISVDTSKNQFSLKSSVTAADTAVYYCAR--YGRVFFDYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVYYCARDYGGNSYFDYWGQGLTVTVSS 118

RESULT 11
US-10-383-447-26
; Sequence 26, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaaskar, Vinay
; APPLICANT: de la Calle, Agustin
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TWEFP2 and Uses Thereof
; FILE REFERENCE: 05982.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: Patent In version 3.2
; SEQ ID NO 26
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 3.0
US-10-383-447-26

Query Match      82.3%; Score 514.5; DB 4; Length 120;
Best Local Similarity 82.4%; Pred. No. 3.5e-38;
Matches 98; Conservative 7; Mismatches 11; Indels 3; Gaps 1;

Qy 2 VOLQESGPGLVKPSSTLSLTCTVSGYSISGGYLMNWIROPKGLWIGYISYDGTNNYK 61
Db 2 VOLQESGPGLVKPSSTLSLTCAVSGYSITSGYYWSWIRQPPKGLWIGYISYDGTNNYK 61

Qy 62 PSLKDRVTISVDTSKNQFSLKSSVTAADTAVYYCA---RYGRVFFDYWGQGLTVTVSS 117
Db 62 PSLKNRITISRTSKNQFSLKSSVTAADTAVYYCARGLRGRDYSMDYWGQGLTVTVSS 120

RESULT 12
US-10-805-177-56
```

```
; Sequence 56, Application US/10805177
; Publication No. US2005008449A1
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Chen, Francine
; APPLICANT: Bezabeh, Binyam
; APPLICANT: Foltz, Ian
; APPLICANT: Tse, Kam Fai
; APPLICANT: Jeffers, Michael
; APPLICANT: Mesri, Mehdi
; APPLICANT: Starling, Gary
; APPLICANT: Mezes, Peter
; APPLICANT: Khrantsov, Nikolai
; TITLE OF INVENTION: ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN
; FILE REFERENCE: ABXCUR.006A
; CURRENT APPLICATION NUMBER: US/10/805,177
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/456,652
; PRIOR FILING DATE: 2003-03-19
; NUMBER OF SEQ ID NOS: 141
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 56
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-805-177-56

Query Match      82.2%; Score 513.5; DB 5; Length 121;
Best Local Similarity 85.0%; Pred. No. 4.4e-38;
Matches 102; Conservative 3; Mismatches 12; Indels 3; Gaps 2;

QY      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSI-SGGYLNWIRQPPGKGLWIGYISYDGTNN 59
Db      1 QVQLQESGPGLVKPSSETLSLTCTVSGGVSIGGYWIRQPPGKGLWIGYISYSGSTN 60

QY      60 YKPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARYG--RVFFDYWGQGLTIVTSS 117
Db      61 YNPSLKSRTVISVDTSKNQFSLKSSVTAADTAVVYCARNNNNNFDYWGQGLTIVTSS 120

RESULT 13
US-10-309-762-25
; Sequence 25, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-25

Query Match      82.2%; Score 513.5; DB 4; Length 122;
Best Local Similarity 83.7%; Pred. No. 4.4e-38;
Matches 103; Conservative 2; Mismatches 11; Indels 7; Gaps 2;

QY      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 60
Db      1 QVQLQESGPGLVKPSSETLSLTCTVSGGSI-SYYWISWIRQPPGKGLWIGYIYSGSTNY 59

US-10-309-762-128
; Sequence 128, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 128
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-128
```

```
QY      61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARYGRVF-----FDYWGQGLTIVT 114
Db      60 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVVYCARRGYDLTGVDYFDYWGQGLTIVT 119

QY      115 VSS 117
Db      120 VSS 122

RESULT 14
US-10-309-762-29
; Sequence 29, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-29

Query Match      82.2%; Score 513.5; DB 4; Length 122;
Best Local Similarity 83.7%; Pred. No. 4.4e-38;
Matches 103; Conservative 2; Mismatches 11; Indels 7; Gaps 2;

QY      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 60
Db      1 QVQLQESGPGLVKPSSETLSLTCTVSGGSI-SYYWISWIRQPPGKGLWIGYIYSGSTNY 59

QY      61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARYGRVF-----FDYWGQGLTIVT 114
Db      60 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVVYCARRGYDLTGVDYFDYWGQGLTIVT 119

QY      115 VSS 117
Db      120 VSS 122

RESULT 15
US-10-309-762-128
; Sequence 128, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 128
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-128
```

Query Match 82.0%; Score 512.5; DB 4; Length 120;  
Best Local Similarity 85.0%; Pred. No. 5.3e-38;  
Matches 102; Conservative 4; Mismatches 11; Indels 3; Gaps 2;  
  
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYS- ISGGYLNWNIROPPGKGLEWIGYISYDGTNN 59  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGVSISGGYYSWIRQPPGKLEWIGYIYSGSSN 60  
  
Qy 60 YKPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYYCAR--YGRVFDYWGQGTLLTVSS 117  
Db 61 YNPSLKSRVTISVDASKNQFSLRLSSVTAADTAVYYCARSMVRGVSFYWGQGTLLTVSS 120

Search completed: January 10, 2006, 21:35:33  
Job time : 64.1754 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.96642 Seconds  
(without alignments)  
166.558 Million cell updates/sec

Title: US-10-735-916A-83  
Perfect score: 625  
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGLVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications AA\_New:\*  
1: /cgn2\_6/ptodata/1/pubpaa/US08\_NEW\_PUB.pap:\*  
2: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pap:\*  
3: /cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pap:\*  
4: /cgn2\_6/ptodata/1/pubpaa/PTCT\_NEW\_PUB.pap:\*  
5: /cgn2\_6/ptodata/1/pubpaa/US05\_NEW\_PUB.pap:\*  
6: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pap:\*  
7: /cgn2\_6/ptodata/1/pubpaa/US11\_NEW\_PUB.pap:\*  
8: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	625	100.0	117	US-11-012-353-83	Sequence 83, Appl
2	625	100.0	135	US-11-012-353-85	Sequence 85, Appl
3	615	98.4	117	US-11-012-353-79	Sequence 79, Appl
4	615	98.4	135	US-11-012-353-81	Sequence 81, Appl
5	611	97.8	117	US-11-012-353-75	Sequence 75, Appl
6	611	97.8	135	US-11-012-353-77	Sequence 77, Appl
7	546	87.4	117	US-11-012-353-162	Sequence 162, Appl
8	529	84.6	117	US-11-012-353-69	Sequence 69, Appl
9	529	84.6	127	US-11-012-353-52	Sequence 52, Appl
10	492	78.7	123	US-11-012-353-73	Sequence 73, Appl
11	491.5	78.6	247	US-11-054-515-1551	Sequence 1651, Ap
12	491.5	78.6	250	US-11-054-515-1548	Sequence 1548, Ap
13	483	77.3	117	US-11-012-353-72	Sequence 72, Appl
14	482	77.1	253	US-11-054-515-1619	Sequence 1619, Ap
15	479.5	76.7	146	US-10-721-763-17	Sequence 17, Appl
16	477.5	76.4	252	US-11-054-515-1394	Sequence 1394, Ap
17	475.5	76.1	252	US-11-054-515-1329	Sequence 1329, Ap
18	471.5	75.4	116	US-11-054-669-112	Sequence 112, App
19	471.5	75.4	250	US-11-054-669-110	Sequence 110, Appl
20	470.5	75.3	118	US-11-012-353-70	Sequence 70, Appl
21	470	75.2	251	US-11-054-515-990	Sequence 990, Appl
22	469	75.0	253	US-11-054-515-1339	Sequence 1339, Ap
23	468	74.9	120	US-11-102-201-1	Sequence 1, Appl
24	466.5	74.6	154	US-10-721-763-25	Sequence 25, Appl
25	465.5	74.5	254	US-11-054-515-1578	Sequence 1578, Ap

ALIGNMENTS

RESULT 1

US-11-012-353-83  
; Sequence 83, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, LILLIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFOIS, ALAIN  
; APPLICANT: HAEUO, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012.353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: Patentin Ver. 3.3  
; SEQ ID NO 83  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-11-012-353-83

Query Match 100.0%; Score 625; DB 7; Length 117;  
Best Local Similarity 100.0%; Pred. No. 2.2e-48;  
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGFLVKPSETLSLCTVSGYISGGLNWIROPKGLWIGYISYDGTNNY 60  
Db 1 QVQLQESGFLVKPSETLSLCTVSGYISGGLNWIROPKGLWIGYISYDGTNNY 60  
QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAIVYCARVGRVFFDYWGQGLVTVSS 117  
Db 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAIVYCARVGRVFFDYWGQGLVTVSS 117

```
RESULT 2
US-11-012-353-85
; Sequence 85, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 85
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-85

Query Match      100.0%; Score 625; DB 7; Length 135;
Best Local Similarity 100.0%; Pred. No. 2.6e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTAVTVSS 117
Db 79 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTAVTVSS 135

RESULT 3
US-11-012-353-79
; Sequence 79, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
```

```
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 79
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-79

Query Match      98.4%; Score 615; DB 7; Length 117;
Best Local Similarity 98.3%; Pred. No. 1.7e-47;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITCGYLNWIRQPPGKLEWIGYISYDGTNNY 60

Qy 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTAVTVSS 117
Db 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTAVTVSS 117

RESULT 4
US-11-012-353-81
; Sequence 81, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-81

Query Match      98.4%; Score 615; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 1.9e-47;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITCGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTAVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTAVTVSS 135
```

RESULT 5  
US-11-012-353-75  
; Sequence 75, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFLOS, ALAIN  
; APPLICANT: HAEUW, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012,353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: PatentIn Ver. 3.3  
; SEQ ID NO 75  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-11-012-353-75

Query Match 97.8%; Score 611; DB 7; Length 117;  
Best Local Similarity 96.6%; Pred. No. 3.7e-47;  
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60  
Qy 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117  
Db 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117

RESULT 6  
US-11-012-353-77  
; Sequence 77, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFLOS, ALAIN  
; APPLICANT: HAEUW, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012,353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20

; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: PatentIn Ver. 3.3  
; SEQ ID NO 77  
; LENGTH: 135  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-11-012-353-77

Query Match 97.8%; Score 611; DB 7; Length 135;  
Best Local Similarity 96.6%; Pred. No. 4.2e-47;  
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60  
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 78  
Qy 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117  
Db 79 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 135

RESULT 7  
US-11-012-353-162  
; Sequence 162, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFLOS, ALAIN  
; APPLICANT: HAEUW, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012,353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: PatentIn Ver. 3.3  
; SEQ ID NO 162  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-11-012-353-162

Query Match 87.4%; Score 546; DB 7; Length 117;  
Best Local Similarity 88.0%; Pred. No. 1.7e-41;  
Matches 103; Conservative 4; Mismatches 10; Indels 0; Gaps 0;  
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYISGGYNNWIRQPPGKLEWIGSIFHSGSSY 60  
Qy 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117



```

Db      61  NPSLKSRRVTISVDTSKNQSFSLQSRVTAADTAVYYCAR-GRYCSSTSCNWFDPWGQGLTV 113
QY      114  TVSS 117
Db      120  TVSS 123

RESULT 11
US-11-054-515-1651
; Sequence 1651, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1651
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1651

Query Match      78.6%; Score 491.5; DB 7; Length 247;
Best Local Similarity 79.0%; Pred. No. 1.8e-36;
Matches 98; Conservative 4; Mismatches 15; Indels 7; Gaps 2;

QY      1  QVQLQSGGPGLVKPSFSLTCTVSGYSTISGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60
Db      1  QVQLQSGGPGLVKPSFSLTCTVSGYSTISGGYWGWIIRQPPGKGLEWISYISYSGTTY 60
QY      61  KPSELKDRVTISVDTSKNQSFSLKSSVTAADTAVYYCARY-----GRVFP-FDYWGQGLTV 113
Db      61  NPSLKSRRVTISVDTSKNQSFSLKSSVTAADTAVYYCARFRYDILTGYYDMDVWGRCTLV 120
QY      114  TVSS 117
Db      121  TVSS 124

RESULT 12
US-11-054-515-1548
; Sequence 1548, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10

```

```
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 72
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: MOD RES
; LOCATION: (59)
; OTHER INFORMATION: Variable amino acid
US-11-012-353-72

Query Match      77.1%; Score 482; DB 7; Length 117;
Best Local Similarity 81.2%; Pred. No. 5e-36;
Matches 95; Conservative 5; Mismatches 17; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSQTLSTCTVSGYSISGGYLNWIRQPPGKLEWIGVISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSQTLSTCTVSGGSVSSYWSNWIROPQPGKLEWIGRIYYSGSTY 60

Qy 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117
Db 61 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVVYCARLPGGYDVWGQGLTVTVSS 117

RESULT 14
US-11-054-515-1619
; Sequence 1619, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS
; FILE REFERENCE: PF23P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; PRIOR FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-16
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1619
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1619

Query Match      77.1%; Score 482; DB 7; Length 253;
Best Local Similarity 77.2%; Pred. No. 1.3e-35;
Matches 98; Conservative 6; Mismatches 13; Indels 10; Gaps 3;

Qy 1 QVQLQESGPGLVKPSQTLSTCTVSGYSI-SCGYLNWIRQPPGKLEWIGVISYDGTNN 59
Db 1 QVQLQESGPGLVKPSQTLSTCTVSGGSISGGYWSNWIROPQPGKLEWIGRIYYSGSTY 60

Qy 60 YKPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117
Db 60 YKPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 144

Search completed: January 10, 2006, 21:36:24
Job time : 5.96642 secs
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 22.847 Seconds  
(without alignments)  
423.384 Million cell updates/sec

Title: US-10-735-916A-83  
Perfect score: 625  
Sequence: 1 QVQLQESGFLVLPSEITLSL.....RYGRVFFDYWGQGLVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents AA\*  
1: /cgn2\_6/ptodata/1/1aa/5 COMB.pep.\*  
2: /cgn2\_6/ptodata/1/1aa/6 COMB.pep.\*  
3: /cgn2\_6/ptodata/1/1aa/H COMB.pep.\*  
4: /cgn2\_6/ptodata/1/1aa/pCTUS COMB.pep.\*  
5: /cgn2\_6/ptodata/1/1aa/RE COMB.pep.\*  
6: /cgn2\_6/ptodata/1/1aa/backfiles.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	510	81.6	119	2	US-09-025-7698-39
2	510	81.6	119	2	US-09-025-7698-65
3	510	81.6	119	2	US-09-490-070A-39
4	510	81.6	119	2	US-09-490-070A-65
5	510	81.6	119	2	US-09-490-153-39
6	510	81.6	119	2	US-09-490-153-65
7	510	81.6	119	2	US-09-490-324-39
8	510	81.6	119	2	US-09-490-324-65
9	507	81.1	117	2	US-09-720-493-2
10	497	79.5	117	2	US-10-330-613A-13
11	493.5	79.0	118	2	US-09-025-7698-25
12	493.5	79.0	118	2	US-09-490-070A-25
13	493.5	79.0	118	2	US-09-490-153-25
14	493.5	79.0	118	2	US-09-490-324-25
15	492.5	78.8	244	2	US-08-918-148-79
16	492.5	78.8	244	2	US-09-138-091A-77
17	492.5	78.8	473	2	US-09-049-672A-4
18	485	77.6	121	2	US-10-330-613A-1
19	485	77.6	121	2	US-10-330-613A-17
20	484.5	77.5	487	2	US-09-800-729-145
21	483	77.3	117	2	US-10-330-613A-5
22	482.5	77.2	118	2	US-09-343-698-6
23	482.5	77.2	118	2	US-08-325-955-6
24	481.5	77.0	832	2	US-08-630-820-7
25	481.5	77.0	832	2	US-09-273-453-7
26	481	77.0	121	2	US-10-330-613A-9
27	478.5	76.6	139	2	US-09-471-276-837

28	478.5	76.6	278	2	US-09-260-527-3	Sequence 3, Appli
29	477	76.3	142	1	US-08-480-774A-2	Sequence 2, Appli
30	476	76.2	119	1	US-08-360-125-5	Sequence 5, Appli
31	476	76.2	119	1	US-08-450-578-5	Sequence 5, Appli
32	476	76.2	119	1	US-09-017-628-5	Sequence 5, Appli
33	476	76.2	119	1	US-09-014-880-5	Sequence 5, Appli
34	476	76.2	119	2	US-08-450-363-5	Sequence 5, Appli
35	476	76.2	119	2	US-09-467-903-5	Sequence 5, Appli
36	475.5	76.1	122	1	US-08-360-125-11	Sequence 11, Appl
37	475.5	76.1	122	1	US-08-450-578-11	Sequence 11, Appl
38	475.5	76.1	122	1	US-09-017-628-11	Sequence 11, Appl
39	475.5	76.1	122	1	US-09-014-880-11	Sequence 11, Appl
40	475.5	76.1	122	2	US-08-450-363-11	Sequence 11, Appl
41	475.5	76.1	122	2	US-09-467-903-11	Sequence 11, Appl
42	474	75.8	123	1	US-08-137-117D-64	Sequence 64, Appl
43	474	75.8	123	1	US-08-436-717-64	Sequence 64, Appl
44	474	75.8	138	1	US-08-137-117D-69	Sequence 69, Appl
45	474	75.8	138	1	US-08-436-717-69	Sequence 69, Appl

ALIGNMENTS

RESULT 1  
US-09-025-769B-39  
; Sequence 39, Application US/09025769B  
; Patent No. 6300064  
; GENERAL INFORMATION:  
; APPLICANT: Knappik, Achim  
; APPLICANT: Pack, Peter  
; APPLICANT: Ilag, Vic  
; APPLICANT: Ge, Liming  
; APPLICANT: Moroney, Simon  
; APPLICANT: Plueckthun, Andreas  
; TITLE OF INVENTION: Protein/(poly)peptide libraries  
; NUMBER OF SEQUENCES: 373  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
; STREET: 1251 Avenue of the Americas  
; CITY: New York  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10021  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/025,769B  
; FILING DATE: 18-FEB-1998  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: EP 95 11 3021.0  
; FILING DATE: 18-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: James F. Haley, Jr., Esq.  
; REGISTRATION NUMBER: 27,794  
; REFERENCE/DOCKET NUMBER: MORPHO/5  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212)596-9000  
; TELEFAX: (212)596-9090  
; INFORMATION FOR SEQ ID NO: 39:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 119 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-09-025-769B-39

Query Match 81.6%; Score 510; DB 2; Length 119;  
Best Local Similarity 85.0%; Pred. No. 2.8e-43;  
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;



White & McAuliffe  
STREET: 1666 K Street, N.W., Suite 300  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20006  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,070A  
FILING DATE: 24-Jan-2000  
PRIORITY APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Colin G. Sandercock, Esq.  
REGISTRATION NUMBER: 31,298  
REFERENCE/DOCKET NUMBER: 37629-0005  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 912-2000  
TELEFAX: (202) 912-2020  
INFORMATION FOR SEQ ID NO: 65:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 119 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 65:  
US-09-490-070A-65  
Query Match 81.6%; Score 510; DB 2; Length 119;  
Best Local Similarity 85.0%; Pred. No. 2.8e-43;  
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKGLEWIGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKGLEWIGYISYDGTNNY 59  
QY 61 KPSLKDRVTISVDTSKNQPSLSSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 117  
DB 60 NPSLSKRVITISVDTSKNQPSLSSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 119  
RESULT 5  
US-09-490-153-39  
Sequence 39, Application US/09490153  
Patent No. 6706484  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
Pack, Peter  
Ilag, Vic  
Ge, Liming  
Moroney, Simon  
Plueckthun, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,153  
FILING DATE: 24-Jan-2000  
PRIORITY APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5

FILING DATE: 24-Jan-2000  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212)596-9000  
TELEFAX: (212)596-9090  
INFORMATION FOR SEQ ID NO: 39:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 119 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 39:  
US-09-490-153-39  
Query Match 81.6%; Score 510; DB 2; Length 119;  
Best Local Similarity 85.0%; Pred. No. 2.8e-43;  
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKGLEWIGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKGLEWIGYISYDGTNNY 59  
QY 61 KPSLKDRVTISVDTSKNQPSLSSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 117  
DB 60 NPSLSKRVITISVDTSKNQPSLSSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 119  
RESULT 6  
US-09-490-153-65  
Sequence 65, Application US/09490153  
Patent No. 6706484  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
Pack, Peter  
Ilag, Vic  
Ge, Liming  
Moroney, Simon  
Plueckthun, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,153  
FILING DATE: 24-Jan-2000  
PRIORITY APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5

```

;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-153-65

Query Match      81.6%; Score 510; DB 2; Length 119;
Best Local Similarity 85.0%; Pred. No. 2.8e-43;
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVMSWIRQPPGKLEWIGYIYSGSTNY 59

Qy 61 KPSLKDRVITISVDTSKNQFSLKLSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVVYCARWGGDFYAMDYWGQGLTVTVSS 119

RESULT 7
US-09-490-324-39
; Sequence 39, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 39:

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVMSWIRQPPGKLEWIGYIYSGSTNY 59

Qy 61 KPSLKDRVITISVDTSKNQFSLKLSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVVYCARWGGDFYAMDYWGQGLTVTVSS 119

US-09-490-324-39
Query Match      81.6%; Score 510; DB 2; Length 119;
Best Local Similarity 85.0%; Pred. No. 2.8e-43;
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVMSWIRQPPGKLEWIGYIYSGSTNY 59

Qy 61 KPSLKDRVITISVDTSKNQFSLKLSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVVYCARWGGDFYAMDYWGQGLTVTVSS 119

RESULT 8
US-09-490-324-65
; Sequence 65, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-324-65

Query Match      81.6%; Score 510; DB 2; Length 119;
Best Local Similarity 85.0%; Pred. No. 2.8e-43;
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVMSWIRQPPGKLEWIGYIYSGSTNY 59

Qy 61 KPSLKDRVITISVDTSKNQFSLKLSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVVYCARWGGDFYAMDYWGQGLTVTVSS 119
```

Db 60 NPSLSKRVTSISVDTSKNQFSLKSLSSVTAADTAVVYCARWGGDFYAMDYWGQGLTVTVSS 117  
|||||  
RESULT 9  
US-09-720-493-2  
; Sequence 2, Application US/09720493  
; Patent No. 6827925  
; GENERAL INFORMATION:  
; APPLICANT: Cambridge Antibody Technology Limited  
; APPLICANT: Williams, Andrew J  
; APPLICANT: Tempest, Philip R  
; APPLICANT: Holtet, Thor L  
; APPLICANT: Main, Sarah H  
; APPLICANT: Jackson, Helen  
; APPLICANT: Daramola, Olalekan  
; TITLE OF INVENTION: Improvements relating to antibodies  
; FILE REFERENCE: AHB/CP5775333  
; CURRENT APPLICATION NUMBER: US/09/720,493  
; PRIOR FILING DATE: 2002-10-23  
; PRIOR APPLICATION NUMBER: GB 9814383.7  
; NUMBER OF SEQ ID NOS: 22  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-720-493-2  
Query Match 81.1%; Score 507; DB 2; Length 117;  
Best Local Similarity 84.6%; Pred. No. 5.5e-43;  
Matches 99; Conservative 2; Mismatches 16; Indels 0; Gaps 0;  
QY 1 QVQLQESGFLVKPSETLSLCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 60  
Db 1 QVQLQESGFLVKPSETLSLCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 60  
QY 61 KPSLKDRVTISVDTSKNQFSLKSLSSVTAADTAVVYCARVFFDYWGQGLTVTVSS 117  
Db 61 NPSLSKRVTSISVDTSKNQFSLKSLSSVTAADTAVVYCARWGGDFYAMDYWGQGLTVTVSS 117  
RESULT 10  
US-10-330-613A-13  
; Sequence 13, Application US/10330613A  
; Patent No. 6924360  
; GENERAL INFORMATION:  
; APPLICANT: Gudas, Jean  
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN  
; FILE REFERENCE: ABGENIX.022A  
; CURRENT APPLICATION NUMBER: US/10/330,613A  
; CURRENT FILING DATE: 2002-12-26  
; PRIOR APPLICATION NUMBER: 60/346299  
; PRIOR FILING DATE: 2001-12-18  
; NUMBER OF SEQ ID NOS: 90  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 13  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo Sapiens  
US-10-330-613A-13  
Query Match 79.5%; Score 497; DB 2; Length 117;  
Best Local Similarity 84.7%; Pred. No. 5.4e-42;  
Matches 100; Conservative 3; Mismatches 13; Indels 2; Gaps 2;  
QY 1 QVQLQESGFLVKPSETLSLCTVSGYSI-SGGYLNWIRQPPGKGLWIGYISYDGTNN 59  
Db 1 QVQLQESGFLVKPSETLSLCTVSGYSISGGYVWIRQHPGKGLWIGYISYDGTNN 60  
QY 60 YKPSLKDRVTISVDTSKNQFSLKSLSSVTAADTAVVYCARVFFDYWGQGLTVTVSS 117  
|||||

Db 61 YNPSLSKRVTSISVDTSKNQFSLKSLSSVTAADTAVVYCAREGD-GFDYWGQGLTVTVSS 117  
RESULT 11  
US-09-025-769B-25  
; Sequence 25, Application US/09025769B  
; Patent No. 6300064  
; GENERAL INFORMATION:  
; APPLICANT: Knappik, Achim  
; APPLICANT: Pack, Peter  
; APPLICANT: Ilag, Vic  
; APPLICANT: Ge, Liming  
; APPLICANT: Moroney, Simon  
; APPLICANT: Plueckthun, Andreas  
; TITLE OF INVENTION: Protein/(Poly)peptide libraries  
; NUMBER OF SEQUENCES: 373  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
; STREET: 1251 Avenue of the Americas  
; CITY: New York  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10021  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/025,769B  
; FILING DATE: 18-FEB-1998  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: EP 95 11 3021.0  
; FILING DATE: 18-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: James F. Haley, Jr., Esq.  
; REGISTRATION NUMBER: 27,794  
; REFERENCE/DOCKET NUMBER: MORPHO/5  
; TELEPHONE: (212)596-9000  
; TELEFAX: (212)596-9090  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 118 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-025-769B-25  
Query Match 79.0%; Score 493.5; DB 2; Length 118;  
Best Local Similarity 84.0%; Pred. No. 1.2e-41;  
Matches 100; Conservative 3; Mismatches 13; Indels 3; Gaps 2;  
QY 1 QVQLQESGFLVKPSETLSLCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 60  
Db 1 QVQLQESGFLVKPSETLSLCTVSGGSIS-SYVMSWIRQPPGKGLWIGYISYDGTNNY 59  
QY 61 KPSLKDRVTISVDTSKNQFSLKSLSSVTAADTAVVYCA--RYGRVFFDYWGQGLTVTVSS 117  
Db 60 NPSLSKRVTSISVDTSKNQFSLKSLSSVTAADTAVVYCARGGGGVFDYWGQGLTVTVSS 118  
RESULT 12  
US-09-490-070A-25  
; Sequence 25, Application US/09490070A  
; Patent No. 6696248  
; GENERAL INFORMATION:  
; APPLICANT: Knappik, Achim  
; APPLICANT: Pack, Peter  
; APPLICANT: Ilag, Vic  
; APPLICANT: Ge, Liming  
; APPLICANT: Moroney, Simon

;  
; Plueckthun, Andreas  
; TITLE OF INVENTION: Protein/(poly)peptide libraries  
; NUMBER OF SEQUENCES: 373  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman  
; STREET: 1666 K Street, N.W., Suite 300  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20006  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/490,070A  
; FILING DATE: 24-Jan-2000  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: EP 95 11 3021.0  
; FILING DATE: 18-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Colin G. Sandercock, Esq.  
; REGISTRATION NUMBER: 31,298  
; REFERENCE/DOCKET NUMBER: 37629-0005  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 912-2000  
; TELEFAX: (202) 912-2020  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 118 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: <Unknown>  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:  
US-09-490-070A-25  
  
Query Match 79.0%; Score 493.5; DB 2; Length 118;  
Best Local Similarity 84.0%; Pred. No. 1.2e-41;  
Matches 100; Conservative 3; Mismatches 13; Indels 3; Gaps 2;  
  
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGLVNWIRQPPGKLEWIGVISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVWSWIRQPPGKLEWIGIYHSGSTNY 59  
Qy 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYYCA--RYGRVFFDYWGQGTLLTVSS 117  
Db 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVYYCARGGGGVFDYWGQGTLLTVSS 118  
  
RESULT 13  
US-09-490-153-25  
; Sequence 25, Application US/09490153  
; Patent No. 6706484  
; GENERAL INFORMATION:  
; APPLICANT: Knappik, Achim  
; Pack, Peter  
; Ilag, Vic  
; Ge, Liming  
; Moroney, Simon  
; Plueckthun, Andreas  
; TITLE OF INVENTION: Protein/(poly)peptide libraries  
; NUMBER OF SEQUENCES: 373  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
; STREET: 1251 Avenue of the Americas  
; CITY: New York  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10021  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/490,324  
; FILING DATE: 24-Jan-2000  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: EP 95 11 3021.0  
; FILING DATE: 18-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: James F. Haley, Jr., Esq.  
; REGISTRATION NUMBER: 27,794  
; REFERENCE/DOCKET NUMBER: MORPHO/5  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 596-9000  
; TELEFAX: (212) 596-9090  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 118 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: <Unknown>  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:  
US-09-490-153-25  
  
Query Match 79.0%; Score 493.5; DB 2; Length 118;  
Best Local Similarity 84.0%; Pred. No. 1.2e-41;  
Matches 100; Conservative 3; Mismatches 13; Indels 3; Gaps 2;  
  
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGLVNWIRQPPGKLEWIGVISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVWSWIRQPPGKLEWIGIYHSGSTNY 59  
Qy 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYYCA--RYGRVFFDYWGQGTLLTVSS 117  
Db 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVYYCARGGGGVFDYWGQGTLLTVSS 118  
  
RESULT 14  
US-09-490-324-25  
; Sequence 25, Application US/09490324  
; Patent No. 6828422  
; GENERAL INFORMATION:  
; APPLICANT: Knappik, Achim  
; Pack, Peter  
; Ilag, Vic  
; Ge, Liming  
; Moroney, Simon  
; Plueckthun, Andreas  
; TITLE OF INVENTION: Protein/(poly)peptide libraries  
; NUMBER OF SEQUENCES: 373  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
; STREET: 1251 Avenue of the Americas  
; CITY: New York  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10021  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/490,324  
; FILING DATE: 24-Jan-2000  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: EP 95 11 3021.0  
; FILING DATE: 18-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: James F. Haley, Jr., Esq.  
; REGISTRATION NUMBER: 27,794  
; REFERENCE/DOCKET NUMBER: MORPHO/5  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 596-9000  
; TELEFAX: (212) 596-9090  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 118 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: <Unknown>  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:  
US-09-490-153-25

;  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/490,153  
; FILING DATE: 24-Jan-2000  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: US/09/025,769B  
; FILING DATE: 18-FEB-1998  
; APPLICATION NUMBER: EP 95 11 3021.0  
; FILING DATE: 18-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: James F. Haley, Jr., Esq.  
; REGISTRATION NUMBER: 27,794  
; REFERENCE/DOCKET NUMBER: MORPHO/5  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 596-9000  
; TELEFAX: (212) 596-9090  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 118 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: <Unknown>  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:  
US-09-490-153-25  
  
Query Match 79.0%; Score 493.5; DB 2; Length 118;  
Best Local Similarity 84.0%; Pred. No. 1.2e-41;  
Matches 100; Conservative 3; Mismatches 13; Indels 3; Gaps 2;  
  
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGLVNWIRQPPGKLEWIGVISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVWSWIRQPPGKLEWIGIYHSGSTNY 59  
Qy 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYYCA--RYGRVFFDYWGQGTLLTVSS 117  
Db 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVYYCARGGGGVFDYWGQGTLLTVSS 118  
  
RESULT 14  
US-09-490-324-25  
; Sequence 25, Application US/09490324  
; Patent No. 6828422  
; GENERAL INFORMATION:  
; APPLICANT: Knappik, Achim  
; Pack, Peter  
; Ilag, Vic  
; Ge, Liming  
; Moroney, Simon  
; Plueckthun, Andreas  
; TITLE OF INVENTION: Protein/(poly)peptide libraries  
; NUMBER OF SEQUENCES: 373  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
; STREET: 1251 Avenue of the Americas  
; CITY: New York  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10021  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/490,324  
; FILING DATE: 24-Jan-2000  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: EP 95 11 3021.0  
; FILING DATE: 18-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: James F. Haley, Jr., Esq.  
; REGISTRATION NUMBER: 27,794  
; REFERENCE/DOCKET NUMBER: MORPHO/5  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 596-9000  
; TELEFAX: (212) 596-9090  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 118 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: <Unknown>  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:  
US-09-490-153-25

APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212)596-9000  
TELEFAX: (212)596-9090  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 118 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 25:  
US-09-490-324-25

Query Match 79.0%; Score 493.5; DB 2; Length 118;  
Best Local Similarity 84.0%; Pred. No. 1.2e-41;  
Matches 100; Conservative 3; Mismatches 13; Indels 3; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKGLEWIGEYHSGSTNY 59  
QY 61 KPSLKDRTVISVDTSKNQFSLKLSVTAADTAVYYCA--RYGRVFPFDYWGQGLTVTVSS 117  
DB 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVYYCARGRGGGGVFDYWGQGLTVTVSS 118

RESULT 15  
US-08-918-148-79  
Sequence 79, Application US/08918148A  
Patent No. 6342220  
GENERAL INFORMATION:  
APPLICANT: W.  
APPLICANT: Adams, Camellia  
APPLICANT: Carter, Paul J.  
APPLICANT: Fendly, Brian M.  
APPLICANT: Gurney, Austin L.  
TITLE OF INVENTION: Agonist Antibodies  
FILE REFERENCE: P0979  
CURRENT APPLICATION NUMBER: US/08/918,148A  
CURRENT FILING DATE: 1997-08-25  
NUMBER OF SEQ ID NOS: 79  
SEQ ID NO 79  
LENGTH: 244  
TYPE: PRT  
ORGANISM: artificial  
US-08-918-148-79

Query Match 78.8%; Score 492.5; DB 2; Length 244;  
Best Local Similarity 83.8%; Pred. No. 3.7e-41;  
Matches 98; Conservative 7; Mismatches 9; Indels 3; Gaps 3;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60  
DB 3 QVQLQESGPGLVKPSSETLSLTCTVSGDSIS-SYYWSWIRQPPGKGLEWIGEYHSGSTNY 61  
QY 61 KPSLKDRTVISVDTSKNQFSLKLSVTAADTAVYYCARYGRVFPFDYWGQGLTVTVSS 117  
DB 62 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVYYCAR-GR-YFDVWGRGTWTVTVSS 116

Search completed: January 10, 2006, 20:58:05  
Job time : 22.847 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 80.7649 Seconds  
(without alignments)  
636.505 Million cell updates/sec

Title: US-10-735-916A-83  
Perfect score: 625  
Sequence: 1 QVQLGSGFGLVKPSETLSL.....RYGRVFDFYWGQGLVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_21.\*  
1: Geneseqp1980s:\*  
2: Geneseqp1990s:\*  
3: Geneseqp2000s:\*  
4: Geneseqp2001s:\*  
5: Geneseqp2002s:\*  
6: Geneseqp2003as:\*  
7: Geneseqp2003bs:\*  
8: Geneseqp2004s:\*  
9: Geneseqp2005s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	625	100.0	117	7	Adj76917 Anti-IGF-
2	625	100.0	117	9	Adj67087 Human ant
3	625	100.0	135	7	Adj76919 Anti-IGF-
4	625	100.0	135	9	Adj67089 Human ant
5	615	98.4	117	7	Adj76913 Anti-IGF-
6	615	98.4	117	9	Adj67083 Human ant
7	615	98.4	135	7	Adj76915 Anti-IGF-
8	615	98.4	135	9	Adj67085 Human ant
9	611	97.8	117	7	Adj76909 Anti-IGF-
10	611	97.8	117	9	Adj67079 Human ant
11	611	97.8	135	7	Adj76911 Anti-IGF-
12	611	97.8	135	9	Adj67081 Human ant
13	529	84.6	117	7	Adj76903 Anti-IGF-
14	529	84.6	117	9	Adj67073 Murine im
15	529	84.6	127	7	Adj76886 Anti-IGF-
16	529	84.6	127	9	Adj67056 Murine im
17	519.5	83.1	246	3	Aay15126 Anti-mur
18	517	82.7	119	7	Adp03973 Murine-ex
19	516.5	82.6	121	8	Adsl6559 Human ant
20	514.5	82.3	120	7	Adc27457 Humanised
21	513.5	82.2	122	7	Adp03885 Murine-ex
22	513.5	82.2	122	7	Adp03889 Murine-ex
23	512.5	82.0	120	7	Adp03958 Murine-ex
24	510.5	81.7	116	7	Adp03957 Murine-ex

25	510.5	81.7	121	5	ABB07171	Abb07171	ebvHlgM M
26	510.5	81.7	121	8	ADl26658	Human ant	Adl26658
27	510.5	81.7	122	7	ADp03887	Murine-ex	Adp03887
28	510.5	81.7	122	7	ADp03884	Murine-ex	Adp03884
29	510	81.6	119	2	AAw27554	Human Ab	Aaw27554
30	510	81.6	119	6	ABJ18676	Antibody	Abj18676
31	508	81.3	119	9	ADY74798	Human IGS	Ady74798
32	507	81.1	117	3	AAy44615	Human ant	Aay44615
33	507	81.1	121	7	ADe28455	Human ant	Ade28455
34	507	81.1	466	7	ADe28479	Human ant	Ade28479
35	507	81.1	580	6	AAO30915	di-NHS76	Aao30915
36	507	81.1	580	6	AAO30913	di-NHS76	Aao30913
37	505.5	80.9	122	9	AEa21456	Human ant	Aea21456
38	505.5	80.9	139	9	ADx98267	Human ant	Adx98267
39	504.5	80.7	121	8	ADS16505	Human ant	Ads16505
40	504.5	80.7	169	8	ADs16613	Human ant	Ads16613
41	504	80.6	121	7	ADe28491	Human ant	Ade28491
42	504	80.6	466	7	ADe28471	Human ant	Ade28471
43	503	80.5	121	9	ADx01828	SARS coro	Adx01828
44	503	80.5	123	7	ADP03870	Murine-ex	Adp03870
45	503	80.5	248	9	ADx01838	SARS coro	Adx01838

ALIGNMENTS

RESULT 1  
ADJ76917  
ID ADJ76917 standard; protein; 117 AA.  
XX  
AC ADJ76917;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-IR related protein #26.  
XX  
KW cytostatic; antipsooriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX Homo sapiens.  
XX  
PN WO2003059951-A2.  
XX  
PD 24-JUL-2003.  
XX  
PF 20-JAN-2003; 2003WO-FR000178.  
XX  
PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX  
(FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
PI Goetsch L, Corvaia N, Leger O;  
XX  
DR WPI; 2003-569653/53.  
XX  
PT New antibodies that bind to human insulin-like growth factor receptor,  
XX useful for treatment, prevention and diagnosis of cancers.  
XX  
PS Disclosure; SEQ ID NO 83; 164pp; French.  
XX  
CC The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit  
CC transformation of normal cells to tumor cells, inhibit growth and/or  
CC proliferation of tumor cells, so are useful against cancers of the  
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
CC protein sequence used to generate the Ab of the invention.  
XX  
SQ Sequence 117 AA;

Query Match 100.0%; Score 625; DB 7; Length 117;  
Best Local Similarity 100.0%; Pred. No. 1.9e-49;  
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKGLEWIGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKGLEWIGYISYDGTNNY 60

QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYTCARYGRVFFDYWGQGLTVTVSS 117  
DB 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYTCARYGRVFFDYWGQGLTVTVSS 117

RESULT 2  
ID ADZ67087 standard; protein; 117 AA.  
XX  
AC ADZ67087;  
XX  
DT 30-JUN-2005 (first entry)  
XX  
DE Human antibody 7C10 3 heavy chain variable region SEQ ID NO:83.  
XX  
KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
KW musculoskeletal disease; respiratory disease; lung tumor;  
KW endocrine disease; gynecology and obstetrics; breast tumor;  
KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
KW heavy chain variable region.  
XX  
OS Homo sapiens.  
XX  
PN US2005084906-A1.  
XX  
XX 21-APR-2005.  
XX  
XX 16-DEC-2003; 2003US-00735916.  
XX  
XX 18-JAN-2002; 2002FR-00000653.  
XX  
XX 18-JAN-2002; 2002FR-00000654.  
XX  
XX 07-MAY-2002; 2002FR-00005753.  
XX  
XX 20-JAN-2003; 2003WO-FR000178.  
XX  
XX 11-JUL-2003; 2003FR-00008538.  
XX  
XX (GOET/) GOETSCH L.  
XX  
XX (CORV/) CORVAIA N.  
XX  
XX (LEGE/) LEGER O.  
XX  
XX (DUPL/) DUFLOS A.  
XX  
XX (HAEU/) HAEUW J.  
XX  
XX (BECK/) BECK A.  
XX  
PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
XX  
XX WPI; 2005-321968/33.  
XX  
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
XX antibody or its functional fragment, being capable of binding human IGF-  
XX IR and specifically inhibiting tyrosine kinase activity of receptor,  
XX useful for treating cancer.  
XX  
PS Example 13; SEQ ID NO 83; 125pp; English.  
XX

CC The invention relates to a novel isolated anti-insulin-like growth factor  
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
CC capable of binding to human IGF-IR and, if necessary, capable of  
CC specifically inhibiting tyrosine kinase activity of the receptor,  
CC comprising a light or heavy chain having at least one complementary  
CC determining region (CDR) consisting of one of two fully defined 16 amino  
CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
CC the preparation of a medicament intended for the prevention or treatment  
CC of an illness connected with an overexpression and/or an abnormal  
CC activation of the IGF-IR and/or EGFR, and/or connected with a  
CC hyperactivation of the transduction pathway of the signal mediated by the  
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
CC the administration of the medicament does not induce or only slightly  
CC induces secondary effects connected with inhibition of the insulin  
CC receptor. The antibody is useful for preparation of a medicament intended  
CC to inhibit the transformation of normal cells into cells with tumoral  
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
CC dependent and/or EGF-dependent and/or HRP2/neu-dependent cells. (I) is  
CC useful for preparation of a medicament intended to inhibit the growth  
CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
CC HRP2/neu-dependent cells. (I) is useful in the preparation of a  
CC medicament intended for prevention or for the treatment of cancer, where  
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
CC preparation of a medicament intended for the prevention or for the  
CC treatment of psoriasis. (I) is useful in preparation of a medicament  
CC intended for the specific targeting of a biologically active compound to  
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
CC is useful for in vitro diagnosis of illnesses induced by an  
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
CC starting from a biological sample in which the abnormal presence, of IGF-  
CC IR and/or EGFR receptor is suspected, which involves contacting the  
CC biological sample with (I), which is optionally labeled. The present  
CC sequence is used in the exemplification of the invention.  
XX  
SQ Sequence 117 AA;

Query Match 100.0%; Score 625; DB 9; Length 117;  
Best Local Similarity 100.0%; Pred. No. 1.9e-49;  
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKGLEWIGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKGLEWIGYISYDGTNNY 60

QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYTCARYGRVFFDYWGQGLTVTVSS 117  
DB 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYTCARYGRVFFDYWGQGLTVTVSS 117

RESULT 3  
ADJ76919  
ID ADJ76919 standard; protein; 135 AA.  
XX  
AC ADJ76919;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-IR related protein #27.  
XX  
XX cytostatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX  
OS Homo sapiens.  
XX  
XX WO2003059951-A2.  
XX  
XX 24-JUL-2003.  
XX

PF 20-JAN-2003; 2003WO-FR000178.  
 XX 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
 PA  
 XX Goetsch L, Corvaia N, Leger O;  
 PI WPI; 2003-569653/53.  
 XX  
 DR New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.  
 PT  
 XX Disclosure; SEQ ID NO 85; 164pp; French.  
 PS  
 XX The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 135 AA;  
 Query Match 100.0%; Score 625; DB 7; Length 135;  
 Best Local Similarity 100.0%; Pred. No. 2.2e-49;  
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QVQLQESGPGLVKPKSTLTCTVSGYSISGGYLNWIRQPKGLEWIGYISYDGTNNY 60  
 DB 19 QVQLQESGPGLVKPKSTLTCTVSGYSISGGYLNWIRQPKGLEWIGYISYDGTNNY 78  
 QY 61 KPSLKDRTVISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYGQGLTLVTSS 117  
 DB 79 KPSLKDRTVISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYGQGLTLVTSS 135  
 RESULT 4  
 ID ADZ67089  
 XX ADZ67089 standard; protein; 135 AA.  
 AC ADZ67089;  
 XX  
 DT 30-JUN-2005 (first entry)  
 XX  
 DE Human antibody 7C10 3 heavy chain variable region SEQ ID NO:85.  
 XX  
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW heavy chain variable region.  
 XX  
 OS Homo sapiens.  
 XX  
 PH Location/Qualifiers  
 FT Key 1..18  
 FT Peptide /note= "leader peptide"  
 FT Region 49..54  
 FT /note= "CDR1"

FT Region 69..84  
 FT /note= "CDR2"  
 FT Region 117..124  
 FT /note= "CDR3"  
 XX  
 PN US2005084906-A1.  
 XX  
 XX 21-APR-2005.  
 XX  
 PF 16-DEC-2003; 2003US-00735916.  
 XX  
 PR 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 PR 20-JAN-2003; 2003WO-FR000178.  
 PR 11-JUL-2003; 2003FR-00008538.  
 XX  
 PA (GOET/) GOETSCH L.  
 PA (CORV/) CORVAIA N.  
 PA (LEGE/) LEGER O.  
 PA (DUFLO/) DUFLOS A.  
 PA (HAUW/) HAUW J.  
 PA (BECK/) BECK A.  
 XX  
 PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 WPI; 2005-321968/33.  
 XX  
 CC Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)  
 CC antibody or its functional fragment, being capable of binding human IGF-  
 CC IR and specifically inhibiting tyrosine kinase activity of receptor,  
 CC useful for treating cancer.  
 XX  
 PS Example 13; SEQ ID NO 85; 125pp; English.  
 XX  
 CC The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-1R) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-1R and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-1R and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent, and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-1R and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-1R and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.  
 XX  
 SQ Sequence 135 AA;



CC induces secondary effects connected with inhibition of the insulin  
CC receptor. The antibody is useful for preparation of a medicament intended  
CC to inhibit the transformation of normal cells into cells with tumoral  
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
CC useful for preparation of a medicament intended to inhibit the growth  
CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
CC especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or  
CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
CC medicament intended for prevention or for the treatment of cancer, where  
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
CC preparation of a medicament intended for the prevention or for the  
CC treatment of psoriasis. (II) is useful in preparation of a medicament  
CC intended for the specific targeting of a biologically active compound to  
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
CC is useful for in vitro diagnosis of illnesses induced by an  
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
CC starting from a biological sample in which the abnormal presence, of IGF-  
CC IR and/or EGFR receptor is suspected, which involves contacting the  
CC biological sample with (I), which is optionally labeled. The present  
CC sequence is used in the exemplification of the invention.

XX SQ Sequence 117 AA;  
Query Match 98.4%; Score 615; DB 9; Length 117;  
Best Local Similarity 98.3%; Pred. No. 1.6e-48;  
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60  
QY 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTLVTSS 117  
DB 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTLVTSS 117

RESULT 7  
ADJ76915  
ID ADJ76915 standard; protein; 135 AA.  
XX AC ADJ76915;  
XX DT 06-MAY-2004 (first entry)  
XX DE Anti-IGF-IR related protein #25.  
XX KW cytostatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX OS Homo sapiens.  
XX PN WO2003059951-A2.  
XX PD 24-JUL-2003.  
XX PF 20-JAN-2003; 2003WO-FR000178.  
XX PR 18-JAN-2002; 2002FR-00000653.  
XX PR 18-JAN-2002; 2002FR-00000654.  
XX PR 07-MAY-2002; 2002FR-00005753.  
XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX PA Goetsch L, Corvaia N, Leger O;  
XX PI WPI; 2003-569653/53.  
XX DR New antibodies that bind to human insulin-like growth factor receptor,  
XX PT

PT useful for treatment, prevention and diagnosis of cancers.  
XX Disclosure; SEQ ID NO 81; 164pp; French.

XX The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of  
CC these receptors with their ligands. Especially they inhibit  
CC transformation of normal cells to tumor cells, inhibit growth and/or  
CC proliferation of tumor cells, so are useful against cancers of the  
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
CC protein sequence used to generate the Ab of the invention.

XX SQ Sequence 135 AA;

Query Match 98.4%; Score 615; DB 7; Length 135;  
Best Local Similarity 98.3%; Pred. No. 1.8e-48;  
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60  
DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 78  
QY 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTLVTSS 117  
DB 79 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTLVTSS 135

RESULT 8  
ADZ67085  
ID ADZ67085 standard; protein; 135 AA.  
XX AC ADZ67085;  
XX DT 30-JUN-2005 (first entry)  
XX DE Human antibody 7C10 2 heavy chain variable region SEQ ID NO:81.  
XX KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
KW musculoskeletal disease; respiratory disease; lung tumor;  
KW endocrine disease; gynecology and obstetrics; breast tumor;  
KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
KW heavy chain variable region.

XX OS Homo sapiens.  
XX FH Key Location/Qualifiers  
FT Peptide 1..18  
FT /note= "leader peptide"  
FT Region 49..54  
FT /note= "CDR1"  
FT Region 69..84  
FT /note= "CDR2"  
FT Region 117..124  
FT /note= "CDR3"

XX US2005084906-A1.  
XX PD 21-APR-2005.  
XX PF 16-DEC-2003; 2003US-00735916.  
XX PR 18-JAN-2002; 2002FR-00000653.  
XX PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.  
PR 20-JAN-2003; 2003WO-FR000178.  
PR 11-JUL-2003; 2003FR-00008538.  
XX (GOET/) GOETSCH L.  
PA (CORV/) CORVAIA N.  
PA (LEGE/) LEGER O.  
PA (DUF/) DUFLOS A.  
PA (HAEU/) HAEUW J.  
PA (BECK/) BECK A.  
XX  
PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
XX WPI; 2005-321968/33.  
XX N-PSDB; ADZ67084.  
XX  
PT Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
PT antibody or its functional fragment, being capable of binding human IGF-  
PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
PT useful for treating cancer.  
XX  
PS Example 13; SEQ ID NO 81; 125pp; English.  
XX  
CC The invention relates to a novel isolated anti-insulin-like growth factor  
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
CC capable of binding to human IGF-IR and, if necessary, capable of  
CC specifically inhibiting tyrosine kinase activity of the receptor,  
CC comprising a light or heavy chain having at least one complementary  
CC determining region (CDR) consisting of one of two fully defined 16 amino  
CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
CC the preparation of a medicament intended for the prevention or treatment  
CC of an illness connected with an overexpression and/or an abnormal  
CC activation of the IGF-IR and/or EGFR, and/or connected with a  
CC hyperactivation of the transduction pathway of the signal mediated by the  
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
CC the administration of the medicament does not induce or only slightly  
CC induces secondary effects connected with inhibition of the insulin  
CC receptor. The antibody is useful for preparation of a medicament intended  
CC to inhibit the transformation of normal cells into cells with tumoral  
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
CC useful for preparation of a medicament intended to inhibit the growth  
CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
CC medicament intended for prevention or for the treatment of cancer, where  
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
CC preparation of a medicament intended for the prevention or for the  
CC treatment of psoriasis. (I) is useful in preparation of a medicament  
CC intended for the specific targeting of a biologically active compound to  
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
CC is useful for in vitro diagnosis of illnesses induced by an  
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
CC starting from a biological sample in which the abnormal presence, of IGF-  
CC IR and/or EGFR receptor is suspected, which involves contacting the  
CC biological sample with (I), which is optionally labeled. The present  
CC sequence is used in the exemplification of the invention.  
XX  
SQ Sequence 135 AA;  
  
Query Match 98.4%; Score 615; DB 9; Length 135;  
Best Local Similarity 98.3%; Pred. No. 1.8e-48;  
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78  
  
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAIVYICARYGRVFFDYWGQGLTVTVSS 117  
DB 79 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAIVYICARYGRVFFDYWGQGLTVTVSS 135

RESULT 9  
ADJ76909  
ID ADJ76909 standard; protein; 117 AA.  
XX  
AC ADJ76909;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-IR related protein #22.  
XX  
XX cytostatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX  
XX Homo sapiens.  
XX  
XX WO2003059951-A2.  
XX  
XX PD 24-JUL-2003.  
XX  
XX PF 20-JAN-2003; 2003WO-FR000178.  
XX  
XX PR 18-JAN-2002; 2002FR-00000653.  
XX PR 18-JAN-2002; 2002FR-00000654.  
XX PR 07-MAY-2002; 2002FR-00005753.  
XX  
XX PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
XX PI Goetsch L, Corvaia N, Leger O;  
XX WPI; 2003-569653/53.  
XX  
XX PT New antibodies that bind to human insulin-like growth factor receptor,  
XX useful for treatment, prevention and diagnosis of cancers.  
XX  
XX PS Disclosure; SEQ ID NO 75; 164pp; French.  
XX  
CC The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of  
CC these receptors with their ligands. Especially they inhibit  
CC transformation of normal cells to tumor cells, inhibit growth and/or  
CC proliferation of tumor cells, so are useful against cancers of the  
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
CC protein sequence used to generate the Ab of the invention.  
XX  
SQ Sequence 117 AA;  
  
Query Match 97.8%; Score 611; DB 7; Length 117;  
Best Local Similarity 96.6%; Pred. No. 3.7e-48;  
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
  
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAIVYICARYGRVFFDYWGQGLTVTVSS 117  
DB 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAIVYICARYGRVFFDYWGQGLTVTVSS 117  
  
RESULT 10  
ADZ67079

ID AD267079 standard; protein; 117 AA.  
XX AC AD267079;  
XX DT 30-JUN-2005 (first entry)  
XX DE Human antibody 7C10 1 heavy chain variable region SEQ ID NO:75.  
XX DE Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
KW musculoskeletal disease; respiratory disease; lung tumor;  
KW endocrine disease; gynecology and obstetrics; breast tumor;  
KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
KW heavy chain variable region.  
XX OS Homo sapiens.  
XX XX US2005084906-A1.  
XX PN US2005084906-A1.  
XX PD 21-APR-2005.  
XX PF 16-DEC-2003; 2003US-00735916.  
XX PR 18-JAN-2002; 2002FR-00000653.  
XX PR 18-JAN-2002; 2002FR-00000654.  
XX PR 07-MAY-2002; 2002FR-00005753.  
XX PR 20-JAN-2003; 2003WO-FR000178.  
XX PR 11-JUL-2003; 2003FR-00008538.  
XX PA (GOET/) GOETSCH L.  
XX PA (CORV/) CORVAIA N.  
XX PA (LEGE/) LEGER O.  
XX PA (DUFL/) DUFLOS A.  
XX PA (HAUW/) HAEUW J.  
XX PA (BECK/) BECK A.  
XX PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
XX WPI; 2005-321968/33.  
XX DR Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
XX PT antibody or its functional fragment, being capable of binding human IGF-  
XX PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
XX PT useful for treating cancer.  
XX PS Example 13; SEQ ID NO 75; 125pp; English.  
XX CC The invention relates to a novel isolated anti-insulin-like growth factor  
XX CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
XX CC capable of binding to human IGF-IR and, if necessary, capable of  
XX CC specifically inhibiting tyrosine kinase activity of the receptor,  
XX CC comprising a light or heavy chain having at least one complementary  
XX CC determining region (CDR) consisting of one of two fully defined 16 amino  
XX CC acids (AD267006 and AD267014). An antibody of the invention is useful in  
XX CC the preparation of a medicament intended for the prevention or treatment  
XX CC of an illness connected with an overexpression and/or an abnormal  
XX CC activation of the IGF-IR and/or EGFR, and/or connected with a  
XX CC hyperactivation of the transduction pathway of the signal mediated by the  
XX CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
XX CC the administration of the medicament does not induce or only slightly  
XX CC induces secondary effects connected with inhibition of the insulin  
XX CC receptor. The antibody is useful for preparation of a medicament intended  
XX CC to inhibit the transformation of normal cells into cells with tumoral  
XX CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
XX CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
XX CC useful for preparation of a medicament intended to inhibit the growth  
XX CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
XX CC especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or  
XX CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
XX CC medicament intended for prevention or for the treatment of cancer, where  
XX CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
XX CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the

CC preparation of a medicament intended for the prevention or for the  
CC treatment of psoriasis. (I) is useful in preparation of a medicament  
CC intended for the specific targeting of a biologically active compound to  
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
CC is useful for in vitro diagnosis of illnesses induced by an  
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
CC starting from a biological sample in which the abnormal presence, of IGF-  
CC IR and/or EGFR receptor is suspected, which involves contacting the  
CC biological sample with (I), which is optionally labeled. The present  
CC sequence is used in the exemplification of the invention.  
XX XX Sequence 117 AA;  
XX Query Match 97.8%; Score 611; DB 9; Length 117;  
XX Best Local Similarity 96.6%; Pred. No. 3.7e-48;  
XX Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGVLWNWIRQPPGKLEWIGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGVLWNWIRQPPGKLEWIGYISYDGTNNY 60  
QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117  
DB 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117  
RESULT 11  
ADJ76911  
ID ADJ76911 standard; protein; 135 AA.  
XX AC ADJ76911;  
XX DT 06-MAY-2004 (first entry)  
XX DE Anti-IGF-IR related protein #23.  
XX KW cytostatic; antipsoriatic; antibody;  
XX KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
XX KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
XX KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
XX KW CDR.  
XX OS Homo sapiens.  
XX XX WO2003059951-A2.  
XX PN WO2003059951-A2.  
XX PD 24-JUL-2003.  
XX PF 20-JAN-2003; 2003WO-FR000178.  
XX PR 18-JAN-2002; 2002FR-00000653.  
XX PR 18-JAN-2002; 2002FR-00000654.  
XX PR 07-MAY-2002; 2002FR-00005753.  
XX PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX PI Goetsch L, Corvaia N, Leger O;  
XX WPI; 2003-569653/53.  
XX DR New antibodies that bind to human insulin-like growth factor receptor,  
XX PT useful for treatment, prevention and diagnosis of cancers.  
XX PS Disclosure; SEQ ID NO 77; 164pp; French.  
XX CC The invention relates to an isolated antibody (Ab), and its functional  
XX CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
XX CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
XX CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
XX CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
XX CC treat diseases associated with overexpression and/or abnormal activity of  
XX CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with  
XX CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.

XX Sequence 135 AA;

Query Match 97.8%; Score 611; DB 7; Length 135;  
 Best Local Similarity 96.6%; Pred. No. 4.3e-48;  
 Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60

Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWGWYISYDGTNNY 78

Qy 61 KPSLKDRVTISVDTSKNQFSLKLSSTVAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117

Db 79 KPSLKDRITISRDTSKNQFSLKLSSTVAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 12

ADZ67081

ID ADZ67081 standard; protein; 135 AA.

AC ADZ67081;

DT 30-JUN-2005 (first entry)

XX Human antibody 7C10 1 heavy chain variable region SEQ ID NO:77.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW heavy chain variable region.

OS Homo sapiens.

XX Key Location/Qualifiers

PH Peptide 1..18 "leader peptide"

FT Region 49..54

FT Region 49..54 /note= "CDR1"

FT Region 69..84

FT Region 69..84 /note= "CDR2"

FT Region 117..124

FT Region 117..124 /note= "CDR3"

XX US2005084906-A1.

FN 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR0001178.

PR 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

PA (CORV/) CORVAIA N.

PA (LEGE/) LEGER O.

PA (DUFL/) DUFLOS A.

PA (HAEU/) HAEUW J.

PA (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX WPI; 2005-321968/33.  
 DR N-PSDB; ADZ67080.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 FT antibody or its functional fragment, being capable of binding human IGF-  
 FT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 FT useful for treating cancer.

XX Example 13; SEQ ID NO 77; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor.  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HIR2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

XX Sequence 135 AA;

Query Match 97.8%; Score 611; DB 9; Length 135;  
 Best Local Similarity 96.6%; Pred. No. 4.3e-48;  
 Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60

Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWGWYISYDGTNNY 78

Qy 61 KPSLKDRVTISVDTSKNQFSLKLSSTVAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117

Db 79 KPSLKDRITISRDTSKNQFSLKLSSTVAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 13

ADJ76903

ID ADJ76903 standard; protein; 117 AA.

XX AC ADJ76903;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #16.

XX KW cytostatic; antipsoriatic; antibody;

KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003059951-A2.  
 XX  
 PD 24-JUL-2003.  
 XX  
 XX 20-JAN-2003; 2003WO-FR000178.  
 XX  
 PR 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 XX  
 PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
 XX  
 PI Goetsch L, Corvaia N, Leger O;  
 XX  
 DR WPI; 2003-569653/53.  
 XX  
 PT New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.  
 XX  
 PS Disclosure; SEQ ID NO 69; 164pp; French.  
 XX  
 CC The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC IR) and optionally; (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 117 AA;  
 Query Match 84.6%; Score 529; DB 7; Length 117;  
 Best Local Similarity 82.8%; Pred. No. 1.2e-40;  
 Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;  
 QY 2 VOLQSGGLVLPKPSLTLCTVSGYSISGGYLMNWIROPKGLWIGYISYDGTNNYK 61  
 DB 2 VOLQSGGLVLPKPSGLSLTCSVTGYISITGGYLMNWIQFPGNKLEWGWYISYDGTNNYK 61  
 QY 62 PSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYGQSTLTVTS 117  
 DB 62 PSLKDRISITRDTSKNQPFKLNSVTNEDTATYYCARYGRVFFDYGQSTLTVTS 117  
 RESULT 14  
 ADZ67073  
 ID ADZ67073 standard; protein; 117 AA.  
 XX  
 AC ADZ67073;  
 XX  
 DT 30-JUN-2005 (first entry)  
 XX  
 DE Murine immunoglobulin heavy chain variable region 7C10 VH SEQ ID NO:69.  
 XX  
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
 KW antiporiatic; psoriasis; dermatological disease; immune disorder;  
 KW immunoglobulin; heavy chain variable region.  
 OS Mus musculus.  
 XX  
 PN US2005084906-A1.  
 XX  
 PD 21-APR-2005.  
 XX  
 XX 16-DEC-2003; 2003US-00735916.  
 XX  
 PR 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 PR 20-JAN-2003; 2003WO-FR000178.  
 PR 11-JUL-2003; 2003FR-00008538.  
 XX  
 PA (GOET/) GOETSCH L.  
 PA (CORV/) CORVAIA N.  
 PA (LEGE/) LEGER O.  
 PA (DUFL/) DUFLOS A.  
 PA (HAEU/) HAEUW J.  
 PA (BECK/) BECK A.  
 XX  
 PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 XX  
 DR WPI; 2005-321968/33.  
 XX  
 CC Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)  
 CC antibody or its functional fragment, being capable of binding human IGF-  
 CC IR and specifically inhibiting tyrosine kinase activity of receptor,  
 CC useful for treating cancer.  
 XX  
 PS Example 13; SEQ ID NO 69; 125pp; English.  
 XX  
 CC The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-1R) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-1R and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (AD267006 and AD267014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-1R and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer, where  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-1R and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-1R and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.  
 XX  
 SQ Sequence 117 AA;

Query Match 84.6%; Score 529; DB 9; Length 117;  
Best Local Similarity 82.8%; Pred. No. 1.2e-40;  
Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;  
Qy 2 VOLQESGPGLVKPSQSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61  
Db 2 VOLQESGPGLVKPSQSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61  
Qy 62 PSLKDRVTISVDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGTTLTVSS 117  
Db 62 PSLKDRISITRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGTTLTVSS 117

## RESULT 15

ADJ76886  
ID ADJ76886 standard; protein; 127 AA.

XX AC ADJ76886;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-1R related protein #4.

XX KW cytostatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
XX CDR.

XX OS Mus musculus.

XX PN WO2003059951-A2.

XX PD 24-JUL-2003.

XX PF 20-JAN-2003; 2003WO-PR000178.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX PA (FABR ) FABRE MEDICAMENT SA PIERRE.

XX PI Goetsch L, Corvaia N, Leger O;

XX DR WPI; 2003-569653/53.

XX PT New antibodies that bind to human insulin-like growth factor receptor,  
XX useful for treatment, prevention and diagnosis of cancers.

XX PS Disclosure; SEQ ID NO 52; 164pp; French.

XX CC The invention relates to an isolated antibody (Ab), and its functional  
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
XX 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
XX treat diseases associated with overexpression and/or abnormal activity of  
XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
XX hyperactivity of signal transduction pathways mediated by interaction of  
XX these receptors with their ligands. Especially they inhibit  
XX transformation of normal cells to tumor cells, inhibit growth and/or  
XX proliferation of tumor cells, so are useful against cancers of the  
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
XX also for treating psoriasis. Ab are also used to diagnose diseases caused  
XX by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
XX protein sequence used to generate the Ab of the invention.

XX SQ Sequence 127 AA;

Query Match 84.6%; Score 529; DB 7; Length 127;  
Best Local Similarity 82.8%; Pred. No. 1.3e-40;

Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;  
Qy 2 VOLQESGPGLVKPSQSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61  
Db 12 VOLQESGPGLVKPSQSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNYK 71  
Qy 62 PSLKDRVTISVDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGTTLTVSS 117  
Db 72 PSLKDRISITRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGTTLTVSS 127

Search completed: January 10, 2006, 20:44:18  
Job time : 81.7649 secs



F:20-102/Domain: immunoglobulin homology <IMM>

Query Match 80.6%; Score 504; DB 2; Length 130;  
Best Local Similarity 80.2%; Pred. No. 1.2e-38;  
Matches 101; Conservative 5; Mismatches 10; Indels 10; Gaps 3;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
Db QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYYWSWSRQPPGKLEWIGYIYSGSTNY 64  
QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYCAR-----YGRV--FFDYWGQGT 111  
Db 65 NPSLKSRVTISVDTSKNQFSLKLSVTAADTAATVYCARSSVLLWFGELLYFDYWGQGT 124  
QY 112 LTVSS 117  
Db 125 LTVSS 130

RESULT 3  
S30530  
Ig heavy chain V region - human  
C:Species: Homo sapiens (man)  
C:Date: 03-Mar-1994 #sequence\_revision 10-Nov-1995 #text\_change 16-Aug-1996  
C:Accession: S30530  
R:Marlette, X.  
submitted to the EMBL Data Library, October 1992  
A:Reference number: S30520  
A:Accession: S30530  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-123 <MAR>  
A:Cross-references: UNIPARC:UPI0000176C83; EMBL:Z18116  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 78.6%; Score 491; DB 2; Length 123;  
Best Local Similarity 79.0%; Pred. No. 1.7e-37;  
Matches 98; Conservative 6; Mismatches 12; Indels 8; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYWGIRQPPGKLEWIGSMFHSGSVY 60  
QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYCARGV-----FFDYWGQGTILV 113  
Db 61 NPSLKSRVTISVDTSKNQFSLQLRSVTAADTAATVYCAR-GRYCSSTSCNWFDPWGQGTILV 119  
QY 114 TVSS 117  
Db 120 TVSS 123

RESULT 4  
S13519  
Ig heavy chain V region precursor - human  
C:Species: Homo sapiens (man)  
C:Date: 25-Feb-1994 #sequence\_revision 10-Nov-1995 #text\_change 23-Jul-1999  
C:Accession: S13519  
R:Mortari, F.; Ochs, H.D.; Wedgwood, R.J.P.; Schroeder Jr., H.W.  
Nucleic Acids Res. 19, 673, 1991  
A:Title: Immunoglobulin variable heavy chain cDNA sequence from a patient with X-linked  
A:Reference number: S13519; MUID:91187691; PMID:2011536  
A:Accession: S13519  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-147 <MOR>  
A:Cross-references: UNIPARC:UPI0000115EB5; EMBL:X56158; NID:G37724; PIDN:CAA39626.1; PID  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:41-125/Domain: immunoglobulin homology <IMM>

Query Match 78.1%; Score 488; DB 2; Length 147;  
Best Local Similarity 81.1%; Pred. No. 3.8e-37;  
Matches 99; Conservative 4; Mismatches 13; Indels 6; Gaps 3;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSI-SGGYLNWIRQPPGKLEWIGYISYDGTNN 59  
Db 27 QVQLQESGPGLVKPSSETLSLTCTVSGGISISSYYWGIRQPPGKLEWIGSIYSGSTY 86  
QY 60 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYCAR---YGRVFFDYWGQGTILTV 115  
Db 87 YNPSLKSRVTISVDTSKNQFSLKLSVTAADTAATVYCARPLLWFGEL-FDYWGQGTILTV 145  
QY 116 SS 117  
Db 146 SS 147

RESULT 5  
S31511  
Ig heavy chain - human  
C:Species: Homo sapiens (man)  
C:Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 23-Jul-1999  
C:Accession: S31511  
R:Chastagner, P.; Demaison, C.; Theze, J.; Zouali, M.  
submitted to the EMBL Data Library, December 1992  
A:Description: Dominance of clonotypic patterns and variable gene usage of anti-DNA auto  
A:Reference number: S31509  
A:Accession: S31511  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-155 <CHA>  
A:Cross-references: UNIPARC:UPI00001160FF; EMBL:X69866; NID:G33094; PIDN:CAA49500.1; PIC  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:47-129/Domain: immunoglobulin homology <IMM>

Query Match 76.5%; Score 478; DB 2; Length 155;  
Best Local Similarity 78.2%; Pred. No. 3.2e-36;  
Matches 97; Conservative 6; Mismatches 13; Indels 8; Gaps 3;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
Db 33 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYYMSWIRQPPGKLEWIGYIYTGSAFY 91  
QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYCARGV--FFDY-----WCQGTILV 113  
Db 92 NPPLKSRVTISVDTSKNQFSLKVSSTVTAADTAATVYCARGGGSISSWIDYIGMDVWGQGTIV 151  
QY 114 TVSS 117  
Db 152 TVSS 155

RESULT 6  
S24443  
Ig heavy chain V region (VH4DJ) - human  
C:Species: Homo sapiens (man)  
C:Date: 22-Jan-1993 #sequence\_revision 22-Jan-1993 #text\_change 20-Jun-2000  
C:Accession: S24443; S19667  
R:Jones, P.T.  
submitted to the EMBL Data Library, October 1991  
A:Reference number: S24442  
A:Accession: S24443  
A:Molecule type: mRNA  
A:Residues: 1-118 <JON>  
A:Cross-references: UNIPARC:UPI0000115FE9; EMBL:X61650; NID:G37720; PIDN:CAA43831.1; PII  
R:Marks, J.D.; Hoogenboom, H.R.; Bonnett, T.P.; McCafferty, J.; Griffiths, A.D.; Winter,  
J. Mol. Biol. 222, 581-597, 1991  
A:Title: By-passing immunization. Human antibodies from V-gene libraries displayed on p  
A:Reference number: S19663; MUID:92085276; PMID:1748994  
A:Accession: S19667  
A:Molecule type: mRNA  
A:Residues: 1-55, 57-118 <MAR>





Search completed: January 10, 2006, 20:55:16  
Job time : 15.1157 secs

Query Match 74.6%; Score 466; DB 2; Length 140;

RESULT 15

S78051  
IG heavy chain precursor V-D-J region (clone mAB 61VH) - human (fragment)  
C/Species: Homo sapiens (man)  
C/Date: 19-Nov-1997 #sequence\_revision 05-Dec-1997 #text\_change 23-Jul-1999  
C/Accession: S78051; S23716  
R/Harindranath, N.  
submitted to the EMBL Data Library, August 1990  
A/Reference number: S78051  
A/Accession: S78051  
A/Molecule type: mRNA  
A/Residues: 1-135 <HAR>  
A/Cross-references: UNIPARC:UPT0000115E87; EMBL:X54437; NID:g37814; PIDN:CAA38306.1; PID  
R/Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Burastero, S.E.; Wilder, R.L.; Nockings  
Int. Immunol. 3, 865-875, 1991  
A/Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and H  
patient.

Reference number: S23716; MUID:92031262; PMID:1718404

Query Match	74.4%	Score 465	DB 2	Length 135
-------------	-------	-----------	------	------------

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:26:41 ; Search time 78.8731 Seconds  
(without alignments)  
1046.577 Million cell updates/sec

Title: US-10-735-916A-83  
Perfect score: 625  
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGLVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt\_05.80.\*

1: uniprot\_eprot.\*

2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	496	79.4	119	2	Q9UL73 HUMAN
2	493.5	79.0	465	2	Q6GMX6 HUMAN
3	473	75.7	476	2	Q6GMX1 HUMAN
4	468.5	75.0	477	2	Q6GMX7 HUMAN
5	464.5	74.3	150	2	Q95973 HUMAN
6	464.5	74.3	576	2	Q6P418 HUMAN
7	459	73.4	479	2	Q99M22 MOUSE
8	457.5	73.2	620	2	Q96EY0 HUMAN
9	448.5	71.8	478	2	Q72379 HUMAN
10	448	71.7	492	2	Q72374 HUMAN
11	444.5	71.1	139	2	Q86SX2 HUMAN
12	444.5	71.1	496	2	Q96KX8 HUMAN
13	443.5	71.0	136	2	Q6LBU5 MOUSE
14	443.5	71.0	483	2	Q5U413 MOUSE
15	442	70.7	137	1	HV46 MOUSE
16	435	69.6	119	2	Q53VQ5 MOUSE
17	434	69.4	595	2	Q8WUX4 HUMAN
18	434	69.4	597	2	Q9BU10 HUMAN
19	434	69.4	597	2	Q6GMX5 HUMAN
20	434	69.4	625	2	Q6GAA6 HUMAN
21	433.5	69.4	146	1	HV21 HUMAN
22	432	69.1	597	2	Q9QB8 HUMAN
23	423.5	67.8	130	2	Q81ZD7 HUMAN
24	421	67.4	115	2	Q53VQ1 MOUSE
25	419	67.0	478	2	Q6NYH3 HUMAN
26	418.5	67.0	120	2	Q53VR7 MOUSE
27	418	66.9	615	2	Q569B6 RATTUS NORV
28	416	66.6	590	2	Q569B8 RATTUS NORV
29	413	66.1	119	2	Q53VR3 MOUSE
30	412	65.9	117	1	HV2G HUMAN
31	409	65.4	116	1	HV60_MOUSE

32	403.5	64.6	116	2	Q723Y6 HUMAN	Q723Y6 homo sapien
33	403	64.5	98	2	Q53VQ4_MOUSE	Q53VQ4 mus musculus
34	402	64.3	129	1	HV2F HUMAN	P01824 homo sapien
35	400	64.0	476	2	Q6MZX7 HUMAN	Q6mzx7 homo sapien
36	397.5	63.6	122	2	Q9UL75 HUMAN	Q9ul75 homo sapien
37	396	63.4	119	2	Q53VQ9_MOUSE	Q53VQ9 mus musculus
38	396	63.4	477	2	Q510J1_RAT	Q510j1 rattus norv
39	395.5	63.3	473	2	Q8TC63_HUMAN	Q8tc63 homo sapien
40	390	62.4	98	2	Q53VR6_MOUSE	Q53VR6 mus musculus
41	386.5	61.8	591	2	Q510L9_RAT	Q510l9 rattus norv
42	386	61.8	98	2	Q53VQ0_MOUSE	Q53VQ0 mus musculus
43	385	61.6	98	2	Q53VR2_MOUSE	Q53VR2 mus musculus
44	385	61.6	469	2	Q5M839_RAT	Q5m839 rattus norv
45	381	61.0	113	1	HV47_MOUSE	P01823 mus musculus

ALIGNMENTS

RESULT 1  
Q9UL73\_HUMAN PRELIMINARY; PRT; 119 AA.  
AC Q9UL73;  
DT 01-MAY-2000 (Tremblrel. 13, Created)  
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)  
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)  
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;  
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,  
RA Young D.C.;  
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus."  
RL Clin. Immunol. Immunopathol. 87:184-192(1998).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=1660528;  
RA Manheimer-Lory A., Katz J.B., Pillingner M., Ghossein C., Smith A., Diamond B.;  
RT "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype."  
RL J. Exp. Med. 174:1639-1652(1991).  
RN [3]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=2511001;  
RA Sanz I., Kelly P., Williams C., Scholl S., Tucker P., Capra J.D.;  
RT "The smaller human VH gene families display remarkably little polymorphism."  
RL EMBO J. 8:3741-3748(1989).  
DR EMBL; AF035041; AAD56277.1; -, mRNA.  
DR PIR; PH0876; PH0876.  
DR PIR; S12416; S12416.  
DR HSRF; P01820; IGJ1.  
DR SMR; Q9UL73; 1-119.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003596; Ig\_v.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS50835; IG\_LIKE; 1.  
FT NON\_TER 1  
FT NON\_TER 119  
SQ SEQUENCE 119 AA; 13219 MW; 1BDB86B6420A0BE CRC64;

Query Match 79.4%; Score 496; DB 2; Length 119;  
Best Local Similarity 80.8%; Pred No. 2.6e-42;  
Matches 97; Conservative 7; Mismatches 12; Indels 4; Gaps 2;

```

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGSIC-SYYWSWIRQPPGKLEWIGVIYISGSTNY 59
Qy 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYICAR--YGRVFFDYWGQGLTIVTSS 117
Db 60 TPSLSKRSVTISVDTSKNQFSLKLSLTAAVTAVYFCARLSNMGPFYFDYWGQGLTIVTSS 119

RESULT 2
O6GMX6 HUMAN
ID O6GMX6 HUMAN PRELIMINARY; PRT; 465 AA.
AC O6GMX6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M.J., Udwin T.B., Toshlyuki S., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Raha S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Bobak S.A., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Buttefield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences.";
RL proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073766; AAH73766.1; -, mRNA.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS0835; IG LIKE; 4.
DR PROSITE; PS0290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 465 AA; 51083 MW; B3A9B7D0FDB1386E CRC64;

Query Match 79.0%; Score 493.5; DB 2; Length 465;
Best Local Similarity 83.8%; Pred. No. 2.1e-41;
Matches 98; Conservative 4; Mismatches 14; Indels 1; Gaps 1;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 60

```

```

Db 20 QVQLQESGPGLVKPSSETLSLTCTVSGSIS-GYYWSWIRQPPGKLEWIGRIYTSSTNY 78
Qy 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYICARVGRVFDYWGQGLTIVTSS 117
Db 79 NPSLSKRSVTISVDTSKNQFSLKLSVTAADTAVYICARGRTYFDYWGQGLTIVTSS 135

RESULT 3
O6GMX1 HUMAN
ID O6GMX1 HUMAN PRELIMINARY; PRT; 476 AA.
AC O6GMX1;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshlyuki S., Carninci P., Prange C.,
RA Raha S.A., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Brownstein M.J., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bobak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Buttefield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences.";
RL proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073773; AAH73773.1; -, mRNA.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR InterPro; IPR003599; IG-like.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS0835; IG LIKE; 4.
DR PROSITE; PS0290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 476 AA; 52286 MW; 622AABA5C62DDE9D CRC64;

Query Match 75.7%; Score 473; DB 2; Length 476;
Best Local Similarity 74.8%; Pred. No. 2.6e-39;
Matches 95; Conservative 10; Mismatches 12; Indels 10; Gaps 3;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGSYISGG-YLWNIWIRQPPGKLEWIGVISYDGTNN 59
Db 20 QVQLQESGPGLVKPSSETLSLTCTVSGSISGDIYWSWIRQPPGKLEWIGIYISGSTY 79

```

Qy	60	YPSLKDRTVISVDFSKNQPSLKLSSTVTAADTAVYCYARG----	RVF-----FDYWGOG	110
		: :	: :	
Db	80	YNPSLKSRVTISLDTSKNQFSLKQNSVTAADTAVYFCARAGVMS	FRSWAIDGFINWGOG	139
Qy	111	TLTVTVSS	117	
		: :	: :	
Db	140	TWTVTVSS	146	

RESULT 4				
ID	Q6GMX7 HUMAN PRELIMINARY;	PRT;	477 AA.	
AC	Q6GMX7;			
DT	05-JUL-2004 (TrEMBLrel. 27, Created)			
DT	05-JUL-2004 (TrEMBLrel. 27, Last sequence update)			
DT	05-JUL-2004 (TrEMBLrel. 27, Last annotation update)			
DE	Hypothetical protein.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;			
OC	Homo.			
NCBI	NCBI_TaxID=9606;			
1]	NUCLEOTIDE SEQUENCE.			
RP	TISSUE=Primary B-Cells;			
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;			
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,			
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,			
RA	Altschul S.P., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,			
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heish F.,			
RA	Diatchenko L., Marusina K., Farmer A.F., Rubin G.M., Hong L.,			
RA	Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,			
RA	Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,			
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,			
RA	Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,			
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,			
RA	Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,			
RA	Fahney J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,			
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,			
RA	Blakesley R.W., Touchman J.W., Green E.D., Dixon M.C.,			
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,			
RA	Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalls D.E.,			
RA	Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;			
RT	"Generation and initial analysis of more than 15,000 full-length human			
RT	and mouse cDNA sequences."			
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).			
RL	12]			

RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Primary B-Cells;  
RA Strausberg R.;  
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.  
RR EMBL; BC073765; AAH3765.1; -; mRNA.  
DR SMR; Q6GMX7; 247-455.  
GO; GO:0016021; C:Integral to membrane; IEA.  
DR InterPro; IPR003599; IG.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003597; IG cl.  
DR InterPro; IPR003006; IG\_MHC.  
DR InterPro; IPR003596; IG\_v.  
DR Pfam; PF07654; Cl-set; 2.  
DR SMART; SM00409; IG; 4.  
DR SMART; SM00407; IGC1; 3.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS50835; IG\_LIKE; 4.  
DR PROSITE; PS00290; IG\_MHC; UNKNOWN 2.  
KW Hypothetical protein.  
SQ SEQUENCE 477 AA; 51631 MW; 9F859C09C50CFF85 CRC64;

Query Match 75.0%; Score 468.5; DB 2; Length 477;  
Best Local Similarity 78.3%; Pred. No. 7.4e-39;  
Matches 94; Conservative 9; Mismatches 12; Indels 5; Gaps 3;  
QY 1 QVQLQESGGPGLVKPSETLSLTCTVTSYGISGCVLNNWIROPFGKLEWIGVISYDGTNNY 60

[illegible]

RESULT 5	
O95973 HUMAN	
ID	O95973 HUMAN PRELIMINARY; PRT; 150 AA.
AC	O95973;
DT	01-MAY-1999 (TtEMBLrel. 10, Created)
DT	01-MAY-1999 (TtEMBLrel. 10, Last sequence update)
DT	01-MAR-2004 (TtEMBLrel. 26, Last annotation update)
DE	VH4 heavy chain variable region precursor (Fragment).
GN	Names:IGM;
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC	Homo.
OX	NCBI_TaxID=9606;
RN	[1]
RP	NUCLEOTIDE SEQUENCE.
RA	Suh C.-H., Song C.-H., Lee C.-H., Lee S.-K.;
RT	"Clonal proliferation of IGM secreting B cell in the synovium of
RT	Behcet's patient with arthritis.;"
RL	Submitted (OCT-1998) to the EMBL/GenBank/DBJ databases.
RP	[2]
RP	NUCLEOTIDE SEQUENCE.
RX	PubMed=1718404;
RA	Harindranath N., Goldfarb I.S., Ikematsu H., Burastero S.E.,
RA	Wilder R.L., Notkins A.L., Casali P.;
RT	"Complete sequence of the genes encoding the VH and VL regions of low-
RT	and high-affinity monoclonal IGM and IgA1 rheumatoid factors produced
RT	by CD5+ B cells from a rheumatoid arthritis patient.;"
RL	Int. Immunol. 3:865-875(1991).
DR	EMBL; AF103795; AAC79084.1; -; mRNA.
DR	PIR; S31673; S31673.
DR	PIR; S78056; S78056.
DR	HSP; P01820; IG7J.
DR	SMR; O95973; 20-147.
DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003596; Ig_v.
DR	SMART; SM00406; IGV; 1.
DR	PROSITE; PS50835; IG_LIKE; 1.
KW	Signal.
FT	SIGNAL 1 19 Potential.
FT	CHAIN 20 >150 VH4 heavy chain variable region.
FT	NON TER 150 150
SO	SEQUENCE 150 AA; 16315 MW; 85664E04938AA7C9 CRC64;

Query Match	74.3%	Score	464.5;	DB	2;	Length	150;	
Best Local Similarity	77.1%;	Pred.	No. 5.4e-39;					
Matches	91;	Conservative	8;	Mismatches	18;	Indels	1; Gaps	1;

  

Qy	1	QVQLQSGLPGLVPSETLSLTCTVSGYSISG-GYLNNWIRPPCKGLEWIGYISYDGTNN	59
	:	:::::	:::
	:	:::::	:::
Db	20	QLQLQSGLPGLVPSETLSLTCTVSGGISSTYYMGWIRPPCKGLEWIGSLHNSGDY	79
	:	:::::	:::
	:	:::::	:::
Qy	60	KFSLKDRVTIIVDTSKNPGLSSVTAADTAVYICARYGRVFDFYWGOGTLVTVSS	117
	:	:::::	:::
	:	:::::	:::
Db	80	YNPLKSRRVTIIVDTSKNPFSLRLSSVTAADTAVYICARLGMGAFFPWGHGTIVTVSS	137
	:	:::::	:::
	:	:::::	:::

RESULT 6	
Q6P4I8 HUMAN	
ID Q6P4I8 HUMAN PRELIMINARY;	PRT; 576 AA.
AC Q6P4I8;	
DT 05-JUL-2004	(TREMBlrel. 27, Created)
DT 05-JUL-2004	(TREMBlrel. 27, Last sequence update)
DT 05-JUL-2004	(TREMBlrel. 27, Last annotation update)
DE IGHD protein.	

```

GN Name=IGHD;
OS Homo sapiens (Human);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominoidea;
OC Homo;
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schuler G.D.,
RA Klausner R.D., Collins F.S., Wagner K.H., Schaefer C.F., Bhat N.K.,
RA Altschul S.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Hopkins R.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC063384; AAH63384.1; -; mRNA.
DR HSSP; P01820; 1A7N.
DR Ensembl; ENSG00000196122; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.c1.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; CI-set; 1.
DR Pfam; PF00047; Ig; 2.
DR SMART; SM00409; Ig; 1.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG MHC; UNKNOWN 2.
SQ SEQUENCE 576 AA; 63364 MW; FBB97C949D720F1E CRC64;

Query Match 74.3%; Score 464.5; DB 2; Length 576;
Best Local Similarity 75.8%; Pred. No. 2.3e-38;
Matches 91; Conservative 7; Mismatches 19; Indels 3; Gaps 1;

Qy 1 QVQLQESGPGLVKPSKETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 27 QVQLQESGPGLVKPSGTLSTLCAVSGSISNWSWVRQPPGKLEWIGIYHSGSTNY 86

Qy 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 117
Db 87 NPSLSKRVTVISVDKSKNQFSLKLSVTAADTAVYVCASLGIIYYIGMDVWGQGLTVTVSS 146

RESULT 7
Q99M22_MOUSE
ID Q99M22_MOUSE PRELIMINARY; PRT; 479 AA.
AC Q99M22
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE LOC238447 protein.

```

```

GN Name=LOC238447;
OS Mus musculus (Mouse);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Mix FVB/N;
RX TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner K.H., Schaefer C.F., Bhat N.K.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Mix FVB/N;
RX TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;
RG NIH MGC Project;
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC002091; AAH02091.1; -; mRNA.
DR HSSP; P01820; 1G7J.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.c1.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; CI-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG MHC; UNKNOWN 2.
KW Immunoglobulin domain.
SQ SEQUENCE 479 AA; 51992 MW; 768E39A138918892 CRC64;

Query Match 73.4%; Score 459; DB 2; Length 479;
Best Local Similarity 72.4%; Pred. No. 6.9e-38;
Matches 84; Conservative 15; Mismatches 17; Indels 0; Gaps 0;

Qy 2 VQLQESGPGLVKPSKETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
Db 20 VQLQESGPGLVKPSQSLSLTCSVTGYTSYNNWIRQPPGKLEWIGYINYGNNYN 79

Qy 62 PSLKDRVTISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
Db 80 PSLKDRVTISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 135

RESULT 8
Q96EY0_HUMAN
ID Q96EY0_HUMAN PRELIMINARY; PRT; 620 AA.
AC Q96EY0
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
GN Name=IGHM;

```



RC TISSUE=Human rectum tumor;  
RA Bloeker H., Boecher M., Mewes H.W., Weil B., Amid C., Oeanger A.,  
RA Fobo G., Han M., Wiemann S.; EMBL/GenBank/DBJ databases.  
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BX538077; CAD98001.1; -, mRNA.  
DR HSSP; P01820; 1G7J.  
DR SMR; Q72374; 262-470.  
DR Ensembl; ENSG00000130076; Homo sapiens.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003597; IG-cl.  
DR InterPro; IPR003006; IG\_MHC.  
DR InterPro; IPR003596; IG\_v.  
DR Pfam; PF07654; Cl-set; 2.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS50835; IG LIKE; 4.  
DR PROSITE; PS00290; IG\_MHC; UNKNOWN\_2.  
KW Hypothetical protein.  
FT NON\_TER 1  
SQ SEQUENCE 492 AA; 53776 MW; 1E7A15760F0CA74B CRC64;

Query Match 71.7%; Score 448; DB 2; Length 492;  
Best Local Similarity 74.0%; Pred. No. 9.3e-37;  
Matches 91; Conservative 7; Mismatches 17; Indels 8; Gaps 3;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISG-GYLWNWIRPPGKGLWIGYISYDGTNN 59  
DB 32 QLQLQESGPGLVKPSSETLSLTCTVSGGSVSNRYWGWIRPPGKGLWIGSIYNNY 91

QY 60 YKPSLKRVTISVDTSKNQFSLKSSVTAADTAVYCAR-----YGRVFFYWGQGLT 114  
DB 92 YSPSLKSLRTTFVDTSKNHFSLRTSVTAADTAVYCVRHVEPGYV--WFPDWQGGTL 149

QY 115 VSS 117  
DB 150 VSS 152

RESULT 11  
ID Q86SX2 HUMAN PRELIMINARY; PRT; 139 AA.  
AC Q86SX2;  
RC TISSUE=B cells;  
RP Li W.B., Gruber C., Jessee J., Polayes D.;  
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=B cells;  
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BX248300; CAD62627.1; -, mRNA.  
DR HSSP; P01820; 1G7J.  
DR SMR; Q86SX2; 33-129.  
DR Ensembl; ENSG00000130076; Homo sapiens.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003596; IG\_v.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS50835; IG LIKE; 1.  
FT NON\_TER 1  
SQ SEQUENCE 139 AA; 15573 MW; 7D1E2302410B4F8C CRC64;

Query Match 71.1%; Score 444.5; DB 2; Length 139;

Best Local Similarity 88.8%; Pred. No. 5.3e-37;  
Matches 87; Conservative 2; Mismatches 8; Indels 1; Gaps 1;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISG-YLWNWIRPPGKGLWIGYISYDGTNNY 60  
DB 33 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYSWIRPPGKGLWIGYISYSGSTNY 91

QY 61 KPSLKRVTISVDTSKNQFSLKSSVTAADTAVYCAR 98  
DB 92 NPSLKSRTISVDTSKNQFSLKSSVTAADTAVYCAR 129

RESULT 12  
ID Q96KX8 HUMAN PRELIMINARY; PRT; 496 AA.  
AC Q96KX8;  
DT 01-DEC-2001 (TrEMBLrel. 19, Created)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE MGC27165 protein.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Lung;  
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Udutin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Hulyk S.W.,  
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalish D.E.,  
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Lung;  
RA Strausberg R.;  
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BC016369; AAH16369.1; -, mRNA.  
DR HSSP; P01876; 1OW0.  
DR SMR; Q96KX8; 266-474.  
DR Ensembl; ENSG00000130076; Homo sapiens.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003597; IG-cl.  
DR InterPro; IPR003006; IG\_MHC.  
DR InterPro; IPR003596; IG\_v.  
DR Pfam; PF07654; Cl-set; 2.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS50835; IG LIKE; 4.  
DR PROSITE; PS00290; IG\_MHC; UNKNOWN\_1.  
KW Immunoglobulin domain.  
SQ SEQUENCE 496 AA; 53392 MW; D346929849040D69 CRC64;

Query Match 71.1%; Score 444.5; DB 2; Length 496;  
Best Local Similarity 73.4%; Pred. No. 2.1e-36;  
Matches 91; Conservative 4; Mismatches 22; Indels 7; Gaps 2;

```

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSI -SGGYLNNWIRQPPGKGLWIGYISYDGTNN 59
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 QVQLQESGPGLVKPSSETLSLTCTVSGGSISSSYWGWIRQPPGKGLWIANITYSGITY 79
QY 60 YKPSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYICARYG-----RVFFDYWGQGLV 113
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 YNPFLKSRVTISVDTSKNQFSLKLSVTAADTAATVYICARHGYSRSGRTGADIDYWGQGLV 139
QY 114 TVSS 117
Db :|||||:
140 TVSS 143

RESULT 13
Q6LBQ5 MOUSE
ID Q6LBQ5 MOUSE PRELIMINARY; PRT; 136 AA.
AC Q6LBQ5;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE VH gene product (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=90067954; PubMed=2587273;
RA Urakov D.N., Deev S.M., Polyakovskiy O.L.;
RT "The structure of the expressible VH gene from a hybridoma producing
RL Nucleic Acids Res. 17:9481-9481(1989).
DR EMBL; X16740; CAA34714.1; -; Genomic DNA.
DR HSSP; P18532; 1KCV.
DR SMR; Q6LBQ5; 20-136.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON TER 1
SQ SEQUENCE 136 AA; 15307 MW; 5B0F439CCFB15C3A CRC64;

Query Match 71.0%; Score 443.5; DB 2; Length 136;
Best Local Similarity 70.9%; Pred. No. 6.5e-37;
Matches 83; Conservative 15; Mismatches 18; Indels 1; Gaps 1;

QY 2 VQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 VQLQESGPGLVKPSQSLSLTCTSVTDFSIISGYWIRQPPGKGLWIGYISYDGSNGYN 79
QY 62 PSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYICAR -YGRVFFDYWGQGLVTVSS 117
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 PSLKRSITRDTSKNQFSLKLSVTTEDTATYYCTRGDGYHFFTYWGQGLVTVSA 136

RESULT 14
Q5U413 MOUSE
ID Q5U413 MOUSE PRELIMINARY; PRT; 483 AA.
AC Q5U413;
DT 01-FEB-2005 (TrEMBLrel. 29, Created)
DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)
DE 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)
DE LOC544903 protein.
GN Name=LOC544903;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]

```

```

RP NUCLEOTIDE SEQUENCE.
RX STRAIN=FVB/N; TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Lequellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
FT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX STRAIN=FVB/N; TISSUE=Colon;
RG NIH MGC Project;
RL Submitted (OCT-2004) to the EMBL/GenBank/DBSJ databases.
DR EMBL; BC085312; AAH85312.1; -; mRNA.
DR Ensembl; ENSMUSG0000054328; Mus musculus.
GO: GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG_c1.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 3.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 483 AA; 52714 MW; 7C272DA501AA0D1 CRC64;

Query Match 71.0%; Score 443.5; DB 2; Length 483;
Best Local Similarity 70.6%; Pred. No. 2.6e-36;
Matches 84; Conservative 13; Mismatches 19; Indels 3; Gaps 1;

QY 2 VQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 VQLQESGPGLVKPSQSLSLTCTVTGYSITSGYWHWIRQPPGKGLWIGYISYSGSNYN 79
QY 62 PSLKDRVTISVDTSKNQFSLKLSVTAADTAATVYICARYGRVF---FDYWGQGLVTVSS 117
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 PSLKRSITRDTSKNQFSLKLSVTTEDTATYYCTRGDGYHFFTYWGQGLVTVSS 138

RESULT 15
HV46 MOUSE
ID HV46 MOUSE STANDARD; PRT; 137 AA.
AC P01822;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V region MOPC 315 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=89238351; PubMed=2497341; DOI=10.1016/0161-5890(89)90133-8;

```



GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.96642 Seconds  
(without alignments)  
166.558 Million cell updates/sec

Title: US-10-735-916a-79  
Perfect score: 627  
Sequence: 1 QVQLQESGPGLVKPSSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA New:\*

- 1: /cgn2\_6/ptodata/1/pubpaa/US08 NEW PUB.pap.\*
- 2: /cgn2\_6/ptodata/1/pubpaa/US06 NEW PUB.pap.\*
- 3: /cgn2\_6/ptodata/1/pubpaa/US07 NEW PUB.pap.\*
- 4: /cgn2\_6/ptodata/1/pubpaa/PCT\_NEW\_PUB.pap.\*
- 5: /cgn2\_6/ptodata/1/pubpaa/US09 NEW PUB.pap.\*
- 6: /cgn2\_6/ptodata/1/pubpaa/US10 NEW PUB.pap.\*
- 7: /cgn2\_6/ptodata/1/pubpaa/US11 NEW PUB.pap.\*
- 8: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pap.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	627	100.0	117	7	US-11-012-353-79
2	627	100.0	135	7	US-11-012-353-81
3	623	99.4	117	7	US-11-012-353-75
4	623	99.4	135	7	US-11-012-353-77
5	615	98.1	117	7	US-11-012-353-83
6	615	98.1	135	7	US-11-012-353-85
7	541	86.3	117	7	US-11-012-353-69
8	541	86.3	127	7	US-11-012-353-52
9	536	85.5	117	7	US-11-012-353-162
10	482.5	77.0	118	7	US-11-012-353-70
11	482	76.9	123	7	US-11-012-353-73
12	481.5	76.8	247	7	US-11-054-515-1651
13	481.5	76.8	250	7	US-11-054-515-1548
14	473	75.4	117	7	US-11-012-353-72
15	473	75.4	120	7	US-11-102-201-1
16	473	75.4	253	7	US-11-054-515-1619
17	469.5	74.9	146	6	US-10-721-763-17
18	469.5	74.9	259	6	US-10-512-184-34
19	469.5	74.9	371	6	US-10-512-184-71
20	469.5	74.9	626	6	US-10-512-184-49
21	467.5	74.6	252	7	US-11-054-515-1994
22	465.5	74.2	252	7	US-11-054-515-1329
23	461.5	73.6	116	7	US-11-054-669-112
24	461.5	73.6	250	7	US-11-054-669-110
25	461	73.5	255	7	US-11-054-515-841

ALIGNMENTS

RESULT 1

US-11-012-353-79  
; Sequence 79, Application US/11012353  
; Publication No. US20050249730A1

; GENERAL INFORMATION:  
; APPLICANT: GOETTSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUPLOS, ALAIN  
; APPLICANT: HAEUM, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN

; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012,353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: PatentIn Ver. 3.3  
; SEQ ID NO 79

; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-11-012-353-79

Query Match 100.0%; Score 627; DB 7; Length 117;

Best Local Similarity 100.0%; Pred. No. 1.2e-48;

Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPKGLWIGYISYDGTNNY 60

DB 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPKGLWIGYISYDGTNNY 60

QY 61 KPSLKDRTVTSRDTSKNQFSLKLSVTAADTAATVYTCARYGRVFFDYWGQGLTVTVSS 117

DB 61 KPSLKDRTVTSRDTSKNQFSLKLSVTAADTAATVYTCARYGRVFFDYWGQGLTVTVSS 117

```
RESULT 2
US-11-012-353-81
; Sequence 81, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR FILING DATE: 2004-12-16
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-81

Query Match 100.0%; Score 627; DB 7; Length 135;
Best Local Similarity 100.0%; Pred. No. 1.4e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSSTAAADTAVVYCYARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQFSLKLSSTAAADTAVVYCYARYGRVFFDYWGQGLTVTVSS 135

RESULT 3
US-11-012-353-75
; Sequence 75, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 75
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-75

Query Match 99.4%; Score 623; DB 7; Length 117;
Best Local Similarity 98.3%; Pred. No. 2.7e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSSTAAADTAVVYCYARYGRVFFDYWGQGLTVTVSS 117
Db 61 KPSLKDRVTISRDTSKNQFSLKLSSTAAADTAVVYCYARYGRVFFDYWGQGLTVTVSS 117

RESULT 4
US-11-012-353-77
; Sequence 77, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 77
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-77

Query Match 99.4%; Score 623; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 3.1e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSSTAAADTAVVYCYARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQFSLKLSSTAAADTAVVYCYARYGRVFFDYWGQGLTVTVSS 135
```





```

; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1651
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-1651

Best Match          76.8%; Score 481.5; DB 7; Length 247;
Query Local Similarity 77.4%; Pred. No. 1.2e-35;
Matches 96; Conservative 5; Mismatches 16; Indels 7; Gaps 0

QY      1  QVQLQESGPGLVKPSFELSITCTVSGYSITCGYLNWIRQPPGKLEWIGVISYDGG
Db      1  QVQLQESGPGLVKPSFELSITCTVSNYSISSGYWGIRQPPGKLEWIGISYISYG
QY      61  PPSLKORVTTSRDTSKNQPSLKLSVTAADTAVYICARY-----GRVF-PDYWGQC
Db      61  NPSLSRVTSVDTSRKNQPSLKLSVTAADTAVYICARFYDILTGYTYDMDVWGR
QY      114  TVSS 117
Db      121  TVSS 124

RESULT 13
US-11-054-515-1548
; Sequence 1548, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Bly5
; FILE REFERENCE: PFS23P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1548
; LENGTH: 250

```

```
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1548

Query Match      76.8%; Score 481.5; DB 7; Length 250;
Best Local Similarity 77.4%; Pred. No. 1.2e-35;
Matches 96; Conservative 6; Mismatches 15; Indels 7; Gaps 2;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCAVSGYSISGGYWGWRQPPGKLEWIGYSYHSGSTYY 60

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAVVYCARY-----GRVF-PDYWGQGLTV 113
Db 61 NPSLSRVTISVDTSKNQFSLKLSVTAADTAVVYCARVHVDILTGYLWAFDINGQGTAV 120

Qy 114 TVSS 117
Db 121 TVSS 124

RESULT 14
US-11-012-353-72
; Sequence 72, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 72
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MOD RES
; LOCATION: {59}
; OTHER INFORMATION: Variable amino acid
US-11-012-353-72

Query Match      75.4%; Score 473; DB 7; Length 117;
Best Local Similarity 79.5%; Pred. No. 3.2e-35;
Matches 93; Conservative 6; Mismatches 18; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSQTLTLCTVSGGSVSSVSWNNWIRQPPGKLEWIGRIYYSGSTYY 60

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 61 NPSLSRVTISVDTSKNQFSLKLSVTAADTAVVYCARLPGDYDVGQGLTVTVSS 117

RESULT 15
US-11-102-201-1
; Sequence 1, Application US/11102201
; Publication No. US20050265994A1
; GENERAL INFORMATION:
; APPLICANT: MANTYH, Patrick W.
; APPLICANT: SHELTON, David L.
; TITLE OF INVENTION: METHODS FOR TREATING BONE CANCER PAIN BY
; TITLE OF INVENTION: ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST
; FILE REFERENCE: 51471-20021.00
; CURRENT APPLICATION NUMBER: US/11/102,201
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: US 60/620,654
; PRIOR FILING DATE: 2004-10-19
; PRIOR APPLICATION NUMBER: US 60/560,781
; PRIOR FILING DATE: 2004-04-07
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-102-201-1

Query Match      75.4%; Score 473; DB 7; Length 120;
Best Local Similarity 78.5%; Pred. No. 3.3e-35;
Matches 95; Conservative 7; Mismatches 13; Indels 6; Gaps 2;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGFSLI-GYDLNWIROPFGKLEWIGDGTIDY 59

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAVVYCARYG-----RVFFDYWGQGLTVTV 115
Db 60 NSAVKSRVTISKDTSKNQFSLKLSVTAADTAVVYCARGGYWYATSYFYDYWGQGLTVTV 119

Qy 116 S 116
Db 120 S 120

Search completed: January 10, 2006, 21:36:24
Job time : 5.96642 secs
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 64.1754 Seconds  
(without alignments)  
761.757 Million cell updates/sec

Title: US-10-735-916A-79

Perfect score: 627

Sequence: 1 QVQLQESGPGLVKPESETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Published Applications AA Main:

- 1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*
- 2: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*
- 3: /cgn2\_6/ptodata/1/pubpaa/US09\_PUBCOMB.pep.\*
- 4: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*
- 5: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*
- 6: /cgn2\_6/ptodata/1/pubpaa/US11\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	627	100.0	117	5	US-10-735-916A-79
2	627	100.0	135	5	US-10-735-916A-81
3	623	99.4	117	5	US-10-735-916A-75
4	623	99.4	135	5	US-10-735-916A-77
5	615	98.1	117	5	US-10-735-916A-83
6	615	98.1	135	5	US-10-735-916A-85
7	541	86.3	117	5	US-10-735-916A-69
8	541	86.3	127	5	US-10-735-916A-52
9	526.5	84.0	120	4	US-10-383-447-26
10	507	80.9	119	4	US-10-309-762-143
11	506.5	80.8	120	4	US-10-383-447-24
12	504.5	80.5	118	4	US-10-292-088-109
13	503.5	80.3	120	4	US-10-383-447-28
14	503.5	80.3	121	5	US-10-805-177-56
15	503.5	80.3	122	4	US-10-309-762-25
16	503.5	80.3	122	4	US-10-309-762-29
17	502.5	80.1	120	4	US-10-309-762-128
18	500.5	79.8	116	4	US-10-309-762-127
19	500.5	79.8	121	4	US-10-010-729-11
20	500.5	79.8	122	4	US-10-309-762-24
21	500.5	79.8	122	4	US-10-309-762-27
22	500	79.7	119	5	US-10-125-687-5
23	500	79.7	119	5	US-10-996-191-5
24	500	79.7	121	4	US-10-292-088-82
25	500	79.7	466	4	US-10-292-088-86
26	498	79.4	119	5	US-10-537-596-23
27	497	79.3	117	5	US-10-890-945-2

ALIGNMENTS

RESULT 1  
US-10-735-916A-79  
; Sequence 79, Application US/10735916A  
; Publication No. US20050084906A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, Liliane  
; APPLICANT: CORVAIA, Nathalie  
; APPLICANT: LEGER, Olivier  
; APPLICANT: DUFLOS, Alain  
; APPLICANT: BECK, Alain  
; APPLICANT: HAEUW, Jean-Francois  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-183  
; CURRENT APPLICATION NUMBER: US/10735-916A  
; CURRENT FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 03/08 538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 02/00 653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/00 654  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/05 753  
; PRIOR FILING DATE: 2002-05-07  
; NUMBER OF SEQ ID NOS: 156  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 79  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-735-916A-79

Query Match 100.0%; Score 627; DB 5; Length 117;  
Best Local Similarity 100.0%; Pred. No. 8.7e-48;  
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 QVQLQESGPGLVKPESETLSLCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPESETLSLCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60  
  
QY 61 KPSLKDRVTISGRDTSKNQFSKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117  
Db 61 KPSLKDRVTISGRDTSKNQFSKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117  
  
RESULT 2  
US-10-735-916A-81  
; Sequence 81, Application US/10735916A  
; Publication No. US20050084906A1

Sequence 98, Appl  
Sequence 70, Appl  
Sequence 35, Appl  
Sequence 37, Appl  
Sequence 20, Appl  
Sequence 39, Appl  
Sequence 2, Appl  
Sequence 11, App  
Sequence 66, Appl  
Sequence 14, Appl  
Sequence 10, Appl  
Sequence 138, App  
Sequence 10, Appl  
Sequence 9, Appl  
Sequence 11, Appl  
Sequence 142, App

```

; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-81

Query Match 100.0%; Score 627; DB 5; Length 135;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 3
US-10-735-916A-75
; Sequence 75, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-75

Query Match 99.4%; Score 623; DB 5; Length 135;
Best Local Similarity 98.3%; Pred. No. 2e-47;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 5
US-10-735-916A-83
; Sequence 83, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 77
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-77

Query Match 99.4%; Score 623; DB 5; Length 135;
Best Local Similarity 98.3%; Pred. No. 2.3e-47;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 4
US-10-735-916A-77
; Sequence 77, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 77
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-77

Query Match 99.4%; Score 623; DB 5; Length 135;
Best Local Similarity 98.3%; Pred. No. 2.3e-47;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 135
```

FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 83  
LENGTH: 117  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-735-916A-83

Query Match 98.1%; Score 615; DB 5; Length 117;  
Best Local Similarity 98.3%; Pred. No. 9.9e-47;  
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60

QY 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117  
DB 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117

RESULT 6  
US-10-735-916A-85  
Sequence 85, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USBS THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
PRIOR FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 85  
LENGTH: 135  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-735-916A-85

Query Match 98.1%; Score 615; DB 5; Length 135;  
Best Local Similarity 98.3%; Pred. No. 1.1e-46;  
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60

DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 78  
QY 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117  
DB 79 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 135

RESULT 7  
US-10-735-916A-69  
Sequence 69, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USBS THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
PRIOR FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 69  
LENGTH: 117  
TYPE: PRT  
ORGANISM: Mus musculus  
US-10-735-916A-69

Query Match 86.3%; Score 541; DB 5; Length 117;  
Best Local Similarity 84.5%; Pred. No. 3.4e-40;  
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

QY 2 VQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNYK 61  
DB 2 VQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNYK 61

QY 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117  
DB 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117

RESULT 8  
US-10-735-916A-52  
Sequence 52, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USBS THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653

```
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-52

Query Match      86.3%; Score 541; DB 5; Length 127;
Best Local Similarity 84.5%; Pred. No. 3.7e-40;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

Qy  2  VQLQESGPGLVKPSLTLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
Db  12 VQLQESGPGLVKPSLTLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 71

Qy  62  PSLKDRVTISRDTSKNQSLSSVTAADTAVVYCARVFFDYWGQGLTVTVSS 117
Db  72  PSLKDRVTISRDTSKNQSLSSVTAADTAVVYCARVFFDYWGQGLTVTVSS 127

RESULT 9
US-10-383-447-26
; Sequence 26, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaekar, Vinay
; APPLICANT: de la Calle, Agustín
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TWEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 3.0
US-10-383-447-26

Query Match      84.0%; Score 526.5; DB 4; Length 120;
Best Local Similarity 84.0%; Pred. No. 6.7e-39;
Matches 100; Conservative 6; Mismatches 10; Indels 3; Gaps 1;

Qy  2  VQLQESGPGLVKPSLTLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
Db  2  VQLQESGPGLVKPSLTLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61

Qy  62  PSLKDRVTISRDTSKNQSLSSVTAADTAVVYCARVFFDYWGQGLTVTVSS 117
Db  62  PSLKDRVTISRDTSKNQSLSSVTAADTAVVYCARVFFDYWGQGLTVTVSS 120

RESULT 10
US-10-309-762-143
; Sequence 143, Application US/10309762
```

```
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Poltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 143
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-143

Query Match      80.9%; Score 507; DB 4; Length 119;
Best Local Similarity 83.3%; Pred. No. 3.5e-37;
Matches 100; Conservative 5; Mismatches 11; Indels 4; Gaps 2;

Qy  1  QVQLQESGPGLVKPSLTLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db  1  QVQLQESGPGLVKPSLTLCTVSGGSIS-SYVSWIRQPPGKLEWIGYIYSGSTNY 59

Qy  61  KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARVRY---FFDYWGQGLTVTVSS 117
Db  60  NPSLKSRVTISVDTSKNQFSLKSSVTAADTAVVYCARVDILTGYFFDYWGQGLTVTVSS 119

RESULT 11
US-10-383-447-24
; Sequence 24, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaekar, Vinay
; APPLICANT: de la Calle, Agustín
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TWEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 2.0
US-10-383-447-24

Query Match      80.8%; Score 506.5; DB 4; Length 120;
Best Local Similarity 79.8%; Pred. No. 3.9e-37;
Matches 95; Conservative 10; Mismatches 11; Indels 3; Gaps 1;

Qy  2  VQLQESGPGLVKPSLTLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
Db  2  VQLQESGPGLVKPSLTLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
```



```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-25

Query Match      80.3%; Score 503.5; DB 4; Length 122;
Best Local Similarity 82.1%; Pred. No. 7,3e-37;
Matches 101; Conservative 3; Mismatches 12; Indels 7; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGCGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-syywswirQPPGKGLEWIGYIYSGSTNY 59
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 KPSLKDRVTIISDTSKNQFSLKLSVTAADTAVYYCARYGRVF-----FDYWGQGTLVLT 114
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVYYCARRGYDFLTGVDYFDYWGQGTLVLT 119
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 115 VSS 117
   |||
Db 120 VSS 122
```

Search completed: January 10, 2006, 21:35:33  
Job time : 65.1754 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 22.847 Seconds  
(without alignments)  
423.384 Million cell updates/sec

Title: US-10-735-916A-79  
Perfect score: 627  
Sequence: 1 QVQLGSGPLVKPSETLSL.....RYGRVFDFYWGQGLTVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/prodata/1/iaa/5 COMB.pep.\*  
2: /cgn2\_6/prodata/1/iaa/6 COMB.pep.\*  
3: /cgn2\_6/prodata/1/iaa/H COMB.pep.\*  
4: /cgn2\_6/prodata/1/iaa/PCTUS COMB.pep.\*  
5: /cgn2\_6/prodata/1/iaa/RE COMB.pep.\*  
6: /cgn2\_6/prodata/1/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	500	79.7	119	2	US-09-025-769B-39
2	500	79.7	119	2	US-09-025-769B-65
3	500	79.7	119	2	US-09-490-070A-39
4	500	79.7	119	2	US-09-490-070A-65
5	500	79.7	119	2	US-09-490-153-39
6	500	79.7	119	2	US-09-490-153-65
7	500	79.7	119	2	US-09-490-324-39
8	500	79.7	119	2	US-09-490-324-65
9	497	79.3	117	2	US-09-720-493-2
10	487	77.7	117	2	US-10-330-613A-13
11	486.5	77.6	473	2	US-09-049-672A-4
12	486	77.5	123	1	US-08-137-117D-64
13	486	77.5	123	1	US-08-436-717-64
14	486	77.5	138	1	US-08-137-117D-69
15	486	77.5	138	1	US-08-436-717-69
16	483.5	77.1	118	2	US-09-025-769B-25
17	483.5	77.1	118	2	US-09-490-070A-25
18	483.5	77.1	118	2	US-09-490-153-25
19	483.5	77.1	118	2	US-09-490-324-25
20	482.5	77.0	244	2	US-08-918-148-79
21	482.5	77.0	244	2	US-09-138-091A-77
22	475	75.8	118	2	US-09-065-059-11
23	475	75.8	118	2	US-08-913-555-11
24	475	75.8	121	2	US-10-330-613A-1
25	475	75.8	121	2	US-10-330-613A-17
26	474.5	75.7	487	2	US-09-800-729-145
27	473	75.4	117	2	US-10-330-613A-5

28	472.5	75.4	118	2	US-09-343-698-6	Sequence 6, Appli
29	472.5	75.4	118	2	US-08-325-955-6	Sequence 6, Appli
30	471.5	75.2	832	2	US-08-630-820-7	Sequence 7, Appli
31	471.5	75.2	832	2	US-09-273-453-7	Sequence 9, Appli
32	471	75.1	121	2	US-10-330-613A-9	Sequence 5, Appli
33	470	75.0	119	1	US-08-360-125-5	Sequence 5, Appli
34	470	75.0	119	1	US-08-450-578-5	Sequence 5, Appli
35	470	75.0	119	1	US-09-017-628-5	Sequence 5, Appli
36	470	75.0	119	2	US-09-014-880-5	Sequence 5, Appli
37	470	75.0	119	2	US-08-450-363-5	Sequence 5, Appli
38	470	75.0	119	2	US-09-467-903-5	Sequence 837, App
39	468.5	74.7	139	2	US-09-471-276-837	Sequence 3, Appli
40	468.5	74.7	278	2	US-09-260-527-3	Sequence 2, Appli
41	467	74.5	142	1	US-08-480-774A-2	Sequence 13, Appli
42	466	74.3	121	1	US-08-275-053-13	Sequence 11, Appli
43	465.5	74.2	122	1	US-08-360-125-11	Sequence 11, Appli
44	465.5	74.2	122	1	US-08-450-578-11	Sequence 11, Appli
45	465.5	74.2	122	1	US-09-017-628-11	Sequence 11, Appli

ALIGNMENTS

RESULT 1  
US-09-025-769B-39  
; Sequence 39, Application US/09025769B  
; Patent No. 6300064  
; GENERAL INFORMATION:  
; APPLICANT: Knappik, Achim  
; APPLICANT: Pack, Peter  
; APPLICANT: Ilag, Vic  
; APPLICANT: Ge, Liming  
; APPLICANT: Moroney, Simon  
; APPLICANT: Plueckthun, Andreas  
; TITLE OF INVENTION: Protein/(Poly)peptide libraries  
; NUMBER OF SEQUENCES: 373  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
; STREET: 1251 Avenue of the Americas  
; CITY: New York  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10021  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION NUMBER: US/09/025,769B  
; FILING DATE: 18-FEB-1998  
; PRIOR APPLICATION NUMBER: EP 95 11 3021.0  
; FILING DATE: 18-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: James F. Haley, Jr., Esq.  
; REGISTRATION NUMBER: 27,794  
; REFERENCE/DOCKET NUMBER: MORPHO/5  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212)596-9000  
; TELEFAX: (212)596-9090  
; INFORMATION FOR SEQ ID NO: 39:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 119 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-09-025-769B-39

Query Match 79.7%; Score 500; DB 2; Length 119;  
Best Local Similarity 83.3%; Pred. No. 4.6e-42;  
Matches 100; Conservative 4; Mismatches 12; Indels 4; Gaps 2;



White & McAlliffe  
STREET: 1666 K Street, N.W., Suite 300  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20006  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,070A  
FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Colin G. Sandercock, Esq.  
REGISTRATION NUMBER: 31,298  
REFERENCE/DOCKET NUMBER: 37629-0005  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 912-2000  
TELEFAX: (202) 912-2020  
INFORMATION FOR SEQ ID NO: 65:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 119 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 65:  
US-09-490-070A-65  
Query Match 79.7%; Score 500; DB 2; Length 119;  
Best Local Similarity 83.3%; Pred. No. 4.6e-42;  
Matches 100; Conservative 4; Mismatches 12; Indels 4; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLGWIGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYYNSWIRQPPGKGLGWIGYIYSGSTNY 59  
QY 61 KPSLKDRTVITSDTSKNQPSLKLSVTAADTAIVYICARYGRVFF---DYWGQGLTVTVSS 117  
Db 60 NPSLKSRTVITSDTSKNQPSLKLSVTAADTAIVYICARYGRVFF---DYWGQGLTVTVSS 119  
RESULT 5  
US-09-490-153-39  
Sequence 39, Application US/09490153  
Patent No. 6706484  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
Pack, Peter  
Ilag, Vic  
Ge, Liming  
Moroney, Simon  
Plueckthun, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,153

FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 596-9000  
TELEFAX: (212) 596-9090  
INFORMATION FOR SEQ ID NO: 39:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 119 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 39:  
US-09-490-153-39  
Query Match 79.7%; Score 500; DB 2; Length 119;  
Best Local Similarity 83.3%; Pred. No. 4.6e-42;  
Matches 100; Conservative 4; Mismatches 12; Indels 4; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLGWIGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYYNSWIRQPPGKGLGWIGYIYSGSTNY 59  
QY 61 KPSLKDRTVITSDTSKNQPSLKLSVTAADTAIVYICARYGRVFF---DYWGQGLTVTVSS 117  
Db 60 NPSLKSRTVITSDTSKNQPSLKLSVTAADTAIVYICARYGRVFF---DYWGQGLTVTVSS 119  
RESULT 6  
US-09-490-153-65  
Sequence 65, Application US/09490153  
Patent No. 6706484  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
Pack, Peter  
Ilag, Vic  
Ge, Liming  
Moroney, Simon  
Plueckthun, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,153  
FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5

```
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9090
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-153-65

Query Match 79.7%; Score 500; DB 2; Length 119;
Best Local Similarity 83.3%; Pred. No. 4.6e-42;
Matches 100; Conservative 4; Mismatches 12; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59

QY 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFF---DYWGQGLTVTVSS 117
DB 60 NPSLSKRVITISVDTSKNQFSLKSSVTAADTAVYYCARWGGDGFYAMDYWGQGLTVTVSS 119

RESULT 7
US-09-490-324-39
; Sequence 39, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9090
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 39:

US-09-490-324-39

Query Match 79.7%; Score 500; DB 2; Length 119;
Best Local Similarity 83.3%; Pred. No. 4.6e-42;
Matches 100; Conservative 4; Mismatches 12; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59

QY 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFF---DYWGQGLTVTVSS 117
DB 60 NPSLSKRVITISVDTSKNQFSLKSSVTAADTAVYYCARWGGDGFYAMDYWGQGLTVTVSS 119

RESULT 8
US-09-490-324-65
; Sequence 65, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9090
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-324-65

Query Match 79.7%; Score 500; DB 2; Length 119;
Best Local Similarity 83.3%; Pred. No. 4.6e-42;
Matches 100; Conservative 4; Mismatches 12; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59

QY 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFF---DYWGQGLTVTVSS 117
DB 60 NPSLSKRVITISVDTSKNQFSLKSSVTAADTAVYYCARWGGDGFYAMDYWGQGLTVTVSS 119
```

Db 60 NFSLKSRVTISVDTSKNQFSLKSSVTAADTAVVYCARWGSGDFYANDYWGQGLTVTVSS 119

RESULT 9

US-09-720-493-2

; Sequence 2, Application US/09720493

; Patent No. 6827925

; GENERAL INFORMATION:

; APPLICANT: Cambridge Antibody Technology Limited

; APPLICANT: Williams, Andrew J

; APPLICANT: Tempest, Philip R

; APPLICANT: Holtet, Thor L

; APPLICANT: Main, Sarah H

; APPLICANT: Jackson, Helen

; APPLICANT: Daramola, Olalekan

; TITLE OF INVENTION: Improvements relating to antibodies

; FILE REFERENCE: AHB/CP5775333

; CURRENT APPLICATION NUMBER: US/09/720,493

; CURRENT FILING DATE: 2002-10-23

; PRIOR APPLICATION NUMBER: GB 9814383.7

; PRIOR FILING DATE: 1998-07-02

; NUMBER OF SEQ ID NOS: 22

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 2

; LENGTH: 117

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-720-493-2

Query Match 79.3%; Score 497; DB 2; Length 117;

Best Local Similarity 82.9%; Pred. No. 8.8e-42;

Matches 97; Conservative 3; Mismatches 17; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSTLSLTCTVSGYSITGGYLNWIRQPPKGLGWIGYISYDGTNNY 60

Db 1 QVQLQESGPGLVKPSSTLSLTCAVSGYSISGGYMWIRQPPKGLGWIGYSYHSGSTY 60

QY 61 KPSLKDRTVTSRDTSKNQFSLKSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117

Db 61 NFSLKSRVTISVDTSKNQFSLKSSVTAADTAVVYCARGWKSKFDYWGQGLTVTVSS 117

RESULT 10

US-10-330-613A-13

; Sequence 13, Application US/10330613A

; Patent No. 6924360

; GENERAL INFORMATION:

; APPLICANT: Gudas, Jean

; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN

; FILE REFERENCE: AGENIX.022A

; CURRENT APPLICATION NUMBER: US/10/330,613A

; CURRENT FILING DATE: 2002-12-26

; PRIOR APPLICATION NUMBER: 60/346239

; PRIOR FILING DATE: 2001-12-18

; NUMBER OF SEQ ID NOS: 90

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 13

; LENGTH: 117

; TYPE: PRT

; ORGANISM: Homo Sapiens

US-10-330-613A-13

Query Match 77.7%; Score 487; DB 2; Length 117;

Best Local Similarity 83.1%; Pred. No. 8.6e-41;

Matches 98; Conservative 4; Mismatches 14; Indels 2; Gaps 2;

QY 1 QVQLQESGPGLVKPSSTLSLTCTVSGYSI-TGGYLNWIRQPPKGLGWIGYISYDGTNN 59

Db 1 QVQLQESGPGLVKPSSTLSLTCTVSGGSISGGYIYTWIRQHPKGLGWIGFYISGSTY 60

QY 60 YKPSLKDRTVTSRDTSKNQFSLKSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117

Db 61 YNPSLKSRVTISVDTSKNQFSLKSSVTAADTAVVYCCAREGD-GFDYNGQGLTVTVSS 117

RESULT 11

US-09-049-672A-4

; Sequence 4, Application US/09049672A

; Patent No. 6135941

; GENERAL INFORMATION:

; APPLICANT: Hillman, Jennifer L.

; APPLICANT: Lal, Preeti

; APPLICANT: Tang, Y. Tom

; APPLICANT: Yue, Henry

; APPLICANT: Au-Young, Janice

; APPLICANT: Corley, Neil C.

; APPLICANT: Guegler, Karl J.

; APPLICANT: Baughn, Mariah R.

; TITLE OF INVENTION: HUMAN IMMUNE SYSTEM ASSOCIATED PROTEINS

; NUMBER OF SEQUENCES: 28

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Incyte Pharmaceuticals, Inc.

; STREET: 3174 Porter Drive

; CITY: Palo Alto

; STATE: CA

; COUNTRY: USA

; ZIP: 94304

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS

; SOFTWARE: FastSeq for Windows Version 2.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/049,672A

; FILING DATE: HERewith

; CLASSIFICATION: 536

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER:

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Cerrone, Michael C

; REGISTRATION NUMBER: 39,132

; REFERENCE/DOCKET NUMBER: PF-0497 US

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 650-855-0555

; TELEFAX: 650-845-4166

; TELEX:

; INFORMATION FOR SEQ ID NO: 4:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 473 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; IMMEDIATE SOURCE:

; LIBRARY: PANCYTUT01

; CLONE: 1513264

US-09-049-672A-4

Query Match 77.6%; Score 486.5; DB 2; Length 473;

Best Local Similarity 78.7%; Pred. No. 5.1e-40;

Matches 100; Conservative 2; Mismatches 12; Indels 13; Gaps 3;

QY 1 QVQLQESGPGLVKPSSTLSLTCTVSGYSIT-GGYLNWIRQPPKGLGWIGYISYDGTNN 59

Db 20 QVQLQESGPGLVKPSSTLSLTCAVSGSITSGYYWSWIRQPPKGLGWIGYIYSGSTL 79

QY 60 YKPSLKDRTVTSRDTSKNQFSLKSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 110

Db 80 YNPSLKSRVTISVDTSKNQFSLKSSVTAADTAVVYCARDVDVGLRGNGYG---MDVWGQGL 136

QY 111 TLTVTVSS 117

Db 137 TLTVTVSS 143

3

CITY: Washington  
 STATE: D.C.  
 COUNTRY: USA  
 ZIP: 20007-5109  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/436,717  
 FILING DATE:  
 CLASSIFICATION: 536  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US/08/137,117  
 FILING DATE: 20-DEC-1993  
 APPLICATION NUMBER: WO PCT/JP92/00544  
 FILING DATE: 24-APR-1992  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: JP 4-32084  
 FILING DATE: 19-FEB-1992  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: JP 3-95476  
 FILING DATE: 25-APR-1991  
 ATTORNEY/AGENT INFORMATION:  
 NAME: WEGNER, Harold C.  
 REGISTRATION NUMBER: 25,258  
 REFERENCE/DOCKET NUMBER: 53466/126/AAOK  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (202)672-5300  
 TELEFAX: (202)672-5399  
 TELEX: 904136  
 INFORMATION FOR SEQ ID NO: 69:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 138 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: protein  
 PS-08-436-717-69

```
Query Match      77.5%; Score 486; DB 1; Length 138;
Best Local Similarity 77.3%; Pred. No. 1.3e-40;
Matches          92; Conservative 9; Mismatches 16; Indels 2; Gaps 1;

Qy   1 QVQLQESGGGLYKPSSETLSLTCTVSYSITGTVLWNIQRPPCKGLEWIGIYISVDGTNNY 60
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db   20 QVQLQESGPGLVKRPSTLSLTCTVSYSITSDHAWSVRQPCKGLEWIGIYISYGITTY 79
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy   61 KPSLKDRVTISRDTSKNQPSKLSSVTAADTAVYYCAR--YGRVFEDYQGQGLTAVTSS 117
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db   80 NPISKRVTLMDRTSKNQPSKLSSVTAADTAVYYCARSLARTAMDYQGQSLAVTSS 138
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
```

```

RESULT 15
US-08-436-717-69
; Sequence 69, Application US/08436717
; Patent No. 5817790
; GENERAL INFORMATION:
; APPLICANT: TSUCHIYA, Masayuki
; APPLICANT: SATO, Koh
; APPLICANT: BENDIG, Mary
; APPLICANT: JONES, Steven
; APPLICANT: SALDANHA, Jose
; TITLE OF INVENTION: RESHAPED HUMAN ANTIBODY TO HUMAN
; TITLE OF INVENTION: INTERLEUKIN-6 RECEPTOR
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500

```

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 14.1157 Seconds  
(without alignments)  
797.508 Million cell updates/sec

Title: US-10-735-916A-79  
Perfect score: 627  
Sequence: 1 QVQLQESGPGLVKPSSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR 80:.\*  
1: pir1:.\*  
2: pir2:.\*  
3: pir3:.\*  
4: pir4:.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	509	81.2	140	2 I37782	Ig variable region
2	494	78.8	130	2 S31690	Ig heavy chain V r
3	481	76.7	123	2 S30530	Ig heavy chain V r
4	478	76.2	147	2 S13519	Ig heavy chain V r
5	469.5	74.9	118	2 S24443	Ig heavy chain V r
6	468	74.6	155	2 S31511	Ig heavy chain - h
7	463.5	73.9	130	2 S30534	Ig heavy chain V r
8	463.5	73.9	139	2 S31586	Ig heavy chain V r
9	462.5	73.8	129	2 S44114	Ig heavy chain V r
10	462	73.7	155	2 S31512	Ig heavy chain - h
11	461.5	73.6	140	2 S78052	Ig heavy chain pre
12	459.5	73.3	145	2 S78055	Ig heavy chain pre
13	458	73.0	121	2 S37200	Ig heavy chain V r
14	457	72.9	121	2 S44113	Ig heavy chain V r
15	456	72.7	140	2 A49045	Ig heavy chain V r
16	455.5	72.6	136	2 S07637	Ig heavy chain V r
17	455	72.6	135	2 S07637	Ig heavy chain pre
18	454	72.4	137	1 AVMS35	Ig heavy chain pre
19	453.5	72.3	116	2 S38718	Ig heavy chain V r
20	452.5	72.2	137	2 S31676	Ig heavy chain V r
21	452	72.1	146	2 S09711	Ig heavy chain V r
22	450.5	71.9	126	2 S47010	Ig heavy chain V4.
23	450	71.8	127	2 I28195	Ig heavy chain V r
24	447.5	71.4	118	2 S20780	Ig heavy chain V r
25	447	71.3	119	2 E25114	Ig heavy chain V r
26	446	71.1	140	2 A24770	hypothetical hybri
27	439.5	70.1	118	2 A26340	Ig heavy chain pre
28	439	70.0	119	2 C53285	Ig heavy chain V a
29	439	70.0	146	2 S09710	Ig heavy chain V r

ALIGNMENTS

RESULT 1

I37782  
Ig variable region (VDJ) (clone T23-9) - human (fragment)  
C:Species: Homo sapiens (man)  
C>Date: 16-Feb-1996 #sequence\_revision 13-Mar-1997 #text\_change 23-Jul-1999  
C:Accession: I37782; S25476

R:Demaison, C.; Chastagner, P.; Theze, J.; Zouali, M.  
Proc. Natl. Acad. Sci. U.S.A. 91, 514-518, 1994

A:Title: Somatic diversification in the heavy chain variable region genes expressed by T

A:Reference number: A36876; MUID:94119917; PMID:8290556

A:Accession: I37782

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-140 <RES>

A:Cross-references: UNIPARC:UPI0000176883; EMBL:X67906; NID:g33582; PIDN:CAA48104.1; PFI

C:Superfamily: immunoglobulin V region; immunoglobulin homology

F:46-128/Domain: immunoglobulin homology <IMM>

Query Match 81.2%; Score 509; DB 2; Length 140;

Best Local Similarity 82.9%; Pred. No. 1.9e-39; Mismatches 9; Indels 8; Gaps 3;  
Matches 102; Conservative 4;

QY	1	QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY	60
Db	20	QVQLQESGPGLVKPSSETLSLCTVSGGIS-SYYNSWIRQPPGKLEWIGYIYSGSTNY	78
QY	61	KPSLRDRTISRDTSKNQFSLKLSVTAADTAATVYYCAR-----YGRVFFDYWGQGLTVT	114
Db	79	NPSLKSRTVISVDTSKNQFSLKLSVTAADTAATVYYCARHNSSSWYGR-YFDYWGQGLTVT	137
QY	115	VSS 117	
Db	138	VSS 140	

RESULT 2

S31690  
Ig heavy chain V region - human (fragment)

C:Species: Homo sapiens (man)

C>Date: 22-Nov-1993 #sequence\_revision 10-Nov-1995 #text\_change 23-Jul-1999

C:Accession: S31690

R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnel, C.

submitted to the EMBL Data Library, June 1992

A:Description: Mechanisms that generate human immunoglobulin diversity operate from the

A:Reference number: S31585

A:Accession: S31690

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-130 <CUI>

A:Cross-references: UNIPARC:UPI0000116471; EMBL:Z14199; NID:g30984; PIDN:CAA78568.1; PFI

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F;20-102/Domain: immunoglobulin homology <IMM>

Query Match	78.8%;	Score 494;	DB 2;	Length 130;
Best Local Similarity	78.6%;	Pred. No. 4.1e-38;		
Matches 99; Conservative 6;	Mismatches 11;	Indels 10;	Gaps 3;	
Qy	1	QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISVDGTNNY	60	
Dd	6	QVQLQESGPGLVKPSETLSLTCTVSGGISL:-SYTWSNSRQPPGKLEWIGYIYVSGSTNY	64	
Qy	61	KPSLKDRVTISRDTSSKNQFSKLSSVTAADTAIVYYCAR-----YGRV--FFDYWGQGT	111	
Dd	65	NPSLKRSVTLISDTSKKQFSLKSSVTAADTAIVYYCARGSSVLWFGBELLVYFYDWGQGT	124	
Qy	112	LVTVSS	117	
Dd	125	LVTVSS	130	

```

RESULT 3
S30530
IG heavy chain V region - human
C/Species: Homo sapiens (man)
C/Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996
C/Accession: S30530
R/Mariette, X.
submitted to the EMBL Data Library, October 1992
A/Reference number: S30520
A/Accession: S30530
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-123 <MAR>
A/Cross-references: UNIPARC:UPI0000176C83; EMBL:Z18316
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F/15-98/Domain: immunoglobulin homology <IMM>

```

[illegible]

RESULT 4

S13519  
IG heavy chain V region precursor - human  
C/Species: Homo sapiens (man)  
C/Date: 25-Feb-1994 #sequence\_revision 10-Nov-1995 #text\_change 23-Jul-1999  
C/Accession: S13519  
R/Mortari, F.; Ochs, H.D.; Wedgwood, R.J.P.; Schroeder Jr., H.W.  
Nucleic Acids Res. 19, 673, 1991  
A/Title: Immunoglobulin variable heavy chain cDNA sequence from a patient with X-linked  
A/Reference number: S13519; MUID:91187691; PMID:2011536  
A/Accession: S13519  
A/Status: preliminary  
A/Molecule type: mRNA  
A/Residues: 1-147 <MOR>  
A/Cross-references: UNIPARC:UPI000115EB5; EMBL:X56158; NID:G37724; PID:CAA93626.1; PID:  
C/Superfamily: immunoglobulin V region; immunoglobulin homology  
C/Keywords: heterotetramer; immunoglobulin  
F/41-125/Domain: immunoglobulin homology <IMM>

```

Query Match          76.2%; Score 478; DB 2; Length 147;
Best Local Similarity 79.5%; Pred. No. 1.4e-36;
Matches 97; Conservative 5; Mismatches 14; Indels 6; Gaps 3;

Qy      1 QVQLQESGPGLVKPSSETLSITCTVSIGYSI-TGGYLNMNWIROPKGLIEWIGIYSYDGTNN 59
         | : ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      27 QLQLQESGPGLVKPSSETLSITCTVSIGSISSSSYVMGWIRPQPKGLEWIGSIYSGSTY 86
         | : ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy      60 YKPSLKDRTVTISRDTSKNQFSLKLSSVTAADTAVYYCAR---YGRVPEDYWGOGTLVTV 115
         ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      87 YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARPLLPFGEL-FDWGGGTLVTV 145
         ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy      116 SS 117
         ||
Db      146 SS 147

RESULT 5
$24443
lg heavy chain V region (VH4DJ) - human
C;Species: Homo sapiens (man)
C;Date: 22-Jan-1993 #sequence_revision 22-Jan-1993 #text_change 20-Jun-2000
C;Accession: S24443; S19667
```

```

RESULT 5
S24443
Ig heavy chain V region (VH4DJ) - human
C:Species: Homo sapiens (man)
C:Date: 22-Jan-1993 #sequence_revision 22-Jan-1993 #text_change 20-Jun-2000
C:Accession: S24443; S19667
R:Jones, P.T.
submitted to the EMBL Data Library, October 1991
A:Reference number: S24442
A:Accession: S24443
A:Molecule type: mRNA
A:Residues: 1-118 <JON>
A:Cross-references: UNIPARC:UPI0000115FE9; EMBL:X61650; NID:g37720; PIDN:CAA438
R:Mark, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.
J. Mol. Biol. 222, 581-597, 1991
A:Title: By-passing immunization. Human antibodies from V-gene libraries displayed on phage
A:Reference number: S19663; MUID:92085276; PMID:1748994
A:Accession: S19667
A:Molecule type: mRNA
A:Residues: 1-55, 57-118 <VAR>
A:Cross-references: UNIPARC:UPI0000176B52; EMBL:X61650
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

```

Query Match	74.9%	Score	469.5	DB 2	Length	118			
Best Local Similarity	79.0%	Pred. No.	6.4e-36						
Matches	94	Conservative	6	Mismatches	16	Indels	3	Gaps	2

  

Qy	1	QVQLQSGPGLVPSSETLSLTCTVSGYSITGGLNWIROPPCKGLEWIGHVSIYDGTNNY	60
		:::	
Db	1	QVQLQSGPGLVPSSETLSLTCTVSGGSLFSY-WGWIROPPCKGLEWIGYISHRGSTDY	59
		:::	
Qy	61	KPSLKDRVTISRDTSKNQPSKLSSVTAADTAIVYCAR--YGRVFFPYWGCGTLVTWSS	117
		:::	
Db	60	NSLSLRVTLSADTSKNQPSKLSSVTAADTAIVYCARSPNSPFFCYWGCGTLVTWSS	118
		:::	

```

RESULT 6
S31511
IG heavy chain - human
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999
C:Accession: S31511
R:Chastagner, P.; Demaison, C.; Theze, J.; Zouali, M.
submitted to the EMBL Data Library, December 1992
A:Description: Dominance of clonotypic patterns and variable gene usage of anti-
A:Reference number: S31509
A:Accession: S31511
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-155 <CHA>
A:Cross-references: UNIPARC:UPI00001160PF; EMBL:X59866; NID:g33094; PIDN:CAA495
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
F:47-129/Domain: immunoglobulin homology <IMM>

```

Query Match 74.6%; Score 468; DB 2; Length 155;  
Best Local Similarity 76.6%; Pred. No. 1.2e-35;  
Matches 95; Conservative 7; Mismatches 14; Indels 8; Gaps 3;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGIISYDGTNNY 60  
DB 33 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYWSWIRQPPGKGLEWIGIYYTGSATY 91  
QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVAVYCARVGRV--PFDDY-----WGQGTFLV 113  
DB 92 NPPLKSRVTISVDTSKNQFSLKLSVTAADTAATVAVYCARGGGSISSWIDYGMVWGQGTIV 151  
QY 114 TVSS 117  
DB 152 TVSS 155

## RESULT 7

S30534  
Ig heavy chain V region - human  
C:Species: Homo sapiens (man)  
C:Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 16-Aug-1996  
C:Accession: S30534  
R:Marlette, X.  
submitted to the EMBL Data Library, October 1992  
A:Reference number: S30520  
A:Accession: S30534  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-130 <MAR>  
A:Cross-references: UNIPARC:UPI0000113P45; EMBL:Z18320  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:15-99/Domain: immunoglobulin homology <IMM>

Query Match 73.9%; Score 463.5; DB 2; Length 130;  
Best Local Similarity 73.1%; Pred. No. 2.5e-35;  
Matches 95; Conservative 5; Mismatches 17; Indels 13; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSI-TGGYLWNWIRQPPGKGLEWIGIISYDGTNN 59  
DB 1 QVQLQESGPGLVKPSQTLSTCTVSGGISISSGYSYWSWIRQPPGKGLEWIGRIYTSGSTN 60  
QY 60 YKPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVAVYCA-----RYGRVFFDYW 107  
DB 61 YNPLKSRVTISVDTSKNQFSLKLSVTAADTAATVAVYCARDKGGFWGYYTRNSRAAFDIW 120  
QY 108 GQGTFLTVSS 117  
DB 121 GQGTMTVTSS 130

## RESULT 8

S31586  
Ig heavy chain V region - human (fragment)  
C:Species: Homo sapiens (man)  
C:Date: 22-Nov-1993 #sequence\_revision 10-Nov-1995 #text\_change 23-Jul-1999  
C:Accession: S31586  
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.  
submitted to the EMBL Data Library, June 1992  
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the  
A:Reference number: S31585  
A:Accession: S31586  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-139 <CUI>  
A:Cross-references: UNIPARC:UPI000011646E; EMBL:Z14196; NID:G30978; PIDN:CAA78565.1; PID  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:34-116/Domain: immunoglobulin homology <IMM>

Query Match 73.9%; Score 463.5; DB 2; Length 139;

Best Local Similarity 78.5%; Pred. No. 2.7e-35;  
Matches 95; Conservative 5; Mismatches 16; Indels 5; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGIISYDGTNNY 60  
DB 20 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYWSWIRQPPGKGLEWIGRIYTSGSTNY 78  
QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVAVYCARYG-----RVFFDYWGQGTFLTVTS 116  
DB 79 NPPLKSRVTISVDTSKNQFSLKLSVTAADTAATVAVYCARGGGLGIRRGAFDIWGQGTMTVTS 138  
QY 117 S 117  
DB 139 S 139

## RESULT 9

S44114  
Ig heavy chain V region - human  
C:Species: Homo sapiens (man)  
C:Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 24-May-2001  
C:Accession: S44114  
R:Hawkins, R.E.; Zhu, D.; Ovecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.  
submitted to the EMBL Data Library, March 1994  
A:Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable r  
A:Reference number: S44105  
A:Accession: S44114  
A>Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-129 <HAW>  
A:Cross-references: UNIPARC:UPI0000116639; EMBL:Z31579; NID:G472968; PIDN:CAA83451.1; PI  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 73.8%; Score 462.5; DB 2; Length 129;  
Best Local Similarity 73.4%; Pred. No. 3e-35;  
Matches 91; Conservative 7; Mismatches 19; Indels 7; Gaps 1;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGIISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSGTLSTLCAVSGGISISSNWSWVRQPPGKGLEWIGIYHSGSTNY 60  
QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVAVYCARVGRV-----FDYWGQGTFLV 113  
DB 61 NPSPKSRVTISADTSKNQFSLKLSVTAADTAATVAVYCARNDYDFWSGGDPPDYWGQGTILV 120  
QY 114 TVSS 117  
DB 121 TVSS 124

## RESULT 10

S31512  
Ig heavy chain - human  
C:Species: Homo sapiens (man)  
C:Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 23-Jul-1999  
C:Accession: S31512  
R:Chaataigner, P.; Demaison, C.; Theze, J.; Zouali, M.  
submitted to the EMBL Data Library, December 1992  
A:Description: Dominance of clonotypic patterns and variable gene usage of anti-DNA auto  
A:Reference number: S31509  
A:Accession: S31512  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-155 <CHA>  
A:Cross-references: UNIPARC:UPI00001160F9; EMBL:X69860; NID:G33082; PIDN:CAA49494.1; PID  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:47-129/Domain: immunoglobulin homology <IMM>

Query Match 73.7%; Score 462; DB 2; Length 155;  
Best Local Similarity 75.0%; Pred. No. 4.1e-35;

```
Matches 93; Conservative 6; Mismatches 17; Indels 8; Gaps 2;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60
Db 33 QVQLQESGPGLVKPSSETLSLTCTVSGGSGIS-SYYWSWIRQPPGKGLEWIGYIYTGSAFY 91
QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAIVYVCARYGRVF-----FDYWGQGLTV 113
Db 92 NPPIKSRVTISVDTSKNQFSLKLVSSVTAADTAIVYVCARGGSGISWYVYVGHQDVMGQGITV 151
QY 114 TVSS 117
Db 152 TVSS 155
RESULT 11
S78052
Ig heavy chain precursor V-D-J region (clone mAb 63VH) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78052; S23717
R:Harindranath, N.
A:Reference number: S78051
A:Reference number: S78052
A:Accession: S78052
A:Molecule type: mRNA
A:Residues: 1-140 <HAW>
A:Cross-references: UNIPARC:UPI0000115B89; EMBL:X54441; NID:g37815; PIDN:CAA38308.1; PID
R:Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Buraastero, S.E.; Wilder, R.L.; Notkins
Int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and h
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23717
A:Molecule type: mRNA
A:Residues: 15-111 <HAW>
A:Cross-references: UNIPARC:UPI0000116417; EMBL:X54441
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-14/Domain: signal sequence (fragment) #status predicted <SIG>
F:15-140/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:29-111/Domain: immunoglobulin homology <IMM>
Query Match 73.6%; Score 461.5; DB 2; Length 140;
Best Local Similarity 73.2%; Pred. No. 4.1e-35;
Matches 93; Conservative 7; Mismatches 16; Indels 11; Gaps 2;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60
Db 15 QVQLQWAGNGLKPSSETLSLTCAVYGGSGFS-GYYWSWIRQPPGKGLEWIGEINHSGSTNY 73
QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAIVYVCARYGRVF-----FDYWGQGLTV 110
Db 74 NPPLKSRVTISVDTSKNQFSLKLSVTAADTAIVYVCARGGSGVIRFLEWLLYPAFDYWGQGLTV 133
QY 111 TLTVSS 117
Db 134 TLTVSS 140
RESULT 12
S78055
Ig heavy chain precursor V-D-J region (clone mAb 67VH) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78055; S23720
R:Harindranath, N.
A:Reference number: S78051
A:Reference number: S78055
A:Accession: S78055
A:Molecule type: mRNA
A:Residues: 1-145 <HAW>
A:Cross-references: UNIPARC:UPI0000115B8C; EMBL:X54445; NID:g37817; PIDN:CAA38312.1; PID
```

```
R:Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Buraastero, S.E.; Wilder, R.L.; Notkins
Int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and h
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23720
A:Molecule type: mRNA
A:Residues: 18-115 <HAW>
A:Cross-references: UNIPARC:UPI00001769D2; EMBL:X54445
A>Note: the authors translated the codon GCA for residue 67 as Arg
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-17/Domain: signal sequence (fragment) #status predicted <SIG>
F:18-145/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:32-115/Domain: immunoglobulin homology <IMM>
Query Match 73.3%; Score 459.5; DB 2; Length 145;
Best Local Similarity 72.7%; Pred. No. 6.5e-35;
Matches 93; Conservative 6; Mismatches 16; Indels 11; Gaps 2;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60
Db 18 QVQLQESGPGLVKPSSETLSLTCAVGGSSISSNWSWVRQPPGKGLEWIGIYHSGSTNY 77
QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAIVYCAR-----YGR-VFFDYWGQGLTV 109
Db 78 NPPLKSAVTISVDTSKNQFSLKLSVTAADTAIVYCARVTGTFWSGYVTRGYVFDYWGQGLTV 137
QY 110 TLTVSS 117
Db 138 TLTVSS 145
RESULT 13
S37200
Ig heavy chain V region - mouse
C:Species: Mus musculus (house mouse)
C>Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 21-Jan-2000
C:Accession: S37200
R:Fischer, R.; Voss, A.; Hunziker, W.; Stierhof, Y.D.; Kreuzaler, F.
A:Submitted to the EMBL Data Library, August 1993
A:Description: Production and cloning of TMV-specific monoclonal antibodies.
A:Reference number: S37200
A:Accession: S37200
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-121 <FIS>
A:Cross-references: UNIPARC:UPI00001161AC; EMBL:X74587; NID:g402639; PID:g402640
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:15-98/Domain: immunoglobulin homology <IMM>
Query Match 73.0%; Score 458; DB 2; Length 121;
Best Local Similarity 71.7%; Pred. No. 7.3e-35;
Matches 86; Conservative 13; Mismatches 17; Indels 4; Gaps 1;
QY 2 VQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYK 61
Db 2 VQLQESGPGLVKPSQSLSLTCSVTGYSITSSYYWNWIRQPPGKLEWNGYISYDGRNDYN 61
QY 62 PSLKDRVTISRDTSKNQFSLKLSVTAADTAIVYVCARYGRV----FFDYWGQGLTVTVSS 117
Db 62 PSLKNRISITRDTSKNQFFLNLSVTEDTATYYCARGGIYGDYDFDSWGQGLTVTVSS 121
RESULT 14
S44113
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001
C:Accession: S44113
R:Hawkins, R.E.; Zhu, D.; Ovecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.
A:Submitted to the EMBL Data Library, March 1994
A:Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable r
```

A:Reference number: S44105  
 A:Accession: S44113  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-121 <HAW>  
 A:Cross-references: UNIPARC:UPI000011662F; EMBL:Z31389; NID:G472967; PIDN:CAA83264.1; PI  
 C:Superfamily: immunoglobulin V region; immunoglobulin homology  
 C:Keywords: heterotetramer; immunoglobulin  
 F:15-99/Domain: immunoglobulin homology <IMM>

Query Match 72.9%; Score 457; DB 2; Length 121;  
 Best Local Similarity 75.2%; Pred. No. 9e-35;  
 Matches 91; Conservative 5; Mismatches 21; Indels 4; Gaps 2;  
 QY 1 QVQLQESGPGLVKPSSETLSLTCTVS-GYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 59  
 Db 1 QVQLQESGPGLVKPSSETLSLTCTVS-GYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 59  
 QY 60 YKPSLKDRTVISRDTSKNQFSLKSSVTAADTAVYTCARYGRV---FDYWGQGTLTVTVS 116  
 Db 61 YNPSLKSRTVLSVDTSKNQFSLKSSVTAADTGVYTCARYGRV---FDYWGQGTLTVTVS 120  
 QY 117 S 117  
 Db 121 S 121

## RESULT 15

A49045  
 Ig heavy chain V region (anti-B cell autoantibody) - human (fragment)  
 C:Species: Homo sapiens (man)  
 C:Date: 19-Dec-1993 #sequence\_revision 18-Nov-1994 #text\_change 23-Jul-1999  
 C:Accession: A49045  
 R:Grillot-Courvalin, C.; Brouet, J.C.; Pillier, F.; Rassenti, L.Z.; Labaume, S.; Silverma  
 Eur. J. Immunol. 22, 1781-1788, 1992  
 A:Title: An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes i bl  
 A:Reference number: A49045; MUID:92324290; PMID:1623923  
 A:Accession: A49045  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-140 <GRI>  
 A:Cross-references: UNIPARC:UPI0000113EDD; GB:S39381; NID:G250899; PIDN:AAB22441.1; PID:  
 A>Note: sequence extracted from NCBI backbone (NCBI:108086, NCBI:108089)  
 C:Superfamily: immunoglobulin V region; immunoglobulin homology  
 C:Keywords: heterotetramer; immunoglobulin  
 F:34-116/Domain: immunoglobulin homology <IMM>

Query Match 72.7%; Score 456; DB 2; Length 140;  
 Best Local Similarity 75.4%; Pred. No. 1.3e-34;  
 Matches 92; Conservative 7; Mismatches 17; Indels 6; Gaps 2;  
 QY 1 QVQLQESGPGLVKPSSETLSLTCTVS-GYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60  
 Db 20 QVQLQWAGLGLKPKSETLSLTCTAVYGGSPS-GYVSWIRQPPGKGLEWIGYISYDGTNNY 78  
 QY 61 KPSLKDRTVISRDTSKNQFSLKSSVTAADTAVYTCARYGRV-----FDYWGQGTLTVTV 115  
 Db 79 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVYTCARYGRV-----FDYWGQGTLTVTV 138  
 QY 116 SS 117  
 Db 139 SS 140

Search completed: January 10, 2006, 20:55:15  
 Job time : 14.1157 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model  
Run on: January 10, 2006, 20:26:41 ; Search time 78.8731 Seconds  
(without alignments)  
1046.577 Million cell updates/sec

Title: US-10-735-916A-79  
Perfect score: 627  
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Uniprot 05.80:\*  
1: uniprot\_spriot:\*  
2: uniprot\_trembl:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	489	78.0	119	2 Q9UL73 HUMAN	Q9ul73 homo sapien
2	483.5	77.1	465	2 Q6GMX6 HUMAN	Q6gmx6 homo sapien
3	471	75.1	479	2 Q99M22 MOUSE	Q99m22 mus musculus
4	467	74.5	476	2 Q6GMX1 HUMAN	Q6gmx1 homo sapien
5	462.5	73.8	477	2 Q6GMX7 HUMAN	Q6gmx7 homo sapien
6	455.5	72.6	136	2 Q6LBQ5 MOUSE	Q6lbq5 mus musculus
7	455.5	72.6	483	2 Q5U413 MOUSE	Q5u413 mus musculus
8	454.5	72.5	150	2 Q95973 HUMAN	Q95973 homo sapien
9	454.5	72.5	576	2 Q6P418 HUMAN	Q6p418 homo sapien
10	454	72.4	137	1 HV46 MOUSE	P01822 mus musculus
11	447.5	71.4	620	2 Q96EY0 HUMAN	Q96ey0 homo sapien
12	447	71.3	119	2 Q53VQ5 MOUSE	Q53vq5 mus musculus
13	439.5	70.1	478	2 Q72379 HUMAN	Q72379 homo sapien
14	438	69.9	492	2 Q72374 HUMAN	Q72374 homo sapien
15	434.5	69.3	139	2 Q86SX2 HUMAN	Q86sx2 homo sapien
16	434.5	69.3	496	2 Q96KX8 HUMAN	Q96kx8 homo sapien
17	430.5	68.7	120	2 Q53VR7 MOUSE	Q53vr7 mus musculus
18	430	68.6	115	2 Q53VQ1 MOUSE	Q53vq1 mus musculus
19	430	68.6	615	2 Q569B6 RAT	Q569b6 rattus norv
20	428	68.3	590	2 Q569B8 RAT	Q569b8 rattus norv
21	427.5	68.2	146	1 HV21 HUMAN	P06331 homo sapien
22	425	67.8	119	2 Q53VR3 MOUSE	Q53vr3 mus musculus
23	424	67.6	595	2 Q8WUX4 HUMAN	Q8wux4 homo sapien
24	424	67.6	597	2 Q9BU10 HUMAN	Q9bu10 homo sapien
25	424	67.6	597	2 Q6GMX5 HUMAN	Q6gmx5 homo sapien
26	424	67.6	625	2 Q96AA6 HUMAN	Q96aa6 homo sapien
27	422	67.3	597	2 Q9BQB8 HUMAN	Q9bqb8 homo sapien
28	421	67.1	116	1 HV60 MOUSE	P18531 mus musculus
29	415	66.2	98	2 Q53VQ4 MOUSE	Q53vq4 mus musculus
30	413.5	65.9	130	2 Q81ZD7 HUMAN	Q81zd7 homo sapien
31	411	65.6	478	2 Q6NYH3 HUMAN	Q6nyh3 homo sapien

32	404	64.4	477	2 Q51QJ1 RAT	Q51qj1 rattus norv
33	403	64.3	119	2 Q53VQ3 MOUSE	Q53vq3 mus musculus
34	402	64.1	98	2 Q53VR6 MOUSE	Q53vr6 mus musculus
35	402	64.1	117	1 HV2G HUMAN	P01825 homo sapien
36	398.5	63.6	591	2 Q51OL9 RAT	Q51ol9 rattus norv
37	397	63.3	98	2 Q53VR2 MOUSE	Q53vr2 mus musculus
38	397	63.3	469	2 Q5M839 RAT	Q5m839 rattus norv
39	395	63.0	98	2 Q53VQ0 MOUSE	Q53vq0 mus musculus
40	395	63.0	129	1 HV2F HUMAN	P01824 homo sapien
41	394.5	62.9	122	1 HV2F HUMAN	Q9ul75 homo sapien
42	393.5	62.8	116	2 Q723Y6 HUMAN	Q723y6 homo sapien
43	393	62.7	113	1 HV47 MOUSE	P01823 mus musculus
44	392	62.5	476	2 Q6MZX7 HUMAN	Q6mzx7 homo sapien
45	391.5	62.4	473	2 Q8TC63 HUMAN	Q8tc63 homo sapien

ALIGNMENTS

RESULT 1  
Q9UL73 HUMAN  
ID Q9UL73 HUMAN PRELIMINARY; PRT; 119 AA.  
AC Q9UL73;  
DT 01-MAY-2000 (Tremblrel. 13, Created)  
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)  
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)  
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531; Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., Young D.C.,  
RA "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus.",  
RT Clin. Immunol. Immunopathol. 87:184-192(1998).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=1660528; Manheimer-Lory A., Katz J.B., Pillinger M., Ghossein C., Smith A., Diamond B.;  
RA "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype",  
RT J. Exp. Med. 174:1639-1652(1991).  
RN [3]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=2511001; Sanz I., Kelly P., Williams C., Scholl S., Tucker P., Capra J.D.;  
RT "The smaller human VH gene families display remarkably little polymorphism.",  
RL EMBO J. 8:3741-3748(1989).  
DR EMBL; AF035041; AAD56277.1; -, mRNA.  
DR PIR; PH0876; PH0876.  
DR PIR; S12416; S12416.  
DR HSSP; P01820; LG7J.  
DR SMR; Q9UL73; 1-119.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003596; Ig\_v.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS50835; IG\_LIKE; 1.  
FT NON\_TER 1  
FT NON\_TER 119  
SQ SEQUENCE 119 AA; 13219 MW; 1BD86B6420EA0BE CRC64;

Query Match 78.0%; Score 489; DB 2; Length 119;  
Best Local Similarity 80.0%; Pred. No. 6.9e-43;  
Matches 96; Conservative 7; Mismatches 13; Indels 4; Gaps 2;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLNWNIRQPPGKLEWIGYISYDGTNNY 60  
 Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIIC-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59  
 Qy 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAFTAVYCAR---YGRVFFDYWGQGLTLVTSS 117  
 Db 60 TPLSKSRVTISVDRSKNQPSLKLTLTAADTAFTAVYCARLSNWNQPPYFDYWGQGLTLVTSS 119

## RESULT 2

Q6GMX6\_HUMAN  
 ID Q6GMX6\_HUMAN PRELIMINARY; PRT; 465 AA.  
 AC Q6GMX6;  
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
 DE Hypothetical protein.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
 OC Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]

## NUCLEOTIDE SEQUENCE.

RC TISSUE=Primary B-Cells;  
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).  
 RN [2]

## NUCLEOTIDE SEQUENCE.

RC TISSUE=Primary B-Cells;  
 RA Strausberg R.;  
 RL Submitted (JUN-2004) to the EMBL/GenBank/DBSJ databases.  
 DR EMBL; BC073766; AAH3766.1; -; mRNA.  
 DR GO; GO:0016021; C:integral to membrane; IEA.  
 DR InterPro; IPR003599; IG.  
 DR InterPro; IPR007110; IG-like.  
 DR InterPro; IPR003597; IG cl.  
 DR InterPro; IPR003006; IG\_MHC.  
 DR InterPro; IPR003596; IG\_v.  
 DR Pfam; PF07654; CI-set; 3.  
 DR SMART; SM00409; IG; 2.  
 DR SMART; SM00407; IGcl; 3.  
 DR SMART; SM00406; IGv; 1.  
 DR PROSITE; PS50835; IG\_LIKE; 4.  
 DR PROSITE; PS00290; IG\_MHC; UNKNOWN\_2.  
 KW Hypothetical protein.  
 SQ SEQUENCE 465 AA; 51083 MW; B3A9B7D0FDB1386E CRC64;

Query Match 77.1%; Score 483.5; DB 2; Length 465;

Best Local Similarity 82.1%; Pred. No. 1.2e-41;

Matches 96; Conservative 5; Mismatches 15; Indels 1; Gaps 1;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLNWNIRQPPGKLEWIGYISYDGTNNY 60  
 Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIIC-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59

Db 20 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYYWSWIRQPPGKLEWIGYITSGSTNY 78  
 Qy 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAFTAVYCARVGRVFDYWGQGLTLVTSS 117  
 Db 79 NPSLSRVTSVDRSKNQPSLKLSSVTAADTAFTAVYCARGRFTYFDYWGQGLTLVTSS 135

## RESULT 3

Q99M22\_MOUSE  
 ID Q99M22\_MOUSE PRELIMINARY; PRT; 479 AA.  
 AC Q99M22;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
 DE LOC238447 protein.  
 GN Name=LOC238447;  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
 OC Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]

## NUCLEOTIDE SEQUENCE.

RC STRAIN=Mix FVB/N;  
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).  
 RN [2]

## NUCLEOTIDE SEQUENCE.

RC STRAIN=Mix FVB/N;  
 RX TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;  
 RG NIH MGC Project;  
 RL Submitted (JAN-2001) to the EMBL/GenBank/DBSJ databases.  
 DR EMBL; BC002091; AAH02091.1; -; mRNA.  
 DR HSSP; P01820; 1G7J.  
 DR GO; GO:0003823; F:antigen binding; IEA.  
 DR InterPro; IPR007110; IG-like.  
 DR InterPro; IPR003597; IG cl.  
 DR InterPro; IPR003006; IG\_MHC.  
 DR InterPro; IPR003596; IG\_v.  
 DR Pfam; PF07654; CI-set; 2.  
 DR SMART; SM00406; IGv; 1.  
 DR PROSITE; PS50835; IG\_LIKE; 4.  
 DR PROSITE; PS00290; IG\_MHC; UNKNOWN\_2.  
 KW Immunoglobulin domain.  
 SQ SEQUENCE 479 AA; 51992 MW; 768E39A138918892 CRC64;

Query Match

Best Local Similarity 75.1%; Score 471; DB 2; Length 479;

Matches 86; Conservative 14; Mismatches 16; Indels 0; Gaps 0;

Qy 2 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLNWNIRQPPGKLEWIGYISYDGTNNY 61  
 Db 20 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLNWNIRQPPGKLEWIGYIYSGSTNY 79



Db 20 QVQLQSGPGLVKPSETLSLTCTVSGSGSIS-SYYWSWIRQTAGKLEWIGYISHSGSTTY 78  
QY 61 KPSLKDRTVTSRDTSKNQFSLKLSVTAADTAVVYCARVGRVF---FDYWGQGLTVTVSS 117  
Db 79 NPSLKSRVTLSDTSKQFSLKLSVTAADTAVVYCARVGRVDFDYWGQGLTVTVSS 137

## RESULT 6

OSLB05 MOUSE  
ID Q6LB05\_MOUSE PRELIMINARY; PRT; 136 AA.  
AC Q6LB05;  
DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
DE VH gene product (Fragment).  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
OC Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RX MEDLINE=90067954; PubMed=2587273;  
RA Urakov D.N., Deev S.M., Polyakovskiy O.L.;  
RT "The structure of the expressible VH gene from a hybridoma producing  
RT monoclonal antibodies against porcine transferrin.";  
RL Nucleic Acids Res. 17:9481-9481(1989).  
DR EMBL; X16740; CAA347114.1; -; Genomic\_DNA.  
DR HSSP; P18532; 1KCV.  
DR SMR; Q6LB05; 20-136.  
DR InterPro; IPR003599; IG.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003596; IG\_V.  
DR SMART; SM00409; IG; 1.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS0835; IG LIKE; 1.  
FT NON TER 1  
SQ SEQUENCE 136 AA; 15307 MW; 5B0F439CCFB15C3A CRC64;

Query Match 72.6%; Score 455.5; DB 2; Length 136;  
Best Local Similarity 72.6%; Pred. No. 2.5e-39;  
Matches 85; Conservative 14; Mismatches 17; Indels 1; Gaps 1;

QY 2 VQLQSGPGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61  
Db 20 VQLQSGPGLVKPQSLSLTCTVTSITSYGYHWHIRQPPGKLEWIGYISYDGSNGYN 79  
QY 62 PSLKDRVTISRDTSKNQFSLKLSVTAADTAVVYCAR-YGRVFFDYWGQGLTVTVSS 117  
Db 80 PSLKSRISITRDTSKNQFSLKLSVTTEDTATYCTRGDGHFFTYWGQGLTVTVSA 136

## RESULT 7

Q5U413 MOUSE  
ID Q5U413\_MOUSE PRELIMINARY; PRT; 483 AA.  
AC Q5U413;  
DT 01-FEB-2005 (TrEMBLrel. 29, Created)  
DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)  
DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)  
DE LOC544903 protein.  
GN Name=LOC544903;  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
OC Muroidea; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC STRAIN=FVB/N; Tissue=Colon;  
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Stapchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Diatlenko M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Rana S.A., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,  
RA Bosak S.S., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Pahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
RA Butlerfield V.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,  
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16999-16903 (2002).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RC STRAIN=FVB/N; Tissue=Colon;  
RG NIH MGC Project;  
RL Submitted (Oct-2004) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BC085312; AAH85312.1; -; mRNA.  
DR Ensembl; ENSMUG00000054328; Mus musculus.  
DR GO; GO:0003823; F:antigen binding; IEA.  
DR InterPro; IPR003599; IG.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003597; IG\_CL.  
DR InterPro; IPR003006; IG\_MHC.  
DR InterPro; IPR003596; IG\_V.  
DR Pfam; PF07654; CI-set; 2.  
DR SMART; SM00409; IG; 3.  
DR SMART; SM00407; IGV; 3.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS0835; IG LIKE; 4.  
DR PROSITE; PS00290; IG\_MHC; UNKNOWN 2.  
SQ SEQUENCE 483 AA; 52714 MW; 7C372DA501A4A0D1 CRC64;

Query Match 72.6%; Score 455.5; DB 2; Length 483;  
Best Local Similarity 72.3%; Pred. No. 1e-38;  
Matches 86; Conservative 12; Mismatches 18; Indels 3; Gaps 1;

QY 2 VQLQSGPGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61  
Db 20 VQLQSGPGLVKPQSLSLTCTVTSITSYGYHWHIRQPPGKLEWIGYISYSGSNYN 79  
QY 62 PSLKDRVTISRDTSKNQFSLKLSVTAADTAVVYCARVGRVF---FDYWGQGLTVTVSS 117  
Db 80 PSLKSRISITRDTSKNQFSLKLSVTTEDTATYCTRGDGHFFTYWGQGLTVTVSS 138

## RESULT 8

O95973 HUMAN  
ID O95973\_HUMAN PRELIMINARY; PRT; 150 AA.  
AC O95973;  
DT 01-MAY-1999 (TrEMBLrel. 10, Created)  
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE VH4 heavy chain variable region precursor (fragment).  
GN Name=IGH;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RA Suh C.-H., Song C.-H., Lee C.-H., Lee S.-K.;  
RT "Clonal proliferation of IgM secreting B cell in the synovium of  
RT Behcet's patient with arthritis.";  
RL Submitted (Oct-1998) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP NUCLEOTIDE SEQUENCE.

```
RX PubMed=1718404;
RA Harindranath N., Goldfarb I.S., Ikematsu H., Burastero S.E.,
RA Wilder R.L., Notkins A.L., Casali P.;
RT "Complete sequence of the genes encoding the VH and VL regions of low-
RT and high-affinity monoclonal IgM and IgA1 rheumatoid factors produced
RT by CD5+ B cells from a rheumatoid arthritis patient.;"
RL Int. Immunol. 3:865-875(1991).
DR EMBL; AF103795; AAC79084.1; -; mRNA.
DR PIR; S31673; S31673.
DR PIR; S78056; S78056.
DR HSSP; P01820; 1G7J.
DR SMR; O95973; 20-147.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 1.
KW Signal.
FT SIGNAL.
FT CHAIN
FT NON TER
FT SEQUENCE
SQ SEQUENCE 150 AA; 16315 MW; 85664E04938AA7C9 CRC64;

Query Match 72.5%; Score 454.5; DB 2; Length 150;
Best Local Similarity 75.4%; Pred. No. 3.5e-39;
Matches 89; Conservative 9; Mismatches 19; Indels 1; Gaps 1;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITG-GYLWNIRQPPGKLEWIGVISYDGTNN 59
DB 20 QLQLQESGPGLVKPSSETLSLTCTVSGYSISTNYWGVIQPPGKLEWIGSLHNSGSDY 79

QY 60 YKPSLKDRTVTSRDTSKNQFSKLSSVTAADTAVVYCYARYGVFF--DYWGQGLTVTVSS 117
DB 80 YNPSLKSRTVTSVDTSKNQFSKLSSVTAADTAVVYCYARYGVFF--DYWGQGLTVTVSS 137

RESULT 9
Q6P4I8 HUMAN PRELIMINARY; PRT; 576 AA.
AC Q6P4I8;
DT 05-JUL-2004 (TremBLrel. 27, Created)
DT 05-JUL-2004 (TremBLrel. 27, Last sequence update)
DE IG heavy chain V region MOPC 315 precursor.
DE IGHD protein.
GN Name=IGHD;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.D., Feingold E.A., Grouse L.H., Derge J.G.,
RA Strausberg R.L., Collins F.S., Wagner L., Shenmen C.W., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Ioshizuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S.S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.;"
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
```

```
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (DSC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC063384; AAH63384.1; -; mRNA.
DR HSSP; P01820; 1A7N.
DR Ensembl; ENSG00000196122; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig ci.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; CI-set; 1.
DR PIR; PF00047; Ig; 2.
DR SMART; SM00407; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 4.
DR PROSITE; PS0290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 576 AA; 63364 MW; FBB97C949D720F1E CRC64;

Query Match 72.5%; Score 454.5; DB 2; Length 576;
Best Local Similarity 74.2%; Pred. No. 1.6e-38;
Matches 89; Conservative 8; Mismatches 20; Indels 3; Gaps 1;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNIRQPPGKLEWIGVISYDGTNNY 60
DB 27 QVQLQESGPGLVKPSSETLSLTCTVSGYSISSNWSWVRQPPGKLEWIGIYHSGSTNY 86

QY 61 KPSLKDRTVTSRDTSKNQFSKLSSVTAADTAVVYCYARYGVFF--DYWGQGLTVTVSS 117
DB 87 NPSLKSRTVTSVDTSKNQFSKLSSVTAADTAVVYCYARYGVFF--DYWGQGLTVTVSS 146

RESULT 10
HV46 MOUSE
ID HV46 MOUSE STANDARD; PRT; 137 AA.
AC P01822;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V region MOPC 315 precursor.
DE Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=89238351; PubMed=2497341; DOI=10.1016/0161-5890(89)90133-8;
RA Rinfret A., Horne C., Dorrington K.J., Klein M.;
RT "Cloning, sequencing and expression of the rearranged MOPC 315 VH gene
RT segment.;"
RL Mol. Immunol. 26:431-434(1989).
RN [2]
RP PROTEIN SEQUENCE OF 1-31.
RX MEDLINE=78094475; PubMed=414225;
RA Jilka R.L., Pestka S.;
RT "Amino acid sequence of the precursor region of MOPC-315 mouse
RT immunoglobulin heavy chain.;"
RL Proc. Natl. Acad. Sci. U.S.A. 74:5692-5696(1977).
RN [3]
RP PROTEIN SEQUENCE OF 1-21.
RX MEDLINE=79148758; PubMed=428562;
RA Schechter I., Wolf O., Zemall R., Burstein Y.;
RT "Structure and function of immunoglobulin genes and precursors.;"
RL Fed. Proc. 38:1839-1845(1979).
RN [4]
RP PROTEIN SEQUENCE OF 19-136.
RX MEDLINE=74170779; PubMed=4524622;
RA Francis S.H., Leslie R.G.Q., Hood L., Eisen H.N.;
RT "Amino-acid sequence of the variable region of the heavy (alpha) chain
```

of a mouse myeloma protein with anti-hapten activity.";  
Proc. Natl. Acad. Sci. U.S.A. 71:1123-1127(1974).

SEQUENCE REVISION TO 53  
MEDLINE=77244979; PubMed=268248;  
Hood L., Margolies M.N., Givol D., Zakut R.;  
Unpublished results, cited by:  
Padlan E.A., Davies D.R., Peck I., Givol D., Wright C.;  
Cold Spring Harb. Symp. Quant. Biol. 41:627-637(1977).  
-I- MISCELLANEOUS: This alpha chain was isolated from a myeloma  
protein that has anti-dinitrophenyl activity.  
-----  
This Swiss-Prot entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use as long as its content is in no way modified and this statement is not  
removed.

EMBL; M27638; AAA61337.1; -; Genomic DNA.

EMBL; X07880; CAA30727.1; -; Genomic DNA.

PIR; P0102; AVMS35.

HSSP; P01820; 1G7J.

SMR; P01822; 20-137.

Ensembl; ENSMUSG00000057049; Mus musculus.

InterPro; IPR007110; Ig-like.

SMART; SM00406; IGV; 1

PROSITE; PS50835; IG\_LIKE; 1.

Direct protein sequencing; Immunoglobulin domain;

Immunoglobulin V region; Signal.

SIGNAL 1 18

CHAIN 19 137 Ig heavy chain V region MOPC 315.

REGION 19 48 Framework-1.

REGION 49 54 Complementarity-determining-1.

REGION 55 68 Framework-2.

REGION 69 84 Complementarity-determining-2.

REGION 85 116 Framework-3.

REGION 117 126 Complementarity-determining-3.

REGION 127 137 Framework-4.

DISULFID 40 114 By similarity.

CONFLICT 15 15 G -> GG (in Ref. 1; CAA30727).

CONFLICT 15 15 G -> H (in Ref. 2).

CONFLICT 77 78 G -> YG (in Ref. 4).

CONFLICT 102 102 N -> D (in Ref. 4).

CONFLICT 123 123 Missing (in Ref. 4).

NON\_TER 137 137

SEQUENCE 137 AA; 15399 MW; FB3828304C2B81DC CRC64;

Query Match 72.4%; Score 454; DB 1; Length 137;

Best Local Similarity 71.2%; Pred. No. 3.6e-39;

Matches 84; Conservative 14; Mismatches 18; Indels 2; Gaps 1;

QY 2 VQLQESGGLVKPSTLSLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61

DB 20 VQLQESGGLVKPQSLSLCTVSGYSITSGYFNWIRQPPGKLEWIGYIKYDGSNGYN 79

QY 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCA--RYGRVFPDYQGQGLTVTVSS 117

DB 80 PSLKRVISITRDTSENQPFLLKNSVTTEDTATYYCAGDNDHLYYPDYQGQGLTVTVSS 137

RESULT 11

ID Q96EY0 HUMAN

AC Q96EY0 HUMAN PRELIMINARY; PRT; 620 AA.

DT 01-DEC-2001 (TRENBLrel. 19, Created)

DT 01-DEC-2001 (TRENBLrel. 19, Last sequence update)

DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)

DE IGHM protein.

GN Name=IGHM;

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;

OC Homo.

OX NCBI\_TaxID=9606;

RN [1]

RP NUCLEOTIDE SEQUENCE

RC TISSUE=Primary B-Cells;

RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

RA Brownstein M.J., Ugin T.B., Toshiyuki S., Carninci P., Prange C.,

RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,

RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,

RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,

RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,

RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;

RT "Generation and initial analysis of more than 15,000 full-length human

and mouse cDNA sequences.";

Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

RL [2]

RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Primary B-Cells;

RG NIH MGC Project;

RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.

RN [3]

RP NUCLEOTIDE SEQUENCE.

RX PubMed=1904154;

RA Neale G.A., Kitchingman G.R.;

RT "mRNA transcripts initiating within the human immunoglobulin mu heavy

chain enhancer region contain a non-translatable exon and are

extremely heterogeneous at the 5' end.";

Nucleic Acids Res. 19:2427-2433(1991).

EMBL; BC011857; AH01857.2; -; mRNA.

PIR; S15590; S15590.

HSSP; P01820; 1G7J.

SMR; Q96EY0; 27-251.

Ensembl; ENSG00000130076; Homo sapiens.

InterPro; IPR003599; Ig.

InterPro; IPR007110; Ig-like.

InterPro; IPR003597; Ig.CI.

InterPro; IPR003006; Ig.MHC.

InterPro; IPR003596; Ig.V.

Pfam; PF07654; CI-set; 4.

SMART; SM00409; IG; 2.

SMART; SM00407; IG1; 4.

SMART; SM00406; IGV; 1.

PROSITE; PS50835; IG\_LIKE; 5.

PROSITE; PS00290; IG\_MHC; UNKNOWN 3.

SEQUENCE 620 AA; 68125 MW; 950A1A4A6E8FF27B CRC64;

Query Match 71.4%; Score 447.5; DB 2; Length 620;

Best Local Similarity 76.9%; Pred. No. 9e-38;

Matches 93; Conservative 4; Mismatches 19; Indels 5; Gaps 2;

QY 1 QVQLQESGGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60

DB 27 QVQLQESGGLVKPSETLSLCTVSGGSIS-SYTWIRQPPGKLEWIGYISYDGTNNY 85

QY 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCA----RYGRVFPDYQGQGLTVTVS 116

DB 86 NPSLKSRVTMSVDTSKNQFSLKSSVTAADTAVYYCASQPWELPTVGLFYQGQGLTVTVS 145

QY 117 S 117

DB 146 S 146

```

RESULT 12
Q53V05 MOUSE
ID Q53V05_MOUSE PRELIMINARY; PRT; 119 AA.
AC Q53V05
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN NUCLEOTIDE SEQUENCE.
RP MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., There J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBO J. 4:3681-3688(1985).
RN NUCLEOTIDE SEQUENCE OF 28-39.
RP Fougereau M.;
RA Submitted (NOV-1986) to the EMBL/GenBank/DDBJ databases.
DR EMBL; X03378; CAA27095.1; -; mRNA.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13931 MW; 502E51A5213F056E CRC64;

Query Match 71.3%; Score 447; DB 2; Length 119;
Best Local Similarity 70.3%; Pred. No. 1.6e-38;
Matches 83; Conservative 14; Mismatches 13; Indels 8; Gaps 2;

Qy 2 VQLQESGPGLVKPSSETLSLCTVSGYSITGGYLWNWIRPPGKGLWIGYISYDGTNNYK 61
Db 2 VQLQESGPGLVKPSSETLSLCTVSGYSITGGYLWNWIRPPGKGLWIGYISYDGTNNYK 61
Qy 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCAR---YGRVFFDYWGQGLTVT 111
Db 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCAR---YGRVFFDYWGQGLTVT 111

RESULT 13
Q72379 HUMAN
ID Q72379_HUMAN PRELIMINARY; PRT; 478 AA.
AC Q72379
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein DKFZp686K04218 (Fragment).
GN Name=DKFZp686K04218;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN NUCLEOTIDE SEQUENCE.
RP TISSUE=Human rectum tumor;
RA Bloecker H., Boecher M., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
DR EMBL; BX538066; CAD97996.1; -; mRNA.
DR HSSP; P01820; 1G7J.
DR SMR; Q72379; 248-456.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig MHC.
DR Hypothetical protein DKFZp686K04218 (Fragment).
GN Name=DKFZp686K04218;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN NUCLEOTIDE SEQUENCE.
RP TISSUE=Human rectum tumor;
RA Bloecker H., Boecher M., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
DR EMBL; BX538066; CAD97996.1; -; mRNA.
DR HSSP; P01820; 1G7J.
DR SMR; Q72379; 248-456.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 2.

Query Match 69.9%; Score 438; DB 2; Length 492;
Best Local Similarity 72.4%; Pred. No. 6.8e-37;
Matches 89; Conservative 8; Mismatches 18; Indels 8; Gaps 3;

Qy 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITG-GYLWNWIRPPGKGLWIGYISYDGTNN 59
Db 32 QLQLQESGPGLVKPSSETLSLCTVSGYSITG-GYLWNWIRPPGKGLWIGYISYDGTNN 59
Qy 60 YKPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCAR---YGRVFFDYWGQGLTVT 114
Db 92 YKPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCAR---YGRVFFDYWGQGLTVT 114
Qy 115 VSS 117
Db 115 VSS 117

```

```

Db          150 VSS 152
||||
RESULT 15
Q86SX2_HUMAN
ID Q86SX2_HUMAN PRELIMINARY; PRT; 139 AA.
AC Q86SX2;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Full-length cDNA clone CS0DL004YM19 of B cells (Ramos cell line) of
DE Homo sapiens (human) (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=B cells;
RA Li W.B., Gruber C., Jessee J., Polayes D.;
RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=B cells;
RA Genoscope;
RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
DR EMBL; BX248300; CAD62627.1; -; mRNA.
DR HSSP; F01820; 1G7J.
DR SMR; Q86SX2; 33-129.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 1.
FT NON_TER 1
SQ SEQUENCE 139 AA; 15573 MW; 7D1E2302410E4F8C CRC64;

Query Match      69.3%; Score 434.5; DB 2; Length 139;
Best Local Similarity 86.7%; Pred. No. 3.9e-37;
Matches 85; Conservative 3; Mismatches 9; Indels 1; Gaps 1;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db |||||
Qy 33 QVQLQESGPGLVKPSSETLSLTCTVSGGISIS-SYVSWIRQPPGKLEWIGYIYSGSTNY 91
Db |||||

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAVYYCAR 98
Db |||||
Qy 92 NPSLKSRVTISVDTSKNQFSLKLSVTAADTAVYYCAR 129
Db |||||

```

Search completed: January 10, 2006, 20:53:27  
 Job time : 78.8731 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 80.7649 Seconds  
(without alignments)  
636.505 Million cell updates/sec

Title: US-10-735-916A-79  
Perfect score: 627  
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_21.\*  
1: Geneseqp1980a:\*  
2: Geneseqp1990a:\*  
3: Geneseqp2000a:\*  
4: Geneseqp2001a:\*  
5: Geneseqp2002a:\*  
6: Geneseqp2003a:\*  
7: Geneseqp2003ba:\*  
8: Geneseqp2004a:\*  
9: Geneseqp2005a:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	627	100.0	117	7	ADJ76913
2	627	100.0	117	7	ADJ76913 Anti-IGF-
3	627	100.0	135	7	ADJ76915
4	627	100.0	135	9	ADJ76915 Anti-IGF-
5	623	99.4	117	7	ADJ76909
6	623	99.4	117	9	ADJ76909 Anti-IGF-
7	623	99.4	135	7	ADJ76911
8	623	99.4	135	9	ADJ76911 Anti-IGF-
9	615	98.1	117	7	ADJ76917
10	615	98.1	117	9	ADJ76917 Anti-IGF-
11	615	98.1	135	7	ADJ76919
12	615	98.1	135	9	ADJ76919 Anti-IGF-
13	541	86.3	117	7	ADJ76903
14	541	86.3	117	9	ADJ76903 Anti-IGF-
15	541	86.3	127	7	ADJ76886
16	541	86.3	127	9	ADJ76886 Anti-IGF-
17	526.5	84.0	120	7	ADJ76886 Murine im
18	509.5	81.3	246	3	ADJ76886 Humanised
19	507	80.9	119	7	ADJ76886 Anti-mur
20	506.5	80.8	120	7	ADJ76886 Murine-ex
21	506.5	80.8	121	7	ADJ76886 Humanised
22	503.5	80.3	120	7	ADJ76886 Murine-ex
23	503.5	80.3	122	7	ADJ76886 Humanised
24	503.5	80.3	122	7	ADJ76886 Murine-ex

25	502.5	80.1	120	7	ADP03958
26	500.5	79.8	116	7	ADP03957
27	500.5	79.8	121	5	ADP03957 Murine-ex
28	500.5	79.8	121	8	ADP03957 Human ant
29	500.5	79.8	122	7	ADP03887
30	500.5	79.8	122	7	ADP03887 Murine-ex
31	500	79.7	119	2	ADP03884
32	500	79.7	119	2	ADP03884 Murine Ab
33	500	79.7	119	6	ADP03884 Human Ab
34	500	79.7	121	6	ADP03884 Antibody
35	498	79.4	119	9	ADP03884 Human ant
36	497	79.3	117	3	ADP03884 Human IGG
37	497	79.3	121	7	ADP03884 Human ant
38	497	79.3	121	7	ADP03884 Human ant
39	497	79.3	121	7	ADP03884 Human ant
40	497	79.3	121	7	ADP03884 Human ant
41	495.5	79.0	122	9	ADP03884 Human ant
42	495.5	79.0	122	9	ADP03884 Human ant
43	494.5	78.9	121	8	ADP03884 Human ant
44	494.5	78.9	121	8	ADP03884 Human ant
45	494	78.8	121	7	ADP03884 Human ant

ALIGNMENTS

RESULT 1  
ADJ76913  
ID ADJ76913 standard; protein; 117 AA.  
XX AC ADJ76913;  
XX DT 06-MAY-2004 (first entry)  
XX DE Anti-IGF-IR related protein #24.  
XX KW cytostatic; antiproliferative; antibody;  
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX OS Homo sapiens.  
XX PN WO2003059951-A2.  
XX PD 24-JUL-2003.  
XX PF 20-JAN-2003; 2003WO-FR000178.  
XX PR 18-JAN-2002; 2002FR-00000653.  
XX PR 18-JAN-2002; 2002FR-00000654.  
XX PR 07-MAY-2002; 2002FR-00005753.  
XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX PA Goetsch L, Corvaia N, Leger O;  
XX PI WPI; 2003-569653/53.  
XX DR New antibodies that bind to human insulin-like growth factor receptor,  
XX useful for treatment, prevention and diagnosis of cancers.  
XX PT Disclosure; SEQ ID NO 79; 164pp; French.  
XX PS The invention relates to an isolated antibody (Ab), and its functional  
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
XX IR) and optionally: (i) inhibit natural binding of insulin-like growth  
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
XX kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
XX treat diseases associated with overexpression and/or abnormal activity of  
XX IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with  
XX hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 117 AA;

Query Match 100.0%; Score 627; DB 7; Length 117;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-48;  
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60  
 DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60  
 QY 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAAATVAVYCARVGRVFFDYWGQGLTVTVSS 117  
 DB 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAAATVAVYCARVGRVFFDYWGQGLTVTVSS 117

RESULT 2  
 ID ADZ67083  
 XX ADZ67083 standard; protein; 117 AA.

AC ADZ67083;

XX 30-JUN-2005 (first entry)

XX Human antibody 7C10 2 heavy chain variable region SEQ ID NO:79.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW heavy chain variable region.  
 XX

OS Homo sapiens.

XX US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

XX 18-JAN-2002; 2002FR-00000654.

XX 07-MAY-2002; 2002FR-00005753.

XX 20-JAN-2003; 2003WO-FR000178.

XX 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

XX (CORV/) CORVAIA N.

XX (LEGE/) LEGER O.

XX (DUFLO/) DUFLOS A.

XX (HAEU/) HAEUW J.

XX (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT 1R and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.  
 XX  
 XX Example 13; SEQ ID NO 79; 125pp; English.

CC The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-1R) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-1R and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-1R and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-1R and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-1R and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC 1R and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

XX SQ Sequence 117 AA;

Query Match 100.0%; Score 627; DB 9; Length 117;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-48;  
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60  
 DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60  
 QY 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAAATVAVYCARVGRVFFDYWGQGLTVTVSS 117  
 DB 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAAATVAVYCARVGRVFFDYWGQGLTVTVSS 117

RESULT 3

ADJ76915

ID ADJ76915 standard; protein; 135 AA.

XX ADJ76915;

XX 06-MAY-2004 (first entry)

XX Anti-IGF-1R related protein #25.

XX cytostatic; antipsoriatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.

XX Homo sapiens.

XX WO2003059951-A2.

XX PD 24-JUL-2003.

XX

```

PF 20-JAN-2003; 2003WO-FR000178.
XX
XX 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX
XX (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
XX Goetsch L, Corvaia N, Leger O;
XX
XX WPI; 2003-569653/53.
XX
XX New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
XX Disclosure; SEQ ID NO 81; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX IR) and optionally: (i) inhibit natural binding of insulin-like growth
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX kinase activity of IGF-IR. Ab and its fragments are used to prevent or
XX treat diseases associated with overexpression and/or abnormal activity of
XX IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
XX hyperactivity of signal transduction pathways mediated by interaction of
XX these receptors with their ligands. Especially they inhibit
XX transformation of normal cells to tumor cells, inhibit growth and/or
XX proliferation of tumor cells, so are useful against cancers of the
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX also for treating psoriasis. Ab are also used to diagnose diseases caused
XX by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
XX protein sequence used to generate the Ab of the invention.
XX
XX Sequence 135 AA;
XX
XX Query Match 100.0%; Score 627; DB 7; Length 135;
XX Best Local Similarity 100.0%; Pred. No. 2e-48; 0; Indels 0; Gaps 0;
XX Matches 117; Conservative 0; Mismatches 0;
XX
QY 1 QVQLQESGFLVKPSETLSLTCTVSGYSITGGYLMNWIQPPGKLEWIGYISYDGTNNY 60
DQ |||||
DB 19 QVQLQESGFLVKPSETLSLTCTVSGYSITGGYLMNWIQPPGKLEWIGYISYDGTNNY 78
QY 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117
DQ |||||
DB 79 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 135

RESULT 4
ADZ67085
ID ADZ67085 standard; protein; 135 AA.
XX
AC ADZ67085;
XX
XX 30-JUN-2005 (first entry)
XX
XX Human antibody 7C10 2 heavy chain variable region SEQ ID NO:81.
XX
XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
XX neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
XX musculoskeletal disease; respiratory disease; lung tumor;
XX endocrine disease; gynecology and obstetrics; breast tumor;
XX endometrial carcinoma; gastrointestinal disease; colon tumor;
XX antipsoriatic; psoriasis; dermatological disease; immune disorder;
XX heavy chain variable region.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX FT Peptide 1..18
XX FT Peptide /note= "leader peptide"
XX FT Region 49..54
XX FT /note= "CDR1"

```

```

FT Region 69..84
FT /note= "CDR2"
FT Region 117..124
FT /note= "CDR3"
XX
XX US2005084906-A1.
XX
XX 21-APR-2005.
XX
XX 16-DEC-2003; 2003US-00735916.
XX
XX 18-JAN-2002; 2002FR-00000653.
XX 18-JAN-2002; 2002FR-00000654.
XX 07-MAY-2002; 2002FR-00005753.
XX 20-JAN-2003; 2003WO-FR000178.
XX 11-JUL-2003; 2003FR-00008538.
XX
XX (GOET/) GOETSCH L.
XX (CORV/) CORVAIA N.
XX (LEGE/) LEGER O.
XX (DUFU/) DUFLOS A.
XX (HAEU/) HAEUW J.
XX (BECK/) BECK A.
XX
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX
XX WPI; 2005-321968/33.
XX N-PSDB; ADZ67084.
XX
XX Novel isolated anti-insulin-like growth factor 1 receptor (IGF-IR)
XX antibody or its functional fragment, being capable of binding human IGF-
XX IR and specifically inhibiting tyrosine kinase activity of receptor,
XX useful for treating cancer.
XX
XX Example 13; SEQ ID NO 81; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
XX I receptor (IGF-IR) antibody (I) or its functional fragment, being
XX capable of binding to human IGF-IR and, if necessary, capable of
XX specifically inhibiting tyrosine kinase activity of the receptor,
XX comprising a light or heavy chain having at least one complementary
XX determining region (CDR) consisting of one of two fully defined 16 amino
XX acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
XX the preparation of a medicament intended for the prevention or treatment
XX of an illness connected with an overexpression and/or an abnormal
XX activation of the IGF-IR and/or EGFR, and/or connected with a
XX hyperactivation of the transduction pathway of the signal mediated by the
XX interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
XX the administration of the medicament does not induce or only slightly
XX induces secondary effects connected with inhibition of the insulin
XX receptor. The antibody is useful for preparation of a medicament intended
XX to inhibit the transformation of normal cells into cells with tumoral
XX character, preferably IGF-dependent, especially IGF1 and/or IGF2-
XX dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
XX useful for preparation of a medicament intended to inhibit the growth
XX and/or the proliferation of tumor cells, preferably IGF-dependent,
XX especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
XX HER2/neu-dependent cells. (I) is useful in the preparation of a
XX medicament intended for prevention or for the treatment of cancer, where
XX the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
XX breast cancer, endometrial cancer or colon cancer. (I) is useful in the
XX preparation of a medicament intended for the prevention or for the
XX treatment of psoriasis. (I) is useful in preparation of a medicament
XX intended for the specific targeting of the IGF-IR and/or EGFR receptor. (I)
XX cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
XX is useful for in vitro diagnosis of illnesses induced by an
XX overexpression or an underexpression of the IGF-IR and/or EGFR receptor
XX starting from a biological sample in which the abnormal presence, of IGF-
XX IR and/or EGFR receptor is suspected, which involves contacting the
XX biological sample with (I), which is optionally labeled. The present
XX sequence is used in the exemplification of the invention.
XX
XX Sequence 135 AA;
XX

```

Query Match 100.0%; Score 627; DB 9; Length 135;  
 Best Local Similarity 100.0%; Pred. No. 2e-48; Mismatches 0; Indels 0; Gaps 0;  
 Matches 117; Conservative 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60  
 DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 78  
 QY 61 KPSLKDRTVTSRDTSKNQPSLKLSSVTAADTAIVYVCARYGRVFFDYWGQGLTLVTSS 117  
 DB 79 KPSLKDRTVTSRDTSKNQPSLKLSSVTAADTAIVYVCARYGRVFFDYWGQGLTLVTSS 135

RESULT 5  
 ADJ76909  
 ID ADJ76909 standard; protein; 117 AA.  
 XX AC  
 AC ADJ76909;

DT 06-MAY-2004 (first entry)

XX Anti-IGF-1R related protein #22.

XX cytostatic; antipsoriatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.

XX Homo sapiens.

XX WO2003059951-A2.

PN 24-JUL-2003.

XX 20-JAN-2003; 2003WO-FR000178.

XX 18-JAN-2002; 2002FR-00000653.

XX 07-MAY-2002; 2002FR-00005753.

XX (FABR ) FABRE MEDICAMENT SA PIERRE.

XX Goetsch L, Corvaia N, Leger O;

XX WPI; 2003-569653/53.

XX New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.

XX Disclosure; SEQ ID NO 75; 164pp; French.

XX The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.

XX Sequence 117 AA;

Query Match 99.4%; Score 623; DB 7; Length 117;  
 Best Local Similarity 98.3%; Pred. No. 4e-48;

Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60  
 DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60

QY 61 KPSLKDRTVTSRDTSKNQPSLKLSSVTAADTAIVYVCARYGRVFFDYWGQGLTLVTSS 117

DB 61 KPSLKDRTVTSRDTSKNQPSLKLSSVTAADTAIVYVCARYGRVFFDYWGQGLTLVTSS 117

RESULT 6  
 ADZ67079

ID ADZ67079 standard; protein; 117 AA.

XX AC ADZ67079;

XX 30-JUN-2005 (first entry)

XX Human antibody 7C10 1 heavy chain variable region SEQ ID NO:75.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW heavy chain variable region.

XX Homo sapiens.

XX US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

XX 07-MAY-2002; 2002FR-00005753.

XX 20-JAN-2003; 2003WO-FR000178.

XX 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

XX (CORV/) CORVAIA N.

XX (LEGE/) LEGER O.

XX (DUFL/) DUFLOS A.

XX (HAEU/) HAEUW J.

XX (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)  
 CC antibody or its functional fragment, being capable of binding human IGF-  
 CC 1R and specifically inhibiting tyrosine kinase activity of receptor,  
 CC useful for treating cancer.

XX Example 13; SEQ ID NO 75; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-1R) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-1R and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-1R and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where

CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

XX Sequence 117 AA;

Query Match 99.4%; Score 623; DB 9; Length 117;  
 Best Local Similarity 98.3%; Pred. No. 4e-48;  
 Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60  
 DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60

QY 61 KPSLKDRVTISRDTSKNQPSLKSSVTAADTAVYTCARYGRVFFDYWGQGLTVTVSS 117  
 DB 61 KPSLKDRITISRDTSKNQPSLKSSVTAADTAVYTCARYGRVFFDYWGQGLTVTVSS 117

# RESULT 7

ADJ76911  
 ID ADJ76911 standard; protein; 135 AA.

AC ADJ76911;

DT 06-MAY-2004 (first entry)

XX Anti-IGF-IR related protein #23.

XX cytostatic; antipsoriatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.

XX Homo sapiens.

XX WO2003059951-A2.

XX 24-JUL-2003.

XX 20-JAN-2003; 2003WO-FR000178.

XX 18-JAN-2002; 2002FR-00000653.

XX 07-MAY-2002; 2002FR-00000654.

XX (FABR ) FABRE MEDICAMENT SA PIERRE.

XX Goetsch L, Corvaia N, Leger O;

XX WP1; 2003-569653/53.

XX

PT New antibodies that bind to human insulin-like growth factor receptor,  
 useful for treatment, prevention and diagnosis of cancers.

XX Disclosure; SEQ ID NO 77; 164pp; French.

XX The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.

XX Sequence 135 AA;

Query Match 99.4%; Score 623; DB 7; Length 135;

Best Local Similarity 98.3%; Pred. No. 4.7e-48;

Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60

DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 78

QY 61 KPSLKDRVTISRDTSKNQPSLKSSVTAADTAVYTCARYGRVFFDYWGQGLTVTVSS 117

DB 79 KPSLKDRITISRDTSKNQPSLKSSVTAADTAVYTCARYGRVFFDYWGQGLTVTVSS 135

# RESULT 8

ADZ67081  
 ID ADZ67081 standard; protein; 135 AA.

XX AC ADZ67081;

XX 30-JUN-2005 (first entry)

XX Human antibody 7C10 1 heavy chain variable region SEQ ID NO:77.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW heavy chain variable region.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Peptide 1..18 /note= "leader peptide"

FT Region 49..54 /note= "CDR1"

FT Region 69..84 /note= "CDR2"

FT Region 117..124 /note= "CDR3"

XX US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.



ADZ67087  
 ID ADZ67087 standard; protein; 117 AA.  
 AC ADZ67087;  
 XX  
 XX  
 DT 30-JUN-2005 (first entry)  
 DE Human antibody 7C10 3 heavy chain variable region SEQ ID NO:83.  
 XX  
 XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 XX heavy chain variable region.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2005084906-A1.  
 XX  
 XX 21-APR-2005.  
 XX  
 XX 16-DEC-2003; 2003US-00735916.  
 XX  
 XX 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 PR 20-JAN-2003; 2003WO-FR000178.  
 PR 11-JUL-2003; 2003FR-00008538.  
 XX  
 XX (GORT/) GORTSCH L.  
 PA (CORV/) CORVAIA N.  
 PA (LEGE/) LEGER O.  
 PA (DUFL/) DUFLOS A.  
 PA (HAEU/) HAEUW J.  
 PA (BECK/) BECK A.  
 XX  
 XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 XX WPI; 2005-321968/33.  
 XX  
 XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.  
 XX  
 XX Example 13; SEQ ID NO 83; 125pp; English.  
 XX  
 XX The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor.  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,

CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of the IGF-IR and/or EGFR receptor. (I)  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.  
 XX  
 XX Sequence 117 AA;  
 SQ  
 Query Match 98.1%; Score 615; DB 9; Length 117;  
 Best Local Similarity 98.3%; Pred. No. 2.1e-47;  
 Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 60  
 Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 60  
 QY 61 KPSLKDRVTIISRDTSKNOFSLKLSVTAADTAVVYCARYGRVFDYWGQGLTVTVSS 117  
 Db 61 KPSLKDRVTIISVDTSKNOFSLKLSVTAADTAVVYCARYGRVFDYWGQGLTVTVSS 117  
 RESULT 11  
 ADJ76919  
 ID ADJ76919 standard; protein; 135 AA.  
 XX  
 AC ADJ76919;  
 XX  
 DT 06-MAY-2004 (first entry)  
 XX  
 DE Anti-IGF-IR related protein #27.  
 XX  
 XX cytostatic; antipsoriatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO2003059951-A2.  
 FN  
 XX 24-JUL-2003.  
 XX  
 XX 20-JAN-2003; 2003WO-FR000178.  
 XX  
 XX 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 XX  
 XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
 PA  
 XX Goetsch L, Corvaia N, Leger O;  
 XX WPI; 2003-569653/53.  
 XX  
 XX New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.  
 XX  
 XX Disclosure; SEQ ID NO 85; 164pp; French.  
 PS  
 XX The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with

CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 135 AA;

Query Match 98.1%; Score 615; DB 7; Length 135;  
 Best Local Similarity 98.3%; Pred. No. 2.4e-47;  
 Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 60  
 DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 78  
 QY 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAAADTAVVYICARYGRVFFDYWGQGLTLVTYSS 117  
 DB 79 KPSLKDRVTISRDTSKNQPSLKLSSVTAAADTAVVYICARYGRVFFDYWGQGLTLVTYSS 135

RESULT 12  
 ADZ67089  
 ID ADZ67089 standard; protein; 135 AA.

XX AC ADZ67089;

XX DT 30-JUN-2005 (first entry)

XX DE Human antibody 7C10 3 heavy chain variable region SEQ ID NO:85.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW heavy chain variable region.  
 XX

OS Homo sapiens.

Key	Location/Qualifiers
Peptide	1..18 /note= "leader peptide"
Region	49..54 /note= "CDR1"
Region	69..84 /note= "CDR2"
Region	117..124 /note= "CDR3"

XX US2005084906-A1.

XX 21-APR-2005.

XX PF 16-DEC-2003; 2003US-00735916.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX PR 20-JAN-2003; 2003WO-FR000178.

XX PR 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

XX (CORV/) CORVAIA N.

XX (LEGE/) LEGER O.

XX (DUFL/) DUFLOS A.

XX (HAEU/) HAEUW J.

XX (BECK/) BECK A.

PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 XX WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 FT antibody or its functional fragment, being capable of binding human IGF-  
 FT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 FT useful for treating cancer.  
 XX

PS Example 13; SEQ ID NO 85; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor.  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (AD267006 and AD267014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

XX Sequence 135 AA;

Query Match 98.1%; Score 615; DB 9; Length 135;  
 Best Local Similarity 98.3%; Pred. No. 2.4e-47;  
 Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 60  
 DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 78

QY 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAAADTAVVYICARYGRVFFDYWGQGLTLVTYSS 117

DB 79 KPSLKDRVTISRDTSKNQPSLKLSSVTAAADTAVVYICARYGRVFFDYWGQGLTLVTYSS 135

RESULT 13

ADJ76903

ID ADJ76903 standard; protein; 117 AA.

XX AC ADJ76903;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #16.

XX KW cytostatic; antipsoriatic; antibody;

KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 CDR.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003059951-A2.  
 XX  
 PD 24-JUL-2003.  
 XX  
 PF 20-JAN-2003; 2003WO-FR000178.  
 XX  
 PR 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 XX  
 XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
 PA  
 XX Goetsch L, Corvaia N, Leger O;  
 PI  
 XX WPI; 2003-569653/53.  
 DR  
 XX New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.  
 XX  
 XX Disclosure; SEQ ID NO 69; 164pp; French.  
 XX  
 CC The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 117 AA;  
 Query Match 86.3%; Score 541; DB 7; Length 117;  
 Best Local Similarity 84.5%; Pred. No. 9e-41;  
 Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;  
 QY 2 VQLQESGPGLVKPEITSLTCTGYSITGGYLWNIRQPPGKLEWIGYISYDGTNNYK 61  
 DB 2 VQLQESGPGLVKPEISLSLTCTGYSITGGYLWNIRQPPGKLEWIGYISYDGTNNYK 61  
 QY 62 PSLKDRVTTISRDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117  
 DB 62 PSLKDRISITRDSKNQPFLLKNSVTNEDTATYICARYGRVFFDYWGQGLTVTVSS 117  
 RESULT 14  
 ADZ67073  
 ID ADZ67073 standard; protein; 117 AA.  
 AC  
 XX ADZ67073;  
 XX  
 DT 30-JUN-2005 (first entry)  
 XX  
 DE Murine immunoglobulin heavy chain variable region 7C10 VH SEQ ID NO:69.  
 XX  
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;

KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW immunoglobulin; heavy chain variable region.  
 XX  
 OS Mus musculus.  
 XX  
 PN US2005084906-A1.  
 XX  
 PD 21-APR-2005.  
 XX  
 PF 16-DEC-2003; 2003US-00735916.  
 XX  
 PR 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 PR 20-JAN-2003; 2003WO-FR000178.  
 PR 11-JUL-2003; 2003FR-00008538.  
 XX  
 XX (GOET/) GOETSCH L.  
 PA (CORV/) CORVAIA N.  
 PA (LEGE/) LEGER O.  
 PA (DUFL/) DUFLOS A.  
 PA (HAEU/) HAEUW J.  
 PA (BECK/) BECK A.  
 XX  
 XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 PI  
 XX WPI; 2005-321968/33.  
 DR  
 XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.  
 XX  
 XX Example 13; SEQ ID NO 69; 125pp; English.  
 PS  
 CC The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.  
 XX  
 SQ Sequence 117 AA;

Query Match 86.3%; Score 541; DB 9; Length 117;  
Best Local Similarity 84.5%; Pred. No. 9e-41; 8; Indels 0; Gaps 0;  
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;  
QY 2 VOLQESGPGLVKPSSETLSITCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61  
DB 2 VOLQESGPGLVKPSQSLSITCSVTGYSITGGYLNWIRQPPGKLEWGWYISYDGTNNYK 61  
QY 62 PSLKDRVTISRDTSKNQFSLKLSVTAADTAVYICARYGRVFFDYWGQOTLTIVSS 117  
DB 62 PSLKDRISITRDTSKNQFSLKLSVNTEDTATYICARYGRVFFDYWGQOTLTIVSS 117

RESULT 15  
ADJ76886  
ID ADJ76886 standard; protein; 127 AA.  
XX AC ADJ76886;  
XX DT 06-MAY-2004 (first entry)  
XX DE Anti-IGF-1R related protein #4.  
XX KW cytostatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX OS Mus musculus.  
XX PN WO2003059951-A2.  
XX PD 24-JUL-2003.  
XX PF 20-JAN-2003; 2003WO-FR000178.  
XX PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX Goetsch L, Corvaia N, Leger O;  
XX WPI; 2003-569653/53.  
XX New antibodies that bind to human insulin-like growth factor receptor,  
XX useful for treatment, prevention and diagnosis of cancers.  
XX Disclosure; SEQ ID NO 52; 164pp; French.  
XX The invention relates to an isolated antibody (Ab), and its functional  
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
XX 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
XX treat diseases associated with overexpression and/or abnormal activity of  
XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
XX hyperactivity of signal transduction pathways mediated by interaction of  
XX these receptors with their ligands. Especially they inhibit  
XX transformation of normal cells to tumor cells, inhibit growth and/or  
XX proliferation of tumor cells, so are useful against cancers of the  
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
XX also for treating psoriasis. Ab are also used to diagnose diseases caused  
XX by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
XX protein sequence used to generate the Ab of the invention.

SQ Sequence 127 AA;  
Query Match 86.3%; Score 541; DB 7; Length 127;  
Best Local Similarity 84.5%; Pred. No. 9.8e-41;

Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;  
QY 2 VOLQESGPGLVKPSSETLSITCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61  
DB 12 VOLQESGPGLVKPSQSLSITCSVTGYSITGGYLNWIRQPPGKLEWGWYISYDGTNNYK 71  
QY 62 PSLKDRVTISRDTSKNQFSLKLSVTAADTAVYICARYGRVFFDYWGQOTLTIVSS 117  
DB 72 PSLKDRISITRDTSKNQFSLKLSVNTEDTATYICARYGRVFFDYWGQOTLTIVSS 127  
Search completed: January 10, 2006, 20:44:17  
Job time : 80.7649 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.96642 Seconds  
(without alignments)  
166.558 Million cell updates/sec

Title: US-10-735-916A-75  
Perfect score: 628  
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYGQGLTVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications\_AA\_New.\*  
1: /cgn2\_6/prodata1/pubpaa/US08\_NEW\_PUB.pep.\*  
2: /cgn2\_6/prodata1/pubpaa/US06\_NEW\_PUB.pep.\*  
3: /cgn2\_6/prodata1/pubpaa/US07\_NEW\_PUB.pep.\*  
4: /cgn2\_6/prodata1/pubpaa/PCT\_NEW\_PUB.pep.\*  
5: /cgn2\_6/prodata1/pubpaa/US05\_NEW\_PUB.pep.\*  
6: /cgn2\_6/prodata1/pubpaa/US10\_NEW\_PUB.pep.\*  
7: /cgn2\_6/prodata1/pubpaa/US11\_NEW\_PUB.pep.\*  
8: /cgn2\_6/prodata1/pubpaa/US60\_NEW\_PUB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Length	ID	Description
1	628	100.0	117	7	US-11-012-353-75 Sequence 75, Appl
2	628	100.0	135	7	US-11-012-353-77 Sequence 77, Appl
3	623	99.2	117	7	US-11-012-353-79 Sequence 79, Appl
4	623	99.2	135	7	US-11-012-353-81 Sequence 81, Appl
5	611	97.3	117	7	US-11-012-353-83 Sequence 83, Appl
6	611	97.3	135	7	US-11-012-353-85 Sequence 85, Appl
7	546	86.9	117	7	US-11-012-353-69 Sequence 69, Appl
8	546	86.9	127	7	US-11-012-353-52 Sequence 52, Appl
9	532	84.7	117	7	US-11-012-353-162 Sequence 162, Appl
10	487.5	77.6	117	7	US-11-012-353-70 Sequence 70, Appl
11	478	76.1	123	7	US-11-012-353-73 Sequence 73, Appl
12	477.5	76.0	247	7	US-11-054-515-1651 Sequence 1651, Ap
13	477.5	76.0	250	7	US-11-054-515-1548 Sequence 1548, Ap
14	474.5	75.6	259	6	US-10-512-184-34 Sequence 34, Appl
15	474.5	75.6	371	6	US-10-512-184-71 Sequence 71, Appl
16	474.5	75.6	626	6	US-10-512-184-49 Sequence 49, Appl
17	469	74.7	117	7	US-11-012-353-72 Sequence 72, Appl
18	469	74.7	120	7	US-11-102-201-1 Sequence 1, Appl
19	469	74.7	253	7	US-11-054-515-1619 Sequence 1619, Ap
20	465.5	74.1	146	6	US-10-721-763-17 Sequence 17, Appl
21	463.5	73.8	252	7	US-11-054-515-1994 Sequence 1994, Ap
22	461.5	73.5	252	7	US-11-054-515-1329 Sequence 1329, Ap
23	459	73.1	255	7	US-11-054-515-841 Sequence 841, Appl
24	457.5	72.9	116	7	US-11-054-669-112 Sequence 112, Appl
25	457.5	72.9	250	7	US-11-054-669-110 Sequence 110, Appl

RESULT 1

US-11-012-353-75  
; Sequence 75, Application US/11012353  
; Publication No. US20050249730A1

GENERAL INFORMATION:

; APPLICANT: GOETSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFLOS, ALAIN  
; APPLICANT: HAEUW, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012,353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: Patentin Ver. 3.3  
; SEQ ID NO 75  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo sapiens

ALIGNMENTS

26	457	72.8	253	7	US-11-054-515-1339	Sequence 1339, Ap
27	456.5	72.7	254	7	US-11-054-515-1578	Sequence 1578, Ap
28	456	72.6	251	7	US-11-054-515-990	Sequence 990, Appl
29	455.5	72.5	247	7	US-11-054-515-1981	Sequence 1981, Ap
30	452.5	72.1	154	6	US-10-721-763-25	Sequence 25, Appl
31	451.5	71.9	254	7	US-11-054-515-1659	Sequence 1659, Ap
32	449.5	71.6	146	6	US-10-721-763-21	Sequence 21, Appl
33	446.5	71.1	256	7	US-11-054-515-1607	Sequence 1607, Ap
34	445	70.9	476	7	US-11-139-499-12	Sequence 12, Appl
35	444.5	70.8	256	7	US-11-054-515-1745	Sequence 1745, Ap
36	444	70.7	254	7	US-11-054-515-844	Sequence 844, Appl
37	444	70.7	255	7	US-11-054-515-1597	Sequence 1597, Ap
38	443.5	70.6	251	7	US-11-054-515-1546	Sequence 1546, Ap
39	441.5	70.3	99	7	US-11-084-554-55	Sequence 55, Appl
40	441	70.2	113	7	US-11-144-248-20	Sequence 20, Appl
41	441	70.2	113	7	US-11-144-222-20	Sequence 20, Appl
42	441	70.2	251	7	US-11-054-515-1510	Sequence 1510, Ap
43	441	70.2	253	7	US-11-054-515-954	Sequence 954, Appl
44	439.5	70.0	249	7	US-11-054-515-1321	Sequence 1321, Ap
45	439	69.9	252	7	US-11-054-515-1223	Sequence 1223, Ap

Query Match 100.0%; Score 628; DB 7; Length 117;  
Best Local Similarity 100.0%; Pred. No. 8.7e-49;  
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	QVQLQESGFLVKPSETLSLCTVSGYSITGGYLNWIRQPPKGLWNGYISYDGTNNY	60
Db	1	QVQLQESGFLVKPSETLSLCTVSGYSITGGYLNWIRQPPKGLWNGYISYDGTNNY	60
QY	61	KPSLKDRTISRDTSKNQFSLKLSVTAADTAVYCYGRVFFDYGQGLTVTVSS	117
Db	61	KPSLKDRTISRDTSKNQFSLKLSVTAADTAVYCYGRVFFDYGQGLTVTVSS	117

```
RESULT 2
US-11-012-353-77
; Sequence 77, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 77
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-77

Query Match      100.0%; Score 628; DB 7; Length 135;
Best Local Similarity 100.0%; Pred. No. 9.9e-49; Mismatches 0; Indels 0; Gaps 0;
Matches 117; Conservative 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 78
QY 61 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 3
US-11-012-353-79
; Sequence 79, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 79
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-79

Query Match      99.2%; Score 623; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 2.7e-48; Mismatches 2; Indels 0; Gaps 0;
Matches 115; Conservative 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 78
QY 61 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135
```

```
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 79
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-79

Query Match      99.2%; Score 623; DB 7; Length 117;
Best Local Similarity 98.3%; Pred. No. 2.4e-48; Mismatches 2; Indels 0; Gaps 0;
Matches 115; Conservative 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 60
QY 61 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db 61 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117

RESULT 4
US-11-012-353-81
; Sequence 81, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-81

Query Match      99.2%; Score 623; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 2.7e-48; Mismatches 2; Indels 0; Gaps 0;
Matches 115; Conservative 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 78
QY 61 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135
```

```

; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 85
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-85

Query Match          97.3%; Score 611; DB 7; Length 135;
Best Local Similarity 96.6%; Pred. No. 3e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 78
QY 61 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGTILVTSS 117
Db 79 KPSLKDRTITISVDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGTILVTSS 135

RESULT 7
US-11-012-353-69
; Sequence 89, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 83
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-83

Query Match          97.3%; Score 611; DB 7; Length 117;
Best Local Similarity 96.6%; Pred. No. 2.6e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
QY 61 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGTILVTSS 117
Db 61 KPSLKDRTITISVDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGTILVTSS 117

RESULT 6
US-11-012-353-85
; Sequence 85, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR APPLICATION NUMBER: 2003-01-20
```

```

; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 85
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-85

Query Match          97.3%; Score 611; DB 7; Length 135;
Best Local Similarity 96.6%; Pred. No. 3e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 78
QY 61 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGTILVTSS 117
Db 79 KPSLKDRTITISVDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGTILVTSS 135

RESULT 7
US-11-012-353-69
; Sequence 89, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 69
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-69

Query Match          86.9%; Score 546; DB 7; Length 117;
Best Local Similarity 86.2%; Pred. No. 1.2e-41;
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 2 VQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 61
Db 2 VQLQESGPGLVKPSQSLSTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 61
QY 62 PSLKDRTITISRDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGTILVTSS 117
Db 62 PSLKDRTITISVDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGTILVTSS 117
```



```
DB      62 PSLKNRISIRDTSKNQFLKLNSVTEDTATYYCAREGYGYPFDYWGQGTTLTVSS 118  
|||||::||:||:||||| ||::|| | ||| ||| ||| ||| ||| ::||| :|||  
  
RESULT 11  
US-11-012-353-73  
; Sequence 73, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFLOS, ALAIN  
; APPLICANT: HABUW, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INULIN/IGF-I HYBRID  
; FILE REFERENCE: 01753-198  
; CURRENT APPLICATION NUMBER: US/11/012,353  
; PRIOR FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: PatentIn Ver. 3.3  
; SEQ ID NO 73  
; LENGTH: 123  
; TYPE: PRP  
; ORGANISM: Homo sapiens  
US-11-012-353-73  
  
Query Match          76.1%; Score 478; DB 7; Length 123;  
Best Local Similarity    75.8%; Pred.No. 1.le-35;  
Matches   94; Conservative 10; Mismatches 12; Indels 8; Gaps 2;  
  
QY     1 QVQLQQSGPGVLKPSETLSLTCTVGYSITCGYLNNWIROPKGLEWMGVISYDGNINY 60  
Db      1 QVQLQQSGPGVLKPSETLSLTCTVGYSISSGIYWWSIWRQPFGGLEWIGSMFHSGSYY 60  
  
QY     61 KPALKDRITTISRDTSKNQSFKLKSSTAAADTAFTAVYCARYGRV-----FFDYWGQGGLV 113  
Db      61 NPALKSRVTISVDTSKNQFSIQLKSVTAADTAFTAVYICAR-GRYCSSTSNCWFDPWGQGTLV 119  
|||||::||:||||| SVDTSKNQFSIQLKSVTAADTAFTAVYCAR-GRYCSSTSNCWFDPWGQGTLV 119  
  
QY     114 TVSS 117  
Db      120 TVSS 123  
|||||  
  
RESULT 12  
US-11-054-515-1651  
; Sequence 1651, Application US/11054515  
; Publication No. US20050255532A1  
; GENERAL INFORMATION:  
; APPLICANT: Ruben et al.  
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS  
; FILE REFERENCE: PF523P3  
; CURRENT APPLICATION NUMBER: US/11/054,515  
; CURRENT FILING DATE: 2005-02-10  
; PRIOR APPLICATION NUMBER: 60/543,296  
; PRIOR FILING DATE: 2004-02-11  
; PRIOR APPLICATION NUMBER: 60/580,347  
; PRIOR FILING DATE: 2004-06-18  
; PRIOR APPLICATION NUMBER: 10/293,418  
; PRIOR FILING DATE: 2002-11-14
```

```
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1548

Query Match      76.0%; Score 477.5; DB 7; Length 250;
Best Local Similarity 75.2%; Pred. No. 2.3e-35;
Matches 94; Conservative 8; Mismatches 15; Indels 7; Gaps 2;

QY 1 QVQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLESGLVKPSETLSLTCAVSGYSSGGYNGWIRQPPGKLEWIGSYHSGSTYY 60
QY 61 KPSLDRITISDTSKNQFSLKSLSSVTAADTAVYCAR-----GRVP-FDYWGQGLTV 113
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 NPSLSRVTVISDTSKNQFSLKSLSSVTAADTAVYCARVHYDILGTGLWAFDWCQTMV 120
QY 114 TVSS 117
Db |||||
121 TVSS 124

RESULT 14
US-10-512-184-34
; Sequence 34, Application US/10512184
; Publication No. US20050244901A1
; GENERAL INFORMATION:
; APPLICANT: Fraunhofer Gesellschaft zur Forderung der angewandten Forschung e.V.
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
; TITLE OF INVENTION: resistance against fungi
; FILE REFERENCE: 3581.01US01
; CURRENT APPLICATION NUMBER: US/10/512,184
; CURRENT FILING DATE: 2004-10-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: scFv PL2 with
; OTHER INFORMATION: specificity against Phoma lingam; originates from
; OTHER INFORMATION: Mus musculus.
US-10-512-184-34

Query Match      75.6%; Score 474.5; DB 6; Length 259;
Best Local Similarity 75.2%; Pred. No. 4.4e-35;
Matches 91; Conservative 11; Mismatches 14; Indels 5; Gaps 2;

QY 2 VQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNYK 61
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
4 VQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNNN 63
QY 62 PSLKDRITISDTSKNQFSLKSLSSVTAADTAVYCAR----YGR-VFFDYWGQGLTVTS 116
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
64 PSLKNRISITRDASKNQFPLKNSVTEDTATYHCARGAPYVGKGTWFPYWGQGLTVTS 123
QY 117 S 117
Db |
124 S 124

RESULT 15
US-10-512-184-71
; Sequence 71, Application US/10512184
; Publication No. US20050244901A1
; GENERAL INFORMATION:
; APPLICANT: Fraunhofer Gesellschaft zur Forderung der angewandten Forschung e.V.
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
; TITLE OF INVENTION: resistance against fungi
; FILE REFERENCE: 3581.01US01
; CURRENT APPLICATION NUMBER: US/10/512,184
; CURRENT FILING DATE: 2004-10-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 71
; LENGTH: 371
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: precursor
; OTHER INFORMATION: fusion protein comprising ACE - linker -
; OTHER INFORMATION: scFv PL2.
US-10-512-184-71

Query Match      75.6%; Score 474.5; DB 6; Length 371;
Best Local Similarity 75.2%; Pred. No. 6.1e-35;
Matches 91; Conservative 11; Mismatches 14; Indels 5; Gaps 2;

QY 2 VQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNYK 61
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
116 VQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNNN 175
QY 62 PSLKDRITISDTSKNQFSLKSLSSVTAADTAVYCAR----YGR-VFFDYWGQGLTVTS 116
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
176 PSLKNRISITRDASKNQFPLKNSVTEDTATYHCARGAPYVGKGTWFPYWGQGLTVTS 235
QY 117 S 117
Db |
236 S 236

Search completed: January 10, 2006, 21:36:24
Job time : 6.96642 secs
```

Result No.	Score	Query		DB	ID	Description
		Match	Length			
1	628	100.0	117	5	US-10-735-916A-75	Sequence 75, Appl
2	628	100.0	135	5	US-10-735-916A-77	Sequence 77, Appl
3	623	99.2	117	5	US-10-735-916A-79	Sequence 79, Appl
4	623	99.2	135	5	US-10-735-916A-81	Sequence 81, Appl
5	611	97.3	117	5	US-10-735-916A-83	Sequence 83, Appl
6	611	97.3	135	5	US-10-735-916A-85	Sequence 85, Appl
7	546	86.9	117	5	US-10-735-916A-89	Sequence 69, Appl
8	546	86.9	127	5	US-10-735-916A-52	Sequence 52, Appl
9	531.5	84.6	120	4	US-10-383-447-26	Sequence 26, Appl
10	511.5	81.4	120	4	US-10-383-447-24	Sequence 24, Appl
11	508.5	81.0	120	4	US-10-383-447-28	Sequence 28, Appl
12	503	80.1	119	4	US-10-309-763-143	Sequence 143, App
13	500.5	79.7	118	4	US-10-292-088-109	Sequence 109, App
14	499.5	79.5	121	5	US-10-805-177-56	Sequence 56, Appl
15	499.5	79.5	122	4	US-10-309-763-25	Sequence 25, Appl
16	499.5	79.5	122	4	US-10-309-763-29	Sequence 29, Appl
17	498.5	79.4	120	4	US-10-309-763-138	Sequence 128, App
18	496.5	79.1	116	4	US-10-309-763-127	Sequence 127, App
19	496.5	79.1	121	4	US-10-010-723-11	Sequence 11, Appl
20	496.5	79.1	122	4	US-10-309-763-24	Sequence 24, Appl
21	496.5	79.1	122	4	US-10-309-763-27	Sequence 27, Appl
22	496	79.0	119	4	US-10-125-687-5	Sequence 5, Appl
23	496	79.0	119	5	US-10-996-191-5	Sequence 5, Appl
24	496	79.0	121	4	US-10-292-088-82	Sequence 82, Appl
25	496	79.0	466	4	US-10-292-088-86	Sequence 86, Appl
26	494	78.7	119	5	US-10-937-596-23	Sequence 23, Appl
27	493	78.5	117	5	US-10-890-945-2	Sequence 2, Appl

GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 77  
LENGTH: 135  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-735-916A-77

Query Match 100.0%; Score 628; DB 5; Length 135;  
Best Local Similarity 100.0%; Pred. No. 5.1e-49;  
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWMGYISYDGTNNY 60  
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWMGYISYDGTNNY 78  
QY 61 KPSLKDRTITISRDTSKNQFSLKSSVTAADTAVYCYGRVFFDYWGOGTLVTSS 117  
Db 79 KPSLKDRTITISRDTSKNQFSLKSSVTAADTAVYCYGRVFFDYWGOGTLVTSS 135

RESULT 3  
US-10-735-916A-79  
Sequence 79, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 79  
LENGTH: 117  
TYPE: PRT  
ORGANISM: Homo sapiens

US-10-735-916A-79  
Query Match 99.2%; Score 623; DB 5; Length 117;  
Best Local Similarity 98.3%; Pred. No. 1.2e-48;  
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWMGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWMGYISYDGTNNY 60  
QY 61 KPSLKDRTITISRDTSKNQFSLKSSVTAADTAVYCYGRVFFDYWGOGTLVTSS 117  
Db 61 KPSLKDRTITISRDTSKNQFSLKSSVTAADTAVYCYGRVFFDYWGOGTLVTSS 117

RESULT 4  
US-10-735-916A-81  
Sequence 81, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 81  
LENGTH: 135  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-735-916A-81

Query Match 99.2%; Score 623; DB 5; Length 135;  
Best Local Similarity 98.3%; Pred. No. 1.4e-48;  
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWMGYISYDGTNNY 60  
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWMGYISYDGTNNY 78  
QY 61 KPSLKDRTITISRDTSKNQFSLKSSVTAADTAVYCYGRVFFDYWGOGTLVTSS 117  
Db 79 KPSLKDRTITISRDTSKNQFSLKSSVTAADTAVYCYGRVFFDYWGOGTLVTSS 135

RESULT 5  
US-10-735-916A-83  
Sequence 83, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF



```
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-52

Query Match      86.9%; Score 546; DB 5; Length 127;
Best Local Similarity 86.2%; Pred. No. 1.2e-41;
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY  2 VOLQSGPGLVKPSETLSITCTVSGYSITGGYLNWIRQPPGKGLWWMGYISYDGTNNYK 61
Db  12 VOLQSGPGLVKPQSLSITCSVTGYSITGGYLNWIRQPPGKGLWWMGYISYDGTNNYK 71

QY  62 PS�KDRITTSRDTSKNQFSLKSSVTAADTAVYICARYGRVFDYWGQGLTVTVSS 117
Db  72 PS�KDRITTSRDTSKNQFSLKSSVTAADTAVYICARYGRVFDYWGQGLTVTVSS 127

RESULT 9
US-10-383-447-26
; Sequence 26, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaekar, Vinay
; APPLICANT: de la Calle, Agustin
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 3.0
US-10-383-447-26

Query Match      84.6%; Score 531.5; DB 4; Length 120;
Best Local Similarity 85.7%; Pred. No. 2.3e-40;
Matches 102; Conservative 4; Mismatches 10; Indels 3; Gaps 1;

QY  2 VOLQSGPGLVKPSETLSITCTVSGYSITGGYLNWIRQPPGKGLWWMGYISYDGTNNYK 61
Db  2 VOLQSGPGLVKPSETLSITCAVSGYSITGSYYWIRQPPGKGLWWMGFISYDGSNKYN 61

QY  62 PS�KDRITTSRDTSKNQFSLKSSVTAADTAVYICA---RYGRVFDYWGQGLTVTVSS 117
Db  62 PS�KDRITTSRDTSKNQFSLKSSVTAADTAVYICARGLRGDYSNDYWGQGLTVTVSS 120

RESULT 10
US-10-383-447-24
; Sequence 24, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaekar, Vinay
; APPLICANT: de la Calle, Agustin
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 4.0
US-10-383-447-24

Query Match      81.0%; Score 508.5; DB 4; Length 120;
Best Local Similarity 81.5%; Pred. No. 1.5e-38;
Matches 97; Conservative 8; Mismatches 11; Indels 3; Gaps 1;

QY  2 VOLQSGPGLVKPSETLSITCTVSGYSITGGYLNWIRQPPGKGLWWMGYISYDGTNNYK 61
Db  2 VOLQSGPGLVKPSETLSITCAVTGYSITGSYYWIRQPPGKGLWWMGFISYDGSNKYN 61

QY  62 PS�KDRITTSRDTSKNQFSLKSSVTAADTAVYICA---RYGRVFDYWGQGLTVTVSS 117
Db  62 PS�KDRITTSRDTSKNQFSLKSSVTAADTAVYICARGLRGDYSNDYWGQGLTVTVSS 120

RESULT 11
US-10-383-447-28
; Sequence 28, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaekar, Vinay
; APPLICANT: de la Calle, Agustin
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 4.0
US-10-383-447-28

Query Match      81.0%; Score 508.5; DB 4; Length 120;
Best Local Similarity 81.5%; Pred. No. 1.5e-38;
Matches 97; Conservative 8; Mismatches 11; Indels 3; Gaps 1;

QY  2 VOLQSGPGLVKPSETLSITCTVSGYSITGGYLNWIRQPPGKGLWWMGYISYDGTNNYK 61
Db  2 VOLQSGPGLVKPSETLSITCAVTGYSITGSYYWIRQPPGKGLWWMGFISYDGSNKYN 61

QY  62 PS�KDRITTSRDTSKNQFSLKSSVTAADTAVYICA---RYGRVFDYWGQGLTVTVSS 117
Db  62 PS�KDRITTSRDTSKNQFSLKSSVTAADTAVYICARGLRGDYSNDYWGQGLTVTVSS 120
```

Best Local Similarity 83.2%; Pred. No. 2.8e-38;  
Matches 99; Conservative 4; Mismatches 13; Indels 3; Gaps 1;  
QY 2 VQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWGMGYISYDGTNNYK 61  
Db 2 VQLQESGPGLVKPSSETLSLTCAVSGYSITGGYLNWIRQPPGKLEWGMGFISYDGSNKN 61  
QY 62 PSLKDRITTSRDTSKNQFSLKSSVTAADTAVYCA---RYGRVFPDYWGQGLTVTVSS 117  
Db 62 PSLKDRITTSRDTSKNQFSLKSSVTAADTAVYCA---RYGRVFPDYWGQGLTVTVSS 120

RESULT 12  
US-10-309-762-143  
; Sequence 143, Application US/10309762  
; Publication No. US20040018198A1  
; GENERAL INFORMATION:  
; APPLICANT: Gudae, Jean  
; APPLICANT: Foltz, Ian  
; APPLICANT: Handa, Masahisa  
; APPLICANT: Gallo, Michael  
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX  
; FILE REFERENCE: ABGENIX.027A  
; CURRENT APPLICATION NUMBER: US/10/309,762  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: 60/337275  
; PRIOR FILING DATE: 2001-12-03  
; NUMBER OF SEQ ID NOS: 246  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 143  
; LENGTH: 119  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-309-762-143

Query Match 80.1%; Score 503; DB 4; Length 119;  
Best Local Similarity 81.7%; Pred. No. 8.7e-38;  
Matches 98; Conservative 7; Mismatches 11; Indels 4; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWGMGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59  
QY 61 KPDLKDRITTSRDTSKNQFSLKSSVTAADTAVYCARVGRV---PFYDWGQGLTVTVSS 117  
Db 60 NPFLKSRVTISVDTSKNQFSLKSSVTAADTAVYCARVDILTGYFDYWGQGLTVTVSS 119

RESULT 13  
US-10-292-088-109  
; Sequence 109, Application US/10292088  
; Publication No. US20030211100A1  
; GENERAL INFORMATION:  
; APPLICANT: BEDIAN, VAHE  
; APPLICANT: GLADUE, RONALD P.  
; APPLICANT: CORVALAN, JOSE  
; APPLICANT: JIA, XIAO-CHI  
; APPLICANT: FENG, XIAO  
; TITLE OF INVENTION: ANTIBODIES TO CD40  
; FILE REFERENCE: ABX-PF/3 US  
; CURRENT APPLICATION NUMBER: US/10/292,088  
; CURRENT FILING DATE: 2003-03-14  
; PRIOR APPLICATION NUMBER: 60/348,980  
; PRIOR FILING DATE: 2001-11-09  
; NUMBER OF SEQ ID NOS: 147  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 109  
; LENGTH: 118  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-292-088-109

Query Match 79.7%; Score 500.5; DB 4; Length 118;  
Best Local Similarity 82.4%; Pred. No. 1.5e-37;  
Matches 98; Conservative 6; Mismatches 12; Indels 3; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWGMGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59  
QY 61 KPDLKDRITTSRDTSKNQFSLKSSVTAADTAVYCAR---YGRVFPDYWGQGLTVTVSS 117  
Db 60 NPFLKSRVTISVDTSKNQFSLKSSVTAADTAVYCARVGRV---YGRVFPDYWGQGLTVTVSS 118

RESULT 14  
US-10-805-177-56  
; Sequence 56, Application US/10805177  
; Publication No. US2005008449A1  
; GENERAL INFORMATION:  
; APPLICANT: Landes, Gregory M.  
; APPLICANT: Chen, Francine  
; APPLICANT: Bezabeh, Binyam  
; APPLICANT: Foltz, Ian  
; APPLICANT: Tse, Kam Fai  
; APPLICANT: Jeffers, Michael  
; APPLICANT: Mesri, Mehdi  
; APPLICANT: Starling, Gary  
; APPLICANT: Mezes, Peter  
; APPLICANT: Khrantsov, Nikolai  
; TITLE OF INVENTION: ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN  
; FILE REFERENCE: ABXCUR.006A  
; CURRENT APPLICATION NUMBER: US/10/805,177  
; CURRENT FILING DATE: 2004-03-19  
; PRIOR APPLICATION NUMBER: 60/456,652  
; PRIOR FILING DATE: 2003-03-19  
; NUMBER OF SEQ ID NOS: 141  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 56  
; LENGTH: 121  
; TYPE: PRT  
; ORGANISM: Homo Sapiens  
US-10-805-177-56

Query Match 79.5%; Score 499.5; DB 5; Length 121;  
Best Local Similarity 81.7%; Pred. No. 1.8e-37;  
Matches 98; Conservative 6; Mismatches 13; Indels 3; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSI-TGGYLNWIRQPPGKLEWGMGYISYDGTNN 59  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGGYWSWIRQPPGKLEWIGYIYSGSTN 60  
QY 60 YKPSLKDRTITSRDTSKNQFSLKSSVTAADTAVYVCARYG--RVFFDYWGQGLTVTVSS 117  
Db 61 YNPFLKSRVTISVDTSKNQFSLKSSVTAADTAVYCARNNNNNNFDYWGQGLTVTVSS 120

RESULT 15  
US-10-309-762-25  
; Sequence 25, Application US/10309762  
; Publication No. US20040018198A1  
; GENERAL INFORMATION:  
; APPLICANT: Gudae, Jean  
; APPLICANT: Foltz, Ian  
; APPLICANT: Handa, Masahisa  
; APPLICANT: Gallo, Michael  
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX  
; FILE REFERENCE: ABGENIX.027A  
; CURRENT APPLICATION NUMBER: US/10/309,762  
; CURRENT FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: 60/337275  
; PRIOR FILING DATE: 2001-12-03  
; NUMBER OF SEQ ID NOS: 246

```
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-25

Query Match      79.5%; Score 499.5; DB 4; Length 122;
Best Local Similarity 80.5%; Pred. No. 1.9e-37;
Matches 99; Conservative 5; Mismatches 12; Indels 7; Gaps 2;

QY      1 QVQLQESGFLVKPSETLSLTCTVSGYSITGGYLMNWIQQPPKGLWMGYISYDGTNNY 60
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      1 QVQLQESGFLVKPSETLSLTCTVSGGIS-SYTWSMIRQPPKGLWIGIYIYSGSTNY 59
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY      61 KPSLKDRITISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVP-----FDYWGQGLVT 114
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      60 NPSLKSRVTISVDTSKNQPSLKLSSVTAADTAVYYCARRGYDFTGYDYFDYWGQGLVT 119
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY      115 VSS 117
      |||
Db      120 VSS 122
```

Search completed: January 10, 2006, 21:35:32  
Job time : 64.1754 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 22.847 Seconds  
(without alignments)  
423.384 Million cell updates/sec

Title: US-10-735-916A-75  
Perfect score: 628  
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:\*

1: /cgn2\_6/prodata/1/iaa/5\_COMB.pep:\*

2: /cgn2\_6/prodata/1/iaa/6\_COMB.pep:\*

3: /cgn2\_6/prodata/1/iaa/H\_COMB.pep:\*

4: /cgn2\_6/prodata/1/iaa/PTCUS\_COMB.pep:\*

5: /cgn2\_6/prodata/1/iaa/RE\_COMB.pep:\*

6: /cgn2\_6/prodata/1/iaa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	496	79.0	119	2	US-09-025-769B-39
2	496	79.0	119	2	US-09-025-769B-65
3	496	79.0	119	2	US-09-490-070A-39
4	496	79.0	119	2	US-09-490-070A-65
5	496	79.0	119	2	US-09-490-153-39
6	496	79.0	119	2	US-09-490-153-65
7	496	79.0	119	2	US-09-490-324-39
8	496	79.0	119	2	US-09-490-324-65
9	493	78.5	117	2	US-09-720-493-2
10	483	76.9	117	2	US-10-330-613A-13
11	482.5	76.8	473	1	US-09-049-672A-4
12	482	76.8	123	1	US-08-137-117D-64
13	482	76.8	123	1	US-08-436-717-64
14	482	76.8	138	1	US-08-137-117D-69
15	482	76.8	138	1	US-08-436-717-69
16	480	76.4	118	2	US-09-065-059-11
17	480	76.4	118	2	US-08-913-555-11
18	479.5	76.4	118	2	US-09-025-769B-25
19	479.5	76.4	118	2	US-09-490-070A-25
20	479.5	76.4	118	2	US-09-490-153-25
21	479.5	76.4	118	2	US-09-490-324-25
22	478.5	76.2	244	2	US-08-918-148-79
23	478.5	76.2	244	2	US-09-138-091A-77
24	471	75.0	121	2	US-10-330-613A-1
25	471	75.0	121	2	US-10-330-613A-17
26	470.5	74.9	487	2	US-09-800-729-145
27	469	74.7	117	2	US-10-330-613A-5

28	468.5	74.6	118	2	US-09-343-698-6	Sequence 6, Appli
29	468.5	74.6	118	2	US-08-325-955-6	Sequence 6, Appli
30	467.5	74.4	832	2	US-08-630-820-7	Sequence 7, Appli
31	467.5	74.4	832	2	US-09-273-453-7	Sequence 7, Appli
32	467	74.4	121	2	US-10-330-613A-9	Sequence 9, Appli
33	466	74.2	119	1	US-08-360-125-5	Sequence 5, Appli
34	466	74.2	119	1	US-08-450-578-5	Sequence 5, Appli
35	466	74.2	119	1	US-09-017-628-5	Sequence 5, Appli
36	466	74.2	119	1	US-09-014-880-5	Sequence 5, Appli
37	466	74.2	119	2	US-08-450-363-5	Sequence 5, Appli
38	466	74.2	119	2	US-09-467-903-5	Sequence 5, Appli
39	465.5	74.1	120	2	US-08-554-840-5	Sequence 5, Appli
40	465.5	74.1	120	2	US-08-925-339-5	Sequence 5, Appli
41	465.5	74.1	120	2	US-09-332-595-5	Sequence 5, Appli
42	465	74.0	119	2	US-08-767-128-18	Sequence 18, Appli
43	464.5	74.0	139	2	US-09-471-276-837	Sequence 837, App
44	464.5	74.0	278	2	US-09-260-527-3	Sequence 3, Appli
45	463	73.7	142	1	US-08-480-774A-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1  
US-09-025-769B-39  
; Sequence 39, Application US/09025769B  
; Patent No. 6300064  
; GENERAL INFORMATION:  
; APPLICANT: Knappik, Achim  
; APPLICANT: Pack, Peter  
; APPLICANT: Ilag, Vic  
; APPLICANT: Ge, Liming  
; APPLICANT: Moroney, Simon  
; APPLICANT: Plueckthun, Andreas  
; TITLE OF INVENTION: Protein/(Poly)peptide libraries  
; NUMBER OF SEQUENCES: 373  
; CORRESPONDENCE ADDRESS:  
; ADDRESSES: James F. Haley, Jr., Esq. c/o Fish & Neave  
; STREET: 1251 Avenue of the Americas  
; CITY: New York  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10021  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION DATA:  
; FILING DATE: 18-FEB-1998  
; PRIOR APPLICATION NUMBER: US/09/025,769B  
; APPLICATION NUMBER: EP 95 11 3021.0  
; FILING DATE: 18-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: James F. Haley, Jr., Esq.  
; REGISTRATION NUMBER: 27,794  
; REFERENCE/DOCKET NUMBER: MORPHO/5  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212)596-9000  
; TELEFAX: (212)596-9090  
; INFORMATION FOR SEQ ID NO: 39:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 119 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-09-025-769B-39

Query Match 79.0%; Score 496; DB 2; Length 119;  
Best Local Similarity 81.7%; Pred. No. 4.8e-42;  
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;



White & McAlliff  
STREET: 1666 K Street, N.W., Suite 300  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20006  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,070A  
FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Colin G. Sandercock, Esq.  
REGISTRATION NUMBER: 31,298  
REFERENCE/DOCKET NUMBER: 37629-0005  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 912-2000  
TELEFAX: (202) 912-2020  
INFORMATION FOR SEQ ID NO: 65:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 119 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 65:  
US-09-490-070A-65  
Query Match 79.0%; Score 496; DB 2; Length 119;  
Best Local Similarity 81.7%; Pred. No. 4.8e-42;  
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVSWIRQPPGKGLWMGYISYDGTNNY 59  
QY 61 KPSLKDRTITISDTSKNQPSLKLSSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 117  
DB 60 NPSLKSRTVTSVDTSKNQPSLKLSSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 119  
RESULT 5  
US-09-490-153-39  
Sequence 39, Application US/09490153  
Patent No. 6706484  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
Pack, Peter  
Ilag, Vic  
Ge, Liming  
Moroney, Simon  
Plueckthun, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,153  
FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5

FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 596-9000  
TELEFAX: (212) 596-9090  
INFORMATION FOR SEQ ID NO: 39:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 119 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 39:  
US-09-490-153-39  
Query Match 79.0%; Score 496; DB 2; Length 119;  
Best Local Similarity 81.7%; Pred. No. 4.8e-42;  
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVSWIRQPPGKGLWMGYISYDGTNNY 59  
QY 61 KPSLKDRTITISDTSKNQPSLKLSSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 117  
DB 60 NPSLKSRTVTSVDTSKNQPSLKLSSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 119  
RESULT 6  
US-09-490-153-65  
Sequence 65, Application US/09490153  
Patent No. 6706484  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
Pack, Peter  
Ilag, Vic  
Ge, Liming  
Moroney, Simon  
Plueckthun, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,153  
FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-153-65
Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWMGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59
QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISDTSKNQFSLKSSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 119
RESULT 7
US-09-490-324-39
; Sequence 39, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 39:
US-09-490-324-39
Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWMGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59
QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISDTSKNQFSLKSSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 119
RESULT 8
US-09-490-324-65
; Sequence 65, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-324-65
Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWMGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59
QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISDTSKNQFSLKSSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 119
```

Db	60	NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVYYCARWGDDGYAMDYWGQGLTVTVSS	117
RESULT 9			
US-09-720-493-2			
Sequence 2, Application US/09720493			
Patent No. 6827925			
GENERAL INFORMATION:			
APPLICANT: Cambridge Antibody Technology Limited			
APPLICANT: Williams, Andrew J			
APPLICANT: Tempest, Philip R			
APPLICANT: Holtet, Thor L			
APPLICANT: Main, Sarah H			
APPLICANT: Jackson, Helen			
APPLICANT: Daramola, Olalekan			
TITLE OF INVENTION: Improvements relating to antibodies			
FILE REFERENCE: AHB/CP5775333			
CURRENT APPLICATION NUMBER: US/09/720,493			
CURRENT FILING DATE: 2002-10-23			
PRIOR APPLICATION NUMBER: GB 9814383.7			
PRIOR FILING DATE: 1998-07-02			
NUMBER OF SEQ ID NOS: 22			
SOFTWARE: PatentIn Ver. 2.1			
SEQ ID NO 2			
LENGTH: 117			
TYPE: PRT			
ORGANISM: Homo sapiens			
US-09-720-493-2			
Query Match	78.5%;	Score 493;	DB 2; Length 117;
Best Local Similarity	81.2%;	Pred. No. 9.3e-42;	
Matches	95;	Conservative	5; Mismatches 17; Indels 0; Gaps 0
QY	1	QVQLQSGGGLVKKPSETLSLTCTVSGYSTTGGYLNNWIRQPPGKLEWMGVISYDGTNNY	60
Db	1	QVQLQSGGGLVKKPSETLSLTCAVSGYISGSGYTWIRQPPGKLEWIGSIHSGSTYY	60
QY	61	KPSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFDYWGQGLTVTVSS	117
Db	61	NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVYYCARGKWSKEDYWGQGLTVTVSS	117
RESULT 10			
US-10-330-613A-13			
Sequence 13, Application US/10330613A			
Patent No. 6924360			
GENERAL INFORMATION:			
APPLICANT: Gudas, Jean			
TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN			
FILE REFERENCE: ABGENIX.022A			
CURRENT APPLICATION NUMBER: US/10/330,613A			
CURRENT FILING DATE: 2002-12-26			
PRIOR APPLICATION NUMBER: 60/346299			
PRIOR FILING DATE: 2001-12-18			
NUMBER OF SEQ ID NOS: 90			
SOFTWARE: Fast-SEQ for Windows Version 4.0			
SEQ ID NO 13			
LENGTH: 117			
TYPE: PRT			
ORGANISM: Homo Sapiens			
US-10-330-613A-13			
Query Match	76.9%;	Score 483;	DB 2; Length 117;
Best Local Similarity	81.4%;	Pred. No. 9.3e-41;	
Matches	96;	Conservative	6; Mismatches 14; Indels 2; Gaps 2
QY	1	QVQLQSGGGLVKKPSETLSLTCTVSGYSTTGGYLNNWIRQPPGKLEWMGVISYDGTNN	59
Db	1	QVQLQSGGGLVKKPSETLSLTCTVSGGSISSGGYTWIRQHPGKLEWIGFIYSGSTY	60
QY	60	YKPSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFDYWGQGLTVTVSS	117

## RESULT 12

US-08-137-117D-64  
; Sequence 64, Application US/08137117D  
; Patent No. 5795965  
; GENERAL INFORMATION:  
; APPLICANT: TSUCHIYA, Masayuki  
; APPLICANT: SATO, Koh  
; APPLICANT: BENDIG, Mary  
; APPLICANT: JONES, Steven  
; APPLICANT: SALDANHA, Jose  
; TITLE OF INVENTION: RESHAPED HUMAN ANTIBODY TO HUMAN  
; TITLE OF INVENTION: INTERLEUKIN-6 RECEPTOR  
; NUMBER OF SEQUENCES: 158  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Foley & Lardner  
; STREET: 3000 K Street, N.W., Suite 500  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20007-5109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/137,117D  
; FILING DATE: 20-DEC-1993  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: WO PCT/JP92/00544  
; FILING DATE: 24-APR-1992  
; PRIOR APPLICATION NUMBER: JP 4-32084  
; APPLICATION DATA:  
; FILING DATE: 19-FEB-1992  
; PRIOR APPLICATION NUMBER: JP 3-95476  
; APPLICATION DATA:  
; FILING DATE: 25-APR-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: WEGNER, Harold C.  
; REGISTRATION NUMBER: 25,258  
; REFERENCE/DOCKET NUMBER: 53466/126/AAOK  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202)672-5300  
; TELEFAX: (202)672-5399  
; TELEX: 904136  
; INFORMATION FOR SEQ ID NO: 64:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 123 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-137-117D-64

Query Match 76.8%; Score 482; DB 1; Length 123;

Best Local Similarity 75.6%; Pred. No. 1.2e-40;

Matches 90; Conservative 11; Mismatches 16; Indels 2; Gaps 1;

QY 1 QVQLQESGFLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWNGYISYDGTNNY 60  
Db 5 QVQLQESGFLVKPSETLSLTCTVSGYSITSDHANSWVRQPPGRLGIEWIGYISYGITTY 64  
QY 61 KPSLKDRTITISDTSKNQPSLKLSSVTAADTAATVYICAR--YGRVFDYWGQGLTVTVSS 117  
Db 65 NPSLSKRVTLMDRTSKNQPSLRLSSVTAADTAATVYICARSLARTTAMDYWGQGLTVTVSS 123

## RESULT 13

US-08-436-717-64  
; Sequence 64, Application US/08436717  
; Patent No. 5817790  
; GENERAL INFORMATION:  
; APPLICANT: TSUCHIYA, Masayuki

; APPLICANT: SATO, Koh  
; APPLICANT: BENDIG, Mary  
; APPLICANT: JONES, Steven  
; APPLICANT: SALDANHA, Jose  
; TITLE OF INVENTION: RESHAPED HUMAN ANTIBODY TO HUMAN  
; TITLE OF INVENTION: INTERLEUKIN-6 RECEPTOR  
; NUMBER OF SEQUENCES: 158  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Foley & Lardner  
; STREET: 3000 K Street, N.W., Suite 500  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20007-5109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/436,717  
; FILING DATE:  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/137,117  
; FILING DATE: 20-DEC-1993  
; APPLICATION NUMBER: WO PCT/JP92/00544  
; FILING DATE: 24-APR-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 4-32084  
; FILING DATE: 19-FEB-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 3-95476  
; FILING DATE: 25-APR-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: WEGNER, Harold C.  
; REGISTRATION NUMBER: 25,258  
; REFERENCE/DOCKET NUMBER: 53466/126/AAOK  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202)672-5300  
; TELEFAX: (202)672-5399  
; TELEX: 904136  
; INFORMATION FOR SEQ ID NO: 64:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 123 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-436-717-64

Query Match 76.8%; Score 482; DB 1; Length 123;

Best Local Similarity 75.6%; Pred. No. 1.2e-40;

Matches 90; Conservative 11; Mismatches 16; Indels 2; Gaps 1;

QY 1 QVQLQESGFLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWNGYISYDGTNNY 60  
Db 5 QVQLQESGFLVKPSETLSLTCTVSGYSITSDHANSWVRQPPGRLGIEWIGYISYGITTY 64  
QY 61 KPSLKDRTITISDTSKNQPSLKLSSVTAADTAATVYICAR--YGRVFDYWGQGLTVTVSS 117  
Db 65 NPSLSKRVTLMDRTSKNQPSLRLSSVTAADTAATVYICARSLARTTAMDYWGQGLTVTVSS 123

## RESULT 14

US-08-137-117D-69  
; Sequence 69, Application US/08137117D  
; Patent No. 5795965  
; GENERAL INFORMATION:  
; APPLICANT: TSUCHIYA, Masayuki  
; APPLICANT: SATO, Koh  
; APPLICANT: BENDIG, Mary  
; APPLICANT: JONES, Steven  
; APPLICANT: SALDANHA, Jose



**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 80.7649 Seconds  
(without alignments)  
636.505 Million cell updates/sec

Title: US-10-735-916A-75  
Perfect score: 628  
Sequence: 1 QVQIQESGFLVKPSETLSL.....RYGRVFFDYWGQTLVTSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_21:\*  
1: Geneseqp1980s:\*  
2: Geneseqp1990s:\*  
3: Geneseqp2000s:\*  
4: Geneseqp2001s:\*  
5: Geneseqp2002s:\*  
6: Geneseqp2003as:\*  
7: Geneseqp2003bs:\*  
8: Geneseqp2004s:\*  
9: Geneseqp2005s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	628	100.0	117	7	ADJ76909 Anti-IGF-
2	628	100.0	117	9	ADZ67079 Human ant
3	628	100.0	135	7	ADJ76911 Anti-IGF-
4	628	100.0	135	9	ADZ67081 Human ant
5	623	99.2	117	7	ADJ76913 Anti-IGF-
6	623	99.2	117	9	ADZ67083 Human ant
7	623	99.2	135	7	ADJ76915 Anti-IGF-
8	623	99.2	135	9	ADZ67085 Human ant
9	611	97.3	117	7	ADJ76917 Anti-IGF-
10	611	97.3	117	9	ADZ67087 Human ant
11	611	97.3	135	7	ADJ76919 Anti-IGF-
12	611	97.3	135	9	ADZ67089 Human ant
13	546	86.9	117	7	ADJ76903 Murine im
14	546	86.9	117	9	ADZ67073 Murine im
15	546	86.9	127	7	ADJ76886 Anti-IGF-
16	546	86.9	127	9	ADZ67056 Murine im
17	531.5	84.6	120	7	ADC27457 Humanised
18	511.5	81.4	120	7	ADC27455 Humanised
19	508.5	81.0	120	7	ADC27459 Humanised
20	505.5	80.5	246	3	AAV15126 Anti-muri
21	503	80.1	119	7	ADP03973 Murine-ex
22	502.5	80.0	121	8	ADSL6559 Human ant
23	499.5	79.5	122	7	ADP03885 Murine-ex
24	499.5	79.5	122	7	ADP03889 Murine-ex

25	498.5	79.4	120	7	ADP03958 Murine-ex
26	496.5	79.1	116	7	ADP03957 Murine-ex
27	496.5	79.1	121	5	ABSO7171 ebvfigM M
28	496.5	79.1	121	8	ADI26658 Human ant
29	496.5	79.1	122	7	ADP03887 Murine-ex
30	496.5	79.1	122	7	ADP03884 Murine-ex
31	496	79.0	119	2	AAW27554 Human Ab
32	496	79.0	119	6	ABJ18676 Antibody
33	496	79.0	121	7	ADZ28455 Human ant
34	496	79.0	466	7	ADZ28479 Human ant
35	494	78.7	119	9	ADY74798 Human Igg
36	493.5	78.6	118	9	AEC20804 Low+ mode
37	493.5	78.6	467	9	AEC20877 Low + mod
38	493	78.5	117	3	AAV44615 Human ant
39	493	78.5	121	7	ADZ28491 Human ant
40	493	78.5	466	7	ADZ28471 Human ant
41	493	78.5	580	6	AAO30915 dr-NHS76
42	493	78.5	580	6	AAO30913 dr-NHS76
43	491.5	78.3	122	9	AEA21456 Human ant
44	491.5	78.3	139	9	ADX98267 Human ant
45	490.5	78.1	121	8	ADSL6505 Human ant

ALIGNMENTS

RESULT 1  
ADJ76909  
ID ADJ76909 standard; protein; 117 AA.  
XX  
AC ADJ76909;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-IR related protein #22.  
XX  
KW cytostatic; antiproliferative; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX Homo sapiens.  
XX WO2003059951-A2.  
XX PD 24-JUL-2003.  
XX PF 20-JAN-2003; 2003WO-FR000178.  
XX 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
XX 07-MAY-2002; 2002FR-00005753.  
XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
PA Goetsch L, Corvaia N, Leger O;  
PI WPI; 2003-569653/53.  
XX New antibodies that bind to human insulin-like growth factor receptor,  
PT useful for treatment, prevention and diagnosis of cancers.  
XX Disclosure; SEQ ID NO 75; 164pp; French.  
PS The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 117 AA;

Query Match 100.0%; Score 628; DB 7; Length 117;  
 Best Local Similarity 100.0%; Pred. No. 3.2e-49;  
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60  
 DB 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60  
 QY 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117  
 DB 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117

RESULT 2  
 ADZ67079  
 ID ADZ67079 standard; protein; 117 AA.

AC ADZ67079;

XX 30-JUN-2005 (first entry)

DE Human antibody 7C10 1 heavy chain variable region SEQ ID NO:75.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW heavy chain variable region.

XX Homo sapiens.

OS US2005084906-A1.

PN 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR000178.

PR 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

PA (CORV/) CORVAIA N.

PA (LEGE/) LEGER O.

PA (DUF/) DUFLOS A.

PA (HAEU/) HAEUW J.

PA (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.

XX Example 13; SEQ ID NO 75; 125pp; English.

CC The invention relates to a novel isolated anti-insulin-like growth factor-  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HIR2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

XX Sequence 117 AA;

Query Match 100.0%; Score 628; DB 9; Length 117;  
 Best Local Similarity 100.0%; Pred. No. 3.2e-49;  
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60

DB 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60

QY 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117

DB 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117

RESULT 3

ADJ76911

ID ADJ76911 standard; protein; 135 AA.

XX AC ADJ76911;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #23.

XX KW cytosolic; antipsoriatic; antibody;

XX KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;

XX KW or epidermal growth factor receptor; EGFR; signal transduction pathway;

XX KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 CDR.

XX OS Homo sapiens.

XX XX WO2003059951-A2.

XX XX PD 24-JUL-2003.

XX XX

PF 20-JAN-2003; 2003WO-FR000178.  
 XX  
 PR 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 XX  
 PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
 XX  
 XX Goetsch L, Corvaia N, Leger O;  
 FI  
 XX WPI; 2003-569653/53.  
 DR  
 XX  
 PT New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.  
 XX  
 PS Disclosure; SEQ ID NO 77; 164pp; French.  
 XX  
 CC The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 135 AA;  
  
 Query Match 100.0%; Score 628; DB 7; Length 135;  
 Best Local Similarity 100.0%; Pred. No. 3.8e-49;  
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
 QY 1 QVQLQESGFLVKPSETLSLTCTVSGYSITGGYLNNWIRQPPGKLEWNGYISYDGTNNY 60  
 DB 19 QVQLQESGFLVKPSETLSLTCTVSGYSITGGYLNNWIRQPPGKLEWNGYISYDGTNNY 78  
  
 QY 61 KPSLKDRITISRDTSKQFSLKLSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117  
 DB 79 KPSLKDRITISRDTSKQFSLKLSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 135  
  
 RESULT 4  
 ID ADZ67081  
 XX ADZ67081 standard; protein; 135 AA.  
 AC ADZ67081;  
 XX  
 DT 30-JUN-2005 (first entry)  
 XX  
 DE Human antibody 7C10 1 heavy chain variable region SEQ ID NO:77.  
 XX  
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW heavy chain variable region.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT Peptide 1..18  
 FT /note= "leader peptide"  
 FT 49..54  
 FT Region  
 FT /note= "CDR1"

FT Region 69..84  
 FT /note= "CDR2"  
 FT 117..124  
 FT /note= "CDR3"  
 XX  
 PN US2005084906-A1.  
 XX  
 PD 21-APR-2005.  
 XX  
 PF 16-DEC-2003; 2003US-00735916.  
 XX  
 PR 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 PR 20-JAN-2003; 2003WO-FR000178.  
 PR 11-JUL-2003; 2003FR-00008538.  
 XX  
 PA (GOET/) GOETSCH L.  
 PA (CORV/) CORVAIA N.  
 PA (LEGE/) LEGER O.  
 PA (DUFL/) DUFLOS A.  
 PA (HAEU/) HAEUW J.  
 PA (BECK/) BECK A.  
 XX  
 PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 XX WPI; 2005-321968/33.  
 DR N-PSDB; ADZ67080.  
 XX  
 PT Novel isolated anti-insulin-like growth factor 1 receptor (IGF-1R)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.  
 XX  
 PS Example 13; SEQ ID NO 77; 125pp; English.  
 XX  
 CC The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-1R) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-1R and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-1R and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-1R and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-1R and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.  
 XX  
 SQ Sequence 135 AA;

Query Match 100.0%; Score 628; DB 9; Length 135;  
 Best Local Similarity 100.0%; Pred. No. 3.8e-49;  
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60  
 DB 19 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 78

QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117  
 DB 79 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 135

RESULT 5  
 ADJ76913  
 ID ADJ76913 standard; protein; 117 AA.  
 XX  
 AC ADJ76913;  
 XX  
 DT 06-MAY-2004 (first entry)  
 XX  
 DE Anti-IGF-IR related protein #24.  
 XX  
 KW cytostatic; antipsoriatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 CDR.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003059951-A2.  
 XX  
 PD 24-JUL-2003.  
 XX  
 PF 20-JAN-2003; 2003WO-FR000178.  
 XX  
 PR 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 XX  
 PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
 XX  
 PI Goetsch L, Corvaia N, Leger O;  
 XX  
 DR WPI; 2003-569653/53.  
 XX  
 PT New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.  
 XX  
 PS Disclosure; SEQ ID NO 79; 164pp; French.  
 XX  
 CC The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC 1R), and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 117 AA;

Query Match 99.2%; Score 623; DB 7; Length 117;  
 Best Local Similarity 98.3%; Pred. No. 9.2e-49;

Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60  
 DB 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60

QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117  
 DB 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117

RESULT 6  
 ADZ67083  
 ID ADZ67083 standard; protein; 117 AA.  
 XX  
 AC ADZ67083;  
 XX  
 DT 30-JUN-2005 (first entry)  
 XX  
 DE Human antibody 7C10 2 heavy chain variable region SEQ ID NO:79.  
 XX  
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW heavy chain variable region.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2005084906-A1.  
 XX  
 PD 21-APR-2005.  
 XX  
 PF 16-DEC-2003; 2003US-00735916.  
 XX  
 PR 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 PR 20-JAN-2003; 2003WO-FR000178.  
 PR 11-JUL-2003; 2003FR-00008538.  
 XX  
 PA (GOST/) GOETSCH L.  
 PA (CORV/) CORVAIA N.  
 PA (LEGE/) LEGER O.  
 PA (DUFLO/) DUFLOS A.  
 PA (HAEU/) HAEUW J.  
 PA (BECK/) BECK A.  
 XX  
 PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 XX  
 DR WPI; 2005-321968/33.  
 XX  
 CC Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)  
 CC antibody or its functional fragment, being capable of binding human IGF-  
 CC 1R and specifically inhibiting tyrosine kinase activity of receptor,  
 CC useful for treating cancer.  
 XX  
 PS Example 13; SEQ ID NO 79; 125pp; English.  
 XX  
 CC The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-1R) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-1R and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-1R and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where

CC the administration of the medicament does not induce or only slightly  
CC induces secondary effects connected with inhibition of the insulin  
CC receptor. The antibody is useful for preparation of a medicament intended  
CC to inhibit the transformation of normal cells into cells with tumoral  
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
CC useful for preparation of a medicament intended to inhibit the growth  
CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
CC medicament intended for prevention or for the treatment of cancer, where  
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
CC preparation of a medicament intended for the prevention or for the  
CC treatment of psoriasis. (I) is useful in preparation of a medicament  
CC intended for the specific targeting of a biologically active compound to  
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
CC is useful for in vitro diagnosis of illnesses induced by an  
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
CC starting from a biological sample in which the abnormal presence, of IGF-  
CC IR and/or EGFR receptor is suspected, which involves contacting the  
CC biological sample with (I), which is optionally labeled. The present  
CC sequence is used in the exemplification of the invention.

XX Sequence 117 AA;

Query Match 99.2%; Score 623; DB 9; Length 117;  
Best Local Similarity 98.3%; Pred. No. 9.2e-49;  
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNNWIRQPPGKLEWGWYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNNWIRQPPGKLEWGWYISYDGTNNY 60  
QY 61 KPSLKDRITISRDTSKNQPSLKLSVTAADTAIVYCYARYGRVFFDYWGQGLTVTVSS 117  
DB 61 KPSLKDRVTISRDTSKNQPSLKLSVTAADTAIVYCYARYGRVFFDYWGQGLTVTVSS 117

RESULT 7  
ADJ76915  
ID ADJ76915 standard; protein; 135 AA.  
XX  
AC ADJ76915;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-IR related protein #25.  
XX  
KW cytostatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.

OS Homo sapiens.  
XX  
XX WO2003059951-A2.  
XX  
XX 24-JUL-2003.  
XX  
XX 20-JAN-2003; 2003WO-FR000178.  
XX  
XX 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX

PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
XX Goetsch L, Corvaia N, Leger O;  
PI  
XX WPI; 2003-569653/53.  
XX

PT New antibodies that bind to human insulin-like growth factor receptor,  
XX useful for treatment, prevention and diagnosis of cancers.

XX Disclosure; SEQ ID NO 81; 164pp; French.

XX The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of  
CC these receptors with their ligands. Especially they inhibit  
CC transformation of normal cells to tumor cells, inhibit growth and/or  
CC proliferation of tumor cells, so are useful against cancers of the  
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
CC protein sequence used to generate the Ab of the invention.

XX Sequence 135 AA;

Query Match 99.2%; Score 623; DB 7; Length 135;  
Best Local Similarity 98.3%; Pred. No. 1.1e-48;  
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNNWIRQPPGKLEWGWYISYDGTNNY 60  
DB 19 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNNWIRQPPGKLEWGWYISYDGTNNY 78  
QY 61 KPSLKDRITISRDTSKNQPSLKLSVTAADTAIVYCYARYGRVFFDYWGQGLTVTVSS 117  
DB 79 KPSLKDRVTISRDTSKNQPSLKLSVTAADTAIVYCYARYGRVFFDYWGQGLTVTVSS 135

RESULT 8  
ADZ67085

ID ADZ67085 standard; protein; 135 AA.

XX AC ADZ67085;

XX 30-JUN-2005 (first entry)

XX Human antibody 7C10 2 heavy chain variable region SEQ ID NO:81.

XX Inulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
KW musculoskeletal disease; respiratory disease; lung tumor;  
KW endocrine disease; gynecology and obstetrics; breast tumor;  
KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
KW heavy chain variable region.

XX Homo sapiens.

OS  
XX Key Location/Qualifiers  
XX Peptide 1..18  
XX Region /note= "leader peptide"  
XX Region 49..54  
XX Region /note= "CDR1"  
XX Region 69..84  
XX Region /note= "CDR2"  
XX Region 117..124  
XX Region /note= "CDR3"

XX US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
PR 20-JAN-2003; 2003WO-FR000178.  
PR 11-JUL-2003; 2003FR-00008538.  
XX (GOET/) GOETSCH L.  
PA (CORV/) CORVAIA N.  
PA (LEGE/) LEGER O.  
PA (DUFL/) DUFLOS A.  
PA (HAEU/) HAEUW J.  
PA (BECK/) BECK A.  
XX  
XX  
PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
XX  
XX WPI; 2005-321968/33.  
DR N-PSDB; ADZ67084.  
XX  
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
PT antibody or its functional fragment, being capable of binding human IGF-  
PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
PT useful for treating cancer.  
XX  
PS Example 13; SEQ ID NO 81; 125pp; English.  
XX  
XX The invention relates to a novel isolated anti-insulin-like growth factor  
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
CC capable of binding to human IGF-IR and, if necessary, capable of  
CC specifically inhibiting tyrosine kinase activity of the receptor,  
CC comprising a light or heavy chain having at least one complementary  
CC determining region (CDR) consisting of one of two fully defined 16 amino  
CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
CC the preparation of a medicament intended for the prevention or treatment  
CC of an illness connected with an overexpression and/or an abnormal  
CC activation of the IGF-IR and/or EGFR, and/or connected with a  
CC hyperactivation of the transduction pathway of the signal mediated by the  
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
CC the administration of the medicament does not induce or only slightly  
CC induces secondary effects connected with inhibition of the insulin  
CC receptor. The antibody is useful for preparation of a medicament intended  
CC to inhibit the transformation of normal cells into cells with tumoral  
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
CC useful for preparation of a medicament intended to inhibit the growth  
CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
CC medicament intended for prevention or for the treatment of cancer, where  
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
CC preparation of a medicament intended for the prevention or for the  
CC treatment of psoriasis. (II) is useful in preparation of a medicament  
CC intended for the specific targeting of a biologically active compound to  
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
CC is useful for in vitro diagnosis of illnesses induced by an  
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
CC starting from a biological sample in which the abnormal presence of IGF-  
CC IR and/or EGFR receptor is suspected, which involves contacting the  
CC biological sample with (I), which is optionally labeled. The present  
CC sequence is used in the exemplification of the invention.  
XX  
SQ Sequence 135 AA;  
Query Match 99.2%; Score 623; DB 9; Length 135;  
Best Local Similarity 98.3%; Pred. No. 1.1e-48;  
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
Oy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLNWNIRQPPGKLEWNGYISYDGTNNY 60  
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLNWNIRQPPGKLEWIGYISYDGTNNY 78  
Oy 61 KPSLKDRITISRDTSKNQFSLKLSSTVAADTAVYVCARYGRVFFDYWGQGLTLVTSS 117  
Db 79 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAVYVCARYGRVFFDYWGQGLTLVTSS 135

RESULT 9  
ADJ76917  
ID ADJ76917 standard; protein; 117 AA.  
XX  
XX AC ADJ76917;  
XX  
XX DT 06-MAY-2004 (first entry)  
XX  
XX DE Anti-IGF-1R related protein #26.  
XX  
XX cytotstatic; antipsoxiatic; antibody;  
XX insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
XX or epidermal growth factor receptor; EGFR; signal transduction pathway;  
XX ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
XX CDR.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2003059951-A2.  
XX  
XX PD 24-JUL-2003.  
XX  
XX PF 20-JAN-2003; 2003WO-FR000178.  
XX  
XX PR 18-JAN-2002; 2002FR-00000653.  
XX  
XX PR 18-JAN-2002; 2002FR-00000654.  
XX  
XX PR 07-MAY-2002; 2002FR-00005753.  
XX  
XX PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
XX PI Goetsch L, Corvaia N, Leger O;  
XX  
XX WPI; 2003-569653/53.  
XX  
XX New antibodies that bind to human insulin-like growth factor receptor,  
XX useful for treatment, prevention and diagnosis of cancers.  
XX  
XX Disclosure; SEQ ID NO 83; 164pp; French.  
XX  
XX The invention relates to an isolated antibody (Ab), and its functional  
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
XX IR) and optionally: (i) inhibit natural binding of insulin-like growth  
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
XX treat diseases associated with overexpression and/or abnormal activity of  
XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
XX hyperactivity of signal transduction pathways mediated by interaction of  
XX these receptors with their ligands. Especially they inhibit  
XX transformation of normal cells to tumor cells, inhibit growth and/or  
XX proliferation of tumor cells, so are useful against cancers of the  
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
XX also for treating psoriasis. Ab are also used to diagnose diseases caused  
XX by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
XX protein sequence used to generate the Ab of the invention.  
XX  
XX Sequence 117 AA;  
Query Match 97.3%; Score 611; DB 7; Length 117;  
Best Local Similarity 96.6%; Pred. No. 1.1e-47;  
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
Oy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLNWNIRQPPGKLEWNGYISYDGTNNY 60  
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLNWNIRQPPGKLEWIGYISYDGTNNY 60  
Oy 61 KPSLKDRITISRDTSKNQFSLKLSSTVAADTAVYVCARYGRVFFDYWGQGLTLVTSS 117  
Db 61 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAVYVCARYGRVFFDYWGQGLTLVTSS 117  
RESULT 10

ADZ67087  
ID ADZ67087 standard; protein; 117 AA.  
XX  
AC ADZ67087;  
XX  
DT 30-JUN-2005 (first entry)  
XX  
DE Human antibody 7C10 3 heavy chain variable region SEQ ID NO:83.  
XX  
KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
KW musculoskeletal disease; respiratory disease; lung tumor;  
KW endocrine disease; gynecology and obstetrics; breast tumor;  
KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
KW heavy chain variable region.  
XX  
OS Homo sapiens.  
XX  
FN US2005084906-A1.  
XX  
PD 21-APR-2005.  
XX  
PF 16-DEC-2003; 2003US-00735916.  
XX  
PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
PR 20-JAN-2003; 2003WO-FR000178.  
PR 11-JUL-2003; 2003FR-00008538.  
XX  
PA (GOET/) GOETSCH L.  
PA (CORV/) CORVAIA N.  
PA (LEGE/) LEGER O.  
PA (DUFL/) DUFLOS A.  
PA (HAEU/) HAEUW J.  
PA (BECK/) BECK A.  
XX  
PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
XX WPI; 2005-321968/33.  
XX  
PT Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
PT antibody or its functional fragment, being capable of binding human IGF-  
PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
PT useful for treating cancer.  
XX  
PS Example 13; SEQ ID NO 83; 125pp; English.  
XX  
CC The invention relates to a novel isolated anti-insulin-like growth factor  
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
CC capable of binding to human IGF-IR and, if necessary, capable of  
CC specifically inhibiting tyrosine kinase activity of the receptor,  
CC comprising a light or heavy chain having at least one complementary  
CC determining region (CDR) consisting of one of two fully defined 16 amino  
CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
CC the preparation of a medicament intended for the prevention or treatment  
CC of an illness connected with an overexpression and/or an abnormal  
CC activation of the IGF-IR and/or EGFR, and/or connected with a  
CC hyperactivation of the transduction pathway of the signal mediated by the  
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
CC the administration of the medicament does not induce or only slightly  
CC induces secondary effects connected with inhibition of the insulin  
CC receptor. The antibody is useful for preparation of a medicament intended  
CC to inhibit the transformation of normal cells into cells with tumoral  
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
CC useful for preparation of a medicament intended to inhibit the growth  
CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
CC especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or  
CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
CC medicament intended for prevention or for the treatment of cancer, where  
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
CC

CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
CC preparation of a medicament intended for the prevention or for the  
CC treatment of psoriasis. (I) is useful in preparation of a medicament  
CC intended for the specific targeting of a biologically active compound to  
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
CC is useful for in vitro diagnosis of illnesses induced by an  
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
CC starting from a biological sample in which the abnormal presence, of IGF-  
CC IR and/or EGFR receptor is suspected, which involves contacting the  
CC biological sample with (I), which is optionally labeled. The present  
CC sequence is used in the exemplification of the invention.  
XX  
SQ Sequence 117 AA;  
Query Match 97.3%; Score 611; DB 9; Length 117;  
Best Local Similarity 96.6%; Pred. No. 1.1e-47;  
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWGIYSYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWGIYSYDGTNNY 60  
QY 61 KPSLKDRITISRDTSKNQFSKLSSVTAADTAVYCYGRVFFDYWGQGLTVTVSS 117  
DB 61 KPSLKDRVTISVDTSKNQFSKLSSVTAADTAVYCYGRVFFDYWGQGLTVTVSS 117  
RESULT 11  
ADJ76919  
ID ADJ76919 standard; protein; 135 AA.  
XX  
AC ADJ76919;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-IR related protein #27.  
XX  
KW cytostatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX  
OS Homo sapiens.  
XX  
FN WO2003059951-A2.  
XX  
PD 24-JUL-2003.  
XX  
PF 20-JAN-2003; 2003WO-FR000178.  
XX  
PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX  
PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
PI Goetsch L, Corvaia N, Leger O;  
XX WPI; 2003-569653/53.  
XX  
PT New antibodies that bind to human insulin-like growth factor receptor,  
PT useful for treatment, prevention and diagnosis of cancers.  
XX  
PS Disclosure; SEQ ID NO 85; 164pp; French.  
XX  
CC The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with

CC hyperactivity of signal transduction pathways mediated by interaction of  
CC these receptors with their ligands. Especially they inhibit  
CC transformation of normal cells to tumor cells, inhibit growth and/or  
CC proliferation of tumor cells, so are useful against cancers of the  
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
CC protein sequence used to generate the Ab of the invention.

XX Sequence 135 AA;

Query Match 97.3%; Score 611; DB 7; Length 135;  
Best Local Similarity 96.6%; Pred. No. 1.3e-47;  
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWMGVIYSDGTNNY 60

Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLWNWIRQPPGKLEWIGIYSDGTNNY 78

QY 61 KPSLKDRITISDTSKNQPSLKLSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117

Db 79 KPSLKDRVTISDTSKNQPSLKLSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 135

RESULT 12

ID AD267089 standard; protein; 135 AA.

AC AD267089;

DT 30-JUN-2005 (first entry)

DE Human antibody 7C10 3 heavy chain variable region SEQ ID NO:85.

KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
KW musculoskeletal disease; respiratory disease; lung tumor;  
KW endocrine disease; gynecology and obstetrics; breast tumor;  
KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
KW heavy chain variable region.

XX Homo sapiens.

Key Location/Qualifiers

Peptide 1..18 /note= "leader peptide"

Region 49..54 /note= "CDR1"

Region 69..84 /note= "CDR2"

Region 117..124 /note= "CDR3"

FT US2005084906-A1.

PN 21-APR-2005.

PD 16-DEC-2003; 2003US-00735916.

PP 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR000178.

PR 11-JUL-2003; 2003FR-00008538.

XX (GOETZ) GOETSCH L.

PA (CORV) CORVAIA N.

PA (LEGE) LEGER O.

PA (DUFL) DUFLOS J.

PA (HAEU) HAEUW J.

PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
XX WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
XX antibody or its functional fragment, being capable of binding human IGF-  
XX IR and specifically inhibiting tyrosine kinase activity of receptor,  
XX useful for treating cancer.

XX Example 13; SEQ ID NO 85; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor-  
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
CC capable of binding to human IGF-IR and, if necessary, capable of  
CC specifically inhibiting tyrosine kinase activity of the receptor,  
CC comprising a light or heavy chain having at least one complementary  
CC determining region (CDR) consisting of one of two fully defined 16 amino  
CC acids (AD267006 and AD267014). An antibody of the invention is useful in  
CC the preparation of a medicament intended for the prevention or treatment  
CC of an illness connected with an overexpression and/or an abnormal  
CC activation of the IGF-IR and/or EGFR, and/or connected with a  
CC hyperactivation of the transduction pathway of the signal mediated by the  
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
CC the administration of the medicament does not induce or only slightly  
CC induces secondary effects connected with inhibition of the insulin  
CC receptor. The antibody is useful for preparation of a medicament intended  
CC to inhibit the transformation of normal cells into cells with tumoral  
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
CC useful for preparation of a medicament intended to inhibit the growth  
CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
CC medicament intended for prevention or for the treatment of cancer, where  
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
CC preparation of a medicament intended for the prevention or for the  
CC treatment of psoriasis. (I) is useful in preparation of a medicament  
CC intended for the specific targeting of a biologically active compound to  
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
CC is useful for in vitro diagnosis of illnesses induced by an  
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
CC starting from a biological sample in which the abnormal presence, of IGF-  
CC IR and/or EGFR receptor is suspected, which involves contacting the  
CC biological sample with (I), which is optionally labeled. The present  
CC sequence is used in the exemplification of the invention.

XX Sequence 135 AA;

Query Match 97.3%; Score 611; DB 9; Length 135;  
Best Local Similarity 96.6%; Pred. No. 1.3e-47;  
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWMGVIYSDGTNNY 60

Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLWNWIRQPPGKLEWIGIYSDGTNNY 78

QY 61 KPSLKDRITISDTSKNQPSLKLSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117

Db 79 KPSLKDRVTISDTSKNQPSLKLSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 135

RESULT 13

ADJ76903

ID ADJ76903 standard; protein; 117 AA.

XX AC ADJ76903;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #16.

XX KW cytostatic; antipsoriatic; antibody;

KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX  
OS Homo sapiens.  
XX  
FN WO2003059951-A2.  
XX  
PD 24-JUL-2003.  
XX  
XX 20-JAN-2003; 2003WO-FR000178.  
XX  
XX 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX  
XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
XX Goetsch L, Corvaia N, Leger O;  
PI WPI; 2003-569653/53.  
XX  
XX New antibodies that bind to human insulin-like growth factor receptor,  
PT useful for treatment, prevention and diagnosis of cancers.  
XX  
XX Disclosure; SEQ ID NO 69; 164pp; French.  
XX  
XX The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of  
CC these receptors with their ligands. Especially they inhibit  
CC transformation of normal cells to tumor cells, inhibit growth and/or  
CC proliferation of tumor cells, so are useful against cancers of the  
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
CC protein sequence used to generate the Ab of the invention.  
XX  
SQ Sequence 117 AA;  
  
Query Match 86.9%; Score 546; DB 7; Length 117;  
Best Local Similarity 86.2%; Pred. No. 8.9e-42;  
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;  
  
QY 2 VQLQSGGLVKPSTLSITCTVSGVSTGGYLNWIRPPCKGLEWVGYSYDGTNNYK 61  
DB 2 VQLQSGGLVKPSTLSITCTVSGVSTGGYLNWIRPPCKGLEWVGYSYDGTNNYK 61  
  
QY 62 PSLKDRITTSRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYGQSTLTVSS 117  
DB 62 PSLKDRISITRDTSKNQFPLKNSVNTEDATYICARYGRVFFDYGQSTLTVSS 117  
  
RESULT 14  
ID ADZ67073 standard; protein; 117 AA.  
XX  
AC ADZ67073;  
XX  
DT 30-JUN-2005 (first entry)  
XX  
XX Murine immunoglobulin heavy chain variable region 7C10 VH SEQ ID NO:69.  
XX  
XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
KW musculoskeletal disease; respiratory disease; lung tumor;  
KW endocrine disease; gynecology and obstetrics; breast tumor;  
KW

KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
KW immunoglobulin; heavy chain variable region.  
XX  
OS Mus musculus.  
XX  
XX US2005084906-A1.  
XX  
XX 21-APR-2005.  
XX  
XX 16-DEC-2003; 2003US-00735916.  
XX  
XX 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX  
XX 20-JAN-2003; 2003WO-FR000178.  
PR 11-JUL-2003; 2003FR-00008538.  
XX  
XX (GOET/) GOETSCH L.  
XX (CORV/) CORVAIA N.  
XX (LEGE/) LEGER O.  
XX (DUFL/) DUFLOS A.  
XX (HAEU/) HAEUW J.  
XX (BECK/) BECK A.  
XX  
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
PI WPI; 2005-321968/33.  
XX  
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)  
CC antibody or its functional fragment, being capable of binding human IGF-  
CC 1R and specifically inhibiting tyrosine kinase activity of receptor,  
CC useful for treating cancer.  
XX  
XX Example 13; SEQ ID NO 69; 125pp; English.  
XX  
XX The invention relates to a novel isolated anti-insulin-like growth factor  
CC I receptor (IGF-1R) antibody (I) or its functional fragment, being  
CC capable of binding to human IGF-1R and, if necessary, capable of  
CC specifically inhibiting tyrosine kinase activity of the receptor,  
CC comprising a light or heavy chain having at least one complementary  
CC determining region (CDR) consisting of one of two fully defined 16 amino  
CC acids (AD267006 and AD267014). An antibody of the invention is useful in  
CC the preparation of a medicament intended for the prevention or treatment  
CC of an illness connected with an overexpression and/or an abnormal  
CC activation of the IGF-1R and/or EGFR, and/or connected with a  
CC hyperactivation of the transduction pathway of the signal mediated by the  
CC interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where  
CC the administration of the medicament does not induce or only slightly  
CC induces secondary effects connected with inhibition of the insulin  
CC receptor. The antibody is useful for preparation of a medicament intended  
CC to inhibit the transformation of normal cells into cells with tumoral  
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
CC useful for preparation of a medicament intended to inhibit the growth  
CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
CC especially IGF1- and/or IGF2-dependent and/or EGF-dependent and/or  
CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
CC medicament intended for prevention or for the treatment of cancer, where  
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
CC preparation of a medicament intended for the prevention or for the  
CC treatment of psoriasis. (I) is useful in preparation of a medicament  
CC intended for the specific targeting of a biologically active compound to  
CC cells expressing or overexpressing the IGF-1R and/or EGFR receptor. (I)  
CC is useful for in vitro diagnosis of illnesses induced by an  
CC overexpression or an underexpression of the IGF-1R and/or EGFR receptor  
CC starting from a biological sample in which the abnormal presence, of IGF-  
CC 1R and/or EGFR receptor is suspected, which involves contacting the  
CC biological sample with (I), which is optionally labeled. The present  
CC sequence is used in the exemplification of the invention.  
XX  
XX Sequence 117 AA;

Query Match 86.9%; Score 546; DB 9; Length 117;  
Best Local Similarity 86.2%; Pred. No. 8.9e-42;  
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;  
QY 2 VOLQESGPGLVKPSLTLCTCTVSGYSITGGYLNWIRQPPGKGLWNGYISYDGTNNYK 61  
DB 2 VOLQESGPGLVKPSLTLCTCTVSGYSITGGYLNWIRQPPGKGLWNGYISYDGTNNYK 61  
QY 62 PSLKDRITISRDTSKNQFSLKSSVTAADTAVYTCARYGRVFFDYWGQGTTLTVSS 117  
DB 62 PSLKDRISITRDTSKNQFSLKSSVTAADTAVYTCARYGRVFFDYWGQGTTLTVSS 117

RESULT 15  
ADJ76886  
ID ADJ76886 standard; protein; 127 AA.  
XX AC ADJ76886;  
XX DT 06-MAY-2004 (first entry)  
XX DE Anti-IGF-1R related protein #4.  
XX KW cytostatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX OS Mus musculus.  
XX PN WO2003059951-A2.  
XX PD 24-JUL-2003.  
XX PF 20-JAN-2003; 2003WO-FR000178.  
XX PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX PI Goetsch L, Corvaia N, Leger O;  
XX DR WPI; 2003-569653/53.  
XX PT New antibodies that bind to human insulin-like growth factor receptor,  
PT useful for treatment, prevention and diagnosis of cancers.  
XX PS Disclosure; SEQ ID NO 52; 164pp; French.  
XX CC The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of  
CC these receptors with their ligands. Especially they inhibit  
CC transformation of normal cells to tumor cells, inhibit growth and/or  
CC proliferation of tumor cells, so are useful against cancers of the  
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
CC protein sequence used to generate the Ab of the invention.  
XX SQ Sequence 127 AA;

Query Match 86.9%; Score 546; DB 7; Length 127;  
Best Local Similarity 86.2%; Pred. No. 9.7e-42;

Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;  
QY 2 VOLQESGPGLVKPSLTLCTCTVSGYSITGGYLNWIRQPPGKGLWNGYISYDGTNNYK 61  
DB 12 VOLQESGPGLVKPSLTLCTCTVSGYSITGGYLNWIRQPPGKGLWNGYISYDGTNNYK 71  
QY 62 PSLKDRITISRDTSKNQFSLKSSVTAADTAVYTCARYGRVFFDYWGQGTTLTVSS 117  
DB 72 PSLKDRISITRDTSKNQFSLKSSVTAADTAVYTCARYGRVFFDYWGQGTTLTVSS 127

Search completed: January 10, 2006, 20:44:17  
Job time : 81.7649 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 14.1157 Seconds  
(without alignments)  
797.508 Million cell updates/sec

Title: US-10-735-916A-75  
Perfect score: 628  
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGLTTLVTS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues  
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR 80:.\*  
1: pir1.\*  
2: pir2.\*  
3: pir3.\*  
4: pir4.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	505	80.4	140	2 I37782	Ig variable region
2	490	78.0	130	2 S31690	Ig heavy chain V r
3	477	76.0	123	2 S30530	Ig heavy chain V r
4	474	75.5	147	2 S13519	Ig heavy chain V r
5	465.5	74.1	118	2 S24443	Ig heavy chain V r
6	464	73.9	155	2 S31511	Ig heavy chain - h
7	463	73.7	121	2 S37207	Ig heavy chain V r
8	460.5	73.3	136	2 S07637	Ig heavy chain V r
9	459.5	73.2	130	2 S30534	Ig heavy chain V r
10	459.5	73.2	139	2 S31586	Ig heavy chain V r
11	458.5	73.0	116	2 S38718	Ig heavy chain V r
12	458.5	73.0	129	2 S44114	Ig heavy chain - h
13	458	72.9	155	2 S31512	Ig heavy chain V r
14	457.5	72.9	140	2 S78052	Ig heavy chain pre
15	455.5	72.5	145	2 S78055	Ig heavy chain pre
16	455	72.5	117	2 I28195	Ig heavy chain V r
17	453	72.1	121	2 S44113	Ig heavy chain V r
18	453	72.1	137	1 AVMS35	Ig heavy chain pre
19	452	72.0	119	2 E25114	Ig heavy chain V r
20	452	72.0	140	2 A49045	Ig heavy chain V r
21	451	71.8	135	2 S78051	Ig heavy chain pre
22	448.5	71.4	137	2 S31676	Ig heavy chain V r
23	448	71.3	146	2 S09711	Ig heavy chain V r
24	446.5	71.1	126	2 S47010	Ig heavy chain V4.
25	444	70.7	119	2 C53285	Ig heavy chain V a
26	443.5	70.6	118	2 S20780	Ig heavy chain V r
27	443	70.5	149	2 S30752	Ig heavy chain pre
28	442	70.4	140	2 A24770	hypothetical Hybri
29	441.5	70.3	134	2 B24672	Ig heavy chain pre

30	439.5	70.0	135	2 PL0100	Ig heavy chain pre
31	435.5	69.3	118	2 A26340	Ig heavy chain pre
32	435.5	69.3	120	2 A25114	Ig heavy chain V r
33	435	69.3	115	2 F25114	Ig heavy chain V r
34	435	69.3	146	2 S09710	Ig heavy chain V r
35	434	69.1	98	2 S12421	Ig heavy chain V r
36	434	69.1	134	2 S54906	Ig heavy chain V r
37	434	69.1	139	2 S31696	Ig heavy chain V r
38	430.5	68.6	97	2 S26906	Ig heavy chain V
39	430.5	68.6	105	2 S44125	Ig lambda chain V
40	430	68.5	119	2 C25114	Ig heavy chain V r
41	430	68.5	123	2 S30529	Ig heavy chain V r
42	429.5	68.4	116	2 B26340	Ig heavy chain pre
43	429	68.3	98	2 S26902	Ig heavy chain V r
44	429	68.3	127	2 S19668	Ig heavy chain V r
45	428.5	68.2	139	2 A41287	Ig heavy chain pre

ALIGNMENTS

RESULT 1

I37782  
Ig variable region (VDJ) (clone T23-9) - human (fragment)  
C:Species: Homo sapiens (man)  
C>Date: 16-Feb-1996 #sequence\_revision 13-Mar-1997 #text\_change 23-Jul-1999  
C:Accession: I37782; S25476  
R:Demaision, C.; Chastagner, P.; Theze, J.; Zouali, M.  
Proc. Natl. Acad. Sci. U.S.A. 91, 514-518, 1994  
A>Title: Somatic diversification in the heavy chain variable region genes expressed by i  
A:Reference number: A36876; MUID:94119917; PMID:8290556  
A:Accession: I37782  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-140 <RES>  
A:Cross-references: UNIPARC:UPI0000176883; EMBL:X67906; NID:g33582; PIDN:CAA48104.1; PFI  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
F:46-128/Domain: immunoglobulin homology <IMM>

Query Match 80.4%; Score 505; DB 2; Length 140;  
Best Local Similarity 81.3%; Pred. No. 3.2e-39;  
Matches 100; Conservative 6; Mismatches 9; Indels 8; Gaps 3;

QY	1	QVQLQESGFLVKPSETLSLCTCTGSGYSITGGYLNWIRQPPKGLGEMWGYISYDGTNNY	60
DB	20	QVQLQESGFLVKPSETLSLCTCTGSGGIS-SYYSWIRQPPKGLGEMWGYISYSGSTNY	78
QY	61	KPSLKDRTITSRDTSKNQFSLKLSVVTAAADTAVYTCAR-----YGRVFFDYWGQGLTTLV	114
DB	79	NPSLSKRVITISVDTSKNQFSLKLSVVTAAADTAVYTCARHNSSSWYGR-YFDYWGQGLTTLV	137
QY	115	VSS 117	
DB	138	VSS 140	

RESULT 2

S31690  
Ig heavy chain V region - human (fragment)  
C:Species: Homo sapiens (man)  
C>Date: 22-Nov-1993 #sequence\_revision 10-Nov-1995 #text\_change 23-Jul-1999  
C:Accession: S31690  
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.  
submitted to the EMBL Data Library, June 1992  
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the  
A:Reference number: S31585  
A:Accession: S31690  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-130 <CUI>  
A:Cross-references: UNIPARC:UPI0000116471; EMBL:Z14199; NID:g30984; PIDN:CAA78568.1; PFI  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotrimer; immunoglobulin

F;20-102/Domain: immunoglobulin homology <IMM>

Query Match 78.0%; Score 490; DB 2; Length 130;  
Best Local Similarity 77.0%; Pred. No. 7e-38;  
Matches 97; Conservative 8; Mismatches 11; Indels 10; Gaps 3;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMGYISYDGTNNY 60  
DB 6 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVWSNRQPPGKGLWMGYIYSGSTNY 64  
QY 61 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAIVYCAR-----YGRV--FFDYWGQGT 111  
DB 65 NPSSLKSRVTISVDTSKNQPSLKLSSVTAADTAIVYCARSSVLLWFGELLYYFDYWGQGT 124  
QY 112 LVTSS 117  
DB 125 LVTSS 130

#### RESULT 3

S30530  
Ig heavy chain V region - human  
C:Species: Homo sapiens (man)  
C:Date: 03-Mar-1994 #sequence\_revision 10-Nov-1995 #text\_change 16-Aug-1996  
C:Accession: S30530  
R;Marette, X.

submitted to the EMBL Data Library, October 1992

A:Reference number: S30520  
A:Accession: S30530  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-123 <MAR>  
A:Cross-references: UNIPARC:UPI0000176C83; EMBL:Z18316  
A:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 76.0%; Score 477; DB 2; Length 123;  
Best Local Similarity 75.8%; Pred. No. 1e-36;  
Matches 94; Conservative 9; Mismatches 13; Indels 8; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGYYGWIRQPPGKGLWMGSMFHSGSSY 60  
QY 61 KPSLKDRTITISRDTSKNQPSLKLSSVTAADTAIVYCARGV-----FFDYWGQGT 113  
DB 61 NPSSLKSRVTISVDTSKNQPSLQLRSVTAADTAIVYCAR-GRYCSSTSCNWFDPWGQGT 119  
QY 114 TVSS 117  
DB 120 TVSS 123

#### RESULT 4

S13519  
Ig heavy chain V region precursor - human  
C:Species: Homo sapiens (man)  
C:Date: 25-Feb-1994 #sequence\_revision 10-Nov-1995 #text\_change 23-Jul-1999  
C:Accession: S13519  
R;Mortari, F.; Ochs, H.D.; Wedgwood, R.J.P.; Schroeder Jr., H.W.  
Nucleic Acids Res. 19, 673, 1991  
A:Title: Immunoglobulin variable heavy chain cDNA sequence from a patient with X-linked  
A:Reference number: S13519; MUID:91187691; PMID:2011536  
A:Accession: S13519  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-147 <MOR>  
A:Cross-references: UNIPARC:UPI0000115B85; EMBL:X56158; NID:g37724; PIDN:CAA39626.1; PID  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F;41-125/Domain: immunoglobulin homology <IMM>

Query Match 75.5%; Score 474; DB 2; Length 147;  
Best Local Similarity 77.9%; Pred. No. 2.3e-36;  
Matches 95; Conservative 7; Mismatches 14; Indels 6; Gaps 3;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSI-TGGYLNWIRQPPGKGLWMGYISYDGTNNY 59  
DB 27 QLQLQESGPGLVKPSSETLSLTCTVSGGSISSSSYWGWIRQPPGKGLWIGSIYSGSTY 86  
QY 60 KPSSLKDRTITISRDTSKNQPSLKLSSVTAADTAIVYCAR---YGRVFFDYWGQGT 115  
DB 87 YNPSSLKSRVTISVDTSKNQPSLKLSSVTAADTAIVYCARPLLWFGEL--FDYWGQGT 145  
QY 116 SS 117  
DB 146 SS 147

#### RESULT 5

S24443  
Ig heavy chain V region (VH4DJ) - human  
C:Species: Homo sapiens (man)  
C:Date: 22-Jan-1993 #sequence\_revision 22-Jan-1993 #text\_change 20-Jun-2000  
C:Accession: S24443; S19667  
R;Jones, P.T.  
submitted to the EMBL Data Library, October 1991  
A:Reference number: S24442  
A:Accession: S24443  
A:Molecule type: mRNA  
A:Residues: 1-118 <JON>  
A:Cross-references: UNIPARC:UPI0000115FE9; EMBL:X61650; NID:g37720; PIDN:CAA43831.1; PII  
R;Marks, J.D.; Hoogenboom, H.R.; Bonnett, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, J. Mol. Biol. 222, 581-597, 1991  
A:Title: By-passing immunization. Human antibodies from V-gene libraries displayed on p  
A:Reference number: S19663; MUID:92085276; PMID:1748994  
A:Accession: S19667  
A:Molecule type: mRNA  
A:Residues: 1-55,57-118 <MAR>  
A:Cross-references: UNIPARC:UPI0000176B52; EMBL:X61650  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F;15-97/Domain: immunoglobulin homology <IMM>

Query Match 74.1%; Score 465.5; DB 2; Length 118;  
Best Local Similarity 77.3%; Pred. No. 1.1e-35;  
Matches 92; Conservative 8; Mismatches 16; Indels 3; Gaps 2;  
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMGYISYDGTNNY 60  
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSLSFSY-WGWIRQPPGKGLWIGIYSHRGSTDY 59  
QY 61 KPSSLKDRTITISRDTSKNQPSLKLSSVTAADTAIVYCAR--YGRVFFDYWGQGT 117  
DB 60 NSSLQSRVTISADTSKNQPSLKLSSVTAADTAIVYCARSFNSFPFGWGQGT 118

#### RESULT 6

S31511  
Ig heavy chain - human  
C:Species: Homo sapiens (man)  
C:Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 23-Jul-1999  
C:Accession: S31511  
R;Chaetagner, P.; Demaison, C.; There, J.; Zouali, M.  
submitted to the EMBL Data Library, December 1992  
A:Description: Dominance of clonotypic patterns and variable gene usage of anti-DNA auto  
A:Reference number: S31509  
A:Accession: S31511  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-155 <CHA>  
A:Cross-references: UNIPARC:UPI00001160FF; EMBL:X69866; NID:g33094; PIDN:CAA49500.1; PII  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F;47-129/Domain: immunoglobulin homology <IMM>

Query Match 73.9%; Score 464; DB 2; Length 155;  
Best Local Similarity 75.0%; Pred. No. 2e-35;  
Matches 93; Conservative 9; Mismatches 14; Indels 8; Gaps 3;

QY 1 QVLOESGGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60  
DB 33 QVLOESGGLVKPSETLSLCTVSGYSIS-SYYSWIRQPPGKLEWNGYIYYTGSATY 91

QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAATVYICARYGRV---PFDY-----WQGGTLV 113  
DB 92 NPLKSRVTISVDTSKNQFSLKSSVTAADTAATVYICARGGGISSWYDYIGMDVWGGTTV 151

QY 114 TVSS 117  
DB 152 TVSS 155

RESULT 7  
S37200  
Ig heavy chain V region - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 21-Jan-2000  
C:Accession: S37200  
R:Fischer, R.; Voss, A.; Hunziker, W.; Stierhof, Y.D.; Kreuzaler, F.  
A:Description: Production and cloning of TMV-specific monoclonal antibodies.  
A:Reference number: S37200  
A:Accession: S37200  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-121 <PIS>  
A:Cross-references: UNIPARC:UPI0001161AC; EMBL:X74587; NID:g402639; PID:g402640  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 73.7%; Score 463; DB 2; Length 121;  
Best Local Similarity 73.3%; Pred. No. 1.9e-35;  
Matches 88; Conservative 11; Mismatches 17; Indels 4; Gaps 1;

QY 2 QVLOESGGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 61  
DB 2 QVLOESGGLVKPSETLSLCTVSGYSITSSYWNWIRQPPGKLEWNGYIYDGRNDYN 61

QY 62 PSLKDRITISRDTSKNQFSLKSSVTAADTAATVYICARYGRV---PFDYWGQGTTLTVSS 117  
DB 62 PSLKDRITISRDTSKNQFSLKSSVTAADTAATVYICARGGIYGVDDYFDSWGQGTTLTVSS 121

RESULT 8  
S07637  
Ig heavy chain V region (PTF 02) - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 23-Jul-1999  
C:Accession: S07637  
R:Urakov, D.N.; Deev, S.M.; Polyakovskiy, O.L.  
Nucleic Acids Res. 17, 9481, 1989  
A:Title: The structure of the expressible VH gene from a hybridoma producing monoclonal  
A:Reference number: S07637; MUID:90067954; PMID:2587273  
A:Accession: S07637  
A:Molecule type: DNA  
A:Residues: 1-136 <URA>  
A:Cross-references: UNIPARC:UPI000115E36; EMBL:X16740; NID:g52099; PIDN:CAA34714.1; PID  
A>Note: the authors translated the codon TAT for residue 112 as Ile, TAC for residue 113  
C:Genetics:  
A:introns: 15/3  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:33-116/Domain: immunoglobulin homology <IMM>

Query Match 73.3%; Score 460.5; DB 2; Length 136;  
Best Local Similarity 74.4%; Pred. No. 3.7e-35;  
Matches 87; Conservative 12; Mismatches 17; Indels 1; Gaps 1;

QY 2 QVLOESGGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 61  
DB 20 QVLOESGGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGSNGYN 79

QY 62 PSLKDRITISRDTSKNQFSLKSSVTAADTAATVYICAR-YGRVFFDYWGQGTTLTVSS 117  
DB 80 PSLKDRITISRDTSKNQFSLKSSVTAADTAATVYICARGGYHFFDYWGQGTTLTVSA 136

RESULT 9  
S30534  
Ig heavy chain V region - human  
C:Species: Homo sapiens (man)  
C:Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 16-Aug-1996  
C:Accession: S30534  
R:Marlette, X.  
submitted to the EMBL Data Library, October 1992  
A:Reference number: S30520  
A:Accession: S30534  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-130 <MAR>  
A:Cross-references: UNIPARC:UPI0000113P45; EMBL:Z18320  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:15-99/Domain: immunoglobulin homology <IMM>

Query Match 73.2%; Score 459.5; DB 2; Length 130;  
Best Local Similarity 71.5%; Pred. No. 4.3e-35;  
Matches 93; Conservative 7; Mismatches 17; Indels 13; Gaps 2;

QY 1 QVLOESGGLVKPSETLSLCTVSGYSI-TGGYLNWIRQPPGKLEWNGYISYDGTNN 59  
DB 1 QVLOESGGLVKPSETLSLCTVSGGSTSSGYSYWSIRQPPGKLEWNGYIYTSNSTN 60

QY 60 KPSLKDRITISRDTSKNQFSLKSSVTAADTAATVYICA-----RYGRVFFDYW 107  
DB 61 YNPISLRITISVDTSKNQFSLKSSVTAADTAATVYICARDKGGFWSGYITRSRAAFDIW 120

QY 108 GQGTTLTVSS 117  
DB 121 GQGTTLTVSS 130

RESULT 10  
S31586  
Ig heavy chain V region - human (fragment)  
C:Species: Homo sapiens (man)  
C:Date: 22-Nov-1993 #sequence\_revision 10-Nov-1995 #text\_change 23-Jul-1999  
C:Accession: S31586  
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnel, C.  
submitted to the EMBL Data Library, June 1992  
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the  
A:Reference number: S31585  
A:Accession: S31586  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-139 <CUI>  
A:Cross-references: UNIPARC:UPI000011646E; EMBL:Z14196; NID:g30978; PIDN:CAA78565.1; PI  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:34-116/Domain: immunoglobulin homology <IMM>

Query Match 73.2%; Score 459.5; DB 2; Length 139;  
Best Local Similarity 76.9%; Pred. No. 4.6e-35;  
Matches 93; Conservative 7; Mismatches 16; Indels 5; Gaps 2;

QY 1 QVLOESGGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60  
DB 20 QVLOESGGLVKPSETLSLCTVSGGSIS-SYYSWIRQPPGKLEWNGYIYTSNSTN 78

QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAATVYICARYG-----RVFFDYWGQGTTLTVSS 116





**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:26:41 ; Search time 78.8731 Seconds  
(without alignments)  
1046.577 Million cell updates/sec

Title: US-10-735-916A-75  
Perfect score: 628  
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQTLVTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : UniProt\_05.80.\*  
1: uniprot\_sprot.\*  
2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	485	77.2	119	Q9UL73_HUMAN	Q9ul73 homo sapien
2	479.5	76.4	465	Q6GMX6_HUMAN	Q6gmx6 homo sapien
3	476	75.8	479	Q9SM22_MOUSE	Q9sm22 mus musculus
4	463	73.7	476	Q6GMX1_HUMAN	Q6gmx1 homo sapien
5	460.5	73.3	136	Q6LBO5_MOUSE	Q6lbo5 mus musculus
6	460.5	73.3	483	Q5U413_MOUSE	Q5u413 mus musculus
7	458.5	73.0	477	Q6GMX7_HUMAN	Q6gmx7 homo sapien
8	453	72.1	137	HV46_MOUSE	P01822 mus musculus
9	452	72.0	119	Q53VQ5_MOUSE	Q53vq5 mus musculus
10	450.5	71.7	150	Q95973_HUMAN	Q95973 homo sapien
11	450.5	71.7	576	Q6P418_HUMAN	Q6p418 homo sapien
12	444.5	70.8	478	Q72379_HUMAN	Q72379 homo sapien
13	443.5	70.6	620	Q96EY0_HUMAN	Q96ey0 homo sapien
14	436	69.4	492	Q72374_HUMAN	Q72374 homo sapien
15	435.5	69.3	120	Q53VR7_MOUSE	Q53vr7 mus musculus
16	435	69.3	115	Q53VQ1_MOUSE	Q53vq1 mus musculus
17	433	68.9	590	Q569B8_RAT	Q569b8 rattus norv
18	430.5	68.6	139	Q86SX2_HUMAN	Q86sx2 homo sapien
19	430.5	68.6	496	Q96KX8_HUMAN	Q96kx8 homo sapien
20	430	68.5	119	Q53VR3_MOUSE	Q53vr3 mus musculus
21	428	68.2	615	Q569B6_RAT	Q569b6 rattus norv
22	426	67.8	116	HV60_MOUSE	P18531 mus musculus
23	423.5	67.4	146	HV21_HUMAN	P06331 homo sapien
24	420	66.9	98	Q53VQ4_MOUSE	Q53vq4 mus musculus
25	420	66.9	595	Q8WUX4_HUMAN	Q8wux4 homo sapien
26	420	66.9	597	Q9BU10_HUMAN	Q9bu10 homo sapien
27	420	66.9	597	Q6GMX5_HUMAN	Q6gmx5 homo sapien
28	420	66.9	625	Q96AA6_HUMAN	Q96aa6 homo sapien
29	418	66.6	597	Q96QB8_HUMAN	Q96qb8 homo sapien
30	409.5	65.2	130	Q81ZD7_HUMAN	Q81zd7 homo sapien
31	409	65.1	477	Q510J1_RAT	Q510j1 rattus norv

32	408	65.0	119	2	Q53VQ9_MOUSE	Q53vq9 mus musculus
33	407	64.8	98	2	Q53VR6_MOUSE	Q53vr6 mus musculus
34	407	64.8	478	2	Q6NYH3_HUMAN	Q6nyh3 homo sapien
35	403.5	64.3	591	2	Q510L9_RAT	Q510l9 rattus norv
36	402	64.0	98	2	Q53VR2_MOUSE	Q53vr2 mus musculus
37	402	64.0	469	2	Q5M839_RAT	Q5m839 rattus norv
38	400	63.7	98	2	Q53VQ0_MOUSE	Q53vq0 mus musculus
39	398	63.4	113	1	HV47_MOUSE	P01823 mus musculus
40	398	63.4	117	1	HV2G_HUMAN	P01825 homo sapien
41	395.5	63.0	122	2	Q9UL75_HUMAN	Q9ul75 homo sapien
42	391	62.3	129	1	HV2F_HUMAN	P01824 homo sapien
43	390	62.1	476	2	Q6WZX7_HUMAN	Q6wzx7 homo sapien
44	389.5	62.0	116	2	O7Z3Y6_HUMAN	O7z3y6 homo sapien
45	389	61.9	116	1	HV61_MOUSE	P18532 mus musculus

ALIGNMENTS

RESULT 1  
Q9UL73\_HUMAN  
ID Q9UL73\_HUMAN PRELIMINARY; PRT; 119 AA.  
AC Q9UL73;  
DT 01-MAY-2000 (Tremblrel. 13, Created)  
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)  
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)  
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;  
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,  
RA Young D.C.;  
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus";  
RL Clin. Immunol. Immunopathol. 87:184-192(1998).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=1660528;  
RA Manheimer-Lory A., Katz J.B., Pilling M., Ghossein C., Smith A., Diamond B.;  
RT "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype";  
RL J. Exp. Med. 174:1639-1652(1991).  
RN [3]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=2511001;  
RA Sanz I., Kelly P., Williams C., Scholl S., Tucker P., Capra J.D.;  
RT "The smaller human VH gene families display remarkably little polymorphism";  
RL EMBO J. 8:3741-3748(1989).  
DR EMBL; AF035041; AAD56277.1; -; mRNA.  
DR PIR; PH0876; PH0876.  
DR PIR; S12416; S12416.  
DR HSSP; P01820; 1G7J.  
DR SMR; Q9UL73; 1-119.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003596; Ig\_v.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS50835; IG\_LIKE; 1.  
DR NON\_TER 1  
FT NON\_TER 119 119  
SQ SEQUENCE 119 AA; 13219 MW; 1BD86B6420EA0BE CRC64;

Query Match 77.2%; Score 485; DB 2; Length 119;  
Best Local Similarity 78.3%; Pred. No. 3.6e-42;  
Matches 94; Conservative 9; Mismatches 13; Indels 4; Gaps 2;

Qy	1	QVQLQESGGGLVQPKSETISLTCTVSGYSITGGLYLNWIRQPPGKGLGEMWGISYDGTNNY	60
Db	1	QVQLQESGGGLVQPKSETISLTCTVSGGSGIC-SYYSWIRQPPGKGLGEMIGYIYSGSTNY	59
Qy	61	KPSLKDRITISRDTSKNTSFSLKLSVTAADTAVYVCAR---YGRVFPDYWGQGTLLVTS	117
Db	60	TPSLKSRVITISVDRSKNPFSLKLSLTAAADTAVFCARLSNWGPYPDYWGQGTLLVTS	119

RESULT 2  
Q6GMX6 HUMAN  
ID Q6GMX6 HUMAN PRELIMINARY; PRT; 465 AA.  
AC Q6GMX6;  
DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
DE Hypothetical protein.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI TaxID=9606;

NUCLEOTIDE SEQUENCE.

RP TISSUE=Primary B-Cells;  
RC MEDLINE=22398257; PubMed=1247932; DOI=10.1073/pnas.242603899;  
RX Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
RA Bosak S.A., McSwain P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalon D.K., Munzly D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Helton E., Kettelman M., Madan A.C., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,  
RA Schnerch A., Schein J.Z., Jones S.J.W., Marra M.A.,  
RT "generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [?]

RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Primary B-Cells;  
RA Srausberg R.;  
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.  
RR EMBL; BC073766; AAH73766.1; -; mRNA.  
DR GO; GO:0016021; C:integral to membrane; IEA.  
DR InterPro; IPR003599; IG.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003537; IG\_CI.  
DR InterPro; IPR003006; IG\_MHC.  
DR InterPro; IPR003596; IG\_V.  
DR Pfam; PF07854; C1-set; 3.  
DR SMART; SM00409; IG; 2.  
DR SMART; SM00407; IGL1; 3.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS00835; IG\_LIKE; 4.  
DR PROSITE; PS00290; IG\_MHC; UNKNOWN\_2.  
DR Hypothetical protein.  
SO SEQUENCE 465 AA; 51083 MW; B3A9B7D0FDB1386E CRC64;

Query Match 76.4%; Score 479.5; DB 2; Length 465;  
Best Local Similarity 80.3%; Pred. No. 5.9e-41;  
Matches 94; Conservative 7; Mismatches 15; Indels 1; Gaps 1

Qy 1 QVQLSSEGLVPKETLSLTCTVSXGYSITGGYLNWIRQPPGKLEWMGYISVDGTNNY 60  
: : : : : : : : : : : : : : : :  
: : : : : : : : : : : : : : : :

[illegible]

RESULT 3

Q99M22_MOUSE	Q99M22_MOUSE PRELIMINARY;	PRT; 479 AA.
ID	Q99M22_MOUSE PRELIMINARY;	
AC	Q99M22;	
DT	01-JUN-2001 (TrEMBLrel. 17, Created)	
DT	01-JUN-2001 (TrEMBLrel. 17, Last sequence update)	
DT	01-MAR-2004 (TrEMBLrel. 26, Last annotation update)	
DE	LOC238447 protein.	
GN	Names=LOC238447;	
OS	Mus musculus (Mouse).	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;	
OC	Muridae; Murinae; Mus.	
OX	NCBI_TaxID=10090;	
RN	[1]	
RP	NUCLEOTIDE SEQUENCE.	
RC	STRAIN=Mix FVB/N;	
RC	TISSUE=Wammary tumor. WAP-TGF alpha model. 7 months old;	
RC	MDLNAE=22388257; PubMed12477932; DOI=10.1073/pnas.242603899;	
RX	STRUBERG R.L., Feingold E.A., Grouse L.H., Derge J.G.	
RA	Klausner R.D., Collins F.S., Wagner L., Shennen C.W., Schuler G.D.,	
RA	Altshul S.F., Zedberg B., Buettow K.H., Schaefer C.F., Bhat N.K.,	
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,	
RA	Dlatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,	
RA	Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,	
RA	Brownstein M.J., Uedlin T.B., Tohiyuki S., Carninci P., Prange C.,	
RA	Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,	
RA	Boeak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,	
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,	
RA	Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,	
RA	Fahy J., Helton E., Ketterman M., Madan A., Rodrigues S., Sanchez A.,	
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,	
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,	
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,	
RA	Butterfield Y.S., Krzywinski M.I., Skalska U., Smailus D.E.,	
RA	Schnarch A., Schein J.E., Jones S.J.M., Marra M.A.;	
RT	"generation and initial analysis of more than 15,000 full-length human	
RT	and mouse cDNA sequences."	
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).	
RN	[2]	

RP	NUCLEOTIDE SEQUENCE.
RC	STRAIN=M1x FVB/N;
RC	TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;
RC	NIH WCC Project;
RG	Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
RL	EMBL; BC002091; AAH02091.1; -; mRNA.
DR	HSSP; P01820; 1G7J.
DR	GO; GO:0003823; F:antigen binding; IEA.
DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003597; Ig cl.
DR	InterPro; IPR003006; Ig_MHC.
DR	InterPro; IPR003596; Ig_v.
DR	PFam; PF07654; Cl-set; 2.
DR	SMART; SM00406; IGV; 1.
DR	PROSITE; PS50835; IG_LIKE; 4.
DR	PROSITE; PS00290; IG_MHC; UNKNOWN_2.
DR	Immunoglobulin domain.
KW	SEQUENCE 479 AA.
SO	SEQUENCE 479 AA. 768E39A138918892 CRC64;

Query Match 75.8%; Score 476; DB 2; Length 479;  
Best Local Similarity 75.3%; Pred. No. 1.4e-40;  
Matches 88; Conservative 12; Mismatches 16; Indels 0; Gaps 0;



```

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.P., Jordan H., Moore T., Max S.I., Wang J.M., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Richards S., Worley K.C., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RG NIH MGC Project;
RL Submitted (OCT-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC085312; AAH85312.1; -; mRNA.
DR Ensembl; ENSMUSG0000054328; Mus musculus.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG.cl.
DR InterPro; IPR003006; IG.MHC.
DR InterPro; IPR003596; IG.v.
DR Pfam; PF07654; CI-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00406; IGV; 1.
DR SMART; SM00407; IGC1; 3.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG.MHC; UNKNOWN 2.
DR PROSITE; PS00290; IG.MHC; UNKNOWN 2.
SQ SEQUENCE 483 AA; 52714 MW; 7C272DA501A4A0D1 CRC64;

Query Match 73.3%; Score 460.5; DB 2; Length 483;
Best Local Similarity 73.9%; Pred. No. 5.7e-39;
Matches 88; Conservative 10; Mismatches 18; Indels 3; Gaps 1;

QY 2 VOLQESGGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWGWYISYDGTNNYK 61
DB 20 VOLQESGGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWGWYISYSGNNYN 79

QY 62 PSLKDRITISRTSKNQFSLKLSVTAADTAVYVCARYGRVF---FDYWGQGTLLTVSS 117
DB 80 PSLKSRISITRSTSKNQFSLKLSVTAADTAVYVCARYGRVF---FDYWGQGTLLTVSS 138

RESULT 7
Q6GMX7 HUMAN
ID Q6GMX7_HUMAN PRELIMINARY; PRT; 477 AA.
AC Q6GMX7;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.P., Jordan H., Moore T., Max S.I., Wang J.M., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Richards S., Worley K.C., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RG NIH MGC Project;
RL Submitted (OCT-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC085312; AAH85312.1; -; mRNA.
DR Ensembl; ENSMUSG0000054328; Mus musculus.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG.cl.
DR InterPro; IPR003006; IG.MHC.
DR InterPro; IPR003596; IG.v.
DR Pfam; PF07654; CI-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00406; IGV; 1.
DR SMART; SM00407; IGC1; 3.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG.MHC; UNKNOWN 2.
DR PROSITE; PS00290; IG.MHC; UNKNOWN 2.
SQ SEQUENCE 483 AA; 52714 MW; 7C272DA501A4A0D1 CRC64;

Query Match 73.0%; Score 458.5; DB 2; Length 477;
Best Local Similarity 75.8%; Pred. No. 9.1e-39;
Matches 91; Conservative 11; Mismatches 13; Indels 5; Gaps 3;

QY 1 QVQLQESGFLVKKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWGWYISYDGTNNY 60
DB 20 QVQLQESGFLVKKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWGWYISYSGSTTY 78

QY 61 KPSLKDRITISRTSKNQFSLKLSVTAADTAVYVCARYGRVF---FDYWGQGTLLTVSS 117
DB 79 NPSLKSRVTLSDTSKQFSLRLNSVTAADTAVYCA-HGSSWDPAFDYWGQGTLLTVSS 137

RESULT 8
HV46 MOUSE
ID HV46_MOUSE STANDARD; PRT; 137 AA.
AC P01822;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V region MOPC 315 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC MEDLINE=89238351; PubMed=2497341; DOI=10.1016/0161-5890(89)90133-8;
RA Rinfret A., Horne C., Dorrington K.J., Klein M.;
RT "Cloning, sequencing and expression of the rearranged MOPC 315 VH gene
RL segment."
RL Mol. Immunol. 26:431-434(1989).
RN [2]
RP PROTEIN SEQUENCE OF 1-31.

```

RX MEDLINE=78094475; PubMed=414225;  
 RA Jilka R.L., Pestka S.;  
 RT "Amino acid sequence of the precursor region of MOPC-315 mouse  
 immunoglobulin heavy chain.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 74:5692-5696(1977).  
 RN [3]  
 RP PROTEIN SEQUENCE OF 1-21.  
 RX MEDLINE=79148758; PubMed=428562;  
 RA Schechter I., Wolf O., Zemeil R., Burstein Y.;  
 RT "Structure and function of immunoglobulin genes and precursors.";  
 RL Fed. Proc. 38:1839-1845(1979).  
 RN [4]  
 RP PROTEIN SEQUENCE OF 19-136.  
 RX MEDLINE=74170779; PubMed=4524622;  
 RA Francis S.H., Leslie R.G.Q., Hood L., Eisen H.N.;  
 RT "Amino-acid sequence of the variable region of the heavy (alpha) chain  
 of a mouse myeloma protein with anti-hapten activity.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 71:1123-1127(1974).  
 RN [5]  
 RP SEQUENCE REVISION TO 53.  
 RX MEDLINE=77244979; PubMed=268248;  
 RA Hood L., Margolies M.N., Givol D., Zakut R.;  
 RL Unpublished results, cited by:  
 RL Padlan E.A., Davies D.R., Pecht I., Givol D., Wright C.;  
 RL Cold Spring Harb. Symp. Quant. Biol. 41:627-637(1977).  
 CC -!- MISCELLANEOUS: This alpha chain was isolated from a myeloma  
 protein that has anti-dinitrophenyl activity.  
 CC -----  
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use as long as its content is in no way modified and this statement is not  
 CC removed.  
 CC -----  
 DR EMBL; M27638; AAA61337.1; -; Genomic DNA.  
 DR EMBL; X07880; CAA30727.1; -; Genomic DNA.  
 DR PIR; PLO102; AVMS35.  
 DR SRR; P01820; 1G7J.  
 DR HSR; P01822; 20-137.  
 DR Ensembl; ENSMUSG0000057048; Mus musculus.  
 DR InterPro; IPR007110; IG-like.  
 DR InterPro; IPR003596; IG\_v.  
 DR SMART; SM00406; IGV; 1.  
 DR PROSITE; PS00835; IG\_LIKE; 1.  
 DR Direct protein sequencing; Immunoglobulin domain;  
 KW Immunoglobulin V region; Signal.  
 FT SIGNAL 1 18  
 FT CHAIN 19 137  
 FT REGION 19 48  
 FT REGION 19 48  
 FT REGION 49 54  
 FT REGION 55 68  
 FT REGION 69 84  
 FT REGION 85 116  
 FT REGION 117 126  
 FT REGION 127 137  
 FT REGION 40 114  
 FT DISULFID 40 114  
 FT CONFLICT 15 15  
 FT CONFLICT 15 15  
 FT CONFLICT 77 78  
 FT CONFLICT 102 102  
 FT CONFLICT 123 123  
 FT NON\_TER 137 137  
 SQ SEQUENCE 137 AA; 15399 MW; FB3828304C2B81DC CRC64;  
 Query Match 72.1%; Score 453; DB 1; Length 137;  
 Best Local Similarity 70.3%; Pred. No. 8.6e-39;  
 Matches 83; Conservative 15; Mismatches 18; Indels 2; Gaps 1;  
 QY 2 VOLQESGPGLVKPSSETLSITCVSGYSITGGYLNWIRPPGKLEWVGYSYDGTNNYK 61  
 DB 20 VOLQESGPGLVKPSQSLTCSVTGYSTGYSITGGYFNWIRPPGKLEWVGIFKYGSGNGYN 79  
 QY 62 PSLKDRITTSRDTSKNQPSLKLSSVTAADTAVYCA--RYGRVFFPDYWGQGITLVTS 117

DB 80 PSLKNRVSIITRDTSENQFFLNKSVTTEDTATYTCAGNDHLYFDYWGQGITLVTS 137  
 RESULT 9  
 ID Q53VQ5\_MOUSE PRELIMINARY; PRT; 119 AA.  
 AC Q53VQ5;  
 DT 13-SEP-2005 (TREMBLrel. 31, Created)  
 DT 13-SEP-2005 (TREMBLrel. 31, Last sequence update)  
 DT 13-SEP-2005 (TREMBLrel. 31, Last annotation update)  
 DE VH-D-JH region (Fragment).  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
 OC Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE.  
 RX MEDLINE=86136012; PubMed=3937730;  
 RA Ollier P., Rocca-Serra J., Somme G., These J., Fougereau M.;  
 RT "The idiotypic network and the internal image: possible regulation of  
 RT a germ-line network by paucigen encoded Ab2 (anti-idiotypic)  
 RT antibodies in the GAT system.";  
 RL EMBO J. 4:3681-3688(1985).  
 RN [2]  
 RP NUCLEOTIDE SEQUENCE OF 28-29.  
 RA Fougereau M.;  
 RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; X03378; CAA27095.1; -; mRNA.  
 FT NON\_TER 1 1  
 FT NON\_TER 119 119  
 SQ SEQUENCE 119 AA; 13931 MW; 502E51A5213F056E CRC64;  
 Query Match 72.0%; Score 452; DB 2; Length 119;  
 Best Local Similarity 72.0%; Pred. No. 9.4e-39;  
 Matches 85; Conservative 12; Mismatches 13; Indels 8; Gaps 2;  
 QY 2 VOLQESGPGLVKPSSETLSITCVSGYSITGGYLNWIRPPGKLEWVGYSYDGTNNYK 61  
 DB 2 VOLQESGPGLVKPSQSLTCSVTGYSTGYSITGGYFNWIRPPGKLEWVGYSYDGSNNYN 61  
 QY 62 PSLKDRITTSRDTSKNQPSLKLSSVTAADTAVYCA--RYGRVFFPDYWGQGIT 111  
 DB 62 PSLKNRVSIITRDTSENQFFLNKSVTTEDTATYTCAGNDHLYFDYWGQGIT 119  
 RESULT 10  
 ID O95973\_HUMAN PRELIMINARY; PRT; 150 AA.  
 AC O95973;  
 DT 01-MAY-1999 (TREMBLrel. 10, Created)  
 DT 01-MAY-1999 (TREMBLrel. 10, Last sequence update)  
 DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)  
 DE VH4 heavy chain variable region precursor (Fragment).  
 GN Name=IGM;  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
 OC Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE.  
 RA Suh C.-H., Song C.-H., Lee C.-H., Lee S.-K.;  
 RT "Clonal proliferation of IGM secreting B cell in the synovium of  
 RT Behcet's patient with arthritis.";  
 RL Submitted (OCT-1998) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RP NUCLEOTIDE SEQUENCE.  
 RX PubMed=1718404;  
 RA Harindranath N., Goldfarb I.S., Ikematsu H., Burastero S.E.,  
 RA Wilder R.L., Notkins A.L., Casali P.;  
 RT "Complete sequence of the genes encoding the VH and VL regions of low-



Db 19 QVQLQESGPGLVKPSQTLSTCTVSGSGISGSDYFWWSWIRQAPGRLGLEMWGIYVSGSTY 78  
QY 60 YKPSLKDRITISRDTSKQNFSLKSSVTAADTAVYYCAR---YGRVFFDYWGQGLTVTVS 116  
Db 79 YNPSLESRLSISIDTSKQNFSLRLNSLTAAADTAVVFCARGVGLGTA-FDINGQGVTVTVS 137  
QY 117 S 117  
Db 138 S 138  
RESULT 13  
Q96EYO HUMAN PRELIMINARY; PRT; 620 AA.  
AC Q96EYO;  
DT 01-DEC-2001 (TREMBLrel. 19, Created)  
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)  
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)  
DE IGHM protein.  
GN Name=IGHM;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalón D.K., Murny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahy J., Helton E., Ketterman M., Madan A., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Goughwood J.J., Schmutz J., Myers R.M.,  
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,  
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,  
RT "Generation and initial analysis of more than 15,000 full-length human  
RL and mouse cDNA sequences."  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Primary B-Cells;  
RG NIH MGC Project;  
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RX PubMed=1904154;  
RA Neale G.A., Kitchingman G.R.;  
RT "mRNA transcripts initiating within the human immunoglobulin mu heavy  
RT chain enhancer region contain a non-translatable exon and are  
RT extremely heterogeneous at the 5' end."  
RL Nucleic Acids Res. 19:2427-2433(1991).  
DR EMBL; BC011857; A011857.2; -; mRNA.  
DR PIR; S15590; S15590.  
DR HSSP; P01820; 1G7J.  
DR SMR; Q96EYO; 27-251.  
DR Ensembl; ENSG00000130076; Homo sapiens.  
DR InterPro; IPR003599; Ig.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003597; Ig cl.  
DR InterPro; IPR003006; Ig MHC.  
DR InterPro; IPR003596; Ig v.  
DR Pfam; PF07654; Cl-set; 4.

DR SMART; SM00409; IG; 2.  
DR SMART; SM00407; IGcl; 4.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS0835; IG LIKE; 5.  
DR PROSITE; PS0290; IG MHC; UNKNOWN 3.  
SQ SEQUENCE 620 AA; 58125 MW; 990AJA4A6E8FF27B CRC64;  
Query Match 70.6%; Score 443.5; DB 2; Length 620;  
Best Local Similarity 75.2%; Pred. No. 4.3e-37; Mismatches 6; Indels 5; Gaps 2;  
Matches 91; Conservative 91;  
QY 1 QVQLQESGPGLVKPSQTLSTCTVSGYSITGGLWNIQPPGKLEWGMGIYVDGTNNY 60  
Db 27 QVQLQESGPGLVKPSQTLSTCTVSGGSI-SYYWSNIQPPGKLEWIGRIYTSSTNY 85  
QY 61 KPSLKDRITISRDTSKQNFSLKSSVTAADTAVYYCA---YGRVFFDYWGQGLTVTVS 116  
Db 86 NPSLSKSRVTSVDTSKQNFSLKSSVTAADTAVYYCASQPWELPTVGLFYWGQGLTVTVS 145  
QY 117 S 117  
Db 146 S 146  
RESULT 14  
Q7Z374 HUMAN PRELIMINARY; PRT; 492 AA.  
AC Q7Z374;  
DT 01-OCT-2003 (TREMBLrel. 25, Created)  
DT 01-OCT-2003 (TREMBLrel. 25, Last sequence update)  
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)  
DE Hypothetical protein DKFZp686C02218 (fragment).  
GN Name=DKFZp686C02218;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Human rectum tumor;  
RA Blocker H., Boecher M., Mewes H.W., Weil B., Amid C., Oeanger A.,  
RA Fobo G., Han M., Wiemann S.;  
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BX538077; CAD98001.1; -; mRNA.  
DR HSSP; P01820; 1G7J.  
DR SMR; Q7Z374; 262-470.  
DR Ensembl; ENSG00000130076; Homo sapiens.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003597; Ig cl.  
DR InterPro; IPR003006; Ig MHC.  
DR InterPro; IPR003596; Ig v.  
DR Pfam; PF07654; Cl-set; 2.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS0835; IG LIKE; 4.  
DR PROSITE; PS0290; IG MHC; UNKNOWN 2.  
KW Hypothetical protein.  
FT NON\_TER 1  
SQ SEQUENCE 492 AA; 53776 MW; 1E7A15760F0CA74B CRC64;  
Query Match 69.4%; Score 436; DB 2; Length 492;  
Best Local Similarity 71.5%; Pred. No. 2e-36;  
Matches 88; Conservative 9; Mismatches 18; Indels 8; Gaps 3;  
QY 1 QVQLQESGPGLVKPSQTLSTCTVSGYSITG-GYLWNIQPPGKLEWGMGIYVDGTNN 59  
Db 32 QVQLQESGPGLVKPSQTLSTCTVSGSVSNRYWGIQPPGKLEWIGIYNYNTY 91  
QY 60 YKPSLKDRITISRDTSKQNFSLKSSVTAADTAVYYCAR-----YGRVFFDYWGQGLTVTV 114  
Db 92 YSPSLKSRITIFDTSKHFSLRLTSVTAADTAVYYCVRVHSGPYG--WFDPMGQGLTVTV 149  
QY 115 VSS 117

```
Db      150 VSS 152
|||
RESULT 15
Q53VR7 MOUSE
ID Q53VR7 MOUSE PRELIMINARY; PRT; 120 AA.
AC Q53VR7;
DT 13-SEP-2005 (TREMBLrel. 31, Created)
DT 13-SEP-2005 (TREMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TREMBLrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., These J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBO J. 4:3681-3688(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03375; CAA27077.1; -; mRNA.
DR EMBL; X03374; CAA27071.1; -; mRNA.
FT NON_TER 1
FT NON_TER 120
SQ SEQUENCE 120 AA; 13892 MW; 013452306EBA3BE CRC64;

Query Match 69.3%; Score 435.5; DB 2; Length 120;
Best Local Similarity 68.1%; Pred. No. 4.8e-37;
Matches 81; Conservative 15; Mismatches 14; Indels 9; Gaps 2;

QY 2 VOLQSGPGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNYK 61
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
2 VHLQSGPGLVKPQSLSLTCSVTGYSITRGYNWNIIRFPGNKLEWNGYINYDGSNNYN 61

QY 62 PSLKDRITISRDTSKNPSKLSLSSVTAADTAVYCAR-----YGRVFP--DYWGQGT 111
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
62 PSLKNRISVTRDTSKNQPFKKNVTTEDTATYCARLIPFSDGYEDYAMDYWGQGT 120

Search completed: January 10, 2006, 20:53:27
Job time : 79.8731 secs
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.96642 Seconds  
(without alignments)  
166.558 Million cell updates/sec

Title: US-10-735-916A-69

Perfect score: 636

Sequence: 1 DVQLQSGPGLVKPSQSL.....RYGRVFFDYWGQTTLTSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Published Applications AA New:\*
- 1: /cgn2\_6/protdata/1/pubpaa/US08 NEW PUB.pep:\*
  - 2: /cgn2\_6/protdata/1/pubpaa/US06 NEW PUB.pep:\*
  - 3: /cgn2\_6/protdata/1/pubpaa/US07 NEW PUB.pep:\*
  - 4: /cgn2\_6/protdata/1/pubpaa/US09 NEW PUB.pep:\*
  - 5: /cgn2\_6/protdata/1/pubpaa/US09 NEW PUB.pep:\*
  - 6: /cgn2\_6/protdata/1/pubpaa/US11 NEW PUB.pep:\*
  - 7: /cgn2\_6/protdata/1/pubpaa/US11 NEW PUB.pep:\*
  - 8: /cgn2\_6/protdata/1/pubpaa/US60\_NEW\_PUB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	636	100.0	117	7	US-11-012-353-69
2	636	100.0	127	7	US-11-012-353-52
3	569.5	89.5	118	7	US-11-012-353-70
4	546	85.8	117	7	US-11-012-353-75
5	546	85.8	135	7	US-11-012-353-77
6	541	85.1	117	7	US-11-012-353-79
7	541	85.1	135	7	US-11-012-353-81
8	539.5	84.8	259	6	US-10-512-184-34
9	539.5	84.8	371	6	US-10-512-184-71
10	539.5	84.8	626	6	US-10-512-184-49
11	529	83.2	117	7	US-11-012-353-83
12	529	83.2	135	7	US-11-012-353-85
13	497.5	78.2	118	7	US-11-012-353-71
14	488.5	76.8	118	7	US-11-009-939-22
15	467	73.4	117	7	US-11-012-353-162
16	412.5	64.9	252	7	US-11-054-515-1994
17	408	64.2	107	7	US-11-185-615-2
18	405	63.7	253	7	US-11-054-515-1619
19	402.5	63.3	250	7	US-11-054-515-1548
20	400	62.9	123	7	US-11-012-353-73
21	399	62.7	255	7	US-11-054-515-841
22	397	62.4	102	7	US-11-185-615-4
23	395.5	62.2	247	7	US-11-054-515-1651
24	395	62.1	229	6	US-10-923-327-13
25	395	62.1	233	6	US-10-923-327-18

26	395	62.1	451	6	US-10-923-327-7	Sequence 7, Appli
27	395	62.1	451	6	US-10-923-327-9	Sequence 9, Appli
28	393	61.8	117	7	US-11-012-353-72	Sequence 72, Appl
29	391	61.5	253	7	US-11-054-515-1339	Sequence 1339, Ap
30	391	61.5	253	7	US-11-054-515-1361	Sequence 1361, Ap
31	387	60.8	120	7	US-11-102-201-1	Sequence 1, Appli
32	386.5	60.8	254	7	US-11-054-515-1578	Sequence 1578, Ap
33	384.5	60.5	247	7	US-11-054-515-1981	Sequence 1981, Ap
34	384	60.4	255	7	US-11-054-515-1597	Sequence 1597, Ap
35	383.5	60.3	116	7	US-11-054-669-100	Sequence 100, App
36	383.5	60.3	146	6	US-10-721-763-17	Sequence 17, Appl
37	382.5	60.1	256	7	US-11-054-515-1607	Sequence 1607, Ap
38	381.5	60.0	154	6	US-10-721-763-25	Sequence 25, Appl
39	381.5	60.0	172	7	US-11-128-900-7	Sequence 7, Appli
40	381.5	60.0	172	7	US-11-128-900-86	Sequence 86, Appl
41	380	59.7	229	6	US-10-923-327-14	Sequence 14, Appl
42	380	59.7	233	6	US-10-923-327-19	Sequence 19, Appl
43	380	59.7	248	6	US-10-923-327-15	Sequence 15, Appl
44	380	59.7	451	6	US-10-923-327-11	Sequence 11, Appl
45	379.5	59.7	248	7	US-11-054-515-1960	Sequence 1960, Ap

ALIGNMENTS

RESULT 1  
US-11-012-353-69  
; Sequence 69, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETTSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFLOS, ALAIN  
; APPLICANT: HAEUW, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012,353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: Patent In Ver. 3.3  
; SEQ ID NO 69  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-11-012-353-69

Query Match	100.0%	Score 636;	DB 7;	Length 117;
Best Local Similarity	100.0%	Pred. No. 8.9e-51;		
Matches 117;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	DVQLQSGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWGYISYDGTNNY	60	
DB	1	DVQLQSGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWGYISYDGTNNY	60	
QY	61	KPSLKDRIISITRDTSKNQFFLKLNSVTNEDTATYTCARYGRVFFDYWGQTTLTSS	117	
DB	61	KPSLKDRIISITRDTSKNQFFLKLNSVTNEDTATYTCARYGRVFFDYWGQTTLTSS	117	

```
RESULT 2
US-11-012-353-52
; Sequence 52, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: US/11/012,353
; PRIOR FILING DATE: 2003-12-16
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-52

Query Match      100.0%; Score 636; DB 7; Length 127;
Best Local Similarity 100.0%; Pred. No. 9.6e-51; Indels 0; Gaps 0;
Matches 117; Conservative 0; Mismatches 0;

QY 1 DVQLQESGGLVKPQSLSLTCSTVGYISITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 11 DVQLQESGGLVKPQSLSLTCSTVGYISITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 70

QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117
Db 71 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 127

RESULT 3
US-11-012-353-70
; Sequence 70, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: US/11/012,353
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-70

Query Match      100.0%; Score 636; DB 7; Length 127;
Best Local Similarity 100.0%; Pred. No. 9.6e-51; Indels 0; Gaps 0;
Matches 117; Conservative 0; Mismatches 0;

QY 1 DVQLQESGGLVKPQSLSLTCSTVGYISITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 11 DVQLQESGGLVKPQSLSLTCSTVGYISITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 70

QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117
Db 71 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 127

RESULT 4
US-11-012-353-75
; Sequence 75, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 75
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-75

Query Match      85.8%; Score 546; DB 7; Length 117;
Best Local Similarity 86.2%; Pred. No. 9.7e-43; Indels 0; Gaps 0;
Matches 100; Conservative 8; Mismatches 8;

QY 2 VQLQESGGLVKPQSLSLTCSTVGYISITGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61
Db 2 VQLQESGGLVKPQSLSLTCSTVGYISITGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61

QY 62 PSLKDRISITRDTSKNQFFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117
Db 62 PSLKDRISITRDTSKNQFFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117
```

```

; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 79
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-79

Query Match      85.1%; Score 541; DB 7; Length 117;
Best Local Similarity 84.5%; Pred. No. 2.7e-42;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

QY 2 VOLQESGPGLVKPSQSLTCTSVGTGYSITGGYLNWNIQPPGKLEWGWYISYDGTNNYK 61
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 2 VOLQESGPGLVKPSSETLSLTCTSVGTGYSITGGYLNWNIQPPGKLEWGWYISYDGTNNYK 61
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 62 PSLKDRISITRDTSKNQFPLKLSVNTEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 62 PSLKDRVTISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 7
US-11-012-353-81
; Sequence 81, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012.353
; PRIOR FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-81

Query Match      85.1%; Score 541; DB 7; Length 135;
Best Local Similarity 84.5%; Pred. No. 3.1e-42;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

QY 2 VOLQESGPGLVKPSQSLTCTSVGTGYSITGGYLNWNIQPPGKLEWGWYISYDGTNNYK 61
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 20 VOLQESGPGLVKPSSETLSLTCTSVGTGYSITGGYLNWNIQPPGKLEWGWYISYDGTNNYK 79
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 62 PSLKDRISITRDTSKNQFPLKLSVNTEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 80 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 135
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 6
US-11-012-353-79
; Sequence 79, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012.353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
```

```

; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 79
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-79

Query Match      85.1%; Score 541; DB 7; Length 117;
Best Local Similarity 84.5%; Pred. No. 2.7e-42;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

QY 2 VOLQESGPGLVKPSQSLTCTSVGTGYSITGGYLNWNIQPPGKLEWGWYISYDGTNNYK 61
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 2 VOLQESGPGLVKPSSETLSLTCTSVGTGYSITGGYLNWNIQPPGKLEWGWYISYDGTNNYK 61
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 62 PSLKDRISITRDTSKNQFPLKLSVNTEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 62 PSLKDRVTISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 7
US-11-012-353-81
; Sequence 81, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012.353
; PRIOR FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-81

Query Match      85.1%; Score 541; DB 7; Length 135;
Best Local Similarity 84.5%; Pred. No. 3.1e-42;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

QY 2 VOLQESGPGLVKPSQSLTCTSVGTGYSITGGYLNWNIQPPGKLEWGWYISYDGTNNYK 61
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 20 VOLQESGPGLVKPSSETLSLTCTSVGTGYSITGGYLNWNIQPPGKLEWGWYISYDGTNNYK 79
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 62 PSLKDRISITRDTSKNQFPLKLSVNTEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 80 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 135
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 6
US-11-012-353-79
; Sequence 79, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012.353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
```

Db 80 PSLKDRVITSDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 8

US-10-512-184-34

; Sequence 34, Application US/10512184

; Publication No. US20050244901A1

GENERAL INFORMATION:

; APPLICANT: Fraunhofer Gesellschaft zur F"rderung der angewandten Forschung e.V.

; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant

; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease

; TITLE OF INVENTION: resistance against fungi

; FILE REFERENCE: 3581.01US01

; CURRENT APPLICATION NUMBER: US/10/512,184

; CURRENT FILING DATE: 2004-10-22

; NUMBER OF SEQ ID NOS: 72

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 34

; LENGTH: 259

; TYPE: PRT

; ORGANISM: Artificial Sequence

FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: scFv PL2 with

; OTHER INFORMATION: specificity against Phoma lingam; originates from

; OTHER INFORMATION: Mus musculus.

US-10-512-184-34

Query Match 84.8%; Score 539.5; DB 6; Length 259;

Best Local Similarity 84.4%; Pred. No. 7.8e-42;

Matches 103; Conservative 5; Mismatches 9; Indels 5; Gaps 2;

QY 1 DVQLQESGGLVKPQSLSLTCSTGYSTGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60

Db 3 DVQLQESGGLVKPQSLSLTCSTGYSTGGYLNWIRQPPGNKLEWNGYISYDGTNNN 62

QY 61 KPSLKDRIISITRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGLTVTV 115

Db 63 NPSLKNRISITRDASKNQFSLKLSVTTEDTATYHCARGAPYVGKGTWFFPWGQGLTVTV 122

QY 116 SS 117

Db 123 SS 124

RESULT 9

US-10-512-184-71

; Sequence 71, Application US/10512184

; Publication No. US20050244901A1

GENERAL INFORMATION:

; APPLICANT: Fraunhofer Gesellschaft zur F"rderung der angewandten Forschung e.V.

; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant

; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease

; TITLE OF INVENTION: resistance against fungi

; FILE REFERENCE: 3581.01US01

; CURRENT APPLICATION NUMBER: US/10/512,184

; CURRENT FILING DATE: 2004-10-22

; NUMBER OF SEQ ID NOS: 72

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 71

; LENGTH: 371

; TYPE: PRT

; ORGANISM: Artificial Sequence

FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: precursor

; OTHER INFORMATION: fusion protein comprising ACE - linker -

; OTHER INFORMATION: scFv PL2.

US-10-512-184-71

Query Match 84.8%; Score 539.5; DB 6; Length 371;

Best Local Similarity 84.4%; Pred. No. 1.1e-41;

Matches 103; Conservative 5; Mismatches 9; Indels 5; Gaps 2;

QY 1 DVQLQESGGLVKPQSLSLTCSTGYSTGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60

Db 115 DVQLQESGGLVKPQSLSLTCSTGYSTGGYLNWIRQPPGNKLEWNGYISYDGTNNN 174

QY 61 KPSLKDRIISITRDTSKNQFSLKLSVTTEDTATYHCARGAPYVGKGTWFFPWGQGLTVTV 115

Db 175 NPSLKNRISITRDASKNQFSLKLSVTTEDTATYHCARGAPYVGKGTWFFPWGQGLTVTV 234

QY 116 SS 117

Db 235 SS 236

RESULT 10

US-10-512-184-49

; Sequence 49, Application US/10512184

; Publication No. US20050244901A1

GENERAL INFORMATION:

; APPLICANT: Fraunhofer Gesellschaft zur F"rderung der angewandten Forschung e.V.

; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant

; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease

; TITLE OF INVENTION: resistance against fungi

; FILE REFERENCE: 3581.01US01

; CURRENT APPLICATION NUMBER: US/10/512,184

; CURRENT FILING DATE: 2004-10-22

; NUMBER OF SEQ ID NOS: 72

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 49

; LENGTH: 626

; TYPE: PRT

; ORGANISM: Artificial Sequence

FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: fusion protein

; OTHER INFORMATION: comprising the leader peptide - chitinase- linker

; OTHER INFORMATION: - scFv PL2 - cmyc/His6.

US-10-512-184-49

Query Match 84.8%; Score 539.5; DB 6; Length 626;

Best Local Similarity 84.4%; Pred. No. 1.8e-41;

Matches 103; Conservative 5; Mismatches 9; Indels 5; Gaps 2;

QY 1 DVQLQESGGLVKPQSLSLTCSTGYSTGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60

Db 344 DVQLQESGGLVKPQSLSLTCSTGYSTGGYLNWIRQPPGNKLEWNGYISYDGTNNN 403

QY 61 KPSLKDRIISITRDTSKNQFSLKLSVTTEDTATYHCARGAPYVGKGTWFFPWGQGLTVTV 115

Db 404 NPSLKNRISITRDASKNQFSLKLSVTTEDTATYHCARGAPYVGKGTWFFPWGQGLTVTV 463

QY 116 SS 117

Db 464 SS 465

RESULT 11

US-11-012-353-83

; Sequence 83, Application US/11012353

; Publication No. US20050249730A1

GENERAL INFORMATION:

; APPLICANT: GOETSCH, LILIANE

; APPLICANT: CORVAIA, NATHALIE

; APPLICANT: DUFLOS, ALAIN

; APPLICANT: HAEUW, JEAN-FRANCOIS

; APPLICANT: LEGER, OLIVIER

; APPLICANT: BECK, ALAIN

; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID

; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF

; FILE REFERENCE: 017753-198

; CURRENT APPLICATION NUMBER: US/11/012,353

; CURRENT FILING DATE: 2004-12-16

; PRIOR APPLICATION NUMBER: 10/735,916

; PRIOR FILING DATE: 2003-12-16

; PRIOR APPLICATION NUMBER: FR 0308538

; PRIOR FILING DATE: 2003-07-11





GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 64.1754 Seconds  
(without alignments)  
761.757 Million cell updates/sec

Title: US-10-735-916A-69  
Perfect score: 636  
Sequence: 1 DVQLQSGPGLVKPQSLSL.....RYGRVFEDYWGQGTTLTVSS 117

Scoring table: BLASTUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications\_AA\_Main:\*  
1: /cgn2\_6/prodata/1/pubpaa/US07\_PUBCOMB.pep:\*  
2: /cgn2\_6/prodata/1/pubpaa/US08\_PUBCOMB.pep:\*  
3: /cgn2\_6/prodata/1/pubpaa/US09\_PUBCOMB.pep:\*  
4: /cgn2\_6/prodata/1/pubpaa/US10A\_PUBCOMB.pep:\*  
5: /cgn2\_6/prodata/1/pubpaa/US10B\_PUBCOMB.pep:\*  
6: /cgn2\_6/prodata/1/pubpaa/US11\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	636	100.0	117	5	US-10-735-916A-69
2	636	100.0	127	5	US-10-735-916A-52
3	569.5	89.5	118	5	US-10-735-916A-70
4	548.5	86.2	118	4	US-10-372-481-17
5	548.5	86.2	118	4	US-10-371-797-17
6	546	85.8	117	5	US-10-735-916A-75
7	546	85.8	135	5	US-10-735-916A-77
8	544.5	85.6	136	3	US-09-858-349-2
9	541	85.1	117	5	US-10-735-916A-79
10	541	85.1	135	5	US-10-735-916A-81
11	533.5	83.9	468	5	US-10-943-640-4
12	529	83.2	117	5	US-10-735-916A-83
13	529	83.2	135	5	US-10-735-916A-85
14	522.5	82.2	144	3	US-09-791-551-119
15	521.5	82.0	120	4	US-10-383-447-2
16	518	81.4	119	5	US-10-207-655-258
17	518	81.4	119	5	US-10-627-556-46
18	518	81.4	266	4	US-10-207-655-260
19	518	81.4	266	5	US-10-627-556-48
20	518	81.4	550	4	US-10-207-655-270
21	518	81.4	550	5	US-10-627-556-54
22	518	81.4	550	5	US-10-627-556-440
23	516.5	81.2	116	6	US-11-003-819-4
24	514.5	80.9	121	3	US-09-144-886-70
25	514.5	80.9	121	4	US-10-632-706-67
26	513	80.7	113	4	US-10-741-657A-21
27	513	80.7	141	3	US-09-791-551-109

28	512.5	80.6	118	4	US-10-184-300A-3	Sequence 3, Appli
29	511	80.3	121	3	US-09-920-171-2	Sequence 2, Appli
30	511	80.3	121	4	US-10-113-996-2	Sequence 2, Appli
31	511	80.3	121	5	US-10-791-619-2	Sequence 2, Appli
32	511	80.3	134	3	US-09-802-077-3	Sequence 3, Appli
33	511	80.3	134	3	US-09-802-096-3	Sequence 3, Appli
34	511	80.3	134	3	US-09-925-179-3	Sequence 3, Appli
35	511	80.3	134	5	US-10-968-237-3	Sequence 3, Appli
36	510	80.2	119	4	US-10-713-248-3	Sequence 7, Appli
37	510	80.2	119	4	US-10-713-248-7	Sequence 19, Appl
38	509	80.0	113	4	US-10-741-657A-19	Sequence 131, App
39	508.5	80.0	115	4	US-10-308-817-131	Sequence 131, App
40	508.5	80.0	115	4	US-10-453-698-131	Sequence 131, App
41	508	79.9	117	5	US-10-816-938-29	Sequence 29, Appl
42	507	79.7	121	4	US-10-310-674A-36	Sequence 36, Appl
43	507	79.7	121	4	US-10-389-679-12	Sequence 12, Appl
44	506	79.6	113	4	US-10-741-657A-13	Sequence 13, Appl
45	502.5	79.0	120	4	US-10-383-447-22	Sequence 22, Appl

ALIGNMENTS

RESULT 1  
US-10-735-916A-69  
; Sequence 69, Application US/10735916A  
; Publication No. US20050084906A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, Liliane  
; APPLICANT: CORVAIA, Nathalie  
; APPLICANT: LEGER, Olivier  
; APPLICANT: DUFLOS, Alain  
; APPLICANT: BECK, Alain  
; APPLICANT: HAEUW, Jean-Francois  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-183  
; CURRENT APPLICATION NUMBER: US/10735,916A  
; CURRENT FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 03/08 538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 02/00 653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/00 654  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/05 753  
; PRIOR FILING DATE: 2002-05-07  
; NUMBER OF SEQ ID NOS: 156  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 69  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-10-735-916A-69

Query Match	100.0%	Score 636;	DB 5;	Length 117;
Best Local Similarity	100.0%;	Pred. No. 4.5e-51;		
Matches 117;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	DVQLQSGPGLVKPQSLSLTCSVTGYSITGTYLWNWIRQFPGNKLEWNGYISYDGTNNY	60	
Db	1	DVQLQSGPGLVKPQSLSLTCSVTGYSITGTYLWNWIRQFPGNKLEWNGYISYDGTNNY	60	
QY	61	KPSLKDRIISITRDTSKNOFFKLNSVTNEDTATYTCARYGRVFEDYWGQGTTLTVSS	117	
Db	61	KPSLKDRIISITRDTSKNOFFKLNSVTNEDTATYTCARYGRVFEDYWGQGTTLTVSS	117	
RESULT 2				
US-10-735-916A-52				
; Sequence 52, Application US/10735916A				
; Publication No. US20050084906A1				

```

; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-52

Query Match      100.0%; Score 636; DB 5; Length 127;
Best Local Similarity 100.0%; Pred. No. 4.9e-51;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVQLQESGGLVKPQSLSLTCVTSYITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 11 DVQLQESGGLVKPQSLSLTCVTSYITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 70

QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYGRVFPDYWGQGTTLTVSS 117
Db 71 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYGRVFPDYWGQGTTLTVSS 127

RESULT 3
US-10-735-916A-70
; Sequence 70, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 70
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Mus musculus

```

```

US-10-735-916A-70

Query Match      89.5%; Score 569.5; DB 5; Length 118;
Best Local Similarity 90.7%; Pred. No. 6.4e-45;
Matches 107; Conservative 2; Mismatches 8; Indels 1; Gaps 1;

QY 1 DVQLQESGGLVKPQSLSLTCVTSYITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGGLVKPQSLSLTCVTSYITGGYLNWIRQFPGNKLEWNGYINYGNNY 60

QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYG-RVFPDYWGQGTTLTVSS 117
Db 61 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCAREGYGFYFDYWGQGTTLTVSS 118

RESULT 4
US-10-372-481-17
; Sequence 17, Application US/10372481
; Publication No. US20030202975A1
; GENERAL INFORMATION:
; APPLICANT: Tedder, Thomas F.
; TITLE OF INVENTION: REAGENTS AND TREATMENT METHODS FOR AUTOIMMUNE DISEASES
; FILE REFERENCE: 5405.306
; CURRENT APPLICATION NUMBER: US/10/372.481
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: PCT/US03/05549
; PRIOR FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 60/420,472
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: US 60/359,419
; PRIOR FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-372-481-17

Query Match      86.2%; Score 548.5; DB 4; Length 118;
Best Local Similarity 87.3%; Pred. No. 5.5e-43;
Matches 103; Conservative 5; Mismatches 9; Indels 1; Gaps 1;

QY 1 DVQLQESGGLVKPQSLSLTCVTSYITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 1 EVQLQESGGLVKPQSLSLTCVTSYITGGYLNWIRQFPGNKLEWNGYIRYGSNNY 60

QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYG-RVFPDYWGQGTTLTVSS 117
Db 61 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCARGGITVAMDYWGQGTSTVTVSS 118

RESULT 5
US-10-371-797-17
; Sequence 17, Application US/10371797
; Publication No. US20040001828A1
; GENERAL INFORMATION:
; APPLICANT: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
; APPLICANT: TUSCANO, Joseph
; APPLICANT: TEDDER, Thomas
; TITLE OF INVENTION: TREATMENT METHODS USING ANTI-CD22
; TITLE OF INVENTION: ANTIBODIES
; FILE REFERENCE: 39754-0951
; CURRENT APPLICATION NUMBER: US/10/371,797
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 60/420,472
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: US 60/359,419
; PRIOR FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 118

```



```
; Sequence 79, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 79
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-79

Query Match      85.1%; Score 541; DB 5; Length 117;
Best Local Similarity 84.5%; Pred. No. 2.7e-42;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

Qy 2 VQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61
Db 2 VQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61

Qy 62 PSLKDRISITRDTSKNQFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117
Db 62 PSLKDRVTISRDTSKNQFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117

; RESULT 10
US-10-735-916A-81
; Sequence 81, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 81
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-81

Query Match      85.1%; Score 541; DB 5; Length 117;
Best Local Similarity 84.5%; Pred. No. 2.7e-42;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

Qy 2 VQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61
Db 2 VQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61

Qy 62 PSLKDRISITRDTSKNQFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117
Db 62 PSLKDRVTISRDTSKNQFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117

; RESULT 11
US-10-943-640-4
; Sequence 4, Application US/10943640
; Publication No. US20050152907A1
; GENERAL INFORMATION:
; APPLICANT: LIANG, Tony W.
; APPLICANT: LOO, Deryk T.
; APPLICANT: XU, Xiaolin
; TITLE OF INVENTION: KID3 AND KID3 ANTIBODIES THAT BIND
; FILE REFERENCE: 415072002700
; CURRENT APPLICATION NUMBER: US/10/943,640
; CURRENT FILING DATE: 2004-09-17
; PRIOR APPLICATION NUMBER: US 60/504,441
; PRIOR FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 468
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-943-640-4

Query Match      83.9%; Score 533.5; DB 5; Length 468;
Best Local Similarity 84.2%; Pred. No. 5.6e-41;
Matches 101; Conservative 6; Mismatches 10; Indels 3; Gaps 2;

Qy 1 DVQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 19 DVQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQFPGNKLEWNGYISYSGSTSY 78

Qy 61 KPSLKDRISITRDTSKNQFLKNSVTNEDTATYTCAR-YGRV--FFDYWGQGTTLTVSS 117
Db 79 NPSLKRSVITRDTSKNQFLQLNSVTNEDTATYTCARFYRYADYDFDYWGQGTTLTVSS 138

; RESULT 12
US-10-735-916A-83
; Sequence 83, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
```

; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 83
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-83

Query Match 83.2%; Score 529; DB 5; Length 117;
Best Local Similarity 82.8%; Pred. No. 3.5e-41;
Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 2 VOLQSGPGLVKPQSLSLTCSTGYSGITGGLNNWIRQFPNGKLEWGWYISYDGTNNYK 61
DB 2 VOLQSGPGLVKPQSLSLTCSTGYSGITGGLNNWIRQFPNGKLEWGWYISYDGTNNYK 61

QY 62 PSLKDRISITRDTSKNQFLKNSVTNEDTATYVCARYGRVFFDYWGQGTTLTVSS 117
DB 62 PSLKDRVTISVDTSKNQFLKNSVTNEDTATYVCARYGRVFFDYWGQGTTLTVSS 117

RESULT 13
US-10-735-916A-85
; Sequence 85, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 85
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-85

Query Match 83.2%; Score 529; DB 5; Length 135;
Best Local Similarity 82.8%; Pred. No. 4e-41;
Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 2 VOLQSGPGLVKPQSLSLTCSTGYSGITGGLNNWIRQFPNGKLEWGWYISYDGTNNYK 61
DB 20 VOLQSGPGLVKPQSLSLTCSTGYSGITGGLNNWIRQFPNGKLEWGWYISYDGTNNYK 79

QY 62 PSLKDRISITRDTSKNQFLKNSVTNEDTATYVCARYGRVFFDYWGQGTTLTVSS 117
DB 80 PSLKDRVTISVDTSKNQFLKNSVTNEDTATYVCARYGRVFFDYWGQGTTLTVSS 135

RESULT 14

US-09-791-551-119
; Sequence 119, Application US/09791551
; Publication No. US2003023584A1
; GENERAL INFORMATION:
; APPLICANT: KLOETZER, WILLIAM S.
; APPLICANT: HANNA, NABIL
; TITLE OF INVENTION: METHOD FOR PREPARING ANTI-MIF ANTIBODIES
; FILE REFERENCE: 037003/0277869
; CURRENT APPLICATION NUMBER: US/09/791.551
; CURRENT FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: 60/185,390
; PRIOR FILING DATE: 2000-02-28
; PRIOR APPLICATION NUMBER: 60/233,625
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 119
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 119
; LENGTH: 144
; TYPE: PRT
; ORGANISM: Mus sp.
US-09-791-551-119

Query Match 82.2%; Score 522.5; DB 3; Length 144;
Best Local Similarity 78.2%; Pred. No. 1.7e-40;
Matches 97; Conservative 10; Mismatches 10; Indels 7; Gaps 1;

QY 1 DVQLQESGPGVLKVPQSLSLTCSTGYSGITGGLNNWIRQFPNGKLEWGWYISYDGTNNY 60
DB 19 DVQLQESGPDVLKVPQSLSLTCSTGYSGITGGLNNWIRQFPNGKLEWGWYISYDGSKSH 78
QY 61 KPSLKDRISITRDTSKNQFLKNSVTNEDTATYVCARYGRVFFDYWGQGTTL 113
DB 79 NPSLNRNRSITRDPKSNQFLKNSVTNEDTATYVCARGKIFGYSGYDPPAYWGQGTIV 138
QY 114 TVSS 117
DB 139 TVSS 142

RESULT 15

US-10-383-447-2
; Sequence 2, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaekar, Vinay
; APPLICANT: de la Calle, Agustin
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Heavy chain variable region
US-10-383-447-2

Query Match 82.0%; Score 521.5; DB 4; Length 120;

[illegible]

Search completed: January 10, 2006, 21:35:32  
Job time : 65.1754 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 22.847 Seconds  
(without alignments)  
423.384 Million cell updates/sec

Title: US-10-735-916A-69  
Perfect score: 636  
Sequence: 1 DVQLQESGFLVKPSQSLSL.....RYGRVFDFYWGQGTTLTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/prodata/1/aaa/5 COMB.pep.\*  
2: /cgn2\_6/prodata/1/aaa/6 COMB.pep.\*  
3: /cgn2\_6/prodata/1/aaa/H COMB.pep.\*  
4: /cgn2\_6/prodata/1/aaa/PCITUS COMB.pep.\*  
5: /cgn2\_6/prodata/1/aaa/RE COMB.pep.\*  
6: /cgn2\_6/prodata/1/aaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	550	86.5	118	2	US-09-065-059-11
2	550	86.5	118	2	US-08-913-555-11
3	540	84.9	119	2	US-08-767-128-18
4	511	80.3	121	1	US-08-887-352B-2
5	511	80.3	121	2	US-09-109-207C-2
6	511	80.3	121	2	US-09-296-005-2
7	511	80.3	121	2	US-09-920-171-2
8	511	80.3	121	2	US-09-716-028-2
9	511	80.3	121	2	US-10-113-996-2
10	511	80.3	134	2	US-08-466-151-3
11	511	80.3	134	2	US-08-466-163B-3
12	511	80.3	134	2	US-09-802-096-3
13	511	80.3	134	2	US-09-802-077-3
14	511	80.3	134	2	US-09-925-179-3
15	506.5	79.6	241	2	US-08-902-486-13
16	506.5	79.6	496	2	US-08-902-486-15
17	500	78.6	130	2	US-08-466-151-5
18	500	78.6	130	2	US-08-466-163B-5
19	500	78.6	130	2	US-09-802-096-5
20	500	78.6	130	2	US-09-802-077-5
21	500	78.6	130	2	US-09-925-179-5
22	498.5	78.4	240	1	US-07-956-399-2
23	491.5	77.3	117	1	US-08-308-494A-13
24	485.5	76.3	114	1	US-08-111-080-23
25	485.5	76.3	114	1	US-08-211-980-23
26	485.5	76.3	114	4	PCITUS-07967-23
27	482	75.8	137	1	US-08-137-117D-31

28	482	75.8	137	1	US-08-436-717-31	Sequence 31, Appl
29	478.5	75.2	137	2	US-08-466-151-7	Sequence 7, Appl
30	478.5	75.2	137	2	US-08-466-163B-7	Sequence 7, Appl
31	478.5	75.2	137	2	US-09-802-096-7	Sequence 7, Appl
32	478.5	75.2	137	2	US-09-802-077-7	Sequence 7, Appl
33	478.5	75.2	137	2	US-09-925-179-7	Sequence 7, Appl
34	478	75.2	117	1	US-08-672-345C-13	Sequence 13, Appl
35	478	75.2	117	2	US-09-214-095D-13	Sequence 13, Appl
36	478	75.2	117	2	US-09-940-727B-13	Sequence 13, Appl
37	477	75.0	213	2	US-09-170-769A-2	Sequence 2, Appl
38	463	72.8	117	2	US-09-232-290-32	Sequence 32, Appl
39	456.5	71.8	112	2	US-09-344-587-14	Sequence 14, Appl
40	456	71.7	117	1	US-08-672-345C-10	Sequence 10, Appl
41	456	71.7	117	1	US-08-672-345C-11	Sequence 11, Appl
42	456	71.7	117	1	US-08-672-345C-100	Sequence 100, App
43	456	71.7	117	1	US-08-672-345C-101	Sequence 101, App
44	456	71.7	117	2	US-09-214-095D-10	Sequence 10, Appl
45	456	71.7	117	2	US-09-214-095D-11	Sequence 11, Appl

ALIGNMENTS

RESULT 1  
US-09-065-059-11  
; Sequence 11, Application US/09065059  
; Patent No. 6068841  
; GENERAL INFORMATION:  
; APPLICANT: SEINO, Ken-ichiro  
; APPLICANT: KAYAGAKI, No. 6068841uhiko  
; APPLICANT: YAGITA, Hideo  
; APPLICANT: OKUMURA, Ko  
; APPLICANT: NAKATA, Motomi  
; TITLE OF INVENTION: THERAPEUTIC AGENT FOR HEPATITIS  
; NUMBER OF SEQUENCES: 18  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: McDermott, Will & Emery  
; STREET: 99 Canal Center Plaza  
; CITY: Alexandria  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/065,059  
; FILING DATE:  
; CLASSIFICATION: 424  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Bucca Ph.D., Daniel  
; REGISTRATION NUMBER: P-42,368  
; REFERENCE/DOCKET NUMBER: 50356-151  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-518-5100  
; TELEFAX: 703-684-1124  
; INFORMATION FOR SEQ ID NO: 11:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 118 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-09-065-059-11

Query Match 86.5%; Score 550; DB 2; Length 118;  
Best Local Similarity 88.1%; Pred. No. 8.8e-51;  
Matches 104; Conservative 3; Mismatches 9; Indels 2; Gaps 1;  
QY 2 VOLQESGFLVKPSQSLTCSVTGYSITGGYLNWIRQFGNKLWMCYISVDCGTNNYK 61  
|||||

Db 1 VOLQSGPGLVKPSQSLTCSVTGYSITSGYNNWIRQFPGNKLEWNGYISYDGNMNY 60  
QY 62 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYCA--RYGRVFFDYNGQGTTLTVSS 117  
Db 61 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYCAVYYDSSFDYNGQGTTLTVSS 118

RESULT 2  
US-08-913-555-11  
; Sequence 11, Application US/08913555  
; Patent No. 6946255  
; GENERAL INFORMATION:  
; APPLICANT: KAYAGAKI, No. 6946255uhiko  
; APPLICANT: YAGITA, Kideo  
; APPLICANT: OKUMURA, Ko  
; APPLICANT: NAKATA, Motomi  
; TITLE OF INVENTION: MONOCLONAL ANTIBODY SPECIFICALLY  
; TITLE OF INVENTION: REACTING WITH Fas LIGAND AND PRODUCTION PROCESS THEREOF  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: McDermott, Will & Emery  
; STREET: 99 Canal Center Plaza, Suite 300  
; CITY: Alexandria  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/913,555  
; FILING DATE: 19-SEP-1997  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Bucca Ph.D., Daniel  
; REGISTRATION NUMBER: 42,368  
; REFERENCE/DOCKET NUMBER: 50356-150  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-756-8699  
; TELEFAX: 202-756-8699  
; INFORMATION FOR SEQ ID NO: 11:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 118 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-913-555-11

Query Match 86.5%; Score 550; DB 2; Length 118;  
Best Local Similarity 88.1%; Pred. No. 8.8e-51;  
Matches 104; Conservative 3; Mismatches 9; Indels 2; Gaps 1;  
QY 2 VOLQSGPGLVKPSQSLTCSVTGYSITSGYNNWIRQFPGNKLEWNGYISYDGNMNYK 61  
Db 1 VOLQSGPGLVKPSQSLTCSVTGYSITSGYNNWIRQFPGNKLEWNGYISYDGNMNY 60  
QY 62 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYCA--RYGRVFFDYNGQGTTLTVSS 117  
Db 61 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYCAVYYDSSFDYNGQGTTLTVSS 118

RESULT 3  
US-08-767-128-18  
; Sequence 18, Application US/08767128  
; Patent No. 6111079  
; GENERAL INFORMATION:  
; APPLICANT: WYLIE, DWANE E.  
; APPLICANT: LOPEZ, OSVALDO  
; APPLICANT: MURRAY, PETER JOSEPH  
; APPLICANT: GOEBEL, PETER

; TITLE OF INVENTION: LEAD BINDING POLYPEPTIDES AND  
; TITLE OF INVENTION: NUCLEOTIDES CODING THEREFORE  
; NUMBER OF SEQUENCES: 46  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt  
; STREET: 3100 No. 611079west Center, 90 South Seventh St  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: USA  
; ZIP: 55402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/767,128  
; FILING DATE:  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE: 04-DEC-1996  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US96/09258  
; FILING DATE: 05-JUN-1996  
; APPLICATION NUMBER: 08/541,373  
; FILING DATE: 10-OCT-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/462,798  
; FILING DATE: 05-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Carter, Charles G.  
; REGISTRATION NUMBER: 35,093  
; REFERENCE/DOCKET NUMBER: 8648.49USF1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612/371-5278  
; TELEFAX: 612/332-9081  
; TELEX:  
; INFORMATION FOR SEQ ID NO: 18:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 119 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: internal  
; ORIGINAL SOURCE:  
US-08-767-128-18

Query Match 84.9%; Score 540; DB 2; Length 119;  
Best Local Similarity 84.9%; Pred. No. 1e-49;  
Matches 101; Conservative 5; Mismatches 11; Indels 2; Gaps 1;  
QY 1 DVQLQSGPGLVKPSQSLTCSVTGYSITSGYNNWIRQFPGNKLEWNGYISYDGNMNY 60  
Db 1 DVQLQSGPGLVKPSQSLTCSVTGYSITSDYANNWIRQFPGNKLEWNGYISYSGTSY 60  
QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYCCARYGRV--PFDYWGQGTTLTVSS 117  
Db 61 NPSLKSIRISITRDTSKNQFFLKLNSVTNEDTATYCCARCNYPWFYDWGQGTTLTVSS 119

RESULT 4  
US-08-887-352B-2  
; Sequence 2, Application US/08887352B  
; Patent No. 5994511  
; GENERAL INFORMATION:  
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe  
; TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of

TITLE OF INVENTION: Improving Polypeptides  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Genentech, Inc.  
STREET: 1 DNA Way  
CITY: South San Francisco  
STATE: California  
COUNTRY: USA  
ZIP: 94080  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: WinFatin (Genentech)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/887,352B  
FILING DATE: 03-Jul-1997  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: Svoboda, Craig G.  
REGISTRATION NUMBER: 39,044  
REFERENCE/DOCKET NUMBER: P1123  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650/225-1489  
TELEFAX: 650/952-9881  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 121 amino acids  
TYPE: Amino Acid  
TOPOLOGY: Linear  
US-08-887-352B-2

Query Match 80.3%; Score 511; DB 1; Length 121;  
Best Local Similarity 79.3%; Pred. No. 1.2e-46;  
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;  
Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60  
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60  
Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR----YGRVFFDYMGQGTTLTVS 116  
Db 61 NPSLKNRISVTRDTSQNOFFLKLNSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120  
Qy 117 S 117  
Db 121 S 121

RESULT 5  
US-09-109-207C-2  
Sequence 2, Application US/09109207C  
Patent No. 6172213  
GENERAL INFORMATION:  
APPLICANT: Lowman, Henry B.  
TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptide  
FILE REFERENCE: P112381  
CURRENT APPLICATION NUMBER: US/09/109,207C  
CURRENT FILING DATE: 1998-06-30  
PRIOR APPLICATION NUMBER: US 60/051,554  
PRIOR FILING DATE: 1997-07-03  
NUMBER OF SEQ ID NOS: 44  
SEQ ID NO 2  
LENGTH: 121  
TYPE: PRT  
ORGANISM: Mus musculus  
US-09-109-207C-2

Query Match 80.3%; Score 511; DB 2; Length 121;  
Best Local Similarity 79.3%; Pred. No. 1.2e-46;  
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;  
Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60

Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60  
Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR----YGRVFFDYMGQGTTLTVS 116  
Db 61 NPSLKNRISVTRDTSQNOFFLKLNSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120  
Qy 117 S 117  
Db 121 S 121  
RESULT 6  
US-09-296-005-2  
Sequence 2, Application US/09296005  
Patent No. 6290957  
GENERAL INFORMATION:  
APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe  
TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptides  
FILE REFERENCE: P1123C1r  
CURRENT APPLICATION NUMBER: US/09/296,005  
CURRENT FILING DATE: 1999-04-21  
PRIOR APPLICATION NUMBER: US 08/887,352  
PRIOR FILING DATE: 1997-07-02  
NUMBER OF SEQ ID NOS: 26  
SEQ ID NO 2  
LENGTH: 121  
TYPE: PRT  
ORGANISM: Mus musculus  
US-09-296-005-2

Query Match 80.3%; Score 511; DB 2; Length 121;  
Best Local Similarity 79.3%; Pred. No. 1.2e-46;  
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;  
Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60  
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60  
Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR----YGRVFFDYMGQGTTLTVS 116  
Db 61 NPSLKNRISVTRDTSQNOFFLKLNSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120  
Qy 117 S 117  
Db 121 S 121

RESULT 7  
US-09-920-171-2  
Sequence 2, Application US/09920171  
Patent No. 6682735  
GENERAL INFORMATION:  
APPLICANT: Lowman, Henry B.  
APPLICANT: Presta, Leonard G.  
APPLICANT: Jardieu, Paula M.  
APPLICANT: Lowe, John  
TITLE OF INVENTION: Improved Anti-IgE Antibodies (as amended)  
FILE REFERENCE: P1123C2US  
CURRENT APPLICATION NUMBER: US/09/920,171  
CURRENT FILING DATE: 2001-08-01  
PRIOR APPLICATION NUMBER: US 08/887,352  
PRIOR FILING DATE: 1997-07-02  
PRIOR APPLICATION NUMBER: US 09/296,005  
PRIOR FILING DATE: 1999-04-21  
NUMBER OF SEQ ID NOS: 44  
SEQ ID NO 2  
LENGTH: 121  
TYPE: PRT  
ORGANISM: Mus musculus  
US-09-920-171-2

Query Match 80.3%; Score 511; DB 2; Length 121;

```
Best Local Similarity 79.3%; Pred. No. 1.2e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLSCSVTGYISITGGLNNWIRQPPGNKLEWNGVSYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLSCSVTGYISITGGLNNWIRQPPGNKLEWNGVSYDGTNNY 60
QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR----YGRVFFDYWGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSQNOFFLKLNSATAEDTATYYCARGSHYFGHWHFAVWGAGTTTVTS 120
QY 117 S 117
Db 121 S 121

RESULT 8
US-09-716-028-2
; Sequence 2, Application US/09716028
; Patent No. 6723833
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
; TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptides
; FILE REFERENCE: P1123R1
; CURRENT APPLICATION NUMBER: US/09/716,028
; CURRENT FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: US 09/109,207
; PRIOR FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/051,554
; PRIOR FILING DATE: 1997-07-03
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 2
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-716-028-2

Query Match 80.3%; Score 511; DB 2; Length 121;
Best Local Similarity 79.3%; Pred. No. 1.2e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLSCSVTGYISITGGLNNWIRQPPGNKLEWNGVSYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLSCSVTGYISITGGLNNWIRQPPGNKLEWNGVSYDGTNNY 60
QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR----YGRVFFDYWGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSQNOFFLKLNSATAEDTATYYCARGSHYFGHWHFAVWGAGTTTVTS 120
QY 117 S 117
Db 121 S 121

RESULT 9
US-10-113-996-2
; Sequence 2, Application US/10113996
; Patent No. 6761889
; GENERAL INFORMATION:
; APPLICANT: Lowman, Henry B.
; APPLICANT: Presta, Leonard G.
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Lowe, John
; TITLE OF INVENTION: Improved Anti-IgE Antibodies
; FILE REFERENCE: P1123C3US
; CURRENT APPLICATION NUMBER: US/10/113,996
; CURRENT FILING DATE: 2002-04-01
; PRIOR APPLICATION NUMBER: US 08/887,352
; PRIOR FILING DATE: 1997-07-02
; PRIOR APPLICATION NUMBER: US 09/296,005
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: US 09/920,171
; PRIOR FILING DATE: 2001-08-01
```

```
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 2
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-113-996-2

Query Match 80.3%; Score 511; DB 2; Length 121;
Best Local Similarity 79.3%; Pred. No. 1.2e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLSCSVTGYISITGGLNNWIRQPPGNKLEWNGVSYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLSCSVTGYISITGGLNNWIRQPPGNKLEWNGVSYDGTNNY 60
QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR----YGRVFFDYWGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSQNOFFLKLNSATAEDTATYYCARGSHYFGHWHFAVWGAGTTTVTS 120
QY 117 S 117
Db 121 S 121

RESULT 10
US-08-466-151-3
; Sequence 3, Application US/08466151
; Patent No. 6037453
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Immunoglobulin Variants
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,151
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/466163
; FILING DATE: 06-Jun-1995
; APPLICATION NUMBER: 08/405617
; FILING DATE: 15-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/185899
; FILING DATE: 26-JAN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/879495
; FILING DATE: 07-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/744768
; FILING DATE: 14-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Svoboda, Craig G.
; REGISTRATION NUMBER: 39,044
; REFERENCE/DOCKET NUMBER: P0718P2C1D1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1489
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 134 amino acids
```

```

; AFFILIATION: FIEBIA, JEORARD G.
; TITLE OF INVENTION: Method of Preventing the Onset of Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C3US
;

```



GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 80.7649 Seconds  
(without alignments)  
636.505 Million cell updates/sec

Title: US-10-735-916A-69  
Perfect score: 636  
Sequence: 1 DVQLQSGPGIVKPSQSLSL.....RYGRVFFDYMGQGTTLTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A Geneseq 21:.\*  
1: geneseqp1980s.\*  
2: geneseqp1990s.\*  
3: geneseqp2000s.\*  
4: geneseqp2001s.\*  
5: geneseqp2002s.\*  
6: geneseqp2003as.\*  
7: geneseqp2003bs.\*  
8: geneseqp2004s.\*  
9: geneseqp2005s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	636	100.0	117	7	ADJ76903 Anti-IGF-
2	636	100.0	117	9	ADZ67073 Murine im
3	636	100.0	127	7	ADJ76886 Anti-IGF-
4	636	100.0	127	9	ADZ67056 Murine im
5	569.5	89.5	118	7	ADJ76904 Anti-IGF-
6	569.5	89.5	118	9	ADZ67074 Mouse ant
7	550	86.5	118	2	Aaw00829 Variable
8	550	86.5	118	2	Aaw19015 Anti-huma
9	549	86.3	114	9	AEA40137
10	548.5	86.2	118	7	ABR82776 Hybridoma
11	548.5	86.2	118	7	ABR82886 Hybridoma
12	546	85.8	117	7	ADJ76909 Anti-IGF-
13	546	85.8	117	9	ADZ67079 Human ant
14	546	85.8	119	6	ABB98905 Variable
15	546	85.8	135	7	ADJ76911 Anti-IGF-
16	546	85.8	135	9	ADZ67081 Human ant
17	544.5	85.6	136	3	AAY94391 Mouse VH
18	542	85.2	119	6	ABB98906 Variable
19	541.5	85.1	369	4	AAB73388 Anti-VHSV
20	541	85.1	117	7	ADZ97814 HEV relat
21	541	85.1	117	7	ADJ76913 Anti-IGF-
22	541	85.1	117	9	ADZ67083 Human ant
23	541	85.1	135	7	ADJ76915 Anti-IGF-
24	541	85.1	135	9	ADZ67085 Human ant

25	540	84.9	119	2	AAW01584	Aaw01584	Lead bind
26	539.5	84.8	259	7	ADG32325	Adg32325	Mouse scf
27	539.5	84.8	371	7	ADG32362	Adg32362	Procuror
28	539.5	84.8	626	7	ADG32340	Adg32340	Fusion pr
29	538	84.6	522	9	AEC20775	Aec20775	M-CSF spe
30	536	84.3	119	6	ABB98908	Abb98908	Variable
31	533.5	83.9	119	9	ADZ45405	Adz45405	Murine fa
32	533.5	83.9	468	9	ADY91369	Ady91369	Anti-KiD3
33	532	83.6	116	9	ADZ45341	Adz45341	Murine fa
34	532	83.6	116	9	ADZ51254	Adz51254	Amino aci
35	532	83.6	116	9	ADZ42128	Adz42128	Mouse ant
36	531.5	83.6	118	8	ADT07572	Adt07572	Polypepti
37	531.5	83.6	243	8	ADT07627	Adt07627	Polypepti
38	531.5	83.6	244	8	ADT07628	Adt07628	Polypepti
39	529	83.2	117	7	ADJ76917	Adj76917	Anti-IGF-
40	529	83.2	117	9	ADZ67087	Adz67087	Human ant
41	529	83.2	135	7	ADJ76919	Adj76919	Anti-IGF-
42	529	83.2	135	9	ADZ67089	Adz67089	Human ant
43	527.5	82.9	116	8	ADT89035	Adt89035	Murine pl
44	526	82.7	114	9	AEA40153	Aea40153	Mouse igh
45	524.5	82.5	118	9	ADZ81874	Adz81874	Anti-lami

ALIGNMENTS

RESULT 1  
ADJ76903  
ID ADJ76903 standard; protein; 117 AA.  
XX  
AC ADJ76903;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-1R related protein #16.  
XX  
KW cytotatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX  
OS Homo sapiens.  
XX  
FN WO2003059951-A2.  
XX  
PD 24-JUL-2003.  
XX  
PF 20-JAN-2003; 2003WO-FR000178.  
XX  
PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX  
PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
PI Goetsch L, Corvaia N, Leger O;  
XX  
DR WPI; 2003-569653/53.  
XX  
PT New antibodies that bind to human insulin-like growth factor receptor,  
XX useful for treatment, prevention and diagnosis of cancers.  
XX  
PS Disclosure; SEQ ID NO 69; 164pp; French.  
XX  
CC The invention relates to an isolated antibody (Ab) and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 117 AA;

Query Match 100.0%; Score 636; DB 7; Length 117;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-51;  
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 DVQLQESGPGVLKPSQSLTCSVTGYISITGGYLNWIRQPGNKLWVGYSYDGTNNY 60  
 DB 1 DVQLQESGPGVLKPSQSLTCSVTGYISITGGYLNWIRQPGNKLWVGYSYDGTNNY 60  
 QY 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117  
 DB 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117

RESULT 2  
 ADZ67073  
 ID ADZ67073 standard; protein; 117 AA.

XX AC ADZ67073;  
 XX 30-JUN-2005 (first entry)  
 XX Murine immunoglobulin heavy chain variable region 7C10 VH SEQ ID NO:69.  
 XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW immunoglobulin; heavy chain variable region.  
 XX  
 OS Mus musculus.

XX US2005084906-A1.  
 XX 21-APR-2005.  
 XX 16-DEC-2003; 2003US-00735916.  
 XX 18-JAN-2002; 2002FR-00000653.  
 XX 18-JAN-2002; 2002FR-00000654.  
 XX 07-MAY-2002; 2002FR-00005753.  
 XX 20-JAN-2003; 2003WO-FR000178.  
 XX 11-JUL-2003; 2003FR-00008538.  
 XX (GOET/) GOETSCH L.  
 XX (CORV/) CORVAIA N.  
 XX (LEGE/) LEGER O.  
 XX (DUFL/) DUFLOS A.  
 XX (HAEU/) HAEUW J.  
 XX (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 XX WPI; 2005-321968/33.  
 XX Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.

XX Example 13; SEQ ID NO 69; 125pp; English.

CC The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-1R) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-1R and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-1R and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-1R and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-1R and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

XX Sequence 117 AA;

Query Match 100.0%; Score 636; DB 9; Length 117;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-51;  
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVQLQESGPGVLKPSQSLTCSVTGYISITGGYLNWIRQPGNKLWVGYSYDGTNNY 60  
 DB 1 DVQLQESGPGVLKPSQSLTCSVTGYISITGGYLNWIRQPGNKLWVGYSYDGTNNY 60  
 QY 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117  
 DB 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117

RESULT 3  
 ADJ76886  
 ID ADJ76886 standard; protein; 127 AA.

XX AC ADJ76886;  
 XX 06-MAY-2004 (first entry)  
 XX Anti-IGF-1R related protein #4.

XX cytotstatic; antipsoriatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.

XX Mus musculus.  
 XX WO2003059951-A2.  
 XX 24-JUL-2003.

```

PF 20-JAN-2003; 2003WO-FR000178.
XX
XX 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX
XX (FABR ) FABRE MEDICAMENT SA PIERRE.
PA
XX Goetsch L, Corvaia N, Leger O;
PI
XX WPI; 2003-569653/53.
DR
XX
XX New antibodies that bind to human insulin-like growth factor receptor,
PT useful for treatment, prevention and diagnosis of cancers.
XX
XX Disclosure; SEQ ID NO 52; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of
CC these receptors with their ligands. Especially they inhibit
CC transformation of normal cells to tumor cells, inhibit growth and/or
CC proliferation of tumor cells, so are useful against cancers of the
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
CC also for treating psoriasis. Ab are also used to diagnose diseases caused
CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
CC protein sequence used to generate the Ab of the invention.
XX
XX Sequence 127 AA;
SQ
Query Match 100.0%; Score 636; DB 7; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.3e-51;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 DVQLQSGPLVKPQSLTCSVTGYSITGGLWNWIRQFPNGKLEWNGYISYDGTNNY 60
DB 11 DVQLQSGPLVKPQSLTCSVTGYSITGGLWNWIRQFPNGKLEWNGYISYDGTNNY 70
OY 61 KPFLKDRISITRDTSKNQFFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117
DB 71 KPFLKDRISITRDTSKNQFFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 127
RESULT 4
ADZ67056
ID ADZ67056 standard; protein; 127 AA.
XX
XX AC ADZ67056;
XX
XX 30-JUN-2005 (first entry)
XX
XX Murine immunoglobulin heavy chain variable region 7C10 VH SEQ ID NO:52.
XX
XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
XX neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
XX musculoskeletal disease; respiratory disease; lung tumor;
XX endocrine disease; gynecology and obstetrics; breast tumor;
XX endometrial carcinoma; gastrointestinal disease; colon tumor;
XX antipsoriasis; psoriasis; dermatological disease; immune disorder;
XX immunoglobulin; heavy chain variable region.
XX
XX Mus musculus.
XX
XX Key Location/Qualifiers
XX Peptide 1..10
XX FT /note= "leader peptide"
XX FT 41..46
XX FT /note= "CDRI"

```

---

```

FT Region 61..76
FT /note= "CDR2"
FT Region 109..116
FT /note= "CDR3"
XX
XX US2005084906-A1.
XX
XX 21-APR-2005.
XX
XX 16-DEC-2003; 2003US-00735916.
XX
XX 18-JAN-2002; 2002FR-00000653.
XX 18-JAN-2002; 2002FR-00000654.
XX 07-MAY-2002; 2002FR-00005753.
XX 20-JAN-2003; 2003WO-FR000178.
XX 11-JUL-2003; 2003FR-00008538.
XX
XX (GOET/) GOETSCH L.
PA (CORV/) CORVAIA N.
PA (LEGE/) LEGER O.
PA (DUFL/) DUFLOS A.
PA (HAEU/) HAEUW J.
XX (BECK/) BECK A.
XX
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX
XX WPI; 2005-321968/33.
XX N-PSDB; ADZ67055.
XX
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
XX antibody or its functional fragment, being capable of binding human IGF-
XX IR and specifically inhibiting tyrosine kinase activity of receptor,
XX useful for treating cancer.
XX
XX Example 8; SEQ ID NO 52; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
XX I receptor (IGF-IR) antibody (I) or its functional fragment, being
XX capable of binding to human IGF-IR and, if necessary, capable of
XX specifically inhibiting tyrosine kinase activity of the receptor,
XX comprising a light or heavy chain having at least one complementary
XX determining region (CDR) consisting of one of two fully defined 16 amino
XX acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
XX the preparation of a medicament intended for the prevention or treatment
XX of an illness connected with an overexpression and/or an abnormal
XX activation of the IGF-IR and/or EGFR, and/or connected with a
XX hyperactivation of the transduction pathway of the signal mediated by the
XX interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
XX the administration of the medicament does not induce or only slightly
XX induces secondary effects connected with inhibition of the insulin
XX receptor. The antibody is useful for preparation of a medicament intended
XX to inhibit the transformation of normal cells into cells with tumoral
XX character, preferably IGF-dependent, especially IGF1 and/or IGF2-
XX dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
XX useful for preparation of a medicament intended to inhibit the growth
XX and/or the proliferation of tumor cells, preferably IGF-dependent,
XX especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
XX HER2/neu-dependent cells. (I) is useful in the preparation of a
XX medicament intended for prevention or for the treatment of cancer, where
XX the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
XX breast cancer, endometrial cancer or colon cancer. (I) is useful in the
XX preparation of a medicament intended for the prevention or for the
XX treatment of psoriasis. (I) is useful in preparation of a medicament
XX intended for the specific targeting of a biologically active compound to
XX cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
XX is useful for in vitro diagnosis of illnesses induced by an
XX overexpression or an underexpression of the IGF-IR and/or EGFR receptor
XX starting from a biological sample in which the abnormal presence, of IGF-
XX IR and/or EGFR receptor is suspected, which involves contacting the
XX biological sample with (I), which is optionally labeled. The present
XX sequence is used in the exemplification of the invention.
XX
XX Sequence 127 AA;
SQ

```

```
Query Match          100.0%; Score 636; DB 9; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.3e-51;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWMGYISYDGTNNY 60
DB 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWMGYISYDGTNNY 60
QY 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
DB 71 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 127

RESULT 5
ADJ76904
ID ADJ76904 standard; protein; 118 AA.
XX
AC ADJ76904;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-IGF-IR related protein #17.
XX
KW cytostatic; antipsoriatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX
OS Mus musculus.
XX
FN WO2003059951-A2.
XX
PD 24-JUL-2003.
XX
PF 20-JAN-2003; 2003WO-FR000178.
XX
PR 18-JAN-2002; 2002FR-00000653.
XX
PR 18-JAN-2002; 2002FR-00000654.
XX
PR 07-MAY-2002; 2002FR-00005753.
XX
PA (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI Goetsch L, Corvaia N, Leger O;
XX
XX WPI; 2003-569653/53.
XX
PT New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
PS Disclosure; SEQ ID NO 70; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX 1R) and optionally: (i) inhibit natural binding of insulin-like growth
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or
XX treat diseases associated with overexpression and/or abnormal activity of
XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
XX hyperactivity of signal transduction pathways mediated by interaction of
XX these receptors with their ligands. Especially they inhibit
XX transformation of normal cells to tumor cells, inhibit growth and/or
XX proliferation of tumor cells, so are useful against cancers of the
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX also for treating psoriasis. Ab are also used to diagnose diseases caused
XX by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
XX protein sequence used to generate the Ab of the invention.
XX
XX Sequence 118 AA;

Query Match          89.5%; Score 569.5; DB 7; Length 118;
Best Local Similarity 90.7%; Pred. No. 1.9e-45;

Matches 107; Conservative 2; Mismatches 8; Indels 1; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWMGYISYDGTNNY 60
DB 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWMGYISYDGTNNY 60
QY 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
DB 61 NPSLKNRISITRDTSKNQFFLKLSVNTNEDTATYYCAREGYGYFFDYWGQGTTLTVSS 118

RESULT 6
ADZ67074
ID ADZ67074 standard; protein; 118 AA.
XX
AC ADZ67074;
XX
DT 30-JUN-2005 (first entry)
XX
DE Mouse antibody heavy chain variable region SEQ ID NO:70.
XX
KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
KW musculoskeletal disease; respiratory disease; lung tumor;
KW endocrine disease; gynecology and obstetrics; breast tumor;
KW endometroid carcinoma; gastrointestinal disease; colon tumor;
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
KW heavy chain variable region.
XX
OS Mus musculus.
XX
FN US2005084906-A1.
XX
PD 21-APR-2005.
XX
PF 16-DEC-2003; 2003US-00735916.
XX
PR 18-JAN-2002; 2002FR-00000653.
XX
PR 18-JAN-2002; 2002FR-00000654.
XX
PR 07-MAY-2002; 2002FR-00005753.
XX
PR 20-JAN-2003; 2003WO-FR000178.
XX
PR 11-JUL-2003; 2003FR-00008538.
XX
PA (GOET/) GOETSCH L.
XX
PA (CORV/) CORVAIA N.
XX
PA (LEGE/) LEGER O.
XX
PA (DUFLO/) DUFLOS A.
XX
PA (HAEU/) HAEUW J.
XX
PA (BECK/) BECK A.
XX
PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX
XX WPI; 2005-321968/33.
XX
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
XX antibody or its functional fragment, being capable of binding human IGF-
XX IR and specifically inhibiting tyrosine kinase activity of receptor,
XX useful for treating cancer.
XX
XX Example 13; SEQ ID NO 70; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
XX I receptor (IGF-IR) antibody (I) or its functional fragment, being
XX capable of binding to human IGF-IR and, if necessary, capable of
XX specifically inhibiting tyrosine kinase activity of the receptor,
XX comprising a light or heavy chain having at least one complementary
XX determining region (CDR) consisting of one of two fully defined 16 amino
XX acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
XX the preparation of a medicament intended for the prevention or treatment
XX of an illness connected with an overexpression and/or an abnormal
XX activation of the IGF-IR and/or EGFR, and/or connected with a
XX hyperactivation of the transduction pathway of the signal mediated by the
XX interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
```

CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent, and/or  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer, where  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of the IGF-IR and/or EGFR receptor  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

XX  
 SQ Sequence 118 AA;

Query Match 89.5%; Score 569.5; DB 9; Length 118;  
 Best Local Similarity 90.7%; Pred. No. 1.9e-45; Indels 1; Gaps 1;  
 Matches 107; Conservative 2; Mismatches 8;

QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPNGKLEWNGYISYDGTNNY 60  
 DB 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPNGKLEWNGYINYGNNY 60

QY 61 KPSLKDRIISITRDTSKNQFFLNKNSVTNEDTATYYCARVG-RVFPDYWGQGTTLTVSS 117  
 DB 61 NPSLKNRISITRDTSKNQFFLNKNSVTNEDTATYYCAVEGYGFFDYWGQGTTLTVSS 118

RESULT 7  
 AA000829  
 ID AA000829 standard; protein; 118 AA.  
 AC AA000829;  
 XX  
 DT 19-MAY-1997 (first entry)  
 XX  
 DE Variable heavy chain of anti-human Fas ligand antibody NOK-4.  
 XX  
 KW Variable region; heavy chain; human; Fas ligand; monoclonal; antibody;  
 KW NOK-4 hybridoma; inhibition; apoptosis; assay; diagnosis; disease;  
 KW hepatitis; infectious mononucleosis; systemic lupus erythematosus.  
 XX  
 OS Mus musculus.  
 XX  
 PN WO9629350-A1.  
 XX  
 PD 26-SEP-1996.  
 XX  
 PF 21-MAR-1996; 96WO-JP000734.  
 XX  
 PR 20-MAR-1995; 95JP-00087420.  
 PR 27-OCT-1995; 95JP-00303492.  
 XX  
 PA (SUME ) SUMITOMO ELECTRIC IND CO.  
 XX  
 PI Kayagaki N, Yagita H, Okumura K, Nakata M;  
 XX  
 DR WPI; 1996-443140/44.  
 DR N-PSDB; AAT39555.  
 XX  
 PT Monoclonal antibody specifically recognising the Fas ligand - useful for  
 PT the detection of Fas ligands either on cell surface or in solution.

XX  
 PS  
 XX

Claim 25; Page 86-87; 133pp; Japanese.

The present sequence is the heavy chain variable region of the anti-human  
 Fas ligand monoclonal antibody (MAB) NOK-4. NOK-4 is produced by the  
 hybridoma NOK-4 (FERM BP-5047), which was prepared by immunising mice  
 with transformed human Fas ligand expressing COS cells, and fusing spleen  
 cells isolated from the mice with myeloma P3x63Ag8.653 (ATCC CRU-1580)  
 cells. The MAB recognises the human Fas ligand on the cell surface or in  
 solution, and can be used to inhibit the apoptosis inducing cell surface  
 Fas ligand/Fas reaction. The MAB can also be used for a Fas ligand assay  
 in biological samples (e.g. human blood), especially for disease  
 diagnosis, e.g. hepatitis, infectious mononucleosis and systemic lupus  
 erythematosus

SQ Sequence 118 AA;

Query Match 86.5%; Score 550; DB 2; Length 118;

Best Local Similarity 88.1%; Pred. No. 1.3e-43;  
 Matches 104; Conservative 3; Mismatches 9; Indels 2; Gaps 1;

QY 2 VOLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPNGKLEWNGYISYDGTNNYK 61  
 DB 1 VOLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPNGKLEWNGYISYDGSNNY 60

QY 62 PSLKDRIISITRDTSKNQFFLNKNSVTNEDTATYYCA--RYGRVFFDYWGQGTTLTVSS 117  
 DB 61 PSLKNRISITRDTSKNQFFLNKNSVTNEDTATYYCAVYVDSSFDYWGQGTTLTVSS 118

RESULT 8  
 AA019015  
 ID AA019015 standard; protein; 118 AA.

AC AA019015;

XX 14-JAN-1998 (first entry)

XX Anti-human FasL antibody (NOK4) heavy chain variable region.

XX Heavy chain; variable region; mouse; murine; human; Fas ligand; FasL;  
 KW monoclonal antibody; MAB; hybridoma; treatment; hepatitis;  
 KW hepatitis B virus; HBV; hepatitis C virus; HCV; apoptosis; liver cell;  
 KW glutamate oxaloacetate; pyruvate transaminase.

XX Mus sp.

XX WO9715326-A1.

XX 01-MAY-1997.

XX 24-OCT-1996; 96WO-JP003089.

XX 27-OCT-1995; 95JP-00303491.

XX (SUME ) SUMITOMO ELECTRIC IND CO.

XX Seino K, Kayagaki N, Yagita H, Okumura K, Nakata M;

XX WPI; 1997-258767/23.

XX N-PSDB; AAT69539.

XX Anti-human Fas Ligand antibody to treat hepatitis - controls apoptosis in  
 PT liver cells and improves liver function.

XX Claim 6; Page 36-37; 51pp; Japanese.

XX The present sequence is the heavy chain variable region of the murine  
 CC anti-human Fas ligand (FasL) monoclonal antibody (MAB) NOK4, which is  
 CC expressed by the hybridoma NOK4 (FERM BP-5044). The MAB can be used in  
 CC the preparation of a composition for the effective oral or parenteral  
 CC treatment of hepatitis, including hepatitis caused by hepatitis B or C  
 CC virus. The composition controls apoptosis in liver cells caused by the

CC binding of FasL to Fas expressing liver cells, and improves liver  
CC function by improving blood glutamate oxaloacetate and pyruvate  
CC transaminase levels. The composition is given in a dosage of 0.0001-1000,  
CC preferably 0.01-600 mg/day. Spleen cells from mice immunised with FasL  
CC expressing COS cells were fused with mouse myeloma cells to produce  
CC hybridomas. The hybridomas were screened for anti-FasL activity, and the  
CC active clones NOK1-5 isolated

XX  
SQ Sequence 118 AA;

Query Match 86.5%; Score 550; DB 2; Length 118;  
Best Local Similarity 88.1%; Pred. No. 1.3e-43;  
Matches 104; Conservative 3; Mismatches 9; Indels 2; Gaps 1;

QY 2 VQLQSGGLVKPSQSLSTCSVTGYSITGGVLLNNWIRQFPGNKLEWGWGYSYDGTNNYK 61  
DB 1 VQLQSGGLVKPSQSLSTCSVTGYSITGGVLLNNWIRQFPGNKLEWGWGYSYDGSNNYN 60

QY 62 PSLKDRISITRDTSKNQFFLKLSVTNEDTATYYCA--RYGRVFFDYWGQGTTLTVSS 117  
DB 61 PSLKDRISITRDTSKNQFFLKLSVTNEDTATYYCAVYYDGSFDYWGQGTTLTVSS 118

RESULT 9  
AEA40137  
ID AEA40137 standard; protein; 114 AA.  
XX  
AC AEA40137;  
XX  
DT 28-JUL-2005 (first entry)  
XX  
DE TNF resistant monoclonal antibody VH region, F6VH protein.  
XX  
KW tumor necrosis factor; TNF; monoclonal antibody; F6 mAb;  
KW light chain variable region; heavy chain variable region; F6VH.  
XX  
OS Unidentified.  
XX  
FH Key Location/Qualifiers  
FT Region 28..33  
FT /note= "CDR1"  
FT /note= "Specifically claimed in Claim 1"  
FT Region 48..63  
FT /note= "CDR2"  
FT /note= "Specifically claimed in Claim 1"  
FT Region 96..103  
FT /note= "CDR3"  
FT /note= "Specifically claimed in Claim 1"  
XX  
PN CN1544466-A.  
XX  
PD 10-NOV-2004.  
XX  
PF 13-NOV-2003; 2003CN-01105919.  
XX  
PR 13-NOV-2003; 2003CN-01105919.  
XX  
PA (UYFO-) UNIV FOURTH MILITARY MEDICAL.  
XX  
PI Jin B, Liu X, Zhu C;  
XX  
DR WPI; 2005-153078/17.  
DR N-PSDB; AEA40136.  
XX  
PT Variable region gene of high affinity monoclonal antibody of tumor  
PT necrosis factor and its preparation.  
XX  
PS Claim 1; Page 2-3; 20pp; Chinese.  
XX  
CC The invention relates to a method for preparing variable region genes of  
CC high affinity tumor necrosis factor (TNF) resistant monoclonal antibody  
CC (F6 mAb). The method comprises using recombinant human TNF immune BALB/c  
CC mouse to prepare mouse anti-TNF monoclonal antibody, screening high

CC affinity F6 mAb using an indirect enzyme linked immunosorbent assay  
CC (ELISA). By cloning the monoclonal antibody light chain and heavy chain  
CC variable region (VL and VH respectively) genes, the monoclonal antibody  
CC light chain and heavy chain variable region gene sequence and amino acid  
CC sequence can be obtained, and the unicity of the gene sequence and  
CC protein sequence can be confirmed. This sequence represents the amino  
CC acid sequence for F6VH.

XX  
SQ Sequence 114 AA;

Query Match 86.3%; Score 549; DB 9; Length 114;  
Best Local Similarity 88.6%; Pred. No. 1.5e-43;  
Matches 101; Conservative 5; Mismatches 8; Indels 0; Gaps 0;

QY 4 LQESGGLVKPSQSLSTCSVTGYSITGGVLLNNWIRQFPGNKLEWGWGYSYDGTNNYKPS 63  
DB 1 LQESGGLVKPSQSLSTCSVTGYSITGGVLLNNWIRQFPGNKLEWGWGYSYDGSNNYPS 60

QY 64 LKDRISITRDTSKNQFFLKLSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117  
DB 61 LKDRISITRDTSKNQFFLKLSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 114

RESULT 10  
ABR82776  
ID ABR82776 standard; protein; 118 AA.  
XX  
AC ABR82776;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Hybridoma HB22-33 anti-CD22 MAb heavy chain Vh-D-Jh junction sequence.  
XX  
KW CD22; B-cell malignancy; anti-CD22 antibody; cytostatic; human; HB22-33.  
XX  
OS Homo sapiens.  
XX  
PN WO2003072036-A2.  
XX  
PD 04-SEP-2003.  
XX  
PF 20-FEB-2003; 2003WO-US005323.  
XX  
PR 21-FEB-2002; 2002US-0359419P.  
PR 21-OCT-2002; 2002US-0420472P.  
XX  
PA (UYDU-) UNIV DUKE.  
PA (REGC) UNIV CALIFORNIA.  
XX  
PI Tedder T, Tusciano J;  
XX  
DR WPI; 2003-712652/67.  
DR N-PSDB; ACF36426.  
XX  
PT Treating a human patient diagnosed with a B-cell malignancy by  
PT administering a blocking anti-CD22 monoclonal antibody binding to the  
PT first two Ig-like domains of native human CD22 (hCD22).  
XX  
PS Claim 31; Fig 15; 72pp; English.  
XX  
CC The invention relates to treating a human patient diagnosed with a B-cell  
CC malignancy. The method involves (a) administering to the human patient a  
CC blocking anti-CD22 monoclonal antibody binding to the first two Ig-like  
CC domains, or to an epitope within the first two Ig-like domains of native  
CC human CD22 (hCD22) (ABR82771) and (b) monitoring the response of the  
CC malignancy to the treatment. The method is useful for treating a human  
CC patient diagnosed with a B-cell malignancy comprising Hodgkin's lymphoma,  
CC Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia, hairy  
CC cell leukemia or polymphocytic leukemia. The present sequence represents  
CC the amino acid sequence for heavy chain Vh-D-Jh junction for anti-CD22  
CC antibody from hybridoma HB22-33

XX  
SQ Sequence 118 AA;

Query Match	86.2%; Score 548.5; DB 7; Length 118;
Best Local Similarity	87.3%; Pred. No. 1.8e-43;
Matches 103; Conservative	5; Mismatches 9; Indels 1; Gaps 1;
QY	1 DVQLQESGPGGLVKPESQSLTCSVTGYSITGGYLWNWIROPFGNKLKLEWGMGYSIDGTNNY 60
Db	1 EVQLQESGPGGLVKPESQSLTCSVTGYSITGGYWNWIROPFGNKLKLEWGMGIVRDGSNNY 60
QY	61 KPSLKDRIISITRDTSKNQPFKLKNSVTNEDTATYYCARYG-RVFFDFWQGQGTTLTVSS 117
Db	61 NPSLKNRISITRDTSKNQPFKLKNSVTEDTATYTCARGGITVAMDYWGQGTSTVTSS 118
RESULT 11	
ABR82886	
ID	ABR82886 standard; protein; 118 AA.
XX	
AC	ABR82886;
XX	
DT	18-DEC-2003 (first entry)
XX	
DE	Hybridoma HB22-33 anti-CD22 MAb heavy chain (VH) fragment.
XX	
KW	CD22; autoimmune disease; anti-CD22 antibody; iImmunosuppressive;
KW	cytostatic; nephrotropic; dermatological; antiinflammatory; anti-ulcer;
KW	antirheumatic; antiarthritic; antiporiatic; thyromimetic; antianemic;
KW	antidiabetic; antiallergic; gene therapy; HB22-33.
XX	
OS	Homo sapiens.
XX	
WO	WO2003072736-A2.
PN	
XX	
PD	04-SEP-2003.
XX	
PF	21-FEB-2003; 2003WO-US005549.
XX	
PR	21-FEB-2002; 2002US-0359419P.
PR	21-OCT-2002; 2002US-0420472P.
XX	
PA	(UYDU-) UNIV DUKE.
XX	
PI	Tedder TF;
XX	
WPI	WPI; 2003-721765/68.
DR	N-PSDB; ACF36494.
XX	
PT	Treating an autoimmune disease or a B-cell malignancy in a human patient
PT	comprises administering an amount of an anti-CD22 monoclonal antibody to
PT	the patient and monitoring the response of the disease to the treatment.
XX	
PS	Claim 1; Fig 15; 69pp; English.
XX	
CC	The invention relates to treating a human patient diagnosed with an
CC	autoimmune disease. The method involves administering to the patient an
CC	amount of a blocking anti-CD22 monoclonal antibody and monitoring the
CC	response of the autoimmune disease to the treatment. The method is useful
CC	in treating autoimmune diseases (e.g. glomerulonephritis, systemic lupus
CC	erythematosus, rheumatoid arthritis, psoriasis, ulcerative colitis,
CC	Hashimoto's thyroiditis, autoimmune haemolytic anemias, diabetes or
CC	allergies) or B-cell malignancies (e.g. lymphomas or leukemias). The
CC	present sequence represents the amino acid sequence for heavy chain Vh-D-
CC	Uh junction for anti-CD22 antibody from hybridoma HB22-33
XX	
SQ	Sequence 118 AA;
Query Match	86.2%; Score 548.5; DB 7; Length 118;
Best Local Similarity	87.3%; Pred. No. 1.8e-43;
Matches 103; Conservative	5; Mismatches 9; Indels 1; Gaps 1;
QY	1 DVQLQESGPGGLVKPESQSLTCSVTGYSITGGYLWNWIROPFGNKLKLEWGMGYSIDGTNNY 60
Db	1 EVQLQESGPGGLVKPESQSLTCSVTGYSITGGYWNWIROPFGNKLKLEWGMGIVRDGSNNY 60

Db 62 PSLKDRITISRDTSKNQFSLKSLSSVTAADTAVYCYGRVFFDYWGQGLTLTVSS 117

RESULT 13

ADZ67079

ID ADZ67079 standard; protein; 117 AA.

AC ADZ67079;

XX

XX 30-JUN-2005 (first entry)

XX

XX Human antibody 7C10 1 heavy chain variable region SEQ ID NO:75.

DE

DE Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;

KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;

KW musculoskeletal disease; respiratory disease; lung tumor;

KW endocrine disease; gynecology and obstetrics; breast tumor;

KW endometrial carcinoma; gastrointestinal disease; colon tumor;

KW antipsoriatic; psoriasis; dermatological disease; immune disorder;

KW heavy chain variable region.

XX

OS Homo sapiens.

XX

XX US2005084906-A1.

XX

XX 21-APR-2005.

XX

XX 16-DEC-2003; 2003US-00735916.

XX

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR0001178.

PR 11-JUL-2003; 2003FR-00008538.

XX

XX (GOET/) GOETSCH L.

PA (CORV/) CORVAIA N.

PA (LEGE/) LEGER O.

PA (DUEL/) DUFLOS A.

PA (HAEU/) HAEUW J.

PA (BECK/) BECK A.

XX

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

PI

XX

XX WPI; 2005-321968/33.

DR

XX

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR) antibody or its functional fragment, being capable of binding human IGF-IR and specifically inhibiting tyrosine kinase activity of receptor, useful for treating cancer.

PT

PT

PT

XX

XX Example 13; SEQ ID NO 75; 125pp; English.

PS

XX

XX The invention relates to a novel isolated anti-insulin-like growth factor I receptor (IGF-IR) antibody (I) or its functional fragment, being capable of binding to human IGF-IR and, if necessary, capable of specifically inhibiting tyrosine kinase activity of the receptor, comprising a light or heavy chain having at least one complementary determining region (CDR) consisting of one of two fully defined 16 amino acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in the preparation of a medicament intended for the prevention or treatment of an illness connected with an overexpression and/or an abnormal activation of the IGF-IR and/or EGFR, and/or connected with a hyperactivation of the transduction pathway of the signal mediated by the interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where the administration of the medicament does not induce or only slightly induces secondary effects connected with inhibition of the insulin receptor. The antibody is useful for preparation of a medicament intended to inhibit the transformation of normal cells into cells with tumoral character, preferably IGF-dependent, especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is useful for preparation of a medicament intended to inhibit the growth and/or the proliferation of tumor cells, preferably IGF-dependent,

CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is useful in the preparation of a medicament intended for prevention or for the treatment of cancer, where the cancer is chosen from prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer or colon cancer. (I) is useful in the preparation of a medicament intended for the prevention or for the treatment of psoriasis. (I) is useful in preparation of a medicament intended for the specific targeting of a biologically active compound to cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I) is useful for in vitro diagnosis of illnesses induced by an overexpression or an underexpression of the IGF-IR and/or EGFR receptor starting from a biological sample in which the abnormal presence, of IGF-IR and/or EGFR receptor is suspected, which involves contacting the biological sample with (I), which is optionally labeled. The present sequence is used in the exemplification of the invention.

XX

XX Sequence 117 AA;

Query Match 85.8%; Score 546; DB 9; Length 117;

Best Local Similarity 86.2%; Pred. No. 3e-43;

Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 2 VQLQESGPGLVKPSQSLTCSVTGYSITGGLNNWIRQFFGNKLEWNGYISYDGTNNYK 61

DB 2 VQLQESGPGLVKPSSETLSLTCTVSGYSITGGLNNWIRQPPGKLEWNGYISYDGTNNYK 61

QY 62 PSLKDRISITDTSKNQFFLKLNSVTNEDTATYCYGRVFFDYWGQGLTLTVSS 117

DB 62 PSLKDRITISRDTSKNQFSLKSLSSVTAADTAVYCYGRVFFDYWGQGLTLTVSS 117

RESULT 14

ABB98905

ID ABB98905 standard; protein; 119 AA.

XX

XX ABB98905;

AC

XX

XX 28-MAR-2003 (first entry)

DT

XX

XX Variable region anti-bisphenol A antibody chain #1.

DE

XX

XX Variable region; anti-bisphenol A; antibody; murine; heavy chain; light chain.

KW

XX

XX Mus sp

OS

XX

XX JP2002253259-A.

PN

XX

XX 10-SEP-2002.

PD

XX

XX 02-MAR-2001; 2001JP-00058673.

PF

XX

XX 02-MAR-2001; 2001JP-00058673.

PR

XX

XX (BIOS-) BIO APPLIED SYSTEMS KK.

PA

XX

XX WPI; 2003-096537/09.

DR

XX

XX N-PSDB; ABZ21157.

DR

XX

XX Gene encoding anti-bisphenol A antibody, a recombinant protein and its preparation, a DNA, a vector, a transformant, preparation of a recombinant protein, a kit for determining bisphenol A.

PT

XX

XX Claim 1; Page 11; 19pp; Japanese.

PS

XX

XX The present invention relates to sequences for murine heavy chain variable region or light chain variable region of anti-bisphenol A antibody (ABZ21157-ABZ21164 and ABB98905-ABB98912). The sequences are useful for the preparation of recombinant protein

CC

XX

XX Sequence 119 AA;

SQ

Query Match 85.8%; Score 546; DB 6; Length 119;

Best Local Similarity 87.4%; Pred. No. 3.1e-43;  
Matches 104; Conservative 5; Mismatches 8; Indels 2; Gaps 2;  
Qy 1 DVQLOESGPGLVKPSQSLSLTCSTGYSLTNWIRQPPGNKLEWVGYSYDGTNNY 60  
Db 1 DVQLOESGPGLVKPSQSLSLTCSTGYSLTNWIRQPPGNKLEWVGYSYDGTNNY 60  
Qy 61 KPSLKDRIISITRDTSKNOFFLKLNSVTNEDTATYYCAR-YGRVP-FDYWGQGTTLTVSS 117  
Db 61 NPSLKNRISITRDTSKNOFFLKLNSVTNEDTATYYCARVLGRGYGLDYWGQGTSLTVSS 119

RESULT 15  
ADJ76911  
ID ADJ76911 standard; protein; 135 AA.  
XX ADJ76911;  
AC ADJ76911;  
DT 06-MAY-2004 (first entry)  
XX Anti-IGF-IR related protein #23.  
XX cytostatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX Homo sapiens.  
OS  
XX  
XX WO2003059951-A2.  
PN  
XX  
XX 24-JUL-2003.  
PD  
XX  
XX 20-JAN-2003; 2003WO-FR000178.  
PF  
XX  
XX 18-JAN-2002; 2002FR-00000653.  
PR  
XX 18-JAN-2002; 2002FR-00000654.  
PR  
XX 07-MAY-2002; 2002FR-00005753.  
PR  
XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
PA  
XX  
XX Goetsch L, Corvaia N, Leger O;  
PI  
XX  
XX WPI; 2003-569653/53.  
DR  
XX  
XX New antibodies that bind to human insulin-like growth factor receptor,  
PT useful for treatment, prevention and diagnosis of cancers.  
PT  
XX  
XX Disclosure; SEQ ID NO 77; 164pp; French.  
PS  
XX

The invention relates to an isolated antibody (Ab), and its functional fragments, that bind to human insulin-like growth factor-1 receptor (IGF-1R) and optionally: (i) inhibit natural binding of insulin-like growth factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine kinase activity of IGF-1R. Ab and its fragments are used to prevent or treat diseases associated with overexpression and/or abnormal activity of IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with hyperactivity of signal transduction pathways mediated by interaction of these receptors with their ligands. Especially they inhibit transformation of normal cells to tumor cells, inhibit growth and/or proliferation of tumor cells, so are useful against cancers of the prostate, lung, breast, endometrium and colon, also osteosarcoma, and also for treating psoriasis. Ab are also used to diagnose diseases caused by abnormal expression of IGF-1R and/or EGFR. This sequence represents a protein sequence used to generate the Ab of the invention.

XX SQ Sequence 135 AA;  
Query Match 85.8%; Score 546; DB 7; Length 135;  
Best Local Similarity 86.2%; Pred. NO. 3.5e-43;  
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

Qy 2 VQLOESGPGLVKPSQSLSLTCSTGYSLTNWIRQPPGNKLEWVGYSYDGTNNYK 61  
Db 20 VQLOESGPGLVKPSQSLSLTCSTGYSLTNWIRQPPGNKLEWVGYSYDGTNNYK 79  
Qy 62 PSLKDRIISITRDTSKNOFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117  
Db 80 PSLKDRIISITRDTSKNOFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 135

Search completed: January 10, 2006, 20:44:16  
Job time : 81.7649 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 14.1157 Seconds  
(without alignments)  
797.508 Million cell updates/sec

Title: US-10-735-916A-69  
Perfect score: 636  
Sequence: 1 DVQLQESGGLVKPSQSLSL.....RYGRVFFDYWGQGTTLTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR 80:\*  
1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	545	85.7	121	2 S37200	Ig heavy chain V r
2	535	84.1	137	1 AVMS35	Ig heavy chain pre
3	523	82.2	119	2 E25114	Ig heavy chain V r
4	521.5	82.0	116	2 S38718	Ig heavy chain V r
5	521	81.9	117	2 I28195	Ig heavy chain V r
6	519.5	81.7	136	2 S07637	Ig heavy chain V r
7	510	80.2	119	2 C53285	Ig heavy chain V a
8	508.5	80.0	120	2 A25114	Ig heavy chain V r
9	504	79.2	115	2 F25114	Ig heavy chain V r
10	503.5	79.2	135	2 PLO100	Ig heavy chain pre
11	503	79.1	119	2 C25114	Ig heavy chain V r
12	503	79.1	149	2 S30752	Ig heavy chain pre
13	499.5	78.5	114	2 T01262	Ig heavy chain V r
14	499.5	78.5	134	2 B24672	Ig heavy chain pre
15	499	78.5	116	1 HVMS31	Ig heavy chain pre
16	476	74.8	110	2 D25114	Ig heavy chain V r
17	470.5	74.0	104	2 S26467	Ig heavy chain V r
18	463	72.8	123	2 S42771	Ig heavy chain - m
19	462	72.6	117	2 I57810	gene C72-3A1 prote
20	461.5	72.6	106	2 S26464	Ig heavy chain V r
21	457	71.9	106	2 S59639	Ig heavy chain V r
22	455	71.5	116	1 HVMS1B	Ig heavy chain pre
23	447	70.3	113	1 G2MS60	Ig heavy chain V r
24	425	66.8	100	2 S14485	Ig heavy chain V r
25	423.5	66.6	101	2 S14484	Ig heavy chain V r
26	423	66.5	140	2 I37782	Ig variable region
27	422.5	66.4	115	2 D33932	Ig mu chain precu
28	420.5	66.1	102	2 S14488	Ig heavy chain V r
29	413	64.9	102	2 S14486	Ig heavy chain V r

30	408	64.2	130	2 S31690	Ig heavy chain V r
31	406	63.8	112	2 S13685	Ig heavy chain V r
32	404.5	63.6	117	1 HVMS73	Ig heavy chain pre
33	403	63.4	112	2 S13686	Ig heavy chain V r
34	401	63.1	102	2 S14487	Ig heavy chain V r
35	400	62.9	111	2 S13687	Ig heavy chain V r
36	399	62.7	123	2 S30530	Ig heavy chain V r
37	393	61.8	155	2 S31511	Ig heavy chain - h
38	392.5	61.7	129	2 S44114	Ig heavy chain V r
39	392	61.6	147	2 S31519	Ig heavy chain V r
40	388.5	61.1	116	2 S42484	Ig heavy chain V r
41	387	60.8	155	2 S31512	Ig heavy chain - h
42	385.5	60.6	130	2 S30534	Ig heavy chain V r
43	384	60.4	110	2 S13688	Ig heavy chain V r
44	383.5	60.3	118	2 S24443	Ig heavy chain V r
45	383.5	60.3	140	2 S78052	Ig heavy chain pre

ALIGNMENTS

RESULT 1

S37200  
Ig heavy chain V region - mouse  
C:Species: Mus musculus (house mouse)  
C>Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 21-Jan-2000  
C:Accession: S37200  
R:Fischer, R.; Voss, A.; Hunziker, W.; Stierhof, Y.D.; Kreuzaler, F.  
submitted to the EMBL Data Library, August 1993  
A:Description: Production and cloning of TMV-specific monoclonal antibodies.  
A:Reference number: S37200  
A:Accession: S37200  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-121 <FIS>  
A:Cross-references: UNIPARC:UPI00001161AC; EMBL:X74587; NID:g402639; PID:g402640  
A:Superfamily: immunoglobulin V region; immunoglobulin homology  
F:15-98/Domain: immunoglobulin homology <INM>

Query Match 85.7%; Score 545; DB 2; Length 121;  
Best Local Similarity 86.0%; Pred. No. 5.3e-43;  
Matches 104; Conservative 3; Mismatches 10; Indels 4; Gaps 1;  
QY 1 DVQLQESGGLVKPSQSLSLTCSVTGYSITGGYLNWIRQFPGNKLWNGYISYDGTNNY 60  
Db 1 DVQLQESGGLVKPSQSLSLTCSVTGYSITSSYYNWNIRQFPGNKLWNGYISYDGRNDY 60

QY 61 KPSLKDRIISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRV----FFDYWGQGTTLTVS 116  
Db 61 NPSLKNRISITRDTSKNQFFLKLNSVTNEDTATYYCARGGIYDYDFDSWGQGTTLTVS 120  
QY 117 S 117  
Db 121 S 121

RESULT 2

AVMS35  
Ig heavy chain precursor V region (MOPC 315) - mouse  
C:Species: Mus musculus (house mouse)  
C>Date: 24-Apr-1984 #sequence\_revision 30-Jun-1992 #text\_change 09-Jul-2004  
C:Accession: PL0102; S03262; A93814; A91462; A93787; S23599  
R:Rinfret, A.; Horne, C.; Dorrington, K.J.; Klein, M.  
Mol. Immunol. 26, 431-434, 1989  
A:Title: Cloning, sequencing and expression of the rearranged MOPC 315 VH gene segment.  
A:Reference number: PL0102; MUID:89238351; PMID:2497341  
A:Accession: PL0102  
A:Molecule type: mRNA  
A:Residues: 1-137 <RIN>  
A:Cross-references: UNIPROT:P01822; UNIPARC:UPI000002727B; GB:M27638; NID:g602706; PIDN  
A:Experimental source: strain MOPC 315  
R:Rinfret, A.; Dorrington, K.J.; Klein, M.  
submitted to the EMBL Data Library, June 1988

A;Reference number: S03262  
A;Accession: S03262  
A;Molecule type: DNA  
A;Residues: 1-15, 'G', 16-137 <RI2>  
A;Cross-references: UNIPARC:UPI000016CB1C; EMBL:X07880; NID:G51760; PIDN:CAA30727.1; PID  
R;Jilika, R.L.; Pestka, S.  
Proc. Natl. Acad. Sci. U.S.A. 74, 5692-5696, 1977  
A;Title: Amino acid sequence of the precursor region of MOPC-315 mouse immunoglobulin he  
A;Reference number: A93814; MUID:78094475; PMID:414225  
A;Accession: A93814  
A;Molecule type: protein  
A;Residues: 1-14, 'H', 16-31 <JIL>  
A;Cross-references: UNIPARC:UPI000017373E  
A;Note: the authors translated mRNA in vitro to obtain the precursor protein  
R;Schechter, I.; Wolf, O.; Zemell, R.; Burstein, Y.  
Fed. Proc. 38, 1839-1845, 1979  
A;Title: Structure and function of immunoglobulin genes and precursors.  
A;Reference number: A91462; MUID:79148758; PMID:428562  
A;Accession: A91462  
A;Molecule type: protein  
A;Residues: 1, 'X', 3-11, 'X', 14-21 <SCH>  
A;Cross-references: UNIPARC:UPI000017373F  
A;Note: the authors translated mRNA in vitro to obtain the precursor protein  
R;Francis, S.H.; Leslie, R.G.Q.; Hood, L.; Eisen, H.N.  
Proc. Natl. Acad. Sci. U.S.A. 71, 1123-1127, 1974  
A;Title: Amino-acid sequence of the variable region of the heavy (alpha) chain of a mouse  
A;Reference number: A93787; MUID:74107079; PMID:4524622  
A;Accession: A93787  
A;Molecule type: protein  
A;Residues: 19-52, 'K', 53-75, 'BYGB', 80-101, 'D', 103-106, 'ZB', 109-122, 124-137 <FRA>  
A;Cross-references: UNIPARC:UPI0000173740  
R;Hood, L.; Margolies, M.; Givol, D.; Zakut, R.  
unpublished results, cited by Padlan, E.A., Davies, D.R., Pecht, I., Givol, D., and Wrig  
A;Reference number: A94484  
A;Contents: annotation; revision to residue 53  
R;Cheadle, C.; Hook, L.E.; Givol, D.; Ricca, G.A.  
Mol. Immunol. 29, 21-30, 1992  
A;Title: Cloning and expression of the variable regions of mouse myeloma protein MOPC315  
A;Reference number: S23599; MUID:92114886; PMID:1731188  
A;Accession: S23599  
A;Molecule type: mRNA  
A;Residues: 19-137 <CHE>  
A;Cross-references: UNIPARC:UPI0000113794; EMBL:X63972; NID:G53532; PIDN:CAA45384.1; PID  
C;Comment: This alpha chain was isolated from a myeloma protein that has anti-dinitrope  
C;Genetics:  
A;Introns: 15/1  
A;Superfamily: immunoglobulin V region; immunoglobulin homology  
C;Keywords: heterotetramer; immunoglobulin  
F;1-18/Domain: signal sequence #status experimental <SIG>  
F;19-136/Product: Ig heavy chain V region (MOPC 315) #status experimental <MAT>  
F;33-116/Domain: immunoglobulin homology <IMM>  
  
Query Match 84.1%; Score 535; DB 1; Length 137;  
Best Local Similarity 83.2%; Pred. No. 5e-42;  
Matches 99; Conservative 7; Mismatches 11; Indels 2; Gaps 1;  
  
Qy 1 DVQLQESGPGLVKPSQSLSLTCSTGYGYSITGGYLNWIRQPGNKLEWNGYISYDGTNNY 60  
Db 19 DVQLQESGPGLVKPSQSLSLTCSTGYGYSITGGYLNWIRQPGNKLEWNGYISYDGTNNY 78  
  
Qy 61 KPSLKDRISITRDTSKNQFFLKLSNVTTEDTATYYCA--RYGRVFFDYWGQGTTLTVSS 117  
Db 79 NPSLKNRISITRDTSENQFFLKLSNVTTEDTATYYCAGDNHLYYFDWGQGTTLTVSS 137  
  
RESULT 3  
E25114  
Ig heavy chain V region (HP25) - mouse  
C;Species: Mus musculus (house mouse)  
C;Date: 29-Aug-1987 #sequence\_revision 29-Aug-1987 #text\_change 20-Jun-2000  
A;Accession: E25114  
R;Ollier, P.; Rocca-Serra, J.; Somme, G.; These, J.; Fougereau, M.  
EMBO J. 4, 3681-3688, 1985

A;Title: The idiotypic network and the internal image: possible regulation of a germ-lin  
A;Reference number: A91028; MUID:86136012; PMID:3937730  
A;Accession: E25114  
A;Molecule type: mRNA  
A;Residues: 1-119 <OLL>  
A;Cross-references: UNIPARC:UPI0000115D24; GB:X03378; NID:G52007; PIDN:CAA27095.1; PID:Y  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
C;Keywords: heterotetramer; immunoglobulin  
F;15-98/Domain: immunoglobulin homology <IMM>  
  
Query Match 82.2%; Score 523; DB 2; Length 119;  
Best Local Similarity 83.2%; Pred. No. 5.3e-41;  
Matches 99; Conservative 5; Mismatches 7; Indels 8; Gaps 2;  
  
Qy 1 DVQLQESGPGLVKPSQSLSLTCSTGYGYSITGGYLNWIRQPGNKLEWNGYISYDGTNNY 60  
Db 1 DVQLQESGPGLVKPSQSLSLTCSTGYGYSITGGYLNWIRQPGNKLEWNGYISYDGTNNY 60  
  
Qy 61 KPSLKDRISITRDTSKNQFFLKLSNVTTEDTATYYCA---RYGRVFF---DYWGQGT 111  
Db 61 NPSLKNRISITRDTSKNQFFLKLSNVTTEDTATYYCARPLYRYDEEYYANDYWGQGT 119  
  
RESULT 4  
S38718  
Ig heavy chain V region - mouse  
C;Species: Mus musculus (house mouse)  
C;Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 20-Jun-2000  
A;Accession: S38718  
R;Cimanis, A.Y.  
submitted to the EMBL Data Library, November 1993  
A;Reference number: S38713  
A;Accession: S38718  
A;Status: preliminary  
A;Molecule type: mRNA  
A;Residues: 1-116 <CIM>  
A;Cross-references: UNIPARC:UPI0000117542; EMBL:X76018; NID:G416102; PIDN:CAA53605.1; PID  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
C;Keywords: heterotetramer; immunoglobulin  
F;15-98/Domain: immunoglobulin homology <IMM>  
  
Query Match 82.0%; Score 521.5; DB 2; Length 116;  
Best Local Similarity 83.8%; Pred. No. 7.1e-41;  
Matches 98; Conservative 5; Mismatches 13; Indels 1; Gaps 1;  
  
Qy 1 DVQLQESGPGLVKPSQSLSLTCSTGYGYSITGGYLNWIRQPGNKLEWNGYISYDGTNNY 60  
Db 1 DVQLQESGPGLVKPSQSLSLTCSTGYGYSITGGYLNWIRQPGNKLEWNGYISYDGTNNY 60  
  
Qy 61 KPSLKDRISITRDTSKNQFFLKLSNVTTEDTATYYCARVGRVFRDYWGQGTTLTVSS 117  
Db 61 NPSLKNRISITRDTSKNQFFLQLNSVTTEDTATYYCAR--GGTGTFFWGQGTTLTVSA 116  
  
RESULT 5  
I28195  
Ig heavy chain V region (anti-haloperidol antibody D) - mouse  
C;Species: Mus musculus (house mouse)  
C;Date: 01-Dec-1989 #sequence\_revision 30-Sep-1991 #text\_change 23-Jul-1999  
A;Accession: I28195  
R;Sherman, M.A.; Deans, R.J.; Bolger, M.B.  
J. Biol. Chem. 263, 4059-4063, 1988  
A;Title: Haloperidol binding to monoclonal antibodies. Hypervariable region amino acid  
A;Reference number: A28195; MUID:88153717; PMID:3267217  
A;Accession: I28195  
A;Molecule type: mRNA  
A;Residues: 1-117 <SHE>  
A;Cross-references: UNIPARC:UPI0000114D72; GB:M19775; NID:G195526; PIDN:AAA38343.1; PID  
A;Note: the authors translated the codon AAC for residue 61 as Thr, and did not translat  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
C;Keywords: heterotetramer; immunoglobulin  
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 81.9%; Score 521; DB 2; Length 117;  
Best Local Similarity 83.8%; Pred. No. 8e-41;  
Matches 98; Conservative 5; Mismatches 14; Indels 0; Gaps 0;

Qy 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60  
Db 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFF--DYWGQGTTLTVSS 117  
Db 61 NPSLXKRISITRDTSKNQFFLKLNSVTNEDTATYYCARDNGCNGDYWGQGTSTVTVSS 117

RESULT 6  
S07637  
Ig heavy chain V region (PTF.02) - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 23-Jul-1999  
C:Accession: S07637  
R:Uraikov, D.N.; Deev, S.M.; Polyanovsky, O.L.  
Nucleic Acids Res. 17, 9481, 1989  
A:Title: The structure of the expressible VH gene from a hybridoma producing monoclonal  
A:Reference number: S07637; MUID:90067954; PMID:2587273  
A:Accession: S07637  
A:Molecule type: DNA  
A:Residues: 1-136 <URA>  
A:Cross-references: UNIPARC:UPI0000115E36; EMBL:X16740; NID:g52099; PIDN:CAA34714.1; PID  
A:Note: the authors translated the codon TAT for residue 112 as Ile, TAC for residue 113  
C:Keywords: heterotetramer; immunoglobulin  
F:33-116/Domain: immunoglobulin homology <IMM>

Query Match 81.7%; Score 519.5; DB 2; Length 136;  
Best Local Similarity 83.8%; Pred. No. 1.3e-40;  
Matches 98; Conservative 6; Mismatches 12; Indels 1; Gaps 1;

Qy 2 VQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61  
Db 20 VQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGSNGYN 79

Qy 62 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR-YGRVFFDYWGQGTTLTVSS 117  
Db 80 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCTRGDGHFFTYWGQGTTLTVTSA 136

RESULT 7  
CS3285  
Ig heavy chain V and J regions, monoclonal antibody OHP7D7.2.3 - mouse (fragment)  
C:Species: Mus musculus (house mouse)  
C:Date: 02-May-1994 #sequence\_revision 18-Nov-1994 #text\_change 20-Jun-2000  
C:Accession: CS3285  
R:Sawada, J.; Mizusawa, S.; Terao, T.; Naito, M.; Kurosawa, Y.  
Mol. Immunol. 28, 1063-1072, 1991  
A:Title: Molecular characterization of monoclonal anti-steroid antibodies: primary struc  
and their pH-reactivity profiles.  
A:Reference number: A53285; MUID:92017897; PMID:1922102  
A:Accession: CS3285  
A>Status: preliminary  
A:Molecule type: mRNA; protein  
A:Residues: 1-119 <SAW>  
A:Cross-references: UNIPARC:UPI000011D0A5; GB:D12734; NID:g220548; PIDN:BA02226.1; PID:  
A:Note: sequence extracted from NCBI backbone (NCBI:63297, NCBI:63302)  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 80.2%; Score 510; DB 2; Length 119;  
Best Local Similarity 78.2%; Pred. No. 8.3e-40;  
Matches 93; Conservative 12; Mismatches 12; Indels 2; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60

Db 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITSDHWVNWVQFPGNKLEWNGYINRGGTGY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFF--DYWGQGTTLTVSS 117  
Db 61 NPSLXKRISITRDTSKNQFFLKLNSVTNEDTATYYCSRGRYYAYDYWGQGTSTVTVSS 119

RESULT 8  
A25114  
Ig heavy chain V region (HP22, HP27) - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 29-Aug-1987 #sequence\_revision 29-Aug-1987 #text\_change 21-Jul-2000  
C:Accession: A25114  
R:Ollier, P.; Rocca-Serra, J.; Somme, G.; Theze, J.; Fougereau, M.  
EMBO J. 4, 3681-3688, 1985  
A:Title: The idiotypic network and the internal image: possible regulation of a germ-lir  
A:Reference number: A91028; MUID:86136012; PMID:3937730  
A:Accession: A25114  
A:Molecule type: mRNA  
A:Residues: 1-120 <OLL>  
A:Cross-references: UNIPARC:UPI0000115D15; GB:X03374; NID:g51983; PIDN:CAA27071.1; PID:  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 80.0%; Score 508.5; DB 2; Length 120;  
Best Local Similarity 79.2%; Pred. No. 1.1e-39;  
Matches 95; Conservative 8; Mismatches 8; Indels 9; Gaps 2;

Qy 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60  
Db 1 DVHLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQFPGNKLEWNGYINYGDSNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR-----YGRVFF--DYWGQGT 111  
Db 61 NPSLXKRISITRDTSKNQFFLKLNSVTNEDTATYYCARLIPSDGYEDYAMDYWGQGT 120

RESULT 9  
F25114  
Ig heavy chain V region (HP12) - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 29-Aug-1987 #sequence\_revision 29-Aug-1987 #text\_change 20-Jun-2000  
C:Accession: F25114  
R:Ollier, P.; Rocca-Serra, J.; Somme, G.; Theze, J.; Fougereau, M.  
EMBO J. 4, 3681-3688, 1985  
A:Title: The idiotypic network and the internal image: possible regulation of a germ-lir  
A:Reference number: A91028; MUID:86136012; PMID:3937730  
A:Accession: F25114  
A:Molecule type: mRNA  
A:Residues: 1-115 <OLL>  
A:Cross-references: UNIPARC:UPI0000115D28; GB:X03379; NID:g52013; PIDN:CAA27101.1; PID:  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 79.2%; Score 504; DB 2; Length 115;  
Best Local Similarity 81.7%; Pred. No. 2.8e-39;  
Matches 94; Conservative 5; Mismatches 12; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60  
Db 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQFPGNKLEWNGYIRYDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYG----RVFFDYWGQGT 111  
Db 61 NPSLXKRISITRDTSKNQFFLKLNSVTNEDTATYYCAVFGYDMDYAMDYWGQGT 115

RESULT 10  
PL0100  
Ig heavy chain precursor V region (40-140) - mouse

C;Species: Mus musculus (house mouse)  
C;Date: 07-Jun-1990 #sequence\_revision 07-Jun-1990 #text\_change 23-Jul-1999  
C;Accession: PL0100  
R;Near, R.I.; Haber, E.  
Mol. Immunol. 26, 371-382, 1989  
A;Title: Characterization of the heavy and light chain immunoglobulin variable region genes  
A;Reference number: PL0100; MUID:89238344; PMID:2497340  
A;Accession: PL0100  
A;Molecule type: DNA  
A;Residues: 1-135 <NEA>  
A;Cross-references: UNIPARC:UPI0000114EA6; GB:M27660; NID:g341745; PIDN:AAA58746.1; PID:  
A;Experimental source: strain A/J  
A;Note: the VH40-140 gene segment is classified as a member of the 36-60 VH gene family  
C;Keywords: heterotetramer; immunoglobulin  
A;Introns: 15/1  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
F;1-18/Domain: signal sequence #status predicted <SIG>  
F;19-115/Domain: V segment #status predicted <VRE>  
F;33-116/Domain: immunoglobulin homology <IMM>  
F;117-118/Domain: D segment #status predicted <DRE>  
F;119-135/Domain: J segment #status predicted <JRE>

Query Match 79.2%; Score 503.5; DB 2; Length 135;  
Best Local Similarity 80.3%; Pred. No. 3.7e-39;  
Matches 94; Conservative 8; Mismatches 14; Indels 1; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60  
DB 19 DVQLQESGPGLVKPSQSLSLTCSTGYISITSDYAMSWIRQPPGNRLEWNGYITNGYTTY 78

QY 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCARYGVFRFDYWGQGTTLTVSS 117  
DB 79 NPSLKSRSITRDTSKNQFFLQLNSVTTEDTATYYCAR-SYDYFDYWGQGTTLTVSS 134

RESULT 11  
CJ25114  
Ig heavy chain V region (HP20) - mouse  
C;Species: Mus musculus (house mouse)  
C;Date: 29-Aug-1987 #sequence\_revision 29-Aug-1987 #text\_change 20-Jun-2000  
C;Accession: CJ25114  
R;Ollier, P.; Rocca-Serra, J.; Somme, G.; These, J.; Fougereau, M.  
EMBO J. 4, 3681-3688, 1985  
A;Title: The idiotypic network and the internal image: possible regulation of a germ-line  
A;Reference number: A91028; MUID:86136012; PMID:3937730  
A;Accession: CJ25114  
A;Molecule type: mRNA  
A;Residues: 1-119 <OLL>  
A;Cross-references: UNIPARC:UPI0000115D1A; GB:X03376; NID:g51995; PIDN:CAA27083.1; PID:g  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
C;Keywords: heterotetramer; immunoglobulin  
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 79.1%; Score 503; DB 2; Length 119;  
Best Local Similarity 79.3%; Pred. No. 3.6e-39;  
Matches 96; Conservative 5; Mismatches 8; Indels 12; Gaps 2;

QY 1 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60  
DB 1 DVQLQESGPGLVKPSQSLSLTCSTGNSITGYYSWIRQPPGNKLEWNGYIKYDGNNSY 60

QY 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCARYGVFRFDYWGQGTTLTVSS 110  
DB 61 NPSLKNRISITRDTSKNQFFLKLSVTTEDTATYYCAR--PLYFRHDEYYDVMWYWGQ 118

QY 111 T 111  
DB 119 T 119

RESULT 12  
S30752

Ig heavy chain precursor V region - mouse  
C;Species: Mus musculus (house mouse)  
C;Date: 31-Dec-1993 #sequence\_revision 31-Dec-1993 #text\_change 23-Jul-1999  
C;Accession: S30752  
R;Grant, F.J.; Levin, S.D.; Gilbert, T.; Kindsvogel, W.  
Nucleic Acids Res. 15, 5496, 1987  
A;Title: Improved RNA sequencing method to determine immunoglobulin mRNA sequence.  
A;Reference number: S30751; MUID:87260030; PMID:3601683  
A;Accession: S30752  
A;Molecule type: mRNA  
A;Residues: 1-149 <GRA>  
A;Cross-references: UNIPARC:UPI0000115D92; EMBL:X05878; NID:g52526; PIDN:CAA29302.1; PID:  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
C;Keywords: heterotetramer; immunoglobulin  
F;33-116/Domain: immunoglobulin homology <IMM>  
F;138-149/Domain: C region (C-gamma 2b) (fragment) #status predicted <CRE>

Query Match 79.1%; Score 503; DB 2; Length 149;  
Best Local Similarity 79.8%; Pred. No. 4.6e-39;  
Matches 95; Conservative 8; Mismatches 14; Indels 2; Gaps 2;

QY 1 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60  
DB 19 DVQLQESGPGLVKPSQSLSLTCSTGYISITGYTWHWIRQPPGNKLEWYVHYSGNTDF 78

QY 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCAR-YGRVRF-FDYWGQGTTLTVSS 117  
DB 79 NPSLKSRSITRDTSKNQFFLQLNSVTAEDTATYYCARGYNYAMDYWGQTSVTSS 137

RESULT 13  
T01262  
Ig heavy chain V region - mouse (fragment)  
C;Species: Mus musculus (house mouse)  
C;Date: 12-Feb-1999 #sequence\_revision 12-Feb-1999 #text\_change 21-Jul-2000  
C;Accession: T01262  
R;Pirofski, L.A.; Thomas, E.K.; Scharff, M.D.  
AIDS Res. Hum. Retroviruses 9, 41-49, 1993  
A;Title: Variable region gene utilization and mutation in a group of neutralizing murine  
A;Reference number: Z14285; MUID:93152285; PMID:7678971  
A;Accession: T01262  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: mRNA  
A;Residues: 1-114 <PRA>  
A;Cross-references: UNIPARC:UPI0000117638; EMBL:S54194; NID:g264864; PIDN:AAB25246.2; PI:  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 78.5%; Score 499.5; DB 2; Length 114;  
Best Local Similarity 81.2%; Pred. No. 7.2e-39;  
Matches 95; Conservative 6; Mismatches 13; Indels 3; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60  
DB 1 DVQLQESGPGLVKPSQSLSHTCTVTGYISITSDYAMWIRQPPGNKLEWNGYISFSGSTSY 60

QY 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCARYGVFRFDYWGQGTTLTVSS 117  
DB 61 NPSLKSRSITRDTSKNLFLLQLNSVTTEDTATYYCA---RGLPDYWGQGTTLTVSS 114

RESULT 14  
B24672  
Ig heavy chain precursor V region (VGAM3-2) - mouse  
C;Species: Mus musculus (house mouse)  
C;Date: 19-Nov-1988 #sequence\_revision 19-Nov-1988 #text\_change 18-Oct-1996  
C;Accession: B24672  
R;Winter, E.; Radbruch, A.; Krawinkel, U.  
EMBO J. 4, 2861-2867, 1985  
A;Reference number: A91022; MUID:86055722; PMID:2998759  
A;Accession: B24672  
A;Molecule type: DNA  
A;Residues: 1-134 <WIN>

Search completed: January 10, 2006, 20:55:14  
Job time : 14.1157 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:26:41 ; Search time 78.8731 Seconds  
(without alignments)  
1046.577 Million cell updates/sec

Title: US-10-735-916A-69  
Perfect score: 636  
Sequence: 1 DVQLQSGPLVKSLSL.....RYGRVFFDYWGQTTLTVSS 117

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt\_05.80.\*

1: uniprot\_sprot.\*

2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	541	85.1	479	2	Q99M22_MOUSE
2	535	84.1	137	1	HV46_MOUSE
3	526.5	82.8	483	2	Q5U413_MOUSE
4	523	82.2	119	2	Q53VQ5_MOUSE
5	519.5	81.7	136	2	Q6LBO5_MOUSE
6	508.5	80.0	120	2	Q53VR7_MOUSE
7	504	79.2	115	2	Q53VQ1_MOUSE
8	503	79.1	119	2	Q53VR3_MOUSE
9	499	78.5	116	1	HV60_MOUSE
10	492	77.4	590	2	Q569B8_RAT
11	491	77.2	98	2	Q53VQ4_MOUSE
12	489	76.9	615	2	Q569B6_RAT
13	480	75.5	98	2	Q53VR6_MOUSE
14	476	74.8	119	2	Q53VQ9_MOUSE
15	475	74.7	98	2	Q53VR2_MOUSE
16	469	73.7	98	2	Q53VQ0_MOUSE
17	455	71.5	116	1	HV61_MOUSE
18	453	71.2	98	2	Q53VQ8_MOUSE
19	447	70.3	113	1	HV47_MOUSE
20	446	70.1	262	2	Q65Z11_MOUSE
21	405	63.7	119	2	Q9UL73_HUMAN
22	404.5	63.6	117	1	HV62_MOUSE
23	400.5	63.0	478	2	Q72379_HUMAN
24	397.5	62.5	465	2	Q6GMX6_HUMAN
25	397	62.4	476	2	Q6GMX1_HUMAN
26	394.5	62.0	477	2	Q6GMX7_HUMAN
27	387.5	60.9	576	2	Q6P418_HUMAN
28	381	59.9	477	2	Q510J1_RAT
29	380.5	59.8	591	2	Q510L9_RAT
30	370.5	58.3	150	2	O95973_HUMAN
31	368	57.9	469	2	Q5M839_RAT

32	364	57.2	144	1	HV43_MOUSE	P01819	mus musculus
33	363.5	57.2	122	2	Q9UL75_HUMAN	Q9UL75	homo sapien
34	363.5	57.2	146	1	HV21_HUMAN	P06331	homo sapien
35	361.5	56.8	620	2	Q96EY0_HUMAN	Q96EY0	homo sapien
36	360	56.6	458	2	Q5M842_RAT	Q5M842	rattus norv
37	359	56.4	492	2	Q72374_HUMAN	Q72374	homo sapien
38	358	56.3	478	2	Q6NYH3_HUMAN	Q6NYH3	homo sapien
39	358	56.3	595	2	Q8WUX4_HUMAN	Q8WUX4	homo sapien
40	358	56.3	597	2	Q9BU10_HUMAN	Q9BU10	homo sapien
41	358	56.3	597	2	Q6GMX5_HUMAN	Q6GMX5	homo sapien
42	358	56.3	625	2	Q96AA6_HUMAN	Q96AA6	homo sapien
43	356.5	56.1	121	2	Q99NG4_MOUSE	Q99NG4	mus musculus
44	356.5	56.1	139	2	Q86SX2_HUMAN	Q86SX2	homo sapien
45	356	56.0	597	2	Q9BQB8_HUMAN	Q9BQB8	homo sapien

ALIGNMENTS

RESULT 1

Q99M22\_MOUSE PRELIMINARY; PRT; 479 AA.

AC Q99M22\_MOUSE PRELIMINARY; PRT; 479 AA.

DT 01-JUN-2001 (Tremblrel. 17, Created)

DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)

DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)

DE LOC238447 protein.

GN Name=LOC238447;

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;

OC Muridae; Murinae; Mus.

OX NCBI\_TaxID=10090;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RC STRAIN=Mix FVB/N;

RC TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;

RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler N.G.,

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Hsieh F.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,

RA Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,

RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,

RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,

RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalish D.E.,

RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,

RT "Generation and initial analysis of more than 15,000 full-length human

RT and mouse cDNA sequences."

RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).

RN [2]

RC NUCLEOTIDE SEQUENCE.

RC STRAIN=Mix FVB/N;

RC TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;

RG NIH MGC Project;

RL	Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
DR	EMBL; BC002091; AA02091.1; -; mRNA.
DR	HSSP; P01820; 1G7J.
DR	GO; GO:0003823; F:antigen binding; IEA.
DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003597; Ig.cl.
DR	InterPro; IPR003006; Ig\_MHC.
DR	InterPro; IPR003596; Ig\_v.
DR	Pfam; PF07654; C1-set; 2.
DR	SMART; SM00406; IGV; 1.

```
DR PROSITE; PS50835; IG LIKE; 4.
KW PROSITE; PS00290; IG MHC; UNKNOWN_2.
DR Immunoglobulin domain.
SQ SEQUENCE 479 AA; 5192 MW; 768E39A138918892 CRC64;

Query Match      85.1%; Score 541; DB 2; Length 479;
Best Local Similarity 85.5%; Pred. No. 1.7e-47;
Matches 100; Conservative 6; Mismatches 11; Indels 0; Gaps 0;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWGYISYDGTNNY 60
Db 19 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWGYINVDGSNNY 78

Qy 61 KPSLKDRISITRDTSKNOFFFLKNSVTNEDTATYICARYGRVFDYWGQGTTLTVSS 117
Db 79 NPSLKNRISITRDTSKNOFFFLKNSVTNEDTATYICASRGYSWFPNMQGGLTVTVA 135

RESULT 2
HV46 MOUSE
ID HV46 MOUSE STANDARD; PRT; 137 AA.
AC P01822;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V region MOPC 315 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]_
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=89238351; PubMed=2497341; DOI=10.1016/0161-5890(89)90133-8;
RA Rinfret A., Horne C., Dorrington K.J., Klein M.;
RT "Cloning, sequencing and expression of the rearranged MOPC 315 VH gene
segment.";
RL Mol. Immunol. 26:431-434(1989).
RN [2]
RP PROTEIN SEQUENCE OF 1-31.
RX MEDLINE=78094475; PubMed=414225;
RA Jilka R.L., Pestka S.;
RT "Amino acid sequence of the precursor region of MOPC-315 mouse
immunoglobulin heavy chain.";
RL Proc. Natl. Acad. Sci. U.S.A. 74:5692-5696(1977).
RN [3]
RP PROTEIN SEQUENCE OF 1-21.
RX MEDLINE=79148758; PubMed=428562;
RA Schechter I., Wolf O., Zemell R., Burstein Y.;
RT "Structure and function of immunoglobulin genes and precursors.";
RL Fed. Proc. 38:1839-1845(1979).
RN [4]
RP PROTEIN SEQUENCE OF 19-136.
RX MEDLINE=74107079; PubMed=4524622;
RA Francis S.H., Leslie R.G.Q., Hood L., Eisen H.N.;
RT "Amino-acid sequence of the variable region of the heavy (alpha) chain
of a mouse myeloma protein with anti-hapten activity.";
RL Proc. Natl. Acad. Sci. U.S.A. 71:1123-1127(1974).
RN [5]
RP SEQUENCE REVISION TO 53.
RX MEDLINE=7724979; PubMed=268248;
RA Hood L., Margolies M.N., Givol D., Zakut R.;
RL Unpublished results, cited by:
RA Padlan E.A., Davies D.R., Pecht I., Givol D., Wright C.;
RL Cold Spring Harb. Symp. Quant. Biol. 41:627-637(1977).
CC -!- MISCELLANEOUS: This alpha chain was isolated from a myeloma
protein that has anti-dinitrophenyl activity.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use as long as its content is in no way modified and this statement is not
removed.
```

```
CC -----
DR EMBL; M27638; AAA61337.1; -; Genomic_DNA.
DR EMBL; X07880; CAA30727.1; -; Genomic_DNA.
DR PIR; P0102; AVMS35.
DR HSP; P01820; 1G7J.
DR SMR; P01822; 20-137.
DR Ensembl; ENSMUSG0000057048; Mus musculus.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 18
FT CHAIN 19 137
FT REGION 19 48
FT REGION 49 54
FT REGION 55 68
FT REGION 69 84
FT REGION 85 116
FT REGION 117 126
FT REGION 127 137
FT DISULFID 40 114
FT CONFLICT 15 15
FT CONFLICT 15 15
FT CONFLICT 77 78
FT CONFLICT 102 102
FT CONFLICT 123 123
FT NON_TER 137 137
SQ SEQUENCE 137 AA; 15399 MW; FB3828304C2B81DC CRC64;

Query Match      84.1%; Score 535; DB 1; Length 137;
Best Local Similarity 83.2%; Pred. No. 1.6e-47;
Matches 99; Conservative 7; Mismatches 11; Indels 2; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWGYISYDGTNNY 60
Db 19 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWGFIKYDGSNGY 78

Qy 61 KPSLKDRISITRDTSKNOFFFLKNSVTNEDTATYICA--RYGRVFDYWGQGTTLTVSS 117
Db 79 NPSLKNRISITRDTSKNOFFFLKNSVTNEDTATYICAGDNHLYYFDYWGQGTTLTVSS 137

RESULT 3
Q5U413 MOUSE
ID Q5U413 MOUSE PRELIMINARY; PRT; 483 AA.
AC Q5U413;
DT 01-FEB-2005 (TrEMBLrel. 29, Created)
DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)
DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)
DE LOC544903 protein.
GN Name=LOC544903;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]_
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Frange C.,
RA Raha S.A., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
```

```

RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RG NIH MGC Project;
RL Submitted (OCT-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC085312; AAH85312.1; -; mRNA.
DR Ensembl; ENSMUSG0000054328; Mus musculus.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG.cl.
DR InterPro; IPR003006; IG.MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 3.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 4.
DR PROSITE; PS00290; IG.MHC; UNKNOWN 2.
SQ SEQUENCE 483 AA; 52714 MW; 7C272DA501A4A0D1 CRC64;

Query Match      82.8%; Score 526.5; DB 2; Length 483;
Best Local Similarity 82.5%; Pred. No. 5.4e-46;
Matches 99; Conservative 7; Mismatches 11; Indels 3; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWGYISYDGTNNY 60
DB 19 DVQLQESGPDVLKPSQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWGYISYGSNNY 78
QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYTCAR_YGRVF---FDYWGQGTTLTVSS 117
DB 79 NPSLKSRSITRDTSKNQFFLQNSVTNEDTATYTCAR_YEGNYDYAMDYWGQGTSTVTVSS 138

RESULT 4
Q53VQ5 MOUSE PRELIMINARY; PRT; 119 AA.
AC Q53VQ5;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., These J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBO J. 4:3681-3688 (1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03378; CAA27095.1; -; mRNA.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13931 MW; 502E51A5213F056E CRC64;

```

```

Query Match      82.2%; Score 523; DB 2; Length 119;
Best Local Similarity 83.2%; Pred. No. 2.5e-46;
Matches 99; Conservative 5; Mismatches 7; Indels 8; Gaps 2;

QY 1 DVQLQESGPGLVKPSQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWGYISYDGTNNY 60
DB 1 DVQLQESGPGLVKPSQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWGYISYDGSNNY 60
QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYTCAR_YGRVF---DYWGQGT 111
DB 61 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYTCARPLYRYDEEYYAMDYWGQGT 119

RESULT 5
Q6LBQ5 MOUSE PRELIMINARY; PRT; 136 AA.
AC Q6LBQ5;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE VH gene product (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=90067954; PubMed=2587273;
RA Urakov D.N., Deev S.M., Polyakovskiy O.L.;
RT "The structure of the expressible VH gene from a hybridoma producing
RT monoclonal antibodies against porcine transferrin.";
RL Nucleic Acids Res. 17:9481-9481 (1989).
DR EMBL; X16740; CAA34714.1; -; Genomic_DNA.
DR HSP; P18532; 1KCV.
DR SMR; Q6LBQ5; 20-136.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 1.
FT NON_TER 1
FT NON_TER 1
SQ SEQUENCE 136 AA; 15307 MW; 5B0F439CCFB15C3A CRC64;

Query Match      81.7%; Score 519.5; DB 2; Length 136;
Best Local Similarity 83.8%; Pred. No. 6.7e-46;
Matches 98; Conservative 6; Mismatches 12; Indels 1; Gaps 1;

QY 2 VQLQESGPGLVKPSQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWGYISYDGTNNYK 61
DB 20 VQLQESGPGLVKPSQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWGYISYDGSNGYN 79
QY 62 PSLKDRISITRDTSKNQFFLKNSVTNEDTATYTCAR_YGRVFYWGQGTTLTVSS 117
DB 80 PSLKNRISITRDTSKNQFFLKNSVTNEDTATYTCAR_YGRVGHFFFTYWGQGTTLTVSA 136

RESULT 6
Q53VR7 MOUSE PRELIMINARY; PRT; 120 AA.
AC Q53VR7;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.

```

```

RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., These J., Fougereau M.;
RT "The idiotypic network and the internal image; possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBL; X03374; CAA27071.1; -; mRNA.
RN NCBI_TaxID=10090;
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03375; CAA27077.1; -; mRNA.
DR EMBL; X03374; CAA27071.1; -; mRNA.
FT NON_TER 1
FT NON_TER 120
SQ SEQUENCE 120 AA; 13892 MW; 013452306EBA3BE CRC64;

Query Match 80.0%; Score 508.5; DB 2; Length 120;
Best Local Similarity 79.2%; Pred. No. 8e-45;
Matches 95; Conservative 8; Mismatches 8; Indels 9; Gaps 2;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGLYLNWIRQPGNKLEWGYISYDGTNNY 60
Db 1 DVHLQESGPGLVKPSQSLTCSVTGYSITRGNWNIWIRPFGNKLEWGYINVDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNOFFLKLNSVTNEDTATYYCAR-----YGRVFF--DYWGQGT 111
Db 61 NPSLKNRISITRDTSKNOFFLKLNSVTNEDTATYYCARLIPSDGYEDYAMDYWGQGT 120

RESULT 7
Q53VQ1_MOUSE PRELIMINARY; PRT; 115 AA.
AC Q53VQ1;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., These J., Fougereau M.;
RT "The idiotypic network and the internal image; possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBL; X03379; CAA27101.1; -; mRNA.
RN NCBI_TaxID=10090;
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03379; CAA27101.1; -; mRNA.
FT NON_TER 1
FT NON_TER 115
SQ SEQUENCE 115 AA; 13257 MW; D465A5854DF459A3 CRC64;

Query Match 79.2%; Score 504; DB 2; Length 115;
Best Local Similarity 81.7%; Pred. No. 2.2e-44;
Matches 94; Conservative 5; Mismatches 12; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGLYLNWIRQPGNKLEWGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSIISGYNNWIRQPGDKLEWGFTRYDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNOFFLKLNSVTNEDTATYYCARYG-----RVFFDYWGQGT 111
Db 61 NPSLKNRISITRDTSKNOFFLKLNSVTNEDTATYYCAVFGYDMDYAMDYWGQGT 115

RESULT 8
Q53VR3_MOUSE PRELIMINARY; PRT; 119 AA.
AC Q53VR3;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., These J., Fougereau M.;
RT "The idiotypic network and the internal image; possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBL; X03376; CAA27083.1; -; mRNA.
RN NCBI_TaxID=10090;
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03376; CAA27083.1; -; mRNA.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13799 MW; 36504D1665BFB59 CRC64;

Query Match 79.1%; Score 503; DB 2; Length 119;
Best Local Similarity 79.3%; Pred. No. 3e-44;
Matches 96; Conservative 5; Mismatches 8; Indels 12; Gaps 2;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGLYLNWIRQPGNKLEWGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCSVTGNSITSGYYSWIRQPGNKLEWGYIKYDGNNSY 60

Qy 61 KPSLKDRISITRDTSKNOFFLKLNSVTNEDTATYYCARYGRVFF-----DYWGQGT 110
Db 61 NPSLKNRISITRDTSKNOFFLKLNSVTNEDTATYYCAR--PLYFRHDEYDYDMDYWGQGT 118

Qy 111 T 111
Db 119 T 119

RESULT 9
HV60_MOUSE PRELIMINARY; PRT; 116 AA.
AC HV60_MOUSE STANDARD; PRT; 116 AA.
AC P18531;
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-NOV-1990 (Rel. 16, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V region M315 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX STRAIN=BALB/cJ;
RX MEDLINE=89279149; PubMed=2499654; DOI=10.1084/jem.169.6.2007;
RA Levy N.S., Malipiero U.V., Lebecque S.G., Gearhart P.J.;
RT "Early onset of somatic mutation in immunoglobulin VH genes during the
RT primary immune response.";
RL J. Exp. Med. 169:2007-2019 (1989).
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
```

```
CC -----
DR PIR; J70509; HVM531.
DR PDB; 1BZV; X-ray; X=22-116.
DR SMR; P18531; 19-116.
DR Ensembl; ENSMUSG0000057048; Mus musculus.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW 3D-structure; Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 18
FT CHAIN 19 116
FT REGION 19 48
FT REGION 49 53
FT REGION 54 67
FT REGION 68 84
FT REGION 85 116
FT DISULFID 40 114
FT NON_TER 116 116
SQ SEQUENCE 116 AA; 13095 MW; 4562E03E53DC9E10 CRC64;

Query Match 78.5%; Score 499; DB 1; Length 116;
Best Local Similarity 93.9%; Pred. No. 7.5e-44;
Matches 92; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPPGNKLEWGYISYDGTNNY 60
Db 19 DVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPPGNKLEWGYISYDGSNNY 78

Qy 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCAR 98
Db 79 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCAR 116

RESULT 10
Q569B8 RAT PRELIMINARY; PRT; 590 AA.
AC Q569B8
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE Similar to Igh-6 protein.
GN Name=LOC29357;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny K.C., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
```

```
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH MGC Project;
RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC092580; AAH92580.1; -; mRNA.
DR GO; GO:0003823; F-antigen binding; IEA.
DR InterPro; IPR003599; Ig-like.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 590 AA; 65088 MW; FAC77FFA82302304 CRC64;

Query Match 77.4%; Score 492; DB 2; Length 590;
Best Local Similarity 79.0%; Pred. No. 2.6e-42;
Matches 94; Conservative 7; Mismatches 16; Indels 2; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPPGNKLEWGYISYDGTNNY 60
Db 17 EVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPPGNKLEWGYISAGSTNY 76

Qy 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYGRVF--FDYWGQGTTLTVSS 117
Db 77 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCARESPSTRFAIWGQGTTLTVSS 135

RESULT 11
Q53VQ4 MOUSE PRELIMINARY; PRT; 98 AA.
AC Q53VQ4;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., Theze J., Fougereau M.;
RT "The idiotypic network and the internal image; possible regulation of
a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
antibodies in the GAT system.";
RL EMBO J. 4:3681-3688 (1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03378; CAA27096.1; -; mRNA.
FT NON_TER 1 1
FT NON_TER 98 98
SQ SEQUENCE 98 AA; 11202 MW; 4049CF8C7E8AAE0 CRC64;

Query Match 77.2%; Score 491; DB 2; Length 98;
Best Local Similarity 92.9%; Pred. No. 4.2e-43;
Matches 91; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPPGNKLEWGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPPGNKLEWGYISYDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCAR 98
Db 61 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCAR 98
```

```

RESULT 12
Q569B6 RAT
ID Q569B6_RAT PRELIMINARY; PRT; 615 AA.
AC Q569B6;
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE LOC314509 protein.
GN Name=LOC314509;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Scheimen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bobak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.N., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Maman A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grinwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH MGC Project;
RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC02582; AA02582.1; -; mRNA.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF07654; CI-set; 4.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 615 AA; 67986 MW; B5C2483C69F186C CRC64;

Query Match 76.9%; Score 489; DB 2; Length 615;
Best Local Similarity 76.4%; Pred. No. 5, 7e-42;
Matches 94; Conservative 10; Mismatches 11; Indels 8; Gaps 3;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYISITGGYLNWIRQPGNKLWGMGIYSYDGTNNY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 19 EVQLQESGPGLVKPSQSLTCSVTGYISITNSY-WGIRKFPGNKMWICHISYSGTSY 77
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVTTEDTATYYCAR-----YGRVFFDYWGQGITLT 114
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 78 NPSLKRISITRDTSKNQFFLQLNSVTTEDTATYYCARHGGLTGR-YFDYWGQGVNMT 136
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 115 VSS 117

```

```

Db 137 VSS 139
|||

RESULT 13
Q53VR6 MOUSE PRELIMINARY; PRT; 98 AA.
AC Q53VR6;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., Theze J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
antibodies in the GAT system."
RL EMO J. 4:3681-3688 (1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03375; CAA27078.1; -; mRNA.
DR EMBL; X03374; CAA27072.1; -; mRNA.
FT NON_TER 1
FT NON_TER 98
FT SEQUENCE 98 AA; 11255 MW; EBC71AA2F8F5FD60 CRC64;

Query Match 75.5%; Score 480; DB 2; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.8e-42;
Matches 87; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYISITGGYLNWIRQPGNKLWGMGIYSYDGTNNY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DVHLQESGPGLVKPSQSLTCSVTGYISITGYNNWIRPFGNKLWGMGIYNDGSNNY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVTTEDTATYYCAR 98
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 NPSLKRISITRDTSKNQFFLKLSVTTEDTATYYCAR 98
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 14
Q53VQ9 MOUSE PRELIMINARY; PRT; 119 AA.
AC Q53VQ9;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., Theze J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
antibodies in the GAT system."
RL EMO J. 4:3681-3688 (1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.

```

DR EMBL; X03377; CAA27089.1; -: mRNA.  
FT NON\_TER 1  
FT NON\_TER 119 119  
SQ SEQUENCE 119 AA; 13844 MW; 6B1BC8C7DC77B147 CRC64;

Query Match 74.8%; Score 476; DB 2; Length 119;  
Best Local Similarity 75.4%; Pred. No. 1.9e-41;  
Matches 89; Conservative 9; Mismatches 12; Indels 8; Gaps 2;  
QY 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60  
DB 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60  
QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCA-----RYGRVFF---DYWGQG 110  
DB 61 NPSLKNRISITRDTSKNQFFLKLNSVTNEDTATYYCA-----RYGRVFF---DYWGQG 118

## RESULT 15

Q53VR2 MOUSE  
ID Q53VR2 MOUSE PRELIMINARY; PRT; 98 AA.  
AC Q53VR2;  
DT 13-SEP-2005 (TremBLrel. 31, Created)  
DT 13-SEP-2005 (TremBLrel. 31, Last sequence update)  
DT 13-SEP-2005 (TremBLrel. 31, Last annotation update)  
DE VH region (Fragment).  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
OC Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RX MEDLINE=86136012; PubMed=3937730;  
RA Ollier P., Rocca-Serra J., Somme G., Theze J., Fougereau M.;  
RT "The idiotypic network and the internal image: possible regulation of  
a germ-line network by paucigene encoded Ab2 (anti-idiotypic)  
antibodies in the GAT system.";  
RL EMBO J. 4:3681-3688(1985).  
RN [2]  
RP NUCLEOTIDE SEQUENCE OF 28-29.  
RA Fougereau M.;  
RL Submitted (NOV-1986) to the EMBL/GenBank/DDBJ databases.  
DR EMBL; X03376; CAA27084.1; -: mRNA.  
FT NON\_TER 1  
FT NON\_TER 98 98  
SQ SEQUENCE 98 AA; 11132 MW; 50878B9A4CF7298B CRC64;

Query Match 74.7%; Score 475; DB 2; Length 98;  
Best Local Similarity 89.8%; Pred. No. 1.9e-41;  
Matches 88; Conservative 3; Mismatches 7; Indels 0; Gaps 0;  
QY 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60  
DB 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60  
QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR 98  
DB 61 NPSLKNRISITRDTSKNQFFLKLNSVTNEDTATYYCAR 98

Search completed: January 10, 2006, 20:53:26  
Job time : 79.8731 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.71144 Seconds  
(without alignments)  
166.558 Million cell updates/sec

Title: US-10-735-916A-65  
Perfect score: 595  
Sequence: 1 DIVMTQSPSLPVTGPEPAS.....CFQGSHPVWTFQGQTKVEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications AA New:\*

- 1: /cgn2\_6/prodata/1/pubpaa/US08\_NEW\_PUB.pep.\*
- 2: /cgn2\_6/prodata/1/pubpaa/US06\_NEW\_PUB.pep.\*
- 3: /cgn2\_6/prodata/1/pubpaa/US07\_NEW\_PUB.pep.\*
- 4: /cgn2\_6/prodata/1/pubpaa/PCT\_NEW\_PUB.pep.\*
- 5: /cgn2\_6/prodata/1/pubpaa/US09\_NEW\_PUB.pep.\*
- 6: /cgn2\_6/prodata/1/pubpaa/US10\_NEW\_PUB.pep.\*
- 7: /cgn2\_6/prodata/1/pubpaa/US11\_NEW\_PUB.pep.\*
- 8: /cgn2\_6/prodata/1/pubpaa/US60\_NEW\_PUB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	595	100.0	112	7	US-11-012-353-65
2	595	100.0	131	7	US-11-012-353-67
3	594	99.8	112	7	US-11-012-353-61
4	594	99.8	131	7	US-11-012-353-63
5	547	91.9	112	6	US-10-959-310-26
6	546	91.8	112	6	US-10-959-310-33
7	544	91.4	112	6	US-10-959-310-34
8	543	91.3	112	6	US-10-959-310-35
9	537	90.3	112	7	US-11-012-353-54
10	537	90.3	122	7	US-11-012-353-49
11	530	89.1	112	7	US-11-012-353-56
12	523	87.9	131	7	US-11-125-837-23
13	521	87.6	263	7	US-11-089-266-66
14	519	87.2	112	7	US-11-012-353-55
15	519	87.2	112	7	US-11-012-353-57
16	519	87.2	149	7	US-11-089-266-2
17	517	86.9	116	7	US-11-065-943-49
18	516	86.7	113	6	US-10-932-334-61
19	514	86.4	112	7	US-11-089-266-15
20	513	86.2	113	6	US-10-932-334-69
21	511	85.9	113	6	US-10-932-334-66
22	511	85.9	113	6	US-10-932-334-68
23	510	85.7	113	6	US-10-932-334-9
24	510	85.7	113	6	US-10-932-334-12
25	510	85.7	113	6	US-10-932-334-83

26	510	85.7	113	6	US-10-932-334-86	Sequence 86, Appl
27	510	85.7	113	6	US-10-932-334-90	Sequence 90, Appl
28	509	85.5	113	6	US-10-932-334-65	Sequence 65, Appl
29	509	85.5	251	6	US-10-512-184-30	Sequence 30, Appl
30	509	85.5	320	6	US-10-512-184-67	Sequence 67, Appl
31	509	85.5	569	6	US-10-512-184-66	Sequence 66, Appl
32	509	85.5	618	6	US-10-512-184-48	Sequence 48, Appl
33	508	85.4	113	6	US-10-932-334-60	Sequence 60, Appl
34	507	85.2	113	6	US-10-932-334-10	Sequence 10, Appl
35	507	85.2	113	6	US-10-932-334-11	Sequence 11, Appl
36	507	85.2	113	6	US-10-932-334-59	Sequence 59, Appl
37	507	85.2	113	6	US-10-932-334-84	Sequence 84, Appl
38	507	85.2	113	6	US-10-932-334-85	Sequence 85, Appl
39	507	85.2	113	6	US-10-932-334-94	Sequence 94, Appl
40	502	84.4	113	6	US-10-932-334-8	Sequence 8, Appl
41	502	84.4	113	6	US-10-932-334-58	Sequence 58, Appl
42	502	84.4	113	6	US-10-932-334-62	Sequence 62, Appl
43	502	84.4	113	6	US-10-932-334-82	Sequence 82, Appl
44	502	84.4	132	6	US-10-932-334-50	Sequence 50, Appl
45	501	84.2	112	7	US-11-012-353-58	Sequence 58, Appl

ALIGNMENTS

RESULT 1  
US-11-012-353-65  
; Sequence 65, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFLOS, ALAIN  
; APPLICANT: HAEUW, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012,353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: PatentIn Ver. 3.3  
; SEQ ID NO 65  
; TYPE: PRT  
; LENGTH: 112  
; ORGANISM: Homo sapiens  
US-11-012-353-65

Query Match 100.0%; Score 595; DB 7; Length 112;  
Best Local Similarity 100.0%; Pred. No. 2.8e-40;  
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLOWYLPKQPSQSPQLLIYKVSRL	60
Db	1	DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLOWYLPKQPSQSPQLLIYKVSRL	60
Qy	61	YGVDPDRFSGSGGTDFTLKISRVEADVGYYCFQGSHPVWTFQGQTKVEIK	112
Db	61	YGVDPDRFSGSGGTDFTLKISRVEADVGYYCFQGSHPVWTFQGQTKVEIK	112

```
RESULT 2
US-11-012-353-67
; Sequence 67, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; PRIOR FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 67
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-67

Query Match          100.0%; Score 595; DB 7; Length 131;
Best Local Similarity 100.0%; Pred. No. 3.2e-40;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1  DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 60
DB      20  DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 79

QY      61  YGVPPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
DB      80  YGVPPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 131

RESULT 3
US-11-012-353-61
; Sequence 61, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; PRIOR FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
```

```
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 61
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-61

Query Match          99.8%; Score 594; DB 7; Length 112;
Best Local Similarity 99.1%; Pred. No. 3.4e-40;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1  DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 60
DB      1  DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 60

QY      61  YGVPPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
DB      61  YGVPPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112

RESULT 4
US-11-012-353-63
; Sequence 63, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; PRIOR FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 63
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-63

Query Match          99.8%; Score 594; DB 7; Length 131;
Best Local Similarity 99.1%; Pred. No. 3.8e-40;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1  DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 60
DB      20  DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 79

QY      61  YGVPPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
DB      80  YGVPPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 131
```





```
QY 61 YGVDRFSGSGGTDFTLKISRVEAEDGCVYYCFQGSHPVPTFGGQTKVEIK 112
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVDRFSGSGGTDFTLKISRVEAEDLGVYYCFQGSHPVPTFGGQTKLEIK 112
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 12
US-11-125-837-23
; Sequence 23, Application US/11125837
; Publication No. US20050266003A1
; GENERAL INFORMATION:
; APPLICANT: Chang, Chung Nan
; APPLICANT: Lin, Rong-Hwa
; APPLICANT: Chen, Pei-Jiun
; APPLICANT: Huang, Chiu-Chen
; TITLE OF INVENTION: ANTIBODIES
; FILE REFERENCE: 13062-011001
; CURRENT APPLICATION NUMBER: US/11/125,837
; CURRENT FILING DATE: 2005-05-10
; PRIOR APPLICATION NUMBER: US 60/569,892
; PRIOR FILING DATE: 2004-05-10
; NUMBER OF SEQ ID NOS: 100
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-125-837-23

Query Match 87.9%; Score 523; DB 7; Length 131;
Best Local Similarity 86.6%; Pred. No. 1.2e-34;
Matches 97; Conservative 10; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSLPLSVPTGEPASISCRSSQSIHNSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 DVLMTQTPLSLPVSLGDAQISCRSSQSIHNSNGNTYLOWYLQKPGSPKLLIYKVSRL 79
      |||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 YGVDRFSGSGGTDFTLKISRVEAEDGCVYYCFQGSHPVPTFGGQTKVEIK 112
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 SGVDRFSGSGGTDFTLKISRVEAEDLGVYYCFQGSHPVPTFGGQTKLEIK 131
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 13
US-11-089-266-66
; Sequence 66, Application US/11089266
; Publication No. US20050287148A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TITLE OF INVENTION: TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FORSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/11/089,266
; FILING DATE: 23-Mar-2005
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/153,401
; FILING DATE: 27-Aug-2002
; APPLICATION NUMBER: US 09/293,533
; FILING DATE: 1999-04-15
```

```
; APPLICATION NUMBER: US 08/372,676
; FILING DATE: 1995-01-17
; APPLICATION NUMBER: US 08/591,196
; FILING DATE: 1996-01-16
; ATTORNEY/AGENT INFORMATION:
; NAME: Catherine M. Polizzi
; REGISTRATION NUMBER: 40,130
; REFERENCE/DOCKET NUMBER: 304142000202
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 263 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-11-089-266-66

Query Match 87.6%; Score 521; DB 7; Length 263;
Best Local Similarity 86.6%; Pred. No. 3e-34;
Matches 97; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 1 DIVMTQSLPLSVPTGEPASISCRSSQSIHNSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 152 DVLMTQTPLSLPVSLGDAQISCRSSQSIHNSNGNTYLOWYLQKPGSPNLLIYFVSNRF 211
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 YGVDRFSGSGGTDFTLKISRVEAEDGCVYYCFQGSHPVPTFGGQTKVEIK 112
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 212 SGVDRFSGSGGTDFTLKISRVEAEDLGVYYCFQGSHPVPTFGGQTKLEIK 263
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 14
US-11-012-353-55
; Sequence 55, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUM, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 55
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-55

Query Match 87.2%; Score 519; DB 7; Length 112;
Best Local Similarity 85.7%; Pred. No. 2.1e-34;
Matches 96; Conservative 11; Mismatches 5; Indels 0; Gaps 0;
```



GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 61.4328 Seconds  
(without alignments)  
761.757 Million cell updates/sec

Title: US-10-735-916A-65  
Perfect score: 595  
Sequence: 1 DIVMTQSPSLPVTGPEPAS.....CFQGSHPVPTFGQTKVEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications AA\_Main:  
1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*  
3: /cgn2\_6/ptodata/1/pubpaa/US09\_PUBCOMB.pep.\*  
4: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*  
5: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*  
6: /cgn2\_6/ptodata/1/pubpaa/US11\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	595	100.0	112	US-10-735-916A-65	Sequence 65, Appl
2	595	100.0	131	US-10-735-916A-67	Sequence 67, Appl
3	594	99.8	112	US-10-735-916A-61	Sequence 61, Appl
4	594	99.8	131	US-10-735-916A-63	Sequence 63, Appl
5	564	94.8	112	US-10-308-817-182	Sequence 182, App
6	564	94.8	112	US-10-453-698-182	Sequence 182, App
7	564	94.8	112	US-10-434-469-19	Sequence 19, Appl
8	564	94.8	112	US-10-482-105-17	Sequence 17, Appl
9	564	94.8	112	US-10-500-207A-19	Sequence 19, Appl
10	562	94.5	112	US-10-258-728-28	Sequence 28, Appl
11	559	93.9	112	US-10-500-207A-47	Sequence 47, Appl
12	559	93.9	132	US-10-388-214A-6	Sequence 6, Appli
13	558	93.8	112	US-10-258-728-27	Sequence 27, Appl
14	557	93.6	112	US-10-258-728-26	Sequence 26, Appl
15	557	93.6	112	US-10-500-207A-46	Sequence 46, Appl
16	556	93.4	112	US-10-434-469-41	Sequence 41, Appl
17	556	93.4	112	US-10-482-105-39	Sequence 39, Appl
18	556	93.4	112	US-10-858-855-7	Sequence 7, Appli
19	556	93.4	112	US-10-500-207A-44	Sequence 44, Appl
20	552	92.8	112	US-10-500-207A-42	Sequence 42, Appl
21	549	92.3	112	US-10-308-817-180	Sequence 180, App
22	549	92.3	112	US-10-453-698-180	Sequence 180, App
23	547	91.9	112	US-10-453-698-181	Sequence 8, Appli
24	547	91.9	112	US-10-453-698-181	Sequence 181, App
25	547	91.9	112	US-10-505-980-12	Sequence 12, Appl
26	547	91.9	112	US-10-500-207A-51	Sequence 51, Appl
27	546	91.8	112	US-10-231-452-12	Sequence 12, Appl

28	546	91.8	112	5	US-10-505-980-19	Sequence 19, Appl
29	546	91.8	112	5	US-10-500-207A-45	Sequence 45, Appl
30	545	91.6	112	5	US-10-500-207A-43	Sequence 43, Appl
31	544	91.4	112	4	US-10-231-452-13	Sequence 13, Appl
32	544	91.4	112	5	US-10-505-980-20	Sequence 20, Appl
33	544	91.4	116	3	US-09-753-436-66	Sequence 66, Appl
34	544	91.4	116	4	US-10-163-942-66	Sequence 66, Appl
35	544	91.4	116	5	US-10-745-115-66	Sequence 66, Appl
36	543	91.3	112	4	US-10-231-452-14	Sequence 14, Appl
37	543	91.3	112	4	US-10-434-469-40	Sequence 40, Appl
38	543	91.3	112	5	US-10-482-105-38	Sequence 38, Appl
39	543	91.3	112	5	US-10-505-980-21	Sequence 21, Appl
40	543	91.3	112	5	US-10-500-207A-50	Sequence 50, Appl
41	543	91.3	131	3	US-09-947-839-95	Sequence 95, Appl
42	538	90.4	112	4	US-10-434-469-21	Sequence 21, Appl
43	538	90.4	112	5	US-10-482-105-19	Sequence 19, Appl
44	538	90.4	112	5	US-10-500-207A-21	Sequence 21, Appl
45	537	90.3	112	5	US-10-735-916A-54	Sequence 54, Appl

ALIGNMENTS

RESULT 1  
US-10-735-916A-65  
; Sequence 65, Application US/10735916A  
; Publication No. US20050084906A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETTSCH, Liliane  
; APPLICANT: CORVAIA, Nathalie  
; APPLICANT: LEGER, Olivier  
; APPLICANT: DUFLOS, Alain  
; APPLICANT: BECK, Alain  
; APPLICANT: HAEUM, Jean-Francois  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 01753-183  
; CURRENT APPLICATION NUMBER: US/10735,916A  
; CURRENT FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 03/08 538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 02/00 653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/00 654  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/05 753  
; PRIOR FILING DATE: 2002-05-07  
; NUMBER OF SEQ ID NOS: 156  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 65  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; US-10-735-916A-65

Query Match	100.0%	Score 595;	DB 5;	Length 112;
Best Local Similarity	100.0%	Pred. No. 1.5e-46;		
Matches 112;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	DIVMTQSPSLPVTGPEPASISCRSSQIVHSNGNTYLOWLYQKPGQSPOLLIIYKVSRL	60	
Db	1	DIVMTQSPSLPVTGPEPASISCRSSQIVHSNGNTYLOWLYQKPGQSPOLLIIYKVSRL	60	
QY	61	YGVPDRFSGSGGTDTLTIKISRVEADGVVYFCQGSHPVPTFGGTVKVEIK	112	
Db	61	YGVPDRFSGSGGTDTLTIKISRVEADGVVYFCQGSHPVPTFGGTVKVEIK	112	

RESULT 2  
US-10-735-916A-67  
; Sequence 67, Application US/10735916A  
; Publication No. US20050084906A1

GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 67  
LENGTH: 131  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-735-916A-67

Query Match 100.0%; Score 595; DB 5; Length 131;  
Best Local Similarity 100.0%; Pred. No. 1.8e-46;  
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLOKPGSPQLLIYKVSRL 60  
DB 20 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLOKPGSPQLLIYKVSRL 79  
QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
DB 80 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 131

RESULT 3  
US-10-735-916A-61  
Sequence 61, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 61  
LENGTH: 112  
TYPE: PRT  
ORGANISM: Homo sapiens

US-10-735-916A-61  
Query Match 99.8%; Score 594; DB 5; Length 112;  
Best Local Similarity 99.1%; Pred. No. 1.9e-46;  
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLOKPGSPQLLIYKVSRL 60  
DB 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLOKPGSPQLLIYKVSRL 60  
QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
DB 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
RESULT 4  
US-10-735-916A-63  
Sequence 63, Application US/10735916A  
Publication No. US20050084906A1  
GENERAL INFORMATION:  
APPLICANT: GOETSCH, Liliane  
APPLICANT: CORVAIA, Nathalie  
APPLICANT: LEGER, Olivier  
APPLICANT: DUFLOS, Alain  
APPLICANT: BECK, Alain  
APPLICANT: HAEUW, Jean-Francois  
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
FILE REFERENCE: 017753-183  
CURRENT APPLICATION NUMBER: US/10/735,916A  
CURRENT FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 03/08 538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 02/00 653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/00 654  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 02/05 753  
PRIOR FILING DATE: 2002-05-07  
NUMBER OF SEQ ID NOS: 156  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 63  
LENGTH: 131  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-735-916A-63

Query Match 99.8%; Score 594; DB 5; Length 131;  
Best Local Similarity 99.1%; Pred. No. 2.2e-46;  
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLOKPGSPQLLIYKVSRL 60  
DB 20 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLOKPGSPQLLIYKVSRL 79  
QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
DB 80 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 131  
RESULT 5  
US-10-308-817-182  
Sequence 182, Application US/10308817  
Publication No. US20030219861A1  
GENERAL INFORMATION:  
APPLICANT: Rother, Russell  
APPLICANT: Wu, Dayang  
TITLE OF INVENTION: HYBRID ANTIBODIES  
FILE REFERENCE: 1087-37  
CURRENT APPLICATION NUMBER: US/10/308,817  
CURRENT FILING DATE: 2002-12-03  
NUMBER OF SEQ ID NOS: 195

; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 182  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: human  
US-10-308-817-182

Query Match 94.8%; Score 564; DB 4; Length 112;  
Best Local Similarity 94.6%; Pred. No. 1e-43;  
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
|||  
DB 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
|||  
QY 61 YGVPRFSGSGGTDFTLKISRVEADVGYYTCFQGSHPVPTFGGTKVEIK 112  
|||  
DB 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYTCFQGSHPVPTFGGTKVEIK 112  
|||

## RESULT 6

US-10-453-698-182  
; Sequence 182, Application US/10453698  
; Publication No. US20040038308A1  
; GENERAL INFORMATION:

; APPLICANT: Rother, Russell  
; TITLE OF INVENTION: HYBRID ANTIBODIES  
; FILE REFERENCE: 82 CIP (1087-37 CIP)  
; CURRENT APPLICATION NUMBER: US/10/453,698  
; CURRENT FILING DATE: 2003-06-03  
; NUMBER OF SEQ ID NOS: 196

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 182  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: human  
US-10-453-698-182

Query Match 94.8%; Score 564; DB 4; Length 112;  
Best Local Similarity 94.6%; Pred. No. 1e-43;  
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
|||  
DB 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
|||  
QY 61 YGVPRFSGSGGTDFTLKISRVEADVGYYTCFQGSHPVPTFGGTKVEIK 112  
|||  
DB 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYTCFQGSHPVPTFGGTKVEIK 112  
|||

## RESULT 7

US-10-434-469-19  
; Sequence 19, Application US/10434469  
; Publication No. US20040091480A1  
; GENERAL INFORMATION:

; APPLICANT: Nobuo HANAI  
; APPLICANT: Motoo YAMASAKI  
; APPLICANT: Akiko FURUYA  
; APPLICANT: Akira TANAKA  
; APPLICANT: Naoki SHIMADA  
; TITLE OF INVENTION: Anti-fibroblast growth factor-8 monoclonal antibody  
; FILE REFERENCE: 249-310  
; CURRENT APPLICATION NUMBER: US/10/434,469  
; CURRENT FILING DATE: 2003-05-09

; PRIOR APPLICATION NUMBER: JP 08-081754  
; PRIOR FILING DATE: 1996-04-03  
; PRIOR APPLICATION NUMBER: US 08/832,236  
; PRIOR FILING DATE: 1997-04-03  
; PRIOR APPLICATION NUMBER: US 09/326,590  
; PRIOR FILING DATE: 1999-06-07  
; PRIOR APPLICATION NUMBER: US 09/876,040

; PRIOR FILING DATE: 2001-06-08  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 19  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: VL synthetic peptide  
US-10-434-469-19

Query Match 94.8%; Score 564; DB 4; Length 112;  
Best Local Similarity 94.6%; Pred. No. 1e-43;  
Matches 106; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
|||  
DB 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
|||  
QY 61 YGVPRFSGSGGTDFTLKISRVEADVGYYTCFQGSHPVPTFGGTKVEIK 112  
|||  
DB 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYTCFQGSHPVPTFGGTKVEIK 112  
|||

## RESULT 8

US-10-482-105-17  
; Sequence 17, Application US/10482105  
; Publication No. US20040253234A1  
; GENERAL INFORMATION:

; APPLICANT: KYOWA HAKKO KOGYO CO., LTD  
; TITLE OF INVENTION: Humanized anti-FGF-8 antibody and the antibody fragment thereof  
; FILE REFERENCE: 11399WO1  
; CURRENT APPLICATION NUMBER: US/10/482,105  
; CURRENT FILING DATE: 2003-12-24  
; PRIOR APPLICATION NUMBER: JP2001-196176  
; PRIOR FILING DATE: 2001-06-28  
; NUMBER OF SEQ ID NOS: 41  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 17  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: synthetic protein  
US-10-482-105-17

Query Match 94.8%; Score 564; DB 5; Length 112;  
Best Local Similarity 94.6%; Pred. No. 1e-43;  
Matches 106; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
|||  
DB 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
|||  
QY 61 YGVPRFSGSGGTDFTLKISRVEADVGYYTCFQGSHPVPTFGGTKVEIK 112  
|||  
DB 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYTCFQGSHPVPTFGGTKVEIK 112  
|||

## RESULT 9

US-10-500-207A-19  
; Sequence 19, Application US/10500207A  
; Publication No. US20050175608A1  
; GENERAL INFORMATION:

; APPLICANT: KYOWA HAKKO KOGYO CO., LTD  
; TITLE OF INVENTION: AGENT FOR TREATING ARTHRITIS  
; FILE REFERENCE: 1442  
; CURRENT APPLICATION NUMBER: US/10/500,207A  
; CURRENT FILING DATE: 2004-06-28  
; PRIOR APPLICATION NUMBER: JP2001-400677  
; PRIOR FILING DATE: 2001-12-28  
; NUMBER OF SEQ ID NOS: 51  
; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 19  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: LV.0, a designed amino acid sequence of VL of  
; OTHER INFORMATION: an anti-FGF-8 CDR-grafted neutralizing antibody  
US-10-500-207A-19

Query Match 94.8%; Score 564; DB 5; Length 112;  
Best Local Similarity 94.6%; Pred. No. 1e-43; Mismatches 4; Indels 0; Gaps 0;  
Matches 106; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
QY 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60  
Db 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRI 60  
QY 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
Db 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112

## RESULT 10

US-10-258-728-28  
; Sequence 28, Application US/10258728  
; Publication No. US20040091485A1  
; GENERAL INFORMATION:  
; APPLICANT: Ellis, John Robert Maxwell  
; APPLICANT: Durrant, Linda Gillian  
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor  
; FILE REFERENCE: 28438-101US01  
; CURRENT APPLICATION NUMBER: US/10/258,728  
; CURRENT FILING DATE: 2003-06-18  
; PRIOR APPLICATION NUMBER: GB 0011981.8  
; PRIOR FILING DATE: 2000-05-19  
; PRIOR APPLICATION NUMBER: GB 0020794.4  
; PRIOR FILING DATE: 2000-08-24  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 28  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-10-258-728-28

Query Match 94.5%; Score 562; DB 4; Length 112;  
Best Local Similarity 92.9%; Pred. No. 1.5e-43;  
Matches 104; Conservative 4; Mismatches 4; Indels 0; Gaps 0;  
QY 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60  
Db 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRI 60  
QY 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
Db 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112

## RESULT 11

US-10-500-207A-47  
; Sequence 47, Application US/10500207A  
; Publication No. US20050175608A1  
; GENERAL INFORMATION:  
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD  
; TITLE OF INVENTION: AGENT FOR TREATING ARTHRITIS  
; FILE REFERENCE: 1442  
; CURRENT APPLICATION NUMBER: US/10/500,207A  
; CURRENT FILING DATE: 2004-06-28  
; PRIOR APPLICATION NUMBER: JP2001-400677  
; PRIOR FILING DATE: 2001-12-28  
; NUMBER OF SEQ ID NOS: 51  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 47

; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: LV.2-2, a designed amino acid sequence of VL of  
; OTHER INFORMATION: an anti-FGF-8 CDR-grafted neutralizing antibody  
US-10-500-207A-47

Query Match 93.9%; Score 559; DB 5; Length 112;  
Best Local Similarity 92.9%; Pred. No. 2.9e-43;  
Matches 104; Conservative 6; Mismatches 2; Indels 0; Gaps 0;  
QY 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60  
Db 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRI 60  
QY 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
Db 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112

## RESULT 12

US-10-388-214A-6  
; Sequence 6, Application US/10388214A  
; Publication No. US20040082762A1  
; GENERAL INFORMATION:  
; APPLICANT: Basi, Gurig  
; APPLICANT: Saidanha, Jose  
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA  
; FILE REFERENCE: ELN-004  
; CURRENT APPLICATION NUMBER: US/10/388,214A  
; CURRENT FILING DATE: 2003-03-12  
; PRIOR APPLICATION NUMBER: US 60/363,751  
; PRIOR FILING DATE: 2002-03-12  
; NUMBER OF SEQ ID NOS: 38  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 6  
; LENGTH: 132  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: humanized 12BaVLv1  
; NAME/KEY: SIGNAL  
; LOCATION: (1)...(20)  
US-10-388-214A-6

Query Match 93.9%; Score 559; DB 4; Length 132;  
Best Local Similarity 93.8%; Pred. No. 3.4e-43;  
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;  
QY 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60  
Db 21 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRI 80  
QY 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
Db 81 SGVPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKLEIK 132

## RESULT 13

US-10-258-728-27  
; Sequence 27, Application US/10258728  
; Publication No. US20040091485A1  
; GENERAL INFORMATION:  
; APPLICANT: Ellis, John Robert Maxwell  
; APPLICANT: Durrant, Linda Gillian  
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor  
; FILE REFERENCE: 28438-101US01  
; CURRENT APPLICATION NUMBER: US/10/258,728  
; CURRENT FILING DATE: 2003-06-18  
; PRIOR APPLICATION NUMBER: GB 0011981.8

```

; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0020794.4
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-27

```

		Query Match	93.8%	Score 558;	DB 4;	Length 112;	
		Best Local Similarity	92.0%;	Pred. No. 3.5e-43;			
		Matches 103;	Conservative	4;	Mismatches	5;	Indels 0; Gaps 0;
<hr/>							
Qy	1	DVWMTQSPLSLPTVPGPASISCRSSQSI	VHNSNGNTYLQWLYLQPGSQPLLIIKVSNRL	60			
		:::::	:::::				
Db	1	DVLMTQPSLSLPTVPGPASACRSSQSI	VHNSNGNTYLEWLQPGSQPLLIIKVSNR	60			
<hr/>							
Qy	61	YGVPDRFSGSGSGLTDFLTKISRVAEDVGVIYCFQGSHPVPTFCGKTVEIK	112				
<hr/>							
Db	61	SGVPDRFSGSGSGLTDFLTKISRVAEDGIYICFGSHVPWTFGGGTKEIK	112				

```

RESULT 14
US-10-258-728-26
; Sequence 26, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Ellis, John Robert Maxwell
; APPLICANT: Durrant, Linda Gillian
; TITLE OF INVENTION: Humanized Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0020794.4
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-26

```

Query Match	93.6%	Score 557	DB 4	Length 112
Best Local Similarity	92.0%	Pred. No. 4.4e-4		
Matches 103	Conservative 4	Mismatches 5	Indels 0	Gaps 0
Qy	1	DVMTQSPFLSLPVTGPGPASISCRSSOSIVHSNGNTYLQWYLRKPGSGPQLLIYKVSNRL	60	
	:	:	:	:
Db	1	DVLTQSPFLSLPVTGPGPASISCRSSQSLVHSNGNTYLEWYLRKPGSGPQLLIYKVSNRF	60	
Qy	61	YGVDPDRFGSGSGDFTLKISRVAEADGVYYICFGSHVPTFGGTVKVEIK	112	
Db	61	SGVDPDRFGSGSGDFTLKISRVAEADGVYYICFGSHVPTFGGTVKVEIK	112	

RESULT 15  
US-10-500-207A-46  
; Sequence 46, Application US/10500207A  
; Publication No. US20050175608A1  
; GENERAL INFORMATION:  
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD  
; TITLE OF INVENTION: AGENT FOR TREATING ARTHRITIS  
; FILE REFERENCE: 1442  
; CURRENT APPLICATION NUMBER: US/10/500,207A  
; CURRENT FILING DATE: 2004-06-28  
; PRIOR APPLICATION NUMBER: JP2001-400677  
; PRIOR FILING DATE: 2001-12-28  
; NUMBER OF SEQ ID NOS: 51

```

; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 46
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: LV.2-1, a designed amino acid sequence of VL of
; OTHER INFORMATION: an anti-FG-8 CDR-grafted neutralizing antibody
US-10-500-207A-46

Query Match          93.6%  Score 557;  DB 5;  Length 112;
Best Local Similarity 92.9%; Pred. No. 4.4e-43;
Matches 104; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      1  DIVMTQSPLSLPTPGEPASISCRSSQSIVHNSNGNTYLQWYLOKPGSGPQLLIYKVSNRL 60
        | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      1  DIVMTQSPLSLPTPGEPASISCRSSQSIVHNSNGRTYLEWYLOKPGSGPQVLIYKVSNRI 60
        | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY      61  YGVDPDRFSGSGSGTDFTLKISRVEADGVVYFCQGSHPVPTFGGKTVEIK 112
        | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      61  SGVDPDRFSGSGSGTDFTLKISRVEADGVVYFCQGSHPVPTFGGKTVEIK 112
        | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Search completed: January 10, 2006, 21:35:31
Job time : 62.4328 secs

```

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 21.8706 Seconds  
(without alignments)  
423.384 Million cell updates/sec

Title: US-10-735-916A-65  
Perfect score: 595  
Sequence: 1 DIVMTQSLPLVTPGPAS.....CFQGSHPVMTFGQTKVEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/ptodata/1/1aa/5 COMB.pep.\*  
2: /cgn2\_6/ptodata/1/1aa/6 COMB.pep.\*  
3: /cgn2\_6/ptodata/1/1aa/H COMB.pep.\*  
4: /cgn2\_6/ptodata/1/1aa/pCTUS COMB.pep.\*  
5: /cgn2\_6/ptodata/1/1aa/RE COMB.pep.\*  
6: /cgn2\_6/ptodata/1/1aa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	559	93.9	112	1 US-08-331-398A-50	Sequence 50, Appl
2	559	93.9	112	1 US-08-331-397B-50	Sequence 50, Appl
3	559	93.9	112	1 US-08-759-804A-50	Sequence 50, Appl
4	559	93.9	112	2 US-09-227-693-50	Sequence 50, Appl
5	557	93.6	112	2 US-08-053-171-15	Sequence 15, Appl
6	557	93.6	112	2 US-08-815-190A-14	Sequence 14, Appl
7	544	91.4	116	1 US-08-482-882-66	Sequence 66, Appl
8	544	91.4	116	1 US-08-483-389-66	Sequence 66, Appl
9	544	91.4	116	1 US-08-487-113D-66	Sequence 66, Appl
10	544	91.4	116	1 US-08-473-503-66	Sequence 66, Appl
11	544	91.4	116	1 US-08-483-932-66	Sequence 66, Appl
12	544	91.4	116	1 US-08-720-420A-66	Sequence 66, Appl
13	544	91.4	116	2 US-08-714-017-66	Sequence 66, Appl
14	544	91.4	116	2 US-08-475-680-66	Sequence 66, Appl
15	543	91.3	131	1 US-08-129-930B-95	Sequence 95, Appl
16	543	91.3	131	2 US-08-134-346A-50	Sequence 50, Appl
17	543	91.3	131	2 US-08-976-288A-95	Sequence 95, Appl
18	527	88.6	112	1 US-08-478-039-88	Sequence 88, Appl
19	527	88.6	112	1 US-08-476-349A-88	Sequence 88, Appl
20	521	87.6	149	2 US-09-192-838B-2	Sequence 2, Appl
21	521	87.6	149	2 US-09-324-191-2	Sequence 2, Appl
22	521	87.6	263	1 US-08-752-844-66	Sequence 66, Appl
23	521	87.6	263	2 US-09-293-533-66	Sequence 66, Appl
24	519	87.2	112	1 US-08-331-398A-48	Sequence 48, Appl
25	519	87.2	112	1 US-08-077-252B-3	Sequence 3, Appl
26	519	87.2	112	1 US-08-331-397B-48	Sequence 48, Appl
27	519	87.2	112	1 US-08-759-804A-48	Sequence 48, Appl

28	519	87.2	112	2 US-09-002-753A-3	Sequence 3, Appl
29	519	87.2	112	2 US-09-227-693-48	Sequence 48, Appl
30	519	87.2	112	2 US-09-657-274-3	Sequence 3, Appl
31	519	87.2	112	4 PCT-US94-06687-3	Sequence 3, Appl
32	519	87.2	125	1 US-08-331-398A-67	Sequence 67, Appl
33	519	87.2	125	1 US-08-331-397B-67	Sequence 67, Appl
34	519	87.2	125	1 US-08-759-804A-66	Sequence 66, Appl
35	519	87.2	149	1 US-08-752-844-2	Sequence 2, Appl
36	519	87.2	149	1 US-08-591-196-2	Sequence 2, Appl
37	519	87.2	149	2 US-09-293-533-2	Sequence 2, Appl
38	519	87.2	247	2 US-09-227-693-34	Sequence 34, Appl
39	519	87.2	248	1 US-08-331-398A-34	Sequence 34, Appl
40	519	87.2	248	1 US-08-331-397B-34	Sequence 34, Appl
41	519	87.2	248	1 US-08-759-804A-34	Sequence 34, Appl
42	517	86.9	112	1 US-08-859-649-19	Sequence 19, Appl
43	517	86.9	112	1 US-08-859-649-29	Sequence 29, Appl
44	517	86.9	112	2 US-08-207-861-19	Sequence 19, Appl
45	517	86.9	112	2 US-08-207-861-29	Sequence 29, Appl

ALIGNMENTS

RESULT 1  
US-08-331-398A-50  
; Sequence 50, Application US/08331398A  
; Patent No. 5608039  
; GENERAL INFORMATION:  
; APPLICANT: Pastan, Ira  
; APPLICANT: Willingham, Mark  
; APPLICANT: Fitzgerald, David  
; APPLICANT: Brinkmann, Ulrich  
; APPLICANT: Fai, Lee  
; TITLE OF INVENTION: Single Chain B3 Antibody Fusion Proteins  
; TITLE OF INVENTION: and Their Uses (as amended)  
; NUMBER OF SEQUENCES: 68  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew  
; STREET: One Market Plaza, Steuart Street Plaza  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94105-1492

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICANT NUMBER: US/08/331.398A  
FILING DATE: 28-OCT-1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/767,331  
FILING DATE: 30-SEP-1991  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/596,289  
FILING DATE: 12-OCT-1990  
ATTORNEY/AGENT INFORMATION:  
NAME: Hunter, Tom  
REGISTRATION NUMBER: 38,498  
REFERENCE/DOCKET NUMBER: 015280-1261100S  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 543-9600  
TELEFAX: (415) 543-5043  
INFORMATION FOR SEQ ID NO: 50:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 112 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
FEATURE:

```
; NAME/KEY: Protein
; LOCATION: 1..112
; OTHER INFORMATION: /note= "Humanized B3 Variable Light
; OTHER INFORMATION: chain (V-L) (HumB3V-L)"
US-08-331-398A-50

Query Match
Best Local Similarity 93.9%; Score 559; DB 1; Length 112;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPGSPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVLMTQSPSLPVTGPGSPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFGSGSGTDFTLKISRVEADVGYYCFQGSHPVPTFGGQTKVEIK 112
Db 61 SGVDPDRFGSGSGTDFTLKISRVEADVGYYCFQGSHPVPTFGGQTKVEIK 112

RESULT 3
US-08-759-804A-50
; Sequence 50, Application US/08759804A
; Patent No. 5990296
; GENERAL INFORMATION:
; APPLICANT: Pastan, Ira
; APPLICANT: Willingham, Mark
; APPLICANT: FitzGerald, David J.
; APPLICANT: Brinkmann, Ulrich
; APPLICANT: Pai, Lee
; TITLE OF INVENTION: Tumor-Specific Antibody Fragments,
; TITLE OF INVENTION: Fusion Proteins, and Uses Thereof
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US 08/331,398
; FILING DATE: 28-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/767,331
; FILING DATE: 30-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/596,289
; FILING DATE: 12-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen L.
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 015280-126140US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..112
; OTHER INFORMATION: /note= "Humanized B3 Variable Light
; OTHER INFORMATION: chain (V-L) (HumB3V-L)"
US-08-759-804A-50

Query Match
93.9%; Score 559; DB 1; Length 112;

; NAME/KEY: Protein
; LOCATION: 1..112
; OTHER INFORMATION: /note= "Humanized B3 Variable Light
; OTHER INFORMATION: chain (V-L) (HumB3V-L)"
US-08-331-397B-50

Query Match
Best Local Similarity 93.8%; Pred. No. 2.6e-47;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPGSPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVLMTQSPSLPVTGPGSPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFGSGSGTDFTLKISRVEADVGYYCFQGSHPVPTFGGQTKVEIK 112
Db 61 SGVDPDRFGSGSGTDFTLKISRVEADVGYYCFQGSHPVPTFGGQTKVEIK 112

RESULT 2
US-08-331-397B-50
; Sequence 50, Application US/08331397B
; Patent No. 5981726
; GENERAL INFORMATION:
; APPLICANT: Pastan, Ira
; APPLICANT: Benhar, Itai
; TITLE OF INVENTION: Chimeric and Mutationally Stabilized Tumor-
; TITLE OF INVENTION: Specific Antibody Fragments, Fusion Proteins, and Uses
; TITLE OF INVENTION: Thereof
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Stewart Street Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105-1492
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/331,397B
; FILING DATE: 28-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/767,331
; FILING DATE: 30-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/596,289
; FILING DATE: 12-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunter, Tom
; REGISTRATION NUMBER: 38,498
; REFERENCE/DOCKET NUMBER: 015280-126120US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 543-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..112
; OTHER INFORMATION: /note= "Humanized B3 Variable Light
; OTHER INFORMATION: chain (V-L) (HumB3V-L)"
US-08-331-397B-50
```

Best Local Similarity 93.8%; Pred. No. 2.6e-47; Mismatches 4; Indels 0; Gaps 0;  
Matches 105; Conservative

QY 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60

Db 1 DVLMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVDPFRFGSGSGTDTFTLKISRVEADVGVVYCFQGSHPVPTFGQGTKEIK 112

Db 61 SGVDPFRFGSGSGTDTFTLKISRVEADVGVVYCFQGSHPVPTFGQGTKEIK 112

## RESULT 4

US-09-227-693-50

; Sequence 50, Application US/09227693

; Patent No. 6287562

; GENERAL INFORMATION:

; APPLICANT: PASTAN, Ira

; APPLICANT: BENHAR, Itai

; APPLICANT: PADLAN, Eduardo A.

; APPLICANT: JUNG, Sun-Hee

; APPLICANT: LEE, Byungkook

; TITLE OF INVENTION: HUMANIZED TUMOR-SPECIFIC ANTIBODY

; NUMBER OF SEQUENCES: 50

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend Kourie and Crew

; STREET: Steuart Street Tower, One Market Plaza

; CITY: San Francisco

; STATE: California

; COUNTRY: US

; ZIP: 94105-1493

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/227,693

; FILING DATE:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/331,396

; FILING DATE:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/767,331

; FILING DATE: 30-SEP-1991

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/596,289

; FILING DATE: 12-OCT-1990

; ATTORNEY/AGENT INFORMATION:

; NAME: Weber, Ellen Lauver

; REGISTRATION NUMBER: 32,762

; REFERENCE/DOCKET NUMBER: 15280-126-1-3

; TELEPHONE: (415) 543-9600

; TELEFAX: (415) 543-5043

; INFORMATION FOR SEQ ID NO: 50:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 112 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; FEATURE:

; NAME/KEY: Protein

; LOCATION: 1..112

; OTHER INFORMATION: /note= "Humanized B3 VL region"

US-09-227-693-50

Query Match

Best Local Similarity 93.8%; Score 559; DB 2; Length 112;

Matches 105; Conservative .4; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60

Db 1 DVLMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVDPFRFGSGSGTDTFTLKISRVEADVGVVYCFQGSHPVPTFGQGTKEIK 112

Db 61 SGVDPFRFGSGSGTDTFTLKISRVEADVGVVYCFQGSHPVPTFGQGTKEIK 112

## RESULT 5

US-08-053-171-15

; Sequence 15, Application US/08053171

; Patent No. 5562903

; GENERAL INFORMATION:

; APPLICANT: Co, Loibner

; TITLE OF INVENTION: Antibody Derivatives

; NUMBER OF SEQUENCES: 32

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend Kourie and Crew

; STREET: 379 Lytton Avenue

; CITY: Palo Alto

; STATE: California

; COUNTRY: US

; ZIP: 94301

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/053,171

; FILING DATE: 22-APR-1993

; CLASSIFICATION: 424

; ATTORNEY/AGENT INFORMATION:

; NAME: Smith, William M

; REGISTRATION NUMBER: 30,223

; REFERENCE/DOCKET NUMBER: 11823-54-1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (415) 326-2400

; TELEFAX: (415) 326-2422

; INFORMATION FOR SEQ ID NO: 15:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 112 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; HYPOTHETICAL: NO

; FEATURE:

; NAME/KEY: Peptide

; LOCATION: 1..112

; OTHER INFORMATION: /note= "Sequence of the Light Chain

; Patent No. 5562903

; OTHER INFORMATION: of Humanized BR55-2 Antibody"

; FEATURE:

; NAME/KEY: Region

; LOCATION: 24..39

; OTHER INFORMATION: /note= "Complementarity-determining

; OTHER INFORMATION: region"

; FEATURE:

; NAME/KEY: Region

; LOCATION: 55..61

; OTHER INFORMATION: /note= "Complementarity-determining

; OTHER INFORMATION: region"

; FEATURE:

; NAME/KEY: Region

; LOCATION: 94..102

; OTHER INFORMATION: /note= "Complementarity-determining

; OTHER INFORMATION: region"

; FEATURE:

; NAME/KEY: Modified-site

; LOCATION: 54

; OTHER INFORMATION: /note= "Residue that has been

; OTHER INFORMATION: replaced with mouse amino acid in the humanized

```
; OTHER INFORMATION: antibody."
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 108
; OTHER INFORMATION: /note= "Residue in the framework
; OTHER INFORMATION: that is replaced with mouse amino acid in the
; OTHER INFORMATION: humanized antibody."
US-08-053-171-15

Query Match      93.6%; Score 557; DB 1; Length 112;
Best Local Similarity 94.6%; Pred. No. 4.1e-47;
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPVLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
DB 1 DIVMTQSPVLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGGTDTFLTKISRVEADVGVYVYCFQGSHPVPTFGGTKEIK 112
DB 61 SGVPRFSGSGGTDTFLTKISRVEADVGVYVYCFQGSHPVPTFGGTKEIK 112

RESULT 6
US-08-815-190A-14
; Sequence 14, Application US/08815190A
; Patent No. 6046310
; GENERAL INFORMATION:
; APPLICANT: Queen, Cary L.
; APPLICANT: Schneider, William P.
; APPLICANT: Vasquez, Maximiliano
; TITLE OF INVENTION: Fas Ligand Fusion Proteins and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/815,190A
; FILING DATE: 11-MAR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/614,584
; FILING DATE: 13-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 011823-00671005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..112
; OTHER INFORMATION: /note= "mature light chain variable
; OTHER INFORMATION: region of humanized ABL 364 antibody"
US-08-815-190A-14
```

```
Query Match      93.6%; Score 557; DB 2; Length 112;
Best Local Similarity 94.6%; Pred. No. 4.1e-47;
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPVLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
DB 1 DIVMTQSPVLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGGTDTFLTKISRVEADVGVYVYCFQGSHPVPTFGGTKEIK 112
DB 61 SGVPRFSGSGGTDTFLTKISRVEADVGVYVYCFQGSHPVPTFGGTKEIK 112

RESULT 7
US-08-482-982-66
; Sequence 66, Application US/08482882
; Patent No. 5773218
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/482,882
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5773218and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-482-982-66

Query Match      91.4%; Score 544; DB 1; Length 116;
Best Local Similarity 92.0%; Pred. No. 7.8e-46;
```

Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNGTYLQWYLOKPGQSPQLLIYKVSRL 60  
DB 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNGTYLHWYLOKPGQSPQLLIYKVSRL 64  
QY 61 YGVDPFRFSGSGTGDTFLTKISRVEADVGVVYCFQSGSHVPWTFGGTKVEIK 112  
DB 65 SGVDPFRFSGSGTGDTFLTKISRVEADVGVVYCSQSTHVPVTFGGTKVEIK 116

## RESULT 8

US-08-483-389-66  
; Sequence 66, Application US/08483389  
; Patent No. 5811517  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; APPLICANT: Vazeux, Rosemay  
; TITLE OF INVENTION: ICAM-RELATED PROTEIN  
; NUMBER OF SEQUENCES: 118  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 233 South Wacker Drive/6300 Sears Tower  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION NUMBER: US/08/483,389  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/102,852  
; FILING DATE: 05-AUG-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/009,266  
; FILING DATE: 22-JAN-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/894,061  
; FILING DATE: 05-JUN-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/889,724  
; FILING DATE: 26-MAY-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/827,689  
; FILING DATE: 27-JAN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Sub, Young J.  
; REGISTRATION NUMBER: P-41,337  
; REFERENCE/DOCKET NUMBER: 27866/32760  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (312) 474-6300  
; TELEFAX: (312) 474-0448  
; TELEX: (312) 474-6600  
; INFORMATION FOR SEQ ID NO: 66:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 116 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-483-389-66

Query Match 91.4%; Score 544; DB 1; Length 116;  
Best Local Similarity 92.0%; Pred. No. 7.8e-46;  
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNGTYLQWYLOKPGQSPQLLIYKVSRL 60  
DB 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNGTYLHWYLOKPGQSPQLLIYKVSRL 64

Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNGTYLHWYLOKPGQSPQLLIYKVSRL 64

QY 61 YGVDPFRFSGSGTGDTFLTKISRVEADVGVVYCFQSGSHVPWTFGGTKVEIK 112  
DB 65 SGVDPFRFSGSGTGDTFLTKISRVEADVGVVYCSQSTHVPVTFGGTKVEIK 116

## RESULT 9

US-08-487-113D-66  
; Sequence 66, Application US/08487113D  
; Patent No. 5837822  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; APPLICANT: Vazeux, Rosemay  
; TITLE OF INVENTION: ICAM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 120  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION NUMBER: US/08/487,113D  
; FILING DATE:  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/286,754  
; FILING DATE: 05-AUG-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/102,852  
; FILING DATE: 05-AUG-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/009,266  
; FILING DATE: 22-JAN-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/894,061  
; FILING DATE: 05-JUN-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/889,724  
; FILING DATE: 26-MAY-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/827,689  
; FILING DATE: 27-JAN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: No. 5837822and, Greta E.  
; REGISTRATION NUMBER: 35,302  
; REFERENCE/DOCKET NUMBER: 32744  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (312) 474-6300  
; TELEFAX: (312) 474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 66:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 116 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-487-113D-66

Query Match 91.4%; Score 544; DB 1; Length 116;  
Best Local Similarity 92.0%; Pred. No. 7.8e-46;  
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNGTYLQWYLOKPGQSPQLLIYKVSRL 60  
DB 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNGTYLHWYLOKPGQSPQLLIYKVSRL 64

QY 61 YGVDRFSGSGGTDFTLKISRVEAEDGVMYFCFGSHVPTFGQGTKEIK 112  
|||||  
Db 65 SGVDRFSGSGGTDFTLKISRVEAEDGVMYFCFGSHVPTFGQGTKEIK 116  
|||||

RESULT 10  
US-08-473-503-66  
; Sequence 66, Application US/08473503  
; Patent No. 5869262  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; APPLICANT: Vazeux, Rosemay  
; TITLE OF INVENTION: ICAM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 116  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 S. Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: USA  
; ZIP: 60606

; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/473,503  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/286,754  
; FILING DATE: 05-AUG-1994  
; APPLICATION NUMBER: US 08/102,852  
; FILING DATE: 05-AUG-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/009,266  
; FILING DATE: 22-JAN-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/894,061  
; FILING DATE: 05-JUN-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/899,724  
; FILING DATE: 26-MAY-1992

; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/827,689  
; FILING DATE: 27-JAN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: No. 5869262and, Greta E.  
; REGISTRATION NUMBER: 35,302  
; REFERENCE/DOCKET NUMBER: 32178  
; TELEPHONE: (312) 474-6300  
; TELEFAX: (312) 474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 66:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 116 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-473-503-66

Query Match 91.4%; Score 544; DB 1; Length 116;  
Best Local Similarity 92.0%; Pred. No. 7.8e-46;  
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSLSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLOKFGQSPQLLIYKVNRL 60  
|||||  
Db 5 DIVMTQSLSLPVTGEPASISCRSSQSLVHNSGDTYLYHWYLOKFGQSPQLLIYKVNRF 64  
|||||  
QY 61 YGVDRFSGSGGTDFTLKISRVEAEDGVMYFCFGSHVPTFGQGTKEIK 112

Db 65 SGVDRFSGSGGTDFTLKISRVEAEDGVMYFCFGSHVPTFGQGTKEIK 116  
|||||

RESULT 11  
US-08-483-932-66  
; Sequence 66, Application US/08483932  
; Patent No. 5880268  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; APPLICANT: Vazeux, Rosemay  
; TITLE OF INVENTION: ICAM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 116  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 S. Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: USA  
; ZIP: 60606

; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/483,932  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 530

; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/286,754  
; FILING DATE: 05-AUG-1994  
; APPLICATION NUMBER: US 08/102,852  
; FILING DATE: 05-AUG-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/009,266  
; FILING DATE: 22-JAN-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/894,061  
; FILING DATE: 05-JUN-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/889,724  
; FILING DATE: 26-MAY-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/827,689  
; FILING DATE: 27-JAN-1992

; ATTORNEY/AGENT INFORMATION:  
; NAME: No. 5880268and, Greta E.  
; REGISTRATION NUMBER: 35,302  
; REFERENCE/DOCKET NUMBER: 32178  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (312) 474-6300  
; TELEFAX: (312) 474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 66:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 116 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-483-932-66

Query Match 91.4%; Score 544; DB 1; Length 116;  
Best Local Similarity 92.0%; Pred. No. 7.8e-46;  
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSLSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLOKFGQSPQLLIYKVNRL 60  
|||||  
Db 5 DIVMTQSLSLPVTGEPASISCRSSQSLVHNSGDTYLYHWYLOKFGQSPQLLIYKVNRF 64  
|||||  
QY 61 YGVDRFSGSGGTDFTLKISRVEAEDGVMYFCFGSHVPTFGQGTKEIK 112  
|||||  
Db 65 SGVDRFSGSGGTDFTLKISRVEAEDGVMYFCFGSHVPTFGQGTKEIK 116  
|||||

## RESULT 12

US-08-720-420A-66  
; Sequence 66, Application US/08720420A  
; Patent No. 5989843  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; APPLICANT: Vazeux, Rosemay  
; TITLE OF INVENTION: ICAM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 120  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/720,420A  
; FILING DATE:  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/487,113  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/286,754  
; FILING DATE: 05-AUG-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/102,852  
; FILING DATE: 05-AUG-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/009,266  
; FILING DATE: 22-JAN-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/894,061  
; FILING DATE: 05-JUN-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/889,724  
; FILING DATE: 26-MAY-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/827,689  
; FILING DATE: 27-JAN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Williams, Joseph A., Jr.  
; REGISTRATION NUMBER: 38,659  
; REFERENCE/DOCKET NUMBER: 33282  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (312) 474-6300  
; TELEFAX: (312) 474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 66:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 116 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-720-420A-66

Query Match 91.4%; Score 544; DB 1; Length 116;  
Best Local Similarity 92.0%; Pred. No. 7.8e-46;  
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHNSNGNTYQLQWYLQKPGQSPQLLIYKVSRL 60  
Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHNSNGDTYLHWYLQKPGQSPQLLIYKVSRL 64  
QY 61 YGVDPFRFSGSGGTDFTLKISRVEADVGYYCFQGSHPVPTFGQGTKEIK 112

Db 65 SGVDPFRFSGSGGTDFTLKISRVEADVGYYCSQSHVPTFGQGTKEIK 116

## RESULT 13

US-08-714-017-66  
; Sequence 66, Application US/08714017  
; Patent No. 6040176  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; APPLICANT: Vazeux, Rosemay  
; TITLE OF INVENTION: ICAM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 116  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 S. Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: USA  
; ZIP: 60606  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/714,017  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/286,754  
; FILING DATE:  
; APPLICATION NUMBER: US 08/102,852  
; FILING DATE: 05-AUG-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/009,266  
; FILING DATE: 22-JAN-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/894,061  
; FILING DATE: 05-JUN-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/889,724  
; FILING DATE: 26-MAY-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/827,689  
; FILING DATE: 27-JAN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: No. 6040176and, Greta E.  
; REGISTRATION NUMBER: 35,302  
; REFERENCE/DOCKET NUMBER: 32178  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (312) 474-6300  
; TELEFAX: (312) 474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 66:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 116 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-714-017-66

Query Match 91.4%; Score 544; DB 2; Length 116;  
Best Local Similarity 92.0%; Pred. No. 7.8e-46;  
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHNSNGNTYQLQWYLQKPGQSPQLLIYKVSRL 60  
Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHNSNGDTYLHWYLQKPGQSPQLLIYKVSRL 64  
QY 61 YGVDPFRFSGSGGTDFTLKISRVEADVGYYCFQGSHPVPTFGQGTKEIK 112  
Db 65 SGVDPFRFSGSGGTDFTLKISRVEADVGYYCSQSHVPTFGQGTKEIK 116

RESULT 15  
US-08-129-930B-95  
; Sequence 95, Application US/08129930B  
; Patent No. 5804187  
; GENERAL INFORMATION:  
; APPLICANT: do Couto Dr., Fernando J.R.  
; APPLICANT: Ceriani Dr., Roberto L.  
; APPLICANT: Peterson Dr., Jerry A.  
; APPLICANT: Padlan Dr., Eduardo A.  
; TITLE OF INVENTION: Analogue Peptides With Broad  
; TITLE OF INVENTION: Carcinoma Specificity, and Kit and  
; TITLE OF INVENTION: Diagnostic Vaccination and  
; TITLE OF INVENTION: Therapeutic Methods  
; NUMBER OF SEQUENCES: 96  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: V. AMZEL & ASSOC.  
; STREET: 2055 No. 5804187th Broadway, Suite 201  
; CITY: Walnut Creek  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94596  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS 5.0  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/129,930B  
; FILING DATE: September 30, 1993  
; CLASSIFICATION: 424  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Amzel Ph.D., Viviana  
; REGISTRATION NUMBER: 30,930  
; REFERENCE/DOCKET NUMBER: CRFCC-008A  
; TELEPHONE: (510) 521-1333  
; TELEFAX: (510) 521-3541  
; TELEX: n.a.  
; INFORMATION FOR SEQ ID NO: 95:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 131 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-129-930B-95  
Query Match 91.3%; Score 543; DB 1; Length 131;  
Best Local Similarity 90.2%; Pred. No. 1.1e-45;  
Matches 101; Conservative 7; Mismatches 4; Indels 0; Gaps 0;  
Qy 1 DIVMTQPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVS NRL 60  
Db 20 DVLMTQTPLSLPVTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSIRF 79  
Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGYVYCFQGSHPVPTFGQGTKEIK 112  
Db 80 SGVDPFRFSGSGGTDFTLKISRVEAEDVGYVYCFQGSHPVPTFGQGTKEIK 131  
Search completed: January 10, 2006, 20:58:03  
Job time : 21.8706 secs

RESULT 14  
US-08-475-680-66  
; Sequence 66, Application US/08475680  
; Patent No. 6100383  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; APPLICANT: Vazeux, Rosemary  
; TITLE OF INVENTION: ICAM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 116  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 S. Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: USA  
; ZIP: 60606  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/475,680  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/286,754  
; FILING DATE: 05-AUG-1994  
; APPLICATION NUMBER: US 08/102,852  
; FILING DATE: 05-AUG-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/009,266  
; FILING DATE: 22-JAN-1993  
; APPLICATION NUMBER: US 07/894,061  
; FILING DATE: 05-JUN-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/889,724  
; FILING DATE: 26-MAY-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/827,689  
; FILING DATE: 27-JAN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: No. 6100383and, Greta E.  
; REGISTRATION NUMBER: 35,302  
; REFERENCE/DOCKET NUMBER: 32178  
; TELEPHONE: (312) 474-6300  
; TELEFAX: (312) 474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 66:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 116 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-475-680-66  
Query Match 91.4%; Score 544; DB 2; Length 116;  
Best Local Similarity 92.0%; Pred. No. 7.8e-46;  
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;  
Qy 1 DIVMTQPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVS NRL 60  
Db 5 DIVMTQPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSIRF 64  
Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGYVYCFQGSHPVPTFGQGTKEIK 112  
Db 65 SGVDPFRFSGSGGTDFTLKISRVEAEDVGYVYCSQSTHVPVPTFGQGTKEIK 116

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:26:41 ; Search time 75.5025 Seconds  
(without alignments)  
1046.577 Million cell updates/sec

Title: US-10-735-916a-65  
Perfect score: 595  
Sequence: 1 DIVMTQSPSLPVTGEPAS.....CFQSGHVPWTFGQTKVEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt\_05.80.\*

1: uniprot\_sprot.\*

2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	519	87.2	248	Q65ZQ7 9MURI	Q65ZQ7 mus sp. b3(
2	499	83.9	117	KV2E_HUMAN	P06309 homo sapien
3	499	83.9	133	KV2F_HUMAN	P06310 homo sapien
4	498	83.7	239	Q8NEK0_HUMAN	Q8NEK0 homo sapien
5	488	82.0	113	KV2D_HUMAN	P01617 homo sapien
6	484.5	81.4	114	Q9UL80_HUMAN	Q9UL80 homo sapien
7	483.5	81.3	115	Q5F210_MOUSE	Q5F210 mus musculus
8	482	81.0	113	KV2G_MOUSE	P01631 mus musculus
9	480	80.7	239	Q8TCD0_HUMAN	Q8TCD0 homo sapien
10	479	80.5	239	Q6P491_HUMAN	Q6P491 homo sapien
11	473.5	79.6	240	Q6PIH6_HUMAN	Q6PIH6 homo sapien
12	471.5	79.2	115	KV2A_HUMAN	P01614 homo sapien
13	471	79.2	219	Q53V88_MOUSE	Q53V88 mus musculus
14	467	78.5	212	Q65ZC0_MOUSE	P01615 homo sapien
15	454	76.3	113	KV2B_HUMAN	P01616 homo sapien
16	450	75.6	239	Q58E08_MOUSE	Q58E08 mus musculus
17	449.5	75.5	112	KV2C_HUMAN	P01616 homo sapien
18	441	74.1	234	Q5XKG4_MOUSE	Q5XKG4 mus musculus
19	434	72.9	113	KV2F_MOUSE	P01630 mus musculus
20	430	72.3	113	KV2E_MOUSE	P03976 mus musculus
21	419	70.4	112	Q6LEM8_MOUSE	Q6LEM8 mus musculus
22	416	69.9	112	KV2D_MOUSE	P01629 mus musculus
23	398.5	67.0	108	KV1_CANFA	P01618 canis faml
24	397.5	66.8	134	KV4C_HUMAN	P06314 homo sapien
25	387	65.0	113	KV2A_MOUSE	P01628 mus musculus
26	385	64.7	112	KV2C_MOUSE	P01626 mus musculus
27	377.5	63.4	114	KV4A_HUMAN	P01625 homo sapien
28	377	63.4	129	KV3M_HUMAN	P18136 homo sapien
29	370	62.2	133	KV4B_HUMAN	P06313 homo sapien
30	368	61.8	109	KV3B_HUMAN	P01620 homo sapien
31	368	61.8	109	KV3D_HUMAN	P01622 homo sapien

32	368	61.8	129	1	KV3L_HUMAN	P18135 homo sapien
33	363	61.0	109	2	Q9UL78_HUMAN	Q9UL78 homo sapien
34	361	60.7	109	1	KV3E_HUMAN	P01623 homo sapien
35	360.5	60.6	111	1	KV3O_MOUSE	P01667 mus musculus
36	360.5	60.6	255	2	Q6KB05_MOUSE	Q6KB05 mus musculus
37	359	60.3	120	1	KV2B_MOUSE	P01627 mus musculus
38	357	60.0	108	1	KV3A_HUMAN	P01619 homo sapien
39	356	59.8	129	1	KV3H_HUMAN	P04207 homo sapien
40	355.5	59.7	236	2	Q6PIL8_HUMAN	Q6PIL8 homo sapien
41	354.5	59.6	111	1	KV3H_MOUSE	P01668 mus musculus
42	354	59.5	109	1	KV3F_HUMAN	P01624 homo sapien
43	354	59.5	110	1	KV3P_MOUSE	P01668 mus musculus
44	353.5	59.4	111	1	KV3Q_MOUSE	P01669 mus musculus
45	353.5	59.4	240	2	Q52L64_MOUSE	Q52L64 mus musculus

ALIGNMENTS

RESULT 1	Q65ZQ7 9MURI PRELIMINARY; PRT; 248 AA.
AC Q65ZQ7;	
DT 25-OCT-2004 (Tremblrel. 28, Created)	
DT 25-OCT-2004 (Tremblrel. 28, Last sequence update)	
DT 25-OCT-2004 (Tremblrel. 28, Last annotation update)	
DE B3(FV)-PE40 (Fragment).	
GN Name=B3(FV)-PE40;	
OS Mus sp.	
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;	
OC Muridae; Murinae; Mus.	
OX NCBI_TaxID=10095;	
RN [1]	
RP NUCLEOTIDE SEQUENCE.	
RX MEDLINE=92020904; PubMed=1924323;	
RA Brinkmann U., Pai L.H., FitzGerald D.J., Willingham M., Pastan I.;	
RT "B3(FV)-PE38KDEL, a single-chain immunotoxin that causes complete	
RT regression of a human carcinoma in mice."	
RL Proc. Natl. Acad. Sci. U.S.A. 88:8616-8620(1991).	
DR EMBL; S57990; AAB19971.2; -; mRNA.	
DR SMR; Q65ZQ7; 4-247.	
DR InterPro; IPR003599; Ig.	
DR InterPro; IPR007110; Ig-like.	
DR InterPro; IPR003596; Ig_v.	
DR SMART; SM00409; Ig; 2.	
DR SMART; SM00406; Ig; 2.	
DR PROSITE; PS50835; IG_LIKE; 2.	
FT NON_TER 248	
SQ SEQUENCE 248 AA; 26634 MW; 7A3759B43E570950 CRC64;	
Query Match 87.2%; Score 519; DB 2; Length 248;	
Best Local Similarity 86.6%; Pred. No. 6.1e-46;	
Matches 97; Conservative 9; Mismatches 6; Indels 0; Gaps 0;	
QY 1 DIVMTQSPSLPVTGEPASICRSQIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 60	
Db 136 DVLMTQSPSLPVSIGDQASISCRSSQIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSNRF 195	
QY 61 YGVPRPFGSGSGTDTFTLKISRVEADGVVYCFQSGSHVPWTFGQTKVEIK 112	
Db 196 SGVPRPFGSGSGTDTFTLKISRVEADGVVYCFQSGSHVPWTFGSGTKLEIK 247	
RESULT 2	
KV2E_HUMAN STANDARD; PRT; 117 AA.	
ID KV2E_HUMAN	
AC P06309;	
DT 01-JAN-1988 (Rel. 06, Created)	
DT 01-JAN-1988 (Rel. 06, Last sequence update)	
DT 10-MAY-2005 (Rel. 47, Last annotation update)	
DE Ig kappa chain V-II region GM607 precursor (Fragment).	
OS Homo sapiens (Human).	

```

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=84191506; PubMed=6325927;
RA Klobeck H.G., Solomon A., Zachau H.G.;
RT "Contribution of human V kappa II germ-line genes to light-chain
diversity.";
RL Nature 309:73-76(1984).
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR EMBL; Z00009; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR PIR; A01889; K2HUGM.
DR HSSP; Q99M37; 1191.
DR SMR; P06309; 5-117.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL <1 4
FT CHAIN 5 117 Ig kappa chain V-II region GM607.
FT REGION 5 27 Framework-1.
FT REGION 28 43 Complementarity-determining-1.
FT REGION 44 58 Framework-2.
FT REGION 59 65 Complementarity-determining-2.
FT REGION 66 97 Framework-3.
FT REGION 98 106 Complementarity-determining-3.
FT REGION 107 116 Framework-4.
FT DISULFID 27 97 By similarity.
FT NON_TER 1 1
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12664 MW; 92C57DC719E558B1 CRC64;

Query Match 83.9%; Score 499; DB 1; Length 117;
Best Local Similarity 86.6%; Pred. No. 3.1e-44;
Matches 97; Conservative 2; Mismatches 13; Indels 0; Gaps 0;

QY 1 DIVMTQSPFLSPVTPGEPASISCRSSQSLVHSNGNTYLQWYLQKPGQSPQLLIYKVSRL 60
Db |||
QY 61 YGVPRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
Db |||
QY 65 SGVPRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGLQTPFPFGQGTKEIK 116
Db |||

RESULT 3
KV2F HUMAN STANDARD; PRT; 133 AA.
AC P06310;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region RPMI 6410 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86041852; PubMed=2997711;

```

```

RA Klobeck H.G., Meindl A., Combratio G., Solomon A., Zachau H.G.;
RT "Human immunoglobulin kappa light chain genes of subgroups II and
III.";
RL Nucleic Acids Res. 13:6499-6513(1985).
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR EMBL; Z00020; CAA77315.1; -; Genomic_DNA.
DR PIR; A01890; K2HURP.
DR HSSP; Q99M37; 1191.
DR SMR; P06310; 21-133.
DR Ensembl; ENSG00000173758; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 20
FT CHAIN 21 133 Ig kappa chain V-II region RPMI 6410.
FT REGION 21 43 Framework-1.
FT REGION 44 59 Complementarity-determining-1.
FT REGION 60 74 Framework-2.
FT REGION 75 81 Complementarity-determining-2.
FT REGION 82 113 Framework-3.
FT REGION 114 122 Complementarity-determining-3.
FT REGION 123 132 Framework-4.
FT DISULFID 43 113 By similarity.
FT NON_TER 133 133
SQ SEQUENCE 133 AA; 14707 MW; 513CCAF3673009EE CRC64;

Query Match 83.9%; Score 499; DB 1; Length 133;
Best Local Similarity 83.9%; Pred. No. 3.7e-44;
Matches 94; Conservative 9; Mismatches 9; Indels 0; Gaps 0;

QY 1 DIVMTQSPFLSPVTPGEPASISCRSSQSLVHSNGNTYLQWYLQKPGQSPQLLIYKVSRL 60
Db |||
QY 21 DVMTQSPFLSPVTLGPASISCRSSQSLVSDGNTYLNWQRFQSPRRLLYKVSND 80
QY 61 YGVPRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
Db |||
QY 81 SGVPRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHTSWTFGQGTKEIK 132
Db |||

RESULT 4
Q8NEKO HUMAN PRELIMINARY; PRT; 239 AA.
ID Q8NEKO;
AC Q8NEKO;
DT 01-OCT-2002 (TREMELrel. 22, Created)
DT 01-OCT-2002 (TREMELrel. 22, Last sequence update)
DT 01-MAR-2004 (TREMELrel. 26, Last annotation update)
DE IGKV1-5 protein.
GN Name=IGKV1-5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RX MEDLINE=23289257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.B., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altshuler S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

```

RA Stapleton M., Soares M.B., Ronaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mulláhy S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Huiyik S.W.,  
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Helton E., Ketterman M., Madan A., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
RA Butterfield Y.S.N., Krzywinski M.I., Skaleka U., Smailus D.E.,  
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,  
RT "Generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences";  
RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Prostate;  
RA Director MSC Project;  
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=1601042;  
RA Huber C., Klobeck H.G., Zachau H.G.;  
RT "Ongoing v kappa-J kappa recombination after formation of a productive  
RT v kappa-J kappa coding joint";  
RL Eur. J. Immunol. 22:1561-1565(1992).  
RN [4]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=8436174;  
RA Wagner S.D., Luzzatto L.;  
RT "v kappa gene segments rearranged in chronic lymphocytic leukemia are  
RT distributed over a large portion of the v kappa locus and do not show  
RT somatic mutation";  
RL Eur. J. Immunol. 23:391-397(1993).  
RN [5]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=8258341;  
RA Klein R., Jaenichen R., Zachau H.G.;  
RT "Expressed human immunoglobulin kappa genes and their hypermutation";  
RL Eur. J. Immunol. 23:3248-3262(1993).  
DR EMBL, BC030814; AAH30814.1; -; mRNA.  
DR PIR, S23638; S23638.  
DR PIR, S34091; S34091.  
DR PIR, S40342; S40342.  
DR PIR, S40357; S40357.  
DR HSSP, P01834; I172.  
DR SMR, Q8NEK0; 21-237.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003597; Ig cl.  
DR InterPro; IPR003006; Ig MHC.  
DR InterPro; IPR003596; Ig v.  
DR Pfam; PF07654; Cl-set; 1.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS00835; IG\_LIKE; 2.  
DR PROSITE; PS00290; IG\_MHC; UNKNOWN\_1.  
KW Immunoglobulin domain.  
SQ SEQUENCE 239 AA; 26024 MW; F5E20AD3B0552C0A CRC64;  
  
Query Match 83.7%; Score 498; DB 2; Length 239;  
Best Local Similarity 84.8%; Pred. No. 9.3e-44;  
Matches 95; Conservative 5; Mismatches 12; Indels 0; Gaps 0;  
  
QY 1 DIVMTQSPSLPVTTCPEPASISCRSSQSVHNGNTYLOWYLOKPCQSPQLLIYKVNRL 60  
Db |||||  
QY 61 YGVDPFRFSGSGGTDTFLKISRVEADVGVYVFCQGSHPVTFGGTKVEIK 112  
Db |||||  
QY 81 SGVPDRFSGSGGTDTFLKISRVEADVGVYVFCQGSHPVTFGGTKVEIK 132  
Db |||||  
RESULT 5

KV2D\_HUMAN  
ID KV2D\_HUMAN STANDARD; PRT; 113 AA.  
AC P01617;  
DT 21-JUL-1986 (Rel. 01, Created)  
DT 21-JUL-1986 (Rel. 01, Last sequence update)  
DE 10-MAY-2005 (Rel. 47, Last annotation update)  
DE Ig kappa chain V-II region TEW.  
OS Homo sapiens (Human)  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP PROTEIN SEQUENCE (BENCE-JONES PROTEIN TEW).  
RX MEDLINE=74148480; PubMed=4596149;  
RA Putnam F.W., Whitley E.J. Jr., Paul C., Davidson J.N.;  
RT "Amino acid sequence of a kappa Bence Jones protein from a case of  
RT primary amyloidosis";  
RL Biochemistry 12:3763-3780(1973).  
RN [2]  
RP PROTEIN SEQUENCE OF 1-27 (AMYLOID PROTEIN TEW).  
RX MEDLINE=73166638; PubMed=4700495;  
RA Terry W.D., Page D.L., Kimura S., Isobe T., Osseman E.F.,  
RA Glenner G.G.;  
RT "Structural identity of Bence Jones and amyloid fibril proteins in a  
RT patient with plasma cell dyscrasia and amyloidosis";  
RL J. Clin. Invest. 52:1276-1281(1973).  
CC -1- MISCELLANEOUS: The major amyloid protein appears to be identical  
CC with the Bence Jones protein isolated from the same patient.  
CC -1- MISCELLANEOUS: This protein was isolated from the urine of a  
CC patient with plasma cell dyscrasia and amyloidosis.  
CC -1- MISCELLANEOUS: The C region of this chain has the INV (1,2)  
CC marker.  
CC -----  
CC This Swiss-Prot entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use as long as its content is in no way modified and this statement is not  
CC removed.  
CC -----  
CC PIR; A90370; K2HUTW.  
DR HSSP; Q99M37; I191.  
DR SMR; P01617; 1-113.  
DR GO; GO:0005576; C:extracellular region; NAS.  
DR GO; GO:0003823; P:antigen binding; NAS.  
DR GO; GO:0006955; P:immune response; NAS.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003596; Ig\_v.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS00835; IG\_LIKE; 1.  
KW Amyloid; Bence-Jones protein; Direct protein sequencing;  
KW Immunoglobulin domain; Immunoglobulin V region.  
FT REGION 1 23 Framework-1.  
FT REGION 24 39 Complementarity-determining-1.  
FT REGION 40 54 Complementarity-determining-2.  
FT REGION 55 61 Complementarity-determining-3.  
FT REGION 62 93 Framework-3.  
FT REGION 94 102 Complementarity-determining-4.  
FT REGION 103 112 Framework-4.  
FT DISULFID 23 93 By similarity.  
FT NON\_TER 113 113  
SQ SEQUENCE 113 AA; 12316 MW; 0C3C38F81F1843CA CRC64;  
  
Query Match 82.0%; Score 488; DB 1; Length 113;  
Best Local Similarity 82.1%; Pred. No. 4.3e-43;  
Matches 92; Conservative 8; Mismatches 12; Indels 0; Gaps 0;  
  
QY 1 DIVMTQSPSLPVTTCPEPASISCRSSQSVHNGNTYLOWYLOKPCQSPQLLIYKVNRL 60  
Db |||||  
QY 61 YGVDPFRFSGSGGTDTFLKISRVEADVGVYVFCQGSHPVTFGGTKVEIK 112  
Db |||||

```
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCMZALQAPITFGQGTREIK 112
RESULT 6
Q9UL80 HUMAN PRELIMINARY; PRT; 114 AA.
AC Q9UL80;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin light chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1322670;
RA Stuber F., Lee S.K., Bridges S.L. Jr, Koopman W.J., Schroeder H.W. Jr,
RA Gaskin F., Fu S.M.;
RT "A rheumatoid factor from a normal individual encoded by VH2 and V
RT kappa II gene segments.";
RL Arthritis Rheum. 35:900-904(1992).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=8436174;
RA Wagner S.D., Luzzatto L.;
RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are
RT distributed over a large portion of the V kappa locus and do not show
RT somatic mutation.";
RL Eur. J. Immunol. 23:391-397(1993).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1601042;
RA Huber C., Klobbeck H.G., Zachau H.G.;
RT "Ongoing V kappa-J kappa recombination after formation of a productive
RT V kappa-J kappa coding joint.";
RL Eur. J. Immunol. 22:1561-1565(1992).
DR EMBL; AF035034; AAD56270.1; -; mRNA.
DR PIR; B49002; B49002.
DR PIR; S23638; S23638.
DR PIR; S34094; S34094.
DR PIR; S34095; S34095.
DR HSP; P01625; ILVE.
DR SMR; Q9UL80; 1-114.
DR InterPro; IPR007110; Ig-like.
DR SMART; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
FT NON_TER 1
FT SEQUENCE 114 AA; 12775 MW; 070E31E210D1CB01 CRC64;
Query Match 81.4%; Score 484.5; DB 2; Length 114;
Best Local Similarity 83.2%; Pred. No. 1e-42;
Matches 94; Conservative 8; Mismatches 10; Indels 1; Gaps 1;

QY 1 DIVMTQPSLSLPTVTPGEPAISCRSSQSIHNSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DVVMTQPSLSLPTVTPGEPAISCRSSQSPVSDGNTYLNWFQRFQSPRLIYKVSNRD 60
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 YGVPRFSGSGGTDFTLKISRVEAEDVGVVYCFQGSN-VPWTFGQGTKEIK 112
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCFQGSN-VPWTFGQGTKEIK 112
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
RESULT 8
KV2G MOUSE STANDARD; PRT; 113 AA.
ID KV2G MOUSE
AC P01631;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE IG kappa chain V-II region 26-10.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP PROTEIN SEQUENCE.
RX STRAIN=A/J;
RX MEDLINE=83178921; PubMed=6404298;
RA Novotny J., Margolies M.N.;
RT "Amino acid sequence of the light chain variable region from a mouse
RT anti-digoxin hybridoma antibody.";
RL Biochemistry 22:1153-1158(1983).
```

```
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCMQGTTHPWPWTFGQGTKEIK 113
RESULT 7
Q5F210 MOUSE PRELIMINARY; PRT; 115 AA.
ID Q5F210 MOUSE
AC Q5F210;
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE Kappa light chain variable region (Fragment).
GN Name=IgG1 anti-TS1 VL;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Erlandsson A., Holm P., Ullen A., Stigbrand T., Sundstrom B.E.;
RT "Studies of the interactions between the anticytokerin 8 monoclonal
RT antibody TS1, its antigen and its anti-idiotypic antibody alphaTS1.";
RL J. Mol. Recognit. 16:157-163(2003).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RA Erlandsson A.;
RL Submitted (FEB-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ884575; CA156337.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
FT NON_TER 1
FT SEQUENCE 115 AA; 12560 MW; E4D3BF3D63E88007 CRC64;
Query Match 81.3%; Score 493.5; DB 2; Length 115;
Best Local Similarity 81.4%; Pred. No. 1.3e-42;
Matches 92; Conservative 12; Mismatches 8; Indels 1; Gaps 1;

QY 1 DIVMTQPSLSLPTVTPGEPAISCRSSQSIHNSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DVVMTQPSLSLPTVTPGEPAISCRSSQSIHNSNGNTYLNWFQRFQSPQLLIYKVSNR 60
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 YGVPRFSGSGGTDFTLKISRVEAEDVGVVYCFQGSN-VPWTFGQGTKEIK 112
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCFQGSN-VPWTFGQGTKEIK 113
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
RESULT 8
KV2G MOUSE STANDARD; PRT; 113 AA.
ID KV2G MOUSE
AC P01631;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE IG kappa chain V-II region 26-10.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP PROTEIN SEQUENCE.
RX STRAIN=A/J;
RX MEDLINE=83178921; PubMed=6404298;
RA Novotny J., Margolies M.N.;
RT "Amino acid sequence of the light chain variable region from a mouse
RT anti-digoxin hybridoma antibody.";
RL Biochemistry 22:1153-1158(1983).
```

```

CC CC -!- MISCELLANEOUS: This chain was isolated from an IgG2a hybridoma
CC CC protein that binds digoxin.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR PIR: A01914; KVM526.
DR HSP: Q99M37; 1191.
DR Ensembl: ENSMUSG00000055315; Mus musculus.
DR InterPro: IPR007110; Ig-like.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS50835; IG LIKE; 1.
KW Direct protein sequencing; Hybridoma; Immunoglobulin domain;
KW Immunoglobulin V region; Monoclonal antibody.
FT REGION 1 23
FT REGION 24 39
FT REGION 40 54
FT REGION 55 61
FT REGION 62 93
FT REGION 94 102
FT REGION 103 112
FT DISULFID 23 93
FT NON_TER 113 113
SQ SEQUENCE 113 AA; 12273 MW; F9F39CE949A84C2A CRC64;

Query Match 81.0%; Score 482; DB 1; Length 113;
Best Local Similarity 81.2%; Pred. No. 1.8e-42;
Matches 91; Conservative 11; Mismatches 10; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLQWYLOKPGQSPOLLIVKVSRL 60
Db 1 DVMTQTPLSLPVSLGDSASISCRSSQSLVHSNGNTYLNWYLOKAGQSPKLLIVKSNRF 60

Qy 61 YGVPRFSSGSGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
Db 61 SGVPRFSSGSGTDFTLKISRVEAEDVGVYYCFQGSHTVPPVFGGQTKLEIK 112

RESULT 9
Q8TCD0 HUMAN PRELIMINARY; PRT; 239 AA.
AC Q8TCD0_
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OC NCBI_TaxID=9606;
RN [1]_
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altshul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

```

```

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]_
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RA Strausberg R.;
RN Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.
RN [3]_
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1598223;
RA Hirabayashi Y., Munakata Y., Sasaki T., Sano H.;
RT "Variable regions of a human anti-DNA antibody O-81 possessing lupus
RT nephritis-associated idiotype.";
RN Nucleic Acids Res. 20:2601-0(1992).
RN [4]_
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1551402;
RA Lautner-Rieske A., Huber C., Meindl A., Pargent W., Schable K.F.,
RA Thiebe R., Zocher I., Zachau H.G.;
RT "The human immunoglobulin kappa locus. Characterization of the
RT duplicated A regions.";
RL Eur. J. Immunol. 22:1023-1029(1992).
RN [5]_
RP NUCLEOTIDE SEQUENCE.
RX PubMed=8258341;
RA Klein R., Jaenichen R., Zachau H.G.;
RT "Expressed human immunoglobulin kappa genes and their hypermutation.";
RN Eur. J. Immunol. 23:3248-3262(1993).
RN [6]_
RP NUCLEOTIDE SEQUENCE.
RX PubMed=8436174;
RA Wagner S.D., Luzatto L.;
RT "v kappa gene segments rearranged in chronic lymphocytic leukemia are
RT distributed over a large portion of the v kappa locus and do not show
RT somatic mutation.";
RL Eur. J. Immunol. 23:391-397(1993).
DR EMBL: BC022362; AAH22362.1; -; mRNA.
DR PIR: S22658; S22658.
DR PIR: S34095; S34095.
DR PIR: S40324; S40324.
DR PIR: S40374; S40374.
DR PIR: S42267; S42267.
DR PIR: S42268; S42268.
DR HSP: P01834; 117Z.
DR SMR: Q8TCD0; 21-237.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003597; Ig cl.
DR InterPro: IPR003006; Ig MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam: PF07654; Cl-set; 1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS50835; IG LIKE; 2.
DR PROSITE: PS00290; IG_MHC; UNKNOWN 1.
KW Hypothetical protein; Immunoglobulin domain.
SQ SEQUENCE 239 AA; 26235 MW; FAGEDC3A3B03871D CRC64;

Query Match 80.7%; Score 480; DB 2; Length 239;
Best Local Similarity 80.4%; Pred. No. 7.2e-42;
Matches 90; Conservative 13; Mismatches 9; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLQWYLOKPGQSPOLLIVKVSRL 60
Db 21 DVMTQTPLSLPVTILGQPASISCRSTQSLVSDGNTYLNWYLOKQSPFRLIVKSNRD 80

Qy 61 YGVPRFSSGSGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
Db 81 SGVPRFSSGSGTDFTLKISRVEAEDVGVYFCMGSTHWPSTFGGQTKLEIK 132

```

## RESULT 10

Q6P491 HUMAN  
 ID Q6P491 HUMAN PRELIMINARY; PRT; 239 AA.  
 AC Q6P491  
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
 DE Hypothetical protein.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
 OC Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE.  
 RC TISSUE=Skin;  
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Buterfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).  
 RN [2]  
 RP NUCLEOTIDE SEQUENCE.  
 RC TISSUE=Skin;  
 RA Strausberg R.;  
 RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; BC063599; AAH63599.1; -; mRNA.  
 DR HSSP; P01837; 1KCU.  
 DR SMR; Q6P491; 21-237.  
 DR InterPro; IPR003599; Ig.  
 DR InterPro; IPR007110; Ig-like.  
 DR InterPro; IPR003597; Ig.cl.  
 DR InterPro; IPR003006; Ig.MHC.  
 DR InterPro; IPR003596; Ig.v.  
 DR Pfam; PF07654; CI-set; 1.  
 DR SMART; SM00409; IG; 2.  
 DR SMART; SM00407; IGcl; 1.  
 DR SMART; SM00406; IGv; 1.  
 DR PROSITE; PS50835; IG LIKE; 2.  
 DR PROSITE; PS00290; IG\_MHC; UNKNOWN\_1.  
 KW Hypothetical protein.  
 SQ SEQUENCE 239 AA; 26245 MW; CD7313DDFFD358B3 CRC64;

Query Match 80.5%; Score 479; DB 2; Length 239;  
 Best Local Similarity 80.4%; Pred. No. 9.1e-42;  
 Matches 90; Conservative 10; Mismatches 12; Indels 0; Gaps 0;

## RESULT 11

QY 1 DIVMTQSPVLTGTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
 DB 21 DIVMTQTPLSSPTLGLQGPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 80  
 QY 61 YGVPRDFSGSGGTDTFTLKISRVEAEDVGVYCFQGSHPVPTFGQGTKEIK 112  
 DB 81 SGVPRDFSGSGGTDTFTLKISRVEAEDVGVYCFQGSHPVPTFGQGTKEIK 132

## RESULT 12

KV2A\_HUMAN

Q6PIH6 HUMAN  
 ID Q6PIH6 HUMAN PRELIMINARY; PRT; 240 AA.  
 AC Q6PIH6  
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
 DE IGKV1-5 protein.  
 GN Name=IGKV1-5;  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
 OC Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE.  
 RC TISSUE=Lung;  
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Buterfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).  
 RN [2]  
 RP NUCLEOTIDE SEQUENCE.  
 RC TISSUE=Lung;  
 RA Director MGC Project;  
 RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; BC034142; AAH34142.1; -; mRNA.  
 DR HSSP; P01837; 1KB5.  
 DR SMR; Q6PIH6; 23-240.  
 DR InterPro; IPR003599; Ig.  
 DR InterPro; IPR007110; Ig-like.  
 DR InterPro; IPR003597; Ig.cl.  
 DR InterPro; IPR003006; Ig.MHC.  
 DR InterPro; IPR003596; Ig.v.  
 DR Pfam; PF07654; CI-set; 1.  
 DR SMART; SM00409; IG; 2.  
 DR SMART; SM00407; IGcl; 1.  
 DR SMART; SM00406; IGv; 1.  
 DR PROSITE; PS50835; IG LIKE; 2.  
 DR PROSITE; PS00290; IG\_MHC; UNKNOWN\_1.  
 SQ SEQUENCE 240 AA; 26234 MW; 188D4DD8BB781EC4 CRC64;

Query Match 79.6%; Score 473.5; DB 2; Length 240;  
 Best Local Similarity 82.3%; Pred. No. 3.5e-41;  
 Matches 93; Conservative 4; Mismatches 15; Indels 1; Gaps 1;

QY 1 DIVMTQSPVLTGTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
 DB 21 DIVMTQSPVLTGTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 80  
 QY 61 YGVPRDFSGSGGTDTFTLKISRVEAEDVGVYCFQGSHPVPTFGQGTKEIK 112  
 DB 81 SGVPRDFSGSGGTDTFTLKISRVEAEDVGVYCFQGSHPVPTFGQGTKEIK 133

ID	KV2A_HUMAN	STANDARD;	PRT;	115 AA.
AC	P01614;			
DT	21-JUL-1986	(Rel. 01, Created)		
DT	21-JUL-1986	(Rel. 01, Last sequence update)		
DT	10-MAY-2005	(Rel. 47, Last annotation update)		
DE	Ig kappa chain V-II region Cum.			
OS	Homo sapiens (Human)			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;			
OC	Homo.			
NCBI_TaxID=9606;				
NCBI_TaxID=9606;				
PROTEIN SEQUENCE.				
MD5LINE=68242259;	PubMed=5586923;			
Hiltschmann N.;				
MD5LINE=70063440;	PubMed=4188189;			
Hiltschmann N.;				
"Molecular basis of antibody formation.";				
Naturwissenschaften 56:195-205(1969).				
-1- MISCELLANEOUS: The C region of this chain has the INV (3) marker.				
-1- MISCELLANEOUS: This is a Bence-Jones protein.				
CC	CC			
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -			
CC	the European Bioinformatics Institute. There are no restrictions on its			
CC	use as long as its content is in no way modified and this statement is not			
CC	removed.			
CC	CC			
PIR; B91639; K2HUCM.				
HSSP; P01751; INQB.				
SMR; P01614; 2-115.				
GO; GO:0005576; C:extracellular region; NAS.				
GO; GO:0003823; F:antigen binding; NAS.				
GO; GO:0006955; P:immune response; NAS.				
InterPro; IPR007110; Ig-like.				
InterPro; IPR003596; Ig_v.				
SMART; SM00406; IGV; 1.				
PROSITE; PS50835; IG_LIKE; 1.				
Bence-Jones protein; Direct protein sequencing; Immunoglobulin domain;				
Immunoglobulin V region.				
DISULFID 24				
FT NON PER 115 115				
FT SEQUENCE 115 AA; 12676 MW; 59E9F90A379569EC CRC64;				
Query Match	79.2%;	Score 471.5; DB 1; Length 115;		
Best Local Similarity	80.5%;	Pred. No. 2.3e-41;		
Matches	91; Conservative	10; Mismatches 11; Indels 1; Gaps 1;		
Qy	1	DIVMTQPSLPLVPTGPGPASICSSSSQSVIHS-NGNTYLOWLYOKPGSPOLLIKYVSNR	59	
Db	2	DIVMTQPSLPLVPTGPGPASICSSSSQSLDSDGNTYLNWYLOKAGOSPOLLITLSYR	61	
Qy	60	LYGVDPDFSGSGSGTDFTLKLSRVEADNGVYVYFCQGHVPWTGQGHKVKIK	112	
Db	62	ASGVDPDFSGSGSGTDFTLKLSRVOAEDNGVYVYCMQRLIEIYTFQGGFKLSIR	114	
RESULT 13				
Q53VP8_MOUSE				
ID	Q53VP8_MOUSE	PRELIMINARY;	PRT;	112 AA.
AC	Q53VP8;			
DT	13-SEP-2005	(TRENBLrel. 31, Created)		
DT	13-SEP-2005	(TRENBLrel. 31, Last sequence update)		
DT	13-SEP-2005	(TRENBLrel. 31, Last annotation update)		
DE	Kappa chain (Fragment).			
OS	Mus musculus (Mouse).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;			

Matches		89; Conservative	11; Mismatches	12; Indels	0; Gaps	0;
QY	1	DIVMTQSPSLSPVLTPEGPASISCRSSQSIHSGNTYLTQWYLOKPGQSPQLLIYKVSNRL	60			
Db	1	ELVMTQSPSLSPVLTPEGPASISCRSSQSLVHTNGNTYLTQWYLOKPGQSPQLLIYKVSNRF	60			
QY	61	YGVPRFSGSGSDTFTLKISRVEAEDGVIYFCQGSHPVPTFGGQTKVEIK	112			
Db	61	SGVPRFSGSGSDTFTLKISRVEAEDGVIYFCQGSHTVPTFGGQTKLEIK	112			
RESULT 15						
KV2B HUMAN						
ID	KV2B HUMAN	STANDARD;	PRT;	113 AA.		
AC	P01615;					
DT	21-JUL-1986 (Rel. 01, Created)					
DT	21-JUL-1986 (Rel. 01, Last sequence update)					
DT	10-MAY-2005 (Rel. 47, Last annotation update)					
DE	Ig kappa chain V-II region FR.					
OS	Homo sapiens (Human)					
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;					
OC	Homo.					
OX	NCBI_TaxID=9606;					
RN	[1]					
RP	PROTEIN SEQUENCE.					
RX	MEDLINE=76253627; PubMed=821524;					
RA	Riesen W.F., Jaton J.-C.;					
RT	"Variable region sequence of the light chain from a Waldenstroms IgM					
RT	with specificity for phosphorylcholine.";					
RL	Biochemistry 15:3829-3833(1976).					
CC	- - MISCELLANEOUS: This chain was isolated from a Waldenstrom's					
CC	macroglobulin that binds phosphorylcholine.					
CC	-----					
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration					
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -					
CC	the European Bioinformatics Institute. There are no restrictions on its					
CC	use as long as its content is in no way modified and this statement is not					
CC	removed.					
CC	-----					
DR	PIR; A01886; K2HUPR.					
DR	HSSP; Q99M37; I191.					
DR	SMR; P01615; 1-109.					
DR	GO; GO:0005576; C:extracellular region; NAS.					
DR	GO; GO:0003823; P:antigen binding; NAS.					
DR	GO; GO:0006955; P:immune response; NAS.					
DR	InterPro; IPR007110; IG-like.					
DR	InterPro; IPR003596; IG_V.					
DR	SMART; SM00406; IGV; 1.					
DR	PROSITE; PS50835; IG_LIKE; 1.					
KW	Direct protein sequencing; Immunoglobulin domain;					
KW	Immunoglobulin V region.					
FT	REGION 1 23					
FT	Complementarity-determining-1.					
FT	REGION 24 39					
FT	Complementarity-determining-2.					
FT	REGION 40 54					
FT	Complementarity-determining-3.					
FT	REGION 55 61					
FT	Complementarity-determining-4.					
FT	REGION 62 93					
FT	By similarity.					
FT	REGION 94 102					
FT	REGION 103 112					
FT	DISULFID 23 93					
FT	NON_TER 113 113					
SQ	SEQUENCE 113 AA; 12660 MW; OC0DA39E46DB96BE CRC64;					
Query Match						
Best Local Similarity 75.9%; Score 454; DB 1; Length 113;						
Pred. No. 1.6e-39;						
Matches		85; Conservative	12; Mismatches	15; Indels	0; Gaps	0;
QY	1	DIVMTQSPSLSPVLTPEGPASISCRSSQSIHSGNTYLTQWYLOKPGQSPQLLIYKVSNRL	60			
Db	1	DVMTQSPSLSPVLTPEGPASISCRSSQSLVHTNGNTYLTQWYLOKPGQSPQLLIYKVSND	60			
QY	61	YGVPRFSGSGSDTFTLKISRVEAEDGVIYFCQGSHPVPTFGGQTKVEIK	112			

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 13.5124 Seconds  
(without alignments)  
797.508 Million cell updates/sec

Title: US-10-735-916A-65  
Perfect score: 595  
Sequence: 1 DIVMTQSLPLVPTGEPAS.....CFQGSHPVPTFGQTKVEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- 1: pir1.\*
- 2: pir2.\*
- 3: pir3.\*
- 4: pir4.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	523	87.9	131	2 B39276	Ig light chain pre
2	522	87.7	113	2 PLO203	anti-DNA autoantib
3	516	86.7	219	2 S52028	Ig kappa chain - m
4	514	86.4	112	2 S58207	Ig light chain v r
5	514	86.4	112	2 S38719	Ig light chain v r
6	514	86.4	136	2 S40357	Ig kappa chain v-j
7	513	86.2	112	2 A31807	Ig kappa chain v r
8	513	86.2	219	2 PC4203	Ig kappa chain (mo
9	512	86.1	110	2 S26335	Ig kappa chain v r
10	509	85.5	114	2 A32967	Ig kappa chain v-i
11	508	85.4	118	2 PT0359	Ig kappa chain v r
12	508	85.4	131	2 B34904	Ig kappa chain pre
13	506	85.0	112	2 B31485	Ig kappa chain v r
14	506	84.7	112	2 C27887	Ig kappa chain v r
15	504	84.7	131	2 C34904	Ig kappa chain pre
16	502	84.4	112	2 A27887	Ig kappa chain v r
17	501	84.2	112	2 F27887	Ig kappa chain v r
18	501	84.2	115	2 S38715	Ig kappa chain v r
19	501	84.2	132	2 S26882	Ig kappa chain v r
20	500	84.0	114	2 B32967	Ig kappa chain v-i
21	500	84.0	135	2 S40342	Ig kappa chain - h
22	499	83.9	112	2 E27887	Ig kappa chain v r
23	499	83.9	117	1 K2HUGM	Ig kappa chain pre
24	499	83.9	131	2 B30577	Ig kappa chain pre
25	499	83.9	133	1 K2HURP	Ig kappa chain pre
26	499	83.9	219	2 S16112	Ig kappa chain v r
27	498	83.7	103	2 PH1043	Ig light chain v r
28	498	83.7	131	2 D34904	Ig kappa chain pre
29	498	83.7	131	2 B32513	Ig kappa chain pre

30	497	83.5	112	2 D28195	Ig kappa chain v r
31	496	83.4	111	2 PLO257	Ig kappa chain v r
32	496	83.4	112	2 A49715	Ig kappa chain v r
33	494.5	83.1	126	2 S40339	Ig kappa chain - h
34	494	83.0	112	2 S53750	antibody Fab Jel 1
35	494	83.0	113	2 B41940	Ig light chain v r
36	493	82.9	112	2 S32189	Ig kappa chain v r
37	493	82.9	225	2 JLO029	Ig kappa chain pre
38	492	82.7	142	2 S22902	Ig kappa chain v r
39	491	82.5	125	2 S40356	Ig kappa chain - h
40	491	82.5	133	1 A24452	Ig kappa chain pre
41	490	82.4	112	2 S58206	Ig light chain v r
42	490	82.4	112	2 D27887	Ig kappa chain v r
43	490	82.4	131	2 D29380	Ig kappa chain pre
44	490	82.4	133	2 S23230	Ig kappa chain pre
45	489	82.2	112	2 B27887	Ig kappa chain v r

ALIGNMENTS

RESULT 1

B39276

Ig light chain precursor V-D-J region (6-19) - mouse

C/Species: Mus musculus (house mouse)

C/Date: 18-Oct-1991 #sequence\_revision 18-Oct-1991 #text\_change 21-Jan-2000

C/Accession: B39276

R/Reininger, L.; Berney, T.; Shibata, T.; Spertini, F.; Merino, R.; Izui, S.

Proc. Natl. Acad. Sci. U.S.A. 87, 10038-10042, 1990

A/Title: Cryoglobulinemia induced by a murine ICG3 rheumatoid factor: skin vasculitis an

A/Reference number: A39276; MUID:91088540; PMID:2263605

A/Accession: B39276

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-131 <REI>

A/Cross-references: UNIPARC:UPI0000115153; GB:M55313; NID:g198095; PIDN:AAA63385.1; PID

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: immunoglobulin

F;35-114/Domain: immunoglobulin homology <IMM>

Query Match 87.9%; Score 523; DB 2; Length 131;  
Best Local Similarity 86.6%; Pred. No. 2.1e-42;  
Matches 97; Conservative 10; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSLPLVPTGEPASISCRSSQSIHVSNGNTYLQWYLQKPGSQPLLIYKVSRL 60

Db 20 DVLMTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLEWYLQKPGSPKLLIYKVSNR 79

QY 61 YGVDPDRFSGSGSGTDFTLKISRVEAEDVGVVYCFQGSHPVPTFGQTKVEIK 112

Db 80 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVVYCFQGSHPVPTFGSGTKLEIK 131

RESULT 2

PLO203

anti-DNA autoantibody BV17-31, kappa chain V region - mouse (fragment)

C/Species: Mus musculus (house mouse)

C/Date: 20-Feb-1995 #sequence\_revision 20-Feb-1995 #text\_change 21-Jan-2000

C/Accession: PLO203

R/Smith, R.G.; Voss Jr., E.W.

Mol. Immunol. 27, 463-470, 1990

A/Title: Variable region primary structures of monoclonal anti-DNA autoantibodies from N

A/Reference number: PLO198; MUID:90309768; PMID:2114528

A/Accession: PLO203

A/Molecule type: mRNA

A/Residues: 1-113 <SML>

A/Cross-references: UNIPARC:UPI0000113786; GB:X53643; NID:g50196; PIDN:CNA37694.1; PID:g

C/Superfamily: immunoglobulin V region; immunoglobulin homology

F;16-95/Domain: immunoglobulin homology <IMM>

F;24-39/Region: complementarity-determining 1

F;55-61/Region: complementarity-determining 2

F;94-102/Region: complementarity-determining 3

F;101-113/Region: D region

```
Query Match      87.7%; Score 522; DB 2; Length 113;
Best Local Similarity 86.6%; Pred. No. 2.3e-42;
Matches 97; Conservative 10; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDGIVGYVCFQGSHPVPTFGQGTKEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYYCFQGSHPVPTFGGTKEIK 112

RESULT 3
S58207
Ig kappa chain - mouse
C:Species: Mus musculus (house mouse)
C:Date: 07-May-1995 #sequence_revision 21-Jul-1995 #text_change 21-Jan-2000
C:Accession: S52028
R:van Engelen, F.; Schouten, A.; Moltzoff, J.W.; Roosien, J.; Dirkse, W.G.; Schote, A.;
submitted to the EMBL Data Library, August 1994
A:Description: Coordinate expression of antibody subunit genes yields high levels of fun
A:Reference number: S52028
A:Accession: S52028
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-219 <V>N>
A:Cross-references: UNIPARC:UPI0000114B22; EMBL:L35138; NID:G522336; PIDN:AAA67525.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
P:16-95/Domain: immunoglobulin homology <IMM>

Query Match      86.7%; Score 516; DB 2; Length 219;
Best Local Similarity 87.5%; Pred. No. 1.8e-41;
Matches 98; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDGIVGYVCFQGSHPVPTFGQGTKEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYYCFQGSHPVPTFGGTKEIK 112

RESULT 4
S58207
Ig light chain V region anti-F(ab')2 - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1996 #sequence_revision 19-Apr-1996 #text_change 21-Jan-2000
C:Accession: S58207
R:Welschof, M.; Terness, P.; Stanescu, D.; Zewe, M.; Hain, C.H.; Doebel, S.; Breitling,
submitted to the EMBL Data Library, July 1995
A:Description: Characterization of heavy and light chain immunoglobulin variable region
A:Reference number: S58206
A:Accession: S58207
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-112 <W>L>
A:Cross-references: UNIPARC:UPI0000116253; EMBL:X89056; NID:G929642; PIDN:CAA61443.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
P:16-95/Domain: immunoglobulin homology <IMM>

Query Match      86.4%; Score 514; DB 2; Length 112;
Best Local Similarity 87.5%; Pred. No. 1.3e-41;
Matches 98; Conservative 2; Mismatches 12; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
```

```
Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDGIVGYVCFQGSHPVPTFGQGTKEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDGIVGYVCFQGSHPVPTFGQGTKEIK 112

RESULT 5
S38719
Ig light chain V region - mouse
C:Species: Mus musculus (house mouse)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 20-Jun-2000
C:Accession: S38719
R:Cimanis, A.Y.
submitted to the EMBL Data Library, November 1993
A:Reference number: S38713
A:Accession: S38719
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-112 <CIM>
A:Cross-references: UNIPARC:UPI0000117543; EMBL:X76021; NID:G416112; PIDN:CAA53608.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
P:16-95/Domain: immunoglobulin homology <IMM>

Query Match      86.4%; Score 514; DB 2; Length 112;
Best Local Similarity 86.6%; Pred. No. 1.3e-41;
Matches 97; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDGIVGYVCFQGSHPVPTFGQGTKEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYYCFQGSHPVPTFGGTKEIK 112

RESULT 6
S40357
Ig kappa chain V-J-C region - human
C:Species: Homo sapiens (man)
C:Date: 19-May-1994 #sequence_revision 26-May-1995 #text_change 31-Dec-2004
C:Accession: S40357
R:Klein, R.; Jaenichen, R.; Zachau, H.G.
Eur. J. Immunol. 23, 3248-3271, 1993
A:Title: Expressed human immunoglobulin chi genes and their hypermutation.
A:Reference number: S40312; MUID:94080891; PMID:8258341
A:Accession: S40357
A>Status: preliminary; translation not shown
A:Molecule type: mRNA
A:Residues: 1-136 <KLE>
A:Cross-references: UNIPROT:Q8NEK0; UNIPARC:UPI0000176CA8; EMBL:X72467
C:Superfamily: immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
P:36-115/Domain: immunoglobulin homology <IMM>

Query Match      86.4%; Score 514; DB 2; Length 136;
Best Local Similarity 87.5%; Pred. No. 1.6e-41;
Matches 98; Conservative 2; Mismatches 12; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
Db 21 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 80

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDGIVGYVCFQGSHPVPTFGQGTKEIK 112
Db 81 SGVPDRFSGSGGTDFTLKISRVEAEDGIVGYVCFQGSHPVPTFGQGTKEIK 132

RESULT 7
A31807
Ig kappa chain V region (PAC1) - mouse
C:Species: Mus musculus (house mouse)
C:Date: 20-Jul-1989 #sequence_revision 20-Jul-1989 #text_change 09-Jul-2004
```

C;Accession: A31807  
J;Taub, R.; Gould, R.J.; Garasky, V.M.; Ciccarone, T.M.; Hoxie, J.; Friedman, P.A.; Shatto  
J. Biol. Chem. 264, 259-265, 1999  
A;Title: A monoclonal antibody against the platelet fibrinogen receptor contains a sequ  
A;Reference number: A31807; MUID:89079661; PMID:2909518  
A;Accession: A31807  
A;Status: preliminary  
A;Molecule type: mRNA  
A;Residues: 1-112 <TAU>  
A;Cross-references: UNIPROT:Q9M37; UNIPARC:UPI00001424F9  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
C;Keywords: heterotetramer; immunoglobulin  
F;16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.2%; Score 513; DB 2; Length 112;  
Best Local Similarity 84.8%; Pred. No. 1.6e-41;  
Matches 95; Conservative 12; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60  
DB 1 DVLMTQTPSLPVLGDAQASISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKVEIK 112  
DB 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 8  
PC4203  
Ig kappa chain (monoclonal antibody MabaA34) - mouse (fragment)  
C;Species: Mus musculus (house mouse)  
C;Date: 31-Dec-1996 #sequence\_revision 31-Dec-1996 #text\_change 11-Jan-2000  
C;Accession: PC4203  
R;Kwak, J.W.; Lee, D.I.; Choi, B.K.; Cho, W.K.; Lee, S.H.; Park, Y.B.; Han, M.H.  
Gene 173, 257-259, 1996  
A;Title: Cloning and characterization of cDNAs coding for heavy and light chains of a m  
A;Reference number: PC4202; MUID:97082978; PMID:8964510  
A;Accession: PC4203  
A;Molecule type: mRNA  
A;Residues: 1-219 <KWA>  
A;Cross-references: UNIPARC:UPI00001157E4; GB:U29147; NID:g1594225; PIDN:AACS2821.1; PID  
C;Comment: This protein is specific for human plasma apolipoprotein A-I of high-density  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
F;1-112/Domain: V region #status predicted <VRG>  
F;113-219/Domain: C region #status predicted <CRG>

Query Match 86.2%; Score 513; DB 2; Length 219;  
Best Local Similarity 85.7%; Pred. No. 3.4e-41;  
Matches 96; Conservative 10; Mismatches 6; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60  
DB 1 DVLMTQTPSLPVLGDAQASISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKVEIK 112  
DB 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 9  
S26335  
Ig kappa chain V region - mouse  
C;Species: Mus musculus (house mouse)  
C;Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 20-Jun-2000  
C;Accession: S26335  
R;Stark, S.E.; Caton, A.J.  
J. Exp. Med. 174, 613-624, 1991  
A;Title: Antibodies that are specific for a single amino acid interchange in a protein e  
A;Reference number: S26309; MUID:91341421; PMID:1908510  
A;Accession: S26335  
A;Status: preliminary  
A;Molecule type: mRNA  
A;Residues: 1-110 <STA>

A;Cross-references: UNIPARC:UPI0000115F78; EMBL:X59183; NID:g52314; PIDN:CAA41893.1; PID  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
C;Keywords: heterotetramer; immunoglobulin  
F;16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.1%; Score 512; DB 2; Length 110;  
Best Local Similarity 86.4%; Pred. No. 1.9e-41;  
Matches 95; Conservative 10; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60  
DB 1 DVLMTQTPSLPVLGDAQASISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKVEIK 110  
DB 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 110

RESULT 10  
A32967  
Ig kappa chain V-II region TE33 - mouse  
C;Species: Mus musculus (house mouse)  
C;Date: 29-Jan-1990 #sequence\_revision 29-Jan-1990 #text\_change 21-Jan-2000  
C;Accession: A32967  
R;Levy, R.; Assulin, O.; Scherf, T.; Levitt, M.; Anglister, J.  
Biochemistry 28, 7168-7175, 1989  
A;Title: Probing antibody diversity by 2D NMR: comparison of amino acid sequences, pred  
A;Reference number: A32967; MUID:90057406; PMID:2819059  
A;Accession: A32967  
A;Status: preliminary; nucleic acid sequence not shown; not compared with conceptual tr  
A;Molecule type: mRNA  
A;Residues: 1-114 <LEV>  
A;Cross-references: UNIPARC:UPI0000114F5D; GB:M30481; NID:g197157; PIDN:AAA38935.1; PID  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
C;Keywords: heterotetramer; immunoglobulin  
F;16-95/Domain: immunoglobulin homology <IMM>

Query Match 85.5%; Score 509; DB 2; Length 114;  
Best Local Similarity 83.0%; Pred. No. 3.8e-41;  
Matches 93; Conservative 13; Mismatches 6; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60  
DB 1 DVLMTQTPSLPVLGDAQASISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKVEIK 112  
DB 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 11  
PT0359  
Ig kappa chain V region (R4A.12) - mouse (fragment)  
C;Species: Mus musculus (house mouse)  
C;Date: 31-Mar-1992 #sequence\_revision 31-Mar-1992 #text\_change 09-Jul-2004  
C;Accession: PT0359  
R;Shefner, R.; Kleiner, G.; Turken, A.; Papazian, L.; Diamond, B.  
J. Exp. Med. 173, 287-296, 1991  
A;Title: A novel class of anti-DNA antibodies identified in BALB/c mice.  
A;Reference number: PT0352; MUID:91108325; PMID:1988536  
A;Accession: PT0359  
A;Molecule type: mRNA  
A;Residues: 1-118 <SHE>  
A;Cross-references: UNIPROT:Q8VCI6; UNIPARC:UPI0000176AF2  
A;Experimental source: strain BALB/c  
C;Comment: This protein is an anti-double-stranded DNA antibody.  
C;Superfamily: immunoglobulin V region; immunoglobulin homology  
F;19-98/Domain: immunoglobulin homology <IMM>

Query Match 85.4%; Score 508; DB 2; Length 118;  
Best Local Similarity 83.9%; Pred. No. 5e-41;  
Matches 94; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

```
Qy 1 DIVMTQSLPLPVTGEPASISCRSSQSIHVSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60
Db 4 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSRRF 63

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCGSHVPWTFGGTKVEIK 112
Db 64 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCSTHVPWTFGGGTTKLEIK 115

RESULT 12
B31485
Ig kappa chain precursor V region (12-40 and 5-14) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 27-Jul-1990 #sequence_revision 27-Jul-1990 #text_change 21-Jul-2000
C:Accession: B31485; H34903
R:Bedzyk, W.D.; Herron, J.N.; Edmondson, A.B.; Voss Jr., E.W.
J. Biol. Chem. 265, 133-138, 1990
A:Title: Active site structure and antigen binding properties of idiotypically cross-reactive
A:Reference number: A34903; MUID:90094387; PMID:2104617
A:Accession: B31485
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-131 <BED>
A:CROSS-references: UNIPROT:Q8VCI6; UNIPARC:UPI0000176AF8
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 85.4%; Score 508; DB 2; Length 131;
Best Local Similarity 83.9%; Pred. No. 5.6e-41;
Matches 94; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

Qy 1 DIVMTQSLPLPVTGEPASISCRSSQSIHVSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60
Db 20 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSRRF 79

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCGSHVPWTFGGTKVEIK 112
Db 80 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCSTHVPWTFGGGTTKLEIK 131

RESULT 13
B31485
Ig kappa chain V region (4-4-20) - mouse (fragment)
C:Species: Mus musculus (house mouse)
C>Date: 31-Jul-1989 #sequence_revision 31-Jul-1989 #text_change 09-Jul-2004
C:Accession: B31485
R:Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.
J. Biol. Chem. 264, 1565-1569, 1989
A:Title: Comparison of variable region primary structures within an anti-fluorescein idiotype
A:Reference number: A31485; MUID:89109167; PMID:2492278
A:Accession: B31485
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-112 <BED>
A:CROSS-references: UNIPROT:Q8VCI6; UNIPARC:UPI0000176AF8
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 85.0%; Score 506; DB 2; Length 112;
Best Local Similarity 83.0%; Pred. No. 7.2e-41;
Matches 93; Conservative 12; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DIVMTQSLPLPVTGEPASISCRSSQSIHVSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60
Db 1 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSRRF 60

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCGSHVPWTFGGTKVEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCSTHVPWTFGGGTTKLEIK 112
```

```
RESULT 14
C27887
Ig kappa chain V region (H37-82) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 15-Dec-1988 #sequence_revision 15-Dec-1988 #text_change 09-Jul-2004
C:Accession: C27887
R:Caton, A.J.; Brownlee, G.G.; Staudt, L.M.; Gerhard, W.
EMBO J. 5, 1577-1587, 1986
A:Title: Structural and functional implications of a restricted antibody response to a
A:Reference number: A91043; MUID:86300658; PMID:2427335
A:Accession: C27887
A:Molecule type: DNA
A:Residues: 1-112 <CAT>
A:CROSS-references: UNIPROT:Q8VCI6; UNIPARC:UPI0000176A17
A:Experimental source: strain Balb/c
A:Note: This sequence was determined from the germline gene
A:Comment: This chain was isolated from a hybridoma protein that binds influenza virus
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 84.7%; Score 504; DB 2; Length 112;
Best Local Similarity 83.0%; Pred. No. 1.1e-40;
Matches 93; Conservative 11; Mismatches 8; Indels 0; Gaps 0;

Qy 1 DIVMTQSLPLPVTGEPASISCRSSQSIHVSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60
Db 1 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSRRF 60

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCGSHVPWTFGGTKVEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCSTHVPWTFGGGTTKLEIK 112

RESULT 15
C34904
Ig kappa chain precursor V region (3-24) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 27-Jul-1990 #sequence_revision 27-Jul-1990 #text_change 09-Jul-2004
C:Accession: C34904; I31485
R:Bedzyk, W.D.; Herron, J.N.; Edmondson, A.B.; Voss Jr., E.W.
J. Biol. Chem. 265, 133-138, 1990
A:Title: Active site structure and antigen binding properties of idiotypically cross-reactive
A:Reference number: A34903; MUID:90094387; PMID:2104617
A:Accession: C34904
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-131 <BED>
A:CROSS-references: UNIPROT:Q8VCI6; UNIPARC:UPI00001767A8
R:Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.
J. Biol. Chem. 264, 1565-1569, 1989
A:Title: Comparison of variable region primary structures within an anti-fluorescein idiotype
A:Reference number: A31485; MUID:89109167; PMID:2492278
A:Accession: I31485
A:Status: preliminary
A:Molecule type: protein
A:Residues: 20-52 <BE2>
A:CROSS-references: UNIPARC:UPI00001767A9
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:35-114/Domain: immunoglobulin homology <IMM>

Query Match 84.7%; Score 504; DB 2; Length 131;
Best Local Similarity 83.0%; Pred. No. 1.3e-40;
Matches 93; Conservative 10; Mismatches 9; Indels 0; Gaps 0;

Qy 1 DIVMTQSLPLPVTGEPASISCRSSQSIHVSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60
Db 20 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSRRF 79

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCGSHVPWTFGGTKVEIK 112
Db 80 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCSTHVPWTFGGGTTKLEIK 131
```

Search completed: January 10, 2006, 20:55:14  
Job time : 13.5124 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 77.3134 Seconds  
(without alignments)  
636.505 Million cell updates/sec

Title: US-10-735-916A-65  
Perfect score: 595  
Sequence: 1 DIVMTQSLPLVPTFGEPAS.....CFQGSHPWTFQGKTKEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq 21:\*  
1: Geneseqp1980a:\*  
2: Geneseqp1990a:\*  
3: Geneseqp2000a:\*  
4: Geneseqp2001a:\*  
5: Geneseqp2002a:\*  
6: Geneseqp2003as:\*  
7: Geneseqp2003bs:\*  
8: Geneseqp2004a:\*  
9: Geneseqp2005a:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	595	100.0	112	7	ADJ76899 Anti-IGF-
2	595	100.0	112	9	ADZ67069 Human ant
3	595	100.0	131	7	ADJ76901 Anti-IGF-
4	595	100.0	131	9	ADZ67071 Human ant
5	594	99.8	112	7	ADJ76895 Anti-IGF-
6	594	99.8	112	9	ADZ67065 Human ant
7	594	99.8	131	7	ADJ76897 Anti-IGF-
8	594	99.8	131	9	ADZ67067 Human ant
9	570	95.8	114	8	ADP84950 Variable
10	567	95.3	112	5	AAE15713 Mouse mon
11	566	95.1	114	8	ADP84948 Variable
12	564	94.8	112	5	AAE15712 Mouse mon
13	564	94.8	112	6	ABP72125 FGF-8 rel
14	564	94.8	112	7	ADZ67071 Human ant
15	564	94.8	114	8	ADP84946 Variable
16	564	94.8	114	8	ADP84951 Variable
17	564	94.8	131	7	ADP84950 Variable
18	563	94.6	114	8	ADP84949 Variable
19	562	94.5	112	5	AAE15711 Mouse mon
20	560	94.1	114	8	ADP84944 Variable
21	559	93.9	112	7	ADZ67065 Human ant
22	559	93.9	112	7	ADZ67065 Human ant
23	559	93.9	114	8	ADP84947 Variable
24	559	93.9	132	7	AAV42969 Humanised

25	557	93.6	112	2	AAE32239 Humanised
26	557	93.6	112	2	AAW27145 Mature li
27	557	93.6	112	3	AAV87571 Humanised
28	557	93.6	112	7	ADZ67071 Human ant
29	557	93.6	114	8	ADP84945 Variable
30	556	93.4	112	6	ABP72129 FGF-8 rel
31	556	93.4	112	7	ADZ67065 Human ant
32	556	93.4	112	9	ADV67310 Amino aci
33	556	93.4	114	8	ADP84952 Variable
34	553	92.9	114	8	ADP84943 Variable
35	552	92.8	112	7	ADZ67065 Human ant
36	549	92.3	112	7	ADJ80420 Hybrid hu
37	549	92.3	132	7	ADH61998 Human ant
38	547	91.9	112	6	ABR40268 Amino aci
39	547	91.9	112	7	ADZ67067 Humanised
40	547	91.9	112	7	ADZ67067 Anti-IGF-
41	547	91.9	112	7	ADJ80422 Murine an
42	547	91.9	112	9	ADZ52545 Anti-CCR4
43	547	91.9	112	9	AEA33234 CC chemok
44	546	91.8	112	6	ABR40272 Amino aci
45	546	91.8	112	7	ADZ67069 Humanised

ALIGNMENTS

RESULT 1  
ADJ76899  
ID ADJ76899 standard; protein; 112 AA.  
XX  
AC ADJ76899;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-1R related protein #14.  
XX  
KW cytosolic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX  
OS Homo sapiens.  
XX  
PN WO2003059951-A2.  
XX  
PD 24-JUL-2003.  
XX  
PF 20-JAN-2003; 2003WO-FR000178.  
XX  
PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
XX  
PR 07-MAY-2002; 2002FR-000005753.  
XX  
PR (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
PI Goetsch L, Corvaia N, Leger O;  
XX  
WPI; 2003-569653/53.  
XX  
PT New antibodies that bind to human insulin-like growth factor receptor,  
PT useful for treatment, prevention and diagnosis of cancers.  
XX  
PS Disclosure; SEQ ID NO 65; 164pp; French.  
XX  
CC The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 112 AA;

Query Match 100.0%; Score 595; DB 7; Length 112;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-43;  
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLQKPGQSPQLLIYKVSNRL 60  
 DB 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLQKPGQSPQLLIYKVSNRL 60  
 QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112  
 DB 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112

RESULT 2  
 ID ADZ67069 standard; protein; 112 AA.  
 XX  
 AC ADZ67069;  
 XX  
 DT 30-JUN-2005 (first entry)  
 XX  
 DE Human antibody 7C10 2 light chain variable region SEQ ID NO:65.  
 XX  
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW light chain variable region.

XX Homo sapiens.  
 XX US2005084906-A1.  
 XX  
 PD 21-APR-2005.  
 XX  
 PF 16-DEC-2003; 2003US-00735916.  
 XX  
 PR 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 PR 20-JAN-2003; 2003WO-FR000178.  
 PR 11-JUL-2003; 2003FR-00008538.  
 XX  
 PA (GOET/) GOETSCH L.  
 PA (CORV/) CORVAIA N.  
 PA (LEGE/) LEGER O.  
 PA (DUFL/) DUFLOS A.  
 PA (HAEU/) HAEUW J.  
 PA (BECK/) BECK A.  
 XX  
 PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 XX  
 DR WPI; 2005-321968/33.  
 XX  
 PT Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.

XX Example 12; SEQ ID NO 65; 125pp; English.

CC The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

SQ Sequence 112 AA;

Query Match 100.0%; Score 595; DB 9; Length 112;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-43;  
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLQKPGQSPQLLIYKVSNRL 60  
 DB 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLQKPGQSPQLLIYKVSNRL 60  
 QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112  
 DB 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112

RESULT 3  
 ID ADJ76901 standard; protein; 131 AA.  
 XX  
 AC ADJ76901;

XX  
 DT 06-MAY-2004 (first entry)  
 XX  
 DE Anti-IGF-IR related protein #15.  
 XX

KW cytostatic; antipsoriatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.

OS Homo sapiens.  
 XX  
 PN WO20003059951-A2.  
 XX  
 PD 24-JUL-2003.  
 XX

```

PF 20-JAN-2003; 2003WO-FR000178.
XX
XX 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX
XX (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
XX Goetsch L, Corvaia N, Leger O;
XX WPI; 2003-569653/53.
XX
XX New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
XX Disclosure; SEQ ID NO 67; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX IR) and optionally; (i) inhibit natural binding of insulin-like growth
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or
XX treat diseases associated with overexpression and/or abnormal activity of
XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
XX hyperactivity of signal transduction pathways mediated by interaction of
XX these receptors with their ligands. Especially they inhibit
XX transformation of normal cells to tumor cells, inhibit growth and/or
XX proliferation of tumor cells, so are useful against cancers of the
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX also for treating psoriasis. Ab are also used to diagnose diseases caused
XX by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
XX protein sequence used to generate the Ab of the invention.
XX
XX Sequence 131 AA;
XX
Query Match 100.0%; Score 595; DB 7; Length 131;
Best Local Similarity 100.0%; Pred. No. 3e-43;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 DIVMTQSLSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLPQSPQLLIYKVSRL 60
Db 20 DIVMTQSLSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLPQSPQLLIYKVSRL 79
Oy 61 YGVDPFRFGSGSGTDTFLKISRVEADVGYYVCFQGSHPVMTFGGTKVEIK 112
Db 80 YGVDPFRFGSGSGTDTFLKISRVEADVGYYVCFQGSHPVMTFGGTKVEIK 131
RESULT 4
ADZ67071
ID ADZ67071 standard; protein; 131 AA.
XX
XX AC ADZ67071;
XX
XX 30-JUN-2005 (first entry)
XX
XX Human antibody 7C10 2 light chain variable region SEQ ID NO:67.
XX
XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
XX neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
XX musculoskeletal disease; respiratory disease; lung tumor;
XX endocrine disease; gynecology and obstetrics; breast tumor;
XX endometroid carcinoma; gastrointestinal disease; colon tumor;
XX antipsoriatic; psoriasis; dermatological disease; immune disorder;
XX light chain variable region.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Peptide 1..19 "leader peptide"
XX FT 43..58
XX FT /note= "CDR1"

```

74..80  
/note= "CDR2"  
113..121  
/note= "CDR3"

US2005084906-A1.

21-APR-2005.

16-DEC-2003; 2003US-00735916.

18-JAN-2002; 2002FR-00000653.  
18-JAN-2002; 2002FR-00000654.  
07-MAY-2002; 2002FR-00005753.  
20-JAN-2003; 2003WO-FR000178.  
11-JUL-2003; 2003FR-00008538.

(GOET/) GOETSCH L.  
(CORV/) CORVAIA N.  
(LEGE/) LEGER O.  
(DUFL/) DUFLOS A.  
(HAEU/) HAEUW J.  
(BECK/) BECK A.

Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

WPI; 2005-321968/33.  
N-PSDB; ADZ67070.

Novel isolated anti-insulin-like growth factor I receptor (IGF-IR) antibody or its functional fragment, being capable of binding human IGF-IR and specifically inhibiting tyrosine kinase activity of receptor, useful for treating cancer.

Example 12; SEQ ID NO 67; 125pp; English.

The invention relates to a novel isolated anti-insulin-like growth factor I receptor (IGF-IR) antibody (I) or its functional fragment, being capable of binding to human IGF-IR and, if necessary, capable of specifically inhibiting tyrosine kinase activity of the receptor, comprising a light or heavy chain having at least one complementary determining region (CDR) consisting of one of two fully defined 16 amino acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in the preparation of a medicament intended for the prevention or treatment of an illness connected with an overexpression and/or an abnormal activation of the IGF-IR and/or EGFR, and/or connected with a hyperactivation of the transduction pathway of the signal mediated by the interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where the administration of the medicament does not induce or only slightly induces secondary effects connected with inhibition of the insulin receptor. The antibody is useful for preparation of a medicament intended to inhibit the transformation of normal cells into cells with tumoral character, preferably IGF-dependent, especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or HSR2/neu-dependent cells. (I) is useful for preparation of a medicament intended to inhibit the growth and/or the proliferation of tumor cells, preferably IGF-dependent, especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or HSR2/neu-dependent cells. (I) is useful in the preparation of a medicament intended for prevention or for the treatment of cancer, where the cancer is chosen from prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer or colon cancer. (I) is useful in the preparation of a medicament intended for the prevention or for the treatment of psoriasis. (I) is useful in preparation of a medicament intended for the specific targeting of a biologically active compound to cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I) is useful for in vitro diagnosis of illnesses induced by an overexpression or an underexpression of the IGF-IR and/or EGFR receptor starting from a biological sample in which the abnormal presence, of IGF-IR and/or EGFR receptor is suspected, which involves contacting the biological sample with (I), which is optionally labeled. The present sequence is used in the exemplification of the invention.

Sequence 131 AA;

Query Match 100.0%; Score 595; DB 9; Length 131;  
 Best Local Similarity 100.0%; Pred. No. 3e-43;  
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRL 60  
 DB 20 DIVMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRL 79  
 QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYVYCFQGSHPVPTFGQGTKEIK 112  
 DB 80 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYVYCFQGSHPVPTFGQGTKEIK 131

## RESULT 5

ADJ76895  
 ID ADJ76895 standard; protein; 112 AA.

AC ADJ76895;

XX 06-MAY-2004 (first entry)

DE Anti-IGF-IR related protein #12.

XX cytostatic; antipsoxiatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 CDR.

XX Homo sapiens.

XX WO2003059951-A2.

XX 24-JUL-2003.

XX 20-JAN-2003; 2003WO-FR000178.

PR 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

XX (FABR ) FABRE MEDICAMENT SA PIERRE.

XX Goetsch L, Corvaia N, Leger O;

XX WPI; 2003-569653/53.

PT New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.

XX Disclosure; SEQ ID NO 61; 164pp; French.

XX The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.

XX Sequence 112 AA;

Query Match 99.8%; Score 594; DB 7; Length 112;  
 Best Local Similarity 99.1%; Pred. No. 3.1e-43;

Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRL 60  
 DB 1 DIVMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRL 60  
 QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYVYCFQGSHPVPTFGQGTKEIK 112  
 DB 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYVYCFQGSHPVPTFGQGTKEIK 112

## RESULT 6

ADZ67065  
 ID ADZ67065 standard; protein; 112 AA.

XX ADZ67065;

XX 30-JUN-2005 (first entry)

XX Human antibody 7C10 1 light chain variable region SEQ ID NO:61.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoxiatic; psoriasis; dermatological disease; immune disorder;  
 KW light chain variable region.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Region 24..39 /note= "CDR1"

FT Region 55..61 /note= "CDR2"

FT Region 94..102 /note= "CDR3"

XX US2005084906-A1.  
 XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR000178.

PR 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

PA (CORV/) CORVAIA N.

PA (LEGE/) LEGER O.

PA (DUPL/) DUPLAS A.

PA (HAU/) HAEUW J.

PA (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

PI WPI; 2005-321968/33.

XX N-PSDB; ADZ67066.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.

XX Example 12; SEQ ID NO 61; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of

specifically inhibiting tyrosine kinase activity of the receptor, comprising a light or heavy chain having at least one complementary determining region (CDR) consisting of one of two fully defined 16 amino acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in the preparation of a medicament intended for the prevention or treatment of an illness connected with an overexpression and/or an abnormal activation of the IGF-IR and/or EGFR, and/or connected with a hyperactivation of the transduction pathway of the signal mediated by the interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where the administration of the medicament does not induce or only slightly induces secondary effects connected with inhibition of the insulin receptor. The antibody is useful for preparation of a medicament intended to inhibit the transformation of normal cells into cells with tumoral character, preferably IGF-dependent, especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is useful for the preparation of a medicament intended for the prevention of cancer, where the cancer is chosen from prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer or colon cancer. (I) is useful in the preparation of a medicament intended for the prevention or for the treatment of psoriasis. (I) is useful in preparation of a medicament intended for the specific targeting of a biologically active compound to cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I) is useful for in vitro diagnosis of illnesses induced by an overexpression or an underexpression of the IGF-IR and/or EGFR receptor starting from a biological sample in which the abnormal presence, of IGF-IR and/or EGFR receptor is suspected, which involves contacting the biological sample with (I), which is optionally labeled. The present sequence is used in the exemplification of the invention.

Sequence 112 AA;

Query Match 99.8%; Score 594; DB 9; Length 112;  
Best Local Similarity 99.1%; Pred. No. 3.1e-43;  
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
QY 61 YGVDPFRFSGSGTDTFTLKISRVEADVGYYVCFQGSHPVPTFGQGTKEIK 112  
Db 61 YGVDPFRFSGSGTDTFTLKISRVEADVGYYVCFQGSHPVPTFGQGTKEIK 112

RESULT 7  
ADJ76897  
ID ADJ76897 standard; protein; 131 AA.  
XX ADJ76897;  
AC ADJ76897;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-1R related protein #13.  
XX  
KW cytostatic; antipsoriatic; antibody;  
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX Homo sapiens.  
OS  
XX  
XX WO2003059951-A2.  
XX  
XX 24-JUL-2003.  
XX  
XX 20-JAN-2003; 2003WO-FR000178.  
XX  
XX 18-JAN-2002; 2002PR-00000653.

PR 18-JAN-2002; 2002PR-00000654.  
PR 07-MAY-2002; 2002PR-00005753.  
XX  
PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
PI Goetsch L, Corvaia N, Leger O;  
XX WPI; 2003-569653/53.  
DR  
XX  
XX New antibodies that bind to human insulin-like growth factor receptor,  
PT useful for treatment, prevention and diagnosis of cancers.  
XX  
PS Disclosure; SEQ ID NO 63; 164pp; French.  
XX  
CC The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of  
CC these receptors with their ligands. Especially they inhibit  
CC transformation of normal cells to tumor cells, inhibit growth and/or  
CC proliferation of tumor cells, so are useful against cancers of the  
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
CC protein sequence used to generate the Ab of the invention.  
XX  
SQ Sequence 131 AA;  
Query Match 99.8%; Score 594; DB 7; Length 131;  
Best Local Similarity 99.1%; Pred. No. 3.6e-43;  
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
Db 20 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 79  
QY 61 YGVDPFRFSGSGTDTFTLKISRVEADVGYYVCFQGSHPVPTFGQGTKEIK 112  
Db 80 YGVDPFRFSGSGTDTFTLKISRVEADVGYYVCFQGSHPVPTFGQGTKEIK 131  
RESULT 8  
ADZ67067  
ID ADZ67067 standard; protein; 131 AA.  
XX  
XX ADZ67067;  
AC  
XX  
XX 30-JUN-2005 (first entry)  
DT  
XX  
DE Human antibody 7C10 1 light chain variable region SEQ ID NO:63.  
XX  
KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
KW musculoskeletal disease; respiratory disease; lung tumor;  
KW endocrine disease; gynecology and obstetrics; breast tumor;  
KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
KW light chain variable region.  
XX  
XX Homo sapiens.  
OS  
XX  
XX  
FH Key Location/Qualifiers  
FT Peptide 1..19  
FT /note= "leader peptide"  
FT Region 43..62  
FT /note= "CDR1"  
FT Region 74..80  
FT /note= "CDR2"  
FT Region 113..121

FT US2005084906-A1. /note= "CDR3"  
PN 21-APR-2005.  
XX  
PD 16-DEC-2003; 2003US-00735916.  
PF 18-JAN-2002; 2002FR-00000653.  
XX 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX 20-JAN-2003; 2003WO-FR000178.  
PR 11-JUL-2003; 2003FR-00008538.  
XX (GOET/) GOETSCH L.  
PA (CORV/) CORVAIA N.  
XX (LEGE/) LEGER O.  
PA (DUFL/) DUFLOS A.  
XX (HAUW/) HAEUW J.  
PA (BECK/) BECK A.  
XX  
PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
XX WPI; 2005-321968/33.  
DR N-PSDB; AD267066.  
XX  
PT Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
XX antibody or its functional fragment, being capable of binding human IGF-  
PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
XX useful for treating cancer.  
XX  
PS Example 12; SEQ ID NO 63; 125pp; English.  
XX  
CC The invention relates to a novel isolated anti-insulin-like growth factor  
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
CC capable of binding to human IGF-IR and, if necessary, capable of  
CC specifically inhibiting tyrosine kinase activity of the receptor,  
CC comprising a light or heavy chain having at least one complementary  
CC determining region (CDR) consisting of one of two fully defined 16 amino  
CC acids (AD267006 and AD267014). An antibody of the invention is useful in  
CC the preparation of a medicament intended for the prevention or treatment  
CC of an illness connected with an overexpression and/or an abnormal  
CC activation of the IGF-IR and/or EGFR, and/or connected with a  
CC hyperactivation of the transduction pathway of the signal mediated by the  
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
CC the administration of the medicament does not induce or only slightly  
CC induces secondary effects connected with inhibition of the insulin  
CC receptor. The antibody is useful for preparation of a medicament intended  
CC to inhibit the transformation of normal cells into cells with tumoral  
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
CC useful for preparation of a medicament intended to inhibit the growth  
CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
CC medicament intended for prevention or for the treatment of cancer, where  
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
CC preparation of a medicament intended for the prevention or for the  
CC treatment of psoriasis. (I) is useful in preparation of a medicament  
CC intended for the specific targeting of a biologically active compound to  
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
CC is useful for in vitro diagnosis of illnesses induced by an  
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
CC starting from a biological sample in which the abnormal presence, of IGF-  
CC IR and/or EGFR receptor is suspected, which involves contacting the  
CC biological sample with (I), which is optionally labeled. The present  
CC sequence is used in the exemplification of the invention.  
XX  
SQ Sequence 131 AA;  
Query Match 99.8%; Score 594; DB 9; Length 131;  
Best Local Similarity 99.1%; Pred. No. 3.6e-43;

Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DIVNTQSPLSLPVTTPGEPASISCRSSOSIVHSNGNTYLOWLYLQKPGQSPQLLIYKVSRL 60  
DB 20 DVVNTQSPLSLPVTTPGEPASISCRSSOSIVHSNGNTYLOWLYLQKPGQSPQLLIYKVSRL 79  
QY 61 YGVPDFRFGSGSGTDFTLKISRVEADVGYYFCQGSHPVMTFGGQTKVEIK 112  
DB 80 YGVPDFRFGSGSGTDFTLKISRVEADVGYYFCQGSHPVMTFGGQTKVEIK 131  
RESULT 9  
ADP84950  
ID ADP84950 standard; protein; 114 AA.  
XX  
AC ADP84950;  
XX  
DT 09-SEP-2004 (first entry)  
XX  
DE Variable light chain VL fragment Kars24 SEQ ID NO 92.  
XX  
KW antibody; Core-1 antigen; framework region; immunoglobulin superfamily;  
KW protease inhibitor; lectin; helix-bundle protein; lipocalin;  
KW variable heavy chain; VH; variable light chain; VL; vaccine; diagnosis;  
KW alleviation; treatment; tumour; breast; colon; stomach; pancreas;  
KW large/small intestine; ovary; cervix; lung; prostate; kidney; liver;  
KW metastasis.  
XX  
OS Mus musculus.  
OS Homo sapiens.  
OS Chimeric.  
XX  
FN WO2004050707-A2.  
XX  
PD 17-JUN-2004.  
XX  
PF 01-DEC-2003; 2003WO-DE003994.  
XX  
PR 29-NOV-2002; 2002DE-01056900.  
XX (NEMO-) NEMOD BIOTHERAPEUTICS GMBH & CO KG.  
XX  
PI Goletz S, Danielczyk A, Karsten U, Ravn P, Stahn R;  
XX Christensen PA;  
XX  
DR WPI; 2004-461095/43.  
XX  
PT New recognition molecules, e.g. antibodies (and nucleic acids) that bind  
PT specifically to Core-1 antigens, useful for diagnosis, treatment and  
PT prevention of tumors and metastases.  
XX  
PS Claim 15; SEQ ID NO 92; 136pp; German.  
XX  
CC This invention describes novel recognition molecules, especially  
CC antibodies that bind specifically to the Core-1 antigen. The recognition  
CC molecules are used to make constructs containing the framework regions  
CC that separate, include and/or flank the specified sequences, especially  
CC where the framework regions are from the immunoglobulin (Ig) superfamily,  
CC protease inhibitors, lectins, helix-bundle proteins and/or lipocalins.  
CC Most especially the framework regions are from antibodies, particularly  
CC the variable heavy chain (VH) and the variable light chain (VL) of human  
CC and/or murine origin. The constructs may also include a His or myc tag, a  
CC lysine-rich region and/or a multimerisation domain, most particularly it  
CC is a single-chain antibody fragment, multibody, Fab fragment, fusion  
CC protein of an antibody fragment with peptide or protein, and/or an Ig of  
CC types G, M, A, E or D and/or their subclasses. It may be human,  
CC humanised, murine or chimeric, e.g. IGM without the J chain. The  
CC additional sequences/structures in the constructs are Ig domains of  
CC various species, interacting or stabilising domains, signal sequences,  
CC fluorescent dyes, toxins, antibodies with catalytic activity or other  
CC specificities, cytolytic agents, enzymes, chelators for radioactive labels,  
CC effectors, MHC molecules, antigens, chelators for radioactive labels,  
CC liposomes, transmembrane domains, viruses and/or cells, specifically

CC macrophages. The antibodies, also constructs containing them, nucleic  
 CC acid encoding them, and related vectors and host cells, are useful for  
 CC prevention (e.g. as vaccine), diagnosis, alleviation, treatment,  
 CC monitoring and/or secondary treatment of tumours (specifically of breast,  
 CC colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,  
 CC prostate, kidney and/or liver) and/or metastases (particularly to liver),  
 CC specifically where these are positive for the CI antigen. The products of  
 CC the invention provide simple, reliable and efficient detection of  
 CC tumours. They are specific for carcinoma and show almost no binding to  
 CC healthy tissue.

XX SQ Sequence 114 AA;

Query Match 95.8%; Score 570; DB 8; Length 114;  
 Best Local Similarity 96.4%; Pred. No. 3.5e-41;  
 Matches 108; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPQLLIYKVSNNRL 60  
 Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPQLLIYKVSNNRF 60  
 QY 61 YGVPPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKVEIK 112  
 Db 61 SGVPPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKVEIK 112

RESULT 10

AAE15713  
 ID AAE15713 standard; protein; 112 AA.

AC AAE15713;

DT 12-MAR-2002 (first entry)

DE Mouse monoclonal antibody alpha 340 Vk region variant, 340VKD.

KW Mouse; humanised form; monoclonal antibody alpha 340; gene therapy;  
 KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;  
 KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;  
 KW inhibitor; mutant; mutein; variant.

OS Mus sp.

OS Synthetic.

Key Location/Qualifiers

FT Misc-difference 7 /note= "wild type Thr substituted with Ser"  
 FT FT  
 FT Misc-difference 14 /note= "wild type Ser substituted with Thr"  
 FT FT  
 FT Misc-difference 15 /note= "wild type Leu substituted with Pro"  
 FT FT  
 FT Misc-difference 17 /note= "wild type Asp substituted with Glu"  
 FT FT  
 FT Misc-difference 18 /note= "wild type Gln substituted with Pro"  
 FT FT  
 FT Misc-difference 50 /note= "wild type Lys substituted with Gln"  
 FT FT  
 FT Misc-difference 88 /note= "wild type Leu substituted with Val"  
 FT FT  
 FT Misc-difference 109 /note= "wild type Leu substituted with Val"  
 FT FT  
 FT Misc-difference 112 /note= "wild type Asn substituted with Lys"  
 FT FT

PN WO200108138-A1.

XX 22-NOV-2001.

XX 21-MAY-2001; 2001WO-GB002226.

XX 19-MAY-2000; 2000GB-00011981.

PR 24-AUG-2000; 2000GB-00020794.

PA (SCAN-) SCANCELL LTD.

XX Ellis JRM, Durrant LG;

XX WPI; 2002-062384/08.

XX New humanized form of mouse monoclonal antibody 340 which binds to  
 FT epidermal growth factor receptor and inhibits binding of growth factor,  
 FT useful for treating colorectal, lung, breast, gastric and ovarian cancer.  
 XX Example 2; Fig 7; 53pp; English.

CC The present invention relates to a humanised form of the antibody 340 (a  
 CC mouse monoclonal antibody which binds to epidermal growth factor (EGF)  
 CC receptor and inhibits binding of EGF), obtainable from the cell line  
 CC deposited with the ECACC under accession number 97021428. The humanised  
 CC form of the antibody 340 is useful in gene therapy, medicine and in the  
 CC manufacture of a medicament for treatment or prophylaxis of cancer. The  
 CC invention is useful for treating colorectal, lung, breast, gastric or  
 CC ovarian cancers or also for preventing the recurrence of cancer after  
 CC initial treatment or surgery. The invention is also useful for enhancing  
 CC a protective immune response against cancer by optimised immunisation  
 CC schedules. The humanised form of the antibody 340 has reduced  
 CC immunogenicity but shows similar binding to cells expressing EGF  
 CC receptor, as the original murine antibody and has increased ability to  
 CC inhibit the growth of EGF receptor expressing cells. The invention is  
 CC used as cell growth and apoptosis inhibitor. The present sequence is  
 CC mouse monoclonal antibody alpha 340 deimmunised light chain variable (VK)  
 CC region variant, 340VKD  
 XX SQ Sequence 112 AA;

Query Match 95.3%; Score 567; DB 5; Length 112;

Best Local Similarity 93.8%; Pred. No. 6.3e-41;  
 Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPQLLIYKVSNNRL 60  
 Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPQLLIYKVSNNRF 60

QY 61 YGVPPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKVEIK 112

Db 61 SGVPPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKVEIK 112

RESULT 11

ADP84948

ID ADP84948 standard; protein; 114 AA.

AC ADP84948;

DT 09-SEP-2004 (first entry)

DE Variable light chain VL fragment Karol1 SEQ ID NO 90.

XX antibody; Core-1 antigen; framework region; immunoglobulin superfamily;  
 KW protease inhibitor; lectin; helix-bundle protein; lipocalin;  
 KW variable heavy chain; VH; variable light chain; VL; vaccine; diagnosis;  
 KW alleviation; treatment; tumour; breast; colon; stomach; pancreas;  
 KW large/small intestine; ovary; cervix; lung; prostate; kidney; liver;  
 KW metastasis.

XX Mus musculus.

OS Homo sapiens.

OS Chimeric.

XX WO2004050707-A2.

XX 17-JUN-2004.

XX 01-DEC-2003; 2003WO-DE003994.

XX 29-NOV-2002; 2002DE-01056900.

```

XX (NEMO-) NEMOD BIOTHERAPEUTICS GMBH & CO KG.
XX PA
XX PI
XX PI Christensen PA;
XX PI
XX DR
XX DR WPI; 2004-461095/43.
XX PT
XX PT New recognition molecules, e.g. antibodies (and nucleic acids) that bind
XX PT specifically to Core-1 antigens, useful for diagnosis, treatment and
XX PT prevention of tumors and metastases.
XX PS
XX PS Claim 15; SEQ ID NO 90; 136pp; German.
XX CC
XX CC This invention describes novel recognition molecules, especially
XX CC antibodies that bind specifically to the Core-1 antigen. The recognition
XX CC molecules are used to make constructs containing the framework regions
XX CC that separate, include and/or flank the specified sequences, especially
XX CC where the framework regions are from the immunoglobulin (Ig) superfamily,
XX CC protease inhibitors, lectins, helix-bundle proteins and/or lipocalins.
XX CC Most especially the framework regions are from antibodies, particularly
XX CC the variable heavy chain (VH) and the variable light chain (VL) of human
XX CC and/or murine origin. The constructs may also include a His or myc tag, a
XX CC lysine-rich region and/or a multimerisation domain, most particularly it
XX CC is a single-chain antibody fragment, multibody, Fab fragment, fusion
XX CC protein of an antibody fragment with peptide or protein, and/or an Ig of
XX CC types G, M, A, E or D and/or their subclasses. It may be human,
XX CC humanised, murine or chimeric, e.g. IgM without the J chain. The
XX CC additional sequences/structures in the constructs are Ig domains of
XX CC various species, interacting or stabilising domains, signal sequences,
XX CC fluorescent dyes, toxins, antibodies with catalytic activity or other
XX CC specificities, cytolytic agents, enzymes, immuno-modulators or -
XX CC effectors, MHC molecules, antigens, chelators for radioactive labels,
XX CC liposomes, transmembrane domains, viruses and/or cells, specifically
XX CC macrophages. The antibodies, also constructs containing them, nucleic
XX CC acid encoding them, and related vectors and host cells, are useful for
XX CC prevention (e.g. as vaccine), diagnosis, alleviation, treatment,
XX CC monitoring and/or secondary treatment of tumours (specifically of breast,
XX CC colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,
XX CC prostate, kidney and/or liver) and/or metastases (particularly to liver),
XX CC specifically where these are positive for the C1 antigen. The products of
XX CC the invention provide simple, reliable and efficient detection of
XX CC tumours. They are specific for carcinoma and show almost no binding to
XX CC healthy tissue.
XX SQ Sequence 114 AA;

Query Match 95.1%; Score 566; DB 8; Length 114;
Best Local Similarity 95.5%; Pred. No. 7.8e-41;
Matches 107; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHNSNGNTYLQWYLOKPGQSPQLLIYKVSNRL 60
DB 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHNSNGNTYLEWYLOKPGQSPQLLIYKVSNRF 60
QY 61 YGVPRFSGSGSGTFTLKISRVEADGVVYFCFGSHVPTFGGTKEIK 112
DB 61 SGVPRFSGSGSGTFTLKISRVEADGVVYFCFGSHVPTFGGTKEIK 112

RESULT 12
AAE15712
ID AAE15712 standard; protein; 112 AA.
AC AAE15712;
XX 12-MAR-2002 (first entry)
XX DE Mouse monoclonal antibody alpha 340 Vk region variant, 340VKC.
XX KW Mouse; humanised form; monoclonal antibody alpha 340; gene therapy;
XX KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;
XX KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;

inhibitor; mutant; mutein; variant.
XX Mus sp.
XX Synthetic.
XX Key Location/Qualifiers
XX FT Misc-difference 7 /note= "Wild type Thr substituted with Ser"
XX FT Misc-difference 14 /note= "Wild type Ser substituted with Thr"
XX FT Misc-difference 15 /note= "Wild type Leu substituted with Pro"
XX FT Misc-difference 17 /note= "Wild type Asp substituted with Glu"
XX FT Misc-difference 18 /note= "Wild type Gln substituted with Pro"
XX FT Misc-difference 50 /note= "Wild type Lys substituted with Gln"
XX FT Misc-difference 88 /note= "Wild type Leu substituted with Thr"
XX FT Misc-difference 90 /note= "Wild type Ile substituted with Val"
XX FT Misc-difference 109 /note= "Wild type Leu substituted with Val"
XX FT Misc-difference 112 /note= "Wild type Asn substituted with Lys"
XX WO200188138-A1.
XX 22-NOV-2001.
XX 21-MAY-2001; 2001WO-GB0022236.
XX 19-MAY-2000; 2000GB-00011981.
XX 24-AUG-2000; 2000GB-00020794.
XX (SCAN-) SCANCELL LTD.
XX Ellis JRM, Durrant LG;
XX WPI; 2002-062384/08.
XX New humanized form of mouse monoclonal antibody 340 which binds to
XX epidermal growth factor receptor and inhibits binding of growth factor,
XX useful for treating colorectal, lung, breast, gastric and ovarian cancer.
XX Example 2; Fig 7; 53pp; English.
XX The present invention relates to a humanised form of the antibody 340 (a
XX mouse monoclonal antibody which binds to epidermal growth factor (EGF)
XX receptor and inhibits binding of EGF), obtainable from the cell line
XX deposited with the ECACC under accession number 97021428. The humanised
XX form of the antibody 340 is useful in gene therapy, medicine and in the
XX manufacture of a medicament for treatment or prophylaxis of cancer. The
XX invention is useful for treating colorectal, lung, breast, gastric or
XX ovarian cancers or also for preventing the recurrence of cancer after
XX initial treatment or surgery. The invention is also useful for enhancing
XX a protective immune response against cancer by optimised immunisation
XX schedules. The humanised form of the antibody 340 has reduced
XX immunogenicity but shows similar binding to cells expressing EGF
XX receptor, as the original murine antibody and has increased ability to
XX inhibit the growth of EGF receptor expressing cells. The invention is
XX used as cell growth and apoptosis inhibitor. The present sequence is
XX mouse monoclonal antibody alpha 340 deimmunised light chain variable (VK)
XX region variant, 340VKC
XX Sequence 112 AA;

Query Match 94.8%; Score 564; DB 5; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.1e-40;
Matches 105; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHNSNGNTYLQWYLOKPGQSPQLLIYKVSNRL 60

```

```

Db      1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVHNGNTYLEWYLQKPGQSPQLLIYKVSRL 60
      61 YGVPRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVMTFGGQTKVEIK 112
      61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVMTFGGQTKVEIK 112

RESULT 13
ABP72125
ID      ABP72125 standard; protein; 112 AA.
XX
AC      ABP72125;
XX
DT      03-JUN-2003 (first entry)
XX
DE      FGF-8 related protein SEQ ID 17.
XX
KW      Humanised; antibody; fibroblast growth factor 8; FGF8; cytostatic;
KW      cancer; prostate; breast; ovarian; testicular.
XX
OS      Synthetic.
XX
PN      WO2003002608-A1.
XX
PD      09-JAN-2003.
XX
PF      28-JUN-2002; 2002WO-JP006591.
XX
PR      28-JUN-2001; 2001JP-00196176.
XX
PA      (KYOW ) KYOWA HAKKO KOGYO KK.
XX
PI      Shitara K, Nakamura K, Hirota M, Shimada N;
XX
DR      WPI; 2003-239169/23.
XX
PT      Humanised antibodies and antibody fragments reacting with fibroblast
PT      growth factor 8 useful for the treatment and diagnosis of cancer.
XX
PS      Claim 19; Page 72; 86pp; Japanese.
XX
CC      The invention relates to novel humanised antibodies and antibody
CC      fragments which react with fibroblast growth factor 8 (FGF8) and inhibit
CC      its biological functions. The polypeptides of the invention have
CC      cytostatic activity. The antibody is useful for the treatment of cancer,
CC      including prostate, breast, ovarian and testicular cancer. The present
CC      sequence is used in the exemplification of the invention
XX
SQ      Sequence 112 AA;

Query Match      94.8%; Score 564; DB 6; Length 112;
Best Local Similarity 94.6%; Pred. No. 1.1e-40;
Matches 106; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVHNGNTYLEWYLQKPGQSPQLLIYKVSRL 60
Db      1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVHNGNTYLEWYLQKPGQSPQLLIYKVSRL 60
QY      61 YGVPRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVMTFGGQTKVEIK 112
Db      61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVMTFGGQTKVEIK 112

RESULT 14
ADE36495
ID      ADE36495 standard; protein; 112 AA.
XX
AC      ADE36495;
XX
DT      29-JAN-2004 (first entry)
XX
DE      Anti-FGF-8 (sic fibroblast growth factor) antibody-related protein #2.

```

```

XX      arthritis; anti-FGF-8; sic fibroblast growth factor;
KW      cartilage protection agent; joint destruction inhibitor;
KW      synovial proliferation inhibitor.
XX
OS      Unidentified.
XX
PN      WO2003057251-A1.
XX
PD      17-JUL-2003.
XX
PF      26-DEC-2002; 2002WO-JP013650.
XX
PR      28-DEC-2001; 2001JP-00400677.
XX
PA      (KYOW ) KYOWA HAKKO KOGYO KK.
XX
PI      Tamura T, Uchii M, Suda T, Miki I, Tanaka A;
XX
DR      WPI; 2003-587078/55.
XX
PT      Treatment and prevention of arthritis comprising the use of anti-FGF-8
PT      (sic fibroblast growth factor) antibody.
XX
PS      Claim 11; SEQ ID NO 19; 193pp; Japanese.
XX
CC      The invention comprises a method for treating and preventing arthritis,
CC      the method involves the use of anti-FGF-8 (sic fibroblast growth factor)
CC      antibody. The antibody and method of the invention is useful for: the
CC      detection, treatment and prevention of arthritis; as a cartilage
CC      protection agent; as a joint destruction inhibitor; and as a synovial
CC      proliferation inhibitor. The present amino acid sequence represents a
CC      protein of the invention.
XX
SQ      Sequence 112 AA;

Query Match      94.8%; Score 564; DB 7; Length 112;
Best Local Similarity 94.6%; Pred. No. 1.1e-40;
Matches 106; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVHNGNTYLEWYLQKPGQSPQLLIYKVSRL 60
Db      1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVHNGNTYLEWYLQKPGQSPQLLIYKVSRL 60
QY      61 YGVPRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVMTFGGQTKVEIK 112
Db      61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVMTFGGQTKVEIK 112

RESULT 15
ADP84946
ID      ADP84946 standard; protein; 114 AA.
XX
AC      ADP84946;
XX
DT      09-SEP-2004 (first entry)
XX
DE      Variable light chain VL fragment Karo18 SEQ ID NO 88.
XX
KW      antibody; Core-1 antigen; framework region; immunoglobulin superfamily;
KW      protease inhibitor; lectin; helix-bundle protein; lipocalin;
KW      variable heavy chain; VH; variable light chain; VL; vaccine; diagnosis;
KW      alleviation; treatment; tumour; breast; colon; stomach; pancreas;
KW      large/small intestine; ovary; cervix; lung; prostate; kidney; liver;
KW      metastasis.
XX
OS      Mus musculus.
OS      Homo sapiens.
OS      Chimeric.
XX
PN      WO2004050707-A2.
XX
PD      17-JUN-2004.

```

XX 01-DEC-2003; 2003WO-DE003994.  
XX 29-NOV-2002; 2002DE-01056900.  
XX (NEMO-) NEMOD BIOTHERAPEUTICS GMBH & CO KG.  
XX Goletz S, Danielczyk A, Karsten U, Ravn P, Stahn R;  
XX Christensen PA;  
XX WPI; 2004-461095/43.  
XX  
XX New recognition molecules, e.g. antibodies (and nucleic acids) that bind  
XX specifically to Core-1 antigens, useful for diagnosis, treatment and  
XX prevention of tumors and metastases.  
XX  
XX Claim 15; SEQ ID NO 88; 136pp; German.  
XX  
XX This invention describes novel recognition molecules, especially  
XX antibodies that bind specifically to the Core-1 antigen. The recognition  
XX molecules are used to make constructs containing the framework regions  
XX that separate, include and/or flank the specified sequences, especially  
XX where the framework regions are from the immunoglobulin (Ig) superfamily,  
XX protease inhibitors, lectins, helix-bundle proteins and/or lipocalins.  
XX Most especially the framework regions are from antibodies, particularly  
XX the variable heavy chain (VH) and the variable light chain (VL) of human  
XX and/or murine origin. The constructs may also include a His or myc tag, a  
XX lysine-rich region and/or a multimerisation domain, most particularly it  
XX is a single-chain antibody fragment, multibody, Fab fragment, fusion  
XX protein of an antibody fragment with peptide or protein, and/or an Ig of  
XX types G, M, A, E or D and/or their subclasses. It may be human,  
XX humanised, murine or chimeric, e.g. IgM without the J chain. The  
XX additional sequences/structures in the constructs are Ig domains of  
XX various species, interacting or stabilising domains, signal sequences,  
XX fluorescent dyes, toxins, antibodies with catalytic activity or other  
XX specificities, cytolytic agents, enzymes, immuno-modulators or -  
XX effectors, MHC molecules, antigens, chelators for radioactive labels,  
XX liposomes, transmembrane domains, viruses and/or cells, specifically  
XX macrophages. The antibodies, also constructs containing them, nucleic  
XX acid encoding them, and related vectors and host cells, are useful for  
XX prevention (e.g. as vaccine), diagnosis, alleviation, treatment,  
XX monitoring and/or secondary treatment of tumours (specifically of breast,  
XX colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,  
XX prostate, kidney and/or liver) and/or metastases (particularly to liver),  
XX specifically where these are positive for the C1 antigen. The products of  
XX the invention provide simple, reliable and efficient detection of  
XX tumours. They are specific for carcinoma and show almost no binding to  
XX healthy tissue.  
XX  
XX SQ Sequence 114 AA;

Query Match 94.8%; Score 564; DB 8; Length 114;  
Best Local Similarity 95.5%; Pred. No. 1.2e-40;  
Matches 107; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIWMTQSPLSLVPTGEPASISCRSSQSIHVSNGNTYLYWYLOKPGQSPOLLIIYKVSRL 60  
DB 1 DIQMTQSPLSLVPTGEPASISCRSSQSIHVSNGNTYLYWYLOKPGQSPOLLIIYKVSRL 60

QY 61 YGVPRFSGSGGTFTLTKISRVEADGVYVYCFQGSHPVMTFGQGTKVEIK 112  
DB 61 SGVPRFSGSGGTFTLTKISRVEADGVYVYCFQGSHPVMTFGQGTKVEIK 112

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

# OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.71144 Seconds  
(without alignments)  
166.558 Million cell updates/sec

Title: US-10-735-916A-61

Perfect score: 595

Sequence: 1 DVMWTSPLSLPVTGEPAS.....CFQSGSHVPTFGQTKVEIK 112

## Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

## Database :

- Published Applications AA New:\*
- 1: /cgn2\_6/ptodata/1/pubpaa/US08\_NEW\_PUB.pap.\*
  - 2: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pap.\*
  - 3: /cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pap.\*
  - 4: /cgn2\_6/ptodata/1/pubpaa/ECT\_NEW\_PUB.pap.\*
  - 5: /cgn2\_6/ptodata/1/pubpaa/US09\_NEW\_PUB.pap.\*
  - 6: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pap.\*
  - 7: /cgn2\_6/ptodata/1/pubpaa/US11\_NEW\_PUB.pap.\*
  - 8: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pap.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	595	100.0	112	7	US-11-012-353-61
2	595	100.0	131	7	US-11-012-353-63
3	594	99.8	112	7	US-11-012-353-65
4	594	99.8	131	7	US-11-012-353-67
5	547	91.9	112	6	US-10-959-310-33
6	546	91.8	112	6	US-10-959-310-26
7	544	91.4	112	6	US-10-959-310-35
8	543	91.3	112	6	US-10-959-310-34
9	538	90.4	112	7	US-11-012-353-54
10	538	90.4	122	7	US-11-012-353-49
11	531	89.2	112	7	US-11-012-353-56
12	524	88.1	131	7	US-11-125-837-23
13	522	87.7	263	7	US-11-089-266-66
14	520	87.4	112	7	US-11-012-353-55
15	520	87.4	112	7	US-11-012-353-57
16	520	87.4	149	7	US-11-089-266-2
17	516	86.7	116	7	US-11-065-943-49
18	515	86.6	112	7	US-11-089-266-15
19	515	86.6	113	6	US-10-932-334-61
20	514	86.4	113	6	US-10-932-334-69
21	512	86.1	113	6	US-10-932-334-66
22	512	86.1	113	6	US-10-932-334-68
23	511	85.9	113	6	US-10-932-334-9
24	511	85.9	113	6	US-10-932-334-12
25	511	85.9	113	6	US-10-932-334-83

26	511	85.9	113	6	US-10-932-334-86	Sequence 86, Appl
27	511	85.9	113	6	US-10-932-334-90	Sequence 90, Appl
28	510	85.7	113	6	US-10-932-334-65	Sequence 65, Appl
29	510	85.7	251	6	US-10-512-184-30	Sequence 30, Appl
30	510	85.7	320	6	US-10-512-184-67	Sequence 67, Appl
31	510	85.7	569	6	US-10-512-184-66	Sequence 66, Appl
32	510	85.7	618	6	US-10-512-184-48	Sequence 48, Appl
33	509	85.5	113	6	US-10-932-334-60	Sequence 60, Appl
34	508	85.4	113	6	US-10-932-334-10	Sequence 10, Appl
35	508	85.4	113	6	US-10-932-334-11	Sequence 11, Appl
36	508	85.4	113	6	US-10-932-334-59	Sequence 59, Appl
37	508	85.4	113	6	US-10-932-334-84	Sequence 84, Appl
38	508	85.4	113	6	US-10-932-334-85	Sequence 85, Appl
39	508	85.4	113	6	US-10-932-334-94	Sequence 94, Appl
40	503	84.5	113	6	US-10-932-334-8	Sequence 8, Appl
41	503	84.5	113	6	US-10-932-334-58	Sequence 58, Appl
42	503	84.5	113	6	US-10-932-334-62	Sequence 62, Appl
43	503	84.5	113	6	US-10-932-334-82	Sequence 82, Appl
44	503	84.5	132	6	US-10-932-334-50	Sequence 50, Appl
45	501	84.2	131	6	US-10-789-273-14	Sequence 14, Appl

## ALIGNMENTS

### RESULT 1

US-11-012-353-61  
; Sequence 61, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, LILLIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFLOS, ALAIN  
; APPLICANT: HAEUW, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012,353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: Patent in Ver. 3.3  
; SEQ ID NO 61  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Homo sapiens

Query Match 100.0%; Score 595; DB 7; Length 112;  
Best Local Similarity 100.0%; Pred. No. 2.5e-40;  
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	DVMWTSPLSLPVTGEPASISCRSSQIVHSNGNTYLOWYLOKFGQSPQLLIYKVSRL	60
DB	1	DVMWTSPLSLPVTGEPASISCRSSQIVHSNGNTYLOWYLOKFGQSPQLLIYKVSRL	60
QY	61	YGVDRFSGSGGTDFTLKISRVEAEDVGVYYCFQSGSHVPTFGQTKVEIK	112
DB	61	YGVDRFSGSGGTDFTLKISRVEAEDVGVYYCFQSGSHVPTFGQTKVEIK	112

```
RESULT 2
US-11-012-353-63
; Sequence 63, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 63
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-63

Query Match      100.0%; Score 595; DB 7; Length 131;
Best Local Similarity 100.0%; Pred. No. 2.9e-40; Indels 0; Gaps 0;
Matches 112; Conservative 0; Mismatches 0;

Qy 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLPKPGSPQLLIYKVSNRL 60
Db 20 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLPKPGSPQLLIYKVSNRL 79

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
Db 80 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 131

RESULT 3
US-11-012-353-65
; Sequence 65, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 65
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-65

Query Match      99.8%; Score 594; DB 7; Length 131;
Best Local Similarity 99.1%; Pred. No. 3.5e-40; Indels 0; Gaps 0;
Matches 111; Conservative 1; Mismatches 0;

Qy 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLPKPGSPQLLIYKVSNRL 60
Db 20 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLPKPGSPQLLIYKVSNRL 79

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
Db 80 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 131
```

```
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 65
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-65

Query Match      99.8%; Score 594; DB 7; Length 112;
Best Local Similarity 99.1%; Pred. No. 3e-40; Indels 0; Gaps 0;
Matches 111; Conservative 1; Mismatches 0;

Qy 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLPKPGSPQLLIYKVSNRL 60
Db 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLPKPGSPQLLIYKVSNRL 60

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
Db 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112

RESULT 4
US-11-012-353-67
; Sequence 67, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 67
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-67

Query Match      99.8%; Score 594; DB 7; Length 131;
Best Local Similarity 99.1%; Pred. No. 3.5e-40; Indels 0; Gaps 0;
Matches 111; Conservative 1; Mismatches 0;

Qy 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLPKPGSPQLLIYKVSNRL 60
Db 20 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLQWYLPKPGSPQLLIYKVSNRL 79

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
Db 80 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 131
```

Db 61 SGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSLLPWTFGQTKVEIK 112

RESULT 7  
US-10-959-310-35  
; Sequence 35, Application US/10959310  
; Publication No. US20050287138A1  
; GENERAL INFORMATION:  
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.  
; TITLE OF INVENTION: CCR4-specific antibody composition  
; FILE REFERENCE: 249-363  
; CURRENT APPLICATION NUMBER: US/10/959,310  
; CURRENT FILING DATE: 2004-10-07  
; PRIOR APPLICATION NUMBER: JP 2003-350162  
; PRIOR FILING DATE: 2003-10-08  
; PRIOR APPLICATION NUMBER: US 60/572,784  
; PRIOR FILING DATE: 2004-05-21  
; NUMBER OF SEQ ID NOS: 46  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 35  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic peptide  
US-10-959-310-35

Query Match 91.4%; Score 544; DB 6; Length 112;  
Best Local Similarity 91.1%; Pred. No. 2.2e-36;  
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;  
QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
Db 1 DVVMTQSPSLPVTGPEPASISCRSSRNIVHNGDTYLEWYLOKPGQSPQLLIYKVSRLF 60  
QY 61 YGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSHPVPTFGQTKVEIK 112  
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSLLPWTFGQTKVEIK 112

RESULT 8  
US-10-959-310-34  
; Sequence 34, Application US/10959310  
; Publication No. US20050287138A1  
; GENERAL INFORMATION:  
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.  
; TITLE OF INVENTION: CCR4-specific antibody composition  
; FILE REFERENCE: 249-363  
; CURRENT APPLICATION NUMBER: US/10/959,310  
; CURRENT FILING DATE: 2004-10-07  
; PRIOR APPLICATION NUMBER: JP 2003-350162  
; PRIOR FILING DATE: 2003-10-08  
; PRIOR APPLICATION NUMBER: US 60/572,784  
; PRIOR FILING DATE: 2004-05-21  
; NUMBER OF SEQ ID NOS: 46  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 34  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic peptide  
US-10-959-310-34

Query Match 91.3%; Score 543; DB 6; Length 112;  
Best Local Similarity 90.2%; Pred. No. 2.7e-36;  
Matches 101; Conservative 7; Mismatches 4; Indels 0; Gaps 0;  
QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
Db 1 DILMTQSPSLPVTGPEPASISCRSSRNIVHNGDTYLEWYLOKPGQSPQLLIYKVSRLF 60  
QY 61 YGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSHPVPTFGQTKVEIK 112

US-10-959-310-33  
; Sequence 33, Application US/10959310  
; Publication No. US20050287138A1  
; GENERAL INFORMATION:  
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.  
; TITLE OF INVENTION: CCR4-specific antibody composition  
; FILE REFERENCE: 249-363  
; CURRENT APPLICATION NUMBER: US/10/959,310  
; CURRENT FILING DATE: 2004-10-07  
; PRIOR APPLICATION NUMBER: JP 2003-350162  
; PRIOR FILING DATE: 2003-10-08  
; PRIOR APPLICATION NUMBER: US 60/572,784  
; PRIOR FILING DATE: 2004-05-21  
; NUMBER OF SEQ ID NOS: 46  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 33  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic peptide  
US-10-959-310-33

Query Match 91.9%; Score 547; DB 6; Length 112;  
Best Local Similarity 92.0%; Pred. No. 1.3e-36;  
Matches 103; Conservative 5; Mismatches 4; Indels 0; Gaps 0;  
QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
Db 1 DVVMTQSPSLPVTGPEPASISCRSSRNIVHNGDTYLEWYLOKPGQSPQLLIYKVSRLF 60  
QY 61 YGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSHPVPTFGQTKVEIK 112  
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSLLPWTFGQTKVEIK 112

RESULT 6  
US-10-959-310-26  
; Sequence 26, Application US/10959310  
; Publication No. US20050287138A1  
; GENERAL INFORMATION:  
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.  
; TITLE OF INVENTION: CCR4-specific antibody composition  
; FILE REFERENCE: 249-363  
; CURRENT APPLICATION NUMBER: US/10/959,310  
; CURRENT FILING DATE: 2004-10-07  
; PRIOR APPLICATION NUMBER: JP 2003-350162  
; PRIOR FILING DATE: 2003-10-08  
; PRIOR APPLICATION NUMBER: US 60/572,784  
; PRIOR FILING DATE: 2004-05-21  
; NUMBER OF SEQ ID NOS: 46  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 26  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic peptide  
US-10-959-310-26

Query Match 91.8%; Score 546; DB 6; Length 112;  
Best Local Similarity 91.1%; Pred. No. 1.6e-36;  
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;  
QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
Db 1 DVVMTQSPSLPVTGPEPASISCRSSRNIVHNGDTYLEWYLOKPGQSPQLLIYKVSRLF 60  
QY 61 YGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSHPVPTFGQTKVEIK 112

```
Db 61 SGVPRFSGSGTDTLTKISRVEADVGVYCFQGSLLPWTFGGTVK 112
|||||
RESULT 9
US-11-012-353-54
; Sequence 54, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 01753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 54
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-54
```

```
Query Match 90.4%; Score 538; DB 7; Length 112;
Best Local Similarity 90.2%; Pred. No. 6.5e-36;
Matches 101; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPOLLIIYKVS 60
Db 1 DVLMTQIPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLTQWYLOKPGQSPKLLIIYKVS 60

Qy 61 YGVPRFSGSGTDTLTKISRVEADVGVYCFQGSHPVPTFGGTVK 112
Db 61 YGVPRFSGSGTDTLTKISRVEADLGVIYCFQGSHPVPTFGGTVK 112
```

```
RESULT 10
US-11-012-353-49
; Sequence 49, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 01753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
```

```
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 49
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-49
```

```
Query Match 90.4%; Score 538; DB 7; Length 122;
Best Local Similarity 90.2%; Pred. No. 7e-36;
Matches 101; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPOLLIIYKVS 60
Db 1 DVLMTQIPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLTQWYLOKPGQSPKLLIIYKVS 70

Qy 61 YGVPRFSGSGTDTLTKISRVEADVGVYCFQGSHPVPTFGGTVK 112
Db 71 YGVPRFSGSGTDTLTKISRVEADLGVIYCFQGSHPVPTFGGTVK 122
```

```
RESULT 11
US-11-012-353-56
; Sequence 56, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 01753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 56
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-56
```

```
Query Match 89.2%; Score 531; DB 7; Length 112;
Best Local Similarity 88.4%; Pred. No. 2.3e-35;
Matches 99; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPOLLIIYKVS 60
Db 1 DVLMTQIPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLTQWYLOKPGQSPKLLIIYKVS 60
```

QY 61 YGVDPFRSGSGTDTFTLKISRVEADVGYYCFQGSHPVPTFGGTTKVEIK 112  
DB 61 SGVDPFRSGSGTDTFTLKISRVEADLGYYCFQGSHPVPTFGGTTKLEIK 112

RESULT 12  
US-11-125-837-23  
; Sequence 23, Application US/11125837  
; Publication No. US20050266003A1  
; GENERAL INFORMATION:  
; APPLICANT: Lin, Rong-Hwa  
; APPLICANT: Chang, Chung Nan  
; APPLICANT: Chen, Pei-Jiun  
; APPLICANT: Huang, Chiu-Chen  
; TITLE OF INVENTION: ANTIBODIES  
; FILE REFERENCE: 13062-011001  
; CURRENT APPLICATION NUMBER: US/11/125,837  
; CURRENT FILING DATE: 2005-05-10  
; PRIOR APPLICATION NUMBER: US 60/569,892  
; PRIOR FILING DATE: 2004-05-10  
; NUMBER OF SEQ ID NOS: 100  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 131  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-11-125-837-23

Query Match 88.1%; Score 524; DB 7; Length 131;  
Best Local Similarity 87.5%; Pred. No. 9e-35; Mismatches 9; Indels 0; Gaps 0;  
Matches 98; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVVMTQSLPLVPTGEPASISCRSSQSIHVHSGNTYLYQWYKQPGSPQLLIYKVSRL 60  
DB 20 DVLMTQTPLSLPVSLGDAQSISCRSSQSIHVHSGNTYLYQWYKQPGSPQLLIYKVSRL 79

QY 61 YGVDPFRSGSGTDTFTLKISRVEADVGYYCFQGSHPVPTFGGTTKVEIK 112  
DB 80 SGVDPFRSGSGTDTFTLKISRVEADLGYYCFQGSHPVPTFGGTTKLEIK 131

RESULT 13  
US-11-089-266-66  
; Sequence 66, Application US/11089266  
; Publication No. US20050287148A1  
; GENERAL INFORMATION:  
; APPLICANT: Chatterjee, Malaya  
; APPLICANT: Foon, Kemech A.  
; APPLICANT: Chatterjee, Sunil K.  
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE  
; TITLE OF INVENTION: TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA  
; NUMBER OF SEQUENCES: 66  
; CORRESPONDENCE ADDRESS:  
; ADDRESSES: MORRISON & FOERSTER  
; STREET: 755 PAGE MILL ROAD  
; CITY: PALO ALTO  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94304-1018  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/11/089,266  
; FILING DATE: 23-Mar-2005  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/10/153,401  
; FILING DATE: 27-Aug-2002  
; APPLICATION NUMBER: US 09/293,533  
; FILING DATE: 1999-04-15

; APPLICATION NUMBER: US 08/372,676  
; FILING DATE: 1995-01-17  
; APPLICATION NUMBER: US 08/591,196  
; FILING DATE: 1996-01-16  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Catherine M. Polizzi  
; REGISTRATION NUMBER: 40,130  
; REFERENCE/DOCKET NUMBER: 304142000202  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 813-5600  
; TELEFAX: (415) 494-0792  
; TELEX: 706141  
; INFORMATION FOR SEQ ID NO: 66:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 263 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-11-089-266-66

Query Match 87.7%; Score 522; DB 7; Length 263;  
Best Local Similarity 87.5%; Pred. No. 2.3e-34;  
Matches 98; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

QY 1 DVVMTQSLPLVPTGEPASISCRSSQSIHVHSGNTYLYQWYKQPGSPQLLIYKVSRL 60  
DB 152 DVLMTQTPLSLPVSLGDAQSISCRSSQSIHVHSGNTYLYQWYKQPGSPQLLIYKVSRL 211

QY 61 YGVDPFRSGSGTDTFTLKISRVEADVGYYCFQGSHPVPTFGGTTKVEIK 112  
DB 212 SGVDPFRSGSGTDTFTLKISRVEADLGYYCFQGSHPVPTFGGTTKLEIK 263

RESULT 14  
US-11-012-353-55  
; Sequence 55, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFLOS, ALAIN  
; APPLICANT: HAEUW, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012,353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735,916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: PatentIn Ver. 3.3  
; SEQ ID NO 55  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-11-012-353-55

Query Match 87.4%; Score 520; DB 7; Length 112;  
Best Local Similarity 86.6%; Pred. No. 1.6e-34;  
Matches 97; Conservative 10; Mismatches 5; Indels 0; Gaps 0;



GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 61.4328 Seconds  
(without alignments)  
761.757 Million cell updates/sec

Title: US-10-735-916A-61  
Perfect score: 595  
Sequence: 1 DVVMTQSPSLPVTGEPAS.....CFQGSHPVWTFGGTKVEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications\_AA\_Main:\*  
1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*  
3: /cgn2\_6/ptodata/1/pubpaa/US09\_PUBCOMB.pep.\*  
4: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*  
5: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*  
6: /cgn2\_6/ptodata/1/pubpaa/US11\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	595	100.0	112	5	US-10-735-916A-61
2	595	100.0	131	5	US-10-735-916A-63
3	594	99.8	112	5	US-10-735-916A-65
4	594	99.8	131	5	US-10-735-916A-67
5	563	94.6	112	4	US-10-308-817-182
6	563	94.6	112	4	US-10-453-698-182
7	563	94.6	112	4	US-10-434-469-19
8	563	94.6	112	4	US-10-258-728-28
9	563	94.6	112	5	US-10-482-105-17
10	563	94.6	112	5	US-10-500-207A-19
11	560	94.1	112	5	US-10-500-207A-47
12	560	94.1	132	4	US-10-388-214A-6
13	559	93.9	112	4	US-10-258-728-27
14	558	93.8	112	4	US-10-258-728-26
15	557	93.6	112	4	US-10-434-469-41
16	557	93.6	112	5	US-10-482-105-39
17	557	93.6	112	5	US-10-858-855-7
18	557	93.6	112	5	US-10-500-207A-44
19	556	93.4	112	5	US-10-500-207A-46
20	553	92.9	112	5	US-10-500-207A-42
21	550	92.4	112	4	US-10-308-817-180
22	550	92.4	112	4	US-10-453-698-180
23	548	92.1	112	4	US-10-453-698-181
24	547	91.9	112	4	US-10-231-452-12
25	547	91.9	112	5	US-10-505-980-19
26	546	91.8	112	4	US-10-231-452-8
27	546	91.8	112	5	US-10-505-980-12

28	546	91.8	112	5	US-10-500-207A-43	Sequence 43, Appl
29	546	91.8	112	5	US-10-500-207A-51	Sequence 51, Appl
30	545	91.6	112	5	US-10-500-207A-45	Sequence 45, Appl
31	544	91.4	112	4	US-10-231-452-14	Sequence 14, Appl
32	544	91.4	112	5	US-10-505-980-21	Sequence 21, Appl
33	544	91.4	131	3	US-09-947-839-95	Sequence 95, Appl
34	543	91.3	112	4	US-10-231-452-13	Sequence 13, Appl
35	543	91.3	112	5	US-10-505-980-20	Sequence 20, Appl
36	543	91.3	116	3	US-09-753-436-66	Sequence 66, Appl
37	543	91.3	116	4	US-10-163-942-66	Sequence 66, Appl
38	543	91.3	116	5	US-10-745-115-66	Sequence 66, Appl
39	542	91.1	112	4	US-10-434-469-40	Sequence 40, Appl
40	542	91.1	112	5	US-10-482-105-38	Sequence 38, Appl
41	542	91.1	112	5	US-10-500-207A-50	Sequence 50, Appl
42	539	90.6	112	4	US-10-434-469-21	Sequence 21, Appl
43	539	90.6	112	5	US-10-482-105-19	Sequence 19, Appl
44	539	90.6	112	5	US-10-500-207A-21	Sequence 21, Appl
45	538	90.4	112	5	US-10-735-916A-54	Sequence 54, Appl

ALIGNMENTS

RESULT 1  
US-10-735-916A-61  
; Sequence 61, Application US/10735916A  
; Publication No. US20050084906A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, Liliane  
; APPLICANT: CORVAIA, Nathalie  
; APPLICANT: LEGER, Olivier  
; APPLICANT: DUFLOS, Alain  
; APPLICANT: BECK, Alain  
; APPLICANT: HAEUW, Jean-Francois  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-183  
; CURRENT APPLICATION NUMBER: US/10735,916A  
; CURRENT FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 03/08 538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 02/00 653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/00 654  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/05 753  
; NUMBER OF SEQ ID NOS: 156  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 61  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-735-916A-61

Query Match 100.0%; Score 595; DB 5; Length 112;  
Best Local Similarity 100.0%; Pred. No. 1.7e-46;  
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLPKPGQSPQLLIYKVSRL 60  
Db 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLPKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGGTFTLKISRVEAEDGYYVFCQGSHPVWTFGGTKVEIK 112  
Db 61 YGVPRFSGSGGTFTLKISRVEAEDGYYVFCQGSHPVWTFGGTKVEIK 112

RESULT 2  
US-10-735-916A-63  
; Sequence 63, Application US/10735916A  
; Publication No. US20050084906A1

;; GENERAL INFORMATION:  
;; APPLICANT: GOETSCH, Liliane  
;; APPLICANT: CORVAIA, Nathalie  
;; APPLICANT: LEGER, Olivier  
;; APPLICANT: DUFLOS, Alain  
;; APPLICANT: BECK, Alain  
;; APPLICANT: HAEUW, Jean-Francois  
;; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
;; FILE REFERENCE: 017753-183  
;; CURRENT APPLICATION NUMBER: US/10/735,916A  
;; PRIOR FILING DATE: 2003-12-16  
;; PRIOR APPLICATION NUMBER: FR 03/08 538  
;; PRIOR FILING DATE: 2003-07-11  
;; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
;; PRIOR FILING DATE: 2003-01-20  
;; PRIOR APPLICATION NUMBER: FR 02/00 653  
;; PRIOR FILING DATE: 2002-01-18  
;; PRIOR APPLICATION NUMBER: FR 02/00 654  
;; PRIOR FILING DATE: 2002-01-18  
;; PRIOR APPLICATION NUMBER: FR 02/05 753  
;; PRIOR FILING DATE: 2002-05-07  
;; NUMBER OF SEQ ID NOS: 156  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 63  
;; LENGTH: 131  
;; TYPE: PRT  
;; ORGANISM: Homo sapiens  
US-10-735-916A-63

Query Match 100.0%; Score 595; DB 5; Length 131;  
Best Local Similarity 100.0%; Pred. No. 2e-46;  
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNGNTYQLQYLPKPGQSPQLLIYKVSRL 60  
Db 20 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNGNTYQLQYLPKPGQSPQLLIYKVSRL 79  
  
Qy 61 YGVDPFRFSGSGTGDTFLKISRVEADVGYYCFQGSHPVWTFGGTKVEIK 112  
Db 80 YGVDPFRFSGSGTGDTFLKISRVEADVGYYCFQGSHPVWTFGGTKVEIK 131

RESULT 3  
US-10-735-916A-65  
;; Sequence 65, Application US/10735916A  
;; Publication No. US20050084906A1  
;; GENERAL INFORMATION:  
;; APPLICANT: GOETSCH, Liliane  
;; APPLICANT: CORVAIA, Nathalie  
;; APPLICANT: LEGER, Olivier  
;; APPLICANT: DUFLOS, Alain  
;; APPLICANT: BECK, Alain  
;; APPLICANT: HAEUW, Jean-Francois  
;; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
;; FILE REFERENCE: 017753-183  
;; CURRENT APPLICATION NUMBER: US/10/735,916A  
;; PRIOR FILING DATE: 2003-12-16  
;; PRIOR APPLICATION NUMBER: FR 03/08 538  
;; PRIOR FILING DATE: 2003-07-11  
;; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
;; PRIOR FILING DATE: 2003-01-20  
;; PRIOR APPLICATION NUMBER: FR 02/00 653  
;; PRIOR FILING DATE: 2002-01-18  
;; PRIOR APPLICATION NUMBER: FR 02/00 654  
;; PRIOR FILING DATE: 2002-01-18  
;; PRIOR APPLICATION NUMBER: FR 02/05 753  
;; PRIOR FILING DATE: 2002-05-07  
;; NUMBER OF SEQ ID NOS: 156  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 65  
;; LENGTH: 112  
;; TYPE: PRT  
;; ORGANISM: Homo sapiens

US-10-735-916A-65  
  
Query Match 99.8%; Score 594; DB 5; Length 112;  
Best Local Similarity 99.1%; Pred. No. 2.1e-46;  
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNGNTYQLQYLPKPGQSPQLLIYKVSRL 60  
Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNGNTYQLQYLPKPGQSPQLLIYKVSRL 60  
  
Qy 61 YGVDPFRFSGSGTGDTFLKISRVEADVGYYCFQGSHPVWTFGGTKVEIK 112  
Db 61 YGVDPFRFSGSGTGDTFLKISRVEADVGYYCFQGSHPVWTFGGTKVEIK 112  
  
RESULT 4  
US-10-735-916A-67  
;; Sequence 67, Application US/10735916A  
;; Publication No. US20050084906A1  
;; GENERAL INFORMATION:  
;; APPLICANT: GOETSCH, Liliane  
;; APPLICANT: CORVAIA, Nathalie  
;; APPLICANT: LEGER, Olivier  
;; APPLICANT: DUFLOS, Alain  
;; APPLICANT: BECK, Alain  
;; APPLICANT: HAEUW, Jean-Francois  
;; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
;; FILE REFERENCE: 017753-183  
;; CURRENT APPLICATION NUMBER: US/10/735,916A  
;; PRIOR FILING DATE: 2003-12-16  
;; PRIOR APPLICATION NUMBER: FR 03/08 538  
;; PRIOR FILING DATE: 2003-07-11  
;; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
;; PRIOR FILING DATE: 2003-01-20  
;; PRIOR APPLICATION NUMBER: FR 02/00 653  
;; PRIOR FILING DATE: 2002-01-18  
;; PRIOR APPLICATION NUMBER: FR 02/00 654  
;; PRIOR FILING DATE: 2002-01-18  
;; PRIOR APPLICATION NUMBER: FR 02/05 753  
;; PRIOR FILING DATE: 2002-05-07  
;; NUMBER OF SEQ ID NOS: 156  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 67  
;; LENGTH: 131  
;; TYPE: PRT  
;; ORGANISM: Homo sapiens  
US-10-735-916A-67

Query Match 99.8%; Score 594; DB 5; Length 131;  
Best Local Similarity 99.1%; Pred. No. 2.5e-46;  
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNGNTYQLQYLPKPGQSPQLLIYKVSRL 60  
Db 20 DIVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNGNTYQLQYLPKPGQSPQLLIYKVSRL 79  
  
Qy 61 YGVDPFRFSGSGTGDTFLKISRVEADVGYYCFQGSHPVWTFGGTKVEIK 112  
Db 80 YGVDPFRFSGSGTGDTFLKISRVEADVGYYCFQGSHPVWTFGGTKVEIK 131  
  
RESULT 5  
US-10-308-817-182  
;; Sequence 182, Application US/10308817  
;; Publication No. US20030219861A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Rother, Russell  
;; APPLICANT: Wu, Dayang  
;; TITLE OF INVENTION: HYBRID ANTIBODIES  
;; FILE REFERENCE: 1087-37  
;; CURRENT APPLICATION NUMBER: US/10/308,817  
;; CURRENT FILING DATE: 2002-12-03  
;; NUMBER OF SEQ ID NOS: 195

```
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 182
; LENGTH: 112
; TYPE: PRT
; ORGANISM: human
US-10-308-817-182

Query Match          94.6%; Score 563; DB 4; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DIVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPWTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPWTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 6
US-10-453-698-182
; Sequence 182, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 182
; LENGTH: 112
; TYPE: PRT
; ORGANISM: human
US-10-453-698-182

Query Match          94.6%; Score 563; DB 4; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DIVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPWTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPWTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 7
US-10-434-469-19
; Sequence 19, Application US/10434469
; Publication No. US20040091480A1
; GENERAL INFORMATION:
; APPLICANT: Nobuo HANAI
; APPLICANT: Motoo YAMASAKI
; APPLICANT: Akiko FURUYA
; APPLICANT: Akira TANAKA
; APPLICANT: Kenya SHITARA
; APPLICANT: Naoki SHIMADA
; TITLE OF INVENTION: Anti-fib1roblast growth factor-8 monoclonal antibody
; FILE REFERENCE: 249-310
; CURRENT APPLICATION NUMBER: US/10/434,469
; CURRENT FILING DATE: 2003-05-09
; PRIOR APPLICATION NUMBER: JP 08-081754
; PRIOR FILING DATE: 1996-04-03
; PRIOR APPLICATION NUMBER: US 08/832,236
; PRIOR FILING DATE: 1997-04-03
; PRIOR APPLICATION NUMBER: US 09/326,590
; PRIOR FILING DATE: 1999-06-07
; PRIOR APPLICATION NUMBER: US 09/876,040
```

```
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: VL synthetic peptide
US-10-434-469-19

Query Match          94.6%; Score 563; DB 4; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DIVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPWTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPWTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 8
US-10-258-728-28
; Sequence 28, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Durrant, John Robert Maxwell
; APPLICANT: Durrant, Linda Gillian
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0020794.4
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-28

Query Match          94.6%; Score 563; DB 4; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPWTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPWTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 9
US-10-482-105-17
; Sequence 17, Application US/10482105
; Publication No. US20040253234A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD
; TITLE OF INVENTION: Humanized anti-FGF-8 antibody and the antibody fragment thereof
; FILE REFERENCE: 11399WO1
; CURRENT APPLICATION NUMBER: US/10/482,105
; CURRENT FILING DATE: 2003-12-24
; PRIOR APPLICATION NUMBER: JP2001-196176
; PRIOR FILING DATE: 2001-06-28
; NUMBER OF SEQ ID NOS: 41
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic protein
US-10-482-105-17

Query Match          94.6%; Score 563; DB 5; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVMVTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 DVMVTQSPSLSPVTPGEPASISCRSSQSLVHNSNGRTYLEWYLQKPGQSPQLLIYKVSRI 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
|||||
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
|||||

RESULT 10
US-10-500-207A-19
; Sequence 19, Application US/10500207A
; Publication No. US20050175608A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD
; TITLE OF INVENTION: AGENT FOR TREATING ARTHRITIS
; FILE REFERENCE: 1442
; CURRENT APPLICATION NUMBER: US/10/500,207A
; CURRENT FILING DATE: 2004-06-28
; PRIOR APPLICATION NUMBER: JP2001-400677
; PRIOR FILING DATE: 2001-12-28
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: LV.0, a designed amino acid sequence of VL of
; OTHER INFORMATION: an anti-FGF-8 CDR-grafted neutralizing antibody
US-10-500-207A-19

Query Match          94.6%; Score 563; DB 5; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVMVTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 DVMVTQSPSLSPVTPGEPASISCRSSQSLVHNSNGRTYLEWYLQKPGQSPQLLIYKVSRI 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
|||||
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
|||||

RESULT 11
US-10-500-207A-47
; Sequence 47, Application US/10500207A
; Publication No. US20050175608A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD
; TITLE OF INVENTION: AGENT FOR TREATING ARTHRITIS
; FILE REFERENCE: 1442
; CURRENT APPLICATION NUMBER: US/10/500,207A
; CURRENT FILING DATE: 2004-06-28
; PRIOR APPLICATION NUMBER: JP2001-400677
; PRIOR FILING DATE: 2001-12-28
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 47

; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: LV.2-2, a designed amino acid sequence of VL of
; OTHER INFORMATION: an anti-FGF-8 CDR-grafted neutralizing antibody
US-10-500-207A-47

Query Match          94.1%; Score 560; DB 5; Length 112;
Best Local Similarity 93.8%; Pred. No. 2.6e-43;
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVMVTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 DVMVTQSPSLSPVTPGEPASISCRSSQSLVHNSNGRTYLEWYLQKPGQSPQLLIYKVSRI 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
|||||
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
|||||

RESULT 12
US-10-388-214A-6
; Sequence 6, Application US/10388214A
; Publication No. US20040082762A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Gurig
; APPLICANT: Saidanha, Jose
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA
; FILE REFERENCE: ELM-004
; CURRENT APPLICATION NUMBER: US/10/388,214A
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/363,751
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: humanized 12BAVLv1
; NAME/KEY: SIGNAL
; LOCATION: (1)...(20)
US-10-388-214A-6

Query Match          94.1%; Score 560; DB 4; Length 132;
Best Local Similarity 94.6%; Pred. No. 3.1e-43;
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 DVMVTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 21 DVMVTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLQKPGQSPQLLIYKVSRI 80
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112
|||||
Db 81 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKLEIK 132
|||||

RESULT 13
US-10-258-728-27
; Sequence 27, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Ellis, John Robert Maxwell
; APPLICANT: Durrant, Linda Gillian
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
```

; PRIOR FILING DATE: 2000-05-19  
; PRIOR APPLICATION NUMBER: GB 0020794.4  
; PRIOR FILING DATE: 2000-08-24  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 27  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-10-258-728-27

Query Match 93.9%; Score 559; DB 4; Length 112;  
Best Local Similarity 92.9%; Pred. No. 3.2e-43;  
Matches 104; Conservative 3; Mismatches 5; Indels 0; Gaps 0;  
  
QY 1 DVVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRL 60  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Db 1 DVLMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRF 60  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
  
QY 61 YGVDPDRFSGSGGTDTFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112  
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Db 61 SGVPDRFSGSGGTDTFTLKISRVEADTGIIYCFQGSHPVPTFGGQTKVEIK 112  
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 14  
US-10-258-728-26  
; Sequence 26, Application US/10258728  
; Publication No. US20040091485A1  
; GENERAL INFORMATION:  
; APPLICANT: Ellis, John Robert Maxwell  
; APPLICANT: Durrant, Linda Gillian  
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor  
; FILE REFERENCE: 28438-101US01  
; CURRENT APPLICATION NUMBER: US/10/258,728  
; CURRENT FILING DATE: 2003-06-18  
; PRIOR APPLICATION NUMBER: GB 0011981.8  
; PRIOR FILING DATE: 2000-05-19  
; PRIOR APPLICATION NUMBER: GB 0020794.4  
; PRIOR FILING DATE: 2000-08-24  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 26  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-10-258-728-25

Query Match 93.8%; Score 558; DB 4; Length 112;  
Best Local Similarity 92.9%; Pred. No. 4e-43;  
Matches 104; Conservative 3; Mismatches 5; Indels 0; Gaps 0;  
  
QY 1 DVVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRL 60  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Db 1 DVLMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRF 60  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
  
QY 61 YGVDPDRFSGSGGTDTFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112  
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Db 61 SGVPDRFSGSGGTDTFTLKISRVEADTGIIYCFQGSHPVPTFGGQTKVEIK 112  
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 15  
US-10-434-469-41  
; Sequence 41, Application US/10434469  
; Publication No. US20040091480A1  
; GENERAL INFORMATION:  
; APPLICANT: Nobuo HANAI  
; APPLICANT: Motoo YAMASAKI  
; APPLICANT: Akiko FURUYA  
; APPLICANT: Akira TANAKA  
; APPLICANT: Kenya SHITARA  
; APPLICANT: Naoki SHIMADA  
; TITLE OF INVENTION: Anti-fibrolblast growth factor-8 monoclonal antibody  
; FILE REFERENCE: 249-310

; CURRENT APPLICATION NUMBER: US/10/434,469  
; CURRENT FILING DATE: 2003-05-09  
; PRIOR APPLICATION NUMBER: JP 08-081754  
; PRIOR FILING DATE: 1996-04-03  
; PRIOR APPLICATION NUMBER: US 08/832,236  
; PRIOR FILING DATE: 1997-04-03  
; PRIOR APPLICATION NUMBER: US 09/326,590  
; PRIOR FILING DATE: 1999-06-07  
; PRIOR APPLICATION NUMBER: US 09/876,040  
; PRIOR FILING DATE: 2001-06-08  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 41  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: LV.3-1 of VL of KM8036  
US-10-434-469-41

Query Match 93.6%; Score 557; DB 4; Length 112;  
Best Local Similarity 92.9%; Pred. No. 4.9e-43;  
Matches 104; Conservative 6; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1 DVVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRL 60  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Db 1 DVVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGRTYLEWYLOKPGQSPQLLIYKVSNNRI 60  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
  
QY 61 YGVDPDRFSGSGGTDTFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112  
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Db 61 SGVPDRFSGSGGTDTFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112  
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Search completed: January 10, 2006, 21:35:30  
Job time : 61.4328 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 21.8706 Seconds  
(without alignments)  
423.384 Million cell updates/sec

Title: US-10-735-916A-61  
Perfect score: 595  
Sequence: 1 DVNMTQSLPLVTPGERPAS.....CFQSHVPTFGQTKVEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents AA.\*  
1: /cgn2\_6/ptodata/1/1aa/5 COMB pep.\*  
2: /cgn2\_6/ptodata/1/1aa/6 COMB pep.\*  
3: /cgn2\_6/ptodata/1/1aa/H COMB pep.\*  
4: /cgn2\_6/ptodata/1/1aa/PCTUS COMB pep.\*  
5: /cgn2\_6/ptodata/1/1aa/RE COMB pep.\*  
6: /cgn2\_6/ptodata/1/1aa/backfiles1 pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	560	94.1	112	1 US-08-331-398A-50	Sequence 50, Appl
2	560	94.1	112	1 US-08-331-397B-50	Sequence 50, Appl
3	560	94.1	112	1 US-08-759-804A-50	Sequence 50, Appl
4	560	94.1	112	2 US-09-227-693-50	Sequence 50, Appl
5	556	93.4	112	1 US-08-053-171-15	Sequence 15, Appl
6	556	93.4	112	1 US-08-815-190A-14	Sequence 14, Appl
7	544	91.4	131	1 US-08-129-930B-95	Sequence 95, Appl
8	544	91.4	131	2 US-08-134-346A-50	Sequence 50, Appl
9	544	91.4	131	2 US-08-976-288A-95	Sequence 95, Appl
10	543	91.3	116	1 US-08-482-882-66	Sequence 66, Appl
11	543	91.3	116	1 US-08-483-389-66	Sequence 66, Appl
12	543	91.3	116	1 US-08-487-113D-66	Sequence 66, Appl
13	543	91.3	116	1 US-08-473-503-66	Sequence 66, Appl
14	543	91.3	116	1 US-08-483-932-66	Sequence 66, Appl
15	543	91.3	116	1 US-08-720-420A-66	Sequence 66, Appl
16	543	91.3	116	2 US-08-714-017-66	Sequence 66, Appl
17	543	91.3	116	2 US-08-475-680-66	Sequence 66, Appl
18	526	88.4	112	1 US-08-478-039-88	Sequence 88, Appl
19	526	88.4	112	1 US-08-476-349A-88	Sequence 88, Appl
20	522	87.7	149	2 US-09-192-838B-2	Sequence 2, Appl
21	522	87.7	149	2 US-09-324-191-2	Sequence 2, Appl
22	522	87.7	263	1 US-08-752-844-66	Sequence 66, Appl
23	522	87.7	263	2 US-09-293-533-66	Sequence 66, Appl
24	520	87.4	112	1 US-08-331-398A-48	Sequence 48, Appl
25	520	87.4	112	1 US-08-077-252B-3	Sequence 3, Appl
26	520	87.4	112	1 US-08-331-397B-48	Sequence 48, Appl
27	520	87.4	112	1 US-08-759-804A-48	Sequence 48, Appl

28	520	87.4	112	2 US-09-002-753A-3	Sequence 3, Appl
29	520	87.4	112	2 US-09-227-633-48	Sequence 48, Appl
30	520	87.4	112	2 US-09-657-274-3	Sequence 3, Appl
31	520	87.4	112	4 PCT-US94-06687-3	Sequence 3, Appl
32	520	87.4	125	1 US-08-331-398A-67	Sequence 67, Appl
33	520	87.4	125	1 US-08-331-397B-67	Sequence 67, Appl
34	520	87.4	125	1 US-08-759-804A-66	Sequence 66, Appl
35	520	87.4	149	1 US-08-752-844-2	Sequence 2, Appl
36	520	87.4	149	1 US-08-591-136-2	Sequence 2, Appl
37	520	87.4	149	2 US-09-293-533-2	Sequence 2, Appl
38	520	87.4	247	2 US-09-227-693-34	Sequence 34, Appl
39	520	87.4	248	1 US-08-331-398A-34	Sequence 34, Appl
40	520	87.4	248	1 US-08-331-397B-34	Sequence 34, Appl
41	520	87.4	248	1 US-08-759-804A-34	Sequence 34, Appl
42	518	87.1	112	1 US-08-859-649-19	Sequence 19, Appl
43	518	87.1	112	1 US-08-859-649-29	Sequence 29, Appl
44	518	87.1	112	2 US-08-207-861-19	Sequence 19, Appl
45	518	87.1	112	2 US-08-207-861-29	Sequence 29, Appl

ALIGNMENTS

RESULT 1  
US-08-331-398A-50  
; Sequence 50, Application US/08331398A  
; Patent No. 5608039  
; GENERAL INFORMATION:  
; APPLICANT: Pastan, Ira  
; APPLICANT: Willingham, Mark  
; APPLICANT: Fitzgerald, David  
; APPLICANT: Brinkmann, Ulrich  
; APPLICANT: Pai, Lee  
; TITLE OF INVENTION: Single Chain B3 Antibody Fusion Proteins  
; TITLE OF INVENTION: and Their Uses (as amended)  
; NUMBER OF SEQUENCES: 68  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew  
; STREET: One Market Plaza, Steuart Street Plaza  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94105-1492

COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/331.398A  
; FILING DATE: 28-OCT-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/767,331  
; FILING DATE: 30-SEP-1991  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/596,289  
; FILING DATE: 12-OCT-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hunter, Tom  
; REGISTRATION NUMBER: 38,498  
; REFERENCE/DOCKET NUMBER: 015280-126110US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 543-9600  
; TELEFAX: (415) 543-5043  
; INFORMATION FOR SEQ ID NO: 50:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 112 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; FEATURE:

NAME/KEY: Protein  
LOCATION: 1..112  
OTHER INFORMATION: /note= "Humanized B3 Variable Light chain (V-L) (HumB3V-L)"  
US-08-331-397B-50

Query Match 94.1%; Score 560; DB 1; Length 112;  
Best Local Similarity 94.6%; Pred. No. 1.8e-47;  
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
Db 1 DVLMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
Db 61 SGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112

RESULT 2

US-08-331-397B-50  
; Sequence 50, Application US/08331397B  
; Patent No. 5981726  
; GENERAL INFORMATION:  
; APPLICANT: Pastan, Ira  
; APPLICANT: Benhar, Itai  
; TITLE OF INVENTION: Chimeric and Mutationally Stabilized Tumor-  
; TITLE OF INVENTION: Specific Antibody Fragments, Fusion Proteins, and Uses  
; TITLE OF INVENTION: Thereof  
; NUMBER OF SEQUENCES: 68  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew  
; STREET: One Market Plaza, Steuart Street Plaza  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94105-1492  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/331.397B  
; FILING DATE: 28-OCT-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/767,331  
; FILING DATE: 30-SEP-1991  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/596,289  
; FILING DATE: 12-OCT-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hunter, Tom  
; REGISTRATION NUMBER: 38,498  
; REFERENCE/DOCKET NUMBER: 015280-126120US  
; TELEPHONE: (415) 543-9600  
; TELEFAX: (415) 543-5043  
; INFORMATION FOR SEQ ID NO: 50:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 112 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; FEATURE:  
; NAME/KEY: Protein  
; LOCATION: 1..112  
; OTHER INFORMATION: /note= "Humanized B3 Variable Light chain (V-L) (HumB3V-L)"  
US-08-331-397B-50

Query Match 94.1%; Score 560; DB 1; Length 112;  
Best Local Similarity 94.6%; Pred. No. 1.8e-47;  
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60  
Db 1 DVLMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
Db 61 SGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112

RESULT 3

US-08-759-804A-50  
; Sequence 50, Application US/08759804A  
; Patent No. 5990296  
; GENERAL INFORMATION:  
; APPLICANT: Pastan, Ira  
; APPLICANT: Willingham, Mark  
; APPLICANT: Fitzgerald, David J.  
; APPLICANT: Brinkmann, Ulrich  
; APPLICANT: Pai, Lee  
; TITLE OF INVENTION: Tumor-Specific Antibody Fragments,  
; TITLE OF INVENTION: Fusion Proteins, and Uses Thereof  
; NUMBER OF SEQUENCES: 68  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, Eighth Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94111-3834  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/759,804A  
; FILING DATE: 03-DEC-1996  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/331,398  
; FILING DATE: 28-OCT-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/767,331  
; FILING DATE: 30-SEP-1991  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/596,289  
; FILING DATE: 12-OCT-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Weber, Ellen L.  
; REGISTRATION NUMBER: 32,762  
; REFERENCE/DOCKET NUMBER: 015280-126140US  
; TELEPHONE: (415) 576-0200  
; TELEFAX: (415) 576-0300  
; INFORMATION FOR SEQ ID NO: 50:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 112 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; FEATURE:  
; NAME/KEY: Protein  
; LOCATION: 1..112  
; OTHER INFORMATION: /note= "Humanized B3 Variable Light chain (V-L) (HumB3V-L)"  
US-08-759-804A-50

Query Match 94.1%; Score 560; DB 1; Length 112;

Best Local Similarity 94.6%; Pred. No. 1.8e-47; Indels 0; Gaps 0;  
Matches 106; Conservative 3; Mismatches 3;

Qy 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLTQWYLRKPGQSPQLLIYKVSRL 60  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Db 1 DVLMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLTQWYLRKPGQSPQLLIYKVSRL 60  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Qy 61 YGVPRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGQTKVEIK 112  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGQTKVEIK 112  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 4  
US-09-227-693-50  
; Sequence 50, Application US/09227693  
; Patent No. 6287562  
; GENERAL INFORMATION:  
; APPLICANT: PASTAN, Ira  
; APPLICANT: BENHAR, Ital  
; APPLICANT: PADLAN, Eduardo A.  
; APPLICANT: JUNG, Sun-Hee  
; APPLICANT: LEE, Byungkook  
; TITLE OF INVENTION: HUMANIZED TUMOR-SPECIFIC ANTIBODY  
; TITLE OF INVENTION: FRAGMENTS, FUSION PROTEINS, AND USES THEREOF  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend Kourie and Crew  
; STREET: Stewart Street Tower, One Market Plaza  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: US  
; ZIP: 94105-1493  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/227,693  
; FILING DATE:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/331,396  
; FILING DATE:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/67,331  
; FILING DATE: 30-SEP-1991  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/596,289  
; FILING DATE: 12-OCT-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Weber, Ellen Lauver  
; REGISTRATION NUMBER: 32,762  
; REFERENCE/DOCKET NUMBER: 15280-126-1-3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 543-9600  
; TELEFAX: (415) 543-5043  
; INFORMATION FOR SEQ ID NO: 50:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 112 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FEATURE:  
; NAME/KEY: Protein  
; LOCATION: 1..112  
; OTHER INFORMATION: /note= "Humanized B3 VL region"  
US-09-227-693-50

Query Match 94.1%; Score 560; DB 2; Length 112;  
Best Local Similarity 94.6%; Pred. No. 1.8e-47;  
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLTQWYLRKPGQSPQLLIYKVSRL 60  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Db 1 DVLMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLTQWYLRKPGQSPQLLIYKVSRL 60  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Qy 61 YGVPRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGQTKVEIK 112  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGQTKVEIK 112  
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 5  
US-08-053-171-15  
; Sequence 15, Application US/08053171  
; Patent No. 5562903  
; GENERAL INFORMATION:  
; APPLICANT: Co, Loibner  
; TITLE OF INVENTION: Antibody Derivatives  
; NUMBER OF SEQUENCES: 32  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend Kourie and Crew  
; STREET: 379 Lytton Avenue  
; CITY: Palo Alto  
; STATE: California  
; COUNTRY: US  
; ZIP: 94301  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/053,171  
; FILING DATE: 22-APR-1993  
; CLASSIFICATION: 424  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Smith, William M  
; REGISTRATION NUMBER: 30,223  
; REFERENCE/DOCKET NUMBER: 11823-54-1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 326-2400  
; TELEFAX: (415) 326-2422  
; INFORMATION FOR SEQ ID NO: 15:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 112 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; FEATURE:  
; NAME/KEY: Peptide  
; LOCATION: 1..112  
; OTHER INFORMATION: /note= "Sequence of the Light Chain  
; Patent No. 5562903  
; OTHER INFORMATION: of Humanized BR55-2 Antibody"  
; FEATURE:  
; NAME/KEY: Region  
; LOCATION: 24..39  
; OTHER INFORMATION: /note= "Complementarity-determining  
; OTHER INFORMATION: region"  
; FEATURE:  
; NAME/KEY: Region  
; LOCATION: 55..61  
; OTHER INFORMATION: /note= "Complementarity-determining  
; OTHER INFORMATION: region"  
; FEATURE:  
; NAME/KEY: Region  
; LOCATION: 94..102  
; OTHER INFORMATION: /note= "Complementarity-determining  
; OTHER INFORMATION: region"  
; FEATURE:  
; NAME/KEY: Modified-site  
; LOCATION: 54  
; OTHER INFORMATION: /note= "Residue that has been  
; OTHER INFORMATION: replaced with mouse amino acid in the humanized

```
;
; OTHER INFORMATION: antibody."
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 108
; OTHER INFORMATION: /note= "Residue in the framework
; OTHER INFORMATION: that is replaced with mouse amino acid in the
; OTHER INFORMATION: humanized antibody."
US-08-053-171-15

Query Match      93.4%; Score 556; DB 1; Length 112;
Best Local Similarity 93.8%; Pred. No. 4.4e-47;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVMTQSPVLSPLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 60
Db 1 DIVMTQSPVLSPLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSNRF 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDVGVYFCQGSHPVPTFGGTTKVEIK 112
Db 61 SGVDPDRFSGSGGTDFTLKISRVEAEDVGVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 6
US-08-815-190A-14
; Sequence 14, Application US/08815190A
; Patent No. 6046310
; GENERAL INFORMATION:
; APPLICANT: Queen, Cary L.
; APPLICANT: Schneider, William P.
; APPLICANT: Vasquez, Maximiliano
; TITLE OF INVENTION: Fas Ligand Fusion Proteins and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/815,190A
; FILING DATE: 11-MAR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/614,584
; FILING DATE: 13-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 011823-006710US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..112
; OTHER INFORMATION: /note= "mature light chain variable
; OTHER INFORMATION: region of humanized ABL 364 antibody"
US-08-815-190A-14
```

```
Query Match      93.4%; Score 556; DB 2; Length 112;
Best Local Similarity 93.8%; Pred. No. 4.4e-47;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVMTQSPVLSPLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 60
Db 1 DIVMTQSPVLSPLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSNRF 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDVGVYFCQGSHPVPTFGGTTKVEIK 112
Db 61 SGVDPDRFSGSGGTDFTLKISRVEAEDVGVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 7
US-08-129-930B-95
; Sequence 95, Application US/08129930B
; Patent No. 5804187
; GENERAL INFORMATION:
; APPLICANT: do Couto Dr., Fernando J.R.
; APPLICANT: Ceriani Dr., Roberto L.
; APPLICANT: Peterson Dr., Jerry A.
; APPLICANT: Padian Dr., Eduardo A.
; TITLE OF INVENTION: Analogue Peptides With Broad
; TITLE OF INVENTION: Carcinoma Specificity, and Kit and
; TITLE OF INVENTION: Diagnostic Vaccination and
; TITLE OF INVENTION: Therapeutic Methods
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: V. AMZEL & ASSOC.
; STREET: 2055 No. 5804187th Broadway, Suite 201
; CITY: Walnut Creek
; STATE: California
; COUNTRY: USA
; ZIP: 94596
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS 5.0
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/129,930B
; FILING DATE: September 30, 1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel Ph.D., Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: CRFCC-008A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 521-1333
; TELEFAX: (510) 521-3541
; TELEX: n.a.
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 131 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-129-930B-95

Query Match      91.4%; Score 544; DB 1; Length 131;
Best Local Similarity 91.1%; Pred. No. 7.7e-46;
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVMTQSPVLSPLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 60
Db 20 DVLMTQTPVLSPLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSIRF 79

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDVGVYFCQGSHPVPTFGGTTKVEIK 112
Db 80 SGVDPDRFSGSGGTDFTLKISRVEAEDVGVYFCQGSHPVPTFGGTTKLEIK 131

RESULT 8
```

```

US-08-134-346A-50
; Sequence 50, Application US/08134346A
; Patent No. 6281335
; GENERAL INFORMATION:
; APPLICANT: do Couto, F.J.R.
; APPLICANT: Ceriani, R.L.C.
; APPLICANT: Petersen, J.A.
; TITLE OF INVENTION: HYBRIDOMA AND ANTI-KC-4 HUMANIZED
; TITLE OF INVENTION: MONOCLONAL ANTIBODY AND DNA AND RNA ENCODING IT, KIT AND
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC METHODS
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ostrager, Chong & Flaherty
; STREET: 300 Park Avenue
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10022-7499
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette-3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/134,346A
; FILING DATE: 08-OCT-1993
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Onofrio, Data L.
; REGISTRATION NUMBER: 34,889
; REFERENCE/DOCKET NUMBER: CLT 149,608
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-826-6565
; TELEFAX: 212-826-5909
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 131 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-134-346A-50

Query Match 91.4%; Score 544; DB 2; Length 131;
Best Local Similarity 91.1%; Pred. No. 7.7e-46;
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVVMTQSLPLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKFGQSPQLLIYKVSRL 60
||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 20 DVLMTQTPLSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKFGQSPQLLIYKVSIRF 79

QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVPTFGGTVKEIK 112
||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 80 SGVPDRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVPTFGGTVKEIK 131

RESULT 9
US-08-976-288A-95
; Sequence 95, Application US/08976288A
; Patent No. 6315997
; GENERAL INFORMATION:
; APPLICANT: do Couto Dr., Fernando J.R.
; APPLICANT: Ceriani Dr., Roberto L.
; APPLICANT: Peterson Dr., Jerry A.
; APPLICANT: Padian Dr., Eduardo A.
; TITLE OF INVENTION: Analogue Peptides With Broad
; TITLE OF INVENTION: Carcinoma Specificity, and Kit and
; TITLE OF INVENTION: Diagnostic Vaccination and
; TITLE OF INVENTION: Therapeutic Methods
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder & Poplawski
; STREET: 444 South Flower St., 19th Floor
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/976,288A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435

```

```

US-08-134-346A-50
; Sequence 50, Application US/08134346A
; Patent No. 6281335
; GENERAL INFORMATION:
; APPLICANT: do Couto, F.J.R.
; APPLICANT: Ceriani, R.L.C.
; APPLICANT: Petersen, J.A.
; TITLE OF INVENTION: HYBRIDOMA AND ANTI-KC-4 HUMANIZED
; TITLE OF INVENTION: MONOCLONAL ANTIBODY AND DNA AND RNA ENCODING IT, KIT AND
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC METHODS
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ostrager, Chong & Flaherty
; STREET: 300 Park Avenue
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10022-7499
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette-3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/134,346A
; FILING DATE: 08-OCT-1993
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Onofrio, Data L.
; REGISTRATION NUMBER: 34,889
; REFERENCE/DOCKET NUMBER: CLT 149,608
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-826-6565
; TELEFAX: 212-826-5909
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 131 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-134-346A-50

Query Match 91.4%; Score 544; DB 2; Length 131;
Best Local Similarity 91.1%; Pred. No. 7.7e-46;
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVVMTQSLPLPVTGEPASISCRSSQSIHNSGNTYQLQWYLOKFGQSPQLLIYKVSRL 60
||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 20 DVLMTQTPLSLPVTGEPASISCRSSQSIHNSGNTYQLQWYLOKFGQSPQLLIYKVSIRF 79

QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVPTFGGTVKEIK 112
||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 80 SGVPDRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVPTFGGTVKEIK 131

RESULT 9
US-08-976-288A-95
; Sequence 95, Application US/08976288A
; Patent No. 6315997
; GENERAL INFORMATION:
; APPLICANT: do Couto Dr., Fernando J.R.
; APPLICANT: Ceriani Dr., Roberto L.
; APPLICANT: Peterson Dr., Jerry A.
; APPLICANT: Padian Dr., Eduardo A.
; TITLE OF INVENTION: Analogue Peptides With Broad
; TITLE OF INVENTION: Carcinoma Specificity, and Kit and
; TITLE OF INVENTION: Diagnostic Vaccination and
; TITLE OF INVENTION: Therapeutic Methods
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder & Poplawski
; STREET: 444 South Flower St., 19th Floor
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS 5.0
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/976,288A
; FILING DATE: No. 6315997ember 21, 1997
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/129,930
; FILING DATE: September 30, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/977,696
; FILING DATE: No. 6315997ember 16, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Viviana Amzel Ph.D.
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: P6639938
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 622-7700
; TELEFAX: (213) 489-4210
; TELEX: n.a.
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 131 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-976-288A-95

Query Match 91.4%; Score 544; DB 2; Length 131;
Best Local Similarity 91.1%; Pred. No. 7.7e-46;
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVVMTQSLPLPVTGEPASISCRSSQSIHNSGNTYQLQWYLOKFGQSPQLLIYKVSRL 60
||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 20 DVLMTQTPLSLPVTGEPASISCRSSQSIHNSGNTYQLQWYLOKFGQSPQLLIYKVSIRF 79

QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVPTFGGTVKEIK 112
||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 80 SGVPDRFSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVPTFGGTVKEIK 131

RESULT 10
US-08-482-882-66
; Sequence 66, Application US/08482882
; Patent No. 5773218
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/482,882
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435

```

;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/286,754  
;; FILING DATE: 05-AUG-1993  
;; APPLICATION NUMBER: US 08/102,852  
;; FILING DATE: 05-AUG-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/009,266  
;; FILING DATE: 22-JAN-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/894,061  
;; FILING DATE: 05-JUN-1992  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/889,724  
;; FILING DATE: 26-MAY-1992  
;; APPLICATION NUMBER: US 07/827,689  
;; FILING DATE: 27-JAN-1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Suh, Young J.  
;; REGISTRATION NUMBER: P-41,337  
;; REFERENCE/DOCKET NUMBER: 27866/32760  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (312) 474-6300  
;; TELEFAX: (312) 474-0448  
;; TELEX: (312) 474-6600  
;; INFORMATION FOR SEQ ID NO: 66:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 116 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
US-08-482-882-66

Query Match 91.3%; Score 543; DB 1; Length 116;  
Best Local Similarity 91.1%; Pred. No. 8.5e-46;  
Matches 102; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVMTQSLPLPVTPGEPASISCRSSQSLVHSGNTYLVHLYLQKQSPQLLIYKVSRL 60  
Db 5 DVMTQSLPLPVTPGEPASISCRSSQSLVHSGNTYLVHLYLQKQSPQLLIYKVSRL 64  
Qy 61 YGVPDRFSGSGGTDTFLKISRVEADVGVIYCFQSGSHVPMTFGGQTKVEIK 112  
Db 65 SGVPDRFSGSGGTDTFLKISRVEADVGVIYCSQSTHVPYTFGGQTKVEIK 116

RESULT 11  
US-08-483-389-66  
; Sequence 66, Application US/08483389  
; Patent No. 581517  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; APPLICANT: Vazeux, Rosemay  
; TITLE OF INVENTION: ICAM-RELATED PROTEIN  
; NUMBER OF SEQUENCES: 118  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 233 South Wacker Drive/6300 Sears Tower  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/483,389  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/102,852

;; FILING DATE: 05-AUG-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/009,266  
;; FILING DATE: 22-JAN-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/894,061  
;; FILING DATE: 05-JUN-1992  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/889,724  
;; FILING DATE: 26-MAY-1992  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/827,689  
;; FILING DATE: 27-JAN-1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Suh, Young J.  
;; REGISTRATION NUMBER: P-41,337  
;; REFERENCE/DOCKET NUMBER: 27866/32760  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (312) 474-6300  
;; TELEFAX: (312) 474-0448  
;; TELEX: (312) 474-6600  
;; INFORMATION FOR SEQ ID NO: 66:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 116 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
US-08-483-389-66  
Query Match 91.3%; Score 543; DB 1; Length 116;  
Best Local Similarity 91.1%; Pred. No. 8.5e-46;  
Matches 102; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVMTQSLPLPVTPGEPASISCRSSQSLVHSGNTYLVHLYLQKQSPQLLIYKVSRL 60  
Db 5 DVMTQSLPLPVTPGEPASISCRSSQSLVHSGNTYLVHLYLQKQSPQLLIYKVSRL 64  
Qy 61 YGVPDRFSGSGGTDTFLKISRVEADVGVIYCFQSGSHVPMTFGGQTKVEIK 112  
Db 65 SGVPDRFSGSGGTDTFLKISRVEADVGVIYCSQSTHVPYTFGGQTKVEIK 116

RESULT 12  
US-08-487-113D-66  
; Sequence 66, Application US/08487113D  
; Patent No. 5837822  
; GENERAL INFORMATION:  
; APPLICANT: Gallatin, W. Michael  
; APPLICANT: Vazeux, Rosemay  
; TITLE OF INVENTION: ICAM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 120  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/487,113D  
; FILING DATE:  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/286,754  
; FILING DATE: 05-AUG-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/102,852  
; FILING DATE: 05-AUG-1993

;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/009,266  
;; FILING DATE: 22-JAN-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/894,061  
;; FILING DATE: 05-JUN-1992  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/889,724  
;; FILING DATE: 26-MAY-1992  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/827,689  
;; FILING DATE: 27-JAN-1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: No. 5837822and, Greta E.  
;; REGISTRATION NUMBER: 35,302  
;; REFERENCE/DOCKET NUMBER: 32744  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (312) 474-6300  
;; TELEFAX: (312) 474-0448  
;; TELEX: 25-3856  
;; INFORMATION FOR SEQ ID NO: 66:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 116 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; US-08-487-113D-66

Query Match 91.3%; Score 543; DB 1; Length 116;  
Best Local Similarity 91.1%; Pred. No. 8.5e-46;  
Matches 102; Conservative 5; Mismatches 5; Indels 0; Gaps 0;  
  
Qy 1 DVMTQPLSLPVTGPEPASISCRSSQSLVHSNGNTYLQWYLPKQSPQLLIYKVSRL 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
Db 5 DIVMTQPLSLPVTGPEPASISCRSSQSLVHSNGDTYHLWYLPKQSPQLLIYKVSRL 64  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
  
Qy 61 YGVDPDRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVMTFGGKTVEIK 112  
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
Db 65 SGVDPDRFGSGSGTDFTLKISRVEADVGVVYCSQSTHVPYTFGGKTVEIK 116  
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 13  
US-08-473-503-66  
;; Sequence 66, Application US/08473503  
;; Patent No. 5869262  
;; GENERAL INFORMATION:  
;; APPLICANT: Gallatin, W. Michael  
;; APPLICANT: Vazeux, Rosemay  
;; TITLE OF INVENTION: ICAM-Related Materials and Methods  
;; NUMBER OF SEQUENCES: 116  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
;; STREET: 6300 Sears Tower, 233 S. Wacker Drive  
;; CITY: Chicago  
;; STATE: Illinois  
;; COUNTRY: USA  
;; ZIP: 60606  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: Patent in Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/473,503  
;; FILING DATE: 07-JUN-1995  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/286,754  
;; FILING DATE: 05-AUG-1994  
;; APPLICATION NUMBER: US 08/102,852  
;; FILING DATE: 05-AUG-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/009,266

;; FILING DATE: 22-JAN-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/894,061  
;; FILING DATE: 05-JUN-1992  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/889,724  
;; FILING DATE: 26-MAY-1992  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/827,689  
;; FILING DATE: 27-JAN-1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: No. 5869262and, Greta E.  
;; REGISTRATION NUMBER: 35,302  
;; REFERENCE/DOCKET NUMBER: 32178  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (312) 474-6300  
;; TELEFAX: (312) 474-0448  
;; TELEX: 25-3856  
;; INFORMATION FOR SEQ ID NO: 66:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 116 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; US-08-473-503-66  
  
Query Match 91.3%; Score 543; DB 1; Length 116;  
Best Local Similarity 91.1%; Pred. No. 8.5e-46;  
Matches 102; Conservative 5; Mismatches 5; Indels 0; Gaps 0;  
  
Qy 1 DVMTQPLSLPVTGPEPASISCRSSQSLVHSNGNTYLQWYLPKQSPQLLIYKVSRL 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
Db 5 DIVMTQPLSLPVTGPEPASISCRSSQSLVHSNGDTYHLWYLPKQSPQLLIYKVSRL 64  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
  
Qy 61 YGVDPDRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVMTFGGKTVEIK 112  
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
Db 65 SGVDPDRFGSGSGTDFTLKISRVEADVGVVYCSQSTHVPYTFGGKTVEIK 116  
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 14  
US-08-483-932-66  
;; Sequence 66, Application US/08483932  
;; Patent No. 5880268  
;; GENERAL INFORMATION:  
;; APPLICANT: Gallatin, W. Michael  
;; APPLICANT: Vazeux, Rosemay  
;; TITLE OF INVENTION: ICAM-Related Materials and Methods  
;; NUMBER OF SEQUENCES: 116  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
;; STREET: 6300 Sears Tower, 233 S. Wacker Drive  
;; CITY: Chicago  
;; STATE: Illinois  
;; COUNTRY: USA  
;; ZIP: 60606  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: Patent in Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/483,932  
;; FILING DATE: 07-JUN-1995  
;; CLASSIFICATION: 530  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/286,754  
;; FILING DATE: 05-AUG-1994  
;; APPLICATION NUMBER: US 08/102,852  
;; FILING DATE: 05-AUG-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/009,266  
;; FILING DATE: 22-JAN-1993  
;; PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5880268and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-483-932-66

Query Match          91.3%; Score 543; DB 1; Length 116;
Best Local Similarity 91.1%; Pred. No. 8.5e-46;
Matches 102; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLWYLRKPGSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHSNGDTYHLWYLRKPGSPQLLIYKVSRL 64
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 61 YGVDPDFSGSGTDFTLKISRVEADVGVYVYCFQGSHPVPTFGQTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 65 SGVPDFSGSGTDFTLKISRVEADVGVYVYCSQSTHVPYTFGQTKVEIK 116
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 15
US-08-720-420A-66
; Sequence 66, Application US/08720420A
; Patent No. 5989843
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/720,420A
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
```

```
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-720-420A-66

Query Match          91.3%; Score 543; DB 1; Length 116;
Best Local Similarity 91.1%; Pred. No. 8.5e-46;
Matches 102; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLWYLRKPGSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHSNGDTYHLWYLRKPGSPQLLIYKVSRL 64
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 61 YGVDPDFSGSGTDFTLKISRVEADVGVYVYCFQGSHPVPTFGQTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 65 SGVPDFSGSGTDFTLKISRVEADVGVYVYCSQSTHVPYTFGQTKVEIK 116
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Search completed: January 10, 2006, 20:58:03
Job time : 22.8706 secs
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 13.5124 Seconds  
(without alignments)  
797.508 Million cell updates/sec

Title: US-10-735-916A-61  
Perfect score: 595  
Sequence: 1 DVWMTQSLSLPVTGEPAS.....CFQGSHPVMTFGQTKVEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues  
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR 80:\*  
1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	524	88.1	131	2 B39276	Ig light chain pre
2	523	87.9	113	2 PL0203	anti-DNA autoantib
3	517	86.9	219	2 S52028	Ig kappa chain - m
4	514	86.4	112	2 A31807	Ig kappa chain v r
5	514	86.4	219	2 PC4203	Ig kappa chain (mo
6	513	86.2	110	2 S26335	Ig kappa chain v r
7	513	86.2	112	2 S58207	Ig light chain v r
8	513	86.2	112	2 S38719	Ig light chain v r
9	513	86.2	136	2 S40357	Ig kappa chain V-J
10	510	85.7	114	2 A32967	Ig kappa chain V-I
11	509	85.5	118	2 PT0359	Ig kappa chain v r
12	509	85.5	131	2 B34904	Ig kappa chain pre
13	507	85.2	112	2 B31485	Ig kappa chain v r
14	505	84.9	112	2 C27887	Ig kappa chain v r
15	505	84.9	131	2 C34904	Ig kappa chain pre
16	503	84.5	112	2 A27887	Ig kappa chain v r
17	502	84.4	112	2 F27887	Ig kappa chain v r
18	502	84.4	115	2 S38715	Ig kappa chain v r
19	501	84.2	114	2 B32967	Ig kappa chain V-I
20	500	84.0	112	2 E27887	Ig kappa chain v r
21	500	84.0	131	2 B03577	Ig kappa chain pre
22	500	84.0	132	2 S26882	Ig kappa chain v r
23	500	84.0	133	1 K2HURP	Ig kappa chain pre
24	500	84.0	219	2 S16112	Ig kappa chain v r
25	499	83.9	103	2 PH1043	Ig light chain v r
26	499	83.9	131	2 D34904	Ig kappa chain pre
27	499	83.9	131	2 B32513	Ig kappa chain v r
28	499	83.9	135	2 S40342	Ig kappa chain - h
29	498	83.7	112	2 D28195	Ig kappa chain v r

30	498	83.7	117	1 K2HUGM	Ig kappa chain pre
31	497	83.5	111	2 PL0257	Ig kappa chain v r
32	497	83.5	112	2 A49715	Ig kappa chain v r
33	495	83.2	112	2 S53750	antibody Fab Jel 1
34	495	83.2	113	2 B41940	Ig light chain v r
35	494	83.0	112	2 S32189	Ig kappa chain v r
36	494	83.0	225	2 JL0029	Ig kappa chain pre
37	493.5	82.9	126	2 S40339	Ig kappa chain - h
38	493	82.9	142	2 S22902	Ig kappa chain v r
39	492	82.7	133	1 A24452	Ig kappa chain pre
40	491	82.5	112	2 D27887	Ig kappa chain v r
41	491	82.5	131	2 D29380	Ig kappa chain pre
42	491	82.5	133	2 S23230	Ig kappa chain pre
43	490	82.4	112	2 B27887	Ig kappa chain v r
44	490	82.4	125	2 S40356	Ig kappa chain - h
45	490	82.4	131	2 G34903	Ig kappa chain pre

ALIGNMENTS

RESULT 1

B39276  
Ig light chain precursor V-D-J region (6-19) - mouse  
C:Species: Mus musculus (house mouse)  
C>Date: 18-Oct-1991 #sequence\_revision 18-Oct-1991 #text\_change 21-Jan-2000  
C:Accession: B39276  
R:Reininger, L.; Berney, T.; Shibata, T.; Spertini, F.; Merino, R.; Izui, S.  
Proc. Natl. Acad. Sci. U.S.A. 87, 10038-10042, 1990  
A:Title: Cryoglobulinemia induced by a murine IgG3 rheumatoid factor: skin vasculitis a  
A:Reference number: A39276; MUID:91088540; PMID:2263605  
A:Accession: B39276  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-131 <REL>  
A:Cross-references: UNIPARC:UPI0000115153; GB:M55313; NID:g198095; PIDN:AAAG3385.1; PID  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: immunoglobulin  
F:35-114/Domain: immunoglobulin homology <IMM>

Query Match 88.1%; Score 524; DB 2; Length 131;  
Best Local Similarity 87.5%; Pred. NO. 1.6e-42;  
Matches 98; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

QY	1	DVWMTQSLSLPVTGEPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPQLLIYKVSNRL	60
Db	20	DVLMTQTPLSLPVSILGDAQISCRSSQSIHVSNGNTYLTQWYLOKPGQSPKLLIYKVSNRF	79
QY	61	YGVDPDRFGSGSGSDTFTLKISRVAEDVGYYCYFCQGSHPVMTFGQTKVEIK	112
Db	80	SGVDPDRFGSGSGSDTFTLKISRVAEDLGYYCYFCQGSHPVMTFGSGTKLEIK	131

RESULT 2

PL0203  
anti-DNA autoantibody BV17-31, kappa chain V region - mouse (fragment)  
C:Species: Mus musculus (house mouse)  
C>Date: 20-Feb-1995 #sequence\_revision 20-Feb-1995 #text\_change 21-Jan-2000  
C:Accession: PL0203  
R:Smith, R.G.; Voss Jr., E.W.  
Mol. Immunol. 27, 463-470, 1990  
A:Title: Variable region primary structures of monoclonal anti-DNA autoantibodies from  
A:Reference number: PL0198; MUID:90309768; PMID:2114528  
A:Accession: PL0203  
A:Molecule type: mRNA  
A:Residues: 1-113 <SM>  
A:Cross-references: UNIPARC:UPI0000113786; GB:X53643; NID:g50196; PIDN:CAA37694.1; PID:  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
F:16-95/Domain: immunoglobulin homology <IMM>  
F:24-39/Region: complementarity-determining 1  
F:55-61/Region: complementarity-determining 2  
F:94-102/Region: complementarity-determining 3  
F:101-113/Region: D region

Query Match 87.9%; Score 523; DB 2; Length 113;  
Best Local Similarity 87.5%; Pred. No. 1.7e-42; Mismatches 5; Indels 0; Gaps 0;  
Matches 98; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60  
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
Db 61 SGVPDRFSGSGGTFTLKISRVEAEDLGVIYFCFGSHVPWTFGGTKLEIK 112

RESULT 3  
S52028  
Ig kappa chain - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 07-May-1995 #sequence\_revision 21-Jul-1995 #text\_change 21-Jan-2000  
C:Accession: S52028  
R:van Engelen, P.; Schouten, A.; Molthoff, J.W.; Roosien, J.; Dirkse, W.G.; Schots, A.;  
submitted to the EMBL Data Library, August 1994  
A:Description: Coordinate expression of antibody subunit genes yields high levels of fun  
A:Reference number: S52028  
A:Accession: S52028  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-219 <VNA>  
A:CROSS-references: UNIPARC:UPI0000114822; EMBL:L35138; NID:G522336; PIDN:AAA67525.1; PI  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.9%; Score 517; DB 2; Length 219;  
Best Local Similarity 88.4%; Pred. No. 1.3e-41;  
Matches 99; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60  
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
Db 61 SGVPDRFSGSGGTFTLKISRVEAEDLGVIYFCFGSHVPWTFGGTKLEIK 112

RESULT 4  
A31807  
Ig kappa chain V region (PAC1) - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 20-Jul-1989 #sequence\_revision 20-Jul-1989 #text\_change 09-Jul-2004  
C:Accession: A31807  
R:Taub, R.; Gould, R.J.; Garabý, V.M.; Ciccarone, T.M.; Hoxie, J.; Friedman, P.A.; Shatt  
J. Biol. Chem. 264, 259-265, 1989  
A:Title: A monoclonal antibody against the platelet fibrinogen receptor contains a seque  
A:Reference number: A31807; MUID:89079661; PMID:2909518  
A:Accession: A31807  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-112 <TAU>  
A:CROSS-references: UNIPROT:Q9M37; UNIPARC:UPI00001424F9  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.4%; Score 514; DB 2; Length 112;  
Best Local Similarity 85.7%; Pred. No. 1.2e-41;  
Matches 96; Conservative 11; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60  
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
Db 61 SGVPDRFSGSGGTFTLKISRVEAEDLGVIYFCFGSHVPWTFGGTKLEIK 112

RESULT 5  
PC4203  
Ig kappa chain (monoclonal antibody MAbA34) - mouse (fragment)  
C:Species: Mus musculus (house mouse)  
C:Date: 31-Dec-1996 #sequence\_revision 31-Dec-1996 #text\_change 11-Jan-2000  
C:Accession: PC4203  
R:Kwak, J.W.; Lee, D.I.; Choi, B.K.; Cho, W.K.; Lee, S.H.; Park, Y.B.; Han, M.H.  
Gene 173, 257-259, 1996  
A:Title: Cloning and characterization of cDNAs coding for heavy and light chains of a m  
A:Reference number: PC4202; MUID:97082978; PMID:8964510  
A:Accession: PC4203  
A:Molecule type: mRNA  
A:Residues: 1-219 <KWA>  
A:CROSS-references: UNIPARC:UPI00001157E4; GB:U29147; NID:G1594225; PIDN:AAC52821.1; PID  
C:Comment: This protein is specific for human plasma apolipoprotein A-I of high-density  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
F:112/Domain: V region #status predicted <VRG>  
F:113-219/Domain: C region #status predicted <CRG>

Query Match 86.4%; Score 514; DB 2; Length 219;  
Best Local Similarity 86.6%; Pred. No. 2.5e-41;  
Matches 97; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60  
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112  
Db 61 SGVPDRFSGSGGTFTLKISRVEAEDLGVIYFCFGSHVPWTFGGTKLEIK 112

RESULT 6  
S26335  
Ig kappa chain V region - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 20-Jun-2000  
C:Accession: S26335  
R:Stark, S.B.; Caton, A.J.  
J. Exp. Med. 174, 613-624, 1991  
A:Title: Antibodies that are specific for a single amino acid interchange in a protein e  
A:Reference number: S26309; MUID:91341421; PMID:1908510  
A:Accession: S26335  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-110 <STA>  
A:CROSS-references: UNIPARC:UPI0000115F78; EMBL:X59183; NID:G52314; PIDN:CAA41893.1; PID  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.2%; Score 513; DB 2; Length 110;  
Best Local Similarity 87.3%; Pred. No. 1.4e-41;  
Matches 96; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60  
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVE 110  
Db 61 SGVPDRFSGSGGTFTLKISRVEAEDLGVIYFCFGSHVPWTFGGTKLE 110

RESULT 7  
S58207  
Ig light chain V region anti-F(ab')2 - human (fragment)  
C:Species: Homo sapiens (man)

C>Date: 13-Jan-1996 #sequence\_revision 19-Apr-1996 #text\_change 21-Jan-2000  
C:Accession: S58207  
R:Weischof, M.; Terness, P.; Stanescu, D.; Zewe, M.; Hain, C.H.; Doebel, S.; Breitling, submitted to the EMBL Data Library, July 1995  
A:Description: Characterization of heavy and light chain immunoglobulin variable region  
A:Reference number: S58206  
A:Accession: S58207  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-112 <WEL>  
A:Cross-references: UNIPARC:UPI0000116253; EMBL:X89056; NID:G929642; PIDN:CAA61443.1; PI  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.2%; Score 513; DB 2; Length 112;  
Best Local Similarity 86.6%; Pred. No. 1.5e-41;  
Matches 97; Conservative 3; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSLHSGNYLDWYLOKPGQSPQLLIYLGSRNA 60

QY 61 YGVDPDRFSGSGSDTFTLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 61 SGVPDRFSGSGSDTFTLKISRVEADGVVYCMQALQTPMTFGQGTKEIK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

## RESULT 8

S38719  
Ig light chain V region - mouse  
C:Species: Mus musculus (house mouse)  
C>Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 20-Jun-2000  
C:Accession: S38719  
R:Cimanis, A.Y.  
submitted to the EMBL Data Library, November 1993  
A:Reference number: S38713  
A:Accession: S38719  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-112 <CIM>  
A:Cross-references: UNIPARC:UPI0000117543; EMBL:X76021; NID:G416112; PIDN:CAA53608.1; PI  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.2%; Score 513; DB 2; Length 112;  
Best Local Similarity 85.7%; Pred. No. 1.5e-41;  
Matches 96; Conservative 10; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||  
Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSIYVNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVDPDRFSGSGSDTFTLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 61 SGVPDRFSGSGSDTFTLKISRVEADGVVYCFQGSHPVPTFGAGTKLEK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

## RESULT 9

S40357  
Ig kappa chain V-J-C region - human  
C:Species: Homo sapiens (man)  
C>Date: 19-May-1994 #sequence\_revision 26-May-1995 #text\_change 31-Dec-2004  
R:Klein, R.; Jaenichen, R.; Zachau, H.G.  
Eur. J. Immunol. 23, 3248-3271, 1993  
A:Title: Expressed human immunoglobulin chi genes and their hypermutation.  
A:Reference number: S40312; MUID:94080891; PMID:8258341  
A:Accession: S40357  
A>Status: preliminary; translation not shown  
A:Molecule type: mRNA  
A:Residues: 1-136 <KLE>

Query Match 86.2%; Score 509; DB 2; Length 118;  
Best Local Similarity 84.8%; Pred. No. 3.7e-41;  
Matches 95; Conservative 9; Mismatches 8; Indels 0; Gaps 0;

A:Cross-references: UNIPROT:Q8NEK0; UNIPARC:UPI0000176CA8; EMBL:X72467  
C:Superfamily: immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:36-115/Domain: immunoglobulin homology <IMM>

Query Match 86.2%; Score 513; DB 2; Length 136;  
Best Local Similarity 86.6%; Pred. No. 1.8e-41;  
Matches 97; Conservative 3; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 21 DIVMTQSPSLPVTGPEPASISCRSSQSLHSGNYLDWYLOKPGQSPQLLIYLGSRNA 80  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 YGVDPDRFSGSGSDTFTLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 81 SGVPDRFSGSGSDTFTLKISRVEADGVVYCMQALQTPMTFGQGTKEIK 132  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

## RESULT 10

A32967  
Ig kappa chain V-II region TE33 - mouse  
C:Species: Mus musculus (house mouse)  
C>Date: 29-Jan-1990 #sequence\_revision 29-Jan-1990 #text\_change 21-Jan-2000  
C:Accession: A32967  
R:Levy, R.; Asulin, O.; Scherf, T.; Levitt, M.; Anglistter, J.  
Biochemistry 28, 7168-7175, 1989  
A:Title: Probing antibody diversity by 2D NMR: comparison of amino acid sequences, predicted from cDNA sequences, and from protein sequences  
A:Reference number: A32967; MUID:90057406; PMID:2819059  
A:Accession: A32967  
A>Status: preliminary; nucleic acid sequence not shown; not compared with conceptual translation  
A:Molecule type: mRNA  
A:Residues: 1-114 <LEV>  
A:Cross-references: UNIPARC:UPI0000114F5D; GB:M30481; NID:G197157; PIDN:AAA38935.1; PID  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 85.7%; Score 510; DB 2; Length 114;  
Best Local Similarity 83.9%; Pred. No. 2.9e-41;  
Matches 94; Conservative 12; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 1 DVLMTQTPLSPVSLGQASISCRSSQSIHVHSGNTYFEWYLOKPGQSPQLLIYKVSRL 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 YGVDPDRFSGSGSDTFTLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 61 SGVPDRFSGSGSDTFTLKISRVEADLGVIYCFQGSHPPTFGSGTKLEIK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

## RESULT 11

PT0359  
Ig kappa chain V region (R4A.12) - mouse (fragment)  
C:Species: Mus musculus (house mouse)  
C>Date: 31-Mar-1992 #sequence\_revision 31-Mar-1992 #text\_change 09-Jul-2004  
C:Accession: PT0359  
R:Shefner, R.; Kleiner, G.; Turken, A.; Papazian, L.; Diamond, B.  
J. Exp. Med. 173, 287-296, 1991  
A:Title: A novel class of anti-DNA antibodies identified in BALB/c mice.  
A:Reference number: PT0352; MUID:91108325; PMID:1988536  
A:Accession: PT0359  
A:Molecule type: mRNA  
A:Residues: 1-118 <SHE>  
A:Cross-references: UNIPROT:Q8VIC6; UNIPARC:UPI0000176AF2  
A:Experimental source: strain BALB/c  
A:Comment: This protein is an anti-double-stranded DNA antibody.  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
F:19-98/Domain: immunoglobulin homology <IMM>

Query Match 85.5%; Score 509; DB 2; Length 118;  
Best Local Similarity 84.8%; Pred. No. 3.7e-41;  
Matches 95; Conservative 9; Mismatches 8; Indels 0; Gaps 0;

```
Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
|||||:|||||:|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 4 DVVMTQTPLSLPVSLGDOASISCRSSQSLVHSGNTYHLHWYLOKPGQSPKLLIYKVSRRF 63

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCQSHVPWTFGGTKVEIK 112
Db 64 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCQSSTHPVWTFGGGTKLEIK 115

RESULT 12
B34904
Ig kappa chain precursor V region (12-40 and 5-14) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 27-Jul-1990 #sequence_revision 27-Jul-1990 #text_change 21-Jul-2000
C:Accession: B34904; H34903
R:Bedzyk, W.D.; Herron, J.N.; Edmondson, A.B.; Voss Jr., E.W.
J. Biol. Chem. 265, 133-138, 1990
A:Title: Active site structure and antigen binding properties of idiotypically cross-reactive
A:Reference number: A34903; MUID:90094387; PMID:2104617
A:Accession: B34904
A>Status: preliminary; not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-131 <BED>
A:CROSS-references: UNIPARC:UPI0000114FC8; GB:M32384; GB:J05237; GB:J05238; NID:G639656;
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F;135-114/Domain: immunoglobulin homology <IMM>

Query Match 85.5%; Score 509; DB 2; Length 131;
Best Local Similarity 84.8%; Pred. No. 4.1e-41;
Matches 95; Conservative 9; Mismatches 8; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
Db 20 DVVMTQTPLSLPVSLGDOASISCRSSQSLVHSGNTYHLHWYLOKPGQSPKLLIYKVSRRF 79

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCQSHVPWTFGGTKVEIK 112
Db 80 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCQSSTHPVWTFGGGTKLEIK 131

RESULT 13
B31485
Ig kappa chain V region (4-4-20) - mouse (fragment)
C:Species: Mus musculus (house mouse)
C>Date: 31-Jul-1989 #sequence_revision 31-Jul-1989 #text_change 09-Jul-2004
C:Accession: B31485
R:Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.
J. Biol. Chem. 264, 1565-1569, 1989
A:Title: Comparison of variable region primary structures within an anti-fluorescein idiotype
A:Reference number: A31485; MUID:89109167; PMID:2492278
A:Accession: B31485
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-112 <BED>
A:CROSS-references: UNIPROT:Q8VC16; UNIPARC:UPI0000176AF8
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F;16-95/Domain: immunoglobulin homology <IMM>

Query Match 85.2%; Score 507; DB 2; Length 112;
Best Local Similarity 83.9%; Pred. No. 5.4e-41;
Matches 94; Conservative 11; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVVMTQTPLSLPVSLGDOASISCRSSQSLVHSGNTYHLRWYLOKPGQSPKLLIYKVSRRF 60

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCQSHVPWTFGGTKVEIK 112
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCQSSTHPVWTFGGGTKLEIK 112
```

```
RESULT 14
C27887
Ig kappa chain V region (H37-82) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 15-Dec-1988 #sequence_revision 15-Dec-1988 #text_change 09-Jul-2004
C:Accession: C27887
R:Caton, A.J.; Brownlee, G.G.; Staudt, L.M.; Gerhard, W.
EMBO J. 5, 1577-1587, 1986
A:Title: Structural and functional implications of a restricted antibody response to a dominant
A:Reference number: A91043; MUID:86300658; PMID:2427335
A:Accession: C27887
A:Molecule type: DNA
A:Residues: 1-112 <CAT>
A:CROSS-references: UNIPROT:Q8VC16; UNIPARC:UPI0000176A17
A:Experimental source: strain Balb/c
A>Note: This sequence was determined from the germline gene
C:Comment: This chain was isolated from a hybridoma protein that binds influenza virus
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F;16-95/Domain: immunoglobulin homology <IMM>

Query Match 84.9%; Score 505; DB 2; Length 112;
Best Local Similarity 83.9%; Pred. No. 8.3e-41;
Matches 94; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVVMTQTPLSLPVSLGDOASISCRSSQSLVHSGNTYHLHWYLOKPGQSPKLLIYKVSRRF 60

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCQSHVPWTFGGTKVEIK 112
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCQSSTHPVWTFGGGTKLEIK 112

RESULT 15
C34904
Ig kappa chain precursor V region (3-24) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 27-Jul-1990 #sequence_revision 27-Jul-1990 #text_change 09-Jul-2004
C:Accession: C34904; I31485
R:Bedzyk, W.D.; Herron, J.N.; Edmondson, A.B.; Voss Jr., E.W.
J. Biol. Chem. 265, 133-138, 1990
A:Title: Active site structure and antigen binding properties of idiotypically cross-reactive
A:Reference number: A34903; MUID:90094387; PMID:2104617
A:Accession: C34904
A>Status: preliminary; not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-131 <BED>
A:CROSS-references: UNIPROT:Q8VC16; UNIPARC:UPI00001767A8
R:Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.
J. Biol. Chem. 264, 1565-1569, 1989
A:Title: Comparison of variable region primary structures within an anti-fluorescein idiotype
A:Reference number: A31485; MUID:89109167; PMID:2492278
A:Accession: I31485
A>Status: preliminary
A:Molecule type: protein
A:Residues: 20-52 <BE2>
A:CROSS-references: UNIPARC:UPI00001767A9
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F;35-114/Domain: immunoglobulin homology <IMM>

Query Match 84.9%; Score 505; DB 2; Length 131;
Best Local Similarity 83.9%; Pred. No. 9.9e-41;
Matches 94; Conservative 9; Mismatches 9; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVHSGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
Db 20 DVVMTQTPLSLPVSLGDOASISCRSSQSLVHSGNTYHLHWYLOKPGQSPKLLIYKVSRRF 79

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCQSHVPWTFGGTKVEIK 112
Db 80 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCQSSTHPVWTFGGGTKLEIK 131
```

Search completed: January 10, 2006, 20:55:14  
Job time : 14.5124 secs

---

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model  
Run on: January 10, 2006, 20:26:41 ; Search time 75.5025 Seconds  
(without alignment)  
1046.577 Million cell updates/sec

Title: US-10-735-916A-61  
Perfect score: 595  
Sequence: 1 DVMWTSPLSLPVTGPBPAS.....CFQSGSHVPTWGQTKVEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues  
Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : UniProt\_05.80.\*  
1: uniprot\_sprot.\*  
2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	520	87.4	248	Q65ZQ7_9MURI	Q65ZQ7 mus sp. b3(
2	500	84.0	133	KV2F_HUMAN	P06310 homo sapien
3	498	83.7	117	KV2E_HUMAN	P06309 homo sapien
4	497	83.5	239	Q8NEK0_HUMAN	Q8NEK0 homo sapien
5	487	81.8	113	KV2D_HUMAN	P01617 homo sapien
6	485	81.6	114	Q9UL80_HUMAN	Q9UL80 homo sapien
7	484.5	81.4	115	Q5F210_MOUSE	Q5F210 mus musculu
8	483	81.2	113	KV2G_MOUSE	P01631 mus musculu
9	481	80.8	239	Q8TCD0_HUMAN	Q8TCD0 homo sapien
10	478	80.3	239	Q6P491_HUMAN	Q6P491 homo sapien
11	472.5	79.4	240	Q6PIH6_HUMAN	Q6PIH6 homo sapien
12	470.5	79.1	115	KV2A_HUMAN	P01614 homo sapien
13	470	79.0	112	Q53VP8_MOUSE	Q53VP8 mus musculu
14	466	78.3	219	Q65ZC0_MOUSE	Q65ZC0 mus musculu
15	455	76.5	113	KV2B_HUMAN	P01615 homo sapien
16	451	75.8	239	Q58EU8_MOUSE	Q58EU8 mus musculu
17	448.5	75.4	112	KV2C_HUMAN	P01616 homo sapien
18	440	73.9	234	Q5XKG4_MOUSE	Q5XKG4 mus musculu
19	433	72.8	113	KV2F_MOUSE	P01630 mus musculu
20	429	72.1	113	KV2E_MOUSE	P03976 mus musculu
21	418	70.3	112	Q6LEM8_MOUSE	Q6LEM8 mus musculu
22	415	69.7	112	KV2D_MOUSE	P01629 mus musculu
23	397.5	66.8	108	KV1_CANFA	P01618 canis famil
24	396.5	66.6	134	KV4C_HUMAN	P06314 homo sapien
25	386	64.9	113	KV2A_MOUSE	P01628 mus musculu
26	384	64.5	112	KV2C_MOUSE	P01626 mus musculu
27	376.5	63.3	114	KV4A_HUMAN	P01625 homo sapien
28	376	63.2	129	KV3M_HUMAN	P18136 homo sapien
29	369	62.0	133	KV4B_HUMAN	P06313 homo sapien
30	367	61.7	109	KV3B_HUMAN	P01622 homo sapien
31	367	61.7	109	KV3D_HUMAN	P01622 homo sapien

32	367	61.7	129	1	KV3L_HUMAN	P18135 homo sapien
33	362	60.8	109	2	Q9UL78_HUMAN	Q9UL78 homo sapien
34	360	60.5	109	1	KV3E_HUMAN	P01623 homo sapien
35	359.5	60.4	111	1	KV3O_MOUSE	P01667 mus musculu
36	359.5	60.4	255	2	Q6KB05_MOUSE	Q6KB05 mus musculu
37	358	60.2	120	1	KV2B_MOUSE	P01627 mus musculu
38	356	59.8	108	1	KV3A_HUMAN	P01619 homo sapien
39	355.5	59.7	236	2	Q6PIL8_HUMAN	Q6PIL8 homo sapien
40	355	59.7	129	1	KV3H_HUMAN	P01620 homo sapien
41	353.5	59.4	111	1	KV3H_MOUSE	P01660 mus musculu
42	353	59.3	109	1	KV3F_HUMAN	P01624 homo sapien
43	353	59.3	110	1	KV3P_MOUSE	P01668 mus musculu
44	352.5	59.2	111	1	KV3Q_MOUSE	P01669 mus musculu
45	352.5	59.2	240	2	Q52L64_MOUSE	Q52L64 mus musculu

ALIGNMENTS

RESULT 1  
Q55ZQ7\_9MURI PRELIMINARY; PRT; 248 AA.  
ID Q65ZQ7\_9MURI PRELIMINARY; PRT; 248 AA.  
AC Q65ZQ7;  
DT 25-OCT-2004 (Tremblrel. 28, Created)  
DT 25-OCT-2004 (Tremblrel. 28, Last sequence update)  
DT 25-OCT-2004 (Tremblrel. 28, Last annotation update)  
DE B3(FV)-PE40 (Fragment).  
GN Name=B3(FV)-PE40;  
OS Mus sp.  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
OC Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10095;  
RN [1]  
RP MEDLINE=92020904; PubMed=1924323;  
RA Brinkmann U., Pai L.H., Fitzgerald D.J., Willingham M., Pastan I.;  
"B3(FV)-PE38KDEL, a single-chain immunotoxin that causes complete  
RT regression of a human carcinoma in mice."  
Proc. Natl. Acad. Sci. U.S.A. 88:8616-8620(1991).  
DR EMBL; S57990; AAB19971.2; -; mRNA.  
DR SMR; Q65ZQ7; 4-247.  
DR InterPro; IPR003599; Ig.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003596; Ig\_v.  
DR SMART; SM00409; IG; 2.  
DR SMART; SM00406; IGV; 2.  
DR PROSITE; PS00835; IG\_LIKE; 2.  
FT NON\_TER 248  
SQ SEQUENCE 248 AA; 26634 MW; 7A3759B43E570950 CRC64;  
Query Match 87.4%; Score 520; DB 2; Length 248;  
Best Local Similarity 87.5%; Pred. No. 5.5e-46;  
Matches 98; Conservative 8; Mismatches 6; Indels 0; Gaps 0;  
QY 1 DVMWTSPLSLPVTGPBPASISCRSSQIVHSNGNTYLQWYLQKPGSPQLLIYKVSNRL 60  
Db 136 DVLMTQSPSLPLFVSLGDAQISCRSSQIIIVHSNGNTYLEWYLQKPGSPQLLIYKVSNRF 195  
QY 61 YGVDPRESGSGTDFTLKISRVEADVGYYVFCQGSHPVPTFGGTVKEIK 112  
Db 196 SGVPDRFSGSGGTDFTLKISRVEADVGYYVFCQGSHPVPTFGGTVKEIK 247  
RESULT 2  
KV2F\_HUMAN STANDARD; PRT; 133 AA.  
ID KV2F\_HUMAN  
AC P06310;  
DT 01-JAN-1988 (Rel. 06, Created)  
DT 01-JAN-1988 (Rel. 06, Last sequence update)  
DT 10-MAY-2005 (Rel. 47, Last annotation update)  
DE Ig kappa chain V-II region RPMI 6410 precursor.  
OS Homo sapiens (Human).

```
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86041852; PubMed=2997711;
RA Klobeck H.G., Meindl A., Combiato G., Solomon A., Zachau H.G.;
RT "Human immunoglobulin kappa light chain genes of subgroups II and
RT III.";
RL Nucleic Acids Res. 13:6499-6513 (1985).
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; Z00020; CAA77315.1; -; Genomic_DNA.
DR PIR; A01890; K2HURP.
DR HSP; Q99M37; I191.
DR SMR; P06310; 21-133.
DR Ensemble; ENSG00000173758; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 20
FT CHAIN 21 133 Ig kappa chain V-II region RPMI 6410.
FT REGION 21 43 Framework-1.
FT REGION 44 59 Complementarity-determining-1.
FT REGION 60 74 Framework-2.
FT REGION 75 81 Complementarity-determining-2.
FT REGION 82 113 Framework-3.
FT REGION 114 122 Complementarity-determining-3.
FT REGION 123 133 Framework-4.
FT DISULFID 43 113 By similarity.
FT NON_TER 133 133
SQ SEQUENCE 133 AA; 14707 MW; 513CCAP3673009EE CRC64;

Query Match 84.0%; Score 500; DB 1; Length 133;
Best Local Similarity 84.8%; Pred. No. 3.3e-44;
Matches 95; Conservative 8; Mismatches 9; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLPKPGQSPQLLIYKVSRL 60
Db |||||
QY 61 YGVDPFRFGSGSGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGGTVK 112
Db |||||
QY 81 SGVDPFRFGSGSGTDFTLKISRVEAEDVGVYYCMQGTHTSWTFGGTVK 132
Db |||||

RESULT 3
KV2E HUMAN
ID KV2E HUMAN STANDARD; PRT; 117 AA.
AC P06309;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region GM607 precursor (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=84191506; PubMed=6325927;
```

```
RA Klobeck H.G., Solomon A., Zachau H.G.;
RT "Contribution of human V kappa II germ-line genes to light-chain
RT diversity.";
RL Nature 309:73-76 (1984).
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; Z00009; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR PIR; A01889; K2HUGM.
DR HSP; Q99M37; I191.
DR SMR; P06309; 5-117.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL <1 4
FT CHAIN 5 117 Ig kappa chain V-II region GM607.
FT REGION 5 27 Framework-1.
FT REGION 28 43 Complementarity-determining-1.
FT REGION 44 58 Framework-2.
FT REGION 59 65 Complementarity-determining-2.
FT REGION 66 97 Framework-3.
FT REGION 98 106 Complementarity-determining-3.
FT REGION 107 116 Framework-4.
FT DISULFID 27 97 By similarity.
FT NON_TER 117 117
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12664 MW; 92C57DC719E558B1 CRC64;

Query Match 83.7%; Score 498; DB 1; Length 117;
Best Local Similarity 85.7%; Pred. No. 4.5e-44;
Matches 96; Conservative 3; Mismatches 13; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLPKPGQSPQLLIYKVSRL 60
Db |||||
QY 61 YGVDPFRFGSGSGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGGTVK 112
Db |||||
QY 65 SGVDPFRFGSGSGTDFTLKISRVEAEDVGVYYCMQGLTPTPTFGGTVK 116
Db |||||

RESULT 4
Q8NEKO HUMAN
ID Q8NEKO HUMAN PRELIMINARY; PRT; 239 AA.
AC Q8NEKO;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGKV1-5 protein.
GN Name=IGKV1-5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=2388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.W., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
```

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C., Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J., Bosak S.A., McSwan P.C., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.J., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.";  
 RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).  
 RN [2]

RN NUCLEOTIDE SEQUENCE.  
 RC TISSUE=Prostate;  
 RA Director MGC Project;  
 RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.  
 RN [3]

RN NUCLEOTIDE SEQUENCE.  
 RX PubMed=1601042;  
 RA Huber C., Klobeck H.G., Zachau H.G.;  
 RT "Ongoing V kappa-J kappa recombination after formation of a productive V kappa-J kappa coding joint.";  
 RT Eur. J. Immunol. 22:1561-1565 (1992).  
 RN [4]

RN NUCLEOTIDE SEQUENCE.  
 RX Wagner S.D., Luzzatto L.;  
 RA Wagner S.D., Luzzatto L.;  
 RT "v kappa gene segments rearranged in chronic lymphocytic leukemia are distributed over a large portion of the V kappa locus and do not show somatic mutation.";  
 RT Eur. J. Immunol. 23:391-397 (1993).  
 RN [5]

RN NUCLEOTIDE SEQUENCE.  
 RX PubMed=8258341;  
 RA Klein R., Jaenichen R., Zachau H.G.;  
 RT "Expressed human immunoglobulin kappa genes and their hypermutation.";  
 RL Eur. J. Immunol. 23:3248-3262 (1993).  
 DR EMBL, BC030814; AAH30814.1; -; mRNA.

DR PIR, S23638; S23638.  
 DR PIR, S34091; S34091.  
 DR PIR, S40342; S40342.  
 DR PIR, S40357; S40357.  
 DR HSP, P01834; I172.  
 DR SMR, Q8NEK0; 21-237.  
 DR InterPro; IPR007110; Ig-like.  
 DR InterPro; IPR003597; Ig cl.  
 DR InterPro; IPR003006; Ig MHC.  
 DR InterPro; IPR003596; Ig\_v.  
 DR Pfam; PF07654; Cl-set; 1.  
 DR SMART; SM00406; IGV; 1.  
 DR PROSITE; PSS0835; IG\_LIKE; 2.  
 DR PROSITE; PS00290; IG\_MHC; UNKNOWN\_1.  
 KW Immunoglobulin domain.  
 SQ SEQUENCE 239 AA; 26024 MW; F5E20AD3B0552C0A CRC64;

Query Match 83.5%; Score 497; DB 2; Length 239;  
 Best Local Similarity 83.9%; Pred. No. 1.3e-43;  
 Matches 94; Conservative 6; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVVMTQSPISLPTVPTEGPASISCRSSQSIHVHNGNTYLOWYLOKPKQSPQLTIYKVSRL 60  
 DB 21 DIVMTQSPISLPTVPTEGPASISCRSSQSLHSDGYNLWYLOKPKQSPQLTIYLGSNRA 80

QY 61 YGVPRFSGSGSGTDFTLKISRVEADGVVYFCQGSHPVTFGQGTKEIK 112  
 DB 81 SGVPRFSGSGSGTDFTLKISRVEADGVVYFCWQGLQTPQIFGQGTKEIK 132

RESULT 5

KV2D\_HUMAN  
 ID KV2D\_HUMAN STANDARD; PRT; 113 AA.  
 AC P01617;  
 DT 21-JUL-1986 (Rel. 01, Created)  
 DT 21-JUL-1986 (Rel. 01, Last sequence update)  
 DT 10-MAY-2005 (Rel. 47, Last annotation update)  
 DE Ig kappa chain V-II region TEW.  
 OS Homo sapiens (Human)  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo.  
 OC Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP PROTEIN SEQUENCE (BENCE-JONES PROTEIN TEW).  
 RX MEDLINE=74148480; PubMed=4596149;  
 RA Putnam F.W., Whitley E.J. Jr., Paul C., Davidson J.N.;  
 RT "Amino acid sequence of a kappa Bence Jones protein from a case of primary amyloidosis.";  
 RL Biochemistry 12:3763-3780 (1973).  
 RN [2]  
 RP PROTEIN SEQUENCE OF 1-27 (AMYLOID PROTEIN TEW).  
 RX MEDLINE=73166638; PubMed=4700495;  
 RA Terry W.D., Page D.L., Kimura S., Isobe T., Osseman E.F., Glenner G.G.;  
 RT "Structural identity of Bence Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis.";  
 RL J. Clin. Invest. 52:1276-1281 (1973).  
 CC -!- MISCELLANEOUS: The major amyloid protein appears to be identical with the Bence Jones protein isolated from the same patient.  
 CC -!- MISCELLANEOUS: This protein was isolated from the urine of a patient with plasma cell dyscrasia and amyloidosis.  
 CC -!- MISCELLANEOUS: The C region of this chain has the INV (1,2) marker.  
 CC -----  
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.  
 CC -----  
 CC PIR; A90370; K2HUTW.  
 DR HSP, Q99M37; I191.  
 DR SMR, P01617; 1-113.  
 DR GO; GO:0005576; C:extracellular region; NAS.  
 DR GO; GO:0003823; P:antigen binding; NAS.  
 DR GO; GO:0006955; F:immune response; NAS.  
 DR InterPro; IPR007110; Ig-like.  
 DR InterPro; IPR003596; Ig\_v.  
 DR SMART; SM00406; IGV; 1.  
 DR PROSITE; PSS0835; IG\_LIKE; 1.  
 KW Amyloid; Bence-Jones protein; Direct protein sequencing;  
 KW Immunoglobulin domain; Immunoglobulin V region.  
 FT REGION 1 23  
 FT REGION 24 39  
 FT REGION 40 54  
 FT REGION 55 61  
 FT REGION 62 93  
 FT REGION 94 102  
 FT REGION 103 112  
 FT REGION 113 113  
 FT DISULFID 23 93  
 FT NON\_TER 113 113  
 SQ SEQUENCE 113 AA; 12316 MW; 0C3C38F81F1843CA CRC64;  
 Query Match 81.8%; Score 487; DB 1; Length 113;  
 Best Local Similarity 81.2%; Pred. No. 6.2e-43;  
 Matches 91; Conservative 9; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVVMTQSPISLPTVPTEGPASISCRSSQSIHVHNGNTYLOWYLOKPKQSPQLTIYKVSRL 60  
 DB 1 DIVMTQSPISLPTVPTEGPASISCRSSQSLHSDGYNLWYLOKPKQSPQLTIYALSNRA 60

QY 61 YGVPRFSGSGSGTDFTLKISRVEADGVVYFCQGSHPVTFGQGTKEIK 112  
 |||||  
 |||||

```
Db 61 SGVDPFRFSGSGSDFTLKISRVEADVGYYCMZALQAPITFGQGTREIK 112
RESULT 6
Q9UL80 HUMAN PRELIMINARY; PRT; 114 AA.
AC Q9UL80;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin light chain variable region
   (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1322670;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
   fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1322670;
RA Stuber F., Lee S.K., Bridges S.L. Jr, Koopman W.J., Schroeder H.W. Jr,
RA Gaskin F., Fu S.M.;
RT "A rheumatoid factor from a normal individual encoded by VH2 and V
   kappa II gene segments.";
RL Arthritis Rheum. 35:900-904(1992).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=8436174;
RA Wagner S.D., Luzzatto L.;
RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are
   distributed over a large portion of the V kappa locus and do not show
   somatic mutation.";
RL Eur. J. Immunol. 23:391-397(1993).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1601042;
RA Huber C., Klobeck H.G., Zachau H.G.;
RT "Ongoing V kappa-J kappa recombination after formation of a productive
   V kappa-J kappa coding joint.";
RL Eur. J. Immunol. 22:1561-1565(1992).
DR EMBL; AF035034; AAD56270.1; -; mRNA.
DR PIR; B49002; B49002.
DR PIR; S23638; S23638.
DR PIR; S34094; S34094.
DR PIR; S34095; S34095.
DR HSP; P01625; 1LVE.
DR SMR; Q9UL80; 1-114.
DR InterPro; IPR007110; Ig-like.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS00835; IG LIKE; 1.
FT NON_TER 1
FT NON_TER 114
SQ SEQUENCE 114 AA; 12775 MW; 070E31E210D1CB01 CRC64;
Query Match 81.6%; Score 485.5; DB 2; Length 114;
Best Local Similarity 84.1%; Pred. No. 8.9e-43;
Matches 95; Conservative 7; Mismatches 10; Indels 1; Gaps 1;
QY 1 DVVMTQSPVLPVTGEPASISCRSSQSVHSNGNTYLQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVVMTQSPVLPVTGEPASISCRSSQSVHSNGNTYLQWYLOKPGQSPQLLIYKVSRL 60
QY 61 YGVDPFRFSGSGSDFTLKISRVEADVGYYCFQGSN-VPMTFGQGTREIK 112
Db 61 YGVDPFRFSGSGSDFTLKISRVEADVGYYCFQGSN-VPMTFGQGTREIK 112
RESULT 7
Q5F210 MOUSE PRELIMINARY; PRT; 115 AA.
AC Q5F210;
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE Kappa light chain variable region (Fragment).
GN Name=IgG1 anti-TS1 VL;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Erlandsson A., Holm P., Ullen A., Stigbrand T., Sundstrom B.E.;
RT "Studies of the interactions between the anticytokerin 8 monoclonal
   antibody TS1, its antigen and its anti-idiotypic antibody alphaTS1.";
RL J. Mol. Recognit. 16:157-163(2003).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RA Erlandsson A.;
RL Submitted (FEB-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ884575; CA156337.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig V.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS00835; IG LIKE; 1.
FT NON_TER 1
FT NON_TER 115
SQ SEQUENCE 115 AA; 12560 MW; E4D3BF3D63E88007 CRC64;
Query Match 81.4%; Score 484.5; DB 2; Length 115;
Best Local Similarity 82.3%; Pred. No. 1.1e-42;
Matches 93; Conservative 11; Mismatches 8; Indels 1; Gaps 1;
QY 1 DVVMTQSPVLPVTGEPASISCRSSQSVHSNGNTYLQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVVMTQSPVLPVTGEPASISCRSSQSVHSNGNTYLQWYLOKPGQSPQLLIYKVSRL 60
QY 61 YGVDPFRFSGSGSDFTLKISRVEADVGYYCFQGSN-VPMTFGQGTREIK 112
Db 61 YGVDPFRFSGSGSDFTLKISRVEADVGYYCFQGSN-VPMTFGQGTREIK 112
RESULT 8
KV2G MOUSE STANDARD; PRT; 113 AA.
AC KV2G MOUSE STANDARD; PRT; 113 AA.
AC P01631;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region 26-10.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP PROTEIN SEQUENCE.
RC STRAIN=A/J;
EX MEDLINE=83178921; PubMed=6404298;
RA Novotny J., Margolies M.N.;
RT "Amino acid sequence of the light chain variable region from a mouse
   anti-digoxin hybridoma antibody.";
RL Biochemistry 22:1153-1158(1983).
```

```
Db 61 SGVDPFRFSGSGSDFTLKISRVEADVGYYCMQGTHTPPTFGQGTREIK 113
RESULT 7
Q5F210 MOUSE PRELIMINARY; PRT; 115 AA.
AC Q5F210;
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE Kappa light chain variable region (Fragment).
GN Name=IgG1 anti-TS1 VL;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Erlandsson A., Holm P., Ullen A., Stigbrand T., Sundstrom B.E.;
RT "Studies of the interactions between the anticytokerin 8 monoclonal
   antibody TS1, its antigen and its anti-idiotypic antibody alphaTS1.";
RL J. Mol. Recognit. 16:157-163(2003).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RA Erlandsson A.;
RL Submitted (FEB-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ884575; CA156337.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig V.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS00835; IG LIKE; 1.
FT NON_TER 1
FT NON_TER 115
SQ SEQUENCE 115 AA; 12560 MW; E4D3BF3D63E88007 CRC64;
Query Match 81.4%; Score 484.5; DB 2; Length 115;
Best Local Similarity 82.3%; Pred. No. 1.1e-42;
Matches 93; Conservative 11; Mismatches 8; Indels 1; Gaps 1;
QY 1 DVVMTQSPVLPVTGEPASISCRSSQSVHSNGNTYLQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVVMTQSPVLPVTGEPASISCRSSQSVHSNGNTYLQWYLOKPGQSPQLLIYKVSRL 60
QY 61 YGVDPFRFSGSGSDFTLKISRVEADVGYYCFQGSN-VPMTFGQGTREIK 112
Db 61 YGVDPFRFSGSGSDFTLKISRVEADVGYYCFQGSN-VPMTFGQGTREIK 112
RESULT 8
KV2G MOUSE STANDARD; PRT; 113 AA.
AC KV2G MOUSE STANDARD; PRT; 113 AA.
AC P01631;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region 26-10.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP PROTEIN SEQUENCE.
RC STRAIN=A/J;
EX MEDLINE=83178921; PubMed=6404298;
RA Novotny J., Margolies M.N.;
RT "Amino acid sequence of the light chain variable region from a mouse
   anti-digoxin hybridoma antibody.";
RL Biochemistry 22:1153-1158(1983).
```

CC -!- MISCELLANEOUS: This chain was isolated from an IgG2a hybridoma  
CC protein that binds digoxin.  
CC -----  
CC This Swiss-Prot entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use as long as its content is in no way modified and this statement is not  
CC removed.  
CC -----  
DR PIR; A01914; KVM26.  
DR HSSP; Q99M37; 1191.  
DR Ensembl; ENSMUSG0000055315; Mus musculus.  
DR InterPro; IPR007110; Ig-like.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS00835; IG LIKE; 1.  
KW Direct protein sequencing; Hybridoma; Immunoglobulin domain;  
KW Immunoglobulin V region; Monoclonal antibody.  
FT REGION 1 23  
FT REGION 24 39  
FT REGION 40 54  
FT REGION 55 61  
FT REGION 62 93  
FT REGION 94 102  
FT REGION 103 112  
FT DISULFID 23 93  
FT NON TER 113 113  
SQ SEQUENCE 113 AA; 12273 MW; F9F39CE949A84C2A CRC64;  
Query Match 81.2%; Score 483; DB 1; Length 113;  
Best Local Similarity 82.1%; Pred. No. 1.6e-42;  
Matches 92; Conservative 10; Mismatches 10; Indels 0; Gaps 0;  
QY 1 DVMTQSPFLSPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
DB 1 DVMTQTPLSPVSLGDSQASISCRSSQSLVHSNGNTYLYQWYLOKAGQSPKLLIYKVSRL 60  
QY 61 YGVDPFRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112  
DB 61 SGVDPFRFSGSGSGTDFTLKISRVEAEDLGIYPCSTTHVPPTFGGQTKLEIK 112  
RESULT 9  
Q8TCD0 HUMAN PRELIMINARY; PRT; 239 AA.  
AC Q8TCD0;  
DT 01-JUN-2002 (TrEMBLrel. 21, Created)  
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE Hypothetical protein.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Lung;  
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schuler G.D.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Frange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Helton E., Kettman M., Madan A.C., Rodriguez S., Sanchez A.,  
RA Whiting M., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,  
RA Sutterch A., Schein J.E., Jones S.J.M., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences.";  
RL proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Lung;  
RA Strausberg R.;  
RL Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=1598223;  
RA Hirabayashi Y., Munakata Y., Sasaki T., Sano H.;  
RT "Variable regions of a human anti-DNA antibody O-81 possessing lupus  
RT nephritis-associated idiotype.";  
RL Nucleic Acids Res. 20:2601-0(1992).  
RN [4]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=1551402;  
RA Lautner-Rieske A., Huber C., Meindl A., Pargent W., Schable K.F.,  
RA Thiele R., Zocher I., Zachau H.G.;  
RT "The human immunoglobulin kappa locus. Characterization of the  
RT duplicated A regions.";  
RL Eur. J. Immunol. 22:1023-1029(1992).  
RN [5]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=8258341;  
RA Klein R., Jaenichen R., Zachau H.G.;  
RT "Expressed human immunoglobulin kappa genes and their hypermutation.";  
RL Eur. J. Immunol. 23:3248-3262(1993).  
RN [6]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=8436174;  
RA Wagner S.D., Luzzatto L.;  
RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are  
RT distributed over a large portion of the V kappa locus and do not show  
RT somatic mutation.";  
RL Eur. J. Immunol. 23:391-397(1993).  
DR EMBL; BC022362; AAH22362.1; -; mRNA.  
DR PIR; S22658; S22658.  
DR PIR; S34095; S34095.  
DR PIR; S40324; S40324.  
DR PIR; S40374; S40374.  
DR PIR; S42267; S42267.  
DR PIR; S42268; S42268.  
DR HSSP; P01834; 1172.  
DR SMR; Q8TCD0; 21-237.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003597; Ig.cl.  
DR InterPro; IPR003006; Ig\_MHC.  
DR InterPro; IPR003596; Ig\_V.  
DR Pfam; PF07654; CI-set; 1.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS00835; IG-LIKE; 2.  
DR PROSITE; PS00290; IG\_MHC; UNKNOWN 1.  
KW Hypothetical protein; Immunoglobulin domain.  
SQ SEQUENCE 239 AA; 26235 MW; FAGEDC3A3B03871D CRC64;

Query Match 80.8%; Score 481; DB 2; Length 239;  
Best Local Similarity 81.2%; Pred. No. 6.3e-42;  
Matches 91; Conservative 12; Mismatches 9; Indels 0; Gaps 0;  
QY 1 DVMTQSPFLSPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
DB 21 DVMTQTPLSPVSLGDSQASISCRSSQSLVSDGNTYLYQWYLOKPGQSPQLLIYKVSRL 80  
QY 61 YGVDPFRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGGQTKVEIK 112  
DB 81 SGVDPFRFSGSGSGTDFTLKISRVEAEDVGVYFCMGTHWPSTFGGQTKLEIK 132

## RESULT 10

```
Q6P491 HUMAN
ID Q6P491 HUMAN PRELIMINARY; PRT; 239 AA.
AC Q6P491
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Skin;
RX MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Boak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Skin;
RA Strausberg R.;
RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC063599; AAH63599.1; -; mRNA.
DR HSSP; P01837; 1KC1.
DR SMR; Q6P491; 21-237.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 239 AA; 26245 MW; CD7313DDFFD358B3 CRC64;
```

```
Query Match 80.3%; Score 478; DB 2; Length 239;
Best Local Similarity 79.5%; Pred. No. 1.3e-41;
Matches 89; Conservative 11; Mismatches 12; Indels 0; Gaps 0;
QY 1 DVVMTQSPFLSLPVTGEPASISCRSSQSIIVHSNGNTYLYQWYLRKPGQSPQLLIYKVSRL 60
Db :||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
21 DIVMTQTPLSSPVTLGQPASISCRSSQSLHSNGNTYLSWLHQRPGQPPRLIYKISNRF 80
QY 61 YGVPRFSGSGGTDTFLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 112
Db :||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
81 SGVPRFSGSGAGTDTFLKISRVEADGVVYCMQVSHFPRTFGQGTKEIK 132
```

## RESULT 11

KV2A\_HUMAN

```
Q6PIH6 HUMAN
ID Q6PIH6 HUMAN PRELIMINARY; PRT; 240 AA.
AC Q6PIH6
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGKV1-5 protein.
GN Name=IGKV1-5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RX MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Boak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RA Director MGC Project;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC034142; AAH34142.1; -; mRNA.
DR HSSP; P01837; 1KB5.
DR SMR; Q6PIH6; 23-240.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
SQ SEQUENCE 240 AA; 26234 MW; 18D4DD8BB781EC4 CRC64;
```

```
Query Match 79.4%; Score 472.5; DB 2; Length 240;
Best Local Similarity 81.4%; Pred. No. 4.9e-41;
Matches 92; Conservative 5; Mismatches 15; Indels 1; Gaps 1;
QY 1 DVVMTQSPFLSLPVTGEPASISCRSSQSIIVHSNGNTYLYQWYLRKPGQSPQLLIYKVSRL 60
Db :||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
21 DIVMAQSPFLSLVPTGEPASISCRSSQSLHSNGNTYFDWYLRKPGQSPQLLIYGSNRA 80
QY 61 YGVPRFSGSGGTDTFLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 112
Db :||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
81 SGVPRFSGSGGTDTFLKISRVEADGVVYCMQALQTFPTFGQGTKEIK 133
```

```
ID KV2A HUMAN STANDARD; PRT; 115 AA.
AC P01614;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE IG kappa chain V-II region CUM.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=68242259; PubMed=5586923;
RA Hilschmann N.;
RT "The complete amino acid sequence of Bence Jones protein Cum (kappa-
type).";
RL Hoppe-Seyler's Z. Physiol. Chem. 348:1718-1722(1967).
RN [2]
RP SEQUENCE REVISION TO 50; 52; 96 AND 97.
RX MEDLINE=70063440; PubMed=4188189;
RA Hilschmann N.;
RT "Molecular basis of antibody formation.";
RL Naturwissenschaften 56:195-205(1969).
CC -!- MISCELLANEOUS: The C region of this chain has the INV (3) marker.
CC -!- MISCELLANEOUS: This is a Bence-Jones protein.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR PIR; B91639; K2HUCM.
DR HSP; P01751; INOB.
DR SMR; P01614; 2-115.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; F:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Bence-Jones protein; Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
FT DISULFID 24 95
FT NON TER 115 115 By similarity.
SQ SEQUENCE 115 AA; 12676 MW; 59E9F90A379569EC CRC64;
Query Match 79.1%; Score 470.5; DB 1; Length 115;
Best Local Similarity 79.6%; Pred. No. 3.4e-41;
Matches 90; Conservative 11; Mismatches 11; Indels 1; Gaps 1;
QY 1 DVVMTQSLPLSVTPGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSNR 59
DB 2 DIVMTQTPLSLPVTGEPASISCRSSQLSDSGDNTYLNWYLOKAGQSPQLLIYLSYR 61
QY 60 LYGVDPFRSGSGSDFTLKISRVAEDVGYYVCFQSGSHVPWTFGGTKVEIK 112
DB 62 ASGVDPFRSGSGSDFTLKISRVAEDVGYYVCFQSGSHVPWTFGGTKLEIR 114
RESULT 13
Q53VP8_MOUSE PRELIMINARY; PRT; 112 AA.
AC Q53VP8;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DE Kappa chain (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
```

```
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RT Ollier P., Rocca-Serra J., Somme G., These J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBO J. 4:3681-3688(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 108-109.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBSJ databases.
DR EMBL; X03386; CAA27113.1; -, mRNA.
FT NON TER 1 1
FT NON TER 112 112
SQ SEQUENCE 112 AA; 12266 MW; C844B7881A89C18A CRC64;
Query Match 79.0%; Score 470; DB 2; Length 112;
Best Local Similarity 79.5%; Pred. No. 3.7e-41;
Matches 89; Conservative 11; Mismatches 12; Indels 0; Gaps 0;
QY 1 DVVMTQSLPLSVTPGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSNR 60
DB 1 DIVMTQTPLSLPVTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSNR 60
QY 61 YGVDPFRSGSGSDFTLKISRVAEDVGYYVCFQSGSHVPWTFGGTKVEIK 112
DB 61 SGVDPFRSGSGSDFTLKISRVAEDVGYYVCFQSGSHVPWTFGGTKLEIK 112
RESULT 14
Q65ZC0_MOUSE PRELIMINARY; PRT; 219 AA.
AC Q65ZC0;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Kappa light chain C region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Balb/c; TISSUE=Spleen;
RX MEDLINE=96319505; PubMed=8768802;
RA Kipp B., Schlaak M., Becker W.M.;
RT "Cloning and expression of a recombinant mouse Fab-fragment
RT recognizing a defined linear epitope of Chironomus thummi major
RT allergen Chi t I.";
RL Int. Arch. Allergy Immunol. 110:348-353(1996).
DR EMBL; Z37499; CAA85724.1; -, mRNA.
DR SMR; Q65ZC0; 1-219.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG_c1.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
FT NON TER 1 1
FT NON TER 219 219
SQ SEQUENCE 219 AA; 23944 MW; 7E1B82A14EAP8445 CRC64;
Query Match 78.3%; Score 466; DB 2; Length 219;
Best Local Similarity 79.5%; Pred. No. 2.1e-40;
```

Matches 89; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVPTGEPASISCRSSQSIHVSNGNTYLGWYLOKPGSPQLLIYKVSNRL 60  
Db 1 ELVMTQSPSLVSGDQASISCRSSQSLVHTNGNTYLGWYLOKPGSPQLLIYIVSNRF 60  
QY 61 YGVPRFSGSGSDFTLTKISRVEAEDVGYYCFQGSHPVPTFGGQTKVEIK 112  
Db 61 SGVPRFSGSGSDFTLTKISRVEAEDLGVPFCSQSTHVPCTFGGQTKLEIK 112

RESULT 15

KV2B HUMAN STANDARD; PRT; 113 AA.  
AC P01615;  
DT 21-JUL-1986 (Rel. 01, Created)  
DT 21-JUL-1986 (Rel. 01, Last sequence update)  
DT 10-MAY-2005 (Rel. 47, Last annotation update)  
DE IG kappa chain V-II region FR.  
OS Homo sapiens (Human)  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP PROTEIN SEQUENCE.  
RX MEDLINE=76253627; PubMed=821524;  
RA Riesen W.F., Jaton J.-C.;  
RT "variable region sequence of the light chain from a Waldenstroms IgM  
RT with specificity for phosphorylcholine."  
RL Biochemistry 15:3829-3833(1976).  
CC -!- MISCELLANEOUS: This chain was isolated from a Waldenstrom's  
CC macroglobulin that binds phosphorylcholine.  
CC -----  
CC This Swiss-Prot entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use as long as its content is in no way modified and this statement is not  
CC removed.  
CC -----  
CC PIR; A01886; K2HUPR.  
DR HSP; Q99M37; I191.  
DR SMR; P01615; 1-109.  
DR GO; GO:0005576; C:extracellular region; NAS.  
DR GO; GO:0003823; F:antigen binding; NAS.  
DR GO; GO:0006955; P:immune response; NAS.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003596; IG\_v.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS50835; IG\_LIKE; 1.  
KW Direct protein sequencing; Immunoglobulin domain;  
KW Immunoglobulin V region.  
FT REGION 1 23 Framework-1.  
FT REGION 24 39 Complementarity-determining-1.  
FT REGION 40 54 Framework-2.  
FT REGION 55 61 Complementarity-determining-2.  
FT REGION 62 93 Framework-3.  
FT REGION 94 102 Complementarity-determining-3.  
FT REGION 103 112 Framework-4.  
FT DISULFID 23 93 By similarity.  
FT NON\_TER 113 113  
SQ SEQUENCE 113 AA; 12660 MW; 0C0DA39E46DB96BE CRC64;

Query Match 76.5%; Score 455; DB 1; Length 113;  
Best Local Similarity 76.8%; Pred. No. 1.4e-39;  
Matches 86; Conservative 11; Mismatches 15; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVPTGEPASISCRSSQSIHVSNGNTYLGWYLOKPGSPQLLIYKVSNRL 60  
Db 1 DVVMTQSPSLPVPTGEPASISCRSSQSLVYRGTLYLWYLOKPGSPQLLIYLSYRD 60  
QY 61 YGVPRFSGSGSDFTLTKISRVEAEDVGYYCFQGSHPVPTFGGQTKVEIK 112

Db 61 SGVPRFSDSGSDFTLTKITRVOAEDVGYYCMQATZSPYTFGGQTKLZIK 112

Search completed: January 10, 2006, 20:53:25  
Job time : 75.5025 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 77.3134 Seconds  
(without alignments)  
636.505 Million cell updates/sec

Title: US-10-735-916A-61  
Perfect score: 595  
Sequence: 1 DVWMTQSLSLPVTGEPAS.....CFQGSHPVWTFQGQTKVEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 43937871 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A.Geneseq 21.\*  
1: Geneseqp1980s.\*  
2: Geneseqp1990s.\*  
3: Geneseqp2000s.\*  
4: Geneseqp2001s.\*  
5: Geneseqp2002s.\*  
6: Geneseqp2003as.\*  
7: Geneseqp2003bs.\*  
8: Geneseqp2004s.\*  
9: Geneseqp2005s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	595	100.0	112	7	ADJ76895 Anti-IGF-
2	595	100.0	112	9	ADZ67065 Human ant
3	595	100.0	131	7	ADJ76897 Anti-IGF-
4	595	100.0	131	9	ADZ67067 Human ant
5	594	99.8	112	7	ADJ76899 Anti-IGF-
6	594	99.8	112	9	ADZ67069 Human ant
7	594	99.8	131	7	ADJ76901 Anti-IGF-
8	594	99.8	131	9	ADZ67071 Human ant
9	569	95.6	114	8	ADP84950 Variable
10	568	95.5	112	5	AAE15713 Mouse mon
11	565	95.0	112	5	AAE15712 Mouse mon
12	565	95.0	114	8	ADP84948 Variable
13	563	94.6	112	5	AAE15711 Mouse mon
14	563	94.6	112	6	ABP72125 FGF-8 rel
15	563	94.6	112	7	ADP84955 Anti-IGF-
16	563	94.6	114	8	ADP84946 Variable
17	563	94.6	114	8	ADP84951 Anti-IGF-
18	563	94.6	131	7	ADZ6530 Anti-IGF-
19	562	94.5	114	8	ADP84949 Variable
20	560	94.1	112	7	ADZ6523 Anti-IGF-
21	560	94.1	112	7	AAE15712 Mouse mon
22	560	94.1	132	7	AAE15712 Mouse mon
23	559	93.9	114	8	ADP84944 Variable
24	558	93.8	114	8	ADP84947 Variable

25	557	93.6	112	6	ABP72129 FGF-8 rel
26	557	93.6	112	7	ADZ6520 Anti-IGF-
27	557	93.6	112	9	ADV67310 Amino aci
28	556	93.4	112	2	AAW27145 Mature li
29	556	93.4	112	2	AAW27145 Mature li
30	556	93.4	112	3	AAW27145 Mature li
31	556	93.4	112	3	AAW27145 Mature li
32	556	93.4	114	8	ADP84945 Variable
33	555	93.3	114	8	ADP84952 Variable
34	553	92.9	112	7	ADZ6518 Anti-IGF-
35	552	92.8	114	8	ADP84943 Variable
36	550	92.4	112	7	ADJ80420 Hybrid hu
37	550	92.4	132	7	ADH61998 Human ant
38	547	91.9	112	6	ABR40272 Amino aci
39	547	91.9	112	7	ADZ67694 Humanised
40	547	91.9	112	9	ADZ65252 Anti-CCR4
41	546	91.8	112	6	ABR40268 Amino aci
42	546	91.8	112	7	ADZ67687 Humanised
43	546	91.8	112	7	ADZ6519 Anti-IGF-
44	546	91.8	112	7	ADZ6527 Anti-IGF-
45	546	91.8	112	7	ADJ80422 Murine an

ALIGNMENTS

RESULT 1  
ADJ76895  
ID ADJ76895 standard; protein; 112 AA.  
XX  
AC ADJ76895;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-IR related protein #12.  
XX  
KW cytostatic; antiproliferative; antibody;  
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX  
OS Homo sapiens.  
XX  
PN WO2003059951-A2.  
XX  
PD 24-JUL-2003.  
XX  
PF 20-JAN-2003; 2003WO-FR000178.  
XX  
PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
(FABR ) FABRE MEDICAMENT SA PIERRE.

Goetsch L, Corvaia N, Leger O;  
WPI; 2003-569653/53.  
New antibodies that bind to human insulin-like growth factor receptor,  
useful for treatment, prevention and diagnosis of cancers.  
Disclosure; SEQ ID NO 61; 164pp; French.

The invention relates to an isolated antibody (Ab), and its functional fragments, that bind to human insulin-like growth factor-1 receptor (IGF-1R) and optionally: (i) inhibit natural binding of insulin-like growth factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine kinase activity of IGF-1R. Ab and its fragments are used to prevent or treat diseases associated with overexpression and/or abnormal activity of IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 112 AA;

Query Match 100.0%; Score 595; DB 7; Length 112;  
 Best Local Similarity 100.0%; Pred. No. 2.4e-43;  
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Db 1 DVVMTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGSGTDTFTLKISRVEADVGYYVYCFQSGSHVPWTFGQGTKVEIK 112

Db 61 YGVPRFSGSGSGTDTFTLKISRVEADVGYYVYCFQSGSHVPWTFGQGTKVEIK 112

# RESULT 2

ADZ67065  
 ID ADZ67065 standard; protein; 112 AA.

AC ADZ67065;

DT 30-JUN-2005 (first entry)

DE Human antibody 7C10 1 light chain variable region SEQ ID NO:61.

KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW light chain variable region.

OS Homo sapiens.

FH Key Location/Qualifiers

FT Region 24..39

FT /note= "CDR1"

FT Region 55..61

FT /note= "CDR2"

FT Region 94..102

FT /note= "CDR3"

FN US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

XX 18-JAN-2002; 2002FR-00000654.

XX 07-MAY-2002; 2002FR-00005753.

XX 20-JAN-2003; 2003WO-FR000178.

XX 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

XX (CORV/) CORVAIA N.

XX (LEGE/) LEGER O.

XX (DUF/) DUFLOS A.

XX (HAU/) HAEUW J.

XX (BECK/) BECK A.

PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX WPI; 2005-321968/33.

5

DR N-PSDB; ADZ67066.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.

XX Example 12; SEQ ID NO 61; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

XX SQ Sequence 112 AA;

Query Match 100.0%; Score 595; DB 9; Length 112;

Best Local Similarity 100.0%; Pred. No. 2.4e-43;

Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Db 1 DVVMTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGSGTDTFTLKISRVEADVGYYVYCFQSGSHVPWTFGQGTKVEIK 112

Db 61 YGVPRFSGSGSGTDTFTLKISRVEADVGYYVYCFQSGSHVPWTFGQGTKVEIK 112

# RESULT 3

ADJ76897

ID ADJ76897 standard; protein; 131 AA.

XX AC ADJ76897;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #13.

XX cytostatic; antipsoriatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;

KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003059951-A2.  
 XX  
 XX 24-JUL-2003.  
 XX  
 XX 20-JAN-2003; 2003WO-FR000178.  
 XX  
 XX 18-JAN-2002; 2002FR-0000653.  
 PR 18-JAN-2002; 2002FR-0000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 XX  
 XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
 PA  
 XX Goetsch L, Corvaia N, Leger O;  
 XX WPI; 2003-569653/53.  
 XX  
 XX New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.  
 PT  
 XX Disclosure; SEQ ID NO 63; 164pp; French.  
 PS  
 XX The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 XX Sequence 131 AA;  
 SQ  
 Query Match 100.0%; Score 595; DB 7; Length 131;  
 Best Local Similarity 100.0%; Pred. No. 2.9e-43;  
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 DVVMTQSPVLSPLPTGCEPASISCRSSQSIHVSNGNTYLYWYLOKPGQSPQLLIYKVSNRL 60  
 Db 20 DVVMTQSPVLSPLPTGCEPASISCRSSQSIHVSNGNTYLYWYLOKPGQSPQLLIYKVSNRL 79  
 QY 61 YGVPRFSGSGGTDFTLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 112  
 Db 80 YGVPRFSGSGGTDFTLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 131  
 RESULT 4  
 ADZ67067  
 ID ADZ67067 standard; protein; 131 AA.  
 XX  
 AC ADZ67067;  
 XX  
 DT 30-JUN-2005 (first entry)  
 XX  
 XX Human antibody 7C10 1 light chain variable region SEQ ID NO:63.  
 DE  
 XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;

KW light chain variable region.  
 XX  
 OS Homo sapiens.  
 XX  
 PH Key Location/Qualifiers  
 FT Peptide 1..19  
 FT /note= "leader peptide"  
 FT Region 43..62  
 FT /note= "CDR1"  
 FT Region 74..80  
 FT /note= "CDR2"  
 FT Region 113..121  
 FT /note= "CDR3"  
 XX  
 PN US2005084906-A1.  
 XX  
 XX 21-APR-2005.  
 XX  
 XX 16-DEC-2003; 2003US-00735916.  
 XX  
 XX 18-JAN-2002; 2002FR-0000653.  
 PR 18-JAN-2002; 2002FR-0000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 PR 20-JAN-2003; 2003WO-FR000178.  
 PR 11-JUL-2003; 2003FR-00008538.  
 XX  
 XX (GOET/) GOETSCH L.  
 PA (CORV/) CORVAIA N.  
 PA (LEGE/) LEGER O.  
 PA (DUF2/) DUFLOS A.  
 PA (HAEU/) HAEUW J.  
 PA (BECK/) BECK A.  
 XX  
 PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 DR WPI; 2005-321968/33.  
 DR N-PSDB; ADZ67066.  
 XX  
 XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.  
 XX  
 XX Example 12; SEQ ID NO 63; 125pp; English.  
 XX  
 XX The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (II) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to

CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

XX Sequence 131 AA;

Query Match 100.0%; Score 595; DB 9; Length 131;  
 Best Local Similarity 100.0%; Pred. No. 2.9e-43;  
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 DVVMTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
 DB 20 DVVMTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 79  
 QY 61 YGVDPFRFSGSGGTDFTLKISRVEADVGVYVFCGSHVPWTFGGTKVEIK 112  
 DB 80 YGVDPFRFSGSGGTDFTLKISRVEADVGVYVFCGSHVPWTFGGTKVEIK 131

## RESULT 5

ADJ76899  
 ID ADJ76899 standard; protein; 112 AA.

XX  
 AC ADJ76899;

XX 06-MAY-2004 (first entry)

XX Anti-IGF-IR related protein #14.

XX cytostatic; antipneumatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.

XX Homo sapiens.

XX WO2003059951-A2.

XX 24-JUL-2003.

XX 20-JAN-2003; 2003WO-FR000178.

XX 18-JAN-2002; 2002FR-00000653.

XX 18-JAN-2002; 2002FR-00000654.

XX 07-MAY-2002; 2002FR-00005753.

XX (FABR ) FABRE MEDICAMENT SA PIERRE.

XX Goetsch L, Corvaia N, Leger O;

XX WPI; 2003-569653/53.

XX New antibodies that bind to human insulin-like growth factor receptor,  
 XX useful for treatment, prevention and diagnosis of cancers.

XX Disclosure; SEQ ID NO 65; 164pp; French.

XX The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the

CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.

XX Sequence 112 AA;

Query Match 99.8%; Score 594; DB 7; Length 112;  
 Best Local Similarity 99.1%; Pred. No. 3e-43;  
 Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 DVVMTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
 DB 1 DVVMTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60  
 QY 61 YGVDPFRFSGSGGTDFTLKISRVEADVGVYVFCGSHVPWTFGGTKVEIK 112  
 DB 61 YGVDPFRFSGSGGTDFTLKISRVEADVGVYVFCGSHVPWTFGGTKVEIK 112

## RESULT 6

ADZ67069  
 ID ADZ67069 standard; protein; 112 AA.

XX ADZ67069;

XX 30-JUN-2005 (first entry)

XX Human antibody 7C10 2 light chain variable region SEQ ID NO:65.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipneumatic; psoriasis; dermatological disease; immune disorder;  
 KW light chain variable region.

XX Homo sapiens.

XX US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

XX 18-JAN-2002; 2002FR-00000654.

XX 07-MAY-2002; 2002FR-00005753.

XX 20-JAN-2003; 2003WO-FR000178.

XX 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

XX (CORV/) CORVAIA N.

XX (LEGE/) LEGER O.

XX (DUFL/) DUFLOS A.

XX (HAEU/) HAEUW J.

XX (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 XX antibody or its functional fragment, being capable of binding human IGF-  
 XX IR and specifically inhibiting tyrosine kinase activity of receptor,  
 XX useful for treating cancer.

XX Example 12; SEQ ID NO 65; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of

CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.

XX SQ Sequence 112 AA;

Query Match 99.8%; Score 594; DB 9; Length 112;  
 Best Local Similarity 99.1%; Pred. No. 3e-43;  
 Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 60  
 DB 1 DIVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 60  
 QY 61 YGVPRFSGSGGTDTFLKISRVEADVGVVYCFQGSHPVPTFGQTKVEIK 112  
 DB 61 YGVPRFSGSGGTDTFLKISRVEADVGVVYCFQGSHPVPTFGQTKVEIK 112

RESULT 7

ID ADJ76901  
 XX ADJ76901 standard; protein; 131 AA.

AC ADJ76901;

XX 06-MAY-2004 (first entry)

XX Anti-IGF-1R related protein #15.

XX cytostatic; antiproliferative; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.

XX Homo sapiens.

XX WO2003059951-A2.

XX 24-JUL-2003.

XX 20-JAN-2003; 2003WO-FR000179.

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.

XX (FABR ) FABRE MEDICAMENT SA PIERRE.

XX Goetsch L, Corvaia N, Leger O;

XX WPI; 2003-569653/53.

XX New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.

PS Disclosure; SEQ ID NO 67; 164pp; French.

XX The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.

XX SQ Sequence 131 AA;

Query Match 99.8%; Score 594; DB 7; Length 131;  
 Best Local Similarity 99.1%; Pred. No. 3.5e-43;  
 Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 60  
 DB 20 DIVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 79

QY 61 YGVPRFSGSGGTDTFLKISRVEADVGVVYCFQGSHPVPTFGQTKVEIK 112

DB 80 YGVPRFSGSGGTDTFLKISRVEADVGVVYCFQGSHPVPTFGQTKVEIK 131

RESULT 8

ADZ67071

ID ADZ67071 standard; protein; 131 AA.

XX ADZ67071;

XX 30-JUN-2005 (first entry)

XX Human antibody 7C10 2 light chain variable region SEQ ID NO:67.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antiproliferative; psoriasis; dermatological disease; immune disorder;  
 KW light chain variable region.

XX Homo sapiens.

XX Key Location/Qualifiers

XX Peptide 1..19

XX Region 43..58 /note= "leader peptide"

XX Region 74..80 /note= "CDR1"

XX Region 113..121 /note= "CDR2"



CC macrophages. The antibodies, also constructs containing them, nucleic  
 CC acid encoding them, and related vectors and host cells, are useful for  
 CC prevention (e.g. as vaccine), diagnosis, alleviation, treatment,  
 CC monitoring and/or secondary treatment of tumours (specifically of breast,  
 CC colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,  
 CC prostate, kidney and/or liver) and/or metastases (particularly to liver),  
 CC specifically where these are positive for the CI antigen. The products of  
 CC the invention provide simple, reliable and efficient detection of  
 CC tumours. They are specific for carcinoma and show almost no binding to  
 CC healthy tissue.

XX Sequence 114 AA;

Query Match 95.6%; Score 569; DB 8; Length 114;  
 Best Local Similarity 95.5%; Pred. No. 4.2e-41;  
 Matches 107; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLYWYLPKPGSPQLLIYKVSNRL 60  
 Db 1 DIVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLYWYLPKPGSPQLLIYKVSNRF 60

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCQGSHPVPTFGQGTKEIK 112

Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYFCQGSHPVPTFGQGTKEIK 112

RESULT 10

AAE15713

ID AAE15713 standard; protein; 112 AA.

AC AAE15713;

DT 12-MAR-2002 (first entry)

DE Mouse monoclonal antibody alpha 340 V<sub>k</sub> region variant, 340VKd.

XX Mouse; humanised form; monoclonal antibody alpha 340; Gene therapy;  
 KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;  
 KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;  
 KW inhibitor; mutant; mutein; variant.

XX Mus sp.

OS Synthetic.

XX Key Location/Qualifiers

FT Misc-difference 7 /note= "Wild type Thr substituted with Ser"

FT Misc-difference 14 /note= "Wild type Ser substituted with Thr"

FT Misc-difference 15 /note= "Wild type Leu substituted with Pro"

FT Misc-difference 17 /note= "Wild type Asp substituted with Glu"

FT Misc-difference 18 /note= "Wild type Gln substituted with Pro"

FT Misc-difference 50 /note= "Wild type Lys substituted with Gln"

FT Misc-difference 88 /note= "Wild type Leu substituted with Val"

FT Misc-difference 109 /note= "Wild type Leu substituted with Val"

FT Misc-difference 112 /note= "Wild type Asn substituted with Lys"

XX WO200188138-A1.

XX 22-NOV-2001.

XX 21-MAY-2001; 2001WO-GB002226.

XX 19-MAY-2000; 2000GB-00011981.

XX 24-AUG-2000; 2000GB-00020794.

XX

PA (SCAN-) SCANCELL LTD.

XX Ellis JRM, Durrant LG;

XX WPI; 2002-062384/08.

XX New humanized form of mouse monoclonal antibody 340 which binds to  
 FT epidermal growth factor receptor and inhibits binding of growth factor,  
 FT useful for treating colorectal, lung, breast, gastric and ovarian cancer.  
 XX Example 2; Fig 7; 53pp; English.

XX The present invention relates to a humanised form of the antibody 340 (a  
 CC mouse monoclonal antibody which binds to epidermal growth factor (EGF)  
 CC receptor and inhibits binding of EGF), obtainable from the cell line  
 CC deposited with the ECACC under accession number 97021428. The humanised  
 CC form of the antibody 340 is useful in gene therapy, medicine and in the  
 CC manufacture of a medicament for treatment or prophylaxis of cancer. The  
 CC invention is useful for treating colorectal, lung, breast, gastric or  
 CC ovarian cancers or also for preventing the recurrence of cancer after  
 CC initial treatment or surgery. The invention is also useful for enhancing  
 CC a protective immune response against cancer by optimised immunisation  
 CC schedules. The humanised form of the antibody 340 has reduced  
 CC immunogenicity but shows similar binding to cells expressing EGF  
 CC receptor, as the original murine antibody and has increased ability to  
 CC inhibit the growth of EGF receptor expressing cells. The invention is  
 CC used as cell growth and apoptosis inhibitor. The present sequence is  
 CC mouse monoclonal antibody alpha 340 deimmunised light chain variable (VK)  
 CC region variant, 340VKd

XX Sequence 112 AA;

Query Match 95.5%; Score 568; DB 5; Length 112;  
 Best Local Similarity 94.6%; Pred. No. 5e-41;  
 Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLYWYLPKPGSPQLLIYKVSNRL 60

Db 1 DVLMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLYWYLPKPGSPQLLIYKVSNRF 60

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCQGSHPVPTFGQGTKEIK 112

Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYFCQGSHPVPTFGQGTKEIK 112

RESULT 11

AAE15712

ID AAE15712 standard; protein; 112 AA.

AC AAE15712;

DT 12-MAR-2002 (first entry)

DE Mouse monoclonal antibody alpha 340 V<sub>k</sub> region variant, 340VKc.

XX Mouse; humanised form; monoclonal antibody alpha 340; gene therapy;  
 KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;  
 KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;  
 KW inhibitor; mutant; mutein; variant.

XX Mus sp.

OS Synthetic.

XX Key Location/Qualifiers

FT Misc-difference 7 /note= "Wild type Thr substituted with Ser"

FT Misc-difference 14 /note= "Wild type Ser substituted with Thr"

FT Misc-difference 15 /note= "Wild type Leu substituted with Pro"

FT Misc-difference 17 /note= "Wild type Asp substituted with Glu"

FT Misc-difference 18

```

FT      /note= "Wild type Gln substituted with Pro"
FT Misc-difference 50
FT      /note= "Wild type Lys substituted with Gln"
FT Misc-difference 88
FT      /note= "Wild type Leu substituted with Thr"
FT Misc-difference 90
FT      /note= "Wild type Ile substituted with Val"
FT Misc-difference 109
FT      /note= "Wild type Leu substituted with Val"
FT Misc-difference 112
FT      /note= "Wild type Asn substituted with Lys"
XX XX
XX WO200188138-A1.
XX
XX 22-NOV-2001.
XX
XX 21-MAY-2001; 2001WO-GB002226.
XX
XX 19-MAY-2000; 2000GB-00011981.
XX
XX 24-AUG-2000; 2000GB-00020794.
XX
XX (SCAN-) SCANCELL LTD.
XX
XX Ellis JRM, Durrant LG;
XX
XX WPI; 2002-062384/08.
XX
XX New humanized form of mouse monoclonal antibody 340 which binds to
XX epidermal growth factor receptor and inhibits binding of growth factor,
XX useful for treating colorectal, lung, breast, gastric and ovarian cancer.
XX
XX Example 2; Fig 7; 53pp; English.
XX
XX The present invention relates to a humanised form of the antibody 340 (a
XX mouse monoclonal antibody which binds to epidermal growth factor (EGF)
XX receptor and inhibits binding of EGF), obtainable from the cell line
XX deposited with the ECACC under accession number 97021428. The humanised
XX form of the antibody 340 is useful in gene therapy, medicine and in the
XX manufacture of a medicament for treatment or prophylaxis of cancer. The
XX invention is useful for treating colorectal, lung, breast, gastric or
XX ovarian cancers or also for preventing the recurrence of cancer after
XX initial treatment or surgery. The invention is also useful for enhancing
XX a protective immune response against cancer by optimised immunisation
XX schedules. The humanised form of the antibody 340 has reduced
XX immunogenicity but shows similar binding to cells expressing EGF
XX receptor, as the original murine antibody and has increased ability to
XX inhibit the growth of EGF receptor expressing cells. The invention is
XX used as cell growth and apoptosis inhibitor. The present sequence is
XX mouse monoclonal antibody alpha 340 deimmunised-light chain variable
XX region variant, 340VKC
XX
XX Sequence 112 AA;
XX
XX Query Match          95.0%; Score 565; DB 5; Length 112;
XX Best Local Similarity 94.6%; Pred. No. 9.1e-41;
XX Matches 106; Conservative 2; Mismatches 4; Indels 0; Gaps 0;
XX
Qy      1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLTQWYLPKPGQSPQLLIYKVSNRL 60
Dy      1 DVLMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLTQWYLPKPGQSPQLLIYKVSNRF 60
Qy      61 YGVDPDRFSGSGSGTDFTLKISRVEAEDTGVYFCQGSHPVMTFGGTKVEIK 112
Dy      61 SGVDPDRFSGSGSGTDFTLKISRVEAEDTGVYFCQGSHPVMTFGGTKVEIK 112
XX
XX RESULT 12
XX ADP84948
XX ID ADP84948 standard; protein; 114 AA.
XX
XX AC ADP84948;
XX
XX DT 09-SEP-2004 (first entry)
XX

```

---

```

XX DE Variable light chain VL fragment Karoll SEQ ID NO 90.
XX
XX antibody; Core-1 antigen; framework region; immunoglobulin superfamily;
XX protease inhibitor; lectin; helix-bundle protein; lipocalin;
XX variable heavy chain; VH; variable light chain; VL; vaccine; diagnosis;
XX alleviation; treatment; tumour; breast; colon; stomach; pancreas;
XX large/small intestine; ovary; cervix; lung; prostate; kidney; liver;
XX metastasis.
XX
XX Mus musculus.
XX OS Homo sapiens.
XX Chimeric.
XX
XX WO2004050707-A2.
XX
XX 17-JUN-2004.
XX
XX 01-DEC-2003; 2003WO-DE003994.
XX
XX 29-NOV-2002; 2002DE-01056900.
XX
XX (NEMO-) NEMOD BIOTHERAPEUTICS GMBH & CO KG.
XX
XX Goletz S, Danielczyk A, Karsten U, Ravn P, Stahn R;
XX Christensen PA;
XX
XX WPI; 2004-461095/43.
XX
XX New recognition molecules, e.g. antibodies (and nucleic acids) that bind
XX specifically to Core-1 antigens, useful for diagnosis, treatment and
XX prevention of tumors and metastases.
XX
XX Claim 15; SEQ ID NO 90; 136pp; German.
XX
XX This invention describes novel recognition molecules, especially
XX antibodies that bind specifically to the Core-1 antigen. The recognition
XX molecules are used to make constructs containing the framework regions
XX that separate, include and/or flank the specified sequences, especially
XX where the framework regions are from the immunoglobulin (Ig) superfamily,
XX protease inhibitors, lectins, helix-bundle proteins and/or lipocalins.
XX Most especially the framework regions are from antibodies, particularly
XX the variable heavy chain (VH) and the variable light chain (VL) of human
XX and/or murine origin. The constructs may also include a His or myc tag, a
XX lysine-rich region and/or a multimerisation domain, most particularly it
XX is a single-chain antibody fragment, multibody, Fab fragment, fusion
XX protein of an antibody fragment with peptide or protein, and/or an Ig of
XX types G, M, A, E or D and/or their subclasses. It may be human,
XX humanised, murine or chimeric, e.g. IGM without the J chain. The
XX additional sequences/structures in the constructs are Ig domains of
XX various species, interacting or stabilising domains, signal sequences,
XX fluorescent dyes, toxins, antibodies with catalytic activity or other
XX specificities, cytolytic agents, enzymes, immuno-modulators or -
XX effectors, MHC molecules, antigens, chelators for radioactive labels,
XX liposomes, transmembrane domains, viruses and/or cells, specifically
XX macrophages. The antibodies, also constructs containing them, nucleic
XX acid encoding them, and related vectors and host cells, are useful for
XX prevention (e.g. as vaccine), diagnosis, alleviation, treatment,
XX monitoring and/or secondary treatment of tumours (specifically of breast,
XX colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,
XX prostate, kidney and/or liver) and/or metastases (particularly to liver),
XX specifically where these are positive for the C1 antigen. The products of
XX the invention provide simple, reliable and efficient detection of
XX tumours. They are specific for carcinoma and show almost no binding to
XX healthy tissue.
XX
XX Sequence 114 AA;
XX
XX Query Match          95.0%; Score 565; DB 8; Length 114;
XX Best Local Similarity 94.6%; Pred. No. 9.2e-41;
XX Matches 106; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
XX
Qy      1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVSNGNTYLTQWYLPKPGQSPQLLIYKVSNRL 60

```

Db 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLYWYQKPGQSPKLLIYKVSNR 60  
Qy 61 YGVDPFRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPMTFGGTKEIK 112  
Db 61 SGVDPFRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPMTFGGTKEIK 112

RESULT 13  
AAE15711  
ID AAE15711 standard; protein; 112 AA.  
XX AAE15711;  
XX DT 12-MAR-2002 (first entry)  
XX Mouse monoclonal antibody alpha 340 Vb region variant, 340Vkb.  
XX Mouse; humanised form; monoclonal antibody alpha 340; gene therapy;  
KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;  
KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;  
KW inhibitor; mutant; mutein; variant.  
XX Mus sp.  
OS Synthetic.XX Key Location/Qualifiers  
FT Misc-difference 7 /note= "Wild type Thr substituted with Ser"  
FT Misc-difference 14 /note= "Wild type Ser substituted with Thr"  
FT Misc-difference 15 /note= "Wild type Leu substituted with Pro"  
FT Misc-difference 17 /note= "Wild type Asp substituted with Glu"  
FT Misc-difference 18 /note= "Wild type Gln substituted with Pro"  
FT Misc-difference 29 /note= "Wild type Ile substituted with Leu"  
FT Misc-difference 50 /note= "Wild type Lys substituted with Gln"  
FT Misc-difference 88 /note= "Wild type Leu substituted with Thr"  
FT Misc-difference 90 /note= "Wild type Ile substituted with Val"  
FT Misc-difference 109 /note= "Wild type Leu substituted with Val"  
FT Misc-difference 112 /note= "Wild type Asn substituted with Lys"  
XX WO200188138-A1.  
XX 22-NOV-2001.  
XX 21-MAY-2001; 2001WO-GB002225.  
XX 19-MAY-2000; 2000GB-00011981.  
XX 24-AUG-2000; 2000GB-00020794.  
XX (SCAN-) SCANCELL LTD.  
XX Ellis JRM, Durrant LG;  
XX WPI; 2002-062384/08.  
XX New humanized form of mouse monoclonal antibody 340 which binds to  
PT epidermal growth factor receptor and inhibits binding of growth factor,  
PT useful for treating colorectal, lung, breast, gastric and ovarian cancer.  
XX Example 2; Fig 7; 53pp; English.  
XX The present invention relates to a humanised form of the antibody 340 (a  
CC mouse monoclonal antibody which binds to epidermal growth factor (EGF)

CC receptor and inhibits binding of EGF), obtainable from the cell line  
CC deposited with the ECACC under accession number 97021428. The humanised  
CC form of the antibody 340 is useful in gene therapy, medicine and in the  
CC manufacture of a medicament for treatment or prophylaxis of cancer. The  
CC invention is useful for treating colorectal, lung, breast, gastric or  
CC ovarian cancers or also for preventing the recurrence of cancer after  
CC initial treatment or surgery. The invention is also useful for enhancing  
CC a protective immune response against cancer by optimised immunisation  
CC schedules. The humanised form of the antibody 340 has reduced  
CC immunogenicity but shows similar binding to cells expressing EGF  
CC receptor, as the original murine antibody and has increased ability to  
CC inhibit the growth of EGF receptor expressing cells. The invention is  
CC used as cell growth and apoptosis inhibitor. The present sequence is  
CC mouse monoclonal antibody alpha 340 deimmunised light chain variable (VK)  
CC region variant, 340Vkb  
XX SQ Sequence 112 AA;  
SQ Query Match 94.6%; Score 563; DB 5; Length 112;  
Best Local Similarity 93.8%; Pred. No. 1.3e-40;  
Matches 105; Conservative 3; Mismatches 4; Indels 0; Gaps 0;  
Qy 1 DVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLYWYQKPGQSPKLLIYKVSNR 60  
Db 1 DVLMTQSPSLPVTGEPASISCRSSQSLVHSNGNTYLYWYQKPGQSPKLLIYKVSNR 60  
Qy 61 YGVDPFRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPMTFGGTKEIK 112  
Db 61 SGVDPFRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPMTFGGTKEIK 112

RESULT 14  
ABP72125  
ID ABP72125 standard; protein; 112 AA.  
XX AC ABP72125;  
XX DT 03-JUN-2003 (first entry)  
XX DE FGF-8 related protein SEQ ID 17.  
XX KW Humanised; antibody; fibroblast growth factor 8; FGF8; cytostatic;  
XX cancer; prostate; breast; ovarian; testicular.  
XX OS Synthetic.  
XX PN WO2003002608-A1.  
XX PD 09-JAN-2003.  
XX PF 28-JUN-2002; 2002WO-JP006591.  
XX PR 28-JUN-2001; 2001JP-00196176.  
XX PA (KYOW ) KYOWA HAKKO KOGYO KK.  
XX PI Shitara K, Nakamura K, Hirota M, Shimada N;  
XX WPI; 2003-239169/23.  
XX Humanised antibodies and antibody fragments reacting with fibroblast  
XX growth factor 8 useful for the treatment and diagnosis of cancer.  
XX Claim 19; Page 72; 86pp; Japanese.  
XX The invention relates to novel humanised antibodies and antibody  
XX fragments which react with fibroblast growth factor 8 (FGF8) and inhibit  
XX its biological functions. The polypeptides of the invention have  
XX cytostatic activity. The antibody is useful for the treatment of cancer,  
XX including prostate, breast, ovarian and testicular cancer. The present  
XX sequence is used in the exemplification of the invention  
XX SQ Sequence 112 AA;

Job time : 78.3134 secs

Query Match 94.6%; Score 563; DB 6; Length 112;  
Best Local Similarity 93.8%; Pred. No. 1.3e-40;  
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHNSNGNTYIQWYKQPGQSPQLLIYKVSRL 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
Db 1 DIVMTQSPSLPVTGEPASISCRSSQSIHNSNGNTYILEWYKQPGQSPQLLIYKVSRI 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
QY 61 YGVPRPFGSGSGTDFTLKISRVEAEDVGVVYCFQGSHPVPTFGGTVKVEIK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
Db 61 SGVPRPFGSGSGTDFTLKISRVEAEDVGVVYCFQGSHPVPTFGGTVKVEIK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 15  
ADE36495  
ID ADE36495 standard; protein; 112 AA.  
XX  
AC ADE36495;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Anti-FGF-8 (sic fibroblast growth factor) antibody-related protein #2.  
KW arthritis; anti-FGF-8; sic fibroblast growth factor;  
KW cartilage protection agent; joint destruction inhibitor;  
KW synovial proliferation inhibitor.  
XX  
OS Unidentified.  
XX  
PN WO2003057251-A1.  
XX  
PD 17-JUL-2003.  
XX  
PF 26-DEC-2002; 2002WO-JP013650.  
XX  
PR 28-DEC-2001; 2001JP-00400677.  
XX  
PA (KYOW ) KYOWA HAKKO KOGYO KK.  
XX  
PI Tamura T, Uchii M, Suda T, Miki I, Tanaka A;  
XX  
WPI; 2003-587078/55.  
XX  
PT Treatment and prevention of arthritis comprising the use of anti-FGF-8  
PT (sic fibroblast growth factor) antibody.  
XX  
PS Claim 11; SEQ ID NO 19; 193pp; Japanese.  
XX  
CC The invention comprises a method for treating and preventing arthritis,  
CC the method involves the use of anti-FGF-8 (sic fibroblast growth factor)  
CC antibody. The antibody and method of the invention is useful for: the  
CC detection, treatment and prevention of arthritis; as a cartilage  
CC protection agent; as a joint destruction inhibitor; and as a synovial  
CC proliferation inhibitor. The present amino acid sequence represents a  
CC protein of the invention.  
XX  
SQ Sequence 112 AA;

Query Match 94.6%; Score 563; DB 7; Length 112;  
Best Local Similarity 93.8%; Pred. No. 1.3e-40;  
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHNSNGNTYIQWYKQPGQSPQLLIYKVSRL 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
Db 1 DIVMTQSPSLPVTGEPASISCRSSQSIHNSNGNTYILEWYKQPGQSPQLLIYKVSRI 60  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
QY 61 YGVPRPFGSGSGTDFTLKISRVEAEDVGVVYCFQGSHPVPTFGGTVKVEIK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
Db 61 SGVPRPFGSGSGTDFTLKISRVEAEDVGVVYCFQGSHPVPTFGGTVKVEIK 112  
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.71144 Seconds  
(without alignments)  
166.558 Million cell updates/sec

Title: US-10-735-916A-54  
Perfect score: 590  
Sequence: 1 DVLMTQIPLSLPSVLGDOAS.....CFQGSHPVPTFGGTTKLEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications AA\_New.\*  
1: /cgn2\_6/ptodata/1/pubpaa/US08\_NEW\_PUB.pep.\*  
2: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pep.\*  
3: /cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pep.\*  
4: /cgn2\_6/ptodata/1/pubpaa/PT\_NEW\_PUB.pep.\*  
5: /cgn2\_6/ptodata/1/pubpaa/US05\_NEW\_PUB.pep.\*  
6: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pep.\*  
7: /cgn2\_6/ptodata/1/pubpaa/US11\_NEW\_PUB.pep.\*  
8: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	590	100.0	112	7 US-11-012-353-54	Sequence 54, Appl
2	590	100.0	122	7 US-11-012-353-49	Sequence 49, Appl
3	564	95.6	112	7 US-11-012-353-56	Sequence 56, Appl
4	557	94.4	131	7 US-11-125-837-23	Sequence 23, Appl
5	551	93.4	263	7 US-11-089-266-66	Sequence 66, Appl
6	548	92.9	112	7 US-11-089-266-15	Sequence 15, Appl
7	547	92.7	112	7 US-11-012-353-57	Sequence 57, Appl
8	547	92.7	113	6 US-10-932-334-69	Sequence 69, Appl
9	547	92.7	149	7 US-11-089-266-2	Sequence 2, Appl
10	545	92.4	112	7 US-11-012-353-55	Sequence 55, Appl
11	544	92.2	113	6 US-10-932-334-61	Sequence 61, Appl
12	543	92.0	251	6 US-10-512-184-30	Sequence 30, Appl
13	543	92.0	320	6 US-10-512-184-67	Sequence 67, Appl
14	543	92.0	569	6 US-10-512-184-66	Sequence 66, Appl
15	543	92.0	618	6 US-10-512-184-48	Sequence 48, Appl
16	542	91.9	113	6 US-10-932-334-60	Sequence 60, Appl
17	541	91.7	113	6 US-10-932-334-59	Sequence 59, Appl
18	541	91.7	116	7 US-11-065-943-49	Sequence 49, Appl
19	538	91.2	112	7 US-11-012-353-61	Sequence 61, Appl
20	538	91.2	131	7 US-11-012-353-63	Sequence 63, Appl
21	537	91.0	112	7 US-11-012-353-65	Sequence 65, Appl
22	537	91.0	113	6 US-10-932-334-66	Sequence 66, Appl
23	537	91.0	113	6 US-10-932-334-68	Sequence 68, Appl
24	537	91.0	131	7 US-11-012-353-67	Sequence 67, Appl
25	536	90.8	113	6 US-10-932-334-8	Sequence 8, Appl

26	536	90.8	113	6	US-10-932-334-58	Sequence 58, Appl
27	536	90.8	113	6	US-10-932-334-62	Sequence 62, Appl
28	536	90.8	113	6	US-10-932-334-82	Sequence 82, Appl
29	536	90.8	132	6	US-10-932-334-50	Sequence 50, Appl
30	535	90.7	113	6	US-10-932-334-65	Sequence 65, Appl
31	531	90.0	131	6	US-10-789-273-14	Sequence 14, Appl
32	527	89.3	113	6	US-10-932-334-10	Sequence 10, Appl
33	527	89.3	113	6	US-10-932-334-84	Sequence 84, Appl
34	527	89.3	113	6	US-10-932-334-94	Sequence 94, Appl
35	525	89.0	113	6	US-10-932-334-63	Sequence 63, Appl
36	524	88.8	113	6	US-10-932-334-11	Sequence 11, Appl
37	524	88.8	113	6	US-10-932-334-85	Sequence 85, Appl
38	524	88.8	113	6	US-10-932-334-86	Sequence 86, Appl
39	524	88.8	113	6	US-10-932-334-86	Sequence 86, Appl
40	523	88.6	113	6	US-10-959-310-23	Sequence 23, Appl
41	523	88.6	144	7	US-11-055-163-15	Sequence 15, Appl
42	522	88.5	113	6	US-10-932-334-67	Sequence 67, Appl
43	521	88.3	113	6	US-10-932-334-9	Sequence 9, Appl
44	521	88.3	113	6	US-10-932-334-83	Sequence 83, Appl
45	521	88.3	113	6	US-10-932-334-90	Sequence 90, Appl

## ALIGNMENTS

RESULT 1  
US-11-012-353-54  
; Sequence 54, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUFLOS, ALAIN  
; APPLICANT: HAEUM, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-198  
; CURRENT APPLICATION NUMBER: US/11/012.353  
; CURRENT FILING DATE: 2004-12-16  
; PRIOR APPLICATION NUMBER: 10/735, 916  
; PRIOR FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 0308538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR03/00178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 0205753  
; PRIOR FILING DATE: 2002-05-07  
; PRIOR APPLICATION NUMBER: FR 0200653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: Patentin Ver. 3.3  
; SEQ ID NO 54  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-11-012-353-54

Query Match 100.0%; Score 590; DB 7; Length 112;  
Best Local Similarity 100.0%; Pred. No. 1.1e-39;  
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DVLMTQIPLSLPSVLGDOASISCRSSQIVHSNGNTYLOWLYLQKPGQPKLIYKVSRL 60  
DB 1 DVLMTQIPLSLPSVLGDOASISCRSSQIVHSNGNTYLOWLYLQKPGQPKLIYKVSRL 60  
QY 61 YGVDPFSSGSGTDTFLKISSVEAEDIGVYCFQGSHPVPTFGGTTKLEIK 112  
DB 61 YGVDPFSSGSGTDTFLKISSVEAEDIGVYCFQGSHPVPTFGGTTKLEIK 112

```
RESULT 2
US-11-012-353-49
; Sequence 49, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 49
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-49

Query Match      100.0%; Score 590; DB 7; Length 122;
Best Local Similarity 100.0%; Pred. No. 1.1e-39;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLPQSPKLLIYKVSNRL 60
Db      11 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLPQSPKLLIYKVSNRL 70

Qy      61 YGVDPFRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112
Db      71 YGVDPFRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 122

RESULT 3
US-11-012-353-56
; Sequence 56, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 56
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-56

Query Match      95.6%; Score 564; DB 7; Length 112;
Best Local Similarity 95.5%; Pred. No. 1.1e-37;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLPQSPKLLIYKVSNRL 60
Db      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLPQSPKLLIYKVSNRF 60

Qy      61 YGVDPFRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112
Db      61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 4
US-11-125-837-23
; Sequence 23, Application US/11125837
; Publication No. US20050266003A1
; GENERAL INFORMATION:
; APPLICANT: Lin, Rong-Hwa
; APPLICANT: Chang, Chung Nan
; APPLICANT: Chen, Pei-Jiun
; APPLICANT: Huang, Chiu-Chen
; TITLE OF INVENTION: ANTIBODIES
; FILE REFERENCE: 13062-011001
; CURRENT APPLICATION NUMBER: US/11/125,837
; CURRENT FILING DATE: 2005-05-10
; PRIOR APPLICATION NUMBER: US 60/569,892
; PRIOR FILING DATE: 2004-05-10
; NUMBER OF SEQ ID NOS: 100
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-125-837-23

Query Match      94.4%; Score 557; DB 7; Length 131;
Best Local Similarity 94.6%; Pred. No. 4.2e-37;
Matches 106; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLPQSPKLLIYKVSNRL 60
Db      20 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLPQSPKLLIYKVSNRF 79

Qy      61 YGVDPFRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112
Db      80 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 131

RESULT 5
US-11-089-266-66
; Sequence 66, Application US/11089266
; Publication No. US20050287148A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TITLE OF INVENTION: TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
```

```
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 56
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-56
```

```
Query Match      95.6%; Score 564; DB 7; Length 112;
Best Local Similarity 95.5%; Pred. No. 1.1e-37;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLPQSPKLLIYKVSNRL 60
Db      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLPQSPKLLIYKVSNRF 60

Qy      61 YGVDPFRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112
Db      61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112
```

```
RESULT 4
US-11-125-837-23
; Sequence 23, Application US/11125837
; Publication No. US20050266003A1
; GENERAL INFORMATION:
; APPLICANT: Lin, Rong-Hwa
; APPLICANT: Chang, Chung Nan
; APPLICANT: Chen, Pei-Jiun
; APPLICANT: Huang, Chiu-Chen
; TITLE OF INVENTION: ANTIBODIES
; FILE REFERENCE: 13062-011001
; CURRENT APPLICATION NUMBER: US/11/125,837
; CURRENT FILING DATE: 2005-05-10
; PRIOR APPLICATION NUMBER: US 60/569,892
; PRIOR FILING DATE: 2004-05-10
; NUMBER OF SEQ ID NOS: 100
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-125-837-23
```

```
Query Match      94.4%; Score 557; DB 7; Length 131;
Best Local Similarity 94.6%; Pred. No. 4.2e-37;
Matches 106; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLPQSPKLLIYKVSNRL 60
Db      20 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLPQSPKLLIYKVSNRF 79

Qy      61 YGVDPFRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112
Db      80 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 131
```

```
RESULT 5
US-11-089-266-66
; Sequence 66, Application US/11089266
; Publication No. US20050287148A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TITLE OF INVENTION: TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
```

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: MORRISON & FOERSTER
STREET: 755 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
COUNTRY: USA
ZIP: 94304-1018
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/11/089,266
FILING DATE: 23-Mar-2005
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/10/153,401
FILING DATE: 27-Aug-2002
APPLICATION NUMBER: US 09/293,533
FILING DATE: 1999-04-15
APPLICATION NUMBER: US 08/372,676
FILING DATE: 1995-01-17
APPLICATION NUMBER: US 08/591,196
FILING DATE: 1996-01-16
ATTORNEY/AGENT INFORMATION:
NAME: Catherine M. Polizzi
REGISTRATION NUMBER: 40,130
REFERENCE/DOCKET NUMBER: 304142000202
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 813-5600
TELEFAX: (415) 494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 66:
SEQUENCE CHARACTERISTICS:
LENGTH: 263 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-11-089-266-66

Query Match          93.4%; Score 551; DB 7; Length 263;
Best Local Similarity 93.8%; Pred. No. 2.1e-36;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY      1 DVLMTQIPLSLPVSLGDAQISCRSSQSIHVSNGNTYLQWLYKQSPKLLIYKVSRL 60
Db      152 DVLMTQIPLSLPVSLGDAQISCRSSQSIHVSNGNTYLQWLYKQSPKLLIYFVSNRF 211

QY      61 YGVDPFRFSGSGTDTFTLKISSVEADLGVYCFQGSHPVWTFGGGKLEIK 112
Db      212 SGVDPFRFSGSGTDTFTLKISRVEADLGVYCFQGSHPVWTFGGGKLEIK 263

RESULT 6
US-11-089-266-15
Sequence 15, Application US/11089266
Publication No. US20050287148A1
GENERAL INFORMATION:
APPLICANT: Chatterjee, Malaya
APPLICANT: Foon, Kenneth A.
APPLICANT: Chatterjee, Sunil K.
TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
TITLE OF INVENTION: TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORRISON & FOERSTER
STREET: 755 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
COUNTRY: USA
ZIP: 94304-1018
COMPUTER READABLE FORM:

```

```

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/11/089,266
FILING DATE: 23-Mar-2005
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/10/153,401
FILING DATE: 27-Aug-2002
APPLICATION NUMBER: US 09/293,533
FILING DATE: 1999-04-15
APPLICATION NUMBER: US 08/372,676
FILING DATE: 1995-01-17
APPLICATION NUMBER: US 08/591,196
FILING DATE: 1996-01-16
ATTORNEY/AGENT INFORMATION:
NAME: Catherine M. Polizzi
REGISTRATION NUMBER: 40,130
REFERENCE/DOCKET NUMBER: 304142000202
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 813-5600
TELEFAX: (415) 494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 112 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-11-089-266-15

Query Match          92.9%; Score 548; DB 7; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.8e-36;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY      1 DVLMTQIPLSLPVSLGDAQISCRSSQSIHVSNGNTYLQWLYKQSPKLLIYKVSRL 60
Db      1 DVLMTQIPLSLPVSLGDAQISCRSSQSIHVSNGNTYLQWLYKQSPKLLIYFVSNRF 60

QY      61 YGVDPFRFSGSGTDTFTLKISSVEADLGVYCFQGSHPVWTFGGGKLEIK 112
Db      61 SGVDPFRFSGSGTDTFTLKISRVEADLGVYCFQGSHPVWTFGGGKLEIK 112

RESULT 7
US-11-012-353-57
Sequence 57, Application US/11012353
Publication No. US20050249730A1
GENERAL INFORMATION:
APPLICANT: GOETSCH, LILIANE
APPLICANT: CORVAIA, NATHALIE
APPLICANT: DUFLOS, ALAIN
APPLICANT: HAEUW, JEAN-FRANCOIS
APPLICANT: LEGER, OLIVIER
APPLICANT: BECK, ALAIN
TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
FILE REFERENCE: 017753-198
CURRENT APPLICATION NUMBER: US/11/012,353
CURRENT FILING DATE: 2004-12-16
PRIOR APPLICATION NUMBER: 10/735,916
PRIOR FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: FR 0308538
PRIOR FILING DATE: 2003-07-11
PRIOR APPLICATION NUMBER: PCT/FR03/00178
PRIOR FILING DATE: 2003-01-20
PRIOR APPLICATION NUMBER: FR 0205753
PRIOR FILING DATE: 2002-05-07
PRIOR APPLICATION NUMBER: FR 0200653
PRIOR FILING DATE: 2002-01-18

```

; PRIOR APPLICATION NUMBER: FR 0200654  
; PRIOR FILING DATE: 2002-01-18  
; NUMBER OF SEQ ID NOS: 162  
; SOFTWARE: PatentIn Ver. 3.3  
; SEQ ID NO 57  
; LENGTH: 112  
; TYPE: PRP  
; ORGANISM: Mus musculus  
US-11-012-353-57

Query Match 92.7%; Score 547; DB 7; Length 112;  
Best Local Similarity 92.0%; Pred. No. 2.2e-36;  
Matches 103; Conservative 5; Mismatches 4; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60  
Db 1 DVMFTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60  
  
QY 61 YGVDPDRFSGSGGTDTFTLKISVVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112  
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYCFQGSHPVPTFGGTTKLEIK 112

RESULT 8  
US-10-932-334-69  
; Sequence 69, Application US/10932334  
; Publication No. US20050249728A1  
; GENERAL INFORMATION:  
; APPLICANT: ImmunoGen, Inc.  
; TITLE OF INVENTION: ANTI-IGF-I RECEPTOR ANTIBODY  
; FILE REFERENCE: A8689  
; CURRENT APPLICATION NUMBER: US/10/932,334  
; CURRENT FILING DATE: 2004-09-02  
; PRIOR APPLICATION NUMBER: US/10/729,441  
; PRIOR FILING DATE: 2003-12-08  
; PRIOR APPLICATION NUMBER: 10/170,390  
; PRIOR FILING DATE: 2002-06-14  
; NUMBER OF SEQ ID NOS: 96  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 69  
; LENGTH: 113  
; TYPE: PRP  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic antibody structure  
; FEATURE:  
; NAME/KEY: MISC\_FEATURE  
; LOCATION: (28)..(28)  
; OTHER INFORMATION: "X" may be any amino acid  
; FEATURE:  
; NAME/KEY: MISC\_FEATURE  
; LOCATION: (101)..(101)  
; OTHER INFORMATION: "X" may be any amino acid  
US-10-932-334-69

Query Match 92.7%; Score 547; DB 6; Length 113;  
Best Local Similarity 93.8%; Pred. No. 2.2e-36;  
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60  
Db 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60  
  
QY 61 YGVDPDRFSGSGGTDTFTLKISVVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112  
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 9  
US-11-089-266-2  
; Sequence 2, Application US/11089266  
; Publication No. US20050287148A1  
; GENERAL INFORMATION:

; APPLICANT: Chatterjee, Malaya  
; APPLICANT: Foon, Kenneth A.  
; APPLICANT: Chatterjee, Sunil K.  
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE  
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA  
; NUMBER OF SEQUENCES: 66  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: MORRISON & FOERSTER  
; STREET: 755 PAGE MILL ROAD  
; CITY: PALO ALTO  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94304-1018  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/11/089,266  
; FILING DATE: 23-Mar-2005  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/10/153,401  
; FILING DATE: 27-Aug-2002  
; APPLICATION NUMBER: US 09/293,533  
; FILING DATE: 1999-04-15  
; APPLICATION NUMBER: US 08/372,676  
; FILING DATE: 1995-01-17  
; APPLICATION NUMBER: US 08/591,196  
; FILING DATE: 1996-01-16  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Catherine M. Polizzi  
; REGISTRATION NUMBER: 40,130  
; REFERENCE/DOCKET NUMBER: 304142000202  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 813-5600  
; TELEFAX: (415) 494-0792  
; TELEX: 706141  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 149 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-11-089-266-2

Query Match 92.7%; Score 547; DB 7; Length 149;  
Best Local Similarity 92.9%; Pred. No. 2.7e-36;  
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60  
Db 20 DVMFTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 79  
  
QY 61 YGVDPDRFSGSGGTDTFTLKISVVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112  
Db 80 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 131

RESULT 10  
US-11-012-353-55  
; Sequence 55, Application US/11012353  
; Publication No. US20050249730A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, LILIANE  
; APPLICANT: CORVAIA, NATHALIE  
; APPLICANT: DUPLOS, ALAIN  
; APPLICANT: HAEUW, JEAN-FRANCOIS  
; APPLICANT: LEGER, OLIVIER  
; APPLICANT: BECK, ALAIN  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID  
; RECEPTORS ANTIBODIES AND USES THEREOF

FILE REFERENCE: 017753-198  
CURRENT APPLICATION NUMBER: US/11/012,353  
CURRENT FILING DATE: 2004-12-16  
PRIOR APPLICATION NUMBER: 10/735,916  
PRIOR FILING DATE: 2003-12-16  
PRIOR APPLICATION NUMBER: FR 0308538  
PRIOR FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: PCT/FR03/00178  
PRIOR FILING DATE: 2003-01-20  
PRIOR APPLICATION NUMBER: FR 0205753  
PRIOR FILING DATE: 2002-05-07  
PRIOR APPLICATION NUMBER: FR 0200653  
PRIOR FILING DATE: 2002-01-18  
PRIOR APPLICATION NUMBER: FR 0200654  
PRIOR FILING DATE: 2002-01-18  
NUMBER OF SEQ ID NOS: 162  
SOFTWARE: PatentIn Ver. 3.3  
SEQ ID NO 55  
LENGTH: 112  
TYPE: PRT  
ORGANISM: Mus musculus  
US-11-012-353-55

Query Match 92.4%; Score 545; DB 7; Length 112;  
Best Local Similarity 92.9%; Pred. No. 3.1e-36;  
Matches 104; Conservative 3; Mismatches 5; Indels 0; Gaps 0;  
QY 1 DVLMTQIPLSPLVSLGDAQASISCRSSQSIHVSNGNTYLQWYLOKPGQSPKLLIYKVSRL 60  
DB 1 DVLMTQIPLSPLVSLGDAQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVSRL 60  
QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112  
DB 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYICFQGSHPVPTFGGTTKLDIK 112

RESULT 11  
US-10-932-334-61  
Sequence 61, Application US/10932334  
Publication No. US20050249728A1  
GENERAL INFORMATION:  
APPLICANT: ImmunoGen, Inc.  
TITLE OF INVENTION: ANTI-IGF-I RECEPTOR ANTIBODY  
FILE REFERENCE: A8689  
CURRENT APPLICATION NUMBER: US/10/932,334  
CURRENT FILING DATE: 2004-09-02  
PRIOR APPLICATION NUMBER: US/10/729,441  
PRIOR FILING DATE: 2003-12-08  
PRIOR APPLICATION NUMBER: 10/170,390  
PRIOR FILING DATE: 2002-06-14  
NUMBER OF SEQ ID NOS: 96  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 61  
LENGTH: 113  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: synthetic antibody structure  
US-10-932-334-61

Query Match 92.2%; Score 544; DB 6; Length 113;  
Best Local Similarity 92.0%; Pred. No. 3.7e-36;  
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;  
QY 1 DVLMTQIPLSPLVSLGDAQASISCRSSQSIHVSNGNTYLQWYLOKPGQSPKLLIYKVSRL 60  
DB 1 DVLMTQIPLSPLVSLGDAQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVSRL 60  
QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112  
DB 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYICFQGSHPVPTFGGTTKLEIK 112

RESULT 12  
US-10-512-184-30  
Sequence 30, Application US/10512184  
Publication No. US20050244901A1  
GENERAL INFORMATION:  
APPLICANT: Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.  
TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant  
TITLE OF INVENTION: antibody fragments and fusions mediated plant disease  
TITLE OF INVENTION: resistance against fungi  
FILE REFERENCE: 3581.01US01  
CURRENT APPLICATION NUMBER: US/10/512,184  
CURRENT FILING DATE: 2004-10-22  
NUMBER OF SEQ ID NOS: 72  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 30  
LENGTH: 251  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: scFv VD2 with  
specificity against Verticillium dahliae;  
OTHER INFORMATION: originates from Mus musculus.  
US-10-512-184-30

Query Match 92.0%; Score 543; DB 6; Length 251;  
Best Local Similarity 92.9%; Pred. No. 8.4e-36;  
Matches 104; Conservative 2; Mismatches 6; Indels 0; Gaps 0;  
QY 1 DVLMTQIPLSPLVSLGDAQASISCRSSQSIHVSNGNTYLQWYLOKPGQSPKLLIYKVSRL 60  
DB 138 DVLMTQIPLSPLVSLGDAQASISCRSSQSIHVSNGNTYLQWYLOKPGQSPKLLIYKASRNF 197  
QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112  
DB 198 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYICFQGSHPVPTFGGTTKLEIK 249

RESULT 13  
US-10-512-184-67  
Sequence 67, Application US/10512184  
Publication No. US20050244901A1  
GENERAL INFORMATION:  
APPLICANT: Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.  
TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant  
TITLE OF INVENTION: antibody fragments and fusions mediated plant disease  
TITLE OF INVENTION: resistance against fungi  
FILE REFERENCE: 3581.01US01  
CURRENT APPLICATION NUMBER: US/10/512,184  
CURRENT FILING DATE: 2004-10-22  
NUMBER OF SEQ ID NOS: 72  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 67  
LENGTH: 320  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: precursor  
OTHER INFORMATION: fusion protein comprising AG - linker - scFv VD2.  
US-10-512-184-67

Query Match 92.0%; Score 543; DB 6; Length 320;  
Best Local Similarity 92.9%; Pred. No. 1e-35;  
Matches 104; Conservative 2; Mismatches 6; Indels 0; Gaps 0;  
QY 1 DVLMTQIPLSPLVSLGDAQASISCRSSQSIHVSNGNTYLQWYLOKPGQSPKLLIYKVSRL 60  
DB 207 DVLMTQIPLSPLVSLGDAQASISCRSSQSIHVSNGNTYLQWYLOKPGQSPKLLIYKASRNF 266  
QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112  
DB 267 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYICFQGSHPVPTFGGTTKLEIK 318

Search completed: January 10, 2006, 21:36:22  
Job time : 5.71144 secs

RESULT 14  
US-10-512-184-66  
; Sequence 66, Application US/10512184  
; Publication NO. US20050244901A1  
; GENERAL INFORMATION:  
; APPLICANT: Fraunhofer Gesellschaft zur F"rderung der angewandten Forschung e.V.  
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant  
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease  
; TITLE OF INVENTION: resistance against fungi  
; FILE REFERENCE: 3581.01US01  
; CURRENT APPLICATION NUMBER: US/10/512,184  
; CURRENT FILING DATE: 2004-10-22  
; NUMBER OF SEQ ID NOS: 72  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 66  
; LENGTH: 569  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: precursor  
; OTHER INFORMATION: fusion protein comprising chitinase - linker -  
; OTHER INFORMATION: scFv VD2.  
US-10-512-184-66

Query Match 92.0%; Score 543; DB 6; Length 569;  
Best Local Similarity 92.9%; Pred. No. 1.6e-35;  
Matches 104; Conservative 2; Mismatches 6; Indels 0; Gaps 0;  
QY 1 DVLMTQIPLSLPSVLGDDQASISCRSSQSIHVSNGNTYQLQYKQPGQSPKLLIYKVSRL 60  
Db 456 DVLMTQIPLSLPSVLGDDQASISCRSSQNIHVSNGNTYQLQYKQPGQSPKLLIYKASNRF 515  
QY 61 YGVPRFSGSGGTDFTLKISVVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112  
Db 516 SGVPARFSGSGGTDFTLKISVVEADLGVIYCFQGSHPVPTFGGTTKLEIK 567

RESULT 15  
US-10-512-184-48  
; Sequence 48, Application US/10512184  
; Publication NO. US20050244901A1  
; GENERAL INFORMATION:  
; APPLICANT: Fraunhofer Gesellschaft zur F"rderung der angewandten Forschung e.V.  
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant  
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease  
; TITLE OF INVENTION: resistance against fungi  
; FILE REFERENCE: 3581.01US01  
; CURRENT APPLICATION NUMBER: US/10/512,184  
; CURRENT FILING DATE: 2004-10-22  
; NUMBER OF SEQ ID NOS: 72  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 48  
; LENGTH: 618  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: fusion protein  
; OTHER INFORMATION: comprising the leader peptide - chitinase - linker  
; OTHER INFORMATION: - scFv VD2 - cmv/His6.  
US-10-512-184-48

Query Match 92.0%; Score 543; DB 6; Length 618;  
Best Local Similarity 92.9%; Pred. No. 1.8e-35;  
Matches 104; Conservative 2; Mismatches 6; Indels 0; Gaps 0;  
QY 1 DVLMTQIPLSLPSVLGDDQASISCRSSQSIHVSNGNTYQLQYKQPGQSPKLLIYKVSRL 60  
Db 479 DVLMTQIPLSLPSVLGDDQASISCRSSQNIHVSNGNTYQLQYKQPGQSPKLLIYKASNRF 538  
QY 61 YGVPRFSGSGGTDFTLKISVVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112  
Db 539 SGVPARFSGSGGTDFTLKISVVEADLGVIYCFQGSHPVPTFGGTTKLEIK 590

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 21.8706 Seconds  
(without alignments)  
423.384 Million cell updates/sec

Title: US-10-735-916A-54  
Perfect score: 590  
Sequence: 1 DVLMTQPLSLPVSILGDOAS.....CFQSHVPWTFGGGKLEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents AA\*  
1: /cgn2\_6/ptodata/1/1aa/5 COMB.pep.\*  
2: /cgn2\_6/ptodata/1/1aa/6 COMB.pep.\*  
3: /cgn2\_6/ptodata/1/1aa/H COMB.pep.\*  
4: /cgn2\_6/ptodata/1/1aa/PCTUS COMB.pep.\*  
5: /cgn2\_6/ptodata/1/1aa/RE COMB.pep.\*  
6: /cgn2\_6/ptodata/1/1aa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	551	93.4	149	2	US-09-192-838B-2
2	551	93.4	149	2	US-09-324-191-2
3	551	93.4	263	1	US-08-752-844-66
4	551	93.4	263	2	US-09-293-533-66
5	548	92.9	112	1	US-08-752-844-15
6	548	92.9	112	2	US-08-591-196-15
7	548	92.9	112	2	US-09-293-533-15
8	547	92.7	149	1	US-08-752-844-2
9	547	92.7	149	1	US-08-591-196-2
10	547	92.7	149	2	US-09-293-533-2
11	545	92.4	113	1	US-08-497-312-18
12	545	92.4	114	1	US-08-560-558E-27
13	545	92.4	125	1	US-08-331-398A-67
14	545	92.4	125	1	US-08-331-397B-67
15	545	92.4	125	1	US-08-759-804A-66
16	544	92.2	249	2	US-09-726-219A-190
17	544	92.2	249	2	US-09-196-522-190
18	543	92.0	112	1	US-08-859-649-19
19	543	92.0	112	1	US-08-859-649-29
20	543	92.0	112	2	US-08-207-861-19
21	543	92.0	112	2	US-08-207-861-29
22	543	92.0	112	2	US-08-859-648-19
23	543	92.0	112	2	US-08-859-648-29
24	543	92.0	238	2	US-09-192-545-4
25	542	91.9	112	1	US-08-888-366-16
26	541	91.7	112	1	US-08-331-398A-48
27	541	91.7	112	1	US-08-077-252B-3

28	541	91.7	112	1	US-08-331-397B-48	Sequence 48, Appl
29	541	91.7	112	1	US-08-759-804A-48	Sequence 48, Appl
30	541	91.7	112	2	US-09-002-753A-3	Sequence 3, Appl
31	541	91.7	112	2	US-09-227-693-48	Sequence 48, Appl
32	541	91.7	112	2	US-09-657-274-3	Sequence 3, Appl
33	541	91.7	112	4	PCT-US94-06687-3	Sequence 3, Appl
34	541	91.7	247	2	US-09-227-693-34	Sequence 34, Appl
35	541	91.7	248	1	US-08-331-398A-34	Sequence 34, Appl
36	541	91.7	248	1	US-08-331-397B-34	Sequence 34, Appl
37	541	91.7	248	1	US-08-759-804A-34	Sequence 34, Appl
38	539	91.4	131	1	US-08-053-171-5	Sequence 5, Appl
39	539	91.4	131	1	US-08-053-171-9	Sequence 9, Appl
40	539	91.4	149	2	US-10-226-795-27	Sequence 27, Appl
41	538	91.2	114	2	US-09-217-268B-27	Sequence 27, Appl
42	535	90.7	216	2	US-09-254-180C-132	Sequence 132, App
43	535	90.7	216	2	US-09-254-180C-183	Sequence 183, App
44	534	90.5	114	1	US-08-285-936-4	Sequence 4, Appl
45	534	90.5	114	1	US-08-487-860-4	Sequence 4, Appl

## ALIGNMENTS

### RESULT 1

US-09-192-838B-2  
; Sequence 2, Application US/09192838B  
; Patent No. 6355244  
; GENERAL INFORMATION:  
; APPLICANT: CHATTERJEE, Malaya  
; APPLICANT: FOON, Kenneth A.  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS  
; FILE REFERENCE: 304142000500  
; CURRENT APPLICATION NUMBER: US/09/192.838B  
; CURRENT FILING DATE: 1998-11-16  
; PRIOR APPLICATION NUMBER: 60/065,774  
; PRIOR FILING DATE: 1997-11-17  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 149  
; TYPE: PRT  
; ORGANISM: Mus Musculus  
US-09-192-838B-2

Query Match 93.4%; Score 551; DB 2; Length 149;  
Best Local Similarity 93.8%; Pred. No. 7.6e-46;  
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy	1	DVLMTQPLSLPVSILGDOASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSNRL	60
Db	20	DVLMTQTSLPVSILGDOASISCRSSQSIHVSNGNTYLOWYLOKPGQSPNLLIYFVSNRF	79
Qy	61	YGVDPDRFGSGSGTDFTLKISSVEAEDLGVTTCFQGHVPWTFGGGTGLEIK	112
Db	80	SGVDPDRFGSGSGTDFTLKISRVEAEDLGVTTCFQGHVPWTFGGGTGLEIK	131

### RESULT 2

US-09-324-191-2  
; Sequence 2, Application US/09324191  
; Patent No. 6562798  
; GENERAL INFORMATION:  
; APPLICANT: THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION  
; APPLICANT: CHATTERJEE, Malaya  
; APPLICANT: FOON, Kenneth A.  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS  
; FILE REFERENCE: 304142000540  
; CURRENT APPLICATION NUMBER: US/09/324.191  
; CURRENT FILING DATE: 1999-06-02  
; EARLIER APPLICATION NUMBER: 60/065,774  
; EARLIER FILING DATE: 1997-11-17  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: PatentIn Ver. 2.0

RESULT 5  
US-08-752-844-15  
; Sequence 15, Application US/08752844  
; Patent No. 5935821  
; GENERAL INFORMATION:  
; APPLICANT: Chatterjee, Malaya  
; APPLICANT: Poon, Kenneth A.  
; APPLICANT: Chatterjee, Sunil K.  
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE  
; TITLE OF INVENTION: TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA  
; NUMBER OF SEQUENCES: 66  
; CORRESPONDENCE ADDRESS:

```

; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/752,844
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 30414-20002.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-752-844-15

Query Match          92.9%; Score 548; DB 1; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.1e-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIIVHSGNTYLYQWYLOKQSPKLIYKVSRL 60
Db 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIIVHSGNTYLYQWYLOKQSPKLIYFVSNRF 60

QY 61 YGVPDRFSGSGGTDTFLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112
Db 61 SGVPDRFSGSGGTDTFLKISRVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 6
US-08-591-196-15
; Sequence 15, Application US/08591196
; Patent No. 5977316
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/591,196
; FILING DATE: 16-JAN-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 30414-20002.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-752-844-15
```

```

; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 30414-20002.20
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-591-196-15

Query Match          92.9%; Score 548; DB 1; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.1e-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIIVHSGNTYLYQWYLOKQSPKLIYKVSRL 60
Db 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIIVHSGNTYLYQWYLOKQSPKLIYFVSNRF 60

QY 61 YGVPDRFSGSGGTDTFLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112
Db 61 SGVPDRFSGSGGTDTFLKISRVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 7
US-09-293-533-15
; Sequence 15, Application US/09293533
; Patent No. 6509016
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/293,533
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/752,844
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 30414-20002.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-591-196-15
```

```

US-08-591-196-2
; Sequence 2, Application US/08591196
; Patent No. 5977316
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Poon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/591,196
; FILING DATE: 16-JAN-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 30414-20002.20
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 149 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-591-196-2

Query Match          92.7%; Score 547; DB 1; Length 149;
Best Local Similarity 92.9%; Pred. No. 1.8e-45;
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0

QY      1  DVLMTQPLSLPVLISLGDQASISCRSSQISVHSNGNTYLQWYLOKPGQSPKLLIYKVSIN
DB      20  DVFMTQTPLSLPVLISLGDQASISCRSSQISVHSNGNTYLEWYLOKPGQSPNLLIYFVSIN
QY      61  YGVPDRFSGSGGTDTFTLKISVVEAEDLGVIYCFQGSHVPWTFGGGTKLEIK 112
DB      80  SGVPRFSGSGGTDTFTLKISVVEAEDLGVIYCFQGSHVPWTFGGGTKLEIK 131

RESULT 10
US-09-293-533-2
; Sequence 2, Application US/09293533
; Patent No. 6509016
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Poon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018

```

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/293,533  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/752,844  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Schiff, J. Michael  
REGISTRATION NUMBER: 40,253  
REFERENCE/DOCKET NUMBER: 30414-20002.21  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 813-5600  
TELEFAX: (415) 494-0792  
TELEX: 706141  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 149 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-09-293-533-2

Query Match 92.7%; Score 547; DB 2; Length 149;  
Best Local Similarity 92.9%; Pred. No. 1.8e-45;  
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0;  
  
Qy 1 DVLMTQPLSLPVSILGDAQISCRSSQSIHVSNGNTYLOWYLOKPGSPKLLIYKVSRL 60  
Db 20 DVFMTQTPLSLPVSILGDAQISCRSSQSIHVSNGNTYLOWYLOKPGSPNLLIYFVSNRF 79  
  
Qy 61 YGVPDRFSGSGGTDTFTLKISSVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112  
Db 80 SGVPDRFSGSGGTDTFTLKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 131

RESULT 11  
US-08-497-312-18  
Sequence 18, Application US/08497312  
Patent No. 5712120  
GENERAL INFORMATION:  
APPLICANT:  
TITLE OF INVENTION: Method for obtaining modified  
TITLE OF INVENTION: immunoglobulins with reduced immunogenicity of murine  
TITLE OF INVENTION: antibody variable domains, compositions containing them.  
NUMBER OF SEQUENCES: 31  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CENTRO DE INMUNOLOGIA MOLECULAR  
STREET: 215 Y 15, ATABEY PLAYA  
CITY: HAVANA  
STATE:  
COUNTRY: CUBA  
ZIP: 11600  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/497,312  
FILING DATE: 30-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: CU 80/94  
FILING DATE: 30-JUN-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: BOND, LAURENCE B.  
REGISTRATION NUMBER: 30,549  
REFERENCE/DOCKET NUMBER: 262995

TELECOMMUNICATION INFORMATION:  
TELEPHONE: 801/532-1922  
TELEFAX: 801/531-9168  
TELEX: 388961 1PM04UT  
INFORMATION FOR SEQ ID NO: 18:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 113 amino acids  
TYPE: amino acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: protein  
HYPOTHETICAL: NO  
US-08-497-312-18

Query Match 92.4%; Score 545; DB 1; Length 113;  
Best Local Similarity 92.9%; Pred. No. 2.1e-45;  
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0;  
  
Qy 1 DVLMTQPLSLPVSILGDAQISCRSSQSIHVSNGNTYLOWYLOKPGSPKLLIYKVSRL 60  
Db 1 DVLMTQPLSLPVSILGDAQISCRSSQNIHVSNGNTYLDWYLOKPGSPNLLIYKVSNR 60  
  
Qy 61 YGVPDRFSGSGGTDTFTLKISSVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112  
Db 61 SGVPDRFSGSGGTDTFTLKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 12  
US-08-560-558E-27  
Sequence 27, Application US/08560558E  
Patent No. 5891996  
GENERAL INFORMATION:  
APPLICANT:  
TITLE OF INVENTION: Humanized and chimeric monoclonal  
TITLE OF INVENTION: antibodies that recognize epidermal growth factor receptor  
TITLE OF INVENTION: EGF-R; diagnostic and therapeutic use.  
NUMBER OF SEQUENCES: 34  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Allen C. Turner, TRASK, BRITT & ROSSA  
STREET: P.O. Box 2250  
CITY: Salt Lake City  
STATE: Utah  
COUNTRY: United States of America  
ZIP: 84110  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: WINDOWS95  
SOFTWARE: WordPerfect 5.1/5.2  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/560,558E  
FILING DATE: No. 5891996ember 17, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Turner, Allen C.  
REGISTRATION NUMBER: 33,041  
REFERENCE/DOCKET NUMBER: 272005  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (801) 532-1922  
TELEFAX: (801) 531-9168  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 114 amino acids  
TYPE: amino acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: protein  
HYPOTHETICAL: NO  
US-08-560-558E-27

Query Match 92.4%; Score 545; DB 1; Length 114;  
Best Local Similarity 92.9%; Pred. No. 2.1e-45;  
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

1	DVLMTQIPIUSLPSVSLGDQASISCRSSQSIVHNSGNTYLOWYLOKFGQSPKLLIYKVS	NR	60
	1	DB	60
61	YGVPRFRSGSGGTDFTLKISSVEAFDLGVVYCFQGSHPVPTFGGKTLEIK	112	
	61	DB	112

RESULT 13  
US-08-331-398A-67  
; Sequence 67, Application US/08331398A  
; Patent No. 5608039  
; GENERAL INFORMATION:  
; APPLICANT: Pastan, Ira  
; APPLICANT: Willingham, Mark  
; APPLICANT: Fitzgerald, David  
; APPLICANT: Brinkmann, Ulrich  
; APPLICANT: Pai, Lee  
; TITLE OF INVENTION: Single Chain B3 Antibody Fusion Proteins  
; TITLE OF INVENTION: and Their Uses (as amended)  
; NUMBER OF SEQUENCES: 68  
; CORRESPONDENCE ADDRESS:

	Query Match	92.4%	Score 545;	DB 1;	Length 125;
	Best Local Similarity	92.9%;	Pred.No. 2.4e-45;		
	Matches 104; Conservative	3;	Mismatches 5;	Indels 0;	Gaps 0;
QY	1	DVLMTGPIPLSLPVSGLGPDAISICRSSOSIVHNSNGNTYLQWLPKPGOSPILLIYKVSNRL	60		
	:	:			
db	1	DVLLTTFELSPVLSLGPDAISCSSSOSIVHNSNGNTYLEWLTKFGPSPKLIYKVNRF	60		
	:	:			

Qy	61	YGVDRFSGSGGTDFTLKISRVEAEDLGVYCFQGSHPDWTFEGGKLEIK	112
Db	61	SGVDRFSGSGGTDFTLKISRVEAEDLGVYCFQGSHPDFTFGSGKLEIK	112

RESULT 14  
US-08-331-397B-67

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999

```

Query Match	92.4%;	Score	545;	DB	1;	Length	125;
Best Local Similarity	92.9%;	Pred. NO.	2.4e-45;				
Matches	104;	Conservative	3;	Mismatches	5;	Indels	0;
Gaps	0;						
Qy	1	DVLMTQIPLSLPSVSLGDQASISCRSSQSIVHSGNGNTYLOWLKPGSQKLLIYKVSNRL	60				
Db	1	DVLTTQTPLSLPSVSLGDQASISCRSSQSIVHSGNGNTYLEWLYKPGSQKLLIYKVSNRF	60				
Qy	61	YGVPDRFSGSGGSTDFTLTKISRVEADLGYYVCFQGSHVPWTFCGGTGKLEIK	112				
Db	61	SGVPDRFSGSGGSTDFTLTKISRVEADLGYYVCFQGSHVPWTFGSGTGKLEIK	112				
RESULT	15						

US-08-759-804A-66  
; Sequence 66, Application US/08759804A  
; Patent No. 5990296  
; GENERAL INFORMATION:  
; APPLICANT: Pastan, Ira  
; APPLICANT: Willingham, Mark  
; APPLICANT: FitzGerald, David J.  
; APPLICANT: Brinkmann, Ulrich  
; APPLICANT: Pai, Lee  
; TITLE OF INVENTION: Tumor-Specific Antibody Fragments,  
; TITLE OF INVENTION: Fusion Proteins, and Uses Thereof  
; NUMBER OF SEQUENCES: 68  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, Eighth Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94111-3834  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/759,804A  
; FILING DATE: 03-DEC-1996  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/331,398  
; FILING DATE: 28-OCT-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/767,331  
; FILING DATE: 30-SEP-1991  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/596,289  
; FILING DATE: 12-OCT-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Weber, Ellen L.  
; REGISTRATION NUMBER: 32,762  
; REFERENCE/DOCKET NUMBER: 015280-126140US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 576-0200  
; TELEFAX: (415) 576-0300  
; INFORMATION FOR SEQ ID NO: 66:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 125 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; FEATURE:  
; NAME/KEY: Region  
; LOCATION: 1..125  
; OTHER INFORMATION: /note= "Mouse monoclonal antibody B5 Fv  
; OTHER INFORMATION: Light chain region"  
US-08-759-804A-66

Query Match 92.4%; Score 545; DB 1; Length 125;  
Best Local Similarity 92.9%; Pred. No. 2.4e-45;  
Matches 104; Conservative 3; Mismatches 5; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSPLVSLGDAQSISCRSSQSI VHSNGNTYLOWYLOKPGQSPKLLIYKVSREL 60  
Db |||||  
1 DVLTTQIPLSPLVSLGDAQSISCRSSQSI VHSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60  
QY 61 YGVPRFSGSGSGTDFTLKISSVEAEDLGYYICFQGSHPVPTFGGSKLEIK 112  
Db |||||  
61 SGVPRFSGSGSGTDFTLKISRVEADLGYYICFQGSHPVPTFGGSKLEIK 112

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 61.4328 Seconds  
(without alignments)  
761.757 Million cell updates/sec

Title: US-10-735-916A-54  
Perfect score: 590  
Sequence: 1 DVLMTQIPLSLPSVLGDAQS.....CFQGSHPVPTFGGTTKLEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications AA Main:  
1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*  
3: /cgn2\_6/ptodata/1/pubpaa/US09\_PUBCOMB.pep.\*  
4: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*  
5: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*  
6: /cgn2\_6/ptodata/1/pubpaa/US11\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	590	100.0	112	5	US-10-735-916A-54 Sequence 54, Appl
2	590	100.0	122	3	US-10-735-916A-49 Sequence 49, Appl
3	564	95.6	112	3	US-09-995-529-10 Sequence 10, Appl
4	564	95.6	112	3	US-09-995-529-10 Sequence 10, Appl
5	564	95.6	112	5	US-10-735-916A-56 Sequence 56, Appl
6	558	94.6	112	4	US-10-258-728-4 Sequence 4, Appl
7	553	93.7	112	4	US-10-258-728-25 Sequence 25, Appl
8	551	93.4	149	3	US-09-990-205-2 Sequence 2, Appl
9	551	93.4	263	4	US-10-153-401-66 Sequence 66, Appl
10	550	93.2	219	4	US-10-454-660-10 Sequence 10, Appl
11	548	92.9	112	4	US-10-153-401-15 Sequence 15, Appl
12	547	92.7	112	5	US-10-735-916A-57 Sequence 57, Appl
13	547	92.7	113	5	US-10-735-916A-57 Sequence 57, Appl
14	547	92.7	113	5	US-10-729-441-69 Sequence 69, Appl
15	547	92.7	113	5	US-10-897-406-69 Sequence 69, Appl
16	547	92.7	149	4	US-10-153-401-2 Sequence 2, Appl
17	545	92.4	249	6	US-11-093-103-84 Sequence 84, Appl
18	545	92.4	112	5	US-10-735-916A-55 Sequence 55, Appl
19	544	92.2	237	5	US-10-828-782A-16 Sequence 16, Appl
20	544	92.2	113	5	US-10-729-441-61 Sequence 61, Appl
21	544	92.2	113	5	US-10-897-406-61 Sequence 61, Appl
22	544	92.2	249	4	US-10-803-622-190 Sequence 190, App
23	543	92.0	114	6	US-10-803-653-190 Sequence 190, App
24	542	91.9	112	4	US-10-434-469-43 Sequence 43, Appl
25	542	91.9	112	5	US-10-434-469-43 Sequence 43, Appl
26	542	91.9	112	5	US-10-482-105-41 Sequence 6, Appl
27	542	91.9	113	5	US-10-500-207A-6 Sequence 60, Appl

28	542	91.9	113	5	US-10-897-406-60 Sequence 60, Appl
29	542	91.9	131	4	US-10-434-469-6 Sequence 6, Appl
30	542	91.9	131	5	US-10-482-105-4 Sequence 4, Appl
31	542	91.9	131	5	US-10-409-611-75 Sequence 75, Appl
32	542	91.9	131	5	US-10-409-608A-17 Sequence 17, Appl
33	542	91.9	131	5	US-10-500-207A-4 Sequence 4, Appl
34	541	91.7	113	5	US-10-729-441-59 Sequence 59, Appl
35	541	91.7	113	5	US-10-897-406-59 Sequence 59, Appl
36	541	91.7	114	6	US-11-009-443-75 Sequence 75, Appl
37	541	91.7	116	5	US-10-787-219A-49 Sequence 49, Appl
38	540	91.5	131	4	US-10-388-214A-2 Sequence 2, Appl
39	540	91.5	220	6	US-11-013-537-55 Sequence 55, Appl
40	539	91.4	149	4	US-10-226-795-27 Sequence 27, Appl
41	538	91.2	112	4	US-10-308-817-172 Sequence 172, App
42	538	91.2	112	4	US-10-308-817-181 Sequence 181, App
43	538	91.2	112	4	US-10-453-698-172 Sequence 61, App
44	538	91.2	112	5	US-10-735-916A-61 Sequence 61, Appl
45	538	91.2	114	3	US-09-217-268B-27 Sequence 27, Appl

ALIGNMENTS

RESULT 1  
US-10-735-916A-54  
; Sequence 54, Application US/10735916A  
; Publication No. US20050084906A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, Liliane  
; APPLICANT: CORVAIA, Nathalie  
; APPLICANT: LEGER, Olivier  
; APPLICANT: DUFLOS, Alain  
; APPLICANT: BECK, Alain  
; APPLICANT: BAUM, Jean-Francois  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 017753-183  
; CURRENT APPLICATION NUMBER: US/10/735,916A  
; CURRENT FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 03/08 538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 02/00 653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/00 654  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/05 753  
; PRIOR FILING DATE: 2002-05-07  
; NUMBER OF SEQ ID NOS: 156  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 54  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-10-735-916A-54  
Query Match 100.0%; Score 590; DB 5; Length 112;  
Best Local Similarity 100.0%; Pred. No. 3.4e-49;  
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 DVLMTQIPLSLPSVLGDAQSISCRSSQSIHVSNGNTYLOWYLOKPKQSPKLIYKVSRL 60  
Db 1 DVLMTQIPLSLPSVLGDAQSISCRSSQSIHVSNGNTYLOWYLOKPKQSPKLIYKVSRL 60  
QY 61 YGVPRFSGSGSDTFTLKISSVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112  
Db 61 YGVPRFSGSGSDTFTLKISSVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112  
RESULT 2  
US-10-735-916A-49  
; Sequence 49, Application US/10735916A  
; Publication No. US20050084906A1

; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, Liliane  
; APPLICANT: CORVAIA, Nathalie  
; APPLICANT: LEGER, Olivier  
; APPLICANT: DUFLOS, Alain  
; APPLICANT: BECK, Alain  
; APPLICANT: HAEUW, Jean-Francois  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 01753-183  
; CURRENT APPLICATION NUMBER: US/10/735,916A  
; CURRENT FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 03/08 538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 02/00 653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/00 654  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/05 753  
; PRIOR FILING DATE: 2002-05-07  
; NUMBER OF SEQ ID NOS: 156  
; SOFTWARE: Patentin Ver. 2.1  
; SEQ ID NO 49  
; LENGTH: 122  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-10-735-916A-49

Query Match 100.0%; Score 590; DB 5; Length 122;  
Best Local Similarity 100.0%; Pred. No. 3.7e-49;  
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 60  
Db 11 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 70  
  
QY 61 YGVPRFSGSGGTDTLTKISSVEAEDLGYYVYCFQGSHPVWTFGGGTKEIK 112  
Db 71 YGVPRFSGSGGTDTLTKISSVEAEDLGYYVYCFQGSHPVWTFGGGTKEIK 122

## RESULT 3

; Sequence 10, Application US/09995529  
; Publication No. US2003009655A1  
; GENERAL INFORMATION:  
; APPLICANT: Watkins, Jeffrey D.  
; APPLICANT: Huse, William D.  
; APPLICANT: Tang, Ying  
; TITLE OF INVENTION: Humanized Collagen Antibodies and  
; TITLE OF INVENTION: Related Methods  
; FILE REFERENCE: P-IX 4976  
; CURRENT APPLICATION NUMBER: US/09/995,529  
; CURRENT FILING DATE: 2001-11-26  
; NUMBER OF SEQ ID NOS: 358  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 10  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-09-995-529-10

Query Match 95.6%; Score 564; DB 3; Length 112;  
Best Local Similarity 95.5%; Pred. No. 1.1e-46;  
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 60  
Db 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 60  
  
QY 61 YGVPRFSGSGGTDTLTKISSVEAEDLGYYVYCFQGSHPVWTFGGGTKEIK 112

Db 61 SGVPRFSGSGGTDTLTKISRVEAEDLGYYVYCFQGSHPVWTFGGGTKEIK 112  
  
RESULT 4  
US-09-995-529-10  
; Sequence 10, Application US/09995529  
; Publication No. US20040091482A9  
; GENERAL INFORMATION:  
; APPLICANT: Watkins, Jeffrey D.  
; APPLICANT: Huse, William D.  
; APPLICANT: Tang, Ying  
; TITLE OF INVENTION: Humanized Collagen Antibodies and  
; TITLE OF INVENTION: Related Methods  
; FILE REFERENCE: P-IX 4976  
; CURRENT APPLICATION NUMBER: US/09/995,529  
; CURRENT FILING DATE: 2001-11-26  
; NUMBER OF SEQ ID NOS: 358  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 10  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-09-995-529-10

Query Match 95.6%; Score 564; DB 3; Length 112;  
Best Local Similarity 95.5%; Pred. No. 1.1e-46;  
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 60  
Db 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 60  
  
QY 61 YGVPRFSGSGGTDTLTKISSVEAEDLGYYVYCFQGSHPVWTFGGGTKEIK 112  
Db 61 SGVPRFSGSGGTDTLTKISRVEAEDLGYYVYCFQGSHPVWTFGGGTKEIK 112

## RESULT 5

US-10-735-916A-56  
; Sequence 56, Application US/10735916A  
; Publication No. US20050084906A1  
; GENERAL INFORMATION:  
; APPLICANT: GOETSCH, Liliane  
; APPLICANT: CORVAIA, Nathalie  
; APPLICANT: LEGER, Olivier  
; APPLICANT: DUFLOS, Alain  
; APPLICANT: BECK, Alain  
; APPLICANT: HAEUW, Jean-Francois  
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF  
; FILE REFERENCE: 01753-183  
; CURRENT APPLICATION NUMBER: US/10/735,916A  
; CURRENT FILING DATE: 2003-12-16  
; PRIOR APPLICATION NUMBER: FR 03/08 538  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178  
; PRIOR FILING DATE: 2003-01-20  
; PRIOR APPLICATION NUMBER: FR 02/00 653  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/00 654  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: FR 02/05 753  
; PRIOR FILING DATE: 2002-05-07  
; NUMBER OF SEQ ID NOS: 156  
; SOFTWARE: Patentin Ver. 2.1  
; SEQ ID NO 56  
; LENGTH: 112  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-10-735-916A-56

Query Match 95.6%; Score 564; DB 5; Length 112;  
Best Local Similarity 95.5%; Pred. No. 1.1e-46;  
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY	1	DVLMTQIPLSLPVSIGDQASISCRSSQSIHNSGNTYLQWLYLQKQSPKLLIYKVS	NR 60
DB	1	DVLMTQIPLSLPVSIGDQASISCRSSQSIHNSGNTYLEWLYLQKQSPKLLIYKVS	NR 60
QY	61	YGVPRDFSGSGSGTDFTLKISVVEADLCVYVYFCQSHVPMVTFGGTKLEIK	112
DB	61	SGVPRDFSGSGSGTDFTLKISVVEADLCVYVYFCQSHVPMVTFGGTKLEIK	112

## RESULT 6

```

US-10-258-728-4
; Sequence 4, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Ellis, John Robert Maxwell
; APPLICANT: Durtant, Linda Gillian
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0020794.4
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-4

```

[illegible]

## RESULT 7

```

US-10-258-728-25
; Sequence 25, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Ellis, John Robert Maxwell
; APPLICANT: Durrant, Linda Gillian
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0020794.4
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-25

```

Query Match	93.7%	Score 53;	DB 4;	Length 112;
Best Local Similarity	93.7%	Pred. NO. 1.3e-45;		
Matches 104;	Conservative	2;	Mismatches 5;	Indels 0;
Gaps 0;				

[illegible]

## RESULT 8

```

US-09-990-205-2
; Sequence 2, Application US/09990205
; Patent No. US20020150572A1
; GENERAL INFORMATION:
; APPLICANT: FOON, Kenneth A.
; APPLICANT: CHATTERJEE, Malaya
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS
; FILE REFERENCE: 304142000501
; CURRENT APPLICATION NUMBER: US/09/990,205
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: U.S. 09/192,838
; PRIOR FILING DATE: 1998-11-16
; PRIOR APPLICATION NUMBER: U.S. 60/065,774
; PRIOR FILING DATE: 1997-11-17
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 149
; TYPE: PRT
; ORGANISM: Mus Musculus
US-09-990-205-2

```

	Query Match	93.4%; Score 551; DB 3; Length 149;
	Best Local Similarity	93.8%; Pred. No. 2,7e-45;
Matches	Conservative	1; Mismatches 6; Indels 0; Gaps 0;
QY	1 DVLMTQIPSLPSVSGDQASISCRSSQSIVHNGNTYLWYLOKPGSQPKLIYYKVSNRL	60
Dd	20 DVLMTQTPLSPSVLGDQASISCRSSQSIVHNGNTYLEWLKPGSQPNLLIIFYVSNRF	79
QY	61 YGVDRPFGSGGSTDFTLKISSVEADLGVIYCQGSHVPWTGGGTGLEIK	112
Dd	80 SGVDRPFGSGGSTDFTLKISRVAEDLVGYICQGSHVPWTGGGTGLEIK	131

## RESULT 9

US-10-153-401-66  
; Sequence 66, Application US/10153401  
; Publication NO. US20030114398A1  
; GENERAL INFORMATION:  
; APPLICANT: Chatterjee, Malaya  
; Poon, Kenneth A.  
; Chatterjee, Sunil K.  
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE  
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA  
; NUMBER OF SEQUENCES: 66  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: MORRISON & FOERSTER  
; STREET: 755 PAGE MILL ROAD  
; CITY: PALO ALTO  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94304-1018  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/153,401  
; FILING DATE: 27-Aug-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 09/293,533  
FILING DATE: 1999-04-15  
FILING DATE: 1999-04-15  
FILING DATE: 1995-01-17  
FILING DATE: 1995-01-17  
FILING DATE: 1996-01-16  
FILING DATE: 1996-01-16  
ATTORNEY/AGENT INFORMATION:  
NAME: Catherine M. Polizzi  
REGISTRATION NUMBER: 40,130  
REFERENCE/DOCKET NUMBER: 304142000202  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 813-5600  
TELEFAX: (415) 494-0792  
TELEX: 706141  
INFORMATION FOR SEQ ID NO: 66:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 263 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 66:  
US-10-153-401-66

Query Match 93.4%; Score 551; DB 4; Length 263;  
Best Local Similarity 93.8%; Pred. No. 5e-45;  
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDOASISCRSSQSIHVSNGNTYLOWYLQKPGQSPKLLIYKVSRL 60  
DB 152 DVLMTQIPLSLPVSLGDOASISCRSSQSIHVSNGNTYLOWYLQKPGQSPKLLIYFVSNRF 211

QY 61 YGVDPFRFSGSGTDTFLTKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112  
DB 212 SGVDPFRFSGSGTDTFLTKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 263

RESULT 10  
US-10-454-660-10  
Sequence 10, Application US/10454660  
Publication No. US20040005550A1  
GENERAL INFORMATION:  
APPLICANT: Shattil, Sanford J.  
APPLICANT: Nemerow, Glen  
APPLICANT: Hato, Taka  
APPLICANT: Stupack, Wayne  
APPLICANT: Pampori, Nisar  
TITLE OF INVENTION: METHODS AND COMPOSITIONS USEFUL FOR TARGETING  
TITLE OF INVENTION: ACTIVATED VITROECTIN RECEPTOR ALPHA V BETA 3  
FILE REFERENCE: NOV01495  
CURRENT APPLICATION NUMBER: US/10/454,660  
CURRENT FILING DATE: 2003-06-03  
PRIOR APPLICATION NUMBER: PRIOR APPLICATION NUMBER: US/09/454,925A  
PRIOR FILING DATE: 1999-12-03  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: Patent In Ver. 2.1  
SEQ ID NO 10  
LENGTH: 219  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: WOW-1 Fab light  
OTHER INFORMATION: chain amino acid sequence  
US-10-454-660-10

Query Match 93.2%; Score 550; DB 4; Length 219;  
Best Local Similarity 93.8%; Pred. No. 5.1e-45;  
Matches 105; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDOASISCRSSQSIHVSNGNTYLOWYLQKPGQSPKLLIYKVSRL 60  
DB 1 DVLMTQIPLSLPVSLGDOASISCRSSQSIHVSNGNTYLOWYLQKPGQSPKLLIYFVSNRF 60  
QY 61 YGVDPFRFSGSGTDTFLTKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112

DB 61 SGVDPFRFSGSGTDTFLTKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 11  
US-10-153-401-15  
Sequence 15, Application US/10153401  
Publication No. US20030114398A1  
GENERAL INFORMATION:  
APPLICANT: Chatterjee, Malaya  
Foon, Kenneth A.  
Chatterjee, Sunil K.  
TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE  
TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA  
NUMBER OF SEQUENCES: 66  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: MORRISON & FOERSTER  
STREET: 755 PAGE MILL ROAD  
CITY: PALO ALTO  
STATE: CA  
COUNTRY: USA  
ZIP: 94304-1018  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/153,401  
FILING DATE: 27-Aug-2002  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 09/293,533  
FILING DATE: 1999-04-15  
APPLICATION NUMBER: US 08/372,676  
FILING DATE: 1995-01-17  
APPLICATION NUMBER: US 08/591,196  
FILING DATE: 1996-01-16  
ATTORNEY/AGENT INFORMATION:  
NAME: Catherine M. Polizzi  
REGISTRATION NUMBER: 40,130  
REFERENCE/DOCKET NUMBER: 304142000202  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 813-5600  
TELEFAX: (415) 494-0792  
TELEX: 706141  
INFORMATION FOR SEQ ID NO: 15:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 112 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 15:  
US-10-153-401-15

Query Match 92.9%; Score 548; DB 4; Length 112;  
Best Local Similarity 93.8%; Pred. No. 3.8e-45;  
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDOASISCRSSQSIHVSNGNTYLOWYLQKPGQSPKLLIYKVSRL 60  
DB 1 DVLMTQIPLSLPVSLGDOASISCRSSQSIHVSNGNTYLOWYLQKPGQSPKLLIYFVSNRF 60  
QY 61 YGVDPFRFSGSGTDTFLTKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112  
DB 61 SGVDPFRFSGSGTDTFLTKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 12  
US-10-735-916A-57  
Sequence 57, Application US/10735916A  
Publication No. US20050084906A1

```

RESULT 13
US-10-729-441-69
; Sequence 69, Application US/10729441
; Publication No. US20040265307A1
; GENERAL INFORMATION:
; APPLICANT: Immunogen, Inc.
; TITLE OF INVENTION: ANTI-IGP-1 RECEPTOR ANTIBODY
; FILE REFERENCE: A8689
; CURRENT APPLICATION NUMBER: US/10/729,441
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: 10/170,390
; PRIOR FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: synthetic antibody structure
;
; FEATURES:
; NAME/KEY: MISC FEATURE
; LOCATION: (28)..(28)
; OTHER INFORMATION: "x" may be any amino acid
;
; FEATURES:
; NAME/KEY: MISC FEATURE
; LOCATION: (101)..(101)
; OTHER INFORMATION: "x" may be any amino acid
;
US-10-729-441-69

```

```

Query Match          92.7%; Score 547; DB 5; Length 113;
Best Local Similarity 93.8%; Pred. No. 4.8e-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0

Qy      1  DVLMTQPLSLPSVLGDAQISCRSSOSIVHSNGNTYLQWYLRKPGSGPKLLIYKVSRL 60
Db      1  DVLMTQPLSLPSVLGDAQISCRSSQXIVHSNGNTYLEWYLRKPGSGPKLLIYKVSRRF 60

Qy      61  YGVPDFRSGSGSGTDFTLKTISSVEABDLGVYVYCFQGSHPVPTFGGTYKLEIK 112
Db      61  SGVPDRSGSGSGTDFTLKISRVEABDLGVYVYCFQGSHPVPTFGGTYKLEIK 112

RESULT 15
US-10-153-401-2
; Sequence 2, Application US/10153401
; Publication No. US20030114398A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
;              Foon, Kenneth A.
;              Chatterjee, Sunil K.
; TITLE OF INVENTION: TREATMENT OF MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
;                   TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018

```

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/153,401  
FILING DATE: 27-Aug-2002  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 09/293,533  
FILING DATE: 1999-04-15  
APPLICATION NUMBER: US 08/372,676  
FILING DATE: 1995-01-17  
APPLICATION NUMBER: US 08/591,196  
FILING DATE: 1996-01-16  
ATTORNEY/AGENT INFORMATION:  
NAME: Catherine M. Polizzi  
REGISTRATION NUMBER: 40,130  
REFERENCE/DOCKET NUMBER: 304142000202  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 813-5600  
TELEFAX: (415) 494-0792  
TELEX: 706141  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 149 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 2:  
US-10-153-401-2

Query Match 92.7%; Score 547; DB 4; Length 149;  
Best Local Similarity 92.9%; Pred. No. 6.5e-45;  
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0;  
QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQIVHSNGNTYLQWYLQKPGQSPKLLIYKVSNRL 60  
Db 20 DVFMTQTPLSLPVSIGDQASISCRSSQIVHSNGNTYLEWYLQKPGQSPNLLIYFVSNRF 79  
QY 61 YGVPPDRFSGSGGTDFTLKISVVEADLGVIYCYFQGSHPVPTFGGTTKLEIK 112  
Db 80 SGVPPDRFSGSGGTDFTLKISRVEADLGVIYCYFQGSHPVPTFGGTTKLEIK 131

Search completed: January 10, 2006, 21:35:30  
Job time : 62.4328 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 77.3134 Seconds  
(without alignments)  
636.505 Million cell updates/sec

Title: US-10-735-916A-54  
Perfect score: 590  
Sequence: 1 DVLMTQIPLSLFVSLGDOAS.....CFQGSHPVWTFGGTKLEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq 21:\*  
1: Geneseqp1980s:\*  
2: Geneseqp1990s:\*  
3: Geneseqp2000s:\*  
4: Geneseqp2001s:\*  
5: Geneseqp2002s:\*  
6: Geneseqp2003as:\*  
7: Geneseqp2003bs:\*  
8: Geneseqp2004s:\*  
9: Geneseqp2005s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	590	100.0	112	7	ADJ76888 Anti-IGF-
2	590	100.0	112	9	ADZ67058 Murine im
3	590	100.0	122	7	ADJ76883 Anti-IGF-
4	590	100.0	122	9	ADZ67053 Murine im
5	564	95.6	112	7	ADP94125 Mouse HUI
6	564	95.6	112	7	ADJ76890 Anti-IGF-
7	564	95.6	112	9	ADZ67060 Mouse ant
8	558	94.6	112	5	AAE15704 Mouse mon
9	558	94.6	114	9	AEb21358 Mouse ant
10	558	94.6	114	9	AEb31116 Antibody
11	556	94.2	114	8	ADI26498 Human ECL
12	555	94.1	114	8	ADP84941 Variable
13	555	94.1	139	9	AEC21825 Mouse lig
14	555	94.1	238	8	ADS88785 Sequence
15	553	93.7	114	8	ADP84942 Variable
16	552	93.6	249	1	AAp80154 Biosynthe
17	551	93.4	149	2	AAW03199 Anti-Idio
18	551	93.4	149	2	AAy21545 Monoclonal
19	551	93.4	263	2	AAy28470 Vh-(Lk)-v
20	551	93.4	263	6	ADA14828 Anti-Idio
21	551	93.4	263	6	ADc35357 Monoclonal
22	551	93.4	263	7	ADc35357 Monoclonal
23	550	93.2	113	8	ADs88781 Amino aci
24	550	93.2	115	1	AAp81364 Light cha

25	550	93.2	115	1	AAb62301	Chimeric
26	550	93.2	219	3	AAy95258	WOW-1 Fab
27	550	93.2	298	8	ADs88777	Amino aci
28	549	93.1	109	5	ABP52310	Fv region
29	548	92.9	112	2	AAy49217	Light cha
30	548	92.9	112	6	ADA14777	Peptide f
31	548	92.9	112	7	ADc35319	Anti-Idio
32	548	92.9	114	8	ADP84938	Variable
33	548	92.9	219	8	ADP84966	Murine an
34	548	92.9	219	8	ADP84971	Chimeric
35	548	92.9	257	8	ADP84964	Single ch
36	548	92.9	258	8	ADP84963	Single ch
37	548	92.9	259	8	ADP84962	Single ch
38	548	92.9	260	8	ADP84961	Single ch
39	548	92.9	261	8	ADP84960	Single ch
40	548	92.9	262	8	ADP84959	Single ch
41	548	92.9	263	8	ADP84958	Single ch
42	548	92.9	264	8	ADP84957	Single ch
43	548	92.9	265	8	ADP84956	Single ch
44	548	92.9	266	8	ADP84955	Single ch
45	548	92.9	267	8	ADP84954	Single ch

ALIGNMENTS

RESULT 1  
ID ADJ76888 standard; protein; 112 AA.  
XX  
AC ADJ76888;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-1R related protein #5.  
XX  
KW Cytostatic; antiproliferative; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX  
OS Mus musculus.  
XX  
FN WO2003059951-A2.  
XX  
PD 24-JUL-2003.  
XX  
PF 20-JAN-2003; 2003WO-FR000178.  
XX  
PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX  
PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
PI Goetsch L, Corvaia N, Leger O;  
XX  
DR WPI; 2003-569653/53.  
XX  
PT New antibodies that bind to human insulin-like growth factor receptor,  
PT useful for treatment, prevention and diagnosis of cancers.  
XX  
PS Disclosure; SEQ ID NO 54; 164pp; French.  
XX  
CC The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 112 AA;

Query Match 100.0%; Score 590; DB 7; Length 112;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-45;  
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSILGDAQISCRSSQSIIVHSNGNTYIQWYLQKPGQSPKLLIYKVSNRL 60  
 DB 1 DVLMTQIPLSLPVSILGDAQISCRSSQSIIVHSNGNTYIQWYLQKPGQSPKLLIYKVSNRL 60  
 QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYVCFQGSHPVPTFGGTTKLEIK 112  
 DB 61 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYVCFQGSHPVPTFGGTTKLEIK 112

RESULT 2  
 ID ADZ67058  
 AC ADZ67058 standard; protein; 112 AA.

XX ADZ67058;

XX 30-JUN-2005 (first entry)

DE Murine immunoglobulin light chain variable region 7C10 VL SEQ ID NO:54.

KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW immunoglobulin; light chain variable region.

OS Mus musculus.

XX US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

XX 18-JAN-2002; 2002FR-00000654.

XX 07-MAY-2002; 2002FR-00005753.

XX 20-JAN-2003; 2003WO-FR000178.

XX 11-JUL-2003; 2003FR-00008538.

XX (GORT/) GOETSCH L.

XX (CORV/) CORVAIA N.

XX (LEGE/) LEGER O.

XX (DUF/) DUFLOS A.

XX (HAEU/) HAEUW J.

XX (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.  
 XX  
 XX Example 12; SEQ ID NO 54; 125pp; English.

CC The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.  
 XX

SQ Sequence 112 AA;

Query Match 100.0%; Score 590; DB 9; Length 112;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-45;  
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSILGDAQISCRSSQSIIVHSNGNTYIQWYLQKPGQSPKLLIYKVSNRL 60  
 DB 1 DVLMTQIPLSLPVSILGDAQISCRSSQSIIVHSNGNTYIQWYLQKPGQSPKLLIYKVSNRL 60

QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYVCFQGSHPVPTFGGTTKLEIK 112  
 DB 61 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYVCFQGSHPVPTFGGTTKLEIK 112

RESULT 3

ID ADJ76883

XX ADJ76883 standard; protein; 122 AA.

XX ADJ76883;

XX 06-MAY-2004 (first entry)

XX Anti-IGF-IR related protein #3.

KW Cytostatic; antipsoriatic; antibody;  
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;  
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
 KW CDR.

OS Mus musculus.

XX WO2003059951-A2.

XX 24-JUL-2003.

XX

PF 20-JAN-2003; 2003WO-FR000178.  
 XX 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 XX (FABR ) FABRE MEDICAMENT SA PIERRE.  
 PA  
 XX  
 XX Goetsch L, Corvaia N, Leger O;  
 PI WPI; 2003-569653/53.  
 DR  
 XX  
 XX New antibodies that bind to human insulin-like growth factor receptor,  
 PT useful for treatment, prevention and diagnosis of cancers.  
 XX  
 XX Disclosure; SEQ ID NO 49; 164pp; French.  
 PS  
 XX  
 CC The invention relates to an isolated antibody (Ab), and its functional  
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth  
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
 CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or  
 CC treat diseases associated with overexpression and/or abnormal activity of  
 CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with  
 CC hyperactivity of signal transduction pathways mediated by interaction of  
 CC these receptors with their ligands. Especially they inhibit  
 CC transformation of normal cells to tumor cells, inhibit growth and/or  
 CC proliferation of tumor cells, so are useful against cancers of the  
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a  
 CC protein sequence used to generate the Ab of the invention.  
 XX  
 SQ Sequence 122 AA;  
  
 Query Match 100.08; Score 590; DB 7; Length 122;  
 Best Local Similarity 100.08; Pred. No. 1.3e-45;  
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
 Qy 1 DVLMTQIPLSLPVSLGDAQSISCRSSQSIIVHSNGNTYQLWYLOKPGQSPKLLIYKVSRL 60  
 Db 11 DVLMTQIPLSLPVSLGDAQSISCRSSQSIIVHSNGNTYQLWYLOKPGQSPKLLIYKVSRL 70  
  
 Qy 61 YGVDPFRFSSGSGTDTFLKISSVEAEDLGVIYCFQSGSHVPMTFGGTGLEIK 112  
 Db 71 YGVDPFRFSSGSGTDTFLKISSVEAEDLGVIYCFQSGSHVPMTFGGTGLEIK 122  
  
 RESULT 4  
 ADZ67053  
 ID ADZ67053 standard; protein; 122 AA.  
 XX  
 AC ADZ67053;  
 XX  
 DT 30-JUN-2005 (first entry)  
 XX  
 DE Murine immunoglobulin light chain variable region 7C10 VL SEQ ID NO:49.  
 XX  
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
 KW musculoskeletal disease; respiratory disease; lung tumor;  
 KW endocrine disease; gynecology and obstetrics; breast tumor;  
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
 KW immunoglobulin; light chain variable region.  
 XX  
 OS Mus musculus.  
 XX  
 FH Key Location/Qualifiers  
 FT Peptide 1..10  
 FT /note= "leader peptide"  
 FT 34..49  
 FT Region  
 FT /note= "CDR1"

FT Region 65..71  
 FT /note= "CDR2"  
 FT Region 104..111  
 FT /note= "CDR3"  
 XX  
 XX US2005084906-A1.  
 XX  
 XX 21-APR-2005.  
 XX  
 XX 16-DEC-2003; 2003US-00735916.  
 XX  
 XX 18-JAN-2002; 2002FR-00000653.  
 PR 18-JAN-2002; 2002FR-00000654.  
 PR 07-MAY-2002; 2002FR-00005753.  
 PR 20-JAN-2003; 2003WO-FR000178.  
 PR 11-JUL-2003; 2003FR-00008538.  
 XX  
 XX (GOET/ GOETSCH L.  
 PA (CORV/ CORVAIA N.  
 PA (LSGE/ Leger O.  
 PA (DUFL/ DUFLOS A.  
 PA (HAUJ/ HAEUW J.  
 PA (BECK/ BECK A.  
 XX  
 XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
 PI WPI; 2005-321968/33.  
 XX N-PSDB; ADZ67052.  
 DR  
 XX  
 XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)  
 PT antibody or its functional fragment, being capable of binding human IGF-  
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,  
 PT useful for treating cancer.  
 XX  
 XX Example 8; SEQ ID NO 49; 125pp; English.  
 PS  
 XX The invention relates to a novel isolated anti-insulin-like growth factor  
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being  
 CC capable of binding to human IGF-IR and, if necessary, capable of  
 CC specifically inhibiting tyrosine kinase activity of the receptor,  
 CC comprising a light or heavy chain having at least one complementary  
 CC determining region (CDR) consisting of one of two fully defined 16 amino  
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in  
 CC the preparation of a medicament intended for the prevention or treatment  
 CC of an illness connected with an overexpression and/or an abnormal  
 CC activation of the IGF-IR and/or EGFR, and/or connected with a  
 CC hyperactivation of the transduction pathway of the signal mediated by the  
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where  
 CC the administration of the medicament does not induce or only slightly  
 CC induces secondary effects connected with inhibition of the insulin  
 CC receptor. The antibody is useful for preparation of a medicament intended  
 CC to inhibit the transformation of normal cells into cells with tumoral  
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-  
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is  
 CC useful for preparation of a medicament intended to inhibit the growth  
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,  
 CC especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or  
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a  
 CC medicament intended for prevention or for the treatment of cancer, where  
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,  
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the  
 CC preparation of a medicament intended for the prevention or for the  
 CC treatment of psoriasis. (I) is useful in preparation of a medicament  
 CC intended for the specific targeting of a biologically active compound to  
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)  
 CC is useful for in vitro diagnosis of illnesses induced by an  
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor  
 CC starting from a biological sample in which the abnormal presence, of IGF-  
 CC IR and/or EGFR receptor is suspected, which involves contacting the  
 CC biological sample with (I), which is optionally labeled. The present  
 CC sequence is used in the exemplification of the invention.  
 XX  
 SQ Sequence 122 AA;

Query Match 100.0%; Score 590; DB 9; Length 122;  
Best Local Similarity 100.0%; Pred. No. 1.3e-45;  
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLQWYLPQPGQSPKLLIYKVSNRL 60  
DB 11 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLQWYLPQPGQSPKLLIYKVSNRL 70

QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYFCQGSHPVMTFGGTTKLEIK 112  
DB 71 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYFCQGSHPVMTFGGTTKLEIK 122

RESULT 5  
ADD94125  
ID ADD94125 standard; protein; 112 AA.

AC ADD94125;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Mouse HUI77 variable region light chain partial amino acid sequence.  
XX  
KW grafted antibody; complementarity determining region; CDR; light CDR;  
XX heavy CDR; cryptic collagen epitope; solid tumour;  
KW new blood vessel growth; angiogenesis; tumour growth; cytostatic;  
KW collagen agonist; collagen antagonist; cancer metastasis;  
KW anti-cryptic collagen; antibody; HUI77; variable region light chain;  
KW mouse; murine.  
XX  
OS Mus musculus.  
XX  
FN WO2003046204-A2.  
XX  
PD 05-JUN-2003.  
XX  
PF 26-NOV-2002; 2002WO-US038147.  
XX  
PR 26-NOV-2001; 2001US-00995529.  
XX  
PR 06-DEC-2001; 2001US-00011250.  
XX  
PA (CELL-) CELL MATRIX INC.  
XX  
PI Watking JD, Huse WD, Tang Y, Broek D, Brooks PC;  
XX  
DR WPI; 2003-513649/48.  
DR N-PSDB; ADD94124.  
XX

XX New cryptic collagen antibody with one or more complementarity  
PT determining regions, useful for diagnosing and treating disorders  
PT associated with angiogenesis, tumor growth and/or cancer metastasis.  
XX  
PS Example 1; SEQ ID NO 10; 232pp; English.  
XX  
CC This invention relates to a novel grafted antibody or its functional  
CC fragment comprising one or more complementarity determining regions  
CC (CDRs) of a defined light CDR and a heavy CDR with at least one amino  
CC acid (aa) substitution where the antibody has specific binding activity  
CC for a cryptic collagen epitope. The growth of all solid tumours requires  
CC new blood vessel growth, angiogenesis, inhibition of which is an approach  
CC to limiting tumour growth. The invention may allow development of  
CC therapeutics with a cytostatic activity as a collagen agonist or  
CC antagonist. The invention is useful for diagnosing and treating disorders  
CC associated with angiogenesis, tumour growth and/or cancer metastasis. The  
CC present sequence is the partial amino acid sequence of the mouse anti-  
CC cryptic collagen site antibody HUI77 variable region light chain used  
CC during the creation of the antibody of the invention.

XX Sequence 112 AA;

Query Match 95.6%; Score 564; DB 7; Length 112;  
Best Local Similarity 95.5%; Pred. No. 2.6e-43;

Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLQWYLPQPGQSPKLLIYKVSNRL 60  
DB 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLQWYLPQPGQSPKLLIYKVSNRL 60

QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYFCQGSHPVMTFGGTTKLEIK 112  
DB 61 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYFCQGSHPVMTFGGTTKLEIK 112

RESULT 6  
ADJ76890  
ID ADJ76890 standard; protein; 112 AA.

AC ADJ76890;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Anti-IGF-1R related protein #7.  
XX  
KW cytostatic; antiproliferative; antibody;  
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;  
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;  
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;  
KW CDR.  
XX  
OS Mus musculus.  
XX  
FN WO2003059951-A2.  
XX  
PD 24-JUL-2003.  
XX  
PF 20-JAN-2003; 2003WO-FR000178.  
XX  
PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
XX  
PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
XX  
PI Goetsch L, Corvaia N, Leger O;  
XX  
DR WPI; 2003-569653/53.  
XX  
PT New antibodies that bind to human insulin-like growth factor receptor,  
PT useful for treatment, prevention and diagnosis of cancers.  
XX  
PS Disclosure; SEQ ID NO 56; 164pp; French.

XX The invention relates to an isolated antibody (Ab), and its functional  
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-  
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth  
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine  
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or  
CC treat diseases associated with overexpression and/or abnormal activity of  
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with  
CC hyperactivity of signal transduction pathways mediated by interaction of  
CC these receptors with their ligands. Especially they inhibit  
CC transformation of normal cells to tumor cells, inhibit growth and/or  
CC proliferation of tumor cells, so are useful against cancers of the  
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and  
CC also for treating psoriasis. Ab are also used to diagnose diseases caused  
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a  
CC protein sequence used to generate the Ab of the invention.

XX Sequence 112 AA;

Query Match 95.6%; Score 564; DB 7; Length 112;  
Best Local Similarity 95.5%; Pred. No. 2.6e-43;  
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLQWYLPQPGQSPKLLIYKVSNRL 60

Db 1 DVLMTQTPSLPVSIGDQASISCRSSQSVHSNGNTYLEWYLOKFGQSPKLLIYKVSNR 60  
Qy 61 YGVPRFSGSGSGTDTFLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112  
Db 61 SGVPRFSGSGSGTDTFLKISRVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 7  
ADZ67060  
ID ADZ67060 standard; protein; 112 AA.  
XX  
AC ADZ67060;  
XX  
DT 30-JUN-2005 (first entry)  
XX  
DE Mouse antibody light chain variable region SEQ ID NO:56.  
XX  
KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;  
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;  
KW musculoskeletal disease; respiratory disease; lung tumor;  
KW endocrine disease; gynecology and obstetrics; breast tumor;  
KW endometroid carcinoma; gastrointestinal disease; colon tumor;  
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;  
KW light chain variable region.  
XX  
OS Mus musculus.  
XX  
PN US2005084906-A1.  
XX  
PD 21-APR-2005.  
XX  
PF 16-DEC-2003; 2003US-00735916.  
XX  
PR 18-JAN-2002; 2002FR-00000653.  
PR 18-JAN-2002; 2002FR-00000654.  
PR 07-MAY-2002; 2002FR-00005753.  
PR 20-JAN-2003; 2003WO-FR000178.  
PR 11-JUL-2003; 2003FR-00008538.  
XX  
(GOET/) GOETSCH L.  
PA (CORV/) CORVAIA N.  
PA (LEGE/) LEGER O.  
PA (DUFL/) DUFLOS A.  
PA (HAEU/) HAEUW J.  
PA (BECK/) BECK A.  
XX  
Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;  
WPI; 2005-321968/33.

Novel isolated anti-insulin-like growth factor I receptor (IGF-IR) antibody or its functional fragment, being capable of binding human IGF-IR and specifically inhibiting tyrosine kinase activity of receptor, useful for treating cancer.

Example 12; SEQ ID NO 56; 125pp; English.

The invention relates to a novel isolated anti-insulin-like growth factor I receptor (IGF-IR) antibody (I) or its functional fragment, being capable of binding to human IGF-IR and, if necessary, capable of specifically inhibiting tyrosine kinase activity of the receptor, comprising a light or heavy chain having at least one complementary determining region (CDR) consisting of one of two fully defined 16 amino acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in the preparation of a medicament intended for the prevention or treatment of an illness connected with an overexpression and/or an abnormal activation of the IGF-IR and/or EGFR, and/or connected with a hyperactivation of the transduction pathway of the signal mediated by the interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where the administration of the medicament does not induce or only slightly induces secondary effects connected with inhibition of the insulin receptor. The antibody is useful for preparation of a medicament intended

to inhibit the transformation of normal cells into cells with tumoral character, preferably IGF-dependent, especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is useful for preparation of a medicament intended to inhibit the growth and/or the proliferation of tumor cells, preferably IGF-dependent, especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is useful in the preparation of a medicament intended for prevention or for the treatment of cancer, where the cancer is chosen from prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer or colon cancer. (I) is useful in the preparation of a medicament intended for the prevention or for the treatment of psoriasis. (I) is useful in preparation of a medicament intended for the specific targeting of a biologically active compound to cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I) is useful for in vitro diagnosis of illnesses induced by an overexpression or an underexpression of the IGF-IR and/or EGFR receptor starting from a biological sample in which the abnormal presence, of IGF-IR and/or EGFR receptor is suspected, which involves contacting the biological sample with (I), which is optionally labeled. The present sequence is used in the exemplification of the invention.

Sequence 112 AA;  
Query Match 95.6%; Score 564; DB 9; Length 112;  
Best Local Similarity 95.5%; Pred. No. 2.6e-43;  
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVLMTQTPSLPVSIGDQASISCRSSQSVHSNGNTYLEWYLOKFGQSPKLLIYKVSNR 60  
Db 1 DVLMTQTPSLPVSIGDQASISCRSSQSVHSNGNTYLEWYLOKFGQSPKLLIYKVSNR 60  
Qy 61 YGVPRFSGSGSGTDTFLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112  
Db 61 SGVPRFSGSGSGTDTFLKISRVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 8  
AAE15704  
ID AAE15704 standard; protein; 112 AA.  
XX  
AC AAE15704;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Mouse monoclonal antibody alpha 340 light chain variable (VK) region.  
XX  
KW Mouse; humanised form; monoclonal antibody alpha 340; gene therapy;  
KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;  
KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;  
KW inhibitor.  
XX  
OS Mus sp.  
XX  
FH Key  
FH Region  
FT  
FT /label= CDR1  
FT /note= "Complementarity determining region 1"  
FT  
FT /label= CDR2  
FT /note= "Complementarity determining region 2"  
FT  
FT /label= CDR3  
FT /note= "Complementarity determining region 3"  
XX  
WO2001188138-A1.  
PD 22-NOV-2001.  
XX  
PF 21-MAY-2001; 2001WO-GB002226.  
XX  
PR 19-MAY-2000; 2000GB-00011981.  
PR 24-AUG-2000; 2000GB-00020794.  
XX

```

PA (SCAN-) SCANCELL LTD.
XX
XX Ellis JRM, Durrant LG;
XX
XX WPI; 2002-062384/08.
DR N-PSDB; AAD25247.
XX
XX New humanized form of mouse monoclonal antibody 340 which binds to
PT epidermal growth factor receptor and inhibits binding of growth factor.
PT useful for treating colorectal, lung, breast, gastric and ovarian cancer.
XX
XX Claim 6; Fig 2; 53pp; English.
XX
XX The present invention relates to a humanised form of the antibody 340 (a
CC mouse monoclonal antibody which binds to epidermal growth factor (EGF)
CC receptor and inhibits binding of EGF), obtainable from the cell line
CC deposited with the ECACC under accession number 97021428. The humanised
CC form of the antibody 340 is useful in gene therapy, medicine and in the
CC manufacture of a medicament for treatment or prophylaxis of cancer. The
CC invention is useful for treating colorectal, lung, breast, gastric or
CC ovarian cancers or also for preventing the recurrence of cancer after
CC initial treatment or surgery. The invention is also useful for enhancing
CC a protective immune response against cancer by optimised immunisation
CC schedules. The humanised form of the antibody 340 has reduced
CC immunogenicity but shows similar binding to cells expressing EGF
CC receptor, as the original murine antibody and has increased ability to
CC inhibit the growth of EGF receptor expressing cells. The invention is
CC used as cell growth and apoptosis inhibitor. The present sequence is
CC mouse monoclonal antibody alpha 340 light chain variable (VK) region
XX
XX Sequence 112 AA;
SQ
Query Match 94.6%; Score 558; DB 5; Length 112;
Best Local Similarity 94.6%; Pred. No. 9.1e-43;
Matches 105; Conservative 2; Mismatches 4; Indels 0; Gaps 0;
QY 1 DVLMTQITPLSLPVSLGDAQSIICRSSQSIIVHSNGNTYQLQWYLPQPGQSPKLLIYKVSNNRL 60
DB 1 DVLMTQITPLSLPVSLGDAQSIICRSSQSIIVHSNGNTYQLQWYLPQPGQSPKLLIYKVSNNRF 60
QY 61 YGVDPDRFSGSGGTDFTLKISVVEADLGVIYFCQGSHPVPTFGGTTKLEIK 111
DB 61 SGVDPDRFSGSGGTDFTLKISVVEADLGVIYFCQGSHPVPTFGGTTKLEIK 111
RESULT 9
AEB21358
ID AEB21358 standard; protein; 114 AA.
XX
XX AEB21358;
XX
XX 22-SEP-2005 (first entry)
XX
XX Mouse anti-IL-13 antibody 227-26 light chain variable region (VK).
XX
XX Interleukin-13; IL-13; antibody engineering; humanized antibody;
XX Antiasthmatic; Antiinflammatory; Dermatological; Antiallergic;
XX Respiratory-Gen.; Antiulcer; Gastrointestinal-Gen.; Ophthalmological;
XX Osteopathic; Virucide; asthma; allergic rhinitis; atopic dermatitis;
XX allergic conjunctivitis; eczema; urticaria; allergy;
XX chronic obstructive pulmonary disease; ulcerative colitis;
XX respiratory syncytial virus infection; uveitis; scleroderma;
XX osteoporosis; monoclonal antibody; light chain variable region.
XX
XX Mus sp.
XX
XX WO2005062967-A2.
XX
XX 14-JUL-2005.
XX
XX 23-DEC-2004; 2004WO-US043501.
XX
XX 23-DEC-2003; 2003US-0532130P.
XX

```

---

```

XX (TANO-) TANOX INC.
XX
XX Fung SC, Moyle M, Lu M, Yan C, Singh S, Huang D;
XX
XX WPI; 2005-506603/51.
XX
XX New antibody or its antigen-binding fragment that binds specifically and
PT with high affinity to glycosylated and non-glycosylated human interleukin
PT -13 (IL-13), useful for treating IL-13-mediated disorders, such as asthma
PT and eczema.
XX
XX Claim 10; SEQ ID NO 7; 129pp; English.
XX
XX The invention relates to an antibody or its antigen-binding fragment that
CC binds specifically and with high affinity to glycosylated and non-
CC glycosylated human interleukin-13 (IL-13), does not bind mouse IL-13, and
CC neutralizes human IL-13 activity at an approximate molar ratio of 1:2
CC (Mab:IL13). Also included are an antibody that binds to the same epitope
CC as the antibody cited above, an antibody comprising antigen binding
CC regions derived from the light and heavy chain variable regions of the
CC novel antibody, a hybridoma cell line that produces a monoclonal antibody
CC (selected from 228B/C-1, 228A-4, 227-26, and 227-43 and designated with
CC the ATCC deposit number PTA-5657, PTA-5656, PTA-5654, and PTA-5655,
CC respectively), a cell line comprising a nucleic acid encoding the
CC antibody, a vector comprising the nucleic acid encoding the antibody, a
CC composition (comprising the antibody and a physiologically acceptable
CC carrier, diluent, excipient, or stabilizer), a variable light chain
CC region (comprising an amino acid sequence having the formula: FRL1-CDRL1-
CC FRL2-CDRL2-FRL3-CDRL3-FRL4) a variable heavy chain region (comprising an
CC amino acid sequence having the formula: FRH1-CDRH1-FRH2-CDRH2-FRH3-CDRH3-
CC FRH4), an antibody (or its antigen binding fragment, comprising the
CC variable light or heavy chain region, where the antibody binds
CC specifically to IL-13), treating a subject suffering from asthmatic
CC symptoms (comprising administering an antibody to reduce the asthmatic
CC symptoms), an inhalation device that delivers the antibody to a patient,
CC detecting interleukin-13 protein in a sample, diagnosing overexpression
CC of IL-13 in a subject, producing the antibody, a recombinant antibody
CC molecule (or an IL-13-binding fragment, comprising at least one antibody
CC heavy chain, or an IL-13-binding fragment, comprising non-human CDRA at
CC positions 31-35 (CDR1), 50-65 (CDR2) and 95-102 (CDR3) (Kabat numbering)
CC from a mouse anti-IL-13 antibody, where positions 27-30 have the amino
CC acid Gly 26, Phe 27, Ser 28, Leu 29, Asn 30), and at least one antibody
CC light chain (or an IL-13-binding fragment, comprising non-human CDRA at
CC positions 24-34 (CDR1), 50-56 (CDR2) and 89-97 (CDR3) from a mouse anti-
CC IL13 antibody and framework regions from a monoclonal antibody), a vector
CC comprising the DNA sequence, a host cell comprising the vector,
CC inhibiting IgG antibody production in a patient, treating an IL-13-
CC mediated disorder in a patient, reducing the severity of asthma in a
CC mammal, and an IL-13 epitope peptide appearing as AEB21369 or AEB21370.
XX The antibody and methods are useful for treating IL-13-mediated
XX disorders, such as allergic asthma, non-allergic (intrinsic) asthma,
XX allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema,
XX urticaria, food allergies, chronic obstructive pulmonary disease,
XX ulcerative colitis, RSV infection, uveitis, scleroderma, or osteoporosis.
XX The present sequence represents a the light chain variable region of a
XX mouse anti-IL-13 monoclonal antibody.
XX
XX Sequence 114 AA;
SQ
Query Match 94.6%; Score 558; DB 9; Length 114;
Best Local Similarity 95.5%; Pred. No. 9.3e-43;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
QY 1 DVLMTQITPLSLPVSLGDAQSIICRSSQSIIVHSNGNTYQLQWYLPQPGQSPKLLIYKVSNNRL 60
DB 1 DVLMTQITPLSLPVSLGDAQSIICRSSQSIIVHSNGNTYQLQWYLPQPGQSPKLLIYKVSNNRF 60
QY 61 YGVDPDRFSGSGGTDFTLKISVVEADLGVIYFCQGSHPVPTFGGTTKLEIK 112
DB 61 SGVDPDRFSGSGGTDFTLKISVVEADLGVIYFCQGSHPVPTFGGTTKLEIK 112

```

```

CC associated with a cytotoxic agent, such as a radioisotope or a
CC chemotherapeutic agent. The methods and antibodies are useful for
CC treating neoplasms such as Hodgkin's lymphoma, skin cancer, stomach
CC cancer, colon cancer, breast cancer, pancreatic cancer, liver cancer,
CC prostate cancer, lung cancer, head-and-neck cancer, renal cell cancer,
CC squamous cell carcinoma, AIDS-associated Kaposi's carcinoma and brain
CC cancer. This sequence represents the humanized mouse monoclonal antibody
CC 227-26 and 227-26-1 variable light chain.
XX
SQ Sequence 114 AA;
Query Match 94.6%; Score 558; DB 9; Length 114;
Best Local Similarity 95.5%; Pred. No. 9.3e-43;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0
QY 1 DVLMTQIPLSLPVSILGDOQASISCRSSQSI VHSNGNTYLYWLYQKPGQSPKLLIYKVSNRL 60
DB 1 DVLMTQTPLSLPVSILGDOQASISCRSSQSI VHSNGNTYLYWLYQKPGQSPKLLIYKVSNRF 60
QY 61 YGVPRFSGSGSGTDFTLKISSVEAEGLGVYFCQGSHPVPTFGGTTKLEIK 112
DB 61 SGVPRFSGSGSGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 112
RESULT 11
AD126498
ID AD126498 standard; protein; 114 AA.
XX AC AD126498;
XX XX
DT 15-APR-2004 (first entry)
XX DE Human ECL2B-4-L SEQ ID NO:34.
XX XX
KW antibody; enzyme; virucide; anti-HIV; cytostatic; antibacterial;
KW helicobacter pylori urasee inhibitor;
KW chemokine receptor CCR-5 antagonist; cancer; infectious disease;
KW Helicobacter pylori; HIV; human.
XX XX
OS Homo sapiens.
XX XX
PN WO2004009805-A1.
XX XX
PD 29-JAN-2004.
XX XX
PR 18-JUL-2003; 2003WO-JP009147.
XX XX
PR 19-JUL-2002; 2002JP-00211756.
PR 19-JUL-2002; 2002JP-00211768.
PR 27-FEB-2003; 2003JP-00051943.
PR 17-JUL-2003; 2003JP-00198270.
PR 17-JUL-2003; 2003JP-00198281.
PR 17-JUL-2003; 2003JP-00198292.
XX XX
PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
XX XX
PI Uda T, Hifumi E;
XX XX
WPI: 2004-132963/13.
DR N-PSDB; AD126499.
XX XX
Screening potential antibody enzymes by identification of a catalytic
PT triplet residue in the stereostructure for production of antibody enzymes
PT as diagnostic and therapeutic agents for cancer and infectious diseases
PT including HIV infection.
XX XX
Claim 41; SEQ ID NO 34; 232pp; Japanese.
XX XX
The invention relates to a novel method for producing antibody enzymes
CC comprising a structural analysis step which confirms the existence in the
CC predicted stereostructure of the antibody based on its amino acid
CC sequence of a catalytic triplet residue structure in which a serine
CC residue, an aspartic acid residue, and a histidine or glutamic acid

```



CC lysine-rich region and/or a multimerisation domain, most particularly it  
 CC is a single-chain antibody fragment, multibody, Fab fragment, fusion  
 CC protein of an antibody fragment with peptide or protein, and/or an Ig of  
 CC types G, M, A, E or D and/or their subclasses. It may be human,  
 CC humanised, murine or chimeric, e.g. IgM without the J chain. The  
 CC additional sequences/structures in the constructs are Ig domains of  
 CC various species, interacting or stabilising domains, signal sequences,  
 CC fluorescent dyes, toxins, antibodies with catalytic activity or other  
 CC specificities, cytolytic agents, enzymes, immuno-modulators or -  
 CC effectors, MHC molecules, antigens, chelators for radioactive labels,  
 CC liposomes, transmembrane domains, viruses and/or cells, specifically  
 CC macropages. The antibodies, also constructs containing them, nucleic  
 CC acid encoding them, and related vectors and host cells, are useful for  
 CC prevention (e.g. as vaccine), diagnosis, alleviation, treatment,  
 CC monitoring and/or secondary treatment of tumours (specifically of breast,  
 CC colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,  
 CC prostate, kidney and/or liver) and/or metastases (particularly to liver),  
 CC specifically where these are positive for the C1 antigen. The products of  
 CC the invention provide simple, reliable and efficient detection of  
 CC tumours. They are specific for carcinoma and show almost no binding to  
 CC healthy tissue.

XX SQ Sequence 114 AA;

Query Match 94.1%; Score 555; DB 8; Length 114;  
 Best Local Similarity 94.6%; Pred. No. 1.7e-42;  
 Matches 106; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDOASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSNRL 60  
 DB 1 DVLMTQIPLSLPVSLGDOASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSNRF 60  
 QY 61 YGVPRFSGSGSGTDTFLKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112  
 DB 61 SGVPRFSGSGSGTDTFLKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 14

AEC21825  
 ID AEC21825 standard; protein; 139 AA.

AC AEC21825;

XX 20-OCT-2005 (first entry)

XX Mouse light chain variable region amino acid sequence SEQ ID NO:1.

XX chimeric antibody; basic fibroblast growth factor;  
 KW light chain variable region; pulmonary fibrosis.

XX Mus sp.

XX CN1560082-A.

XX 05-JAN-2005.

XX 08-MAR-2004; 2004CN-00015583.

XX 08-MAR-2004; 2004CN-00015583.

XX (UYJI-) UNIV JINAN.

XX Xiang J, Deng N, Li H;

XX WPI; 2005-296785/31.

DR N-PSDB; AEC21824.

XX Chimeric antibody specific for human basic fibroblast growth factor,  
 PT useful for preventing and treating pneumosilicosis.

XX Claim 2; SEQ ID NO 1; 17pp; Chinese.

XX The invention relates to a chimeric antibody specific for human basic

CC fibroblast growth factor (bFGF) and its encoding gene. The chimeric  
 CC antibody contains mouse variable regions and human constant regions of  
 CC human IgG1C. The antibody is useful for preventing and treating  
 CC pneumosilicosis. The present sequence represents a mouse light chain  
 CC variable region which can be used in a chimeric antibody of the  
 CC invention.

XX SQ Sequence 139 AA;

Query Match 94.1%; Score 555; DB 9; Length 139;  
 Best Local Similarity 94.6%; Pred. No. 2.2e-42;  
 Matches 106; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDOASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSNRL 60  
 DB 20 DVLMTQIPLSLPVSLGDOASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSNRF 79

QY 61 YGVPRFSGSGSGTDTFLKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112

DB 80 SGVPRFSGSGSGTDTFLKISRVEADLGVIYCFQGSHPVPTFGGTTKLEIK 131

RESULT 15

ADS88785

ID ADS88785 standard; protein; 238 AA.

AC ADS88785;

XX 16-DEC-2004 (first entry)

XX Sequence of the chimeric IC2 kappa light chain in M13mp19 clone M609.

XX G glycoprotein; respiratory syncytial virus;

KW respiratory syncytial virus infection; RSV; RSV infection; IC2; IgG1;  
 KW chimeric.

XX Mus sp.

OS Homo sapiens.

OS Chimeric.

XX Key Location/Qualifiers

FT Peptide 1..19  
 FT /note= "Ig leader sequence"

XX WO2004083373-A2.

XX 30-SEP-2004.

XX 22-MAR-2004; 2004WO-GB001239.

XX 22-MAR-2003; 2003GB-00006618.

XX (UYNE-) UNIV NEWCASTLE-UPON-TYNE.

XX Toms G, Routledge E, Mekseepralarad C;

XX WPI; 2004-691033/67.

DR N-PSDB; ADS88784.

XX New antibody against the G glycoprotein of RSV with a variable region  
 PT having a first and second domain from a VL and VH region, respectively,  
 PT useful for treating respiratory syncytial virus (RSV) infections.

XX Example 4; SEQ ID NO 55; 93pp; English.

XX The specification describes an against the G glycoprotein of respiratory  
 CC syncytial virus, with a variable region comprising a first domain from a  
 CC variable light chain region and a second domain a variable heavy chain  
 CC region. The antibodies of the invention are useful for treating and  
 CC preventing the development of infections caused by the respiratory  
 CC syncytial virus (RSV). The present sequence represents the chimeric IC2  
 CC kappa light chain carried by pEE12 plasmid p533. IC2 is a murine  
 CC monoclonal antibody known to bind to the RSV G glycoprotein. The above

CC clone carries a mouse-human IgG1 chimeric antibody comprising IC2  
CC variable regions and human kappa light chain and gamma1 heavy chain  
CC constant regions.

XX  
SQ Sequence 238 AA;

Query Match 94.1%; Score 555; DB 8; Length 238;  
Best Local Similarity 92.9%; Pred. No. 3.8e-42;  
Matches 104; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVLMTQIPFLSLPVLGLDQASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60  
Db 20 DVLMTQIPFLSLPVLGLDQASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPKLLIYKVSRL 79

Qy 61 YGVDPDRFSGSGGTDFTLKISSVRAEDIGVYFCFGSHVPWTFGGGTKLEIK 112

Db 80 SGVDPDRFSGSGGTDFTLKISRVEAEDLGVYFCFGSHIPWTFGGGTKLEIK 131

Search completed: January 10, 2006, 20:44:13  
Job time : 79.3134 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 13.5124 Seconds  
(without alignments)  
797.508 Million cell updates/sec

Title: US-10-735-916A-54  
Perfect score: 590  
Sequence: 1 DVLMTQIPLSLPVSLGDAQS.....CFQGSHPVPTFGGTYKLEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	549	93.1	131	2 B39276	Ig kappa chain pre
2	547	92.7	112	2 A31807	Ig kappa chain v r
3	547	92.7	219	2 FC4203	Ig kappa chain (no
4	546	92.5	110	2 S26335	Ig kappa chain v r
5	542	91.9	113	2 PL0203	anti-DNA autoantib
6	540	91.5	219	2 S52028	Ig kappa chain - m
7	536	90.8	118	2 PT0359	Ig kappa chain v r
8	536	90.8	131	2 B34904	Ig kappa chain pre
9	535	90.7	112	2 F27887	Ig kappa chain v r
10	535	90.7	114	2 A32967	Ig kappa chain v-I
11	534	90.5	112	2 B31485	Ig kappa chain v r
12	533	90.3	112	2 S38719	Ig kappa chain v r
13	532	90.2	131	2 C34904	Ig kappa chain pre
14	531	90.0	225	2 JL0029	Ig kappa chain pre
15	530	89.8	112	2 A27887	Ig kappa chain v r
16	528	89.5	112	2 D28195	Ig kappa chain v r
17	527	89.3	112	2 E27887	Ig kappa chain v r
18	527	89.3	112	2 C27887	Ig kappa chain v r
19	527	89.3	219	2 S16112	Ig kappa chain v-I
20	526	89.2	114	2 B32967	Ig kappa chain v-I
21	526	89.2	131	2 B32513	Ig kappa chain pre
22	524	88.8	112	2 A49715	Ig kappa chain v r
23	522	88.5	112	2 S53750	antibody Fab Jel 1
24	521	88.3	112	2 S32189	Ig kappa chain v r
25	521	88.3	115	2 S38715	Ig kappa chain v r
26	521	88.3	131	2 S09259	Ig kappa chain pre
27	519	88.0	114	2 A34353	anti-peptide Fab
28	518	87.8	112	2 D27887	Ig kappa chain v r
29	518	87.8	131	2 D34904	Ig kappa chain pre

ALIGNMENTS

RESULT 1

B39276

Ig light chain precursor V-D-J region (6-19) - mouse

C:Species: Mus musculus (house mouse)

C>Date: 18-Oct-1991 #sequence\_revision 18-Oct-1991 #text\_change 21-Jan-2000

C:Accession: B39276

R:Reininger, L.; Berney, T.; Shibata, T.; Spertini, F.; Merino, R.; Izui, S.

Proc. Natl. Acad. Sci. U.S.A. 87, 10038-10042, 1990

A:Title: Cryoglobulinemia induced by a murine IgG3 rheumatoid factor: skin vasculitis a

A:Reference number: A39276; MUID:91088540; PMID:2263605

A:Accession: B39276

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-131 <REI>

A:Cross-references: UNIPARC:UPI0000115153; GB:M55313; NID:9198095; PIDN:AAA63385.1; PID

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: immunoglobulin

F:35-114/Domain: immunoglobulin homology <IMM>

Query Match 93.1%; Score 549; DB 2; Length 131;

Best Local Similarity 93.8%; Pred. No. 3.3e-43;

Matches 105; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQSISCRSSQSIIVHNGNTYQLQWYLPKQSQSKLLIYKVSRL 60

Db 20 DVLMTQIPLSLPVSLGDAQSISCRSSQSIIVHNGNTYQLQWYLPKQSQSKLLIYKVSRL 79

QY 61 YGVDPDRFSGSGSDTFTLKISSVEAEDLGYYVYCFQGSHPVPTFGGTYKLEIK 112

Db 80 YGVDPDRFSGSGSDTFTLKISSVEAEDLGYYVYCFQGSHPVPTFGGTYKLEIK 131

RESULT 2

A31807

Ig kappa chain V region (PAC1) - mouse

C:Species: Mus musculus (house mouse)

C>Date: 20-Jul-1989 #sequence\_revision 20-Jul-1989 #text\_change 09-Jul-2004

C:Accession: A31807

R:Taub, R.; Gould, R.J.; Garasky, V.M.; Ciccarone, T.M.; Hoxie, J.; Friedman, P.A.; Shatt

J. Biol. Chem. 264, 259-265, 1989

A:Title: A monoclonal antibody against the platelet fibrinogen receptor contains a sequ

A:Reference number: A31807; MUID:89079661; PMID:2909518

A:Accession: A31807

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-112 <TAU>

A:Cross-references: UNIPROT:Q9M37; UNIPARC:UPI00001424F9

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotrimer; immunoglobulin

F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 92.7%; Score 547; DB 2; Length 112;

Best Local Similarity 92.9%; Pred. No. 4.3e-43;  
Matches 104; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60  
Db |||||  
1 DVLMTQTPLSLPVSLGDAQASISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSNR 60  
QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYFCQGSHPVPTFGGTTKLEIK 112  
Db |||||  
61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 3  
PC4203  
Ig kappa chain (monoclonal antibody MAbA34) - mouse (fragment)  
C:Species: Mus musculus (house mouse)  
C>Date: 31-Dec-1996 #sequence\_revision 31-Dec-1996 #text\_change 11-Jan-2000  
C:Accession: PC4203  
R:Kwak, J.W.; Lee, D.I.; Choi, B.K.; Cho, W.K.; Lee, S.H.; Park, Y.B.; Han, M.H.  
Gene 173, 257-259, 1996  
A:Title: Cloning and characterization of cDNAs coding for heavy and light chains of a m  
A:Reference number: PC4202; MUID:97082978; PMID:8964510  
A:Accession: PC4203  
A:Molecule type: mRNA  
A:Residues: 1-219 <KWA>  
A:Cross-references: UNIPARC:UPI00001157E4; GB:U29147; NID:G1594225; PIDN:AAC52821.1; PID  
C:Comment: This protein is specific for human plasma apolipoprotein A-I of high-density  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
F:112/Domain: V region #status predicted <VRG>  
F:113-219/Domain: C region #status predicted <CRG>

Query Match 92.7%; Score 547; DB 2; Length 219;  
Best Local Similarity 93.8%; Pred. No. 8.7e-43; Mismatches 5; Indels 0; Gaps 0;  
Matches 105; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60  
Db |||||  
1 DVLMTQTPLSLPVSLGDAQASISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSNR 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYFCQGSHPVPTFGGTTKLEIK 112  
Db |||||  
61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 4  
S26335  
Ig kappa chain V region - mouse  
C:Species: Mus musculus (house mouse)  
C>Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 20-Jun-2000  
C:Accession: S26335  
R:Stark, S.E.; Caton, A.J.  
J. Exp. Med. 174, 613-624, 1991  
A:Title: Antibodies that are specific for a single amino acid interchange in a protein e  
A:Reference number: S26309; MUID:91341421; PMID:1908510  
A:Accession: S26335  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-110 <STA>  
A:Cross-references: UNIPARC:UPI0000115F78; EMBL:X59183; NID:g52314; PIDN:CRA41893.1; PID  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 92.5%; Score 546; DB 2; Length 110;  
Best Local Similarity 94.5%; Pred. No. 5.2e-43;  
Matches 104; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60  
Db |||||  
1 DVLMTQTPLSLPVSLGDAQASISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSNR 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYFCQGSHPVPTFGGTTKLE 110  
Db |||||

Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYFCQGSHPVPTFGGTTKLE 110

RESULT 5  
PL0203  
anti-DNA autoantibody BV17-31, kappa chain V region - mouse (fragment)  
C:Species: Mus musculus (house mouse)  
C>Date: 20-Feb-1995 #sequence\_revision 20-Feb-1995 #text\_change 21-Jan-2000  
C:Accession: PL0203  
R:Smith, R.G.; Voss Jr., E.W.  
Mol. Immunol. 27, 463-470, 1990  
A:Title: Variable region primary structures of monoclonal anti-DNA autoantibodies from n  
A:Reference number: PL0198; MUID:90309768; PMID:2114528  
A:Accession: PL0203  
A:Molecule type: mRNA  
A:Residues: 1-113 <SMI>  
A:Cross-references: UNIPARC:UPI0000113786; GB:X53643; NID:g50196; PIDN:CMA37694.1; PID:5  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
F:16-95/Domain: immunoglobulin homology <IMM>  
F:24-39/Region: complementarity-determining 1  
F:55-61/Region: complementarity-determining 2  
F:94-102/Region: complementarity-determining 3  
F:101-113/Region: 2 region

Query Match 91.9%; Score 542; DB 2; Length 113;  
Best Local Similarity 92.0%; Pred. No. 1.2e-42;  
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60  
Db |||||  
1 DVLMTQTPLSLPVSLGDAQASISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSNR 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYFCQGSHPVPTFGGTTKLEIK 112  
Db |||||  
61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 6  
S52028  
Ig kappa chain - mouse  
C:Species: Mus musculus (house mouse)  
C>Date: 07-May-1995 #sequence\_revision 21-Jul-1995 #text\_change 21-Jan-2000  
C:Accession: S52028  
R:van Engelen, F.; Schouten, A.; Moltisoff, J.W.; Roosien, J.; Dirkse, W.G.; Schots, A.;  
submitted to the EMBL Data Library, August 1994  
A:Description: Coordinate expression of antibody subunit genes yields high levels of fur  
A:Reference number: S52028  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-219 <VAN>  
A:Cross-references: UNIPARC:UPI0000114B22; EMBL:L35138; NID:g522336; PIDN:AAA67525.1; P  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 91.5%; Score 540; DB 2; Length 219;  
Best Local Similarity 92.9%; Pred. No. 3.8e-42;  
Matches 104; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60  
Db |||||  
1 DVLMTQTPLSLPVSLGDAQASISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSNR 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYFCQGSHPVPTFGGTTKLEIK 112  
Db |||||  
61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYFCQGSHPVPTFGGTTNLEIK 112

RESULT 7  
PT0359  
Ig kappa chain V region (R4A.12) - mouse (fragment)  
C:Species: Mus musculus (house mouse)

C>Date: 31-Mar-1992 #sequence\_revision 31-Mar-1992 #text\_change 09-Jul-2004  
C:Accession: PT0359  
R:Shefner, R.; Kleiner, G.; Turken, A.; Papazian, L.; Diamond, B.  
J. Exp. Med. 173, 287-296, 1991  
A:Title: A novel class of anti-DNA antibodies identified in BALB/c mice.  
A:Reference number: PT0352; MUID:91108325; PMID:1988536  
A:Accession: PT0359  
A:Molecule type: mRNA  
A:Residues: 1-118 <SHE>  
A:CROSS-references: UNIPROT:Q8VC16; UNIPARC:UPI0000176AF2  
A:Experimental source: strain BALB/c  
C:Comment: This protein is an anti-double-stranded DNA antibody.  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
F:19-98/Domain: immunoglobulin homology <IMM>  
  
Query Match 90.8%; Score 536; DB 2; Length 118;  
Best Local Similarity 90.2%; Pred. No. 4.5e-42;  
Matches 101; Conservative 4; Mismatches 7; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60  
DB 4 DVMVTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 63  
  
QY 61 YGVPRFSGSGSGTDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 112  
DB 64 SGVPDRFSGSGSGTDTFTLKISRVEAEDLGVYFCSQSTHVPWTFGGTTKLEIK 115  
  
RESULT 8  
B34904  
Ig kappa chain precursor V region (12-40 and 5-14) - mouse  
C:Species: Mus musculus (house mouse)  
C>Date: 27-Jul-1990 #sequence\_revision 27-Jul-1990 #text\_change 21-Jul-2000  
C:Accession: B34904; H34903  
R:Bedzyk, W.D.; Herron, J.N.; Edmundson, A.B.; Voss Jr., E.W.  
J. Biol. Chem. 265, 133-138, 1990  
A:Title: Active site structure and antigen binding properties of idiotypically cross-reacting antibodies to a murine kappa chain V region.  
A:Reference number: A34903; MUID:90094387; PMID:2104617  
A:Accession: B34904  
A:Status: preliminary; not compared with conceptual translation  
A:Molecule type: mRNA  
A:Residues: 1-131 <BED>  
A:CROSS-references: UNIPARC:UPI0000114FC8; GB:M32384; GB:J05237; GB:J05238; NID:G639656;  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:35-114/Domain: immunoglobulin homology <IMM>  
  
Query Match 90.8%; Score 536; DB 2; Length 131;  
Best Local Similarity 90.2%; Pred. No. 5.1e-42;  
Matches 101; Conservative 4; Mismatches 7; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60  
DB 20 DVMVTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 79  
  
QY 61 YGVPRFSGSGSGTDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 112  
DB 80 SGVPDRFSGSGSGTDTFTLKISRVEAEDLGVYFCSQSTHVPWTFGGTTKLEIK 131  
  
RESULT 9  
F27887  
Ig kappa chain V region (HIC5-4D1) - mouse  
C:Species: Mus musculus (house mouse)  
C>Date: 15-Dec-1988 #sequence\_revision 15-Dec-1988 #text\_change 09-Jul-2004  
C:Accession: F27887  
R:Caton, A.J.; Brownlee, G.G.; Staudt, L.M.; Gerhard, W.  
EMBO J. 5, 1577-1587, 1986  
A:Title: Structural and functional implications of a restricted antibody response to a self-antigen.  
A:Reference number: A91043; MUID:86300658; PMID:2427335  
A:Accession: F27887  
A:Molecule type: DNA  
A:Residues: 1-112 <CAT>

A:CROSS-references: UNIPROT:Q9M37; UNIPARC:UPI0000176A19  
A:Experimental source: strain Balb/c  
A:Note: This sequence was determined from the germline gene  
C:Comment: This chain was isolated from a hybridoma protein that binds influenza virus  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>  
  
Query Match 90.7%; Score 535; DB 2; Length 112;  
Best Local Similarity 92.0%; Pred. No. 5.3e-42;  
Matches 103; Conservative 2; Mismatches 7; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60  
DB 1 DVMVTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60  
  
QY 61 YGVPRFSGSGSGTDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 112  
DB 61 SGVPDRFSGSGSGTDTFTLKISRVEAEDLGVYFCSQSTHVPWTFGGTTKLEIK 112  
  
RESULT 10  
A32967  
Ig kappa chain V-II region TE33 - mouse  
C:Species: Mus musculus (house mouse)  
C>Date: 29-Jan-1990 #sequence\_revision 29-Jan-1990 #text\_change 21-Jan-2000  
C:Accession: A32967  
R:Levy, R.; Asgulin, O.; Scherf, T.; Levitt, M.; Anglistter, J.  
Biochemistry 28, 7168-7175, 1989  
A:Title: Probing antibody diversity by 2D NMR: comparison of amino acid sequences, predicted and observed.  
A:Reference number: A32967; MUID:90057406; PMID:2819059  
A:Accession: A32967  
A:Status: preliminary; nucleic acid sequence not shown; not compared with conceptual translation  
A:Molecule type: mRNA  
A:Residues: 1-114 <LEV>  
A:CROSS-references: UNIPARC:UPI0000114F5D; GB:M30481; NID:G197157; PIDN:AAA38935.1; PID  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>  
  
Query Match 90.7%; Score 535; DB 2; Length 114;  
Best Local Similarity 90.2%; Pred. No. 5.4e-42;  
Matches 101; Conservative 5; Mismatches 6; Indels 0; Gaps 0;  
  
QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60  
DB 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60  
  
QY 61 YGVPRFSGSGSGTDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 112  
DB 61 SGVPDRFSGSGSGTDTFTLKISRVEAEDLGVYFCSQSTHVPWTFGGTTKLEIK 112  
  
RESULT 11  
B31485  
Ig kappa chain V region (4-4-20) - mouse (fragment)  
C:Species: Mus musculus (house mouse)  
C>Date: 31-Jul-1989 #sequence\_revision 31-Jul-1989 #text\_change 09-Jul-2004  
C:Accession: B31485  
R:Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.  
J. Biol. Chem. 264, 1565-1569, 1989  
A:Title: Comparison of variable region primary structures within an anti-fluorescein idiotype.  
A:Reference number: A31485; MUID:89109167; PMID:2492278  
A:Accession: B31485  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-112 <BED>  
A:CROSS-references: UNIPROT:Q8VC16; UNIPARC:UPI0000176AF8  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F:16-95/Domain: immunoglobulin homology <IMM>  
  
Query Match 90.5%; Score 534; DB 2; Length 112;

Best Local Similarity 89.3%; Pred. No. 6.5e-42;  
Matches 100; Conservative 6; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYLOWYLQKPGQSPKLLIYKVSRL 60  
DB 1 DVVMTQTPLSLPVSLGDAQASISCRSSQSIHVHNGNTYLRWYLQKPGQSPKLLIYKVSRLF 60  
QY 61 YGVDPDRFSGSGGTFTLKISSVEAEADLGVIYFCQSHVPWTFGGGTGLEIK 112  
DB 61 SGVDPDRFSGSGGTFTLKISRVEAEDLGVYFCQSSTHVPWTFGGGTGLEIK 112

## RESULT 12

S38719  
Ig kappa chain V region - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 20-Jun-2000  
C:Accession: S38719  
R:Cimanis, A.Y.  
submitted to the EMBL Data Library, November 1993  
A:Reference number: S38713  
A:Accession: S38719  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-112 <C1M>  
A:CROSS-references: UNIPARC:UPI0000117543; EMBL:X76021; NID:G416112; PIDN:CAA53608.1; P1  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: immunoglobulin  
F16-95/Domain: immunoglobulin homology <IMM>

Query Match 90.3%; Score 533; DB 2; Length 112;  
Best Local Similarity 90.2%; Pred. No. 8.1e-42;  
Matches 101; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYLOWYLQKPGQSPKLLIYKVSRL 60  
DB 1 DIVMTQTPLSLPVSLGDAQASISCRSSQSIHVHNGNTYLEWYLQKPGQSPKLLIYKVSRLF 60  
QY 61 YGVDPDRFSGSGGTFTLKISSVEAEADLGVIYFCQSHVPWTFGGGTGLEIK 112  
DB 61 SGVDPDRFSGSGGTFTLKISRVEAEDLGVYFCQSSTHVPWTFGGGTGLEIK 112

## RESULT 13

C34904  
Ig kappa chain precursor V region (3-24) - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 27-Jul-1990 #sequence\_revision 27-Jul-1990 #text\_change 09-Jul-2004  
C:Accession: C34904; I31485  
R:Bedzyk, W.D.; Herron, J.N.; Edmundson, A.B.; Voss Jr., E.W.  
J. Biol. Chem. 265, 133-138, 1990  
A:Title: Active site structure and antigen binding properties of idiotypically cross-re  
A:Reference number: A34903; MUID:90094387; PMID:2104617  
A:Accession: C34904  
A>Status: preliminary; not compared with conceptual translation  
A:Molecule type: mRNA  
A:Residues: 1-131 <BED>  
A:CROSS-references: UNIPROT:Q8VCI6; UNIPARC:UPI00001767A8  
R:Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.  
J. Biol. Chem. 264, 1565-1569, 1989  
A:Title: Comparison of variable region primary structures within an anti-fluorescein idi  
A:Reference number: A31485; MUID:89109167; PMID:2492278  
A:Accession: I31485  
A>Status: preliminary  
A:Molecule type: protein  
A:Residues: 20-52 <BE2>  
A:CROSS-references: UNIPARC:UPI00001767A9  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F135-114/Domain: immunoglobulin homology <IMM>

Query Match 90.2%; Score 532; DB 2; Length 131;  
Best Local Similarity 89.3%; Pred. No. 1.2e-41;

Matches 100; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYLOWYLQKPGQSPKLLIYKVSRL 60  
DB 20 DVVMTQTPLSLPVSLGDAQASISCRSSQSIHVHNGNTYLRWYLQKPGQSPKLLIYKVSRLF 79  
QY 61 YGVDPDRFSGSGGTFTLKISSVEAEADLGVIYFCQSHVPWTFGGGTGLEIK 112  
DB 80 SGVDPDRFSGSGGTFTLKISRVEAEDLGVYFCQSSTHVPWTFGGGTGLEIK 131

## RESULT 14

JL0029  
Ig kappa chain precursor (RP93) - mouse (fragment)  
C:Species: Mus musculus (house mouse)  
C:Date: 31-Dec-1991 #sequence\_revision 31-Dec-1991 #text\_change 09-Jul-2004  
C:Accession: JL0029  
R:Chien, N.C.; Pollock, R.R.; Desaynard, C.; Scharff, M.D.  
J. Exp. Med. 167, 954-973, 1988  
A:Title: Point mutations cause the somatic diversification of IgM and IgG2a antiphospho  
A:Reference number: JL0029; MUID:88171315; PMID:3127529  
A:Accession: JL0029  
A:Molecule type: mRNA  
A:Residues: 1-225 <CHI>  
A:CROSS-references: UNIPROT:Q99M37; UNIPARC:UPI000017697F  
A:Experimental source: strain BALB/c, cell line RP93 hybridoma cell  
A>Note: the authors translated the codon CGG for residue 106 as Pro, ACC for residue 132  
A>Note: the nucleotide sequence shown is inconsistent with authors' translation because  
ect except for four positions shown above  
C:Comment: The protein is an anti-phosphorylcholine antibody.  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: immunoglobulin  
F:7-225/Product: Ig kappa chain #status predicted <ILC>  
F:7-106/Domain: V region #status predicted <VAR>  
F:107-119/Domain: J region #status predicted <JIR>  
F:120-225/Domain: C region #status predicted <COR>

Query Match 90.0%; Score 531; DB 2; Length 225;  
Best Local Similarity 89.3%; Pred. No. 2.6e-41;

Matches 100; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYLOWYLQKPGQSPKLLIYKVSRL 60  
DB 7 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYLEWYLQKPGQSPNLLIYKISNRF 66  
QY 61 YGVDPDRFSGSGGTFTLKISSVEAEADLGVIYFCQSHVPWTFGGGTGLEIK 112  
DB 67 SGVDPDRFSGSGGTFTLKISRVEAEDLGVYFCQSSTHVPWTFGGGTGLEIK 118

## RESULT 15

A27887  
Ig kappa chain V region (H37-60) - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 15-Dec-1988 #sequence\_revision 15-Dec-1988 #text\_change 09-Jul-2004  
C:Accession: A27887  
R:Caton, A.J.; Brownlee, G.G.; Staudt, L.M.; Gerhard, W.  
EMBO J. 5, 1577-1587, 1986  
A:Title: Structural and functional implications of a restricted antibody response to a  
A:Reference number: A91043; MUID:86300658; PMID:2427335  
A:Accession: A27887  
A:Molecule type: DNA  
A:Residues: 1-112 <CAT>  
A:CROSS-references: UNIPROT:Q8VCI6; UNIPARC:UPI0000176A14  
A:Experimental source: strain Balb/c  
A>Note: this sequence was determined from the germline gene  
C:Comment: This chain was isolated from a hybridoma protein that binds influenza virus  
C:Superfamily: immunoglobulin V region; immunoglobulin homology  
C:Keywords: heterotetramer; immunoglobulin  
F16-95/Domain: immunoglobulin homology <IMM>

Query Match 89.8%; Score 530; DB 2; Length 112;  
Best Local Similarity 88.4%; Pred. No. 1.5e-41;

	Matches	99;	Conservative	6;	Mismatches	7;	Indels	0;	Gaps	0;
QY	1	DVLTQIPLSLPVS	LGDOASISCRSSQSI	VHSGNTYLQWYL	KPQSPKLLIYKVS	NRL	60			
Db	1	DVMTQTPLSLPVS	LGDOASISCRSSQSI	VHSGNTYLHMYL	KPQSPKLLIYKVS	NRP	60			
QY	61	YGVPRDFSGSG	GTDFTLKISSVEAD	LGVIYCFQGS	SHVPWTFGGT	KLEIK	112			
Db	61	SGVPRDFSGSG	GTDFTLRISLEAD	LGVIYCFQGS	STHVPWTFGGT	KLEIK	112			

Search completed: January 10, 2006, 20:55:13  
Job time : 14.5124 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:26:41 ; Search time 75.5025 Seconds  
(without alignments)  
1046.577 Million cell updates/sec

Title: US-10-735-916A-54  
Perfect score: 590  
Sequence: 1 DVLMTQIPLSLVSLGDOAS.....CFQGSHPVMTFGGKLEIK 112

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : UniProt 05.80.\*  
1: uniprot\_sprot.\*  
2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	541	91.7	248	2 Q65ZQ7_9MURI	Q65ZQ7 mus sp. b3 (
2	511.5	86.7	115	2 Q5F210_MOUSE	Q5F210 mus musculus
3	510	86.4	113	1 KV2G_MOUSE	P01631 mus musculus
4	491	83.2	112	2 Q53VP8_MOUSE	Q53VP8 mus musculus
5	489	82.9	219	2 Q65ZC0_MOUSE	Q65ZC0 mus musculus
6	466	79.0	133	1 KV2F_HUMAN	P06310 homo sapien
7	453	76.8	239	2 Q8TCD0_HUMAN	Q8TCD0 homo sapien
8	451.5	76.5	114	2 Q9UL80_HUMAN	Q9UL80 homo sapien
9	449	76.1	239	2 Q58E08_MOUSE	Q58E08 mus musculus
10	448	75.9	239	2 Q6P491_HUMAN	Q6P491 homo sapien
11	444	75.3	239	2 Q8NEK0_HUMAN	Q8NEK0 homo sapien
12	441	74.7	117	1 KV2E_HUMAN	P06309 homo sapien
13	438	74.2	113	1 KV2D_HUMAN	P01617 homo sapien
14	426	72.2	113	1 KV2E_MOUSE	P03976 mus musculus
15	424	71.9	113	1 KV2B_HUMAN	P01615 homo sapien
16	423.5	71.8	115	1 KV2A_HUMAN	P01614 homo sapien
17	421.5	71.4	240	2 Q6PIH6_HUMAN	Q6PIH6 homo sapien
18	417	70.7	234	2 Q5XKG4_MOUSE	Q5XKG4 mus musculus
19	410	69.8	112	1 KV2D_MOUSE	P01629 mus musculus
20	410	69.5	113	1 KV2F_MOUSE	P01630 mus musculus
21	408.5	69.2	112	1 KV2C_HUMAN	P01616 homo sapien
22	395	66.9	112	2 Q6LEM8_MOUSE	Q6LEM8 mus musculus
23	393.5	66.7	134	1 KV4C_HUMAN	P06314 homo sapien
24	381	64.6	133	1 KV4B_HUMAN	P06313 homo sapien
25	379.5	64.3	114	1 KV4A_HUMAN	P01625 homo sapien
26	369	62.5	113	1 KV2C_MOUSE	P01628 mus musculus
27	368.5	62.5	111	1 KV3H_MOUSE	P01660 mus musculus
28	368.5	62.5	111	1 KV3Q_MOUSE	P01667 mus musculus
29	368.5	62.5	255	2 Q6KB05_MOUSE	Q6KB05 mus musculus
30	366.5	62.1	131	1 KV3I_MOUSE	P01661 mus musculus
31	364.5	61.8	108	1 KV1_CANFA	P01618 canis famil

32	364.5	61.8	111	1 KV3L_MOUSE	P01664 mus musculus
33	364.5	61.8	240	2 Q52L64_MOUSE	Q52L64 mus musculus
34	362	61.4	110	1 KV3P_MOUSE	P01668 mus musculus
35	362	61.4	112	1 KV2A_MOUSE	P01626 mus musculus
36	361.5	61.3	111	1 KV3Q_MOUSE	P01669 mus musculus
37	360.5	61.1	111	1 KV3C_MOUSE	P01656 mus musculus
38	360.5	61.1	111	2 Q920E9_MOUSE	Q920E9 mus musculus
39	358.5	60.8	111	1 KV3M_MOUSE	P01665 mus musculus
40	357.5	60.6	111	1 KV3A_MOUSE	P01654 mus musculus
41	357.5	60.6	111	1 KV3J_MOUSE	P01659 mus musculus
42	356.5	60.4	112	1 KV3G_MOUSE	P01634 mus musculus
43	356.5	60.4	136	1 KV5B_MOUSE	P01670 mus musculus
44	355.5	60.3	111	1 KV3R_MOUSE	P01658 mus musculus
45	355.5	60.3	132	1 KV3F_MOUSE	P01658 mus musculus

ALIGNMENTS

RESULT 1  
Q65ZQ7\_9MURI PRELIMINARY; PRT; 248 AA.  
AC Q65ZQ7  
DT 25-OCT-2004 (Tremblrel. 28, Created)  
DT 25-OCT-2004 (Tremblrel. 28, Last sequence update)  
DT 25-OCT-2004 (Tremblrel. 28, Last annotation update)  
DE B3(FV)-PE40 (Fragment).  
GN Name=B3(FV)-PE40;  
OS Mus sp.  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
OC Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10095;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RX MEDLINE=92020904; PubMed=1924323;  
RA Brinkmann U., Pai L.H., Fitzgerald D.J., Willingham M., Pastan I.;  
RT "B3(FV)-PE38KDEL, a single-chain immunotoxin that causes complete  
RT regression of a human carcinoma in mice."  
RL Proc. Natl. Acad. Sci. U.S.A. 88:8616-8620(1991).  
DR EMBL; S57990; AAB19971.2; -; mRNA.  
DR SMR; Q65ZQ7; 4-247.  
DR InterPro; IPR003599; Ig.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003596; Ig\_v.  
DR SMART; SM00409; IG; 2.  
DR SMART; SM00406; IGV; 2.  
DR PROSITE; PS50835; IG LIKE; 2.  
FT NON\_TER 248 248  
SQ SEQUENCE 248 AA; 26634 MW; 7A3759B43E570950 CRC64;

Query Match 91.7%; Score 541; DB 2; Length 248;  
Best Local Similarity 92.9%; Pred. No. 1.4e-49;  
Matches 104; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLVSLGDOASISCRSSQSIIVHSGNTYQLQWYKQPGQSPKLIYKVSRL 60  
Db 136 DVLMTQSPLSLVSLGDOASISCRSSQSIIVHSGNTYQLQWYKQPGQSPKLIYKVSRL 195  
QY 61 YGVPRFRFGSGSGTDTFTLKISVEAEDELGVYVYFCQGSHPVMTFGGKLEIK 112  
Db 196 SGVPRFRFGSGSGTDTFTLKISVEAEDELGVYVYFCQGSHPVMTFGGKLEIK 247

RESULT 2  
Q5F210\_MOUSE PRELIMINARY; PRT; 115 AA.  
AC Q5F210;  
DT 10-MAY-2005 (Tremblrel. 30, Created)

DT 10-MAY-2005 (Tremblrel. 30, Last sequence update)  
DT 10-MAY-2005 (Tremblrel. 30, Last annotation update)  
DE Kappa light chain variable region (Fragment).  
GN Name=IgG1 anti-TS1 V1;

```
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Erlandson A.; Holm P.; Ullen A.; Stigbrand T.; Sundstrom B.E.;
RT "Studies of the interactions between the anticytokerin 8 monoclonal
RT antibody Tsl, its antigen and its anti-idiotypic antibody alphaTS1.";
RL J. Mol. Recognit. 16:157-163(2003).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RA Erlandson A.;
RL Submitted (FEB-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ884575; CA156337.1; -; mRNA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
FT NON_TER 1
FT NON_TER 115
SQ SEQUENCE 115 AA; 12560 MW; E4D3BF3D63E88007 CRC64;

Query Match 86.7%; Score 511.5; DB 2; Length 115;
Best Local Similarity 87.6%; Pred. No. 8.1e-47;
Matches 99; Conservative 6; Mismatches 7; Indels 1; Gaps 1;

QY 1 DVLMTQITPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
DB 1 DVVMTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLNWYLOKPGQSPKLLIYKVSNR 60

QY 61 YGVDPDRFSGSGGTDTFTLKISVVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112
DB 61 SGVDPDRFSGSGGTDTFTLKISVVEADLGVIYCFQGSQTHVPTFGGTTKLEMK 113

RESULT 3
KV2G MOUSE STANDARD; PRT; 113 AA.
AC P01631;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region 26-10.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muroidae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP PROTEIN SEQUENCE.
RC STRAIN=A/J;
RX MEDLINE=83178921; PubMed=6404298;
RA Novotny J.; Margolies M.N.;
RT "Amino acid sequence of the light chain variable region from a mouse
RT anti-digoxin hybridoma antibody.";
RL Biochemistry 22:1153-1158(1983).
CC -!- MISCELLANEOUS: This chain was isolated from an IgG2a hybridoma
CC protein that binds digoxin.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC PIR; A01914; KMS26.
DR HSP; O99M37; 1191.
DR Ensembl; ENSMUSG00000055315; Mus musculus.
```

```
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Direct protein sequencing; Hybridoma; Immunoglobulin domain;
KW Immunoglobulin V region; Monoclonal antibody.
FT REGION 1 23
FT REGION 24 39
FT REGION 40 54
FT REGION 55 61
FT REGION 62 93
FT REGION 94 102
FT REGION 103 112
FT DISULFID 23 93
FT NON_TER 113
SQ SEQUENCE 113 AA; 12273 MW; F9F39CE949A84C2A CRC64;

Query Match 86.4%; Score 510; DB 1; Length 113;
Best Local Similarity 87.5%; Pred. No. 1.1e-46;
Matches 98; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 1 DVLMTQITPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
DB 1 DVVMTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLNWYLOKPGQSPKLLIYKVSNR 60

QY 61 YGVDPDRFSGSGGTDTFTLKISVVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112
DB 61 SGVDPDRFSGSGGTDTFTLKISVVEADLGVIYCFQGSQTHVPTFGGTTKLEIK 112

RESULT 4
Q53VP8 MOUSE PRELIMINARY; PRT; 112 AA.
AC Q53VP8;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE Kappa chain (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P.; Rocca-Serra J.; Somme G.; Theze J.; Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBO J. 4:3681-3688(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 108-109.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03386; CAA27113.1; -; mRNA.
FT NON_TER 1
FT NON_TER 112
SQ SEQUENCE 112 AA; 12266 MW; C844B7881A89C18A CRC64;

Query Match 83.2%; Score 491; DB 2; Length 112;
Best Local Similarity 83.0%; Pred. No. 1.2e-44;
Matches 93; Conservative 8; Mismatches 11; Indels 0; Gaps 0;

QY 1 DVLMTQITPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
DB 1 DVVMTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLNWYLOKPGQSPKLLIYKVSNR 60

QY 61 YGVDPDRFSGSGGTDTFTLKISVVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112
DB 61 SGVDPDRFSGSGGTDTFTLKISVVEADLGVIYCFQGSQTHVPTFGGTTKLEIK 112
```

```

RESULT 5
Q65ZC0 MOUSE PRELIMINARY; PRT; 219 AA.
ID Q65ZC0;
AC Q65ZC0;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Kappa light chain C region (fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Balb/c; TISSUE=Spleen;
RX MEDLINE=96319505; PubMed=8768802;
RA Kipp B., Schlaak M., Becker W.M.;
RT "Cloning and expression of a recombinant mouse Fab-fragment
RT recognizing a defined linear epitope of Chironomus thummi major
RT allergen Chi t I."
RL Int. Arch. Allergy Immunol. 110:348-353 (1996).
DR EMBL; Z37499; CAA85724.1; -; mRNA.
DR SMR; Q65ZC0; 1-219.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
FT NON_TER 1
FT NON_TER 219
SQ SEQUENCE 219 AA; 23944 MW; 7E1B82A14EAF8445 CRC64;

Query Match 82.9%; Score 489; DB 2; Length 219;
Best Local Similarity 83.9%; Pred. No. 4.5e-44;
Matches 94; Conservative 7; Mismatches 11; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLVSLGDOASISCRSSQSIHNGNTYLYQWYKQPSKLLIYKVSRL 60
Db 1 ELVMTQSPLSLVSLGDOASISCRSSQSIHNGNTYLYHWYKQPSKLLIYVSNRF 60

QY 61 YGVPRFSGSGSDTFTLKISVVEADLGYYCFQGSHPVTFGGTKLEIK 112
Db 61 SGVPRFSGSGSDTFTLKISVVEADLGYYCFQGSHPVTFGGTKLEIK 112

RESULT 6
KV2F HUMAN STANDARD; PRT; 133 AA.
ID KV2F HUMAN
AC P06310;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region RPMI 6410 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86041852; PubMed=2997711;
RA Klobbeck H.G., Meindl A., Combrato G., Solomon A., Zachau H.G.;
RT "Human immunoglobulin kappa light chain genes of subgroups II and
RT III."
RL Nucleic Acids Res. 13:6499-6513 (1985).
CC -----

```

```

CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; Z00020; CAA77315.1; -; Genomic_DNA.
DR PIR; A01890; K2HURP.
DR HSSP; Q99M37; 1191.
DR SMR; P06310; 21-133.
DR Ensembl; ENSG00000173758; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1
FT CHAIN 21
FT REGION 21 133
FT REGION 21 43
FT REGION 44 59
FT REGION 60 74
FT REGION 75 81
FT REGION 82 113
FT REGION 114 122
FT REGION 123 132
FT DISULFID 43 113
FT NON_TER 133
SQ SEQUENCE 133 AA; 14707 MW; 513CCAF3673009EE CRC64;

Query Match 79.0%; Score 466; DB 1; Length 133;
Best Local Similarity 78.6%; Pred. No. 7.4e-42;
Matches 88; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLVSLGDOASISCRSSQSIHNGNTYLYQWYKQPSKLLIYKVSRL 60
Db 21 DVVMTQSPLSLVSLGDOASISCRSSQSIHNGNTYLYHWYKQPSKLLIYVSNRD 80

QY 61 YGVPRFSGSGSDTFTLKISVVEADLGYYCFQGSHPVTFGGTKLEIK 112
Db 81 SGVPRFSGSGSDTFTLKISVVEADLGYYCFQGSHPVTFGGTKLEIK 132

RESULT 7
Q8TCD0 HUMAN PRELIMINARY; PRT; 239 AA.
ID Q8TCD0;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

```

RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalish D.E.,  
RA Schnerch A., Schlein J.E., Jones S.J.M., Marra M.A.,  
RT "Generation and initial analysis of more than 15,000 full-length human  
RL and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE: Lung;  
RA Strausberg R.;  
RN Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=1598223;  
RA Hirabayashi Y., Munakata Y., Sasaki T., Sano H.;  
RT "Variable regions of a human anti-DNA antibody O-81 possessing lupus  
RT nephritis-associated idiotype.";  
RL Nucleic Acids Res. 20:2601-0(1992).  
RN [4]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=1551402;  
RA Lautner-Rieske A., Huber C., Meindl A., Pargent W., Schable K.F.,  
RA Thiele R., Zocher I., Zachau H.G.;  
RT "The human immunoglobulin kappa locus. Characterization of the  
RT duplicated A regions.";  
RL Eur. J. Immunol. 22:1023-1029(1992).  
RN [5]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=8258341;  
RA Klein R., Jaenichen R., Zachau H.G.;  
RT "Expressed human immunoglobulin kappa genes and their hypermutation.";  
RL Eur. J. Immunol. 23:3248-3262(1993).  
RN [6]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=8436174;  
RA Wagner S.D., Luzzatto L.;  
RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are  
RT distributed over a large portion of the V kappa locus and do not show  
RT somatic mutation.";  
RL Eur. J. Immunol. 23:391-397(1993).  
DR EMBL; BC022362; AAH22362.1; -; mRNA.  
DR PIR; S22658; S22658.  
DR PIR; S34095; S34095.  
DR PIR; S40324; S40324.  
DR PIR; S40374; S40374.  
DR PIR; S42267; S42267.  
DR PIR; S42268; S42268.  
DR HSP; P01834; I17Z.  
DR SMR; Q8TCD0; 21-237.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003597; Ig cl.  
DR InterPro; IPR003006; Ig\_MHC.  
DR InterPro; IPR003596; Ig\_v.  
DR Pfam; PF07654; Cl-set; 1.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS00835; IG\_LIKE; 2.  
DR PROSITE; PS00290; IG\_MHC; UNKNOWN 1.  
KW Hypothetical protein, Immunoglobulin domain.  
SQ SEQUENCE 239 AA; 26235 MW; 26235 MW; FACEDC3A3803871D CRC64;

Query Match 76.8%; Score 453; DB 2; Length 239;  
Best Local Similarity 76.8%; Pred. No. 3.7e-40;  
Matches 86; Conservative 13; Mismatches 13; Indels 0; Gaps 0;  
QY 1 DVLMTQIPLSVSLGDOASISCRSSQSIHNSNGNTYLQWYLOKQSPKLIYKVSRL 60  
DB 21 DVMVTQSPSLVPLTLRQSPASISCRSSQSPVYSDGNTYLNWFOQRFGQSPRLIYKVSRL 80  
QY 61 YGVPRFSGSGGTDFTLKISSVEARDLGVIYCFQGSHPVPTFGGKLEIK 112  
|||||

Db 81 SGVPDRFSGSGGTDFTLKIRVEAEDVGIVFCMQGTHWPSTFGGKLEIK 132  
RESULT 8  
Q9UL80 HUMAN PRELIMINARY; PRT; 114 AA.  
AC Q9UL80;  
DT 01-MAY-2000 (TRENBLrel. 13, Created)  
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)  
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)  
DE Myosin-reactive immunoglobulin light chain variable region  
DS (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;  
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,  
RA Young D.C.;  
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal  
RT fetus.";  
RL Clin. Immunol. Immunopathol. 87:184-192(1998).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=1322670;  
RA Stuber F., Lee S.K., Bridges S.L. Jr, Koopman W.J., Schroeder H.W. Jr,  
RA Gaskin F., Fu S.M.;  
RT "A rheumatoid factor from a normal individual encoded by VH2 and V  
RT kappa II gene segments.";  
RL Arthritis Rheum. 35:900-904(1992).  
RN [3]  
RP NUCLEOTIDE SEQUENCE.  
RX Wagner S.D., Luzzatto L.;  
RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are  
RT distributed over a large portion of the V kappa locus and do not show  
RT somatic mutation.";  
RL Eur. J. Immunol. 23:391-397(1993).  
RN [4]  
RP NUCLEOTIDE SEQUENCE.  
RX PubMed=1601042;  
RA Huber C., Klebeck H.G., Zachau H.G.;  
RT "Ongoing V kappa-J kappa recombination after formation of a productive  
RT V kappa-J kappa coding joint.";  
RL Eur. J. Immunol. 22:1561-1565(1992).  
DR EMBL; AF035034; AAD56270.1; -; mRNA.  
DR PIR; B49002; B49002.  
DR PIR; S23638; S23638.  
DR PIR; S34094; S34094.  
DR PIR; S34095; S34095.  
DR HSP; P01625; ILVE.  
DR SMR; Q9UL80; 1-114.  
DR InterPro; IPR007110; Ig-like.  
DR InterPro; IPR003596; Ig\_v.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS00835; IG\_LIKE; 1.  
FT NON TER 114  
FT NON TER 114  
SQ SEQUENCE 114 AA; 12775 MW; 070E31E210D1CB01 CRC64;

Query Match 76.5%; Score 451.5; DB 2; Length 114;  
Best Local Similarity 77.9%; Pred. No. 2.2e-40;  
Matches 88; Conservative 10; Mismatches 14; Indels 1; Gaps 1;  
QY 1 DVLMTQIPLSVSLGDOASISCRSSQSIHNSNGNTYLQWYLOKQSPKLIYKVSRL 60  
DB 1 DVMVTQSPSLVPLTLRQSPASISCRSSQSPVYSDGNTYLNWFOQRFGQSPRLIYKVSRL 60  
QY 61 YGVPRFSGSGGTDFTLKISSVEARDLGVIYCFQGSHPVPTFGGKLEIK 112  
|||||

21 DIVMTQTLSPVTLGPASISCRSSSLHSGNTYLSWLPQPGPRLLYIKISNRF 80



```
FT REGION 98 106 Complementarity-determining-3.
FT REGION 107 116 Framework-4.
FT DISULFID 27 97 By similarity.
FT NON_TER 1 1
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12664 MW; 92C57DC719E558B1 CRC64;

Query Match
Best Local Similarity 74.7%; Score 441; DB 1; Length 117;
Matches 85; Conservative 9; Mismatches 18; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPSVSLGDOASISCRSSQSIIVHSNGNTYLQWYKQPGSPKLLIYKVSRL 60
Db 5 DIVMTQSPSLPVTGPBPASISCRSSQSLHSHNGNTYLQWYKQPGSPKLLIYKVSRL 64

QY 61 YGVDPFRFSGSGSDTFTLKISSVEADLGVYVCFQGSHPVPTFGGTTKLEIK 112
Db 65 SGVPDRFSGSGSDTFTLKISRVEADGVYVCMQGLQTPPTFGGTTKVEIK 116

RESULT 13
KV2D HUMAN STANDARD; PRT; 113 AA.
AC P01617;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region TEW.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE (BENCE-JONES PROTEIN TEW).
EX MEDLINE=74148480; PubMed=4596149;
RA Putnam F.W., Whitley E.J. Jr., Paul C., Davidson J.N.;
RT "Amino acid sequence of a kappa Bence Jones protein from a case of
primary amyloidosis."
RL Biochemistry 12:3763-3780 (1973).
RN [2]
RP PROTEIN SEQUENCE OF 1-27 (AMYLOID PROTEIN TEW).
EX MEDLINE=73166638; PubMed=4700495;
RA Terry W.D., Page D.L., Kimura S., Isobe T., Osseerman E.F.,
RA Glenner G.G.;
RT "Structural identity of Bence Jones and amyloid fibril proteins in a
patient with plasma cell dyscrasia and amyloidosis."
RL J. Clin. Invest. 52:1276-1281 (1973).
CC -!- MISCELLANEOUS: The major amyloid protein appears to be identical
with the Bence Jones protein isolated from the same patient.
CC -!- MISCELLANEOUS: This protein was isolated from the urine of a
patient with plasma cell dyscrasia and amyloidosis.
CC -!- MISCELLANEOUS: The C region of this chain has the INV (1,2)
marker.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use as long as its content is in no way modified and this statement is not
removed.
CC
CC PIR; A90370; K2HTWT.
CC HSSP; Q99M37; 1191.
CC SMR; P01617; 1-113.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; IG-like.
CC InterPro; IPR003596; IG_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS50835; IG_LIKE; 1.
CC Amyloid; Bence-Jones protein; Direct protein sequencing;
KW Immunoglobulin domain; Immunoglobulin V region.
```

```
FT REGION 1 23 Framework-1.
FT REGION 24 39 Complementarity-determining-1.
FT REGION 40 54 Framework-2.
FT REGION 55 61 Complementarity-determining-2.
FT REGION 62 93 Framework-3.
FT REGION 94 102 Complementarity-determining-3.
FT REGION 103 112 Framework-4.
FT DISULFID 23 93 By similarity.
FT NON_TER 113 113
SQ SEQUENCE 113 AA; 12316 MW; 0C3C9F81F1843A CRC64;

Query Match
Best Local Similarity 74.2%; Score 438; DB 1; Length 113;
Matches 83; Conservative 12; Mismatches 17; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPSVSLGDOASISCRSSQSIIVHSNGNTYLQWYKQPGSPKLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTGPBPASISCRSSQSLHSHNGNTYLQWYKQPGSPKLLIYKVSRL 60

QY 61 YGVDPFRFSGSGSDTFTLKISSVEADLGVYVCFQGSHPVPTFGGTTKLEIK 112
Db 61 SGVPDRFSGSGSDTFTLKISRVEADGVYVCMZALQAPITFGGTTREIK 112

RESULT 14
KV2E MOUSE STANDARD; PRT; 113 AA.
AC P03976;
DT 23-OCT-1986 (Rel. 02, Created)
DT 23-OCT-1986 (Rel. 02, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region 17S29.1.
OS Mus musculus (Mouse)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP PROTEIN SEQUENCE.
RC TISSUE=Hybridoma;
RX MEDLINE=85128968; PubMed=6441768;
RA Aebersold R., Herbst H., Grutter T., Chang J.Y., Braun D.G.;
RT "Murine V kappa 25 and V kappa 27 amino-acid sequences of C57B1/6
origin: monoclonal antibodies 17S29.1 and 2S25.1 specific for the
group A-streptococcal polysaccharide."
RL Hoppe-Seyler's Z. Physiol. Chem. 365:1375-1383 (1984).
CC -!- FUNCTION: Anti-streptococcal group A carbohydrate antibody.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use as long as its content is in no way modified and this statement is not
removed.
CC
CC PIR; A01912; KVM517.
CC HSSP; Q99M37; 1191.
CC SMR; P03976; 1-113.
CC ENSEMBL; ENSMUSG0000055315; Mus musculus.
CC InterPro; IPR007110; IG-like.
CC InterPro; IPR003596; IG_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS50835; IG_LIKE; 1.
CC Direct protein sequencing; Hybridoma; Immunoglobulin domain;
KW Immunoglobulin V region.
FT REGION 1 23 Framework-1.
FT REGION 24 39 Complementarity-determining-1.
FT REGION 40 54 Framework-2.
FT REGION 55 61 Complementarity-determining-2.
FT REGION 62 93 Framework-3.
FT REGION 94 102 Complementarity-determining-3.
FT REGION 103 112 Framework-4.
FT DISULFID 23 93 By similarity.
FT NON_TER 113 113
```

